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Preface
One famous saying by Robert Louis Stevenson “It is not a hard thing to know what to write;
the hard thing is to know what to leave out" holds very true for us while writing the preface
of this book.
Tuberculosis (TB) is as old as mankind and continues to haunt the mankind despite several
spectacular advances in the diagnosis and management of TB. TB is the commonest single
infectious cause of death and accountable for over 25% of avoidable deaths worldwide but
can still be labeled as “Captain of all these men of death”.
In the initial sections of the book chapters covering the basic pathophysiology and the im‐
portant factors contributing to the same viz. epidemiology of TB, iron metabolism, unusual
properties of M. Tuberculosis, lipid inclusion, role of small regulatory RNA and adaptation
to survival in human host, which makes it “tough bug” to treat, has been included in details.
Our understanding of the host pathogen interaction at the molecular level, especially immu‐
nopathogenesis of TB has improved enormously and has been extensively covered in the
book. Chapters have been included to cover several new drug and potential vaccines for TB.
New development such as the interferon-gamma release assays [IGRAs] for latent TB infec‐
tion, use of liquid culture and molecular method of diagnosis are ushering in a new era in
TB diagnostics. Comprehensive knowledge of latest modes of diagnosis has been also incor‐
porated in the book. Furthermore, issues concerning quality assurance in antituberculosis
drug susceptibility testing are getting established.
Data are rapidly accumulating from all over the world regarding the efficacy of standar‐
dized treatment regimens for drug-sensitive, drug-resistant TB and latent TB infection.
While we are facing the menace of multi drug-resistant TB [MDR-TB], extensively drug-re‐
sistant tuberculosis [XDR¬ TB] has emerged threatening to undermine global efforts at TB
control. Hence we have included chapters to cover all aspects of the diagnosis and manage‐
ment of MDR TB. This book will cover all these developments in great detail.
With the widespread availability of internet globally various standard web resources availa‐
ble on TB have also been included so that the readers may get the comprehensive and up‐
dated guidelines from these resources. The changing clinical presentation of TB, advances in
laboratory, imaging diagnostic modalities, therapeutic measures and emergence of MDR TB
all suggest a pressing need to have a updated book on TB. Furthermore, while all physicians
encounter the TB disease in their clinical practice, there have been a lot of controversies and
misconceptions over various issues for the diagnosis and management of TB.
Paucity of a well referenced, updated, standard book of TB has prompted us to undertake
this venture sharing the clinical experience of global experts of TB.
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Our book contains chapters on epidemiology, immune-pathology, diagnosis, treatment and
latest advances for TB, highlighting the global perspective of tuberculosis. World-wide re‐
surgence of MDR TB indicates that the battle against this foe of mankind will continue in the
coming years. TB still remains to be a research priority of paramount importance from
medical, social and financial aspects and we have attempted to highlight all the aspects for
the treatment of TB.
We believe that this book will serve as a practical guide for the diagnosis and management
of TB for practicing physicians (especially pulmonologists and internists) and all those who
are involved in the management of TB.
This book has several contributors, all of them leading authorities from various parts of the
world. All the chapters have been thoroughly re-written and updated with preservation of the
views of the contributors in a uniform format. This effort would not have been possible without
the kind cooperation of our contributors who patiently went through revisions and updating
of their chapters. We convey our heartfelt thanks to all contributors and to InTech Publisher,
Croatia for their encouragement and excellent technical assistance as and when required.
Lastly we would like to thank the almighty god, our parents, wives and children, without
their untiring support and encouragement this book would not have seen the light of the day.
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http://dx.doi.org/10.5772/54956
1. Introduction
Mycobacterium tuberculosis exists exclusively as a pathogen of humans and in some cases of
animals. It is not thought to exist in the environment other than for brief periods during transfer
from an infected host to an uninfected contact. Thus M. tuberculosis must adapt to an in vivo
environment by modifying gene expression. Differential expression can occur in immune cells
such as macrophages, larger immune structures such as granulomas, and within liquefied
lesions of the lung. Within the human body tubercle bacilli experience reactive oxygen
intermediates as well as acidity within the phagosomes of macrophages. In addition within
the centers of caseating granulomas bacilli experience low oxygen tension as well as toxic
lipases and proteases released by dead immune cells. High temperature is present within the
body of a person with active tuberculosis in the form of a fever. There may be other unrecog‐
nized signals and stresses that modulate gene expression within invading M. tuberculosis bacilli
as well. Examination of gene expression during in vivo growth, within macrophages, or during
application of specific stresses can illuminate which critical pathways in the mycobacterium
are upregulated that lead to an M. tuberculosis bacillus exquisitely adapted to in vivo survival.
2. Adaptation to growth in the phagosomal compartment of macrophages
Macrophages are the preferred intracellular location for M. tuberculosis in vivo. Infected
individuals cough and expel droplet nuclei which contain M. tuberculosis bacilli and remain
suspended in the air. After inhalation and within the body, the bacilli are transported to the
small alveoli in the lungs where they encounter alveolar macrophages which are relatively
nonactivated (Dannenberg, 1993; Dannenberg, 1997). These nonactivated macrophages are not
© 2013 Saviola; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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efficient at killing or retarding growth of invading microbes. Initially bacilli are taken up into
phagosomal compartments and may replicate. As the immune system becomes activated,
macrophages are stimulated with INF-γ to increase their efficiency of mycobacterial killing,
becoming more efficient at producing reactive oxygen intermediates and acidic stress. In
response, M. tuberculosis pushes back against the macrophages and differentially regulates key
genes. Within macrophages M. tuberculosis increases its lipid metabolism which may reflect
an environment in the phagosome which lacks available carbohydrates (Table. 1). In addition
the enzyme isocitrate lyase (icl) is strongly induced in vivo, and icl is upregulated in all
macrophage models. Icl is a key enzyme in the glyoxylate shunt and utilizes fatty acids as an
energy source. When icl and other genes in the glyoxylate shunt are mutated this results in
attenuation in vivo. In addition within macrophages, genes involved in stress responses, cell
wall component production, anaerobic respiration, siderophore production to scavange iron,
diverse sigma factor production, and tranposases that may mutate the genome are all upre‐
gulated (Schnappinger et al, 2003, Beste et al, 2007, Ward et al, 2010).
3. Adaptation to granulomas and caseation
Once infection has progressed, tubercle bacilli replicate within incompletely activated mac‐
rophages. Additional macrophages arrive to the site of infection, and engulf newly liberat‐
ed  mycobacteria.  The  immune  cells,  T-cells,  arrive  to  this  location  and  an  immune
structure, the granuloma, composed of macrophages and a mantel of T-cells develops. If
the host is resistant, and can robustly activate the body’s macrophages, then M. tuberculosis
infection is likely controlled. If the host immune system is weak, or is weakened, M. tuber‐
culosis can replicate in the incompletely activated macrophages. Genes of M. tuberculosis re‐
quired  to  resist  macrophages  will  be  important  in  resisting  the  environment  of  the
granuloma as well. As the infection progresses in susceptible individuals, the centers of the
granulomas degenerate and form a caseous, or cheesy, center. At the heart of this is an ele‐
vated lipid metabolism of the host that produces a variety of lipids including cholesterol,
cholesteryl esters, triacyglycerol and others (Kim et al, 2010). Interestingly M. tuberculosis
infection has been shown to induce elevated lipid metabolism in the host (Table 1.). The
cell wall lipid of M. tuberculosis, trehalose dimycolate or cord factor, induces a granuloma‐
tous response in mice, and this was accompanied by foam cell formation which contains
elevated lipids (Kim et al, 2010). It is intriguing to speculate that M. tuberculosis infection
can induce elevated host lipid metabolism, and as discussed previously as part of adapta‐
tion to in vivo growth, M. tuberculosis also switches to lipid metabolism and lipids as a pre‐
ferred  carbon  source  (Eisenreich  et  al,  2010).  Thus  M.  tuberculosis  induces  the  host  to
produce what the microbe has evolved to utilize as an energy source.
4. Liquefied lesions and sputum
Later in infection caseating granulomas continue to breakdown. At a certain point these
granulomas begin to liquefy, and host lipases and proteases are present which damage host
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tissues. Dead macrophages release lytic enzymes, and bacterial products may also result in
host tissue damage and liquefaction ensues. As tissue is damaged, a cavity erodes into the lung
airspace. In rabbit studies, M. tuberculosis can replicate to extremely high levels in this liquefied
environment (Dannenberg 1993, Dannenberg et al 1997, Dannenberg 2006). For the first time
in vivo M. tuberculosis is capable of replicating extracellularly. Liquid containing free M.
tuberculosis is expelled through cavities in the lung by coughing.
M. tuberculosis within sputum contains elevated levels of lipid bodies and tends to be inhibited
in its replicative process ( Table 1.) (Garton et al, 2008). In addition, sputum transcriptome
analysis of M. tuberculosis reveals that triacylglycerol synthase, tgs1 part of the DosR regulon,
is induced and lipid bodies may be composed of increased stores of triacylglycerol (Garton et
al, 2008). Lipid bodies are correlated in vitro with nonreplicating persistence, and may help M.
tuberculosis survive the harsh environment ex vivo before it encounters another human host.
5. Mycobacterium tuberculosis and dormancy
One third of the world’s population is infected with M. tuberculosis in part because it causes a
latent or dormant infection in a majority of those infected. If therapies are to be developed
which can eradicate M. tuberculosis, a better understanding of dormancy is required. M.
tuberculosis can persist for decades in a dormant state within hypoxic granulomas in the lung.
Studies have suggested that in a dormant state M. tuberculosis is occupied mainly with
maintaining cell wall integrity, membrane potential, and protecting its DNA structure. The
mycobacterium must also resist the host’s immune system. A number of in vivo and in vitro
models have been used to investigate dormancy. These models include exposing mycobacteria
to environments that are likely encountered within the host. In one model cultures are stirred
slowly and sealed so that oxygen is gradually consumed. In another model nutrient starvation
of the bacteria may induce dormancy. In addition, infection of mice, partial treatment with
antibiotics, and exposure to immune suppression can lead to dormancy and reactivation
(Murphy and Brown, 2007).
The gene encoding a transcriptional regulator, dosR (devR), part of a two component system
that responds to low oxygen seems to be very important in a shift from replicating M.
tuberculosis to a nonreplicating form (Table 1.). Carbohydrate limitation also upregulated dosR
and there is indeed an overlap of genes upregulated in phagosomes of macrophages and low
carbohydrate availability. In dormancy models aerobic respiratory metabolism was down
regulated while anaerobic respiration was upregulated as were DosR controlled genes
(Murphy and Brown, 2007). Amino acid and carbon starvation results in the activation of the
stringent response. RelA (Rv2583c) mediates this stringent response in M. tuberculosis and can
globally down regulate components necessary in protein translation, and thus conserve badly
needed resources in the mycobacterium during times of stress. RelA may be a target to prevent
M. tuberculosis from entering dormancy or a target to force M. tuberculosis out of dormancy
(Murphy and Brown, 2007).
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gulated (Schnappinger et al, 2003, Beste et al, 2007, Ward et al, 2010).
3. Adaptation to granulomas and caseation
Once infection has progressed, tubercle bacilli replicate within incompletely activated mac‐
rophages. Additional macrophages arrive to the site of infection, and engulf newly liberat‐
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tissues. Dead macrophages release lytic enzymes, and bacterial products may also result in
host tissue damage and liquefaction ensues. As tissue is damaged, a cavity erodes into the lung
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Studies have suggested that in a dormant state M. tuberculosis is occupied mainly with
maintaining cell wall integrity, membrane potential, and protecting its DNA structure. The
mycobacterium must also resist the host’s immune system. A number of in vivo and in vitro
models have been used to investigate dormancy. These models include exposing mycobacteria
to environments that are likely encountered within the host. In one model cultures are stirred
slowly and sealed so that oxygen is gradually consumed. In another model nutrient starvation
of the bacteria may induce dormancy. In addition, infection of mice, partial treatment with
antibiotics, and exposure to immune suppression can lead to dormancy and reactivation
(Murphy and Brown, 2007).
The gene encoding a transcriptional regulator, dosR (devR), part of a two component system
that responds to low oxygen seems to be very important in a shift from replicating M.
tuberculosis to a nonreplicating form (Table 1.). Carbohydrate limitation also upregulated dosR
and there is indeed an overlap of genes upregulated in phagosomes of macrophages and low
carbohydrate availability. In dormancy models aerobic respiratory metabolism was down
regulated while anaerobic respiration was upregulated as were DosR controlled genes
(Murphy and Brown, 2007). Amino acid and carbon starvation results in the activation of the
stringent response. RelA (Rv2583c) mediates this stringent response in M. tuberculosis and can
globally down regulate components necessary in protein translation, and thus conserve badly
needed resources in the mycobacterium during times of stress. RelA may be a target to prevent
M. tuberculosis from entering dormancy or a target to force M. tuberculosis out of dormancy
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The ability of M. tuberculosis to survive in a dormant state relies on maintaining cell integrity,
viability, and a proton motive (Rustad et al, 2008). Entry into a dormant state may be followed
later by reactivation and growth of this microorganism, and may occur due to waning
immunity, age, or disease. T-cells originally controlling infection may become less activated
and numbers of T-cells may decrease allowing mycobacteria increased ease of replication in
host macrophages. M. tuberculosis needs energy to exit this dormant phase, and this may be
found in the form of triacylglycerol which is known to accumulate in response to acidic stress,
nitric oxide exposure, and lowered oxygen tension (Table 1.) (Sirakova et al, 2006; Garton et
al, 2008). In fact triacylglycerol has been shown to be important to transition from dormancy
to active growth (Low et al, 2009). The highly pathogenic strain of M. tuberculosis, the Beijing
lineage strain, over produces triacylglycerol perhaps giving the microorganism a competitive
edge in resisting hypoxic stress and dormancy (Fallow et al, 2010).
6. Mycobacterium tuberculosis responses to acidic stress
M. tuberculosis encounters acidity in the body in a number of locations including within
immune cells, macrophages. When macrophages phagocytose tubercle bacilli, phagosomes of
unactivated macrophages are limited in their ability to acidify due to the presence of live M.
tuberculosis. Bacilli can inhibit phagosomal maturation and also inhibit phagosome lysosome
fusion (Armstrong and Hart, 1971; Sturgill-Koszycki et al, 1994; Huynh and Grinstein, 2007).
Virulent M. tuberculosis can exclude a proton ATPase from the phagosome in non-activated
macrophages. Exposure to the cytokine INF-γ can result in increased activation of macro‐
phages and these macrophages that phagocytose live virulent M. tuberculosis can lower the
intra phagosomal pH (Schaible et al,1998; Via et al, 1998; MacMicking et al, 2003; Ehrt and
Schnappinger, 2009). This pH’s can be toxic to bacilli either killing them, or inhibiting their
growth. The robustness of the response seems to lie in the activation and efficiency of the host’s
immune response. Anything that interferes with the host's immune status can negatively
impact acidic modulation within phagosomes, and lead to more mycobacterial replication. In
addition, the tubercle bacillus' ability to respond to acidic stress will likely affect the outcome
of the infection.
Mycobacteria seem to bear an intrinsic ability to resist acidic stress. They have a thick waxy
cell wall as well as an outer membrane that can resist acidic stress. This physical barrier may
serve to inhibit entry of toxic protons, and anything that interferes with this barrier could
increase acid susceptibility. Many mutants that are acid susceptible lie in genes that affect cell
wall and lipid metabolism (Table 1.). Environmental mycobacteria are found in conditions that
may be acidic and can grow at pHs as low as 4.0 (Santos et al, 2007). Pathogenic mycobacteria
have evolved to resist acidic stress, and potentially share similar mechanisms with their
environmental cousins (Kirschner et al, 1992; Kirschner et al, 1999).
Although Mycobacterium smegmatis has been found to have an acid tolerance system it is not
known if M. tuberculosis also possesses one. However, a large number of genes are upregulated
due to acidic stress in M. tuberculosis. Interestingly when M. tuberculosis is engulfed by the
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phagosomes of macrophages many genes are upregulated, and when cocanamycinA is added
which interferes with the development of acidity, 80% of genes in M. tuberculosis that are
normally upregulated in the phagosomes fail to do so (Rohde et al; 2007). This is an indication
that acidity is one of the main environmental signals M. tuberculosis experiences in vivo.
A number of genes that are upregulated by acidic stress have been identified in previous
studies. Looking at rapid response to acidity at 15 or 30 minutes it was found that genes
involved in cell wall ultrastructure were induced (Fisher et al, 2002). The mymA operon was
induced in this study, and is under the control of VirS which is an AraC/XylS family tran‐
scription factor (Singh et al, 2005). The lipF promoter of M. tuberculosis is upregulated, but
requires a longer time frame (Saviola et al, 2001). It fails to be upregulated at 30 minutes, instead
needing more extended exposure to acidic stress of 1.5 hours. LipF is annotated to be an
esterase and may also function to alter the cell wall structure. LipF has been shown to be part
of the two component system phoP/R regulon. In fact many genes involved in the PhoP/PhoR
regulon including pks2, pks3, and pks4 are responsive to acidic stress (Table 1.) (Gonzalo-
Asensio et al, 2009; Rohde et al, 2007). Thus PhoP/R may be responding to acidic stress or
conversely PhoP/R controls a downstream regulator that responds to acidity. The ompATb gene
encodes a porin that is active specifically at low pH and functions to pump ammonia into the
phagosomal environment which serves to neutralize acidity (Song et al, 2011). Longer term
exposure to acidic stress seems to stimulate production of triacylglycerol. Tgs1 is not upregu‐
lated by short term acid exposure but exposure of three weeks duration or more (Sirakova et
al, 2006; Low et al, 2009; Deb et al, 2009). Triacylglycerol production may be important for
mycobacteria to resist stress and survive a dormant period which is induced by stress condi‐
tions. An energy source such as triacylglycerol may be needed to reanimate from dormancy
once stresses such as acidity are removed. Mutatagenesis studies also revealed genes involved
cell wall/cell envelope synthesis when mutated resulted in mycobacteria which were unable
to maintain neutral pH within their microbial cytoplasm in the presence of acidic stress (Vandal
et al, 2008; Vandal et al, 2009, Biswass et al, 2010).
The type VII secretion system, Esx-1, may also may be involved in response to acid stress
(Abdallah et al, 2007). The 6 kDa early secreted antigenic target (Esat-6) and the 10kDa cul‐
ture filtrate protein (CFP-10) are secreted by Esx-1. These two proteins form a heterodimer
that can dissociate at acidic pH. Esat-6 is capable of lysing membranes, and M. tuberculosis
has been identified to reside extraphagosomally in the cytoplasm of macrophages in some
cases.  In addition when the esx-1  gene was mutated it  could result  in an M. tuberculosis
strain that fails to escape from the phagosomal compartment into the cytoplasm (Simeone
et al, 2009). Thus Esat-6 may be involved in mycobacterial responses to acidity and adapta‐
tion to in vivo stressors.
7. Response to oxidative damage
Inside phagosomes of activated macrophages tubercle bacilli are exposed to reactive oxygen
intermediates. M. tuberculosis traffics to phagosomes, and a large number of genes are upre‐
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lineage strain, over produces triacylglycerol perhaps giving the microorganism a competitive
edge in resisting hypoxic stress and dormancy (Fallow et al, 2010).
6. Mycobacterium tuberculosis responses to acidic stress
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immune cells, macrophages. When macrophages phagocytose tubercle bacilli, phagosomes of
unactivated macrophages are limited in their ability to acidify due to the presence of live M.
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Schnappinger, 2009). This pH’s can be toxic to bacilli either killing them, or inhibiting their
growth. The robustness of the response seems to lie in the activation and efficiency of the host’s
immune response. Anything that interferes with the host's immune status can negatively
impact acidic modulation within phagosomes, and lead to more mycobacterial replication. In
addition, the tubercle bacillus' ability to respond to acidic stress will likely affect the outcome
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Mycobacteria seem to bear an intrinsic ability to resist acidic stress. They have a thick waxy
cell wall as well as an outer membrane that can resist acidic stress. This physical barrier may
serve to inhibit entry of toxic protons, and anything that interferes with this barrier could
increase acid susceptibility. Many mutants that are acid susceptible lie in genes that affect cell
wall and lipid metabolism (Table 1.). Environmental mycobacteria are found in conditions that
may be acidic and can grow at pHs as low as 4.0 (Santos et al, 2007). Pathogenic mycobacteria
have evolved to resist acidic stress, and potentially share similar mechanisms with their
environmental cousins (Kirschner et al, 1992; Kirschner et al, 1999).
Although Mycobacterium smegmatis has been found to have an acid tolerance system it is not
known if M. tuberculosis also possesses one. However, a large number of genes are upregulated
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phagosomes of macrophages many genes are upregulated, and when cocanamycinA is added
which interferes with the development of acidity, 80% of genes in M. tuberculosis that are
normally upregulated in the phagosomes fail to do so (Rohde et al; 2007). This is an indication
that acidity is one of the main environmental signals M. tuberculosis experiences in vivo.
A number of genes that are upregulated by acidic stress have been identified in previous
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involved in cell wall ultrastructure were induced (Fisher et al, 2002). The mymA operon was
induced in this study, and is under the control of VirS which is an AraC/XylS family tran‐
scription factor (Singh et al, 2005). The lipF promoter of M. tuberculosis is upregulated, but
requires a longer time frame (Saviola et al, 2001). It fails to be upregulated at 30 minutes, instead
needing more extended exposure to acidic stress of 1.5 hours. LipF is annotated to be an
esterase and may also function to alter the cell wall structure. LipF has been shown to be part
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tions. An energy source such as triacylglycerol may be needed to reanimate from dormancy
once stresses such as acidity are removed. Mutatagenesis studies also revealed genes involved
cell wall/cell envelope synthesis when mutated resulted in mycobacteria which were unable
to maintain neutral pH within their microbial cytoplasm in the presence of acidic stress (Vandal
et al, 2008; Vandal et al, 2009, Biswass et al, 2010).
The type VII secretion system, Esx-1, may also may be involved in response to acid stress
(Abdallah et al, 2007). The 6 kDa early secreted antigenic target (Esat-6) and the 10kDa cul‐
ture filtrate protein (CFP-10) are secreted by Esx-1. These two proteins form a heterodimer
that can dissociate at acidic pH. Esat-6 is capable of lysing membranes, and M. tuberculosis
has been identified to reside extraphagosomally in the cytoplasm of macrophages in some
cases.  In addition when the esx-1  gene was mutated it  could result  in an M. tuberculosis
strain that fails to escape from the phagosomal compartment into the cytoplasm (Simeone
et al, 2009). Thus Esat-6 may be involved in mycobacterial responses to acidity and adapta‐
tion to in vivo stressors.
7. Response to oxidative damage
Inside phagosomes of activated macrophages tubercle bacilli are exposed to reactive oxygen
intermediates. M. tuberculosis traffics to phagosomes, and a large number of genes are upre‐
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gulated by oxidative stress indicating this is an important stress in vivo (Wu et al, 2007). In
addition nutrients are limited in the phagosome which may cause M. tuberculosis to enter a
stationary phase of growth, which has been shown to induce internal oxidative damage. The
gene whiB1 is more active during stationary phase, and the protein produced by this gene has
been shown to reduce cellular disulphide bridges that may predominate during this adapta‐
tional phase (Garge et al, 2009).
Mycobacteria contain a unique substance, mycothiol, which combats oxidative stress. Other
bacterial species utilize glutathione which can also neutralize oxidative stress. Mycothiol
contains cysteine residues which are oxidized when that condition predominates thus forming
disulfide bonds, creating mycothione, and preventing other molecules in the mycobacterial
cell from becoming oxidized (Table 1.). Human cells produce glutathione to combat oxidative
damage, and glutathione is toxic to mycobacterial cells perhaps due to a redox imbalance
generated by this substance in the mycobacteria (Venketaraman et al, 2008; Connell et al,
2008)). Mycobacteria also contain other molecules to detoxify oxidative damage including
superoxide dismutase (SOD) and catalase (KatG) which can inactivate superoxide (Table 1.)
(Shi et al, 2008). SOD and KatG are upregulated early in infection indicating an increase in
oxidative damage due to superoxide. Oxidative damage is capable of harming DNA, and
histone like proteins (LSR2) can protect against damage by compacting DNA and acting as a
physical barrier. UvrB which repairs mycobacterial DNA damage also protects against
oxidative damage (Darwin and Nathan, 2005; Colangeli et al, 2009).
8. Heat shock
One of the hallmarks of tuberculosis is fever and night sweats in which body temperature
increases and is suboptimal for Mycobacterium tuberculosis replication and survival. This allows
the immune system a competitive edge over the invading microbes. Heat stress can cause
damage to M. tuberculosis by causing proteins to unfold which may then be degraded. In
response, M. tuberculosis can upregulate chaperonins which complex with unfolded proteins
and help them refold (Table 1.). The α-crystalline protein, or Acr-2, is activated by heat shock,
and has demonstrated chaperonin activity (Pang and Howard, 2007).
Many proteins that are upregulated in M. tuberculosis in vivo are heat shock proteins that have
chaperonine activity. While these proteins may benefit the organism by complexing with and
refolding heat damaged proteins, they are also recognized by the immune system. Both the
65Kd heat shock protein and the HSP70 protein can be found extracellularly to M. tuberculo‐
sis, and are potent stimulators of an inflammatory response (Anand et al, 2010).
9. Low iron
Normally iron taken up by intestinal epithelial cells and bound to transferrin circulates within
the body. This complex binds to cell surface receptors, and is internalized where it releases its
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iron to be bound by the host cellular factor ferritin. Infection and inflammation are natural
signals to the host to limit availability of iron. Proinflammatory cytokines stimulate hepcidin
production, decrease iron uptake from the gut, and inhibits the iron efflux protein ferroportin
(Johnson and Wessingling-Resnick, 2012). Inflammation thus inhibits iron uptake by the
intestinal epithelium thus preventing iron from being loaded onto transferrin. Interfering with
uptake limits iron availability in the host, and M. tuberculosis has been shown to be severely
growth restricted in a low iron environment. It has been demonstrated in African studies that
iron supplementation increases incidence of tuberculosis. Thus being anemic may be protec‐
tive against infectious processes. Within human macrophages, Nramp1 (natural resistance
associated macrophage protein) is produced and localizes to the phagosomal compartment
where it reduces iron within this site possibly by extrusion. This function confers resistance to
M. tuberculosis infections and mutations in the nramp1 gene can result in increased suscepti‐
bility to active disease due to M. tuberculosis infection (Johnson and Wessingling-Resnick,
2012).
Mycobacteria have a variety of systems which aid in the uptake of iron and the regulation
of iron responsive genes. As mycobacteria have been shown to be somewhat novel among
gram positive bacteria, they possess an outer mycolic acid based membrane, as well as an
inner membrane and periplasmic space. Porins in the outer membrane appear to transport
iron in the presence of high iron conditions (Jones and Niederweis, 2010). M. tuberculosis
under low iron conditions can produce the siderophore carboxymycobactin as well as my‐
cobactin (Table 1.) (Banerjee et al, 2011). These molecules bind with a higher affinity to iron
than the human host’s storage proteins and steal iron from the host. Mycobactin is present
within the  inner  membrane and thus  can only  bind iron imported into  the  periplasmic
space. Interestingly lipid membranes with associated mycobactins may diffuse out, travel
to lipid vesicles in the host cell, and sequester iron. These structures may recycle back to in‐
teract with the mycobacterium. Disruption of the genes responsible for production of my‐
cobactins  can  cause  these  mutant  mycobacteria  to  replicate  less  well  in  macrophages
(Banerjee et al, 2011). Carboxymycobactins are excreted possibly by the type VII secretion
or  ESX  system.  Externally  the  carboxymycobactins  bind  available  iron  from  transferrin
(Banerjee et  al,  2011).  Porins and also ABC transporters may allow import of  these iron
loaded carboxymycobactins (Banerjee et al, 2011). The host cell, in response to infection and
inflammation, produces siderocalins such as lipocalin-2 that can bind to and inactivate my‐
cobactin from M. tuberculosis thus interfering with mycobacterial iron acquisition (Johnson
and Wessingling-Resnick, 2012). In fact mice deleted for genes involved in production of
siderocalin are much more susceptible to mortality due to M. tuberculosis infection (Johnson
and Wessingling-Resnick, 2012). Inside the mycobacterial cell, iron is stored in bacterioferri‐
tin and a ferritin like protein. These proteins are required for replication in human macro‐
phages and guinea pigs, act to store iron, and also to limit excess iron in the cells that can
lead to iron mediated oxidative damage due to the Fenton reaction (Reddy et al, 2011).
Iron responsive genes in M. tuberculosis are controlled in part by the iron dependent regulator
IdeR. This protein can act both as an activator and a repressor depending on where it binds
within a mycobacterial promoter region (Manabe et al, 1999; Banerjee et al, 2011). Within
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and help them refold (Table 1.). The α-crystalline protein, or Acr-2, is activated by heat shock,
and has demonstrated chaperonin activity (Pang and Howard, 2007).
Many proteins that are upregulated in M. tuberculosis in vivo are heat shock proteins that have
chaperonine activity. While these proteins may benefit the organism by complexing with and
refolding heat damaged proteins, they are also recognized by the immune system. Both the
65Kd heat shock protein and the HSP70 protein can be found extracellularly to M. tuberculo‐
sis, and are potent stimulators of an inflammatory response (Anand et al, 2010).
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(Johnson and Wessingling-Resnick, 2012). Inflammation thus inhibits iron uptake by the
intestinal epithelium thus preventing iron from being loaded onto transferrin. Interfering with
uptake limits iron availability in the host, and M. tuberculosis has been shown to be severely
growth restricted in a low iron environment. It has been demonstrated in African studies that
iron supplementation increases incidence of tuberculosis. Thus being anemic may be protec‐
tive against infectious processes. Within human macrophages, Nramp1 (natural resistance
associated macrophage protein) is produced and localizes to the phagosomal compartment
where it reduces iron within this site possibly by extrusion. This function confers resistance to
M. tuberculosis infections and mutations in the nramp1 gene can result in increased suscepti‐
bility to active disease due to M. tuberculosis infection (Johnson and Wessingling-Resnick,
2012).
Mycobacteria have a variety of systems which aid in the uptake of iron and the regulation
of iron responsive genes. As mycobacteria have been shown to be somewhat novel among
gram positive bacteria, they possess an outer mycolic acid based membrane, as well as an
inner membrane and periplasmic space. Porins in the outer membrane appear to transport
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teract with the mycobacterium. Disruption of the genes responsible for production of my‐
cobactins  can  cause  these  mutant  mycobacteria  to  replicate  less  well  in  macrophages
(Banerjee et al, 2011). Carboxymycobactins are excreted possibly by the type VII secretion
or  ESX  system.  Externally  the  carboxymycobactins  bind  available  iron  from  transferrin
(Banerjee et  al,  2011).  Porins and also ABC transporters may allow import of  these iron
loaded carboxymycobactins (Banerjee et al, 2011). The host cell, in response to infection and
inflammation, produces siderocalins such as lipocalin-2 that can bind to and inactivate my‐
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and Wessingling-Resnick, 2012). Inside the mycobacterial cell, iron is stored in bacterioferri‐
tin and a ferritin like protein. These proteins are required for replication in human macro‐
phages and guinea pigs, act to store iron, and also to limit excess iron in the cells that can
lead to iron mediated oxidative damage due to the Fenton reaction (Reddy et al, 2011).
Iron responsive genes in M. tuberculosis are controlled in part by the iron dependent regulator
IdeR. This protein can act both as an activator and a repressor depending on where it binds
within a mycobacterial promoter region (Manabe et al, 1999; Banerjee et al, 2011). Within
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promoters of genes involved in mycobactin synthesis it acts as a repressor, inhibiting expres‐
sion of these genes at high iron concentrations. In promoters of iron storage proteins it acts as
an activator, stimulating expression of these genes at high iron concentrations and thus
avoiding iron stimulated oxidative damage.
10. Hypoxic growth
In vivo M. tuberculosis experiences low oxygen tension that may be encountered in the cen‐
ters of granulomas as previously described. Studies have shown that tuberculous granulo‐
mas  are  hypoxic  in  a  variety  of  animal  models  including  rabbits,  guinea  pigs,  and
nonhuman primates (Via et al, 2008). The response to low oxygen tension is biphasic. There
is an initial  response that predominates and is controlled by the two component system
DosS/DosT-DosR (Table 1.). This two component system upregulates genes that are known
to be part of the "dormancy regulon". DosR is the transcriptional regulator, and Dos T and
DosS are  the sensor kinases  that  respond to low oxygen tension as  well  as  nitric  oxide
(Park et al, 2003; Kumar et al, 2007). hspX ( acr, Rv2031c) is upregulated by low oxygen, is
regulated by DosR, and has chaperonin activity that may aid in refolding proteins which
are damaged by low oxygen tension (Vasudeva-Rao and McDonough, 2008; Florczyk et al,
2003). It is known that this protein is expressed in vivo as latently infected individuals pos‐
sess T-cells that are reactive to the HspX protein (Geluk et al, 2007). Interestingly one half
of the genes in the DosR regulon return to their baseline level after 24 hours. After this ini‐
tial 24 hour period other regulators play a role in hypoxic responses such as sigE and sigC
(Table 1.). An enduring hypoxic response begins after the initial response, and this may be
important for M. tuberculosis to enter and stay in a dormant state (Rustad et al, 2008).
11. Toxin-antitoxin systems
Interestingly there are many toxin-antitoxin systems within the M. tuberculosis genome. These
systems seem to provide a mechanism by which bacteria can alter growth rate rapidly,
potentially in response to environmental stressors. The toxin is not a protein secreted and
targeted against the human host, but targeted against mycobacterial cellular components. The
toxin is a stable protein which may be complexed with an antitoxin forming a toxin-antitoxin
pair. The antitoxin is relatively unstable and environmental stressors can inactivate it causing
release of a free toxin. The toxin is then available to interact with cellular components, and
may function to cleave mRNA thus inhibiting subsequent translation and rapidly halting
growth of the bacterium. As static bacteria are more resistant to environmental stressors and
antibiotics, this system may allow M. tuberculosis to survive in the face of external stressors.
M. tuberculosis possesses 88 toxin-antitoxin systems and four of these have been shown to be
activated by phagocytosis of bacilli, by macrophages, or hypoxia (Table 1.). It appears that the
toxin in these systems acts by cleaving mRNA (Rapage et al, 2009).
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Table 1. Mycobacterial responses to in vivo stressors and conditions.
12. Two component systems
Two components systems are common in many bacteria. These systems are comprised of a
sensor kinase which phosphorylates the response regulator as a result of an environmental
signal, which is often a stress. The sensor kinases are trans membrane proteins which are
embedded into membranes. They sense external stresses and transmit these signals internally
into the bacterial cell by phosphorylating a response regulator that binds to its cognate
promoter DNA, and regulates transcription. The mycobacterial genome contains 11 two
component systems (Hett and Rubin, 2008). The large number of these systems in the myco‐
bacterial coding regions is likely the result of evolution to accommodate bacterial responses
to diverse stresses.
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DosS/DosT-DosR was previously described, and responds to initial hypoxic stress (Table 1.)
(Park et al, 2003). Some of the genes controlled by the transcriptional regulator DosR are
upregulated by hypoxic stress, and are also part of the transcriptional regulator PhoP regulon,
a member of the PhoP/R two component system. While it is unknown what environmental
signal PhoP or the sensor kinase PhoR are responding to, genes controlled by PhoP either
directly or indirectly are upregulated by such stresses as acidity and low oxygen (Table 1.)
(Gonzalo-Asensio et al, 2008).
13. Sigma factors
Mycobacterial RNA polymerase catalyzes RNA synthesis from specific promoter sequences.
This RNA polymerase is composed of subunits that comprise the core holoenzyme, and
include two α subunits, a β, a β' and a ω subunit. The core enzyme, however, cannot target
specific promoter sequences. A sigma factor is required for this function, and can bind and
recognize specific -10 and -35 promoter sequences. As the mycobacterial genome possesses
many different sigma factors, these RNA polymerase components can recognize diverse
mycobacterial promoter sequences to activate a whole class of genes. This activity is in addition
to specific transcription factors which bind to promoters, regulate transcription, and are not
part of the RNA polymerase enzyme.
The mycobacterial genome possesses many different sigma factors that belong to different
categories. The M. tuberculosis σA is responsible for regulating housekeeping genes, and is also
an essential gene for mycobacterial growth in vitro and in vivo. While the sigma factor σB is
highly similar to σA, it is nonessential and is induced by a variety of stresses including oxidative
stress, heat shock, cold shock, stationary phase, and low aeration (Lee et al, 2008). There are a
number of sigma factors designated to have extracellular function, and some respond to
environmental stresses and are involved in the synthesis of the mycobacterial envelope. These
sigma factors are SigC, SigE, SigF, SigG, SigH, SigI, SigJ, SigK, SigL, and SigM. One sigma
factor that is known to respond to nutrient starvation is SigF. The sigma factor SigE is involved
in response to heat shock and SDS exposure (Manganelli et al, 2004). Both SigJ and SigF are
induced in response to antibiotic exposure (Manganelli et al, 2004). The sigma factor SigH also
responds to heat shock and oxidative stress (Manganelli et al, 2004). Thus the use of sigma
factors by the mycobacterial cell is a manner in which "master regulators" can control whole
classes of genes to rapidly facilitate gene regulation in response to specific environmental
stresses (Table 1.).
14. Summary
As mycobacteria invade their human hosts they must respond to a plethora of stresses many
of which are generated by the host's immune system. Under this selective pressure, M.
tuberculosis has evolved mechanisms to combat the toxic insults of the host. Although myco‐
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bacteria are inherently resistant to environmental stresses due to their thick waxy cell envelope,
upregulation of genes further reinforce this defense. In addition there are proteins upregulated
by environmental stressors which can detoxify the mycobacterial cell as is the case of acidic
stress and upregulation of ammonia extruding pumps that neutralize acidic pH of the
macrophage phagosome. Thus inducible systems allow M. tuberculosis to resist environmental
stresses and persist in the human body to cause active or latent disease.
Understanding the specific steps in infection, the stresses associated with each step, and the
mycobacterial response may be of clinical relevance. The knowledge that oxidative stress and
acidic stress may predominate as adaptive immunity makes the host’s macrophages more
activated, may lead to the development of chemotherapeutic agents that target mycobacterial
components produced by these stressors during this infective stage. In addition, the knowl‐
edge that mycobacteria may utilize toxin-antitoxin systems to slow their growth and to
enhance their innate antibiotic resistance may spur the development of therapies that target
these systems which could be used in conjunction with traditional antibiotic treatments.
Chemotherapeutic agents given to decrease activity of triacylglycerol synthase may decrease
infectivity of sputum positive individuals by inhibiting lipid body production in the bacilli
while antibiotic treatment lags in its sterilizing activity. Ultimately treatments may be devel‐
oped which target inducible systems upregulated by stresses, and may interfere with myco‐
bacterial responses to these stressors. By thwarting these adaptive responses potentially with
chemotherapeutic agents, mycobacteria may be rendered more fragile and susceptible to the
host's immune system. In addition a greater understanding of how M. tuberculosis enters a
latent state of persistence could lead to treatments that prevent this microbe from reactivating
from the dormant state, or from becoming dormant to begin with. Greater understanding of
M. tuberculosis responses to in vivo growth will hopefully lead to the development of technol‐
ogies that lessen M. tuberculosis' global impact on human health.
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1. Introduction
The microbe Mycobacterium tuberculosis (MTB) is an ancient cohabiter with humans, infecting al‐
most 3 billion people worldwide, 10% of them developing clinical disease. The 20th century
dream of eradicating the global scourge of tuberculosis (TB) evaporated with the failure of the
old BCG vaccine to protect the populations at greatest risk, low compliance at following the
complicated and lengthy treatment in countries with limited resources, which was followed by
the spread of multiple-drug resistant (MDR) strains. Actually the situation has worsened with a
peak of 9.4 millions of new clinical cases in 2009 and 1.7 million deaths/year [1,2,3].
However, it is intriguing to observe that the incidence and morbidity of the disease varies great‐
ly in different regions of the globe, being highest in Africa and Asia, as well as the response to
BCG vaccination [1,4]. That, in spite of the fact that there are no structurally variable strains of
MTB, therefore all have a similar virulence capacity. One important factor is the introduction of
the human immunodeficiency virus (HIV) into areas and populations already having a high TB
incidence [5], the resulting double infections having a disastrous effect. This is especially promi‐
nent in sub-Saharan Africa. But that factor alone can not explain the global epidemiological var‐
iability in the disease. Also, why only one in ten carriers of the microbe become clinically sick?
In order to address these questions, in the present chapter we will try to delve into the intri‐
cacies of the human immune response to MTB infection and to explore possible differences
in the genetic regulation of the host immune responses in various human populations.
2. The encounter of Mtb with the innate immune system
Most human infections with MTB occur through inhaled carrier droplets into the lower
airways. There the microbe encounters the alveolar macrophage (AMac) and submucosal
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dendritic cell (DC). The outcome of the ensuing battle will determine whether the infection
will remain locally limited within the engulfing cells of the innate immune system, or will
continue to spread, causing the individual to become a clinically active TB patient [1,6,7,8].
During the first contact, the AMac recognizes the microbe through pattern recognition
receptors (PRRs), which sense microbial biochemical components, such as outer coat manno‐
sylated lipoarabinomannan (ManLam), trehalose dimycolate and N-glycolymuramyl dipep‐
tide. These molecules act as pathogen-associated molecular patterns (PAMPs), which trigger
an intracellular signaling cascade in the AMac, which leads to a phagocytic activity, which, if
successful, will result into the complete engulfing of the microbe into cytosolic vesicles- the
phagolysozomes and secretion of pro-inflammatory cytokines, such as tumor-necrosis factor
alpha (TNFα). ManLam also binds directly to mannose receptors on macrophages and DCs.
The best studied PRRs are Toll-like receptors (TLRs) [6,9,10], of which 10 have been identified
in humans. TLR- 2 and TLR-4 recognize bacterial products [9,11], TLR-2 having a major role
in recognizing MTB in the lung. All contain an intracellular TIR domain, the activation of which
initiates a signaling cascade via adapter proteins such as MyD88, interferon-inducing TRIF
and TRIF-related adapter molecule TRAM, which results in the recruitment of interleu‐
kin-1(IL-1) receptor-associated kinase (IRAK) 4, which phosphorylates IRAK-1. The latter
binds to TNFα receptor-associated factor (TRAF) 6, leading to kinase-dependent IkBα
phosphorylation, the degradation of which leads to the activation of nuclear NF-kB, which is
the main nuclear activator of proinflammatory cytokines. Another intracellular PRR is
nucleotide-binding oligomerization domain 2 (NOD2), which binds bacterial cell-wall
muramyl-dipeptide, eliciting secretion of TNFα, IL-1β, IL-6 and bacteridal LL-37 [12,13]
Neutrophils also play a defensive role, not only as first-line non-specific phagocytes, but also
by secreting anti-bacterial proteins, mainly the cathelicidin LL-37 [1,14]. Neutrophils loaded
by phagocytized bacteria become apoptotic, thereby eliciting macrophage activation [15].
NK cells, which are large granular circulating lymphocytes, are attracted to the sites of bacterial
infections, where they specialize in recognizing and destroying infected host cells. During this
process they secrete interferon gamma (IFNγ), which activates macrophages, inducing them
to secrete the cytokines IL-12, IL-15 and IL-18, which activate CD8+T-cells, thus forming the
link to the adaptive immune system [7,16]
The complement is the humoral arm of the innate immune system. It has been shown that M.
bovis BCG may activate the three pathways of complement: the classical pathway by binding
to the C1q protein, the lectin pathway by binding to the bacterial cell surface mannose-binding
lectin (MBL) or L-ficolin and the alternate pathway through the deposition of C3b on the
bacterial surface. Mtb can activate the classical and alternate pathways by binding C3. This
enables complement to perform its major functions-microbial opsonization, microbial cell lysis
through the formation of the attack complex and leukocyte recruitment by eliciting chemokine
secretion [7,17].
Another recently discovered anti-microbial mechanism of phagocytic cells is the use of vital
transition metals, such as iron, zinc and copper, to poison intracellular microorganisms.
However, mycobacteria have developed a resistance mechanism to such intoxication [18,19].
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This contrasts with the function of the phagosomal metal transporter natural resistance-
associated membrane protein (NRAMP) 1 to deprive the microorganisms from essential
nutrients, such as iron and manganese [20]. Such duality existing in the same cell is of interest.
Virulent Mtbs have acquired the capability to dampen the activity of NF-Kb by some of their
antigens [6,7], such as ESAT-6 and ManLam. The latter also inhibits the secretion of IL-12, an
essential cytokine in the anti-MTB inflammatory response. ESAT-6 downregulates MyD88-
IRAK 4 interaction, thereby also interfering with TLR signaling to NFkB. A third antigen-
CFP-10 markedly reduces nitric oxide (NO) and reactive-oxygen species (ROS) production by
the macrophages, thereby inhibiting their non-specific killing ability. The microbe may also
regulate macrophage apoptosis to its advantage and to inhibit IFNγ- mediated macrophage
activation [7]. ESX is a recently discovered protein transport system through the outer
membrane of the microbe, which is essential for its survival. It has been demonstrated, in an
experimental model, that ESX-5 may modulate macrophage reactivity by dampening the
inflammasome activation [21]. These mechanisms enable the microbe to survive in the
macrophage phagosome in a balance which is precarious to the host. In addition Mtb may
escape the phagolysozome into the cytosol by damaging its membrane. Most recently it has
been described that the microbe may secrete toxins, such as the newly discovered MtpA
protein, through its outer membrane into the macrophage cytosol, which may cause the death
of the later by cell necrosis [22].
Vitamin D seems also to play an important role in the microbe-host pull-of-arms [23]. It may
modulate the inflammatory effect of some metalloproteinases (MMPs) in the lung [24] and
Vitamin D supplementation has hastened bacterial eradication in pulmonary tuberculosis in
a clinical trial [25].
Thus, the encounter between MTB and the various components of the innate immune system
induce a complicated and sophisticated series of host responses and counter responses by the
microbe. The later is one of the most ancient human infections, carried by our ancestors since
they fanned-out from Africa across the globe, therefore enabling it to adapt to the human
immune response (26-Cole S, Tuberculosis in time and space, Econference).
However, the next long-term phase of the encounter is played by the activation of the adaptive
immune system, as described in the next section.
3. The role of adaptive immunity in the outcome of the Infection
In the previous section the importance of the host innate immune response in the encounter
with MTB was described. However, it is generally accepted that the long-term outcome of the
primary infection is determined by the effective mobilization of the adaptive immune re‐
sponse. Active TB patients, as well as latently infected carriers, do not suffer from a general
innate or adaptive immune defect. On the contrary, ex-vivo studies of their immunocyte
function demonstrate increased lymphocyte proliferation and the secretion of numerous
cytokines [27]. Thus the disease, in people generally healthy, is a result of a very specific
immune failure in face of MTB, or other mycobacteria.
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will remain locally limited within the engulfing cells of the innate immune system, or will
continue to spread, causing the individual to become a clinically active TB patient [1,6,7,8].
During the first contact, the AMac recognizes the microbe through pattern recognition
receptors (PRRs), which sense microbial biochemical components, such as outer coat manno‐
sylated lipoarabinomannan (ManLam), trehalose dimycolate and N-glycolymuramyl dipep‐
tide. These molecules act as pathogen-associated molecular patterns (PAMPs), which trigger
an intracellular signaling cascade in the AMac, which leads to a phagocytic activity, which, if
successful, will result into the complete engulfing of the microbe into cytosolic vesicles- the
phagolysozomes and secretion of pro-inflammatory cytokines, such as tumor-necrosis factor
alpha (TNFα). ManLam also binds directly to mannose receptors on macrophages and DCs.
The best studied PRRs are Toll-like receptors (TLRs) [6,9,10], of which 10 have been identified
in humans. TLR- 2 and TLR-4 recognize bacterial products [9,11], TLR-2 having a major role
in recognizing MTB in the lung. All contain an intracellular TIR domain, the activation of which
initiates a signaling cascade via adapter proteins such as MyD88, interferon-inducing TRIF
and TRIF-related adapter molecule TRAM, which results in the recruitment of interleu‐
kin-1(IL-1) receptor-associated kinase (IRAK) 4, which phosphorylates IRAK-1. The latter
binds to TNFα receptor-associated factor (TRAF) 6, leading to kinase-dependent IkBα
phosphorylation, the degradation of which leads to the activation of nuclear NF-kB, which is
the main nuclear activator of proinflammatory cytokines. Another intracellular PRR is
nucleotide-binding oligomerization domain 2 (NOD2), which binds bacterial cell-wall
muramyl-dipeptide, eliciting secretion of TNFα, IL-1β, IL-6 and bacteridal LL-37 [12,13]
Neutrophils also play a defensive role, not only as first-line non-specific phagocytes, but also
by secreting anti-bacterial proteins, mainly the cathelicidin LL-37 [1,14]. Neutrophils loaded
by phagocytized bacteria become apoptotic, thereby eliciting macrophage activation [15].
NK cells, which are large granular circulating lymphocytes, are attracted to the sites of bacterial
infections, where they specialize in recognizing and destroying infected host cells. During this
process they secrete interferon gamma (IFNγ), which activates macrophages, inducing them
to secrete the cytokines IL-12, IL-15 and IL-18, which activate CD8+T-cells, thus forming the
link to the adaptive immune system [7,16]
The complement is the humoral arm of the innate immune system. It has been shown that M.
bovis BCG may activate the three pathways of complement: the classical pathway by binding
to the C1q protein, the lectin pathway by binding to the bacterial cell surface mannose-binding
lectin (MBL) or L-ficolin and the alternate pathway through the deposition of C3b on the
bacterial surface. Mtb can activate the classical and alternate pathways by binding C3. This
enables complement to perform its major functions-microbial opsonization, microbial cell lysis
through the formation of the attack complex and leukocyte recruitment by eliciting chemokine
secretion [7,17].
Another recently discovered anti-microbial mechanism of phagocytic cells is the use of vital
transition metals, such as iron, zinc and copper, to poison intracellular microorganisms.
However, mycobacteria have developed a resistance mechanism to such intoxication [18,19].
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This contrasts with the function of the phagosomal metal transporter natural resistance-
associated membrane protein (NRAMP) 1 to deprive the microorganisms from essential
nutrients, such as iron and manganese [20]. Such duality existing in the same cell is of interest.
Virulent Mtbs have acquired the capability to dampen the activity of NF-Kb by some of their
antigens [6,7], such as ESAT-6 and ManLam. The latter also inhibits the secretion of IL-12, an
essential cytokine in the anti-MTB inflammatory response. ESAT-6 downregulates MyD88-
IRAK 4 interaction, thereby also interfering with TLR signaling to NFkB. A third antigen-
CFP-10 markedly reduces nitric oxide (NO) and reactive-oxygen species (ROS) production by
the macrophages, thereby inhibiting their non-specific killing ability. The microbe may also
regulate macrophage apoptosis to its advantage and to inhibit IFNγ- mediated macrophage
activation [7]. ESX is a recently discovered protein transport system through the outer
membrane of the microbe, which is essential for its survival. It has been demonstrated, in an
experimental model, that ESX-5 may modulate macrophage reactivity by dampening the
inflammasome activation [21]. These mechanisms enable the microbe to survive in the
macrophage phagosome in a balance which is precarious to the host. In addition Mtb may
escape the phagolysozome into the cytosol by damaging its membrane. Most recently it has
been described that the microbe may secrete toxins, such as the newly discovered MtpA
protein, through its outer membrane into the macrophage cytosol, which may cause the death
of the later by cell necrosis [22].
Vitamin D seems also to play an important role in the microbe-host pull-of-arms [23]. It may
modulate the inflammatory effect of some metalloproteinases (MMPs) in the lung [24] and
Vitamin D supplementation has hastened bacterial eradication in pulmonary tuberculosis in
a clinical trial [25].
Thus, the encounter between MTB and the various components of the innate immune system
induce a complicated and sophisticated series of host responses and counter responses by the
microbe. The later is one of the most ancient human infections, carried by our ancestors since
they fanned-out from Africa across the globe, therefore enabling it to adapt to the human
immune response (26-Cole S, Tuberculosis in time and space, Econference).
However, the next long-term phase of the encounter is played by the activation of the adaptive
immune system, as described in the next section.
3. The role of adaptive immunity in the outcome of the Infection
In the previous section the importance of the host innate immune response in the encounter
with MTB was described. However, it is generally accepted that the long-term outcome of the
primary infection is determined by the effective mobilization of the adaptive immune re‐
sponse. Active TB patients, as well as latently infected carriers, do not suffer from a general
innate or adaptive immune defect. On the contrary, ex-vivo studies of their immunocyte
function demonstrate increased lymphocyte proliferation and the secretion of numerous
cytokines [27]. Thus the disease, in people generally healthy, is a result of a very specific
immune failure in face of MTB, or other mycobacteria.
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It was thought that the CD4+T cell is the omnipotent determinant of the adaptive immune
response in TB. However, lately it became clear that more T-cell subsets, including CD8+ and
TH17 cells and even B cells participate in the process [1,7,28]. The induction phase seems to be
delayed relatively to the response to more common pathogens. It is initiated by signaling and
presentation of the microbial peptides by the macrophages and DCs to the CD4+ cells via MHC
class II molecules, while mycobacterial membranal lipids are presented through MHC-I
molecules of the CD-1 family [29]. The presentation of mycobacterial antigens occurs within
the draining lung lymph-nodes to which the macrophages have migrated, followed by the
activation of CD4+ and other T cells. These T cells use various receptors, such as TLRs, NOD-
like receptors and C-type lectins, for this purpose. The peptides considered as potentially
immunodominant are the already mentioned ESAT-6 and CFP10 and others, such as Rv2031c,
Rv2654c and Rv1038c. The T cell response to these antigens is not homogenous, various T cell
epitopes being engaged during the different phases of the infection [30]. Other Rv proteins are
binding to T cells mainly during the latent phase [31]. T cell activation, by the recognition of
these antigens in the initiating phase, results in the secretion of numerous cytokines, mostly
proinflammatory, such as IL-1β, IL-6, IL-21 and IL-12p40. The later activates CD4+TH1 cells,
but p40 is also a subunit of IL-23, which induces the TH17 cell lineage, which secretes IL-17,
IL-21 and IL-22. These cytokines are considered to be essential for anti-microbial protection
and IL-17 is thought to have a major role in granuloma formation [32], as well as TNFα, which
is also secreted by CD4+ cells and promotes intra-phagosomal killing of the bacteria in
macrophages. During an acute mycobacterial infection γδ T cells secrete much IL-17 [33],
which also promotes the secretion of IL-12, thus a self-enhancing inflammatory loop is being
formed. This is balanced by the secretion of TGFβ, the role of which is to dampen an over‐
reactive inflammatory response, partly so by inducing T-reg cells. The later may inhibit TH1
responses, thus potentially facilitating mycobacterial replication within macrophages [34]. A
high incidence of T reg Foxp3 cells has been found in extra-pulmonary TB [35].
The activated T cells undergo clonal expansion and migrate out of the lymph nodes into
the site of the infection in the lung, as effector T cells. This process is driven by chemo‐
kines, secreted by various inflammatory cells. Upon arrival to the battle ground they se‐
crete interferon gamma (IFNγ), which is a key cytokine in the ensuing confrontation, by
further  activating  the  microbicidal  machinery  of  the  macrophage  and  causing  it  to  se‐
crete IL-18, amongst other cytokines, which seems to be part of the protective TH1 type
response.  IFNγ  also  induces  the  production  of  toxic  NO  via  inducible  NO  synthase
(iNOS).  Casanova  et  al  [36,37,38]  have  described  in  detail  the  importance  of  the  IFNγ-
IL-12 cytokines loop, including their receptors, for TB immunity. Furthermore they have
described rare Mendelian genetic defects in this system, resulting in susceptibility to seri‐
ous mycobacterial and sometimes salmonellar infections.
CD8+ T cells also participate in the immune reaction, as they have been found in the me‐
diastinal lymph nodes, mixed with CD4+ cells and later at the infection site in the lungs.
Most  evidence  about  them has  been  collected  in  mouse  and  primate  models  and  their
role in human infections has not been fully elucidated [7].It has been demonstrated in vi‐
tro that CD8+ cells recognize bacterial peptides and lipids through the MHC-I CD-1 mol‐
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ecules,  which induce a cytotoxic  response toward the bacteria  and to the phagocytes in
which they reside. They also secrete IFNγ and TNFα. Humans with latent TB develop a
high level of mycobacteria-specific CD8+ T cells [39].
From all the above it is clear that the dominant protective response in TB is Th1 type. However
in multiple-drug resistant (MDR) [40] and in young children [41] there is a skewing towards
a Th2 type response, with greater secretion of IL-4. This may explain why children tend to
develop pulmonary milliary and extrapulmonary disease. In addition it seems that the disease
in children tends to have a Mendelian heritability of specific defects, while in adults there is
no such background, rather some discrete polymorphisms may be found in different popula‐
tions, such as in the natural resistance-associated macrophage protein 1 (NRAMP1) [42].
For a long time it was generally accepted that B-cells and specific antibodies have no protective
role against TB. However monoclonal antibodies against some mycobacterial antigens have
shown a clear protective effect in mice [43]. It has been postulated that the unique phenomenon
of BCG protection against pediatric TB meningitis may be due in part to specific antibodies.
Presently the exact role of B-cells in human TB remains to be determined.
Similarly to the innate immune system, mycobacteria have also developed evasion tactics from
the adaptive immune system [44]. They may interfere with the antigen presentation process,
promote the secretion of IL-10 by T cells, thereby polarizing them toward a TH2 type response,
in which the essential IFNγ secretion is inhibited [7]. They may also attract more T-reg cells to
the infection site, thereby further dampening the protective inflammatory response. It was
demonstrated in a tuberculosis rabbit model, that mycobacteria may delay the macrophage
and T-cells activation process, thereby enabling them to form a permanent infection and
damaging pulmonary tissue [45]. More specifically, the bacteria possess a set of genes- rpf,
which code for the regulatory Rpf proteins, which are believed to be responsible for activating
bacteria from a dormant state in latency. In addition the bacteria have also a set of “anti-
dormancy genes”-DosR, which induce bacterial growth, when appropriate [46].
4. The tuberculous granuloma
The formation of granuloma is the host’s containment effort in response to an infection which
he can not eradicate. In most cases it results in a state of latency, with dormant, but viable,
bacteria residing in it [7, 45, 47]. Therefore the granuloma benefits also the bacteria, who may
emerge from dormancy, proliferate again and cause an active disease, if the host’s immune
system is weakened due to any reason. HIV coinfection, with its damage to T cells, has become
the most prominent example of this situation.
The granuloma contains a nucleus of necrotic lung tissue and intraphagosomal bacteria-
containing macrophages, surrounded by fibroblasts, DCs, neutrophils, B cells and various
subsets of T cells, all of those secreting cytokines, mainly IFNγ and TNFα, and chemokines
which ensure a continuous mobilization of granulocytes to the granuloma. TNFα activates
adhesion molecules on the immunocytes [48]. Thus the granuloma is a dynamic and continu‐
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IL-12 cytokines loop, including their receptors, for TB immunity. Furthermore they have
described rare Mendelian genetic defects in this system, resulting in susceptibility to seri‐
ous mycobacterial and sometimes salmonellar infections.
CD8+ T cells also participate in the immune reaction, as they have been found in the me‐
diastinal lymph nodes, mixed with CD4+ cells and later at the infection site in the lungs.
Most  evidence  about  them has  been  collected  in  mouse  and  primate  models  and  their
role in human infections has not been fully elucidated [7].It has been demonstrated in vi‐
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From all the above it is clear that the dominant protective response in TB is Th1 type. However
in multiple-drug resistant (MDR) [40] and in young children [41] there is a skewing towards
a Th2 type response, with greater secretion of IL-4. This may explain why children tend to
develop pulmonary milliary and extrapulmonary disease. In addition it seems that the disease
in children tends to have a Mendelian heritability of specific defects, while in adults there is
no such background, rather some discrete polymorphisms may be found in different popula‐
tions, such as in the natural resistance-associated macrophage protein 1 (NRAMP1) [42].
For a long time it was generally accepted that B-cells and specific antibodies have no protective
role against TB. However monoclonal antibodies against some mycobacterial antigens have
shown a clear protective effect in mice [43]. It has been postulated that the unique phenomenon
of BCG protection against pediatric TB meningitis may be due in part to specific antibodies.
Presently the exact role of B-cells in human TB remains to be determined.
Similarly to the innate immune system, mycobacteria have also developed evasion tactics from
the adaptive immune system [44]. They may interfere with the antigen presentation process,
promote the secretion of IL-10 by T cells, thereby polarizing them toward a TH2 type response,
in which the essential IFNγ secretion is inhibited [7]. They may also attract more T-reg cells to
the infection site, thereby further dampening the protective inflammatory response. It was
demonstrated in a tuberculosis rabbit model, that mycobacteria may delay the macrophage
and T-cells activation process, thereby enabling them to form a permanent infection and
damaging pulmonary tissue [45]. More specifically, the bacteria possess a set of genes- rpf,
which code for the regulatory Rpf proteins, which are believed to be responsible for activating
bacteria from a dormant state in latency. In addition the bacteria have also a set of “anti-
dormancy genes”-DosR, which induce bacterial growth, when appropriate [46].
4. The tuberculous granuloma
The formation of granuloma is the host’s containment effort in response to an infection which
he can not eradicate. In most cases it results in a state of latency, with dormant, but viable,
bacteria residing in it [7, 45, 47]. Therefore the granuloma benefits also the bacteria, who may
emerge from dormancy, proliferate again and cause an active disease, if the host’s immune
system is weakened due to any reason. HIV coinfection, with its damage to T cells, has become
the most prominent example of this situation.
The granuloma contains a nucleus of necrotic lung tissue and intraphagosomal bacteria-
containing macrophages, surrounded by fibroblasts, DCs, neutrophils, B cells and various
subsets of T cells, all of those secreting cytokines, mainly IFNγ and TNFα, and chemokines
which ensure a continuous mobilization of granulocytes to the granuloma. TNFα activates
adhesion molecules on the immunocytes [48]. Thus the granuloma is a dynamic and continu‐
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ous battlefield balancing the bacteria against the immune system. Occasionally, as described
before, the bacteria may damage the phagosomal membrane and escape, inducing an apoptotic
or necrotic death of the macrophage. This enables the bacteria to proliferate with enhancement
of tissue damaging inflammation, which may result in cavity formation.
5. Shall we ever have an effective immunotherapy or anti-TB vaccine?
Application of highly effective vaccines across the globe is the only way to control and arrest
the spread of infectious diseases. So far BCG is the only available anti-TB vaccine. It is one of
the oldest vaccines and has remained unchanged for a long time. It does confer reasonable
protection to infants at risk and prevents pediatric TB meningitis. However it is ineffective for
protection of large adult populations and has failed to prevent the rise in new infections and
active disease patients and especially in MDR and extreme drug resistant (XDR) cases [49].
Therefore many efforts have been invested in trying many forms of various extracts of other
mycobacteria, such as M. vaccae, which may be considered as immunostimulants of TH1
responses or a kind of vaccines. Most have resulted in a transient enhancement of the anti-
tuberculous inflammatory response, sometimes with severe side-effects, but without long-
term clinical benefit [50]. How can this be explained?
The main reason is  that  decades of  research have not,  as  yet,  demonstrated a universal
clearly  immunodominant  and protective  T  cell  epitope  to  one of  the  bacterial  antigens-
mainly to cell-wall peptides, lipids or glycolipids. An exception may be the 85A and 85B
antigens,  which  may  be  suitable  candidates  for  a  widely  used  anti-tuberculous  vaccine
under various constructs [51]. They show enhancement of TH1-type responses, but long-
term clinical results are still unknown. Additional vaccines are under trials, such as MTB
subunit and DNA preparations [52].
In addition there is the problem in the variability of the host immunogenetic response, both to
BCG and to MTB [53]. Therefore various research projects are trying to identify, already
mentioned, polymorphisms in immune-associated and other genes, which may increase or
decrease the susceptibility to TB, such as the one which has been recently identified in a
Moroccan population [54] and another one in a Chinese ethnic group [55]. This subject lies
outside of the scope of this chapter, but it may lead to a better understanding of the processes
determining the fate of a MTB infection and assist in designing better vaccines, although they
may need to be population-targeted.
6. Summary
It has been attempted, in the present chapter, to describe in some detail the arms race between
MTB and its ancient human host, who uses the full scope of his sophisticated innate and adap‐
tive immune mechanisms to placate the enemy. The bacteria, which succeed to break the physi‐
cal barriers in the respiratory tract and reach the lung, are immediately surrounded by residing
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DCs and AMa, which recognize the bacterial PAMPs with their PRRs, such as surface TLRs.
This recognition triggers DC and macrophage activation, which results in the phagocytosis and
internalization of the bacteria in the phagolysosome, where they are submitted to toxic lysis.
Meanwhile the macrophages emigrate to the mediastinal lymph nodes, where the bacterial lip‐
id and peptide molecules are presented to CD4+ and CD8+ T cells via MHC-I and MHC-II, caus‐
ing T cell activation and clonal proliferation. The later return to the battlefield at the site of the
lung infection and try to complete bacterial elimination, by intensifying local inflammation. To
achieve that, the T cells and the macrophages secrete a series of cytokines, such as IFNγ, IL-12
and TNFα. Secreted chemokines attract more inflammatory cells, such as neutrophils.
Nevertheless, 90% of infected persons, who remain clinically asymptomatic, enter the stage of
latency, in which they continue to harbor dormant, albeit viable, bacteria in their macrophages
and 10% develop active clinical disease. This is due to numerous evasion tactics from the
immune system, that MTB has developed during its long cohabitation with the human host.
The bacterium may damage the phagosomal membrane and escape into the macrophage
cytosol, inducing necrotic cell death. It may interfere with the signaling to T cells via MHC
molecules, downregulate the secretion of IFNγ, promote the secretion of IL-10 and the activity
of CD4+Foxp3 T reg cells, thus dampening the protective inflammatory response. A hallmark
of the latency stage is granuloma formation, which is a complex structure, containing a core
of dormant bacteria in necrotic tissue, surrounded by neutrophils, macrophages, DCs and T
cells. This precarious balance may be easily disrupted, if, for whatever reason, immune
surveillance is weakened, causing bacterial breakthrough and clinical relapse.
So far, BCG is the only antituberculous vaccine widely available, which does confer a measure
of protection in children, but failed to arrest the spread of the infection in adult populations.
Many centers around the world are trying to identify immunodominant bacterial epitopes,
which could form the basis of a universal efficacious vaccine. So far, the 85A and 85B antigens,
in various constructs, seem to be presently the most promising, at least in animal models and
limited clinical trials. In addition, since the beginning of the 20th century, many mycobacterial
formulations and lately also cytokines, have been tried as specific immune stimulants. In most
cases they did induce generalized inflammation with significant side-effects, but with little
clinical benefit. However, recent technological developments, such as recombinant prepara‐
tions and DNA extracts, may obtain better results. To those have to be added numerous
projects trying to unravel the immunogenetic susceptibility or resistance factors.
One may estimate that within a decade, or so, better anti-tuberculous vaccines and treatments
will be developed, possibly targeted to specific populations.
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1. Introduction
M. tuberculosis and M. leprae are intracellular pathogens. M. tuberculosis can survive up to
decades in a phenotypically non-replicating dormant state, primarily in hypoxic granulomas
in the lung [1]. The otherwise drug-susceptible dormant mycobacteria show the remarkable
property to develop drug resistance within the granulomas of the host. These nonreplicative
drug-resistant bacteria within the host´s tissues are called persisters [2].
Mycobacteria have outstanding mechanisms to escape from elimination and have a high
degree of intrinsic resistance to most antibiotics, chemotherapeutic agents and immune
eradication [3,4]. One major obstacle for host defence mechanisms and therapeutic interven‐
tion is the robust, mycolic acid-rich cell wall, which is unique among prokaryotes [3,5]. In the
last years it has become apparent that mycobacteria induce the accumulation of lipids in the
host cells and use them as energy and carbon source. This strategy is regarded as another
crucial factor for the long term-survival of M. tuberculosis and M. leprae in the host. Most
mycobacteria have the ability to synthesize lipid bodies as reservoirs for fatty acids. The lipid
droplet- containing macrophages are called “foamy macrophages” and are the hallmark of M.
tuberculosis and M. leprae infection.
M. leprae is the causative agent of leprosy. Leprosy is a chronic infectious disease caused by
the obligate intracellular bacterium Mycobacterium leprae and is a major source of morbidity in
developing countries [6,7]. Leprosy patients show two major manifestations of the disease,
known as as lepromatous leprosy (LL), and tuberculoid leprosy (TT) [6]. TT is observed in
patients with good T-cell mediated (Th1) immunity and is characterized by granuloma
formation and death of Schwann cells (Scs) leading to myelin degradation and nerve destruc‐
tion [8,9]. Patients with poor T-cell mediated immunity show the lepromatous type leprosy
(LL), which leads to a high bacterial load inside host cells specially in Schwann cells and
macrophages [8,10-12]. For both forms of leprosy damage of the nerves is observed [12].
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1. Introduction
M. tuberculosis and M. leprae are intracellular pathogens. M. tuberculosis can survive up to
decades in a phenotypically non-replicating dormant state, primarily in hypoxic granulomas
in the lung [1]. The otherwise drug-susceptible dormant mycobacteria show the remarkable
property to develop drug resistance within the granulomas of the host. These nonreplicative
drug-resistant bacteria within the host´s tissues are called persisters [2].
Mycobacteria have outstanding mechanisms to escape from elimination and have a high
degree of intrinsic resistance to most antibiotics, chemotherapeutic agents and immune
eradication [3,4]. One major obstacle for host defence mechanisms and therapeutic interven‐
tion is the robust, mycolic acid-rich cell wall, which is unique among prokaryotes [3,5]. In the
last years it has become apparent that mycobacteria induce the accumulation of lipids in the
host cells and use them as energy and carbon source. This strategy is regarded as another
crucial factor for the long term-survival of M. tuberculosis and M. leprae in the host. Most
mycobacteria have the ability to synthesize lipid bodies as reservoirs for fatty acids. The lipid
droplet- containing macrophages are called “foamy macrophages” and are the hallmark of M.
tuberculosis and M. leprae infection.
M. leprae is the causative agent of leprosy. Leprosy is a chronic infectious disease caused by
the obligate intracellular bacterium Mycobacterium leprae and is a major source of morbidity in
developing countries [6,7]. Leprosy patients show two major manifestations of the disease,
known as as lepromatous leprosy (LL), and tuberculoid leprosy (TT) [6]. TT is observed in
patients with good T-cell mediated (Th1) immunity and is characterized by granuloma
formation and death of Schwann cells (Scs) leading to myelin degradation and nerve destruc‐
tion [8,9]. Patients with poor T-cell mediated immunity show the lepromatous type leprosy
(LL), which leads to a high bacterial load inside host cells specially in Schwann cells and
macrophages [8,10-12]. For both forms of leprosy damage of the nerves is observed [12].
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Lepromatous leprosy lesions of the skin, eyes, nerves, and lymph nodes are characterized by
tumor-like accumulations of foamy macrophages. The foamy macrophages are fully packed
with lipid droplets (LDs) and contain high numbers of leprosy bacilli. These aggregations of
foamy macrophages expand slowly and disfigure the body of the host [13].
The finding that M. leprae has insufficient fatty acid synthetase activity to support growth lead
to the hypothesis that M. leprae scavenges lipids from the host cell [14]. Over the last years it
has become evident that survival and persistence of M. tuberculosis is critically dependent on
lipid body formation. Furthermore lipid body formation seems to be the prerequisite for
transition of M. tuberculosis to the dormant state. The formation of foamy macrophages is a
process which appears to be a key event in both sustaining persistent bacteria and release of
infectious bacilli [15]. This goes along with the important observation that sputum from
tuberculosis patients contains lipid body-laden bacilli [16,17].
In the dormant state lipids from lipid bodies appear to be the primary carbon source for M.
tuberculosis in vivo. For M. tuberculosis several bacterial genes are upregulated during the
dormant state and have been reported to be involved in lipid metabolism such as diacylglycerol
acyltransferase (tgs1), lipase (lipY), and isocitrate lyase (icl) [18,19].
M. leprae has a small genome (3.2 Mb). The obligate intracellular organism shows a moderate
genome degradation and several genes are absent when compared with other mycobacterial
species. Due to the gene loss M. leprae is strongly dependent on the host for basic metabolic
functions [8,20]. Macrophages infected with M. leprae contain oxidized host lipids and it has
been observed that M. leprae upregulates 13 host lipid metabolism genes in T-lep lesions and
26 in L-lep lesions. The oxidized lipids inhibit innate immune responses and thus seem to be
an important virulence factor for the organism [21].
This review highlights the importance of the LDs as one of the most unique determinant for
persistence and virulence of M. tuberculosis and M. leprae. The formation of LDs in M. tubercu‐
losis and M. leprae in infected host cells shall be compared and the lipid metabolism of both
organisms will be discussed.
In this review we will use the term “lipid droplets” for lipid-rich inclusions in the host and
“lipid bodies” for lipid-rich inclusions in the pathogen.
2. Biogenesis of lipid inclusions in bacteria and eukaryotes
The current models of lipid droplet biogenesis are still hypothetical and have been reviewed
extensively by Murphy in 1999 and Ohsaki in 2009 [22,23]. The most common model supposes
that the membrane protein diacyltransferase DGAT1 synthesizes triacylglycerols (TAG),
which accumulate between the two membrane leaflets of the endoplasmic reticulum (ER) to
be finally released by budding. The lipids are covered by a phospholipid monolayer from the
ER membrane.
The formation of lipid bodies in bacteria has been even less characterized. Wältermann et al.
suggested in 2005 that a bifunctional wax ester synthase/acyl-CoA:diacylglycerol acyltrans‐
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ferase, (WS/DGAT) synthesizes TAG for lipid body formation. WS/DGAT is an integral
membrane protein and synthesizes a growing globule around the cytoplasmic portion of the
enzyme. Finally the lipid body is released to the cytoplasm. The origin of the surface phos‐
pholipid monolayer is not known [22,24].
2.1. Lipid droplets in the host
The accumulation of lipid droplets occurs also in several infectious, and inflammatory
conditions, including in atherosclerosis [25], bacterial sepsis [26], viral infections [27], and in
mycobacterial infections [15,28,29]. M. tuberculosis infected macrophages store mostly neutral
lipids, while cells infected with M. leprae seem to accumulate next to TAG a high degree of
cholesterol and cholesterol esters [10,30].
LDs are observed in various cells of the immune system including macrophages, neutrophils,
and eosinophils. The structure and composition of LDs is highly conserved. They contain a
core of neutral lipid esters typically TAG, but also sterols and sterol esters [31-36]. The surface
is covered by a phospholipid monolayer, which is composed at least in some cells by unique
fatty acids [37].
M. leprae infects preferentially macrophages and Schwann cells [11]. A typical feature of
lepromatous leprosy is the survival and replication of. M. leprae within the lipid droplets stored
in the enlarged phagosome of histiocytes. Lipid droplets are thought to be an important
nutrient source for the bacillus. A major concern in leprosy is peripheral neuropathy. The
damage to nerves of the peripheral nervous system is caused by the the infection of Schwann
cells (SCs) by M. leprae. In LL nerve biopsies, highly infected SCs also contain lipid droplets
and show a foamy appearance, such as Virchow cells found in dermal lesions [38]. The biology
of the these foamy cells has been characterized poorly until now. Neither the origin or nature
of the lipids has been elucidated yet. Only recently it in vitro studies by Mattos could show
that ML induces the formation of lipid droplets in human SCs [10]. Moreover, the group found
that LDs are promptly recruited to bacterial phagosomes. In SCs LD recruiting by bacterial
phagosomes depends on cytoskeletal reorganization and PI3K signaling, but is independent
of TLR2 bacterial sensing [10].
Important markers for the lipid accumulation in adipocytes or macrophages are lipid-droplet-
associated proteins such as adipose differentiation-related protein ADRP and perilipin, which
play essential roles in lipid-droplet formation [39]. After phagocytosis of live M. leprae ADRP
expression is constantly upregulated in human monocytes. ADRP and perilipin are localized
at the phagosomal membrane (Figure 4) [39].
2.2. Lipid bodies in the pathogen
Prokaryotes do not generally produce lipid bodies containing TAG. Accumulation of TAG
in intracellular lipid-bodies is mostly restricted to bacteria belonging to the actinomycetes
group [40].
Most mycobacterial species accumulate considerable amounts of TAG during infection
[24,41-44]. The intracellular pathogen M. tuberculosis can survive up to decades in a pheno‐
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Lepromatous leprosy lesions of the skin, eyes, nerves, and lymph nodes are characterized by
tumor-like accumulations of foamy macrophages. The foamy macrophages are fully packed
with lipid droplets (LDs) and contain high numbers of leprosy bacilli. These aggregations of
foamy macrophages expand slowly and disfigure the body of the host [13].
The finding that M. leprae has insufficient fatty acid synthetase activity to support growth lead
to the hypothesis that M. leprae scavenges lipids from the host cell [14]. Over the last years it
has become evident that survival and persistence of M. tuberculosis is critically dependent on
lipid body formation. Furthermore lipid body formation seems to be the prerequisite for
transition of M. tuberculosis to the dormant state. The formation of foamy macrophages is a
process which appears to be a key event in both sustaining persistent bacteria and release of
infectious bacilli [15]. This goes along with the important observation that sputum from
tuberculosis patients contains lipid body-laden bacilli [16,17].
In the dormant state lipids from lipid bodies appear to be the primary carbon source for M.
tuberculosis in vivo. For M. tuberculosis several bacterial genes are upregulated during the
dormant state and have been reported to be involved in lipid metabolism such as diacylglycerol
acyltransferase (tgs1), lipase (lipY), and isocitrate lyase (icl) [18,19].
M. leprae has a small genome (3.2 Mb). The obligate intracellular organism shows a moderate
genome degradation and several genes are absent when compared with other mycobacterial
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functions [8,20]. Macrophages infected with M. leprae contain oxidized host lipids and it has
been observed that M. leprae upregulates 13 host lipid metabolism genes in T-lep lesions and
26 in L-lep lesions. The oxidized lipids inhibit innate immune responses and thus seem to be
an important virulence factor for the organism [21].
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losis and M. leprae in infected host cells shall be compared and the lipid metabolism of both
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In this review we will use the term “lipid droplets” for lipid-rich inclusions in the host and
“lipid bodies” for lipid-rich inclusions in the pathogen.
2. Biogenesis of lipid inclusions in bacteria and eukaryotes
The current models of lipid droplet biogenesis are still hypothetical and have been reviewed
extensively by Murphy in 1999 and Ohsaki in 2009 [22,23]. The most common model supposes
that the membrane protein diacyltransferase DGAT1 synthesizes triacylglycerols (TAG),
which accumulate between the two membrane leaflets of the endoplasmic reticulum (ER) to
be finally released by budding. The lipids are covered by a phospholipid monolayer from the
ER membrane.
The formation of lipid bodies in bacteria has been even less characterized. Wältermann et al.
suggested in 2005 that a bifunctional wax ester synthase/acyl-CoA:diacylglycerol acyltrans‐
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ferase, (WS/DGAT) synthesizes TAG for lipid body formation. WS/DGAT is an integral
membrane protein and synthesizes a growing globule around the cytoplasmic portion of the
enzyme. Finally the lipid body is released to the cytoplasm. The origin of the surface phos‐
pholipid monolayer is not known [22,24].
2.1. Lipid droplets in the host
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conditions, including in atherosclerosis [25], bacterial sepsis [26], viral infections [27], and in
mycobacterial infections [15,28,29]. M. tuberculosis infected macrophages store mostly neutral
lipids, while cells infected with M. leprae seem to accumulate next to TAG a high degree of
cholesterol and cholesterol esters [10,30].
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is covered by a phospholipid monolayer, which is composed at least in some cells by unique
fatty acids [37].
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lepromatous leprosy is the survival and replication of. M. leprae within the lipid droplets stored
in the enlarged phagosome of histiocytes. Lipid droplets are thought to be an important
nutrient source for the bacillus. A major concern in leprosy is peripheral neuropathy. The
damage to nerves of the peripheral nervous system is caused by the the infection of Schwann
cells (SCs) by M. leprae. In LL nerve biopsies, highly infected SCs also contain lipid droplets
and show a foamy appearance, such as Virchow cells found in dermal lesions [38]. The biology
of the these foamy cells has been characterized poorly until now. Neither the origin or nature
of the lipids has been elucidated yet. Only recently it in vitro studies by Mattos could show
that ML induces the formation of lipid droplets in human SCs [10]. Moreover, the group found
that LDs are promptly recruited to bacterial phagosomes. In SCs LD recruiting by bacterial
phagosomes depends on cytoskeletal reorganization and PI3K signaling, but is independent
of TLR2 bacterial sensing [10].
Important markers for the lipid accumulation in adipocytes or macrophages are lipid-droplet-
associated proteins such as adipose differentiation-related protein ADRP and perilipin, which
play essential roles in lipid-droplet formation [39]. After phagocytosis of live M. leprae ADRP
expression is constantly upregulated in human monocytes. ADRP and perilipin are localized
at the phagosomal membrane (Figure 4) [39].
2.2. Lipid bodies in the pathogen
Prokaryotes do not generally produce lipid bodies containing TAG. Accumulation of TAG
in intracellular lipid-bodies is mostly restricted to bacteria belonging to the actinomycetes
group [40].
Most mycobacterial species accumulate considerable amounts of TAG during infection
[24,41-44]. The intracellular pathogen M. tuberculosis can survive up to decades in a pheno‐
Lipid Inclusions in Mycobacterial Infections
http://dx.doi.org/10.5772/54526
33
typically non-replicating dormant state, primarily in hypoxic granulomas in the lung [1]. The
otherwise drug-susceptible dormant bacteria develop drug resistance within the granulomas
of the host. These nonreplicative drug-resistant bacteria within the host´s tissues are called
persisters [2].
It has been observed that persisters store large amounts of intracellular triacylglycerol lipid
bodies (LBs) [15,17,28,45,46]. M. tuberculosis uses TAG from the lipid bodies as energy and
carbon source under conditions such as starvation [47], oxygen depletion [48], and pathogen
reactivation [49]. The observation that sputum from tuberculosis patients contains lipid body-
laden bacilli, proves the importance of lipids for the survival of the bacterium in the host [17].
3. M. tuberculosis induces foamy macrophages in the host
M. tuberculosis infects primarily alveolar macrophages, which reside within alveoli. The
infected macrophage leaves the alveoli and migrates then towards the next lung draining
lymph node. M. tuberculosis inhibits the generation of the phagolysosome and the bacteria
begin to multiply within the macrophage [50]. The host’s immune response seems to be unable
to clear the bacillus from the infected macrophages. Infected macrophages secrete TNF-α and
chemokines, which recruit systemic monocytes. The macrophages start to enlarge and
accumulate TAG in lipid droplets. These lipid-filled foamy macrophages (FM) are surrounded
by an outer layer of lymphocytes. Within the foamy macrophages the bacteria resist in
phagosomes, packed with lipid droplets.
Over the last years it has become evident that survival and persistence of M. tuberculosis is
critically dependent on lipid body formation, and induction of foamy macrophages appears
to be a key event in both sustaining persistent bacteria and and release of infectious bacilli [15].
M. tuberculosis-infected phagosomes engulf cellular lipid droplets and finally the bacteria are
completely enclosed by cellular lipid droplets. Only enclosed by lipid droplets the bacteria
form lipid bodies and cell replication comes to a halt and finally the bacteria enter the state of
dormancy and induced drug resistance [19,28]. In the nonreplicative state M. tuberculosis
induces several bacterial genes involved in lipid metabolism such as diacylglycerol acyltrans‐
ferase (tgs1), such as diacylglycerol acyltransferase (tgs1), lipase (lipY), and isocitrate lyase (icl)
are upregulated [19,46]. In conclusion lipid body formation seems to be absolutely necessary
for transition of M. tuberculosis to the dormant state. This goes along with the important
observation that sputum from tuberculosis patients contains lipid body-laden bacilli [17].
The final granuloma consists of a core of infected, lipid-laden macrophages, which are
surrounded by an outer layer of additional differentiated macrophages. The outer shell
consists of T lymphocytes, B lymphocytes, dendritic cells, neutrophils, fibroblasts and an
extracellular matrix [29,51-53].
The development and composition of a human tuberculosis granuloma is depicted in Figure 1.
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Figure 1. Development and structure of the human tuberculosis granuloma. 1, Uptake of M. tuberculosis by alveolar
macrophages. 2, Migration of the infected macrophage towards the next lung draining lymph node. 3, Recruitment of
systemic monocytes. 4, Granuloma formation. L, Lymphocytes at the periphery of the granuloma outside the fibrous
outer layer. F, Fibrous capsule. Contains fibroblasts, collagen and other extracellular matrix proteins. M, Macrophage
region with foamy macrophages. C, Caseum. Contains debris and lipids from necrotic macrophages. Orange, Lipid
droplets of the macrophage. Yellow dots, Lipid bodies.
3.1. Lipid body formation in M. tuberculosis is critically dependent on lipid droplets from
the host
Host lipids from lipid droplets are used by the pathogen as substantial nutrient source.
Middlebrook already demonstrated in the late 1940s that mycobacterial growth in vitro was
enhanced by supplementation with oleic acid [54]. Over the last years several groups have
reported that M. tuberculosis within foamy macrophages produces lipid bodies, suggesting that
they are able to accumulate host cell lipids [19,55]. Mycobacterial growth inside adipocytes is
strictly dependent upon TAG provided by lipid droplets in host cells [55], and it has been
shown that M. tuberculosis incorporates intact host TAG into bacterial TAG [46].
The utilization of host lipids in vivo does not only promote survival but may also increases
virulence and modulate the immune response to infection. Growth of M. tuberculosis on fatty
acids such as such propionate or valerate during infection leads to increased production of the
surface-exposed lipid virulence factors, phthiocerol dimycocerosate (PDIM) and sulfolipid-1
(SL-1) [56].
Cholesterol utilization was also identified to be required for mycobacterial persistence [57]. In
2008 Pandey and Sassetti found that M. tuberculosis can grow using cholesterol as a primary
carbon source and that the mce4 transporter is required for cholesterol uptake. M. tuberculo‐
sis contains four homologous mce operons, mce1–mce4, which are thought to encode lipid
transporters [57,58].
Especially M. leprae infected macrophages show an increased accumulation of cholesterol and
cholesterol [10,30]. But in contrast to M. tuberculosis the M. leprae genome encodes only one
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typically non-replicating dormant state, primarily in hypoxic granulomas in the lung [1]. The
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bodies (LBs) [15,17,28,45,46]. M. tuberculosis uses TAG from the lipid bodies as energy and
carbon source under conditions such as starvation [47], oxygen depletion [48], and pathogen
reactivation [49]. The observation that sputum from tuberculosis patients contains lipid body-
laden bacilli, proves the importance of lipids for the survival of the bacterium in the host [17].
3. M. tuberculosis induces foamy macrophages in the host
M. tuberculosis infects primarily alveolar macrophages, which reside within alveoli. The
infected macrophage leaves the alveoli and migrates then towards the next lung draining
lymph node. M. tuberculosis inhibits the generation of the phagolysosome and the bacteria
begin to multiply within the macrophage [50]. The host’s immune response seems to be unable
to clear the bacillus from the infected macrophages. Infected macrophages secrete TNF-α and
chemokines, which recruit systemic monocytes. The macrophages start to enlarge and
accumulate TAG in lipid droplets. These lipid-filled foamy macrophages (FM) are surrounded
by an outer layer of lymphocytes. Within the foamy macrophages the bacteria resist in
phagosomes, packed with lipid droplets.
Over the last years it has become evident that survival and persistence of M. tuberculosis is
critically dependent on lipid body formation, and induction of foamy macrophages appears
to be a key event in both sustaining persistent bacteria and and release of infectious bacilli [15].
M. tuberculosis-infected phagosomes engulf cellular lipid droplets and finally the bacteria are
completely enclosed by cellular lipid droplets. Only enclosed by lipid droplets the bacteria
form lipid bodies and cell replication comes to a halt and finally the bacteria enter the state of
dormancy and induced drug resistance [19,28]. In the nonreplicative state M. tuberculosis
induces several bacterial genes involved in lipid metabolism such as diacylglycerol acyltrans‐
ferase (tgs1), such as diacylglycerol acyltransferase (tgs1), lipase (lipY), and isocitrate lyase (icl)
are upregulated [19,46]. In conclusion lipid body formation seems to be absolutely necessary
for transition of M. tuberculosis to the dormant state. This goes along with the important
observation that sputum from tuberculosis patients contains lipid body-laden bacilli [17].
The final granuloma consists of a core of infected, lipid-laden macrophages, which are
surrounded by an outer layer of additional differentiated macrophages. The outer shell
consists of T lymphocytes, B lymphocytes, dendritic cells, neutrophils, fibroblasts and an
extracellular matrix [29,51-53].
The development and composition of a human tuberculosis granuloma is depicted in Figure 1.
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Figure 1. Development and structure of the human tuberculosis granuloma. 1, Uptake of M. tuberculosis by alveolar
macrophages. 2, Migration of the infected macrophage towards the next lung draining lymph node. 3, Recruitment of
systemic monocytes. 4, Granuloma formation. L, Lymphocytes at the periphery of the granuloma outside the fibrous
outer layer. F, Fibrous capsule. Contains fibroblasts, collagen and other extracellular matrix proteins. M, Macrophage
region with foamy macrophages. C, Caseum. Contains debris and lipids from necrotic macrophages. Orange, Lipid
droplets of the macrophage. Yellow dots, Lipid bodies.
3.1. Lipid body formation in M. tuberculosis is critically dependent on lipid droplets from
the host
Host lipids from lipid droplets are used by the pathogen as substantial nutrient source.
Middlebrook already demonstrated in the late 1940s that mycobacterial growth in vitro was
enhanced by supplementation with oleic acid [54]. Over the last years several groups have
reported that M. tuberculosis within foamy macrophages produces lipid bodies, suggesting that
they are able to accumulate host cell lipids [19,55]. Mycobacterial growth inside adipocytes is
strictly dependent upon TAG provided by lipid droplets in host cells [55], and it has been
shown that M. tuberculosis incorporates intact host TAG into bacterial TAG [46].
The utilization of host lipids in vivo does not only promote survival but may also increases
virulence and modulate the immune response to infection. Growth of M. tuberculosis on fatty
acids such as such propionate or valerate during infection leads to increased production of the
surface-exposed lipid virulence factors, phthiocerol dimycocerosate (PDIM) and sulfolipid-1
(SL-1) [56].
Cholesterol utilization was also identified to be required for mycobacterial persistence [57]. In
2008 Pandey and Sassetti found that M. tuberculosis can grow using cholesterol as a primary
carbon source and that the mce4 transporter is required for cholesterol uptake. M. tuberculo‐
sis contains four homologous mce operons, mce1–mce4, which are thought to encode lipid
transporters [57,58].
Especially M. leprae infected macrophages show an increased accumulation of cholesterol and
cholesterol [10,30]. But in contrast to M. tuberculosis the M. leprae genome encodes only one
Lipid Inclusions in Mycobacterial Infections
http://dx.doi.org/10.5772/54526
35
operon for cholesterol uptake (mce1). All M. leprae five mce genes were overexpressed during
intracellular growth in mouse and human biopsies [59,60]. This observation suggests, that the
intracellular bacilli population induces cholersterol uptake of the infected cell and subse‐
quently uses the stored cholesterol as carbon and energy source.
Cholesterol is also essential for uptake of M. tuberculosis and M. leprae in macrophages.
Cholesterol accumulates at the site of mycobacterial entry in macrophages and promotes
mycobacterial uptake. Cholesterol mediates the recruitment of TACO from the plasma
membrane to the phagosome [61]. TACO, also termed as CORO1A, is a coat protein that
prevents phagosome-lysosome fusion and thus degradation of mycobacteria in phagolyso‐
somes (Figure 4) [61,62]. This mechanism for the formation of TACO-coated phagosomes
promotes intracellular survival [62,63].
3.2. Lipid body formation in M. tuberculosis is critically dependent on lipid droplets
Host lipids from lipid droplets are used by the pathogen as substantial nutrient source.
Middlebrook already demonstrated in the late 1940s that mycobacterial growth in vitro was
enhanced by supplementation with oleic acid [54]. Host lipids play an important role during
infection. They appear to be the primary carbon source for M. tuberculosis in vivo. Over the last
years several groups have reported that M. tuberculosis within foamy macrophages produces
lipid bodies, suggesting that they are able to accumulate host cell lipids [19,55]. Neyrolles et
al. showed that mycobacterial growth inside adipocytes occurs only after the formation of lipid
droplets in the host cell. This result emphasizes that M. tuberculosis is dependent upon TAG
provided by lipid droplets in host cells [55]. In 2011 Daniel et al. finally demonstrated that M.
tuberculosis inside foamy macrophages imports fatty acids derived from host TAG and
incorporates them intact into bacterial TAG. Moreover the group proved the accumulation of
TAG in lipid bodies [46].
The utilization of host lipids in vivo does not only promote survival but may also increases
virulence and modulate the immune response to infection. Growth of M. tuberculosis on fatty
acids such as such propionate or valerate during infection leads to increased production of the
surface-exposed lipid virulence factors, phthiocerol dimycocerosate (PDIM) and sulfolipid-1
(SL-1) [56].
Cholesterol utilization was also identified to be required for mycobacterial persistence [57]. In
2008 Pandey and Sassetti found that M. tuberculosis can grow using cholesterol as a primary
carbon source and that the mce4 transporter is required for cholesterol uptake. M. tuberculo‐
sis contains four homologous mce operons, mce1–mce4, which are thought to encode lipid
transporters [57,58].
3.3. Biosynthesis of TAG and formation of lipid bodies in M. tuberculosis
Biosynthesis of TAG consists of the sequential esterification of the glycerol moiety with fatty
acyl-residues by various acyltransferases. Fatty acid biosynthesis consists of the stepwise
addition of acetyl groups, which are provided by acetyl-CoA. The initial step is the transfer of
an acetyl group from acetyl-CoA to a small protein, called acyl carrier protein (ACP). In the
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following two-carbon fragments are added sequentially to yield fatty acids of the desired
length. M. tuberculosis uses both type I and type II FAS systems for fatty acid elongation. The
multifunctional FAS I enzyme (Rv2524c) catalyzes the de novo synthesis of C16- and C18-S-ACP.
These fatty acids are converted to the CoA derivative and used primarily for the synthesis of
membrane phospholipids. By continuous elongation of these fatty acids FAS I produces
specifically the C20- and C26-S-ACP products, and these fatty acids are released as the CoA
derivatives. The C20 fatty acid is transferred to the FAS II system for the synthesis of the very-
long-chain mero segment of α-, methoxy-, and ketomycolic acids [64]. The transfer from the
FAS I to the FAS II system occurs by a key condensing enzyme, the ketoacyl ACP synthase III
(FabH). FabH catalyzes the decarboxylative condensation of malonyl-ACP with the acyl-CoA
products of the FAS I system (Figure 2). Two distinct cyclopropane synthases, MmaA2 and
PcaA introduce cyclopropane rings into the the growing acyl chain [64-66].
Figure 2. Fatty acid biosynthesis in Mycobacterium tuberculosis. The FAS-II elongation module uses the substrates R-
CO-S-ACP and malonyl-S-ACP derived from malonyl-S-CoA, generated by FabD. FabH condenses both substrates R,
long-chain alkyl group. Enzymes involved in these reactions are as follows: FabG1, a β-ketoacyl-ACP reductase catalyz‐
es the reduction of beta-ketoacyl-ACP substrates to beta-hydroxyacyl-ACP. β-hydroxyacyl-ACP dehydrase. 2-trans-eno‐
yl-ACP reductase (InhA). The β-ketoacyl-ACP synthase (KasA/KasB) catalyzes the addition of of two carbons from
malonyl-ACP to R-CO-S-ACP (See text for details). R, long-chain alkyl group. ACP, acyl carrier protein. Enzymes are in
bold letters. Selected inhibitors are depicted in red bold letters. TLM, thiolactomycin. CER, cerulenin. ETH, ethionamide.
INH, isoniazid. TRC, triclosan. TAC, thiacetazone.
Esterification  of  fatty  acids  with  glycerol-3-phosphate  occurs  via  sequential  acylation  of
the sn-1,2 and 3 positions of glycerol-3-phosphate,  and removal of the phosphate group
before the last acylation step. The terminal reaction is the esterification of diacylglycerol
(DAG) with acyl-CoA by an diacylglycerol  acyltransferase  [40].  Animals  and plants  use
diacylglycerol acyl‐transferases (DGAT) for the terminal esterification. DGATs catalyze ex‐
clusively  the  esterification  of  acyl-CoA  with  diacylglycerol.  Bacteria  do  not  contain
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operon for cholesterol uptake (mce1). All M. leprae five mce genes were overexpressed during
intracellular growth in mouse and human biopsies [59,60]. This observation suggests, that the
intracellular bacilli population induces cholersterol uptake of the infected cell and subse‐
quently uses the stored cholesterol as carbon and energy source.
Cholesterol is also essential for uptake of M. tuberculosis and M. leprae in macrophages.
Cholesterol accumulates at the site of mycobacterial entry in macrophages and promotes
mycobacterial uptake. Cholesterol mediates the recruitment of TACO from the plasma
membrane to the phagosome [61]. TACO, also termed as CORO1A, is a coat protein that
prevents phagosome-lysosome fusion and thus degradation of mycobacteria in phagolyso‐
somes (Figure 4) [61,62]. This mechanism for the formation of TACO-coated phagosomes
promotes intracellular survival [62,63].
3.2. Lipid body formation in M. tuberculosis is critically dependent on lipid droplets
Host lipids from lipid droplets are used by the pathogen as substantial nutrient source.
Middlebrook already demonstrated in the late 1940s that mycobacterial growth in vitro was
enhanced by supplementation with oleic acid [54]. Host lipids play an important role during
infection. They appear to be the primary carbon source for M. tuberculosis in vivo. Over the last
years several groups have reported that M. tuberculosis within foamy macrophages produces
lipid bodies, suggesting that they are able to accumulate host cell lipids [19,55]. Neyrolles et
al. showed that mycobacterial growth inside adipocytes occurs only after the formation of lipid
droplets in the host cell. This result emphasizes that M. tuberculosis is dependent upon TAG
provided by lipid droplets in host cells [55]. In 2011 Daniel et al. finally demonstrated that M.
tuberculosis inside foamy macrophages imports fatty acids derived from host TAG and
incorporates them intact into bacterial TAG. Moreover the group proved the accumulation of
TAG in lipid bodies [46].
The utilization of host lipids in vivo does not only promote survival but may also increases
virulence and modulate the immune response to infection. Growth of M. tuberculosis on fatty
acids such as such propionate or valerate during infection leads to increased production of the
surface-exposed lipid virulence factors, phthiocerol dimycocerosate (PDIM) and sulfolipid-1
(SL-1) [56].
Cholesterol utilization was also identified to be required for mycobacterial persistence [57]. In
2008 Pandey and Sassetti found that M. tuberculosis can grow using cholesterol as a primary
carbon source and that the mce4 transporter is required for cholesterol uptake. M. tuberculo‐
sis contains four homologous mce operons, mce1–mce4, which are thought to encode lipid
transporters [57,58].
3.3. Biosynthesis of TAG and formation of lipid bodies in M. tuberculosis
Biosynthesis of TAG consists of the sequential esterification of the glycerol moiety with fatty
acyl-residues by various acyltransferases. Fatty acid biosynthesis consists of the stepwise
addition of acetyl groups, which are provided by acetyl-CoA. The initial step is the transfer of
an acetyl group from acetyl-CoA to a small protein, called acyl carrier protein (ACP). In the
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following two-carbon fragments are added sequentially to yield fatty acids of the desired
length. M. tuberculosis uses both type I and type II FAS systems for fatty acid elongation. The
multifunctional FAS I enzyme (Rv2524c) catalyzes the de novo synthesis of C16- and C18-S-ACP.
These fatty acids are converted to the CoA derivative and used primarily for the synthesis of
membrane phospholipids. By continuous elongation of these fatty acids FAS I produces
specifically the C20- and C26-S-ACP products, and these fatty acids are released as the CoA
derivatives. The C20 fatty acid is transferred to the FAS II system for the synthesis of the very-
long-chain mero segment of α-, methoxy-, and ketomycolic acids [64]. The transfer from the
FAS I to the FAS II system occurs by a key condensing enzyme, the ketoacyl ACP synthase III
(FabH). FabH catalyzes the decarboxylative condensation of malonyl-ACP with the acyl-CoA
products of the FAS I system (Figure 2). Two distinct cyclopropane synthases, MmaA2 and
PcaA introduce cyclopropane rings into the the growing acyl chain [64-66].
Figure 2. Fatty acid biosynthesis in Mycobacterium tuberculosis. The FAS-II elongation module uses the substrates R-
CO-S-ACP and malonyl-S-ACP derived from malonyl-S-CoA, generated by FabD. FabH condenses both substrates R,
long-chain alkyl group. Enzymes involved in these reactions are as follows: FabG1, a β-ketoacyl-ACP reductase catalyz‐
es the reduction of beta-ketoacyl-ACP substrates to beta-hydroxyacyl-ACP. β-hydroxyacyl-ACP dehydrase. 2-trans-eno‐
yl-ACP reductase (InhA). The β-ketoacyl-ACP synthase (KasA/KasB) catalyzes the addition of of two carbons from
malonyl-ACP to R-CO-S-ACP (See text for details). R, long-chain alkyl group. ACP, acyl carrier protein. Enzymes are in
bold letters. Selected inhibitors are depicted in red bold letters. TLM, thiolactomycin. CER, cerulenin. ETH, ethionamide.
INH, isoniazid. TRC, triclosan. TAC, thiacetazone.
Esterification  of  fatty  acids  with  glycerol-3-phosphate  occurs  via  sequential  acylation  of
the sn-1,2 and 3 positions of glycerol-3-phosphate,  and removal of the phosphate group
before the last acylation step. The terminal reaction is the esterification of diacylglycerol
(DAG) with acyl-CoA by an diacylglycerol  acyltransferase  [40].  Animals  and plants  use
diacylglycerol acyl‐transferases (DGAT) for the terminal esterification. DGATs catalyze ex‐
clusively  the  esterification  of  acyl-CoA  with  diacylglycerol.  Bacteria  do  not  contain
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DGATs but only bifunctional wax ester synthase/acyl-CoA:diacylglycerol acyltransferases
(WS/DGAT). WS/DGATs, mediate next to TAG formation the synthesis of waxes by ester‐
ification of acyl-CoA with alcohol [67]. The genome of M. tuberculosis  codes for 15 genes
which contain the highly conserved putative active site motif of WS/DGATs (HHxxxDG).
These genes were designated as “tgs”, triacylglycerol synthases, but have only a weak se‐
quence similarity to other WS/DGAT sequences. All 15 expressed mycobacterial Tgs pro‐
teins show diacylglycerol acyltransferase activity and Tgs1 has the highest activity of all
enzymes [48].  Gene disruption of  tgs1  results  in  a  drastic  reduction of  major  C26 long-
chain fatty acid in M. tuberculosis grown under hypoxic conditions. Thus Tgs1 appears to
be a major contributor to TAG synthesis in M. tuberculosis  so far [48,68].  And moreover
two homologous proteins to Tgs1 and Tgs2 (BCG3153c and BCG3794c) and another poor‐
ly characterized acyltransferase (BCG1489c) were found to be exclusively associated to lip‐
id  bodies.  The  disruption  of  BCG3153c,  BCG3794c,  and  BCG1489c  reduces  TAG
accumulation  during  the  hypoxia-induced  nonreplicating  state,  revealing  that  the  en‐
zymes are involved in TAG synthesis during latency and pathogenicity [69].
Ten of the 15 tgs genes in M. tuberculosis are located adjacent or proximal to 11 lip genes that
are annotated as probable phospholipases or lipases-esterases-carboxylesterases. Some tgs
genes may be cotranscribed with neighboring lip genes and may synthesize triacylglycerols
from the released fatty acids from the host [18]. Lip gene products may be important for
utilization of TAGs during dormancy and upon reactivation after dormancy. The tgs gene
Rv0221 is located near lipC (Rv0220), lipW (Rv0217c), acyl-CoA synthetase (Rv0214), acyl-CoA
dehydrogenase (Rv0215c), and an integral membrane acyltransferase (Rv0228). This clustering
of genes of the fatty acid metabolism suggests that these genes may be cotranscribed and may
release fatty acid from host TAG, carry out the transport of fatty acids and finally catalyze the
re-synthesis of TAGs in the pathogen. Rv0221 and LipC have to be shown to be catalytical
active. [18,70].
In summary Tgs enzymes play a major role in TAG synthesis, lipid body formation and
maintenance.
Ag85A, a mycoltransferase, that is known to catalyze the formation of the cord factor was
recently found to have additional DGAT activity [71]. The kinetic parameters are quite similar
to those reported for the M. tuberculosis Tgs1-4, but the primary sequence of Ag85A does not
contain the active site motif of WS/DGATs or TGS enzymes (HHxxxDG) [48,68,71]. Ag85A
belongs to the α/β hydrolase fold family and contains the consensus GXSXG sequence. The
enzyme is a carboxylesterase with an additional acyltransferase activity. Overexpression of
Ag85A induces lipid body formation in M. smegmatis. The enzyme is located in the mycobac‐
terial cell wall, suggesting that it may be involved in the maintenance of lipid droplets in the
host cell [71].
The genome of M.leprae  contains also mycolytransferase 85 complex genes (A, B and C).
Transcripts of these genes are upregulated either in infected nude mouse or human skin
lesions [59].
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The M. leprae genome shows only one predicted gene product which has has a significant
degree of identity to any the Tgs enzymes from M. tuberculosis [18]. The tgs gene product
ML1244 shows 72% identity to Rv2484c from M. tuberculosis. Rv2448 is located next to a
carboxylesterase lipQ, (Rv2485c), a probable glycerol-3-phosphate acyltransferase, (Rv2482c),
a lysophosphatidic acid acyltransferase-like protein (Rv2483c), and a probable enoyl-CoA
hydratase (Rv2486). The gene cluster of lipid metabolism genes suggests a possible involve‐
ment of the gene products in the synthesis of TAG [18]. A few tgs genes (Rv3234c, Rv3233c,
Rv2285, and Rv1425) are located proximal to lipoproteins, which may serve as donors or
acceptors of fatty acids [48]
3.4. Activation of TAG – Lipases and esterases of M. tuberculosis
Neutral lipids in the core of the lipid body are hydrolyzed by lipases or esterases, yielding
fatty acids for energy generation and anabolism of membrane phospholipids.
In the genome of M. tuberculosis  H37Rv twenty-one genes are termed as putative lipases
(lip A to W, except K and S) [72]. The annotation was only based on the presence of the
consensus sequence GXSXG, which is characteristic for the large group of the α/β hydro‐
lase fold protein family, which includes lipases as well as esterases, proteases, peroxidas‐
es, epoxide hydrolases and dehalogenases [72]. Thus the members of the lip group have
only a very low level of sequence identity of ~20% and might have another function apart
from lipid hydrolysis. Only the gene product of Rv3097c (LipY)) shows reasonable hydro‐
lase activity for long-chain TAG with chain lengths ranging from C4 to C18. Overexpres‐
sion of LipY induces extensive TAG hydrolysis. Disruption of lipY markedly reduces but
does  not  completely  inactivate  TAG hydrolase  activity,  which  suggests  the  presence  of
other lipases in M. tuberculosis [47,49].
Overexpression of LipY in M. bovis Bacillus Calmette-Guérin reduces protection against
infection in mice, indicating that lipY plays a central role in TAG hydrolysis and virulence
[47,73,74]. LipY contains a PE (Pro-Glu) domain, that is involved in modulation of LipY activity
[73]. The PE domain contains a signal sequence for secretion of LipY by the ESX-5 system. It
has been implicated that the secreted LipY is loosely associated with the bacterial surface where
it may hydrolyze host’s TAG [75].
Several other esterases, next to the members of the Lip group have been identified and
biochemically characterized. They all belong also to the α/β hydrolase fold family and showing
the minimal GXSXG motif. In 2007 Côtes et al. characterized a novel lipase Rv0183. The enzyme
is only found in the cell wall and culture medium. This observation suggests that Rv0183 is
involved in the degradation of the host cell lipids e.g. when M. tuberculosis infects adipocytes
[55,76]. Another probably cell wall-associated carboxylesterase is encoded by Rv2224c. The
esterase Rv2224c was found to be required for bacterial survival in mice [77]. The substrate
spectrum of Rv2224c is poorly characterized and until now it is unknown whether the enzyme
uses TAG as substrate [77]. Furthermore the three-dimensional structures of the esterases
Rv0045c (PDB 3P2M) [78], Rv1847 (PDB 3S4K), and LipW (3QH4) from M. tuberculosis have
been determined, but unfortunately it is not known whether these enzymes are involved in
TAG hydrolysis.
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DGATs but only bifunctional wax ester synthase/acyl-CoA:diacylglycerol acyltransferases
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terial cell wall, suggesting that it may be involved in the maintenance of lipid droplets in the
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3.5. Lipase genes of M. leprae
In the M. leprae genome only 2 lipase genes (lipG, lipU) were found. But M. tuberculosis has also
only six expressed Lip enzymes, showing reasonable hydrolase activity for long-chain
triacylglycerols. (LipY, LipC, LipL, LipX, LipK, LipG). LipG and LipU from M. leprae are
homologous with LipG and LipU from M. tuberculosis and show sequence identities of 72 and
79%, respectively. The lipases LipG and LipU from M. tuberculosis show very low and no
activity with long chain triacylglycerols as substrates [47]. M. tuberculosis LipY is suspected to
be a major functional lipase, which utilizes stored triacylglycerols (TAG) during dormancy
and reactivation of the pathogen [47,49]. LipY shows only a weak similarity with M. leprae
LipU (23 % identity). In summary it appears that M. leprae uses different lipases for the
hydrolysis of fatty acids than M. tuberculosis.
3.6. Enzymes of the β-oxidation and glyoxylate cycle
M. tuberculosis can grow on fatty acids as sole carbon source and it has been demonstrat‐
ed that fatty acid oxidation is important for survival of the pathogen in the lungs of mice
[79,80]. Fatty acids are oxidized via the β-oxidation cycle and the glyoxylate shunt, to re‐
plenish TCA cycle intermediates during growth [81]. The β-oxidation cycle consists of five
biochemical reactions, where one molecule acetyl-CoA of the fatty acid is split off per cy‐
cle. The genome of M. tuberculosis encodes around 100 genes, designated as fad genes (fat‐
ty acid degradation) with putative roles in the β-oxidation of fatty acids. While E. coli has
only one enzyme for each step of the β-oxidation cycle, M. tuberculosis seems to have sev‐
eral  backup enzymes for each reaction [82].  The initial  step of β-oxidation is  the forma‐
tion  of  acyl-CoA from free  fatty  acids  and  Coenzyme A and is  catalyzed  by  acyl-CoA
synthase.  In M. bovis  BCG one Acyl-CoA synthase (BCG1721)  (Rv1683)  has been identi‐
fied to be exclusively bound to lipid bodies. Nonreplicating mycobacteria, which overex‐
press  a  BCG1721  construct  with  an  inactive  lipase  domain  displayed  a  phenotype  of
attenuated TAG breakdown and regrowth upon resuscitation. These results indicate that
the gene might be essential for TAG hydrolysis and growth [69].
Together with malate synthase, isocitrate lyase (ICL) is the key enzyme of the glyoxylate cycle
that catalyzes the cleavage of isocitrate to glyoxylate and succinate [81,83]. The M. tuberculo‐
sis genome codes for two isocitrate lyases, icl and icl2, which are essential for the fatty acid
metabolism and jointly required for in vivo growth and virulence. Disruption of icl has only
little effect on survival in macrophages and bacterial loads in lungs of infected mice. Only
disruption of both lyase genes results in a fast elimination of bacteria from lungs of infected
mice and infected macrophages [79,80]. These results strongly suggest that both icl genes are
required for mycobacterial persistence.
All enzymes involved in lipid metabolism in lipid bodies are summarized in Table 1.
M. leprae has approximately one-third as many potential fad enzymes with probable roles
in the β-oxidation. Even though M. leprae genome contains less necessary β-oxidation cy‐
cle  genes than M. tuberculosis,  transcript  analysis  revealed expression of  acyl-CoA meta‐
bolic enzymes including echA1 (ML0120, putative enoyl-CoA hydratase), echA12 (ML1241,
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possible  enoyl-CoA  hydratase),  fadA2  (ML2564,  acetyl-CoA-acetyltransferase),  fadB2
(ML2461,  3-hydroxyacyl-CoA  dehydrogenase),  fadD19  (ML0352,  acyl-CoA  synthase),
fadD26 (ML2358, fatty acid-CoA-ligase), fadD29 (ML0132, probable fatty-acid-CoA synthe‐
tase), fadD28 (ML0138, possible fatty-acid-CoA synthetase), fadE25 (ML0737, probable acyl-
CoA  dehydrogenase)  and  fadE5  (ML2563,  acyl-CoA  dehydrogenase)  [59,60].  This  gives
strong evidence that host lipids provide the main carbon and energy sources for M. lep‐
rae during infection.
The M. leprae genome contains a gene, coding for an isocitrate lyase, aceA. The amino acid-
sequence of AceA (ML1985c) shows 80 % identity with its homologue from M. tuberculosis
ICL2 (Rv1915/1916). AceA is upregulated in both M. leprae-infected nude mouse and human
lesions. [59]. A second icl gene, as observed in M. tuberculosis, is not present in the genome of
M. leprae. This finding is of particular interest, because both lyases, icl and icl2, are jointly
required for in vivo growth and virulence [79,80]. Deletion of icl1 or icl2 has little effect on
bacterial growth in macrophages [80]. So far the M. leprae AceA might play a slightly different
role in as the both isocitrate lyases in M. tuberculosis.
4. Lipid composition in M. leprae infected cells
In 1863, Virchow described foamy cells, which form droplets and surround M. leprae within
the phagolysomes. [84,85]. This lipid capsule forms a characteristic electron-transparent zone.
In contrast to M. tuberculosis, the presence of lipid bodies seem to be rather exceptional in M.
leprae [85]. The lipid capsule contains mycoserosoic acids of phthiocerol dimycocerosates as
well as phenolic glycolipids [86,87]. Brennan reported the full characterization of three phenol-
phthiocerol triglycosides by M. leprae [84]. It has been postulated that many of these molecules
together with phosphatidylinositol mannosides and phospholipids are released from the cell
wall after synthesis, forming the capsule-like region [11]. The dominant lipid in the cell wall
which gives M. leprae immunological specificity is phenolic glycolipid-1 (PGL-1). Phenolic
glycolipid 1 has been isolated in relatively high concentrations from purified bacteria and from
M. leprae infected tissues [88]. PGL-1 is thought to be a major component of the capsule in M.
leprae and constitutes an important interface between bacteria and host [89]. It has been
suggested that PGL-1 is involved in the interaction of M. leprae with the laminin of Schwann
cells, thus PGL-1 hight play a role in peripheral nerve-bacillus interactions [90]. Moreover,
phenolic glycolipids seem to be involved in the in the stimulation of suppressor T-cells in
lepromatous leprosy [91]. Recently it was reported that also LDs from M. leprae infected SCs
and macrophages accumulate mainly host derived lipids, such as oxidized phospholipids [92].
BODIPY stains infected SCs, indicating that LDs contain neutral lipids, such as triacylglycerols
(TAG), but it seems as M. leprae-infected cells accumulate large amounts of cholesterol and
choesterol esters [10].
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Table 1. Enzymes involved in lipid body metabolism in M. tuberculosis and M. bovis BCG. Homologous genes in M.
tuberculosis H37Rv are written in square brackets. NA, not applicable. *, expressed in yeast as recombinant protein.
DGAT, diacylglycerol acyltransferase
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5. Induction of lipid droplet biogenesis
Since the biogenesis of lipid droplets in macrophages seems an absolute requirement for
intracellular bacteria to establish infections, we will discuss mechanisms involved in foam cell
formation and development of lipid droplets.
5.1. Scavenger receptor mediated lipid droplet biogenesis in M. tuberculosis
Upon infection with pathogenic bacteria macrophages generate reactive oxygen species (ROS).
The release of ROS generates oxidative stress, and results not only in damage to cellular
structures but also to oxidation of fatty acids, such as low density lipoproteins (OxLDL) in
granulomas. The binding of OxLDL to type 1 scavenger receptors CD36 and LOX1 induces
increased surface expression of both receptors, leading to uptake of OxLDL [96-98]. In addition,
CD36 increases the uptake of M. tuberculosis by macrophages [99]. The increased rate of OxLDL
uptake results in the accumulation of oxidized lipids, which finally leads to the formation of
foamy macrophages [98]. M. tuberculosis and M. leprae benefit from the accumulated OxLDL
in the infected macrophage. OxLDL-laden lung macrophages show enhanced replication of
intracellular M. tuberculosis compared to macrophages loaded with non-oxidized LDL [98].
The presence of oxidized phospholipids in M. leprae infected macrophages down-regulates the
innate immune response and contributes to pathogenesis [92]. Moreover, scavenger receptor-
deficient phagocytes are characterized by a reduced intracellular bacterial survival and a lower
cytokine response [100].
5.2. TLR mediated LD formation in M. bovis and M. leprae
Mycobacterium bovis Bacillus Calmette-Guérin (BCG) and M. leprae are recognised by the Toll-
like receptors (TLR) TLR6 and TLR2 [101,102]. Mycobacterium bovis Bacillus Calmette-Guérin
induced lipid body formation is TLR2 mediated [103]. The mycobacterial surface molecule
lipoarabinomannan (LAM) induces the formation of foamy macrophages by binding to TLR2
[104] (Figure 3).
M. leprae association to macrophages is mediated by binding of the bacteria to TLR2 and TLR6.
Heterodimerization of TLR2 and TLR6 leads to downstream signalling and subsequent LD
formation [102,105]. Macrophage association is not dependent on binding to TLR2 or TLR6.
Neither a TLR2-/- or TLR6-/- knockout macrophage shows reduced binding to M. leprae. This
suggests that both TLR2 and TLR6 can bind M. leprae alone, or/and the presence of other
receptors, binding to M. leprae. The TLR2-/- or TLR6-/- knockout macrophages do also not
completely abolish LD formation, but show only reduced LD formation [102]. This suggests
the presence of additional signalling pathways for LD formation. In SCs TLR6, but not TLR2,
is essential for M. leprae-induced LD biogenesis in [101]. In LL lesions, accumulated with LD
enriched macropages the genes for ADRP and CD36 are up-regulated [30,92,102]. This suggests
also an involvement of CD36 in LD formation of M. leprae (Figure 4) [99].
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5.2. TLR mediated LD formation in M. bovis and M. leprae
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like receptors (TLR) TLR6 and TLR2 [101,102]. Mycobacterium bovis Bacillus Calmette-Guérin
induced lipid body formation is TLR2 mediated [103]. The mycobacterial surface molecule
lipoarabinomannan (LAM) induces the formation of foamy macrophages by binding to TLR2
[104] (Figure 3).
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Heterodimerization of TLR2 and TLR6 leads to downstream signalling and subsequent LD
formation [102,105]. Macrophage association is not dependent on binding to TLR2 or TLR6.
Neither a TLR2-/- or TLR6-/- knockout macrophage shows reduced binding to M. leprae. This
suggests that both TLR2 and TLR6 can bind M. leprae alone, or/and the presence of other
receptors, binding to M. leprae. The TLR2-/- or TLR6-/- knockout macrophages do also not
completely abolish LD formation, but show only reduced LD formation [102]. This suggests
the presence of additional signalling pathways for LD formation. In SCs TLR6, but not TLR2,
is essential for M. leprae-induced LD biogenesis in [101]. In LL lesions, accumulated with LD
enriched macropages the genes for ADRP and CD36 are up-regulated [30,92,102]. This suggests
also an involvement of CD36 in LD formation of M. leprae (Figure 4) [99].
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Figure 3. Induction of lipid droplet biogenesis in macrophages by Mycobacterium tuberculosis. 1) Recognition of bac‐
teria by Toll-like receptors (TLR) trigger phagocytosis and subsequent formation of lipid droplets. 2) The infected mac‐
rophage produces reactive oxygen species (ROS), which oxidize LDL. 3) The binding of OxLDL to type 1 scavenger
receptors CD36 and LOX1 induces increased surface expression of both receptors and increases uptake of host´s oxi‐
dized fatty acids. 4) Mycobacterium-laden phagosomes internalize lipid droplets. 5) Within the lipid droplets the bac‐
teria form lipid bodies and finally enter the dormant state. ApoB-100, apolipoprotein B-100.
Figure 4. Basic mechanisms of lipid droplet induction in M. leprae infected macrophages. M. leprae attaches to TLR2
and TLR6. Heterodimerization of TLR2 and TLR6 induces downstream signalling and subsequent accumulation by LD
formation. [102,105]. In SCs TLR6, but not TLR2, is essential for M. leprae-induced LD biogenesis [101]. Cholesterol
from the LDs accumulates at the site of mycobacterial entry and promotes mycobacterial uptake. Cholesterol also re‐
cruits TACO from the plasma membrane to the phagosome [61]. TACO prevents phagosome-lysosome fusion and pro‐
motes intracellular survival [62,63]. Hypothetical uptake of oxidized lipids by scavenger receptors in M. leprae:
Reactive oxygen species might oxidize low-density lipoprotein (LDL) to oxLDL, which is thought to be subsequently
bound and taken up by scavenger receptors CD36 and LOX1. CHO, cholesterol. Unknown mechanisms for LD induc‐
tion are indicated with a question mark.
5.3. Mycolic acids induce the formation of foamy macrophages
Mycolic  acids  and  oxygenated  mycolic  acids  are  strong  inducers  of  monocyte-derived
macrophages differentiation into foamy macrophages [19,106]. Peyron et al. demonstrated
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that that a set of oxygenated mycolic acids specifically produced by highly virulent myco‐
bacteria  species  (M. tuberculosis,  M. avium)  were responsible  for  the formation of  foamy
macrophages [19].
6. Clinical implications
Several enzymes of the mycobacterial lipid-biosynthesis are regarded as targets for new
antitubercular compounds. The research focused on enzymes, involved in the biosynthesis of
lipid compounds of the mycobacterial cell wall [107]. Especially the biosynthesis of the highly
toxic cord factor is an attractive target. The cord factor is synthesized by the antigen 85 complex
[108,109]. It was recently shown that one member of the complex, antigen 85A is involved in
the formation of intracellular lipid bodies [71]. Antigen 85 is an important virulence factor. It
has been shown that M. tuberculosis requires the expression of Ag85A for growth in macro‐
phages [110]. M. tuberculosis strain lacking Ag85C shows an decrease of 40% in the amount of
cell wall linked mycolic acids [111,112]. The treatment by a trehalose analogue, 6-azido-6-
deoxy-α,α'-trehalose (ADT) inhibits the activity of all members of Ag85 complex in vitro [108,
113]. Also ethambutol targets the synthesis of arabinogalactan, isoniazid and ethionamide
inhibit biosynthesis of mycolic acids [107].
The most potent inhibitor for mycolic acid biosynthesis is isoniazid (INH). INH is a prodrug
which is converted to the isonicotinoyl radical by KatG. INH forms a covalent adduct with
NAD. This INH-NAD adduct inhibits FAS-II enoyl-ACP reductase InhA, which in conse‐
quence leads to inhibition of mycolic acid biosynthesis, and ultimately to cell death [114-117].
The inhibitors of fatty acid biosynthesis are summarized in Figure 2 and Table 2.






FAS-II KasA/KasB TLM (Thiolactomycin) [120-122]
FAS-II KasA/KasB Platensimycin [123]
InhA INH (Isoniazid) [124]
InhA ETH (Ethionamide) [125]
InhA TRC (Triclosan) [126]
InhA alkyl diphenyl ethers (Triclosan derivatives) [127]
InhA 2-(o-Tolyloxy)-5-hexylphenol (PT70) [120]
Cyclopro-panation CMASs (cmaA2, mmaA2 or
pcaA)
TAC (Thiacetazone) [128]
MmaA4 TAC (Thiacetazone) [128]
Table 2. Inhibitors of fatty acid biosynthesis
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The formation of lipid inclusions during infection in the host as well as in the pathogen during
intracellular infection with M. tuberculosis and M. leprae plays an important role in pathogen‐
esis. A hallmark of intracellular infection is the formation of foamy macrophages. M. tubercu‐
losis and M. leprae induce the formation of lipid droplets in the host cell. The accumulated lipids
are used as energy and carbon source. In fact M. tuberculosis seems to switch completely to
fatty acid catabolism at the transition from the acute to the chronic phase of infection. The
central role of fatty acid metabolism during the dormant state of M. tuberculosis is underlined
by the finding that both isocitrate lyase, icl and icl2, are essential for intracellular replication
in the lung [79,80]. The TAG metabolism and the resulting formation of lipid inclusions of host
and pathogen play a fundamental role in infection. Indeed TAG-derived fatty acids from the
host cell are imported into M. tuberculosis and incorporated into bacterial TAG [46]. In
conclusion the enzymes involved in lipid droplet metabolism are essential for survival of the
pathogen in the lung and thus attractive targets for novel drugs. Especially enzymes with
DGAT activity such as Tgs and Ag85A seem to be promising drug target candidates. Another
promising targets seem to be the recently discovered cell wall associated and secreted
esterases, which are involved in the utilization of host cell lipids such as Rv0183 and LipY [55,
75,76]. Future studies should also focus on the lipid metabolism of M. leprae, an organism which
upregulates several genes of the host´s lipid metabolism during infection [92]. The regulation
of lipid droplet formation in the host cell is another important topic. Recent sudies revealed
that intracellular pathogens induce the expression of LDL receptor and scavenger receptors
CD36 and LOX1 for the internalization of native and oxidized fatty acids. Especially the
generation of oxidized lipids by macrophage-derived reactive oxygen species seems to be an
important mechanism for the induction of scavenger receptors.
Author details
Matthias Stehr1, Ayssar A. Elamin1 and Mahavir Singh1,2*
*Address all correspondence to: Mahavir.Singh@helmholtz-hzi.de
1 LIONEX Diagnostics and Therapeutics GmbH, Braunschweig, Germany
2 Department of Genome Analytics, Helmholtz Centre for Infection Research, Braunsch‐
weig, Germany
References
[1] Murphy D. J., Brown J. R. Identification of gene targets against dormant phase
Mycobacterium tuberculosis infections. BMC Infect. Dis. 2007;7 84.
Tuberculosis - Current Issues in Diagnosis and Management46
[2] Zhang Y. Persistent and dormant tubercle bacilli and latent tuberculosis. Front. Biosci.
2004;9 1136-1156.
[3] Brennan P. J., Nikaido H. The envelope of mycobacteria. Annual review of biochemistry
1995;64 29-63.
[4] Coker R. J. Review: multidrug-resistant tuberculosis: public health challenges. Tropical
medicine & international health : TM & IH 2004;9 25-40.
[5] Barry C. E., 3rd, Lee R. E., Mdluli K., Sampson A. E., Schroeder B. G., Slayden R. A.,
Yuan Y. Mycolic acids: structure, biosynthesis and physiological functions. Progress in
lipid research 1998;37 143-179.
[6] Ridley D. S., Jopling W. H. Classification of leprosy according to immunity. A five-
group system. Int Int. J. Lepr. 1966;34 255-273.
[7] WHO, WHO Leprosy Today, WHO, 2010.
[8] Cosma C. L., Sherman D. R., Ramakrishnan L. The secret lives of the pathogenic
mycobacteria. Annu. Rev. Microbiol. 2003;57 641-676.
[9] Scollard D. M. Endothelial cells and the pathogenesis of lepromatous neuritis:insights
from the armadillo model. Microbes Infect. 2000;2 1835-1843.
[10] Mattos K. A., Lara F. A., Oliveira V. G., Rodrigues L. S., D'Avila H., Melo R. C., Manso
P. P., Sarno E. N., Bozza P. T., Pessolani M. C. Modulation of lipid droplets by
Mycobacterium leprae in Schwann cells: a putative mechanism for host lipid acquisition
and bacterial survival in phagosomes. Cell. Microbiol. 2011;13 259-273.
[11] Scollard D. M., Adams L. B., Gillis T. P., Krahenbuhl J. L., Truman R. W., Williams D.
L. The continuing challenges of leprosy. Clin. Microbiol. Rev. 2006;19 338-381.
[12] Vissa V. D., Brennan P. J., Impact of the Mycobacterium leprae genome sequence on
leprosy research in: A. Danchin (Ed.), Genomics of GC-rich Gram-positive bacteria,
Band 2, Caister Academic Press, 2002, pp. 85 - 118.
[13] Raphael Rubin D. S. S., Rubin Emanuel (Ed.), Rubin's Pathology: Clinicopathologic
Foundations of Medicine, Lippincott Williams and Wilkins, 2007.
[14] Wheeler P. R., Bulmer K., Ratledge C. Enzymes for biosynthesis de novo and elongation
of fatty acids in mycobacteria grown in host cells: is Mycobacterium leprae competent in
fatty acid biosynthesis? J. Gen. Microbiol. 1990;136 211-217.
[15] Russell D. G., Cardona P. J., Kim M. J., Allain S., Altare F. Foamy macrophages and the
progression of the human tuberculosis granuloma. Nat. Immunol. 2009;10 943-948.
[16] Neyrolles O., Hernandez-Pando R., Pietri-Rouxel F., Fornes P., Tailleux L., Barrios
Payan J. A., Pivert E., Bordat Y., Aguilar D., Prevost M. C., Petit C., Gicquel B. Is adipose
tissue a place for Mycobacterium tuberculosis persistence? PLoS One 2006;1 e43.
[17] Garton N. J., Waddell S. J., Sherratt A. L., Lee S. M., Smith R. J., Senner C., Hinds J.,
Rajakumar K., Adegbola R. A., Besra G. S., Butcher P. D., Barer M. R. Cytological and




The formation of lipid inclusions during infection in the host as well as in the pathogen during
intracellular infection with M. tuberculosis and M. leprae plays an important role in pathogen‐
esis. A hallmark of intracellular infection is the formation of foamy macrophages. M. tubercu‐
losis and M. leprae induce the formation of lipid droplets in the host cell. The accumulated lipids
are used as energy and carbon source. In fact M. tuberculosis seems to switch completely to
fatty acid catabolism at the transition from the acute to the chronic phase of infection. The
central role of fatty acid metabolism during the dormant state of M. tuberculosis is underlined
by the finding that both isocitrate lyase, icl and icl2, are essential for intracellular replication
in the lung [79,80]. The TAG metabolism and the resulting formation of lipid inclusions of host
and pathogen play a fundamental role in infection. Indeed TAG-derived fatty acids from the
host cell are imported into M. tuberculosis and incorporated into bacterial TAG [46]. In
conclusion the enzymes involved in lipid droplet metabolism are essential for survival of the
pathogen in the lung and thus attractive targets for novel drugs. Especially enzymes with
DGAT activity such as Tgs and Ag85A seem to be promising drug target candidates. Another
promising targets seem to be the recently discovered cell wall associated and secreted
esterases, which are involved in the utilization of host cell lipids such as Rv0183 and LipY [55,
75,76]. Future studies should also focus on the lipid metabolism of M. leprae, an organism which
upregulates several genes of the host´s lipid metabolism during infection [92]. The regulation
of lipid droplet formation in the host cell is another important topic. Recent sudies revealed
that intracellular pathogens induce the expression of LDL receptor and scavenger receptors
CD36 and LOX1 for the internalization of native and oxidized fatty acids. Especially the
generation of oxidized lipids by macrophage-derived reactive oxygen species seems to be an
important mechanism for the induction of scavenger receptors.
Author details
Matthias Stehr1, Ayssar A. Elamin1 and Mahavir Singh1,2*
*Address all correspondence to: Mahavir.Singh@helmholtz-hzi.de
1 LIONEX Diagnostics and Therapeutics GmbH, Braunschweig, Germany
2 Department of Genome Analytics, Helmholtz Centre for Infection Research, Braunsch‐
weig, Germany
References
[1] Murphy D. J., Brown J. R. Identification of gene targets against dormant phase
Mycobacterium tuberculosis infections. BMC Infect. Dis. 2007;7 84.
Tuberculosis - Current Issues in Diagnosis and Management46
[2] Zhang Y. Persistent and dormant tubercle bacilli and latent tuberculosis. Front. Biosci.
2004;9 1136-1156.
[3] Brennan P. J., Nikaido H. The envelope of mycobacteria. Annual review of biochemistry
1995;64 29-63.
[4] Coker R. J. Review: multidrug-resistant tuberculosis: public health challenges. Tropical
medicine & international health : TM & IH 2004;9 25-40.
[5] Barry C. E., 3rd, Lee R. E., Mdluli K., Sampson A. E., Schroeder B. G., Slayden R. A.,
Yuan Y. Mycolic acids: structure, biosynthesis and physiological functions. Progress in
lipid research 1998;37 143-179.
[6] Ridley D. S., Jopling W. H. Classification of leprosy according to immunity. A five-
group system. Int Int. J. Lepr. 1966;34 255-273.
[7] WHO, WHO Leprosy Today, WHO, 2010.
[8] Cosma C. L., Sherman D. R., Ramakrishnan L. The secret lives of the pathogenic
mycobacteria. Annu. Rev. Microbiol. 2003;57 641-676.
[9] Scollard D. M. Endothelial cells and the pathogenesis of lepromatous neuritis:insights
from the armadillo model. Microbes Infect. 2000;2 1835-1843.
[10] Mattos K. A., Lara F. A., Oliveira V. G., Rodrigues L. S., D'Avila H., Melo R. C., Manso
P. P., Sarno E. N., Bozza P. T., Pessolani M. C. Modulation of lipid droplets by
Mycobacterium leprae in Schwann cells: a putative mechanism for host lipid acquisition
and bacterial survival in phagosomes. Cell. Microbiol. 2011;13 259-273.
[11] Scollard D. M., Adams L. B., Gillis T. P., Krahenbuhl J. L., Truman R. W., Williams D.
L. The continuing challenges of leprosy. Clin. Microbiol. Rev. 2006;19 338-381.
[12] Vissa V. D., Brennan P. J., Impact of the Mycobacterium leprae genome sequence on
leprosy research in: A. Danchin (Ed.), Genomics of GC-rich Gram-positive bacteria,
Band 2, Caister Academic Press, 2002, pp. 85 - 118.
[13] Raphael Rubin D. S. S., Rubin Emanuel (Ed.), Rubin's Pathology: Clinicopathologic
Foundations of Medicine, Lippincott Williams and Wilkins, 2007.
[14] Wheeler P. R., Bulmer K., Ratledge C. Enzymes for biosynthesis de novo and elongation
of fatty acids in mycobacteria grown in host cells: is Mycobacterium leprae competent in
fatty acid biosynthesis? J. Gen. Microbiol. 1990;136 211-217.
[15] Russell D. G., Cardona P. J., Kim M. J., Allain S., Altare F. Foamy macrophages and the
progression of the human tuberculosis granuloma. Nat. Immunol. 2009;10 943-948.
[16] Neyrolles O., Hernandez-Pando R., Pietri-Rouxel F., Fornes P., Tailleux L., Barrios
Payan J. A., Pivert E., Bordat Y., Aguilar D., Prevost M. C., Petit C., Gicquel B. Is adipose
tissue a place for Mycobacterium tuberculosis persistence? PLoS One 2006;1 e43.
[17] Garton N. J., Waddell S. J., Sherratt A. L., Lee S. M., Smith R. J., Senner C., Hinds J.,
Rajakumar K., Adegbola R. A., Besra G. S., Butcher P. D., Barer M. R. Cytological and
Lipid Inclusions in Mycobacterial Infections
http://dx.doi.org/10.5772/54526
47
transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS
Med. 2008;5 e75.
[18] Daniel J., Deb C., Dubey V. S., Sirakova T. D., Abomoelak B., Morbidoni H. R., Kolat‐
tukudy P. E. Induction of a novel class of diacylglycerol acyltransferases and triacyl‐
glycerol accumulation in Mycobacterium tuberculosis as it goes into a dormancy-like
state in culture. J. Bacteriol. 2004;186 5017-5030.
[19] Peyron P., Vaubourgeix J., Poquet Y., Levillain F., Botanch C., Bardou F., Daffé M.,
Emile J.-F., Marchou B., Cardona P.-J., de Chastellier C., Altare F. Foamy macrophages
from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M.
tuberculosis persistence. Plos Pathog. 2008;4 e1000204.
[20] Hagge D. A., Oby Robinson S., Scollard D., McCormick G., Williams D. L. A new model
for studying the effects of Mycobacterium leprae on Schwann cell and neuron interac‐
tions. J. Infect. Dis. 2002;186 1283-1296.
[21] Cruz D., Watson A. D., Miller C. S., Montoya D., Ochoa M. T., Sieling P. A., Gutierrez
M. A., Navab M., Reddy S. T., Witztum J. L., Fogelman A. M., Rea T. H., Eisenberg D.,
Berliner J., Modlin R. L. Host-derived oxidized phospholipids and HDL regulate innate
immunity in human leprosy. J. Clin. Invest. 2008;118 2917-2928.
[22] Murphy D. J., Vance J. Mechanisms of lipid-body formation. Trends Biochem. Sci.
1999;24 109-115.
[23] Ohsaki Y., Cheng J., Suzuki M., Shinohara Y., Fujita A., Fujimoto T. Biogenesis of
cytoplasmic lipid droplets: from the lipid ester globule in the membrane to the visible
structure. Biochim. Biophys. Acta. 2009;1791 399-407.
[24] Wältermann M., Steinbüchel A. Neutral lipid bodies in prokaryotes: recent insights into
structure, formation, and relationship to eukaryotic lipid depots. J. Bacteriol. 2005;187
3607-3619.
[25] Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362
801-809.
[26] Pacheco P., Bozza F. A., Gomes R. N., Bozza M., Weller P. F., Castro-Faria-Neto H. C.,
Bozza P. T. Lipopolysaccharide-induced leukocyte lipid body formation in vivo: innate
immunity elicited intracellular loci involved in eicosanoid metabolism. J. Immunol.
2002;169 6498-6506.
[27] Moriishi K., Matsuura Y. Exploitation of lipid components by viral and host proteins
for hepatitis C virus infection. Front. Microbiol. 2012;3 54.
[28] Garton N. J., Christensen H., Minnikin D. E., Adegbola R. A., Barer M. R. Intracellular
lipophilic inclusions of mycobacteria in vitro and in sputum. Microbiology 2002;148
2951-2958.
[29] Russell D. G. Who puts the tubercle in tuberculosis? Nat. Rev. Microbiol. 2007;5 39-47.
Tuberculosis - Current Issues in Diagnosis and Management48
[30] Kurup G., Mahadevan P. R. Cholesterol metobolism of macrophages in relation to the
presence of Mycobacterium leprae. J. Biosci. 1982;4 307–316.
[31] Athenstaedt K., Zweytick D., Jandrositz A., Kohlwein S. D., Daum G. Identification and
characterization of major lipid particle proteins of the yeast Saccharomyces cerevisiae. J.
Bacteriol. 1999;181 6441-6448.
[32] Wan H. C., Melo R. C., Jin Z., Dvorak A. M., Weller P. F. Roles and origins of leukocyte
lipid bodies: proteomic and ultrastructural studies. Faseb J. 2007;21 167-178.
[33] Beller M., Riedel D., Jänsch L., Dieterich G., Wehland J., Jäckle H., Kühnlein R. P.
Characterization of the Drosophila lipid droplet subproteome. Mol. Cell. Proteomics.
2006;5 1082-1094.
[34] D'Avila H., Maya-Monteiro C. M., Bozza P. T. Lipid bodies in innate immune response
to bacterial and parasite infections. Int. Immunopharmacol. 2008;8 1308-1315.
[35] Beller M., Thiel K., Thul P. J., Jäckle H. Lipid droplets: a dynamic organelle moves into
focus. FEBS Lett. 2010;584 2176-2182.
[36] Murphy D. J. The dynamic roles of intracellular lipid droplets: from archaea to
mammals. Protoplasma 2011;15 15.
[37] Tauchi-Sato K., Ozeki S., Houjou T., Taguchi R., Fujimoto T. The surface of lipid
droplets is a phospholipid monolayer with a unique fatty acid composition. J. Biol.
Chem. 2002;277 44507-44512.
[38] Job C. K. Mycobacterium leprae in nerve lesions in lepromatous leprosy. An electron
microscopic study. Arch. Pathol. 1970;89 195-207.
[39] Tanigawa K., Suzuki K., Nakamura K., Akama T., Kawashima A., Wu H., Hayashi M.,
Takahashi S., Ikuyama S., Ito T., Ishii N. Expression of adipose differentiation-related
protein (ADRP) and perilipin in macrophages infected with Mycobacterium leprae. FEMS
Microbiol. Lett. 2008;289 72-79.
[40] Alvarez H. M., Steinbüchel A. Triacylglycerols in prokaryotic microorganisms. Appl.
Microbiol. Biotechnol. 2002;60 367-376.
[41] Barksdale L., Kim K. S. Mycobacterium. Bacteriol. Rev. 1977;41 217-372.
[42] Christensen H., Garton N. J., Horobin R. W., Minnikin D. E., Barer M. R. Lipid domains
of mycobacteria studied with fluorescent molecular probes. Mol. Microbiol. 1999;31
1561-1572.
[43] Wältermann M., Stöveken T., Steinbüchel A. Key enzymes for biosynthesis of neutral
lipid storage compounds in prokaryotes: properties, function and occurrence of wax
ester synthases/acyl-CoA: diacylglycerol acyltransferases. Biochimie 2007;89 230-242.
[44] Burdon K. L. Fatty material in bacteria and fungi revealed by staining dried, fixed slide
preparations. J. Bacteriol. 1946;52 665-678.
Lipid Inclusions in Mycobacterial Infections
http://dx.doi.org/10.5772/54526
49
transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS
Med. 2008;5 e75.
[18] Daniel J., Deb C., Dubey V. S., Sirakova T. D., Abomoelak B., Morbidoni H. R., Kolat‐
tukudy P. E. Induction of a novel class of diacylglycerol acyltransferases and triacyl‐
glycerol accumulation in Mycobacterium tuberculosis as it goes into a dormancy-like
state in culture. J. Bacteriol. 2004;186 5017-5030.
[19] Peyron P., Vaubourgeix J., Poquet Y., Levillain F., Botanch C., Bardou F., Daffé M.,
Emile J.-F., Marchou B., Cardona P.-J., de Chastellier C., Altare F. Foamy macrophages
from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M.
tuberculosis persistence. Plos Pathog. 2008;4 e1000204.
[20] Hagge D. A., Oby Robinson S., Scollard D., McCormick G., Williams D. L. A new model
for studying the effects of Mycobacterium leprae on Schwann cell and neuron interac‐
tions. J. Infect. Dis. 2002;186 1283-1296.
[21] Cruz D., Watson A. D., Miller C. S., Montoya D., Ochoa M. T., Sieling P. A., Gutierrez
M. A., Navab M., Reddy S. T., Witztum J. L., Fogelman A. M., Rea T. H., Eisenberg D.,
Berliner J., Modlin R. L. Host-derived oxidized phospholipids and HDL regulate innate
immunity in human leprosy. J. Clin. Invest. 2008;118 2917-2928.
[22] Murphy D. J., Vance J. Mechanisms of lipid-body formation. Trends Biochem. Sci.
1999;24 109-115.
[23] Ohsaki Y., Cheng J., Suzuki M., Shinohara Y., Fujita A., Fujimoto T. Biogenesis of
cytoplasmic lipid droplets: from the lipid ester globule in the membrane to the visible
structure. Biochim. Biophys. Acta. 2009;1791 399-407.
[24] Wältermann M., Steinbüchel A. Neutral lipid bodies in prokaryotes: recent insights into
structure, formation, and relationship to eukaryotic lipid depots. J. Bacteriol. 2005;187
3607-3619.
[25] Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362
801-809.
[26] Pacheco P., Bozza F. A., Gomes R. N., Bozza M., Weller P. F., Castro-Faria-Neto H. C.,
Bozza P. T. Lipopolysaccharide-induced leukocyte lipid body formation in vivo: innate
immunity elicited intracellular loci involved in eicosanoid metabolism. J. Immunol.
2002;169 6498-6506.
[27] Moriishi K., Matsuura Y. Exploitation of lipid components by viral and host proteins
for hepatitis C virus infection. Front. Microbiol. 2012;3 54.
[28] Garton N. J., Christensen H., Minnikin D. E., Adegbola R. A., Barer M. R. Intracellular
lipophilic inclusions of mycobacteria in vitro and in sputum. Microbiology 2002;148
2951-2958.
[29] Russell D. G. Who puts the tubercle in tuberculosis? Nat. Rev. Microbiol. 2007;5 39-47.
Tuberculosis - Current Issues in Diagnosis and Management48
[30] Kurup G., Mahadevan P. R. Cholesterol metobolism of macrophages in relation to the
presence of Mycobacterium leprae. J. Biosci. 1982;4 307–316.
[31] Athenstaedt K., Zweytick D., Jandrositz A., Kohlwein S. D., Daum G. Identification and
characterization of major lipid particle proteins of the yeast Saccharomyces cerevisiae. J.
Bacteriol. 1999;181 6441-6448.
[32] Wan H. C., Melo R. C., Jin Z., Dvorak A. M., Weller P. F. Roles and origins of leukocyte
lipid bodies: proteomic and ultrastructural studies. Faseb J. 2007;21 167-178.
[33] Beller M., Riedel D., Jänsch L., Dieterich G., Wehland J., Jäckle H., Kühnlein R. P.
Characterization of the Drosophila lipid droplet subproteome. Mol. Cell. Proteomics.
2006;5 1082-1094.
[34] D'Avila H., Maya-Monteiro C. M., Bozza P. T. Lipid bodies in innate immune response
to bacterial and parasite infections. Int. Immunopharmacol. 2008;8 1308-1315.
[35] Beller M., Thiel K., Thul P. J., Jäckle H. Lipid droplets: a dynamic organelle moves into
focus. FEBS Lett. 2010;584 2176-2182.
[36] Murphy D. J. The dynamic roles of intracellular lipid droplets: from archaea to
mammals. Protoplasma 2011;15 15.
[37] Tauchi-Sato K., Ozeki S., Houjou T., Taguchi R., Fujimoto T. The surface of lipid
droplets is a phospholipid monolayer with a unique fatty acid composition. J. Biol.
Chem. 2002;277 44507-44512.
[38] Job C. K. Mycobacterium leprae in nerve lesions in lepromatous leprosy. An electron
microscopic study. Arch. Pathol. 1970;89 195-207.
[39] Tanigawa K., Suzuki K., Nakamura K., Akama T., Kawashima A., Wu H., Hayashi M.,
Takahashi S., Ikuyama S., Ito T., Ishii N. Expression of adipose differentiation-related
protein (ADRP) and perilipin in macrophages infected with Mycobacterium leprae. FEMS
Microbiol. Lett. 2008;289 72-79.
[40] Alvarez H. M., Steinbüchel A. Triacylglycerols in prokaryotic microorganisms. Appl.
Microbiol. Biotechnol. 2002;60 367-376.
[41] Barksdale L., Kim K. S. Mycobacterium. Bacteriol. Rev. 1977;41 217-372.
[42] Christensen H., Garton N. J., Horobin R. W., Minnikin D. E., Barer M. R. Lipid domains
of mycobacteria studied with fluorescent molecular probes. Mol. Microbiol. 1999;31
1561-1572.
[43] Wältermann M., Stöveken T., Steinbüchel A. Key enzymes for biosynthesis of neutral
lipid storage compounds in prokaryotes: properties, function and occurrence of wax
ester synthases/acyl-CoA: diacylglycerol acyltransferases. Biochimie 2007;89 230-242.
[44] Burdon K. L. Fatty material in bacteria and fungi revealed by staining dried, fixed slide
preparations. J. Bacteriol. 1946;52 665-678.
Lipid Inclusions in Mycobacterial Infections
http://dx.doi.org/10.5772/54526
49
[45] Deb C., Lee C. M., Dubey V. S., Daniel J., Abomoelak B., Sirakova T. D., Pawar S., Rogers
L., Kolattukudy P. E. A novel in vitro multiple-stress dormancy model for Mycobacte‐
rium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One
2009;4 e6077.
[46] Daniel J., Maamar H., Deb C., Sirakova T. D., Kolattukudy P. E. Mycobacterium tuber‐
culosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-
like phenotype in lipid-loaded macrophages. PLoS Pathog. 2011;7 e1002093.
[47] Deb C., Daniel J., Sirakova T. D., Abomoelak B., Dubey V. S., Kolattukudy P. E. A novel
lipase belonging to the hormone-sensitive lipase family induced under starvation to
utilize stored triacylglycerol in Mycobacterium tuberculosis. J. Biol. Chem. 2006;281
3866-3875.
[48] Daniel J., Deb C., Dubey V. S., Sirakova T. D., Abomoelak B., Morbidoni H. R., Kolat‐
tukudy P. E. Induction of a novel class of diacylglycerol acyltransferases and triacyl‐
glycerol accumulation in Mycobacterium tuberculosis as it goes into a dormancy-like state
in culture. J. Bacteriol. 2004;186 5017-5030.
[49] Low K. L., Rao P. S., Shui G., Bendt A. K., Pethe K., Dick T., Wenk M. R. Triacylglycerol
utilization is required for regrowth of in vitro hypoxic nonreplicating Mycobacterium
bovis bacillus Calmette-Guerin. J. Bacteriol. 2009;191 5037-5043.
[50] Rohde K., Yates R. M., Purdy G. E., Russell D. G. Mycobacterium tuberculosis and the
environment within the phagosome. Immunol. Rev. 2007;219 37-54.
[51] Peters W., Ernst J. D. Mechanisms of cell recruitment in the immune response to
Mycobacterium tuberculosis. Microbes Infect. 2003;5 151–158.
[52] Flynn J. L., Chan J. Immunology of tuberculosis. Annu. Rev. Immunol. 2001;19 93–129.
[53] Cáceres N., Tapia G., Ojanguren I., Altare F., Gil O., Pinto S., Vilaplana C., Cardona P.
J. Evolution of foamy macrophages in the pulmonary granulomas of experimental
tuberculosis models. Tuberculosis (Edinb) 2009;89 175-182.
[54] Dubos R. J., Middlebrook G. Media for tubercle bacilli. Am. Rev. Tuberc. 1947;56
334-345.
[55] Neyrolles O., Hernandez-Pando R., Pietri-Rouxel F., Fornes P., Tailleux L., Barrios
Payan J. A., Pivert E., Bordat Y., Aguilar D., Prevost M. C., Petit C., Gicquel B. Is adipose
tissue a place for Mycobacterium tuberculosis persistence? PLoS One 2006;1 e43.
[56] Jain M., Petzold C. J., Schelle M. W., Leavell M. D., Mougous J. D., Bertozzi C. R., Leary
J. A., Cox J. S. Lipidomics reveals control of Mycobacterium tuberculosis virulence lipids
via metabolic coupling. Proc. Natl. Acad. Sci. U S A 2007;104 5133-5138.
[57] Pandey A. K., Sassetti C. M. Mycobacterial persistence requires the utilization of host
cholesterol. Proc. Natl. Acad. Sci. U S A 2008;105 4376-4380.
[58] Klepp L. I., Forrellad M. A., Osella A. V., Blanco F. C., Stella E. J., Bianco M. V.,
Santangelo M. D., Sassetti C., Jackson M., Cataldi A. A., Bigi F., Morbidoni H. R. Impact
Tuberculosis - Current Issues in Diagnosis and Management50
of the deletion of the six mce operons in Mycobacterium smegmatis. Microbes Infect.
2012;7-8 590-599.
[59] Williams D. L., Torrero M., Wheeler P. R., Truman R. W., Yoder M., Morrison N., Bishai
W. R., Gillis T. P. Biological implications of Mycobacterium leprae gene expression during
infection. J. Mol. Microbiol. Biotechnol. 2004;8 58-72.
[60] Akama T., Tanigawa K., Kawashima A., Wu H., Ishii N., Suzuki K. Analysis of
Mycobacterium leprae gene expression using DNA microarray. Microb. Pathog. 2010;49
181-185.
[61] Suzuki K., Takeshita F., Nakata N., Ishii N., Makino M. Localization of CORO1A in the
macrophages containing Mycobacterium leprae. Acta Histochem. Cytochem. 2006;39
107-112.
[62] Gatfield J., Pieters J. Essential role for cholesterol in entry of mycobacteria into macro‐
phages. Science. 2000;288 1647-1650.
[63] Anand P. K., Kaul D. Downregulation of TACO gene transcription restricts mycobac‐
terial entry/survival within human macrophages. FEMS Microbiol. Lett. 2005;250
137-144.
[64] Takayama K., Wang C., Besra G. S. Pathway to synthesis and processing of mycolic
acids in Mycobacterium tuberculosis. Clin. Microbiol. Rev. 2005;18 81-101.
[65] Glickman M. S. The mmaA2 gene of Mycobacterium tuberculosis encodes the distal
cyclopropane synthase of the alpha-mycolic acid. J. Biol. Chem. 2003;278 7844-7849..
[66] Glickman M. S., Cox J. S., Jacobs W. R., Jr. A novel mycolic acid cyclopropane synthetase
is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol.
Cell. 2000;5 717-727.
[67] Kalscheuer R., Steinbüchel A. A novel bifunctional wax ester synthase/acyl-CoA:diac‐
ylglycerol acyltransferase mediates wax ester and triacylglycerol biosynthesis in
Acinetobacter calcoaceticus ADP1. J. Biol. Chem. 2003;278 8075-8082.
[68] Sirakova T. D., Dubey V. S., Deb C., Daniel J., Korotkova T. A., Abomoelak B., Kolat‐
tukudy P. E. Identification of a diacylglycerol acyltransferase gene involved in accu‐
mulation of triacylglycerol in Mycobacterium tuberculosis under stress. Microbiology
2006;152 2717-2725.
[69] Low K. L., Shui G., Natter K., Yeo W. K., Kohlwein S. D., Dick T., Rao S. P., Wenk M.
R. Lipid droplet-associated proteins are involved in the biosynthesis and hydrolysis of
triacylglycerol in Mycobacterium bovis bacillus Calmette-Guerin. J. Biol. Chem. 2010;285
21662-21670.
[70] Deb C., Daniel J., Sirakova T. D., Abomoelak B., Dubey V. S., Kolattukudy P. E. A novel
lipase belonging to the hormone-sensitive lipase family induced under starvation to
utilize stored triacylglycerol in Mycobacterium tuberculosis. J. Biol. Chem. 2006;281
3866-3875. Epub 2005 Dec 3813.
Lipid Inclusions in Mycobacterial Infections
http://dx.doi.org/10.5772/54526
51
[45] Deb C., Lee C. M., Dubey V. S., Daniel J., Abomoelak B., Sirakova T. D., Pawar S., Rogers
L., Kolattukudy P. E. A novel in vitro multiple-stress dormancy model for Mycobacte‐
rium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One
2009;4 e6077.
[46] Daniel J., Maamar H., Deb C., Sirakova T. D., Kolattukudy P. E. Mycobacterium tuber‐
culosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-
like phenotype in lipid-loaded macrophages. PLoS Pathog. 2011;7 e1002093.
[47] Deb C., Daniel J., Sirakova T. D., Abomoelak B., Dubey V. S., Kolattukudy P. E. A novel
lipase belonging to the hormone-sensitive lipase family induced under starvation to
utilize stored triacylglycerol in Mycobacterium tuberculosis. J. Biol. Chem. 2006;281
3866-3875.
[48] Daniel J., Deb C., Dubey V. S., Sirakova T. D., Abomoelak B., Morbidoni H. R., Kolat‐
tukudy P. E. Induction of a novel class of diacylglycerol acyltransferases and triacyl‐
glycerol accumulation in Mycobacterium tuberculosis as it goes into a dormancy-like state
in culture. J. Bacteriol. 2004;186 5017-5030.
[49] Low K. L., Rao P. S., Shui G., Bendt A. K., Pethe K., Dick T., Wenk M. R. Triacylglycerol
utilization is required for regrowth of in vitro hypoxic nonreplicating Mycobacterium
bovis bacillus Calmette-Guerin. J. Bacteriol. 2009;191 5037-5043.
[50] Rohde K., Yates R. M., Purdy G. E., Russell D. G. Mycobacterium tuberculosis and the
environment within the phagosome. Immunol. Rev. 2007;219 37-54.
[51] Peters W., Ernst J. D. Mechanisms of cell recruitment in the immune response to
Mycobacterium tuberculosis. Microbes Infect. 2003;5 151–158.
[52] Flynn J. L., Chan J. Immunology of tuberculosis. Annu. Rev. Immunol. 2001;19 93–129.
[53] Cáceres N., Tapia G., Ojanguren I., Altare F., Gil O., Pinto S., Vilaplana C., Cardona P.
J. Evolution of foamy macrophages in the pulmonary granulomas of experimental
tuberculosis models. Tuberculosis (Edinb) 2009;89 175-182.
[54] Dubos R. J., Middlebrook G. Media for tubercle bacilli. Am. Rev. Tuberc. 1947;56
334-345.
[55] Neyrolles O., Hernandez-Pando R., Pietri-Rouxel F., Fornes P., Tailleux L., Barrios
Payan J. A., Pivert E., Bordat Y., Aguilar D., Prevost M. C., Petit C., Gicquel B. Is adipose
tissue a place for Mycobacterium tuberculosis persistence? PLoS One 2006;1 e43.
[56] Jain M., Petzold C. J., Schelle M. W., Leavell M. D., Mougous J. D., Bertozzi C. R., Leary
J. A., Cox J. S. Lipidomics reveals control of Mycobacterium tuberculosis virulence lipids
via metabolic coupling. Proc. Natl. Acad. Sci. U S A 2007;104 5133-5138.
[57] Pandey A. K., Sassetti C. M. Mycobacterial persistence requires the utilization of host
cholesterol. Proc. Natl. Acad. Sci. U S A 2008;105 4376-4380.
[58] Klepp L. I., Forrellad M. A., Osella A. V., Blanco F. C., Stella E. J., Bianco M. V.,
Santangelo M. D., Sassetti C., Jackson M., Cataldi A. A., Bigi F., Morbidoni H. R. Impact
Tuberculosis - Current Issues in Diagnosis and Management50
of the deletion of the six mce operons in Mycobacterium smegmatis. Microbes Infect.
2012;7-8 590-599.
[59] Williams D. L., Torrero M., Wheeler P. R., Truman R. W., Yoder M., Morrison N., Bishai
W. R., Gillis T. P. Biological implications of Mycobacterium leprae gene expression during
infection. J. Mol. Microbiol. Biotechnol. 2004;8 58-72.
[60] Akama T., Tanigawa K., Kawashima A., Wu H., Ishii N., Suzuki K. Analysis of
Mycobacterium leprae gene expression using DNA microarray. Microb. Pathog. 2010;49
181-185.
[61] Suzuki K., Takeshita F., Nakata N., Ishii N., Makino M. Localization of CORO1A in the
macrophages containing Mycobacterium leprae. Acta Histochem. Cytochem. 2006;39
107-112.
[62] Gatfield J., Pieters J. Essential role for cholesterol in entry of mycobacteria into macro‐
phages. Science. 2000;288 1647-1650.
[63] Anand P. K., Kaul D. Downregulation of TACO gene transcription restricts mycobac‐
terial entry/survival within human macrophages. FEMS Microbiol. Lett. 2005;250
137-144.
[64] Takayama K., Wang C., Besra G. S. Pathway to synthesis and processing of mycolic
acids in Mycobacterium tuberculosis. Clin. Microbiol. Rev. 2005;18 81-101.
[65] Glickman M. S. The mmaA2 gene of Mycobacterium tuberculosis encodes the distal
cyclopropane synthase of the alpha-mycolic acid. J. Biol. Chem. 2003;278 7844-7849..
[66] Glickman M. S., Cox J. S., Jacobs W. R., Jr. A novel mycolic acid cyclopropane synthetase
is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol.
Cell. 2000;5 717-727.
[67] Kalscheuer R., Steinbüchel A. A novel bifunctional wax ester synthase/acyl-CoA:diac‐
ylglycerol acyltransferase mediates wax ester and triacylglycerol biosynthesis in
Acinetobacter calcoaceticus ADP1. J. Biol. Chem. 2003;278 8075-8082.
[68] Sirakova T. D., Dubey V. S., Deb C., Daniel J., Korotkova T. A., Abomoelak B., Kolat‐
tukudy P. E. Identification of a diacylglycerol acyltransferase gene involved in accu‐
mulation of triacylglycerol in Mycobacterium tuberculosis under stress. Microbiology
2006;152 2717-2725.
[69] Low K. L., Shui G., Natter K., Yeo W. K., Kohlwein S. D., Dick T., Rao S. P., Wenk M.
R. Lipid droplet-associated proteins are involved in the biosynthesis and hydrolysis of
triacylglycerol in Mycobacterium bovis bacillus Calmette-Guerin. J. Biol. Chem. 2010;285
21662-21670.
[70] Deb C., Daniel J., Sirakova T. D., Abomoelak B., Dubey V. S., Kolattukudy P. E. A novel
lipase belonging to the hormone-sensitive lipase family induced under starvation to
utilize stored triacylglycerol in Mycobacterium tuberculosis. J. Biol. Chem. 2006;281
3866-3875. Epub 2005 Dec 3813.
Lipid Inclusions in Mycobacterial Infections
http://dx.doi.org/10.5772/54526
51
[71] Elamin A. A., Stehr M., Spallek R., Rohde M., Singh M. The Mycobacterium tuberculo‐
sis Ag85A is a novel diacylglycerol acyltransferase involved in lipid body formation.
Mol. Microbiol. 2011;81 1577-1592.
[72] Canaan S., Maurin D., Chahinian H., Pouilly B., Durousseau C., Frassinetti F., Scap‐
puccini-Calvo L., Cambillau C., Bourne Y. Expression and characterization of the
protein Rv1399c from Mycobacterium tuberculosis. A novel carboxyl esterase structurally
related to the HSL family. Eur. J. Biochem. 2004;271 3953-3961.
[73] Mishra K. C., de Chastellier C., Narayana Y., Bifani P., Brown A. K., Besra G. S., Katoch
V. M., Joshi B., Balaji K. N., Kremer L. Functional role of the PE domain and immuno‐
genicity of the Mycobacterium tuberculosis triacylglycerol hydrolase LipY. Infect.
Immun. 2008;76 127-140.
[74] Singh V. K., Srivastava V., Singh V., Rastogi N., Roy R., Shaw A. K., Dwivedi A. K.,
Srivastava R., Srivastava B. S. Overexpression of Rv3097c in Mycobacterium bovis BCG
abolished the efficacy of BCG vaccine to protect against Mycobacterium tuberculosis
infection in mice Vaccine 2011;29 4754-4760.
[75] Daleke M. H., Cascioferro A., de Punder K., Ummels R., Abdallah A. M., van der Wel
N., Peters P. J., Luirink J., Manganelli R., Bitter W. Conserved Pro-Glu (PE) and Pro-
Pro-Glu (PPE) protein domains target LipY lipases of pathogenic mycobacteria to the
cell surface via the ESX-5 pathway. J. Biol. Chem. 2011;286 19024-19034.
[76] Côtes K., Dhouib R., Douchet I., Chahinian H., de Caro A., Carriere F., Canaan S.
Characterization of an exported monoglyceride lipase from Mycobacterium tuberculo‐
sis possibly involved in the metabolism of host cell membrane lipids. Biochem. J.
2007;408 417-427.
[77] Lun S., Bishai W. R. Characterization of a novel cell wall-anchored protein with
carboxylesterase activity required for virulence in Mycobacterium tuberculosis. J. Biol.
Chem. 2007;282 18348-18356.
[78] Zheng X., Guo J., Xu L., Li H., Zhang D., Zhang K., Sun F., Wen T., Liu S., Pang H.
Crystal structure of a novel esterase Rv0045c from Mycobacterium tuberculosis. PLoS One
2011;6 e20506.
[79] McKinney J. D., Honer zu Bentrup K., Muñoz-Elías E. J., Miczak A., Chen B., Chan W.
T., Swenson D., Sacchettini J. C., Jacobs W. R., Jr., Russell D. G. Persistence of Mycobac‐
terium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme
isocitrate lyase. Nature 2000;406 735-738.
[80] Muñoz-Elías E. J., McKinney J. D. Mycobacterium tuberculosis isocitrate lyases 1 and 2
are jointly required for in vivo growth and virulence. Nat. Med. 2005;11 638-644.
[81] Ensign S. A. Revisiting the glyoxylate cycle: alternate pathways for microbial acetate
assimilation. Mol. Microbiol. 2006;61 274-276.
Tuberculosis - Current Issues in Diagnosis and Management52
[82] Williams K. J., Boshoff H. I., Krishnan N., Gonzales J., Schnappinger D., Robertson B.
D. The Mycobacterium tuberculosis beta-oxidation genes echA5 and fadB3 are dispensa‐
ble for growth in vitro and in vivo. Tuberculosis (Edinb) 2011;91 549-555.
[83] Kornberg H. Krebs and his trinity of cycles. Nat. Rev. Mol. Cell. Biol. 2000;1 225-228.
[84] Brennan P. J. Mycobacterium leprae - The outer lipoidal surface J. Biosci. 1984;6 685–689.
[85] Fisher C. A., Barksdale L. Cytochemical reactions of human leprosy bacilli and
mycobacteria: ultrastructural implications. J. Bacteriol. 1973;113 1389-1399.
[86] Sakurai I., Skinsnes O. K. Lipids in leprosy. 2. Histochemistry of lipids in human
leprosy. Int Int. J. Lepr. 1970;38 389-403.
[87] Kaplan G., Van Voorhis W. C., Sarno E. N., Nogueira N., Cohn Z. A. The cutaneous
infiltrates of leprosy. A transmission electron microscopy study. J. Exp. Med. 1983;158
1145-1159.
[88] Hunter S. W., Brennan P. J. A novel phenolic glycolipid from Mycobacterium leprae
possibly involved in immunogenicity and pathogenicity. J. Bacteriol. 1981;147 728-735.
[89] Guenin-Mace L., Simeone R., Demangel C. Lipids of pathogenic Mycobacteria:
contributions to virulence and host immune suppression. Transbound. Emerg. Dis.
2009;56 255-268.
[90] Ng V., Zanazzi G., Timpl R., Talts J. F., Salzer J. L., Brennan P. J., Rambukkana A. Role
of the cell wall phenolic glycolipid-1 in the peripheral nerve predilection of Mycobac‐
terium leprae. Cell. 2000;103 511-524.
[91] Puzo G. The carbohydrate- and lipid-containing cell wall of mycobacteria, phenolic
glycolipids: structure and immunological properties. Crit. Rev. Microbiol. 1990;17
305-327.
[92] Cruz D., Watson A. D., Miller C. S., Montoya D., Ochoa M. T., Sieling P. A., Gutierrez
M. A., Navab M., Reddy S. T., Witztum J. L., Fogelman A. M., Rea T. H., Eisenberg D.,
Berliner J., Modlin R. L. Host-derived oxidized phospholipids and HDL regulate innate
immunity in human leprosy. J. Clin. Invest. 2008;118 2917-2928.
[93] Kumar R., Bhakuni V. Mycobacterium tuberculosis isocitrate lyase (MtbIcl): role of
divalent cations in modulation of functional and structural properties. Proteins 2008;72
892-900.
[94] Höner Zu Bentrup K., Miczak A., Swenson D. L., Russell D. G. Characterization of
activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium
tuberculosis. J. Bacteriol. 1999;181 7161-7167.
[95] Sharma V., Sharma S., Hoener zu Bentrup K., McKinney J. D., Russell D. G., Jacobs W.
R., Jr., Sacchettini J. C. Structure of isocitrate lyase, a persistence factor of Mycobacterium
tuberculosis. Nat. Struct. Biol. 2000;7 663-668.
Lipid Inclusions in Mycobacterial Infections
http://dx.doi.org/10.5772/54526
53
[71] Elamin A. A., Stehr M., Spallek R., Rohde M., Singh M. The Mycobacterium tuberculo‐
sis Ag85A is a novel diacylglycerol acyltransferase involved in lipid body formation.
Mol. Microbiol. 2011;81 1577-1592.
[72] Canaan S., Maurin D., Chahinian H., Pouilly B., Durousseau C., Frassinetti F., Scap‐
puccini-Calvo L., Cambillau C., Bourne Y. Expression and characterization of the
protein Rv1399c from Mycobacterium tuberculosis. A novel carboxyl esterase structurally
related to the HSL family. Eur. J. Biochem. 2004;271 3953-3961.
[73] Mishra K. C., de Chastellier C., Narayana Y., Bifani P., Brown A. K., Besra G. S., Katoch
V. M., Joshi B., Balaji K. N., Kremer L. Functional role of the PE domain and immuno‐
genicity of the Mycobacterium tuberculosis triacylglycerol hydrolase LipY. Infect.
Immun. 2008;76 127-140.
[74] Singh V. K., Srivastava V., Singh V., Rastogi N., Roy R., Shaw A. K., Dwivedi A. K.,
Srivastava R., Srivastava B. S. Overexpression of Rv3097c in Mycobacterium bovis BCG
abolished the efficacy of BCG vaccine to protect against Mycobacterium tuberculosis
infection in mice Vaccine 2011;29 4754-4760.
[75] Daleke M. H., Cascioferro A., de Punder K., Ummels R., Abdallah A. M., van der Wel
N., Peters P. J., Luirink J., Manganelli R., Bitter W. Conserved Pro-Glu (PE) and Pro-
Pro-Glu (PPE) protein domains target LipY lipases of pathogenic mycobacteria to the
cell surface via the ESX-5 pathway. J. Biol. Chem. 2011;286 19024-19034.
[76] Côtes K., Dhouib R., Douchet I., Chahinian H., de Caro A., Carriere F., Canaan S.
Characterization of an exported monoglyceride lipase from Mycobacterium tuberculo‐
sis possibly involved in the metabolism of host cell membrane lipids. Biochem. J.
2007;408 417-427.
[77] Lun S., Bishai W. R. Characterization of a novel cell wall-anchored protein with
carboxylesterase activity required for virulence in Mycobacterium tuberculosis. J. Biol.
Chem. 2007;282 18348-18356.
[78] Zheng X., Guo J., Xu L., Li H., Zhang D., Zhang K., Sun F., Wen T., Liu S., Pang H.
Crystal structure of a novel esterase Rv0045c from Mycobacterium tuberculosis. PLoS One
2011;6 e20506.
[79] McKinney J. D., Honer zu Bentrup K., Muñoz-Elías E. J., Miczak A., Chen B., Chan W.
T., Swenson D., Sacchettini J. C., Jacobs W. R., Jr., Russell D. G. Persistence of Mycobac‐
terium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme
isocitrate lyase. Nature 2000;406 735-738.
[80] Muñoz-Elías E. J., McKinney J. D. Mycobacterium tuberculosis isocitrate lyases 1 and 2
are jointly required for in vivo growth and virulence. Nat. Med. 2005;11 638-644.
[81] Ensign S. A. Revisiting the glyoxylate cycle: alternate pathways for microbial acetate
assimilation. Mol. Microbiol. 2006;61 274-276.
Tuberculosis - Current Issues in Diagnosis and Management52
[82] Williams K. J., Boshoff H. I., Krishnan N., Gonzales J., Schnappinger D., Robertson B.
D. The Mycobacterium tuberculosis beta-oxidation genes echA5 and fadB3 are dispensa‐
ble for growth in vitro and in vivo. Tuberculosis (Edinb) 2011;91 549-555.
[83] Kornberg H. Krebs and his trinity of cycles. Nat. Rev. Mol. Cell. Biol. 2000;1 225-228.
[84] Brennan P. J. Mycobacterium leprae - The outer lipoidal surface J. Biosci. 1984;6 685–689.
[85] Fisher C. A., Barksdale L. Cytochemical reactions of human leprosy bacilli and
mycobacteria: ultrastructural implications. J. Bacteriol. 1973;113 1389-1399.
[86] Sakurai I., Skinsnes O. K. Lipids in leprosy. 2. Histochemistry of lipids in human
leprosy. Int Int. J. Lepr. 1970;38 389-403.
[87] Kaplan G., Van Voorhis W. C., Sarno E. N., Nogueira N., Cohn Z. A. The cutaneous
infiltrates of leprosy. A transmission electron microscopy study. J. Exp. Med. 1983;158
1145-1159.
[88] Hunter S. W., Brennan P. J. A novel phenolic glycolipid from Mycobacterium leprae
possibly involved in immunogenicity and pathogenicity. J. Bacteriol. 1981;147 728-735.
[89] Guenin-Mace L., Simeone R., Demangel C. Lipids of pathogenic Mycobacteria:
contributions to virulence and host immune suppression. Transbound. Emerg. Dis.
2009;56 255-268.
[90] Ng V., Zanazzi G., Timpl R., Talts J. F., Salzer J. L., Brennan P. J., Rambukkana A. Role
of the cell wall phenolic glycolipid-1 in the peripheral nerve predilection of Mycobac‐
terium leprae. Cell. 2000;103 511-524.
[91] Puzo G. The carbohydrate- and lipid-containing cell wall of mycobacteria, phenolic
glycolipids: structure and immunological properties. Crit. Rev. Microbiol. 1990;17
305-327.
[92] Cruz D., Watson A. D., Miller C. S., Montoya D., Ochoa M. T., Sieling P. A., Gutierrez
M. A., Navab M., Reddy S. T., Witztum J. L., Fogelman A. M., Rea T. H., Eisenberg D.,
Berliner J., Modlin R. L. Host-derived oxidized phospholipids and HDL regulate innate
immunity in human leprosy. J. Clin. Invest. 2008;118 2917-2928.
[93] Kumar R., Bhakuni V. Mycobacterium tuberculosis isocitrate lyase (MtbIcl): role of
divalent cations in modulation of functional and structural properties. Proteins 2008;72
892-900.
[94] Höner Zu Bentrup K., Miczak A., Swenson D. L., Russell D. G. Characterization of
activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium
tuberculosis. J. Bacteriol. 1999;181 7161-7167.
[95] Sharma V., Sharma S., Hoener zu Bentrup K., McKinney J. D., Russell D. G., Jacobs W.
R., Jr., Sacchettini J. C. Structure of isocitrate lyase, a persistence factor of Mycobacterium
tuberculosis. Nat. Struct. Biol. 2000;7 663-668.
Lipid Inclusions in Mycobacterial Infections
http://dx.doi.org/10.5772/54526
53
[96] Yoshimoto R., Fujita Y., Kakino A., Iwamoto S., Takaya T., Sawamura T. The discovery
of LOX-1, its ligands and clinical significance. Cardiovasc. Drugs Ther. 2011;25 379-391.
[97] Collot-Teixeira S., Martin J., McDermott-Roe C., Poston R., McGregor J. L. CD36 and
macrophages in atherosclerosis. Cardiovasc. Res. 2007;75 468-477.
[98] Palanisamy G. S., Kirk N. M., Ackart D. F., Obregon-Henao A., Shanley C. A., Orme I.
M., Basaraba R. J. Uptake and accumulation of oxidized low-density lipoprotein during
Mycobacterium tuberculosis infection in guinea pigs. PLoS One 2012;7 e34148.
[99] Philips J. A., Rubin E. J., Perrimon N. Drosophila RNAi screen reveals CD36 family
member required for mycobacterial infection. Science 2005;309 1251-1253.
[100] Leelahavanichkul A., Bocharov A. V., Kurlander R., Baranova I. N., Vishnyakova T. G.,
Souza A. C., Hu X., Doi K., Vaisman B., Amar M., Sviridov D., Chen Z., Remaley A. T.,
Csako G., Patterson A. P., Yuen P. S., Star R. A., Eggerman T. L. Class B scavenger
receptor types I and II and CD36 targeting improves sepsis survival and acute outcomes
in mice. J. Immunol. 2012;188 2749-2758.
[101] Mattos K. A., Oliveira V. G. C., D'Avila H., Rodrigues L. S., Pinheiro R. O., Sarno E. N.,
Pessolani M. C. V., Bozza P. T. TLR6-driven lipid droplets in Mycobacterium leprae-
infected Schwann cells: Immunoinflammatory platforms associated with bacterial
persistence. J. Immunol. 2011;187 2548-2558.
[102] Mattos K. A., D'Avila H., Rodrigues L. S., Oliveira V. G., Sarno E. N., Atella G. C., Pereira
G. M., Bozza P. T., Pessolani M. C. Lipid droplet formation in leprosy: Toll-like receptor-
regulated organelles involved in eicosanoid formation and Mycobacterium leprae
pathogenesis. J. Leukoc. Biol. 2010;87 371-384.
[103] D'Avila H., Melo R. C., Parreira G. G., Werneck-Barroso E., Castro-Faria-Neto H. C.,
Bozza P. T. Mycobacterium bovis bacillus Calmette-Guerin induces TLR2-mediated
formation of lipid bodies: intracellular domains for eicosanoid synthesis in vivo. J.
Immunol. 2006;176 3087-3097.
[104] Almeida P. E., Silva A. R., Maya-Monteiro C. M., Töröcsik D., D'Avila H., Dezsö B.,
Magalhães K. G., Castro-Faria-Neto H. C., Nagy L., Bozza P. T. Mycobacterium bovis
bacillus Calmette-Guérin infection induces TLR2-dependent peroxisome proliferator-
activated receptor gamma expression and activation: functions in inflammation, lipid
metabolism, and pathogenesis. J. Immunol. 2009;183 1337-1345.
[105] Underhill D. M. Toll-like receptors: networking for success. Eur. J. Immunol. 003;33
1767-1775.
[106] Korf J., Stoltz A., Verschoor J., De Baetselier P., Grooten J. The Mycobacterium tubercu‐
losis cell wall component mycolic acid elicits pathogen-associated host innate immune
responses. Eur. J. Immunol. 2005;35 890-900.
[107] Johnson R., Streicher E. M., Louw G. E., Warren R. M., van Helden P. D., Victor T. C.
Drug resistance in Mycobacterium tuberculosis. Curr. Issues Mol. Biol. 2006;8 97-111.
Tuberculosis - Current Issues in Diagnosis and Management54
[108] Belisle J. T., Vissa V. D., Sievert T., Takayama K., Brennan P. J., Besra G. S. Role of the
major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science. 1997;276
1420-1422.
[109] Ronning D. R., Vissa V., Besra G. S., Belisle J. T., Sacchettini J. C. Mycobacterium
tuberculosis antigen 85A and 85C structures confirm binding orientation and conserved
substrate specificity. J. Biol. Chem. 2004;279 36771-36777..
[110] Armitige L. Y., Jagannath C., Wanger A. R., Norris S. J. Disruption of the genes encoding
antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in
culture and in macrophages. Infect. Immun. 2000;68 767-778.
[111] Jackson M., Raynaud C., Laneelle M. A., Guilhot C., Laurent-Winter C., Ensergueix D.,
Gicquel B., Daffe M. Inactivation of the antigen 85C gene profoundly affects the
mycolate content and alters the permeability of the Mycobacterium tuberculosis cell
envelope. Mol. Microbiol. 1999;31 1573-1587.
[112] Sanki A. K., Boucau J., Ronning D. R., Sucheck S. J. Antigen 85C-mediated acyl-transfer
between synthetic acyl donors and fragments of the arabinan. Glycoconj. J. 2009;26
589-596..
[113] Mizuguchi Y., Udou T., Yamada T. Mechanism of antibiotic resistance in Mycobacterium
intracellulare. Microbiol. Immunol. 1983;27 425-431.
[114] Mdluli K., Slayden R. A., Zhu Y., Ramaswamy S., Pan X., Mead D., Crane D. D., Musser
J. M., Barry C. E., 3rd Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP
synthase by isoniazid. Science 1998;280 1607-1610.
[115] Kremer L., Dover L. G., Morbidoni H. R., Vilcheze C., Maughan W. N., Baulard A., Tu
S. C., Honore N., Deretic V., Sacchettini J. C., Locht C., Jacobs W. R., Jr., Besra G. S.
Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-
containing complex in mycobacteria. J. Biol. Chem. 2003;278 20547-20554. Epub 22003
Mar 20524.
[116] Takayama K., Schnoes H. K., Armstrong E. L., Boyle R. W. Site of inhibitory action of
isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. J. Lipid Res.
1975;16 308-317.
[117] Wilming M., Johnsson K. Spontaneous formation of the bioactive form of the tubercu‐
losis drug isoniazid. Angew. Chem. Int. Ed. Engl. 1999;38 2588-2590.
[118] Schroeder E. K., de Souza N., Santos D. S., Blanchard J. S., Basso L. A. Drugs that inhibit
mycolic acid biosynthesis in Mycobacterium tuberculosis. Curr. Pharm. Biotechnol. 2002;3
197-225.
[119] Johansson P., Wiltschi B., Kumari P., Kessler B., Vonrhein C., Vonck J., Oesterhelt D.,
Grininger M. Inhibition of the fungal fatty acid synthase type I multienzyme complex.
P. Natl. Atl. Acad. Sci. USA 2008;105 12803-12808.
Lipid Inclusions in Mycobacterial Infections
http://dx.doi.org/10.5772/54526
55
[96] Yoshimoto R., Fujita Y., Kakino A., Iwamoto S., Takaya T., Sawamura T. The discovery
of LOX-1, its ligands and clinical significance. Cardiovasc. Drugs Ther. 2011;25 379-391.
[97] Collot-Teixeira S., Martin J., McDermott-Roe C., Poston R., McGregor J. L. CD36 and
macrophages in atherosclerosis. Cardiovasc. Res. 2007;75 468-477.
[98] Palanisamy G. S., Kirk N. M., Ackart D. F., Obregon-Henao A., Shanley C. A., Orme I.
M., Basaraba R. J. Uptake and accumulation of oxidized low-density lipoprotein during
Mycobacterium tuberculosis infection in guinea pigs. PLoS One 2012;7 e34148.
[99] Philips J. A., Rubin E. J., Perrimon N. Drosophila RNAi screen reveals CD36 family
member required for mycobacterial infection. Science 2005;309 1251-1253.
[100] Leelahavanichkul A., Bocharov A. V., Kurlander R., Baranova I. N., Vishnyakova T. G.,
Souza A. C., Hu X., Doi K., Vaisman B., Amar M., Sviridov D., Chen Z., Remaley A. T.,
Csako G., Patterson A. P., Yuen P. S., Star R. A., Eggerman T. L. Class B scavenger
receptor types I and II and CD36 targeting improves sepsis survival and acute outcomes
in mice. J. Immunol. 2012;188 2749-2758.
[101] Mattos K. A., Oliveira V. G. C., D'Avila H., Rodrigues L. S., Pinheiro R. O., Sarno E. N.,
Pessolani M. C. V., Bozza P. T. TLR6-driven lipid droplets in Mycobacterium leprae-
infected Schwann cells: Immunoinflammatory platforms associated with bacterial
persistence. J. Immunol. 2011;187 2548-2558.
[102] Mattos K. A., D'Avila H., Rodrigues L. S., Oliveira V. G., Sarno E. N., Atella G. C., Pereira
G. M., Bozza P. T., Pessolani M. C. Lipid droplet formation in leprosy: Toll-like receptor-
regulated organelles involved in eicosanoid formation and Mycobacterium leprae
pathogenesis. J. Leukoc. Biol. 2010;87 371-384.
[103] D'Avila H., Melo R. C., Parreira G. G., Werneck-Barroso E., Castro-Faria-Neto H. C.,
Bozza P. T. Mycobacterium bovis bacillus Calmette-Guerin induces TLR2-mediated
formation of lipid bodies: intracellular domains for eicosanoid synthesis in vivo. J.
Immunol. 2006;176 3087-3097.
[104] Almeida P. E., Silva A. R., Maya-Monteiro C. M., Töröcsik D., D'Avila H., Dezsö B.,
Magalhães K. G., Castro-Faria-Neto H. C., Nagy L., Bozza P. T. Mycobacterium bovis
bacillus Calmette-Guérin infection induces TLR2-dependent peroxisome proliferator-
activated receptor gamma expression and activation: functions in inflammation, lipid
metabolism, and pathogenesis. J. Immunol. 2009;183 1337-1345.
[105] Underhill D. M. Toll-like receptors: networking for success. Eur. J. Immunol. 003;33
1767-1775.
[106] Korf J., Stoltz A., Verschoor J., De Baetselier P., Grooten J. The Mycobacterium tubercu‐
losis cell wall component mycolic acid elicits pathogen-associated host innate immune
responses. Eur. J. Immunol. 2005;35 890-900.
[107] Johnson R., Streicher E. M., Louw G. E., Warren R. M., van Helden P. D., Victor T. C.
Drug resistance in Mycobacterium tuberculosis. Curr. Issues Mol. Biol. 2006;8 97-111.
Tuberculosis - Current Issues in Diagnosis and Management54
[108] Belisle J. T., Vissa V. D., Sievert T., Takayama K., Brennan P. J., Besra G. S. Role of the
major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science. 1997;276
1420-1422.
[109] Ronning D. R., Vissa V., Besra G. S., Belisle J. T., Sacchettini J. C. Mycobacterium
tuberculosis antigen 85A and 85C structures confirm binding orientation and conserved
substrate specificity. J. Biol. Chem. 2004;279 36771-36777..
[110] Armitige L. Y., Jagannath C., Wanger A. R., Norris S. J. Disruption of the genes encoding
antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in
culture and in macrophages. Infect. Immun. 2000;68 767-778.
[111] Jackson M., Raynaud C., Laneelle M. A., Guilhot C., Laurent-Winter C., Ensergueix D.,
Gicquel B., Daffe M. Inactivation of the antigen 85C gene profoundly affects the
mycolate content and alters the permeability of the Mycobacterium tuberculosis cell
envelope. Mol. Microbiol. 1999;31 1573-1587.
[112] Sanki A. K., Boucau J., Ronning D. R., Sucheck S. J. Antigen 85C-mediated acyl-transfer
between synthetic acyl donors and fragments of the arabinan. Glycoconj. J. 2009;26
589-596..
[113] Mizuguchi Y., Udou T., Yamada T. Mechanism of antibiotic resistance in Mycobacterium
intracellulare. Microbiol. Immunol. 1983;27 425-431.
[114] Mdluli K., Slayden R. A., Zhu Y., Ramaswamy S., Pan X., Mead D., Crane D. D., Musser
J. M., Barry C. E., 3rd Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP
synthase by isoniazid. Science 1998;280 1607-1610.
[115] Kremer L., Dover L. G., Morbidoni H. R., Vilcheze C., Maughan W. N., Baulard A., Tu
S. C., Honore N., Deretic V., Sacchettini J. C., Locht C., Jacobs W. R., Jr., Besra G. S.
Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-
containing complex in mycobacteria. J. Biol. Chem. 2003;278 20547-20554. Epub 22003
Mar 20524.
[116] Takayama K., Schnoes H. K., Armstrong E. L., Boyle R. W. Site of inhibitory action of
isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. J. Lipid Res.
1975;16 308-317.
[117] Wilming M., Johnsson K. Spontaneous formation of the bioactive form of the tubercu‐
losis drug isoniazid. Angew. Chem. Int. Ed. Engl. 1999;38 2588-2590.
[118] Schroeder E. K., de Souza N., Santos D. S., Blanchard J. S., Basso L. A. Drugs that inhibit
mycolic acid biosynthesis in Mycobacterium tuberculosis. Curr. Pharm. Biotechnol. 2002;3
197-225.
[119] Johansson P., Wiltschi B., Kumari P., Kessler B., Vonrhein C., Vonck J., Oesterhelt D.,
Grininger M. Inhibition of the fungal fatty acid synthase type I multienzyme complex.
P. Natl. Atl. Acad. Sci. USA 2008;105 12803-12808.
Lipid Inclusions in Mycobacterial Infections
http://dx.doi.org/10.5772/54526
55
[120] Luckner S. R., Liu N., am Ende C. W., Tonge P. J., Kisker C. A slow, tight binding
inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tubercu‐
losis. J. Biol. Chem. 2010;285 14330-14337.
[121] Kremer L., Douglas J. D., Baulard A. R., Morehouse C., Guy M. R., Alland D., Dover L.
G., Lakey J. H., Jacobs W. R., Jr., Brennan P. J., Minnikin D. E., Besra G. S. Thiolactomycin
and related analogues as novel anti-mycobacterial agents targeting KasA and KasB
condensing enzymes in Mycobacterium tuberculosis. J. Biol. Chem. 2000;275 16857-16864.
[122] Douglas J. D., Senior S. J., Morehouse C., Phetsukiri B., Campbell I. B., Besra G. S.,
Minnikin D. E. Analogues of thiolactomycin: potential drugs with enhanced anti-
mycobacterial activity. Microbiology (Reading, England) 2002;148 3101-3109.
[123] Brown A. K., Taylor R. C., Bhatt A., Futterer K., Besra G. S. Platensimycin activity
against mycobacterial beta-ketoacyl-ACP synthases. PLoS One 2009;4 e6306.
[124] Slayden R. A., Lee R. E., Barry C. E., 3rd Isoniazid affects multiple components of the
type II fatty acid synthase system of Mycobacterium tuberculosis. Mol. Microbiol. 2000;38
514-525.
[125] Kremer L., Dover L. G., Morbidoni H. R., Vilcheze C., Maughan W. N., Baulard A., Tu
S. C., Honore N., Deretic V., Sacchettini J. C., Locht C., Jacobs W. R., Jr., Besra G. S.
Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-
containing complex in mycobacteria. J. Biol. Chem. 278 20547-20554.
[126] McMurry L. M., McDermott P. F., Levy S. B. Genetic evidence that InhA of Mycobacte‐
rium smegmatis is a target for triclosan. Antimicrob. Agents Ch. 1999;43 711-713.
[127] Sullivan T. J., Truglio J. J., Boyne M. E., Novichenok P., Zhang X., Stratton C. F., Li H.
J., Kaur T., Amin A., Johnson F., Slayden R. A., Kisker C., Tonge P. J. High affinity InhA
inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS
chemical biology 2006;1 43-53.
[128] Alahari A., Trivelli X., Guerardel Y., Dover L. G., Besra G. S., Sacchettini J. C., Reynolds
R. C., Coxon G. D., Kremer L. Thiacetazone, an antitubercular drug that inhibits
cyclopropanation of cell wall mycolic acids in mycobacteria. PLoS One 2007;2 e1343.
Tuberculosis - Current Issues in Diagnosis and Management56
Chapter 4
The Role of Antibodies in the Defense Against
Tuberculosis
Armando Acosta, Yamile Lopez,
Norazmi Mohd Nor, Rogelio Hernández Pando,
Nadine Alvarez, Maria Elena Sarmiento and
Aharona Glatman-Freedman
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/53950
1. Introduction
Throughout history tuberculosis (TB) has been a health problem for humanity. In the beginning
of civilization, when human population densities were sparse, this disease may have been
fairly harmless. However, with the increase in population densities, probably from the 17th to
19th centuries, TB took epidemic proportions [1].
Bacille Calmette Guérin (BCG) is effective to prevent miliary and meningeal TB in infants [1].
The reports about the efficacy of this vaccine for the prevention of adults pulmonary TB are
contradictory and the consensus is that the protection conferred by BCG against this form of
TB is questionable [1]. The wide use of BCG vaccination has been unable to prevent nearly two
million deaths associated with TB that are produced every year. Currently the World Health
Organization no longer recommends BCG vaccination in children born from HIVpositive
mothers which complicate the implementation of BCG vaccination programs [2]. The imple‐
mentation of standard drug treatment for TB is difficult in the areas of the highest incidence
of the disease. Treatment is further complicated by the limited effectiveness of the current
therapeutic schemes against drug resistant strains of TB [3-5].
Nowadays there is an increasing realization of the need for new animal models to test vaccine
efficacy in more realistic scenarios, overcoming the limitations of current models in use. In
addition, the elucidation of the significance of antibody-mediated defense against intracellular
pathogens, in particular against Mycobacterium tuberculosis, constitutes an exciting new
approach to improve the rational design of new vaccines, therapies and diagnostics.
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1. Introduction
Throughout history tuberculosis (TB) has been a health problem for humanity. In the beginning
of civilization, when human population densities were sparse, this disease may have been
fairly harmless. However, with the increase in population densities, probably from the 17th to
19th centuries, TB took epidemic proportions [1].
Bacille Calmette Guérin (BCG) is effective to prevent miliary and meningeal TB in infants [1].
The reports about the efficacy of this vaccine for the prevention of adults pulmonary TB are
contradictory and the consensus is that the protection conferred by BCG against this form of
TB is questionable [1]. The wide use of BCG vaccination has been unable to prevent nearly two
million deaths associated with TB that are produced every year. Currently the World Health
Organization no longer recommends BCG vaccination in children born from HIVpositive
mothers which complicate the implementation of BCG vaccination programs [2]. The imple‐
mentation of standard drug treatment for TB is difficult in the areas of the highest incidence
of the disease. Treatment is further complicated by the limited effectiveness of the current
therapeutic schemes against drug resistant strains of TB [3-5].
Nowadays there is an increasing realization of the need for new animal models to test vaccine
efficacy in more realistic scenarios, overcoming the limitations of current models in use. In
addition, the elucidation of the significance of antibody-mediated defense against intracellular
pathogens, in particular against Mycobacterium tuberculosis, constitutes an exciting new
approach to improve the rational design of new vaccines, therapies and diagnostics.
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2. Specific antibodies: Players in the defense against TB
In order to develop improved vaccines and new methods for controlling TB, an important
element is the discovery of markers to measure the effectors’ mechanisms of the protective
immune response against M. tuberculosis.
For many years Cell-Mediated Immunity (CMI) was viewed as the exclusive defense mecha‐
nism against intracellular pathogens. The Th1/Th2 classical paradigm prevailed for a long time
and the development of vaccines followed this theory [6]. Based on this theory, only intracel‐
lular pathogens could be effectively controlled by granulomatous inflammation induced by a
Th1 response, whereas a Th2 response induces antibody production that controls extracellular
pathogens and parasites. However, the question of what constitutes a true demarcation
between “extracellular and intracellular” pathogens is important in this regard. During their
infectious cycle, intracellular pathogens could be found in the extracellular space and vice
versa. In the specific case of M. tuberculosis, it can be localized extracellularly at the beginning
of the infection in the upper respiratory tract as well as during advanced stages of the disease,
after rupture of granulomatous lesions occur [7]. This facultative intracellular pathogen was
shown to have an extracellular phase [7] [8] that may include replication [7] which in turn
could potentially be targeted by specific antibodies.
There are several prokaryotic and eukaryotic intracellular pathogens for which antibody have
been shown to modify the course of infection by different mechanisms, as reviewed extensively
by Casadevall and colleagues [9, 10, 11]. In the case of Erhlichia spp., specific antibodies were
shown to mediate protection [12], possibly by blocking cellular entry or promoting the
expression of proinflammatory cytokines. [13,14]. A combination of both humoral and cellular
immune mechanisms could be the optimal choice controlling certain intracellular patho‐
gens,.In this regard, de Valliere and colleagues reported that human antimycobacterial
antibodies enhanced Cell-Mediated Immune responses to mycobacteria that are beneficial to
the host [15].
3. Epidemiological evidence of antibody mediated protection
There is accumulating evidence, in the last few decades, regarding the effect of antibodies in
the context of development of pulmonary or disseminated TB. Children with low serum IgG
against sonicated mycobacterial antigens and LAM, or those who could not mount antibody
responses to these antigens were predisposed to dissemination of M. tuberculosis [16].
M. leprae reactive salivary IgA antibodies were suggested to be important in a mucosal
protective immunity [17]. In study carried out among the Mexican Totonaca Indian population,
the presence of high antibody titers to Ag87 complex antigens were observed in patients with
non-cavitary TB and in patients who were cured with anti-TB chemotherapy. In contrast,
patients without such antibodies had a poor outcome of the disease [18].
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4. Experimental studies
4.1. Animal models
An important criterion for the evaluation of the role of specific antibodies in the protection
against TB is the use of animal models. Currently, there is no optimal model to re-produce the
infection as it occurs in humans [19].
The geographical location, genetic factors of the host, the presence of environmental myco‐
bacteria and other concomitant infections like helminthiasis, are factors that have to be
considered when designing animal experiments [20]. Several animal models have been used
to evaluate different aspects of mycobacterial infection and disease. A crucial aspect is the
delivery of mycobacterial inoculum. In this regard, several routes of inoculation have been
employed experimentally, including intravenous, intraperitoneal, intranasal, intratracheal
and aerosol [21, 22].
The study of the distribution of monoclonal and polyclonal antibody formulations in different
organs and tissues of mice after administration by different routes, including the use of
backpack models have been reported [23-27]. Each model has its advantages and drawbacks.
For example, the backpack model is very useful for the evaluation of the protective role of IgA,
but poses ethical problems in long term experiments due to the increase in tumour size over
time produced by the inoculated hybridoma [28]. In prophylactic and therapeutic models,
antibody formulations have been administered via the intranasal [29], intravenous [30] and
intraperitoneal [26] routes and combined with cytokines and antibiotics [31, 32] before and/or
after the infectious challenge. The administration of M. tuberculosis pre-coated with antibodies
[27, 33] in different models of infection has also contributed to understanding the interactions
between host and microbe.
Another approach has been the use of knockout mice models for IgA [34] polymeric immu‐
noglobulin receptor (pIgR) [34] and B cells [35,36,37,38], as will be discussed later.
4.2. Experimental studies with antibodies
A substantial number of studies utilizing anti mycobacterial antibodies have been conducted
as far back as the end of the 19th century. These experiments can be grouped into several
categories: serum therapies, mouse polyclonal antibodies, human polyclonal antibodies
(including commercial human gamma globulins), secretory human IgA (hsIgA) and studies
with monoclonal antibodies.
4.2.1. Serum therapies
Serum therapy experiments were conducted from the second half of the 19th century (reviewed
in [39,40]). Immune sera was generated by immunizing animals with different mycobacterial
fractions and administered either to animals or humans [39,40] The results obtained were either
beneficiary, variable, inconclusive or contradictory, [39,40]. These variable results led to the
perceived minor role of antibodies in the defense against M. tuberculosis.
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2. Specific antibodies: Players in the defense against TB
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shown to mediate protection [12], possibly by blocking cellular entry or promoting the
expression of proinflammatory cytokines. [13,14]. A combination of both humoral and cellular
immune mechanisms could be the optimal choice controlling certain intracellular patho‐
gens,.In this regard, de Valliere and colleagues reported that human antimycobacterial
antibodies enhanced Cell-Mediated Immune responses to mycobacteria that are beneficial to
the host [15].
3. Epidemiological evidence of antibody mediated protection
There is accumulating evidence, in the last few decades, regarding the effect of antibodies in
the context of development of pulmonary or disseminated TB. Children with low serum IgG
against sonicated mycobacterial antigens and LAM, or those who could not mount antibody
responses to these antigens were predisposed to dissemination of M. tuberculosis [16].
M. leprae reactive salivary IgA antibodies were suggested to be important in a mucosal
protective immunity [17]. In study carried out among the Mexican Totonaca Indian population,
the presence of high antibody titers to Ag87 complex antigens were observed in patients with
non-cavitary TB and in patients who were cured with anti-TB chemotherapy. In contrast,
patients without such antibodies had a poor outcome of the disease [18].
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An important criterion for the evaluation of the role of specific antibodies in the protection
against TB is the use of animal models. Currently, there is no optimal model to re-produce the
infection as it occurs in humans [19].
The geographical location, genetic factors of the host, the presence of environmental myco‐
bacteria and other concomitant infections like helminthiasis, are factors that have to be
considered when designing animal experiments [20]. Several animal models have been used
to evaluate different aspects of mycobacterial infection and disease. A crucial aspect is the
delivery of mycobacterial inoculum. In this regard, several routes of inoculation have been
employed experimentally, including intravenous, intraperitoneal, intranasal, intratracheal
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The study of the distribution of monoclonal and polyclonal antibody formulations in different
organs and tissues of mice after administration by different routes, including the use of
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For example, the backpack model is very useful for the evaluation of the protective role of IgA,
but poses ethical problems in long term experiments due to the increase in tumour size over
time produced by the inoculated hybridoma [28]. In prophylactic and therapeutic models,
antibody formulations have been administered via the intranasal [29], intravenous [30] and
intraperitoneal [26] routes and combined with cytokines and antibiotics [31, 32] before and/or
after the infectious challenge. The administration of M. tuberculosis pre-coated with antibodies
[27, 33] in different models of infection has also contributed to understanding the interactions
between host and microbe.
Another approach has been the use of knockout mice models for IgA [34] polymeric immu‐
noglobulin receptor (pIgR) [34] and B cells [35,36,37,38], as will be discussed later.
4.2. Experimental studies with antibodies
A substantial number of studies utilizing anti mycobacterial antibodies have been conducted
as far back as the end of the 19th century. These experiments can be grouped into several
categories: serum therapies, mouse polyclonal antibodies, human polyclonal antibodies
(including commercial human gamma globulins), secretory human IgA (hsIgA) and studies
with monoclonal antibodies.
4.2.1. Serum therapies
Serum therapy experiments were conducted from the second half of the 19th century (reviewed
in [39,40]). Immune sera was generated by immunizing animals with different mycobacterial
fractions and administered either to animals or humans [39,40] The results obtained were either
beneficiary, variable, inconclusive or contradictory, [39,40]. These variable results led to the
perceived minor role of antibodies in the defense against M. tuberculosis.
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What factors could have led to the heterogeneity in study results? Recognizable differences in
the methods used for serum preparations and their administration, as well as the lack of
appropriate experimental controls probably accounted in part for the studies outcomes.
Furthermore, it is important to recognize that immune serum is a polyclonal preparation that
includes antibodies with multiple specificities and isotypes. Consequently, polyclonal sera
may contain antibodies of different subclasses and functional categories that can affect
theoutcome of infection. For example, IgG3 murine monoclonal antibodies protected against
M.tuberculosis [27] but failed to protect against Cryptococcus neoformans [41]. An IgG3 non-
protectivemonoclonal antibody to C. neoformans, became protective upon subclass switching
to IgG1 [41]. In addition to intrinsic factors associated with the antibody structure, other
parameters such as the genetic background of the microbe and the immunocompetence of the
host could alter the outcome of antibody protection experiments.
For some microorganisms, such as Samonella typhimurium and C. neoformans, passive antibody
therapy efficacy depends on the mouse strain used [42, 43]. In the same way, some microbial
strains are more susceptible to the effects of antibodies [44].
The animal model used is another important parameter that varies between different experi‐
ments cited in the literature [45]. Timing, the route of infection, the magnitude of the infecting
inoculum are some additional variables that could affect antibody protection studies [46].
Despite their variability, the results obtained with serum therapy were valuable, demonstrat‐
ing some beneficial effect of serum on the course of TB in humans, mainly in cases of early or
localized TB [45]. Moreover, it was demonstrated that long periods of treatment were necessary
to achieve a sustained effect [45].
4.2.2. Polyclonal mouse antibodies
A recent study re-examined the usefulness of immune serum in the context of a therapeutic
vaccine against TB [32]. This vaccine, named RUTI, is generated from detoxified M. tuberculo‐
sis cell fragments that facilitate a balanced T helper response to a wide range of antigens along
with intense antibody production [47]. Local accumulation of specific CD8+ T cells and a strong
humoral response after immunization are characteristic features of RUTI that contribute to its
protective properties. In that study, immune serum was generated by immunizing mice with
RUTI [32]. Severe Combined Immunodeficiency (SCID) mice were inoculated with M.
tuberculosis and treated with chemotherapy for 3–8 weeks. After chemotherapy they were
treated for up to 10 weeks with intraperitoneal injections of the generated immune serum. Mice
treated with immune serum from RUTI vaccinated animals showed significant decreases in
lung CFU in addition to reduced extent of granulomatous response and abscess formation [47].
These results indicate that protective serum antibodies can be elicited by vaccination, and that
antibodies may be usefully combined with chemotherapy [32, 47, 48].
4.2.3. Human gammaglobulins
4.2.3.1. Specific human polyclonal antibodies
Evidence for the stimulatory role of specific polyclonal antibodies on cellular immunity in
experimental mycobacterial infections was reported by de Valliere and colleagues in 2005 [15].
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In this study, serum samples containing specific antimycobacterial antibodies were obtained
from volunteers vaccinated twice with BCG by the intradermal route. Significant titres of IgG
antibodies against lipoarabinomannan (LAM) were detected in the sera. BCG internalization
into phagocytic cells was significantly increased in the presence of these BCG induced
antibodies as were the growth inhibitory effects of neutrophils and macrophages on myco‐
bacteria. Furthermore, these antibodies induced significant production of IFN-γ by CD4+ and
CD8+ T cells [15].
4.2.3.2. Commercial immunoglobulin formulations
Human Intravenous Immunoglobulin (IVIG) has been used to treat individuals with immune
deficiencies and patients with inflammatory, autoimmune and infectious conditions [49, 50,
51]. Several groups tested the effect of human immunoglobulin preparation on mycobacterial
infection. Roy and colleagues showed that treatment of M. tuberculosis infected mice with one
cycle of IVIG led to the substantially lower bacterial loads in the spleen and lungs following
its administration either at early or at late stage of infection 52]. The effect of the administration
of a commercial preparation of human immunoglobulin (hIg) in a mouse model of intranasal
infection with BCG was evaluated by Olivares and colleagues [33]. This group demonstrated
the passage of specific antibodies to saliva and lung lavage following the intranasal or
intraperitoneal administration of human hIg to mice. This treatment inhibited BCG coloniza‐
tion of the lungs of treated mice. A similar inhibitory effect was observed after infection of
mice with hIg -opsonized BCG [33].
The same formulation was evaluated also in a mouse model of intratracheal infection with M.
tuberculosis. Animals receiving human hIg intranasally 2h prior to intratracheal challenge
demonstrated a significant decrease in lung bacillary load as compared with non-treated
animals [29]. When M. tuberculosis was pre-incubated with hIg prior to challenge the same
effect was observed [29].
The protective effect of the hIg formulation was abolished following pre-incubation with M.
tuberculosis [29]. These results are suggestive of a potential role for specific human antibodies
in the defense against mycobacterial infections.
Taken together, these studies provide support for the potential use of immunoglobulins
against M. tuberculosis.
4.2.3.3. Human secretory IgA
Human secretory IgA (hsIgA) is the major class of antibody associated with immune protection
of the mucosal surfaces [53]. Colostrum volume is above 102 mL in humans during the first
three days after delivery [54]. The high percentage of (hsIgA) in human colostrum [55] strongly
suggests its important role in passive immune protection against gastrointestinal and respi‐
ratory infections [56]. In one study performed by Alvarez and colleagues, hsIgA from human
colostrum was obtained by anion exchange and gel filtration chromatographic methods, using
DEAE Sepharose FF and Superose 6 preparative grade, respectively [57].
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may contain antibodies of different subclasses and functional categories that can affect
theoutcome of infection. For example, IgG3 murine monoclonal antibodies protected against
M.tuberculosis [27] but failed to protect against Cryptococcus neoformans [41]. An IgG3 non-
protectivemonoclonal antibody to C. neoformans, became protective upon subclass switching
to IgG1 [41]. In addition to intrinsic factors associated with the antibody structure, other
parameters such as the genetic background of the microbe and the immunocompetence of the
host could alter the outcome of antibody protection experiments.
For some microorganisms, such as Samonella typhimurium and C. neoformans, passive antibody
therapy efficacy depends on the mouse strain used [42, 43]. In the same way, some microbial
strains are more susceptible to the effects of antibodies [44].
The animal model used is another important parameter that varies between different experi‐
ments cited in the literature [45]. Timing, the route of infection, the magnitude of the infecting
inoculum are some additional variables that could affect antibody protection studies [46].
Despite their variability, the results obtained with serum therapy were valuable, demonstrat‐
ing some beneficial effect of serum on the course of TB in humans, mainly in cases of early or
localized TB [45]. Moreover, it was demonstrated that long periods of treatment were necessary
to achieve a sustained effect [45].
4.2.2. Polyclonal mouse antibodies
A recent study re-examined the usefulness of immune serum in the context of a therapeutic
vaccine against TB [32]. This vaccine, named RUTI, is generated from detoxified M. tuberculo‐
sis cell fragments that facilitate a balanced T helper response to a wide range of antigens along
with intense antibody production [47]. Local accumulation of specific CD8+ T cells and a strong
humoral response after immunization are characteristic features of RUTI that contribute to its
protective properties. In that study, immune serum was generated by immunizing mice with
RUTI [32]. Severe Combined Immunodeficiency (SCID) mice were inoculated with M.
tuberculosis and treated with chemotherapy for 3–8 weeks. After chemotherapy they were
treated for up to 10 weeks with intraperitoneal injections of the generated immune serum. Mice
treated with immune serum from RUTI vaccinated animals showed significant decreases in
lung CFU in addition to reduced extent of granulomatous response and abscess formation [47].
These results indicate that protective serum antibodies can be elicited by vaccination, and that
antibodies may be usefully combined with chemotherapy [32, 47, 48].
4.2.3. Human gammaglobulins
4.2.3.1. Specific human polyclonal antibodies
Evidence for the stimulatory role of specific polyclonal antibodies on cellular immunity in
experimental mycobacterial infections was reported by de Valliere and colleagues in 2005 [15].
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In this study, serum samples containing specific antimycobacterial antibodies were obtained
from volunteers vaccinated twice with BCG by the intradermal route. Significant titres of IgG
antibodies against lipoarabinomannan (LAM) were detected in the sera. BCG internalization
into phagocytic cells was significantly increased in the presence of these BCG induced
antibodies as were the growth inhibitory effects of neutrophils and macrophages on myco‐
bacteria. Furthermore, these antibodies induced significant production of IFN-γ by CD4+ and
CD8+ T cells [15].
4.2.3.2. Commercial immunoglobulin formulations
Human Intravenous Immunoglobulin (IVIG) has been used to treat individuals with immune
deficiencies and patients with inflammatory, autoimmune and infectious conditions [49, 50,
51]. Several groups tested the effect of human immunoglobulin preparation on mycobacterial
infection. Roy and colleagues showed that treatment of M. tuberculosis infected mice with one
cycle of IVIG led to the substantially lower bacterial loads in the spleen and lungs following
its administration either at early or at late stage of infection 52]. The effect of the administration
of a commercial preparation of human immunoglobulin (hIg) in a mouse model of intranasal
infection with BCG was evaluated by Olivares and colleagues [33]. This group demonstrated
the passage of specific antibodies to saliva and lung lavage following the intranasal or
intraperitoneal administration of human hIg to mice. This treatment inhibited BCG coloniza‐
tion of the lungs of treated mice. A similar inhibitory effect was observed after infection of
mice with hIg -opsonized BCG [33].
The same formulation was evaluated also in a mouse model of intratracheal infection with M.
tuberculosis. Animals receiving human hIg intranasally 2h prior to intratracheal challenge
demonstrated a significant decrease in lung bacillary load as compared with non-treated
animals [29]. When M. tuberculosis was pre-incubated with hIg prior to challenge the same
effect was observed [29].
The protective effect of the hIg formulation was abolished following pre-incubation with M.
tuberculosis [29]. These results are suggestive of a potential role for specific human antibodies
in the defense against mycobacterial infections.
Taken together, these studies provide support for the potential use of immunoglobulins
against M. tuberculosis.
4.2.3.3. Human secretory IgA
Human secretory IgA (hsIgA) is the major class of antibody associated with immune protection
of the mucosal surfaces [53]. Colostrum volume is above 102 mL in humans during the first
three days after delivery [54]. The high percentage of (hsIgA) in human colostrum [55] strongly
suggests its important role in passive immune protection against gastrointestinal and respi‐
ratory infections [56]. In one study performed by Alvarez and colleagues, hsIgA from human
colostrum was obtained by anion exchange and gel filtration chromatographic methods, using
DEAE Sepharose FF and Superose 6 preparative grade, respectively [57].
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hsIgA was administered intranasally to BALB/c mice, and the level of this immunoglobulin in
several biological fluids was determined by ELISA. The results showed the presence of this
antibody in the saliva of animals that received the hsIgA, at all time intervals studied. In
tracheobronchial lavage, hsIgA was detected at 2 and 3 hours after inoculation in animals that
received the hsIgA [58]. Similar studies were performed by Falero and colleagues with
monoclonal antibodies of IgA and IgG class [59]. Following demostration that hsIgA could be
detected in several biological secretions after intranasal administration, the protective effect
of this formulation against M. tuberculosis challenge was evaluated. Mice challenged with M.
tuberculosis preincubated with hsIgA showed a statistically significant decrease in the mean
number of viable bacteria recovered from the lungs compared to control mice and to the group
that received the hsIgA before challenge with M. tuberculosis. Moreover, an increased level of
iNOS production was also reported (Alvarez et al., mannuscript in preparation). Consistently
with this result, a better organization of granulomatous areas with foci of lymphocytes and
abundant activated macrophages were observed in the lungs of mice that received M.
tuberculosis pre-incubated with hsIgA and sacrificed at 2 months postchallenge. Untreated
animals, however, showed an increased area of bronchiectasis and atelectasis as well as fibrin
deposits, accumulation of activated macrophages and lymphocytes.
The pneumonic areas were more prominent in the untreated animals than in the groups treated
with hsIgA and M. tuberculosis pre-incubated with hsIgA (Alvarez et al., manuscript in
preparation)
4.2.4. Monoclonal antibodies
Since the first report on the use of the monoclonal antibody Mab 9d8 against M. tuberculosis
[27], many similar studies have been reported [40]. This IgG3 monoclonal antibody (Mab)
generated against arabinomannan (AM) capsular polysaccharide, increased the survival of
intratracheally infected mice when the M. tuberculosis Erdman strain was pre-coated with it
[27]. In this study, a longer survival associated with an enhanced granulomatous response in
the lungs was found as compared to controls receiving an isotype-specific non-related Mab
[27]. Another Mab, SMITB14, directed against the AM portion of LAM prolonged the survival
of intravenously infected mice associated with reduced lung CFU and prevention of weight
loss [60]. In this study, the authors demonstrated that protection was independent of the
antibody Fc portion, because the F(ab’)2 fragment also conferred a similar protective effect [60].
In another study, mice receiving the Mab 5c11 (an IgM antibody that recognizes other
mycobacterial arabinose-containing carbohydrates in addition to AM) intravenously prior to
Mannosylated lipoarabinomannan (ManLAM) administration, showed a significant clearance
of Man-LAM and redirection of this product to the hepatobiliary system [26]. This study
strongly supports an indirect effect of certain antibodies on the course of mycobacterial
infection, altering problably the pharmacokinetics of mycobacterial components and contri‐
buting to protection against TB [26].
Heparin Binding Hemagglutinin Adhesin (HBHA) is a surface-exposed glycoprotein involved
in the mycobacterial binding to epithelial cells and in mycobacterial dissemination [62].
Monoclonal antibodies 3941E4 (IgG2a) and 4058D2 (IgG3) directed against HBHA were used
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to coat mycobacteria before administration to mice. In this study, spleen CFUs was reduced
while lung CFUs did not [63]. These results suggest that binding of these antibodies to HBHA
can impede mycobacterial dissemination.
The protective efficacy of a monoclonal antibody, TBA63 and IgA anti-Acr administered
intranasally before and after the intranasal or aerosol challenge with M. tuberculosis was
demonstrated in a study by Williams and colleagues [64]. In another series of experiments
carried out by López and colleagues, the protective effect of this Mab administered intratra‐
cheally before an intratracheal challenge with virulent mycobacteria was evaluated. At 21 days
post-infection, pre-treatment of mice with TBA63 caused a significant decrease in viable
bacteria in the lungs compared to control mice or those treated with the Mab against the 38-
kDa protein (TBA86) [65]. Consistent with the reduction of viable bacteria following treatment
with TBA63, the area of peribronchial inflammation was also statistically smaller in this group
compared to the control group [65].
When the lungs of mice were histologically examined, granulomas were better organized in
the infected animals that had received TBA63 than in controls or mice treated with TBA86. The
reduction of CFU in lungs of the treated group was associated with milder histopathological
changes, as indicated by the organization of the granulomas and less pneumonic area. The fact
that this Mab promotes granuloma formation in mice infected intratracheally with M. tuber‐
culosis strongly suggests the close interaction between antibody mediated immunity and cell-
mediated immunity to induce protection against intracellular pathogens (66).
The 16 kDa protein (Acr antigen) has been defined as a major membrane protein peripherally
associated with the membrane [67] carrying epitopes restricted to tubercle bacilli on the basis
of B-cell recognition [68, 69]. The Acr antigen is present on the surface of tubercle bacilli and
is highly expressed in organisms growing within infected macrophages, allowing it to be
potentially targeted by specific antibodies either inside infected cells as well as extracellulary.
A novel immunotherapy, combining treatment with anti-IL-4 antibodies, IgA antibody against
16 kDa protein and IFN-γ, showed the potential for passive immunoprophylaxis against TB.
In genetically deficient IL-4-/- BALB/c mice, infection in both lungs and spleen was substan‐
tially reduced for up to 8 weeks. Administration of rIL-4 to IL-4-/- mice with increased bacterial
counts to wild-type levels and make mice refractory to protection by IgA/IFN-γ [70].
More recently, Balu and colleagues reported that intranasal administration of a human IgA1
Mab, obtained using a single-chain variable fragment derived from an Ab phage library with
high affinity for hspX and the human FcαRI (CD91) IgA receptor together with recombinant
mouse IFN-γ significantly inhibited pulmonary infection with M. tuberculosis H37Rv in mice
transgenic for human CD91 but not in the CD91-negative controls. These results suggested
that binding to CD91 was necessary for the IgA-imparted passive protection [71]. When the
Mab was incubated with human whole-blood or monocyte cultures it inhibited H37Rv
infection.
Inhibition of the infection by the antibody was synergistic with human rIFN-γ in purified
human monocytes cultures but not in whole blood cultures [71]. The demonstration of the role
of FcαRI (CD91) in human IgA mediated protection contributes to understanding the mecha‐
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hsIgA was administered intranasally to BALB/c mice, and the level of this immunoglobulin in
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detected in several biological secretions after intranasal administration, the protective effect
of this formulation against M. tuberculosis challenge was evaluated. Mice challenged with M.
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number of viable bacteria recovered from the lungs compared to control mice and to the group
that received the hsIgA before challenge with M. tuberculosis. Moreover, an increased level of
iNOS production was also reported (Alvarez et al., mannuscript in preparation). Consistently
with this result, a better organization of granulomatous areas with foci of lymphocytes and
abundant activated macrophages were observed in the lungs of mice that received M.
tuberculosis pre-incubated with hsIgA and sacrificed at 2 months postchallenge. Untreated
animals, however, showed an increased area of bronchiectasis and atelectasis as well as fibrin
deposits, accumulation of activated macrophages and lymphocytes.
The pneumonic areas were more prominent in the untreated animals than in the groups treated
with hsIgA and M. tuberculosis pre-incubated with hsIgA (Alvarez et al., manuscript in
preparation)
4.2.4. Monoclonal antibodies
Since the first report on the use of the monoclonal antibody Mab 9d8 against M. tuberculosis
[27], many similar studies have been reported [40]. This IgG3 monoclonal antibody (Mab)
generated against arabinomannan (AM) capsular polysaccharide, increased the survival of
intratracheally infected mice when the M. tuberculosis Erdman strain was pre-coated with it
[27]. In this study, a longer survival associated with an enhanced granulomatous response in
the lungs was found as compared to controls receiving an isotype-specific non-related Mab
[27]. Another Mab, SMITB14, directed against the AM portion of LAM prolonged the survival
of intravenously infected mice associated with reduced lung CFU and prevention of weight
loss [60]. In this study, the authors demonstrated that protection was independent of the
antibody Fc portion, because the F(ab’)2 fragment also conferred a similar protective effect [60].
In another study, mice receiving the Mab 5c11 (an IgM antibody that recognizes other
mycobacterial arabinose-containing carbohydrates in addition to AM) intravenously prior to
Mannosylated lipoarabinomannan (ManLAM) administration, showed a significant clearance
of Man-LAM and redirection of this product to the hepatobiliary system [26]. This study
strongly supports an indirect effect of certain antibodies on the course of mycobacterial
infection, altering problably the pharmacokinetics of mycobacterial components and contri‐
buting to protection against TB [26].
Heparin Binding Hemagglutinin Adhesin (HBHA) is a surface-exposed glycoprotein involved
in the mycobacterial binding to epithelial cells and in mycobacterial dissemination [62].
Monoclonal antibodies 3941E4 (IgG2a) and 4058D2 (IgG3) directed against HBHA were used
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to coat mycobacteria before administration to mice. In this study, spleen CFUs was reduced
while lung CFUs did not [63]. These results suggest that binding of these antibodies to HBHA
can impede mycobacterial dissemination.
The protective efficacy of a monoclonal antibody, TBA63 and IgA anti-Acr administered
intranasally before and after the intranasal or aerosol challenge with M. tuberculosis was
demonstrated in a study by Williams and colleagues [64]. In another series of experiments
carried out by López and colleagues, the protective effect of this Mab administered intratra‐
cheally before an intratracheal challenge with virulent mycobacteria was evaluated. At 21 days
post-infection, pre-treatment of mice with TBA63 caused a significant decrease in viable
bacteria in the lungs compared to control mice or those treated with the Mab against the 38-
kDa protein (TBA86) [65]. Consistent with the reduction of viable bacteria following treatment
with TBA63, the area of peribronchial inflammation was also statistically smaller in this group
compared to the control group [65].
When the lungs of mice were histologically examined, granulomas were better organized in
the infected animals that had received TBA63 than in controls or mice treated with TBA86. The
reduction of CFU in lungs of the treated group was associated with milder histopathological
changes, as indicated by the organization of the granulomas and less pneumonic area. The fact
that this Mab promotes granuloma formation in mice infected intratracheally with M. tuber‐
culosis strongly suggests the close interaction between antibody mediated immunity and cell-
mediated immunity to induce protection against intracellular pathogens (66).
The 16 kDa protein (Acr antigen) has been defined as a major membrane protein peripherally
associated with the membrane [67] carrying epitopes restricted to tubercle bacilli on the basis
of B-cell recognition [68, 69]. The Acr antigen is present on the surface of tubercle bacilli and
is highly expressed in organisms growing within infected macrophages, allowing it to be
potentially targeted by specific antibodies either inside infected cells as well as extracellulary.
A novel immunotherapy, combining treatment with anti-IL-4 antibodies, IgA antibody against
16 kDa protein and IFN-γ, showed the potential for passive immunoprophylaxis against TB.
In genetically deficient IL-4-/- BALB/c mice, infection in both lungs and spleen was substan‐
tially reduced for up to 8 weeks. Administration of rIL-4 to IL-4-/- mice with increased bacterial
counts to wild-type levels and make mice refractory to protection by IgA/IFN-γ [70].
More recently, Balu and colleagues reported that intranasal administration of a human IgA1
Mab, obtained using a single-chain variable fragment derived from an Ab phage library with
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nisms involved as well as for using this knowledge for the future development of new
immunotherapies for TB [71].
4.2.5. Transgenic mice
Mouse models with deficiency in antibody production can provide useful information for
understanding  certain  roles  of  antibodies  in  protection  against  mycobacterial  infections.
Rodríguez and colleagues reported that after immunization of IgA deficient (IgA-/-) and wild
type mice by the intranasal route with the mycobacterial surface antigen PstS-1, IgA-/- mice
were more susceptible to BCG infection than IgA+/+ mice [34]. Cytokine response analysis
demonstrated  reduction  in  the  IFN-γ  and  TNF-α  production  in  the  lungs  of  IgA-/-  as
compared with  IgA+/+  mice,  suggesting  that  IgA may play  a  role  in  protection against
mycobacterial infections in the respiratory tract. Furthermore, these authors demonstrated
that immunized pIgR-/- mice were more susceptible to BCG infection than immunized wild-
type mice [34].
In an attempt to elucidate whether antibody-mediated immunity has a special role in the
defense against TB, different experiments with B cell knockout mice were performed by several
authors. In 11016, Vordermeier and colleagues developed an infection model of TB in μ chain
knockout Ig- mice. Organs from M. tuberculosis infected IgG- mice had three to eight fold
elevated counts of viable bacilli compared with those from normal mice. This result suggested
that B cells play a role in the containment of murine tuberculous infection [35]. In another study
B cell KO mice and controls were infected by aerosol with M. tuberculosis. They were subse‐
quently given chemotherapy to destroy remaining bacilli and then re-challenged by aerosol
exposure. There were not differences in the ability of animals to control this second infection,
indicating that, in this low dose pulmonary infection model, any local production of antibodies
neither impeded nor enhanced the expression of specific acquired resistance [36].
In another series of  experiments the role of  B cells  was evaluated during early immune
responses to infection with a clinical strain of M. tuberculosis (CDC 1561). In this study, despite
comparable  bacillary  loads  in  the  lungs,  B  cell  KO  mice  had  a  less  severe  pulmonary
granuloma formation and delayed dissemination of bacteria from lungs to peripheral organs.
Additional analysis of lung cells demonstrated higher numbers of lymphocytes, particular‐
ly  CD8+  T  cells,  macrophages,  and  neutrophils  in  wild-type  and  reconstituted  mice  as
compared  with  B  cell  KO  mice.  These  results  demonstrate  that  less  severe  granuloma
formation  and  delayed  dissemination  of  mycobacteria  found  in  B  cell  KO  mice  were
dependent  on  B  cells,  (not  antibodies,  at  least  in  this  study)  and  were  associated  with
modification of cellular infiltrate in the lungs [37]. This latter result differs from a study
carried out by Maglione and colleagues in which B cell-/- mice demonstrated exacerbated
immunopathology  corresponding  with  enhanced  pulmonary  recruitment  of  neutrophils
following aerosol challenge with M. tuberculosis Erdman strain [38]. Infected B cell-/- mice
demonstrated increased production of IL-10 in the lungs, while IFN- γ, TNF-α, and IL-10R
were not significantly different from those of wild type mice [38].. B cell-/- mice demonstrat‐
ed enhanced susceptibility to aerosol infection of 300 CFU of M. tuberculosis with elevated
bacterial burden in the lungs but not in the spleen or liver [38].
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Together these studies suggest that B cells may have an important role in host defense against
M. tuberculosis.
5. Mechanisms of action
The various effects of antibodies demonstrated in the studies analyzed, suggest that different
mechanisms of action are involved in the effect of monoclonal and polyclonal antibodies on
M. tuberculosis. Secretions found on mucosal surfaces contain significant levels of Igs, partic‐
ularly, IgA. IgA has both direct and indirect functional roles for combating infectious agents
such as viruses and bacteria that cross the mucosal barrier [72]. Moreover, experimental
evidence suggests that IgA associated with the pIgR may neutralize pathogens and antigens
intracellularly during their transport from the basolateral to the apical zone of epithelial cells
[73,74]. In addition, IgA may interact with Gal-3 (an intracellular binding β-galactosidase
lectin), and interfere with the interaction of mycobacteria with the phagosomal membrane,
resulting in the decrease of bacterial survival and replication in the phagosome [75].
Antibodies may be critical, during the extracellular phases of intracellular facultative patho‐
gens. They may act by interfering with adhesion, by neutralizing toxins and by activating
complement. Moreover, antibodies may be able to penetrate recently infected cells, bind
internalised pathogens, and enhance antigen processing (76). Antibodies may also play a
crucial role in modulating the immune response by activating faster secretion of selected
cytokines that in turn, contribute to more efficient and rapid Th1 response [76,77], increasing
the efficacy of co-stimulatory signals, enhancing Antibody Dependent Cellular Cytotoxicity
(ADCC) and the homing of immune cells to the lungs after the respiratory infection [10,78, 79,
80, 81, 82, 83].
Examples of relevant potential action mechanisms of antibodies against M. tuberculosis were
discussed by Glatman-Freedman [40].
6. Potential uses of antibodies against TB
Future applications of antibody formulations for the control of TB may include several
possibilities including treatment, prevention and diagnosis.
6.1. Treatment
Antibody based therapy could potentially be useful in several scenarios. They could be used
to shorten the standard treatment period of patients with uncomplicated TB when coupled
with standard chemotherapy. However, they would be particularly important in the treatment
of patients infected with Multidrug Resistant (MDR) and Extensively Drug Resistant (XDR)
strains, in combination with the standard treatment.
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Prophylactic use of antibodies could be applied in recent contacts of TB patients, with special
attention to risk groups [84]. In this regard, successful prophylactic use of antibodies in exposed
individuals has been shown in the case of several other pathogens such as varicella, tetanus,
Respiratory Synsicial Virus (RSV), rabies and Hepatitis B [85, 86]
6.3. Vaccines
The induction of specific protective antibody responses by vaccination, either alone or as an
addition to the stimulation of cell mediated immunity could be a novel strategy for the
development of new generation of prophylactic and therapeutic vaccines against TB.
The prevailing past dogma that discounted the role of antibodies in host protection against TB
has resulted in a limited study of B cell immunodominant epitopes as targets for protective
immunity [87].
6.3.1. Polysaccharide conjugate vaccines
Polysaccharide  conjugate  vaccines  are  considered  to  elicit  specific  protective  antibody
responses against a variety of pathogens [88]. However, the polysaccharide conjugate vaccine
against  Salmonella  typhi  [89]  demonstrates  the feasibility  of  this  kind of  vaccines  for  the
prevention  of  infectious  diseases  caused  by  intracellular  pathogens.  In  the  case  of  M.
tuberculosis,  several authors reported the use of polysaccharide conjugated vaccine candi‐
dates [61, 90, 91, 92].
All these vaccine candidates induced the production of specific IgG [61, 90, 91, 92] and some
of them conferred variable levels of protection [61, 91] which validate this strategy as one of
the potential avenues for the development of new generation of vaccines against tuberculosis
6.3.2. Identifying other B-cell immunodominant epitopes
With the development of bioinformatics tools for bacterial genome analysis, it has been
possible to predict in silico microbial regions that trigger immune responses relevant for
protection and vaccine development. A candidate experimental vaccine based on proteolipo‐
somes from M. smegmatis is currently in development [93].
In one study, bibliographic search was used to identify highly expressed proteins in active,
latent and reactivation phases of TB [94]. The subcellular localization of the selected proteins
was defined according to the report on the identification and localization of 1044 M. tubercu‐
losis proteins using two-dimensional, capillary high-performance liquid chromatography
coupled with mass spectrometry (2DLC/MS) method [95] and using prediction algorithms.
Taking into consideration the cell fractions potentially included in the proteoliposome, from
the previously identified proteins, the ones located in the cell membrane and cell wall, as well
as those which are secreted and homologous to those of M. smegmatis were selected.
The regions of the selected proteins containing promiscuous B and T cell epitopes were
determined [94]. Thus the M. smegmatis proteoliposomes were predicted to contain multiple
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B and T epitopes which are potentially cross reactive with those of M. tuberculosis. It is
important to note that there could be conformational B epitopes and additional epitopes related
with lipids and carbohydrates included in the proteoliposomes that could reinforce the
humoral cross reactivity.
Considering the results of the in silico analysis, proteoliposomes of M. smegmatis were obtained
and their immunogenicity was studied in mice [93]. In addition to cellular immune effectors
recognizing antigens from M. tuberculosis, cross reactive humoral immune responses of several
IgG subclasses corresponding with a combined Th1 and Th2 pattern against antigenic
components of M. tuberculosis were elicited. These findings were in concordance with the in
silico predictions [93, 94]. It is interesting to note that differences in the pattern of humoral
recognition of lipidic components was dependent on the characteristics of the adjuvant used,
which could have relevance for the development of vaccines which includes lipidic compo‐
nents [93]. Currently studies are underway to evaluate the protective capacity of M. smegma‐
tis proteoliposomes in challenge models with M. tuberculosis in mice.
Bioinformatics tools for prediction of T and B epitopes were also employed for the design of
multiepitopic constructions, which were used to obtain recombinant BCG strains. Based on
this prediction, B cell epitopes from ESAT-6, CFP-10, Ag87B and MTP40 proteins were selected
and combined with T cell epitopes of the 87B protein and fused to Mtb8.4 protein [96].
A significant IgG antibody response against specific B cell epitopes of ESAT-6 and CFP-10 was
obtained in mice immunized with the recombinant strain. After studying the specific response
of spleen cells by lymphoproliferation assay and detection of intracellular cytokines in CD4 +
and CD8 + subpopulations, the recognition of T epitopes was also observed. The response
showed a Th1 pattern after immunization with this recombinant strain (Mohamud, R, et al.
manuscript in preparation). In another series of experiments, recombinant BCG strains
expressing several combinations of multiepitopic constructions were used to immunize BALB/
c mice subcutaneously and challenged intratracheally with the M. tuberculosis H37Rv strain.
Recombinant BCG strains expressing T epitopes from 87BAg fused to Mtb8.4 protein and BCG
expressing a HSP62 T cell epitope plus different combinations of B cell epitopes from 87BAg,
Mce1A, L7/L12, 16 kDa, HBHA, ESAT6, CFP10 and MTP40 and combinations of B cell epitopes
alone produced significant reductions in lung CFU compared to BCG (Norazmi MN, et al.
manuscript in preparation).
6.3.3. Diagnosis
Although no serological assays are currently recommended for diagnosis of TB [97], largely
due to the possibility of false results and thus incorrect treatments, for many other pathogens,
serological diagnostic tests has been of great value, particularly in poor countries. In some
cases, antibody responses can constitute useful correlates of protection [98]. In the specific case
of TB, several studies of the antibody response have been reported [99]. There is a substantial
amount of variability in antibody response to TB [100]. This variability has been attributed to
several factors. Some of these factors are associated with the pathogen (strain variation, micro-
environment and growth state of bacteria) and others are related to the host, primarily previous
exposure to related antigens and host genetics [99].
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However, it is important to consider that only a small fraction of the genomic regions of M.
tuberculosis encoding proteins has been explored. Currently, novel immunoassay platforms
are being used to dissect the entire proteome of M. tuberculosis, including reacting protein
microarrays with sera from TB patients and controls [101,102]. These studies could lead to the
discovery of new antigens that may constitute suitable diagnostic markers and tools for the
identification of protection correlates.
7. Concluding remarks
The cumulative work reviewed above with regard to the use of antibody formulations and
vaccines suggest that antibodies if present at the right moment at the site of infection could
provide protection against M. tuberculosis. This concept leads the way to the development of
a new generation of vaccines. Such vaccines could work by eliciting specific IgA and/or IgG
antibodies that could recognize and intercept the pathogen at the port of entry, primarily the
mucosal surfaces, inactivating bacterial components essential for the microbial survival in
the host, activating complement for direct lysis of the cells, opsonizing bacteria to promote
their  capture  by  phagocytic  cells  and  inducing  stimulation  of  specific  cellular  immune
responses [103, 104].
Various antibody formulations could potentially be used as immunotherapeutic agents in
combination with the conventional treatment and in the management of patients affected by
Multidrug Resistant (MDR) and Extensively Drug Resistant (XDR) strains.
The study of the role of specific antibodies in the defense against tuberculosis opens new
possibilities for future development of new vaccines, diagnostics tools and therapies against
this pathogen. It is likely that new discoveries will arise from the ongoing studies in this area
that will expedite the introduction of new strategies in the fight against tuberculosis.
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1. Introduction
Tuberculosis (TB) is a major public concern and is the most important single infectious cause
of mortality and morbidity worldwide. According the World Health Organization (WHO)
records, in 2009, there were an estimated 9.4 million new cases, 14 million prevalent cases, and
approximately 1.7 million deaths by TB [1]. Additionally, approximately one third of the
world’s population is infected with the causative bacterium, Mycobacterium tuberculosis (Mtb),
and is at risk for developing active tuberculosis. Interestingly, while approximately 9 million
people develop active TB each year, the majority remain asymptomatically (latently) infected
with the pathogen presumably due to a protective immune response. Without intervention,
approximately five to ten percent of those latently infected will develop overt disease and the
potential to transmit Mtb to others [2].
Familial clustering data, twin studies and complex segregation analysis have all suggested a
strong genetic component in the human susceptibility to the chronic mycobacterial diseases
[3-7] but also a complex picture of geographic heterogeneity in genetic effects on the different
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mycobacterial infections is involved [8, 9]. Several non-HLA genes have been implicated in TB
susceptibility. However, the discrepant data reported may be attributed to a number of
different factors, such as the types of studies, ethnicity, genetic background, and clinical status
of patients with tuberculosis that may be associated with a particular genetic profile. The
interaction among lung cells with pro and anti-inflammatory mediators during the infection
with Mtb have been deeply investigated [10]. Among involved cytokines, the key role of
interferon-gamma (IFN-γ) and tumor necrosis factor (TNF-α) in eliciting an inflammatory
response against Mtb have been emphasized [11-13].
In human studies, the crucial role of TNF-α in protective host immunity against reactiva‐
tion of latent TB was highlighted by the observation that the relapse and severe course of
TB is  over-represented in  rheumatoid arthritis  patients  following the  use  of  anti-TNF-α
antibodies [14]. Concerning the IFN-γ, it is well established that deficiency in IFN-γ gene
expression is  associated with severe impairment of  resistance to infections,  in particular
those  that  are  normally  killed by activated macrophages  [15,  16].  Low synthesis  of  this
cytokine has  been associated with active tuberculosis  [17].  However,  on the contrary of
TNF-α,  the  Interferon gamma conding gene  (IFNG)  is  highly  conserved and few single
nucleotide polymorphisms (SNPs) are found in the intragenic region. Several case-control
studies  to  evaluate  association  of  SNPs  in  these  genes  with  TB  have  produced  mixed
results, with little consensus in most cases on whether any TNF polymorphisms are actually
associated with active TB disease [18, 19].
In the present study we aimed to analyse the existing promoter variability of the IFNG and
TNF-α genes by partial mapping of this region in samples from Brazilians, followed by an
association study of the identified SNPs and TB outcome after infection with Mtb.
2. Method used
2.1. Study population
In a case-control design, five hundred consanguineously unrelated individuals admitted at
the University Hospital Complex: Thoracic Institute/ClementinoFraga University Hospital
from Federal University of Rio de Janeiro-UFRJ were enrolled in this study after signing
informed consent approved by the local Ethics Committee of HUCFF-UFRJ.
Demographic, clinical, and microbiological data as well as the HIV status of the subjects (age
> 18 years old) were collected. Active TB cases (n=265) were defined as those after a positive
culture confirmation in clinical specimen or with clinical, radiographic and laboratory
improvement according to the American Thoracic Statements.They comprised 265 TB patients
to be used for the descriptive genetic analysis. For the association study, TB-HIV comorbity
was considered as an exclusion criteria and sample size was reduced as follow: 140 TB patients,
being 121 with pulmonary TB (PTB) and 19 extrapulmonary forms of TB (TBE). The mean age
of TB patients was ± 51 years (range 18-84 years) including 73 males and 67 females.
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For the control group, a complete questionnaire to document TB risk factors since baseline
testing was used. Individuals were eligible as controls if they had no previous TB history,
consanguinity and negative HIV status. In formations concerning Tuberculin Skin Test (TST)
response were available for all controls. They comprised 235 individuals, to be used for
descriptive genetic analysis. For the association study, after application of the exclusion
criteria, 154 individuals were included in this group, of which, 96 were TST positive (TST+)
and 58 TST negative (TST-). The mean age in this group was ± 50 (range 18 - 82 years) and
included 55 males and 99 females.
Sample Collection and handling
A volume of 3 mL of venous blood was collected from each volunteer and stored at -20°C.
Genomic DNA was isolated from 100 μL of frozen whole blood using the FlexiGene DNA Kit
(Qiagen Inc., USA), according to the manufacturer’s specifications. After extraction, DNA
samples were stored at -20°C.
2.2. IFNG and TNF–α genotyping
Genotyping of the proximal portion of the promoter region in TNF-α and IFNG genes was
achieved by direct sequencing of PCR products.  Two sets of primers for PCR amplifica‐
tion and sequencing of IFNG, DNA fragment of 863bp, (IFN-EF: 5’ GGAACTCCCCCTGG‐
GAATATTCT  3`,  IFNER:  5´AGCTGATCAGGTCCAAAGGA3´,  IFNIF:  5
´CGAAGTGGGGAGGT  ACAAAA  3´  and  IFNIR:  5´  CCCAGGAAACTGCTACTCTG  3´),
and TNF-α, DNA fragment of 855bp (TNFEF: 5´CAGGACCTCCAGGTATGGAA3´, TNFER:
5’ TAGCTGGTCCTCTGCTGTCC3’, TNFIF: 5´CCTGCATCCTGTCTGGAAGT 3´ and TNF-
IR: 5’TTTCAACCCCTGTGTGTTCG 3’) were designed by using the Primer3 software [20].
For PCR-mediated DNA amplification of IFNG, 100 ng of genomic DNA were added to a
50μL reaction mixture containing 200ng of each primer (IFN-EF and IFN-ER),  0.2mM of
each dNTPs,  2.0mM MgCl2  and 1U Taq  DNA polymerase (Invitrogen by Life  Technolo‐
gies,  USA) and submitted to  an initial  denaturation at  94°C for  5  min.,  followed by 35
cycles  of  1  min.  at  94°C,  1  min.  at  65.3°C and 1  min at  72°C.  Final  extension was per‐
formed for 5 min. at 72°C. Likewise, for amplification of the 855pb TNF-α fragment, 100ng
of genomic DNA were added to a 25μL reaction mixture containing 200ng of each primer
(TNF-EF and TNF-ER),  2mM MgCl2,  0.2mM of each dNTPs and 0.5U of  Taq  gold DNA
polymerase (PE Applied BioSystems) and submitted to initial denaturation at 94°C for 15
min, followed by 35 cycles of 1 min. at 94°C, 1 min. at 65.9°C and 1 min at 72°C with a
final extension at 72°C for 5 min. Evaluation of PCR products was done by electrophore‐
sis on 1.2% agarose gel followed by ethidium bromide staining.
For sequencing, PCR products were purified with ChargeSwitch Kit (Invitrogen Life Tech‐
nologies), according to the manufacturer’s recommendations. Sequencing of the amplified
fragments was performed in both DNA strands using a combination of the internal and
external primers using ABI PRISM Big Dye Terminator v. 3.1 Kit (PE Applied BioSystems),
according to the manufacturer’s recommendations, on an ABI PRISM 3730 DNA Analyser (PE
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> 18 years old) were collected. Active TB cases (n=265) were defined as those after a positive
culture confirmation in clinical specimen or with clinical, radiographic and laboratory
improvement according to the American Thoracic Statements.They comprised 265 TB patients
to be used for the descriptive genetic analysis. For the association study, TB-HIV comorbity
was considered as an exclusion criteria and sample size was reduced as follow: 140 TB patients,
being 121 with pulmonary TB (PTB) and 19 extrapulmonary forms of TB (TBE). The mean age
of TB patients was ± 51 years (range 18-84 years) including 73 males and 67 females.
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criteria, 154 individuals were included in this group, of which, 96 were TST positive (TST+)
and 58 TST negative (TST-). The mean age in this group was ± 50 (range 18 - 82 years) and
included 55 males and 99 females.
Sample Collection and handling
A volume of 3 mL of venous blood was collected from each volunteer and stored at -20°C.
Genomic DNA was isolated from 100 μL of frozen whole blood using the FlexiGene DNA Kit
(Qiagen Inc., USA), according to the manufacturer’s specifications. After extraction, DNA
samples were stored at -20°C.
2.2. IFNG and TNF–α genotyping
Genotyping of the proximal portion of the promoter region in TNF-α and IFNG genes was
achieved by direct sequencing of PCR products.  Two sets of primers for PCR amplifica‐
tion and sequencing of IFNG, DNA fragment of 863bp, (IFN-EF: 5’ GGAACTCCCCCTGG‐
GAATATTCT  3`,  IFNER:  5´AGCTGATCAGGTCCAAAGGA3´,  IFNIF:  5
´CGAAGTGGGGAGGT  ACAAAA  3´  and  IFNIR:  5´  CCCAGGAAACTGCTACTCTG  3´),
and TNF-α, DNA fragment of 855bp (TNFEF: 5´CAGGACCTCCAGGTATGGAA3´, TNFER:
5’ TAGCTGGTCCTCTGCTGTCC3’, TNFIF: 5´CCTGCATCCTGTCTGGAAGT 3´ and TNF-
IR: 5’TTTCAACCCCTGTGTGTTCG 3’) were designed by using the Primer3 software [20].
For PCR-mediated DNA amplification of IFNG, 100 ng of genomic DNA were added to a
50μL reaction mixture containing 200ng of each primer (IFN-EF and IFN-ER),  0.2mM of
each dNTPs,  2.0mM MgCl2  and 1U Taq  DNA polymerase (Invitrogen by Life  Technolo‐
gies,  USA) and submitted to  an initial  denaturation at  94°C for  5  min.,  followed by 35
cycles  of  1  min.  at  94°C,  1  min.  at  65.3°C and 1  min at  72°C.  Final  extension was per‐
formed for 5 min. at 72°C. Likewise, for amplification of the 855pb TNF-α fragment, 100ng
of genomic DNA were added to a 25μL reaction mixture containing 200ng of each primer
(TNF-EF and TNF-ER),  2mM MgCl2,  0.2mM of each dNTPs and 0.5U of  Taq  gold DNA
polymerase (PE Applied BioSystems) and submitted to initial denaturation at 94°C for 15
min, followed by 35 cycles of 1 min. at 94°C, 1 min. at 65.9°C and 1 min at 72°C with a
final extension at 72°C for 5 min. Evaluation of PCR products was done by electrophore‐
sis on 1.2% agarose gel followed by ethidium bromide staining.
For sequencing, PCR products were purified with ChargeSwitch Kit (Invitrogen Life Tech‐
nologies), according to the manufacturer’s recommendations. Sequencing of the amplified
fragments was performed in both DNA strands using a combination of the internal and
external primers using ABI PRISM Big Dye Terminator v. 3.1 Kit (PE Applied BioSystems),
according to the manufacturer’s recommendations, on an ABI PRISM 3730 DNA Analyser (PE
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Applied BioSystems). All singletons and even new/rare mutation identified were confirmed
by re-amplification and re-sequencing.
2.3. Computational analysis
The SNPs identification in each individual sample was achieved after alignment of the
generated sequences with the GenBank reference sequences AF3757790 and AB088112 for
IFNG and TNF-α respectively. Transcription starting site sequence definition adopted for both
genes considered as starting point, the first nucleotide immediately preceding position (-1) out
of mRNA. Sequence analysis was carried out through SeqScapev. 2.6 software (Applied
Biosystem). Haplotype reconstruction was achieved through the use of PHASE Vs. 2.1.1
software [21, 22].
2.4. Statistical analysis
Pair-wise linkage disequilibrium was tested for the loci studies. The Hardy-Weinberg equili‐
brium using χ2 test. Statistics were performed in XLSTAT 2008.7 (Addinsoft Software Inc -
New York USA). The magnitude of the associations was estimated by odds ratio values and
the coefficient of associations. All tests were performed at the 0.05 level of significance by Epi
Info version 3.5.1 2008 (Centers for Disease Control and Prevention, USA).
3. Results
In this work, a partial mapping of the promoter regions of IFNG and TNF-α genes was
performed by direct PCR sequencing approach in 265 TB patients and 235 healthy controls
residents in Rio de Janeiro, Brazil. Sequencing approach allowed the identification of new SNPs
and consequently new haplotypes for both genes. Expected genotype frequencies were
calculated from respective single allele frequencies and were consistent with Hard Weinberg
Equilibrium using χ2test.
3.1. Partial mapping of the IFNG promoter region in samples from Brazilians residents in
Rio de Janeiro
Sequence analysis of the proximal portion of IFNG promoter region (863 bp upstream of the
transcription starting site) revealed the presence of seven SNPs, of which, four were new, and
located at positions (-787C>T, -599C>G, -517C>T, and -255A>G). The three remaining SNPs,
already deposited in GenBank-Entrez SNP database, were located at positions (-785C>T,
-200G>T, reported as (-183 and -179) and -172A>G (reported as -155). Table 1 show the allele
and genotype frequencies of the identified SNPs in the whole studied population (500
samples). All SNPs were found in a very low frequency, sometimes as a singleton (-255A>G).
In this case, the SNP was confirmed by new PCR amplification and re-sequencing. The two
more frequent SNPs were the ones located at positions -599C>G and -200G>T, both with 1.4%.
No homozygosity was identified in these positions.










-787* TC 5 .001 0.05
(f) T 5 _
CC 495 0.99
-785 CT 5 0.01 0.05
(f) T 5 _
CC 487 0.974
-599* CG 12 0.024
GG 1 0.002 0.014
(f) G 2 -
CC 497 0.994
-517* CT 3 0.06 0.003
(f)T 3 -
AA 499 0.998




-200 GT 14 0.028 0.014
(f) T 14 -
AA 498 0.996
-172 AG 2 0.004 0.002
(f) G 2
Table 1. Genotype and allele frequencies of SNPs within IFNG promoter in Brazilians from Rio de Janeiro.
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3.2. IFNG haplotypes characterization
Haplotype reconstruction was achieved from genotyping data by using Phase Vs. 2.1.1
software. A total of eight different haplotypes were characterized with basis on the combina‐
tion of the seven SNPs identified within the IFNG promoter. Table 2 shows the frequencies of
the identified haplotypes in the total population. The haplotype 4 was the, more frequent
among the whole samples analyzed.
Haplotypes -787 -785 -599 -517 -255 -200 -172 Frequency
1 C C C C A G A 0.916
2 C T C C A G A 0.010
3 C C G C A G A 0.024
4 C C C C A T A 0.028
5 T C C C A G A 0.010
6 C C C C G G A 0.002
7 C C C C A G G 0.004
8 C C C T A G A 0.006
Table 2. Characterization of the identified haplotypes within IFNG proximal promoter region in Brazilians from Rio de
Janeiro (n=500).
3.3. Partial mapping of the TNF–α promoter region in samples from Brazilians residents in
Rio de Janeiro
The partial mapping of the proximal portion (855 bp upstream of the transcription starting
site) of TNF-α promoter was also performed by direct sequencing of PCR products. Upon
analysis of the generated sequences seven SNPs, all described in the literature, and were
identified in a total of 500 samples. Table 3 shows the allele and genotype frequencies. With
the exception of the most studied SNPs (-238 -308, and -376) presenting frequencies higher
than 3%, all others were present in less than one percent.
3.4. TNF–αhaplotypes characterization
A total of fourteen different haplotypes were characterized. Except for the wild-type, haplo‐
type 1, the higher frequent was the haplotype 3, presenting a mutant variation only at -308
position. As expected, the rare combination presenting polymorphisms only at positions -238
and -308 was present in the sample studied although in a low frequency (Table 4).








GG 495 0.990 -
-646 GA 5 0.010 -
A 5 _ 0.005
AA 495 0.990 -
-572 AC 5 0.010 -
C 5 _ 0.005
CC 499 0.998 _
-422 CT 1 0.002 _
T 1 _ 0.001
GG 471 0.942 _
-376 GA 28 0.056 _
AA 1 0.002 _
A 30 _ 0.030
GG 418 0.836 _
-308 GA 77 0.154 _
AA 5 0.010 _
A 87 _ 0.087
GG 489 0.978 _
-244 GA 11 0.022 _
A 11 _ 0.011
GG 453 0.906 _
-238 GA 44 0.088 _
AA 3 0.006 _
A 50 _ 0.050
Table 3. Genotype and allele frequencies of SNPs within TNF-α promoter in Brazilians from Rio de Janeiro.
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and -308 was present in the sample studied although in a low frequency (Table 4).
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Haplotype -646 -572 -422 -376 -308 -238 -244 Frequency
1 G A C G G G G 0.710
2 G A C A G G G 0.006
3 G A C G A G G 0.146
4 G C C G G G G 0.006
5 G A C G G G A 0.020
6 G A C G G A G 0.040
7 A A C G G G G 0.008
8 G A T G G G G 0.002
9 G A C A G A G 0.044
10 G A C A A A G 0.060
11 G A C A A G G 0.002
12 G A C G A G A 0.002
13 G A C G A A G 0.004
14 G C C G A G G 0.004
Table 4. Haplotypes description and frequencies within TNF-α promoter in Brazilians from Rio de Janeiro.
3.5. Association of the IFNG SNPs and TB outcomes
Association of the identified SNPs variations within the analyzed region ofIFNG with different
TB outcomes (susceptibility per se, protection, severity and susceptibility to latent M. tubercu‐
losis infection) was assessed based in the comparison of allele, genotype and haplotype
frequencies between the stratified groups. The groups used for each evaluation were as follow:
a) susceptibility per se to TB (TB patients versus TST+ controls), b) disease severity (PTB versus
TBE) and c) susceptibility to the latent infection (healthy controls TST+ versus TST-).
As previously stated, for this analysis, the sample size was reduced in groups, (patients and
controls) because of the exclusion criteria of TB-HIV co-infection and consanguinity. After
exclusions, because of the very low frequency of the -255 A>G and -172 A>G these SNPs were
also excluded.
Results of the association study upon comparison of genotype frequencies of the five remaining
SNPs between TB patients (TBP/EPTB) versus TST+ controls are shown in Table 5. Only the
SNP -200G>T presented a significantly higher frequency of the GT genotype in the control
group indicating an association of this genotype with protection to the occurrence of active TB
(χ2 = 3.86, p = 0.033, OR = 0.18 CI = 0.03 -1.00). Evaluation of the identified SNPs with the other
outcomes did not show any association (data not shown).






χ2 p-value OR IC
-787
CC 138 96
















3.86 0.033 0.18 0.03<1.00
GT 2 7
Table 5. Genotype distribution of the IFNG SNPs among TB patients and healthy controls (TST+).
Given that the SNP -200 IFNG was the only one that was associated with any of the studied
outcomes at genotype level, allele frequency was also tested for the same outcomes. Table 6
shows the comparison of the -200T variant between the stratified groups. The results confirm
the association with protection to the occurrence of active TB and, additionally to TBP.
Association of the -200T variant was also seen to occurrence of latent infection (p=0.035).


























Table 6. Distribution of allele frequencies of-200T variant mutant groups according to the different outcomes.
Finally, the more prevalent IFNG polymorphisms (-599C>G and-200G>T) were tested against
demographic variables, such as, gender and age. No significant association was found after
stratified analysis at allele, genotype or haplotype levels (data not shown).
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3.6. Association of the TNF–α SNPs and TB outcomes
Table 7 summarizes the distribution and comparison of genotype frequencies of each indi‐
vidual SNP among TB patients and TST+ controls. No significant difference was observed. The
evaluation of the possible association of different genotypes of TNF-α gene with susceptibility
to the occurrence of TBP or TBE was also carried out separately, however, no association was









GA 1 1 1.00 0.68 0.02<25.33
-572
AA 138 95
CA 2 1 1.00 1.38 0.10<38.92
-422
CC 140 96
CT 0 0 - - -
-376
GG 127 93








GA 4 4 0.71 0.68 0.14<3.31
-238
GG 123 88
GA 15 8 0.47 1.50 0.58<3.97
AA 2 0
Table 7. Genotype distribution of the TNF-α SNPs among PTB patients and healthy controls (TST+).
Comparison of the TNF-α SNPs frequencies between TBP and TBEis shown in (Table 8). Only
the -572A>C (CA genotype) presented a significant difference between these groups, being
absent among the 121 TBP subjects, (RR = 8.12, CI = 5.20 <12.67 and p-value = 0.0175). The results
indicate a risk for disease severity. This association was confirmed upon allele frequency
evaluation (RR = 7.72, CI = 5.69 <10.47 and p = 0.0179) data not shown.

































0.585 0.85 0.22<3.37GA 14 1
AA 1 1
Table 8. Genotypes distribution of the TNF-α SNPs among TBP and TBE.
The association between the TNF-α genotypes with latent infection was also evaluated. No
significant difference was found (data not shown).
The final evaluation of independent SNPs with the different TB outcomes was performed
based in the allele frequencies comparison for the most common TNF-α SNPs (-376G>A,
-308G>A, -244G>A and -238G>A). The SNP -376G>A, allele variant -376A, showed a significant
association with susceptibility to the occurrence of active TB (p = 0.035, OR = 3.57, CI = 0.95 <
15.72) and severity (p = 0.038 and RR = 2.68) (Table 9). All other outcomes showed no significant
association with any of the variants tested, (data not shown).


























Table 9. Distribution of allele frequency of the TNF-α -376A variant and association analysis with different outcomes
studied.
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Table 10 shows the distribution of the 14 identified haplotypes in the different groups used for
the association study. No significant difference was observed in the haplotypes frequencies












1 9567.9%) 82(67.8%) 0 70(72.9%) 40(69%)
2 2(1.4%) 1(0.8%) 0 0 0
3 19(13.6%) 17(14.1%) 2(10.5%) 11(11.5%) 7(12.1%)
4 1(0.7%) 0 1(5.26%) 0 1(1.72%)
5 3(2.1%) 3(2.5%) 0 4(4.2%) 2(3.4%)
6 7(5 %) 6(5%) 1(5.3%) 5(5.2%) 5(8.6%)
7 1(0.7%) 1(0.8%) 0 1(1.1%) 1(1.7%)
9 9(6%) 8(6.6%) 1(5.3%) 3(3.1%) 2(3.4%)
11 1(0.7%) 1(0.8%) 0 1(1.1%) 0
12 1(0.7%) 1(0.8%) 0 0 0
13 1(0.7%) 1(0.8%) 0 0 0
14 1(0.71%) 0 1(5.26%) 1(1.04%) 0
Table 10. Frequency of TNF-α haplotypes in the different groups studied
After the genotyping of all samples and evaluation of the possible association with the different
TB outcomes, the most frequent polymorphisms (-376G>A; -308G>A; -244G>A and -238G>A)
were tested in a stratified analysis against the demographic variables gender and age. No
significant differences were found for gender or age (data not shown).
4. Discussion
It is well known that to M. tuberculosis,  ethiologic agent of human TB can cause a broad
spectrum of effects ranging from no infection to different clinical disease phenotypes [2,
16,  23-25].  However,  the  reasons  for  individual  or  ethnic  differences  in  acquiring infec‐
tion,  active  disease,  disease  severity,  and  different  clinical  outcomes  have  not  been
completely clarified.  It  has long been realized that many human diseases arise from the
complex interplay between environmental exposures and host genetics susceptibilities [26].
In addition, several genetic factors have also been associated with different outcomes: host
susceptibility per se the occurrence of active TB, disease severity and / or protection for the
occurrence of active disease [27-33].
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The establishment of an efficient immune response involves many different molecules, among
which, cytokines and their receptors play an extremely important role. Thus, any genetic
alteration leading to changes in the regulation of gene expression may reflect this response. It
is known that the interindividual variation in the production of these molecules is directly
related to the genetic "background". Literature data have clearly demonstrated that genetic
variability of the genes encoding these molecules can affect the regulation of gene expression
positively or negatively influencing the final yield of the molecule in question. In the last
decade, several single nucleotide polymorphisms (SNPs) in the regulatory region of different
cytokine genes have been described and associated with susceptibility, severity or protection
for a growing number of diseases of different etiologies including tuberculosis [7, 34-35].
Among the possible genetic variations associated with an increased risk of developing TB,
there are several polymorphisms, mainly SNPs, in genes coding for cytokines, cytokine
receptors and several other molecules such as vitamin D receptor, NRAMP1 (SLC11A1), HLA
genes, etc.
The immune defense against M. tuberculosis is complex and involves the interaction between
T CD4+, T CD8+ lymphocytes, macrophages, and monocytes along with the production of
cytokines, such as interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) [36].
Convincing evidence indicating the importance of IFN-γ in particular, in the control of
mycobacterial infections has been found in both experimental and clinical studies [37-38].
Among the mainly important cytokines involved in TB progress after infection with M.
tuberculosis, TNF-α plays a key role. It is also a potent proinflammatory cytokine acting in
protection against intracellular pathogens [39-40].
The genetic variability of TNF-α and IFNG has been described in the last decade [41-46]
including association studies with tuberculosis. However, the frequencies of the polymor‐
phisms already described varies according to the ethnicity of the population studied, ham‐
pering the better interpretation of the value of association studies. Unfortunately, most of these
are performed in ethnically homogeneous populations, and therefore, many of the associations
described for a particular allelic variant in a certain gene may not represent genetic risk factor
in other populations. In Brazil, a country characterized by ethnically mixed population, there
are few data regarding the frequency of single nucleotide polymorphisms in these genes
(IFNG,TNF-α) and the few existing studies refers to one or two SNPs only. In view of the
importance of the promoter region with respect to regulation of gene expression, the major
goal of this work was to proceed a partial mapping of the promoter region of IFNG and TNF-
α genes (approximately, 800bp upstream of the transcription starting site) through PCR-
sequencing approach in samples from TB patients and healthy controls from Rio de Janeiro,
Brazil. Subsequently, based on frequencies of the different SNPs found individually for each
gene, we performed an association study with different TB outcomes.
4.1. Polymorphisms in the promoter region of IFNG and its association with TB
Characterization of the important portion within the IFNGwas firstly identified two decades
ago bydeletion analysisstudies [47-48]. According to authors, it comprises a highly conserved
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Table 10 shows the distribution of the 14 identified haplotypes in the different groups used for
the association study. No significant difference was observed in the haplotypes frequencies












1 9567.9%) 82(67.8%) 0 70(72.9%) 40(69%)
2 2(1.4%) 1(0.8%) 0 0 0
3 19(13.6%) 17(14.1%) 2(10.5%) 11(11.5%) 7(12.1%)
4 1(0.7%) 0 1(5.26%) 0 1(1.72%)
5 3(2.1%) 3(2.5%) 0 4(4.2%) 2(3.4%)
6 7(5 %) 6(5%) 1(5.3%) 5(5.2%) 5(8.6%)
7 1(0.7%) 1(0.8%) 0 1(1.1%) 1(1.7%)
9 9(6%) 8(6.6%) 1(5.3%) 3(3.1%) 2(3.4%)
11 1(0.7%) 1(0.8%) 0 1(1.1%) 0
12 1(0.7%) 1(0.8%) 0 0 0
13 1(0.7%) 1(0.8%) 0 0 0
14 1(0.71%) 0 1(5.26%) 1(1.04%) 0
Table 10. Frequency of TNF-α haplotypes in the different groups studied
After the genotyping of all samples and evaluation of the possible association with the different
TB outcomes, the most frequent polymorphisms (-376G>A; -308G>A; -244G>A and -238G>A)
were tested in a stratified analysis against the demographic variables gender and age. No
significant differences were found for gender or age (data not shown).
4. Discussion
It is well known that to M. tuberculosis,  ethiologic agent of human TB can cause a broad
spectrum of effects ranging from no infection to different clinical disease phenotypes [2,
16,  23-25].  However,  the  reasons  for  individual  or  ethnic  differences  in  acquiring infec‐
tion,  active  disease,  disease  severity,  and  different  clinical  outcomes  have  not  been
completely clarified.  It  has long been realized that many human diseases arise from the
complex interplay between environmental exposures and host genetics susceptibilities [26].
In addition, several genetic factors have also been associated with different outcomes: host
susceptibility per se the occurrence of active TB, disease severity and / or protection for the
occurrence of active disease [27-33].
Tuberculosis - Current Issues in Diagnosis and Management90
The establishment of an efficient immune response involves many different molecules, among
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cytokines, such as interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) [36].
Convincing evidence indicating the importance of IFN-γ in particular, in the control of
mycobacterial infections has been found in both experimental and clinical studies [37-38].
Among the mainly important cytokines involved in TB progress after infection with M.
tuberculosis, TNF-α plays a key role. It is also a potent proinflammatory cytokine acting in
protection against intracellular pathogens [39-40].
The genetic variability of TNF-α and IFNG has been described in the last decade [41-46]
including association studies with tuberculosis. However, the frequencies of the polymor‐
phisms already described varies according to the ethnicity of the population studied, ham‐
pering the better interpretation of the value of association studies. Unfortunately, most of these
are performed in ethnically homogeneous populations, and therefore, many of the associations
described for a particular allelic variant in a certain gene may not represent genetic risk factor
in other populations. In Brazil, a country characterized by ethnically mixed population, there
are few data regarding the frequency of single nucleotide polymorphisms in these genes
(IFNG,TNF-α) and the few existing studies refers to one or two SNPs only. In view of the
importance of the promoter region with respect to regulation of gene expression, the major
goal of this work was to proceed a partial mapping of the promoter region of IFNG and TNF-
α genes (approximately, 800bp upstream of the transcription starting site) through PCR-
sequencing approach in samples from TB patients and healthy controls from Rio de Janeiro,
Brazil. Subsequently, based on frequencies of the different SNPs found individually for each
gene, we performed an association study with different TB outcomes.
4.1. Polymorphisms in the promoter region of IFNG and its association with TB
Characterization of the important portion within the IFNGwas firstly identified two decades
ago bydeletion analysisstudies [47-48]. According to authors, it comprises a highly conserved
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region from positions -117 to -47 and contains two sub regions that can be complexes with
proteins. The sub-proximal region (-90 to -65) shows strong homology to the IL-2 promoter
[49]. Several transcription factors activate transcription of IFNG by binding to this region.
Conversely, several others inhibit factors binds in other regions affecting transcription. Hence,
the interest in investigating the polymorphic sites within IFNG gene promoter, particularly
considering the importance of this cytokine in eliciting the immune response.
Here, analysis of the generated sequences identified seven polymorphic sites, four of which
were new. The transition C →T, was identified at position-787 from the transcription starting
site in five subjects, all heterozygous. The second C → T transition, previously described in the
data base of SNPs at position-785 was also found in five individuals, all heterozygous,
however, no reference to this SNP was found in the literature. The other three SNPs not yet
described, were C to G transition at position -599; C to T at position -517 and A to G at position
-255. Finally, two additional SNPs, transition from G to T at position -200 and A to G at position
-172, already described and well characterized [45] were found in our population.
One of the main problem found during this mapping was the confirmation of the identified
SNPs based on literature data and from different SNPs data bases available online because of
the lack of standardization regarding to the reference nucleotide to define the promoter region
(transcription starting site nt +1). Many authors describe the SNPs identified in relation to the
site of translation or use reference sequences containing sequencing errors leading to misclas‐
sification of SNPs (eg SNP-200G>T, originally described as -183 [45], later called as -179 [50]
and finally, confirmed in this study as -200). The current name, confirmed in this study is based
on the correction of the reference sequence used in previous studies and now available online.
These types of errors greatly hampered the beginning of the sequence analysis regarding the
identification of novel SNPs.
The frequency of each polymorphism was determined in the study population. As noted in
Table 1, the allele frequencies for all the identified SNPs were less than one percent, except for
the variants -599G and -200T, both in a frequency of 1.4%.
Functionally,  it  is  known that  polymorphisms (-200 and -172)  can affect  transcription of
the IFNG. The region from -213 to -200 induces transcription factor through (AP-1) [51]. A
polymorphism at this site (position -200, for example) must change the connection of AP-1
and the promoter activity in T cells. The polymorphism -172 is near to the nuclear factors-
activated T-cells site (NFAT site) (-186TAAAGGAAA-178) and should affect the stability
of this region [50].
The variant IFNG -200T is highly inducible by TNF-α and binds constitutively to nuclear
extracts obtained from T cells, whereas the allele -200G does not respond to TNF-α [50; 52].
The induction of transcriptional activity, when the T allele is present, increases protection
against tuberculosis. Our results corroborate these data, since the IFNG -200T variant showed
to be associated with protection the occurrence of active TB in our study group (P = 0.033, OR=
0.18, CI= 0.03 to 1.00).
According Bream,JH et al., 2002 [50], the promoter region of IFNG is highly conserved,
suggesting that these cytokine production variations are probably due to difference in binding
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to regulatory factors instead of polymorphisms in the gene, which is consistent with our
results. Only seven SNPs were found in our population, five of which were at a low frequency.
The polymorphisms found with a higher frequency were the -200G>T and -599C>G, the latter
being located between two putative binding sites of transcription factors. As this is not yet a
SNP described in the literature, functional studies are needed to better understand their
functional role. The SNP -200 is of great interest for association studies. However, this
polymorphism was not found in Caucasians or Indian populations, suggesting that different
selective forces may be operating in different ethnic or racial groups. These data corroborate
the evidence that IFN-γ is very important in the immune response and that mutations that
interfere with their production may influence the outcome of active tuberculosis as shown by
authors [28,31,53-54], and therefore, a selective force lead the gene to be so conserved.
4.2. Polymorphisms within the promoter region of TNF–α and their association with TB
TNF-α is a proinflammatory and immunoregulaty cytokine which plays a key role in the
initiation, regulation and perpetuation of host defense against infections, but is fatal in excess.
As this molecule plays an important role against a variety of pathogens involving different
patterns of risks and benefits, it is expected that several genetic elements are involved in its
control and production.
The levels of circulating TNF-α are regulated at transcriptional and post-transcriptional levels
and several polymorphisms within the promoter region of TNF-α have been associated with
altered circulating levels of this cytokine.
In humans, the TNF-α gene is located within the complex involving the human leukocyte
antigens (HLA), a highly polymorphic region on chromosome 6p21.3 and hence, many of TNF-
α polymorphisms are in linkage disequilibrium with the HLA genes. Because of differences in
the distribution of HLA alleles we might expect variations in associations between polymor‐
phisms of TNF-α and various conditions in different geographical areas.
The human genome analysis showed that the level of variations in the genome is approxi‐
mately one SNP/1.71Kb [55]. However, the TNF-α promoter has higher density of SNPs.
Despite this level of variation, the regions involved in gene regulation are highly conserved in
humans [56-58].
In our work, we perform the mapping of the first 800pb promoter region, through direct
sequencing of the amplified PCR product in 500 DNA samples from individuals living in the
metropolitan area of Rio de Janeiro, Brazil and found seven polymorphisms previously
described in the literature, most of which well characterized. However, according allele
frequencies, only the variants -376A, -308A, -238A and -244A were present in more than one
percent (0.030, 0.087, 0.011 and 0.050) respectively. The influence of these SNPs in binding of
transcription factors have not been fully explored, most of the studies are focused on the
association of one or two SNPs with different diseases. The SNPs -376, -308 and -238 have been
the most studied but, the results of functional studies performed so far for SNPs -308 and -238
are controversial. It is believed that the variant -308A is associated with an increased tran‐
scription rate, leading to an increased production of TNF-α [59] and the variant-238A with a
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region from positions -117 to -47 and contains two sub regions that can be complexes with
proteins. The sub-proximal region (-90 to -65) shows strong homology to the IL-2 promoter
[49]. Several transcription factors activate transcription of IFNG by binding to this region.
Conversely, several others inhibit factors binds in other regions affecting transcription. Hence,
the interest in investigating the polymorphic sites within IFNG gene promoter, particularly
considering the importance of this cytokine in eliciting the immune response.
Here, analysis of the generated sequences identified seven polymorphic sites, four of which
were new. The transition C →T, was identified at position-787 from the transcription starting
site in five subjects, all heterozygous. The second C → T transition, previously described in the
data base of SNPs at position-785 was also found in five individuals, all heterozygous,
however, no reference to this SNP was found in the literature. The other three SNPs not yet
described, were C to G transition at position -599; C to T at position -517 and A to G at position
-255. Finally, two additional SNPs, transition from G to T at position -200 and A to G at position
-172, already described and well characterized [45] were found in our population.
One of the main problem found during this mapping was the confirmation of the identified
SNPs based on literature data and from different SNPs data bases available online because of
the lack of standardization regarding to the reference nucleotide to define the promoter region
(transcription starting site nt +1). Many authors describe the SNPs identified in relation to the
site of translation or use reference sequences containing sequencing errors leading to misclas‐
sification of SNPs (eg SNP-200G>T, originally described as -183 [45], later called as -179 [50]
and finally, confirmed in this study as -200). The current name, confirmed in this study is based
on the correction of the reference sequence used in previous studies and now available online.
These types of errors greatly hampered the beginning of the sequence analysis regarding the
identification of novel SNPs.
The frequency of each polymorphism was determined in the study population. As noted in
Table 1, the allele frequencies for all the identified SNPs were less than one percent, except for
the variants -599G and -200T, both in a frequency of 1.4%.
Functionally,  it  is  known that  polymorphisms (-200 and -172)  can affect  transcription of
the IFNG. The region from -213 to -200 induces transcription factor through (AP-1) [51]. A
polymorphism at this site (position -200, for example) must change the connection of AP-1
and the promoter activity in T cells. The polymorphism -172 is near to the nuclear factors-
activated T-cells site (NFAT site) (-186TAAAGGAAA-178) and should affect the stability
of this region [50].
The variant IFNG -200T is highly inducible by TNF-α and binds constitutively to nuclear
extracts obtained from T cells, whereas the allele -200G does not respond to TNF-α [50; 52].
The induction of transcriptional activity, when the T allele is present, increases protection
against tuberculosis. Our results corroborate these data, since the IFNG -200T variant showed
to be associated with protection the occurrence of active TB in our study group (P = 0.033, OR=
0.18, CI= 0.03 to 1.00).
According Bream,JH et al., 2002 [50], the promoter region of IFNG is highly conserved,
suggesting that these cytokine production variations are probably due to difference in binding
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to regulatory factors instead of polymorphisms in the gene, which is consistent with our
results. Only seven SNPs were found in our population, five of which were at a low frequency.
The polymorphisms found with a higher frequency were the -200G>T and -599C>G, the latter
being located between two putative binding sites of transcription factors. As this is not yet a
SNP described in the literature, functional studies are needed to better understand their
functional role. The SNP -200 is of great interest for association studies. However, this
polymorphism was not found in Caucasians or Indian populations, suggesting that different
selective forces may be operating in different ethnic or racial groups. These data corroborate
the evidence that IFN-γ is very important in the immune response and that mutations that
interfere with their production may influence the outcome of active tuberculosis as shown by
authors [28,31,53-54], and therefore, a selective force lead the gene to be so conserved.
4.2. Polymorphisms within the promoter region of TNF–α and their association with TB
TNF-α is a proinflammatory and immunoregulaty cytokine which plays a key role in the
initiation, regulation and perpetuation of host defense against infections, but is fatal in excess.
As this molecule plays an important role against a variety of pathogens involving different
patterns of risks and benefits, it is expected that several genetic elements are involved in its
control and production.
The levels of circulating TNF-α are regulated at transcriptional and post-transcriptional levels
and several polymorphisms within the promoter region of TNF-α have been associated with
altered circulating levels of this cytokine.
In humans, the TNF-α gene is located within the complex involving the human leukocyte
antigens (HLA), a highly polymorphic region on chromosome 6p21.3 and hence, many of TNF-
α polymorphisms are in linkage disequilibrium with the HLA genes. Because of differences in
the distribution of HLA alleles we might expect variations in associations between polymor‐
phisms of TNF-α and various conditions in different geographical areas.
The human genome analysis showed that the level of variations in the genome is approxi‐
mately one SNP/1.71Kb [55]. However, the TNF-α promoter has higher density of SNPs.
Despite this level of variation, the regions involved in gene regulation are highly conserved in
humans [56-58].
In our work, we perform the mapping of the first 800pb promoter region, through direct
sequencing of the amplified PCR product in 500 DNA samples from individuals living in the
metropolitan area of Rio de Janeiro, Brazil and found seven polymorphisms previously
described in the literature, most of which well characterized. However, according allele
frequencies, only the variants -376A, -308A, -238A and -244A were present in more than one
percent (0.030, 0.087, 0.011 and 0.050) respectively. The influence of these SNPs in binding of
transcription factors have not been fully explored, most of the studies are focused on the
association of one or two SNPs with different diseases. The SNPs -376, -308 and -238 have been
the most studied but, the results of functional studies performed so far for SNPs -308 and -238
are controversial. It is believed that the variant -308A is associated with an increased tran‐
scription rate, leading to an increased production of TNF-α [59] and the variant-238A with a
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decreased rate of transcription. Regarding the SNP-376G>A different studies show that this
polymorphism is located in a region of multiple interactions between proteins and DNA, and
that the minor allele acts in the recruitment of proteins OCT1 for this region. According Knight
et al (1999) [60] there is a significant interaction between variant -376A and the OCT-1 protein,
this variant binds the proteins while the variant -376G does not. The authors report also by
tests with the reporter gene system, that this mutant variant moderately increases the basal
levels of TNF-α and associate the same with a relative risk of 4 to cerebral malaria. The problem
is that the linkage disequilibrium is strong in this area and it is difficult to study the function
of an isolated SNP. In some Caucasian populations -376A allele variant is liked to -308G and
-238A [60-61], what is not observed in the African Gambia. Thus, association between the
linked allelic variants on TNF-α production and diseases has been studied. According, Hajeer&
Hutchinson (2001), the combined allele variants -238G, -308A and -376G are associated with
high TNF-α levels [62].
A large number of studies have investigated the association between polymorphisms in the
promoter region of the gene for TNF-α and tuberculosis. Results vary according to the different
populations studied, finding no association [63-72] or a positive association [26, 29, 73-75]. In
our analysis of the single SNP association, TB was associated with the -376G>A. In this case,
we observed an association of the minor allele -376A with the outcome of susceptibility per
se the occurrence of active TB (p= 0.035, OR 3.57, IC 0.95 <15.72) and an increased relative risk
for the occurrence of extrapulmonary TB (p= 0.038, OR 2.68, IC 1.22 < 5.86). The association of
this allele variant with the occurrence of TB and an increased relative risk for the development
of extrapulmonary TB is intriguing. Given the influence of this allele with increased expression
of TNF-α, one would expect an association with the protection. One possible explanation for
this observation may be the small sample size in the stratified groups. The large confidence
intervals (CI) for both outcomes could be a reflection of the small sample size.
The PCR-sequencing approach (gold standard) used for the mapping these genes practically
discard the possibility of genotyping errors and all mutants found for all SNPs evaluated were
confirmed twice by new PCR and resequencing. Another possibility would be due to the strong
linkage disequilibrium observed in this region of the gene promoter of TNF-α. It is possible
that other allelic variant (eg, 238A), as opposed to the functional role of variant -376A is
canceling the same level of control of gene expression.
An important aspect of this study relates to the ethnic characteristics of the studied population.
Brazilian population is characterized by mixture of ethnicities and the results obtained here
contribute for a global understanding of the influence of genetic factors in TB outcomes.
Usually, most of the studies on this field are made with ethnically homogeneous populations.
A study conducted by Baena et al., 2002 [76] clearly shows the importance of ethnic difference
in the association study of SNPs in TNF-α promoter with disease. According authors, the -857
SNP is a marker for Amerindians. In that study, SNPs in TNF-α promoter were also used to
identify markers of ancestry, understanding that this region was well characterized previously
with primates and humans. Several studies [77-81] have shown that some polymorphisms as
-238; - 244 and -308 are in association with the HLA genes and in addition, the SNPs -308 [77];
-863 and -857 [81], are markers of Caucasians. The -238 SNP was found in three populations
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studied, although it has also been found in Caucasians [78] and Asian [80]. Instead, the -376
SNP was not detected in any of the non-African analyzed and were found with the -238.
These data demonstrate the importance of taking into account the "background" of the
frequencies of SNPs of TNF-α in studies of gene-disease association.
Association studies of genetic factors with infectious diseases are difficult to conduct because
of the multi factorial nature of these diseases that includes host, pathogen and environmental
variables in different proportions for each disease. This multi factorial nature of TB stresses
the importance to look for haplotypes in the association studies. The fact that our population
is so mixed allowed us to find mutations that do not exist in other populations, such as the
-308, for example, which is relatively rare in Asians and American Indians. Data from the
genotyping of a large number of SNPs for different samples revealed that the human genome
has a block structure haplotype [82-83] and configuration of a haplotype sometimes is more
important than a single SNP genotype to determine phenotype [84]. Moreover, the construc‐
tion of a haplotype block is useful for identifying SNPs that isolates would not influence the
phenotype [85].
5. Conclusions
In conclusion, this study showed that the proximal part of the promoter region of IFNG is
highly conserved, as seen in previous publications and the identified SNPs were in very low
frequency. The -200T allele variant was associated with protection occurring active TB, and
pulmonary TB. In addition, this variant was also associated with latent infection. Concerning
TNF-α, the high genetic variability was confirmed, but only the -376G>A SNP showed an
association with susceptibility per se to TB occurrence and increased risk for the occurrence of
extrapulmonary TB.
The data presented here shows the reality of a population with characteristics of high ethnic
miscegenation, provides the different SNPs identified enabling the realization of real sample
calculation for any association studies that may be idealized with these targets and other
conditions for this population and finally, provides haplotype that can be used in other studies
of association with other diseases.
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et al (1999) [60] there is a significant interaction between variant -376A and the OCT-1 protein,
this variant binds the proteins while the variant -376G does not. The authors report also by
tests with the reporter gene system, that this mutant variant moderately increases the basal
levels of TNF-α and associate the same with a relative risk of 4 to cerebral malaria. The problem
is that the linkage disequilibrium is strong in this area and it is difficult to study the function
of an isolated SNP. In some Caucasian populations -376A allele variant is liked to -308G and
-238A [60-61], what is not observed in the African Gambia. Thus, association between the
linked allelic variants on TNF-α production and diseases has been studied. According, Hajeer&
Hutchinson (2001), the combined allele variants -238G, -308A and -376G are associated with
high TNF-α levels [62].
A large number of studies have investigated the association between polymorphisms in the
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this observation may be the small sample size in the stratified groups. The large confidence
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studied, although it has also been found in Caucasians [78] and Asian [80]. Instead, the -376
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1. Introduction
The interindividual variability in the metabolism of xenobiotics and drug response is extensive
and many factors are involved with this variation including genetic composition, gender, age,
co-administration of medication, individual physiology, pathophysiology and presence of
other environmental factors (alcohol consumption, smoking, eating habits).
To produce their therapeutic effects, the drug must be present in appropriate concentrations
at its site of action. Although the therapeutic concentrations are dependent on the given dose,
they will also depend on the magnitude and rate of absorption, distribution, biotransforma‐
tion, and excretion. Pharmacokinetics studies the course and distribution of drug and its
metabolites in different tissues, covering the mechanisms of absorption, transport, metabolism
and excretion. In addition, pharmacodynamics concentrates on the biochemical and physio‐
logical effects of drugs and their mechanism of action. Proteins involved in drug effects are
defined as target molecules and include not only (direct) receptors, but also proteins associated
with mechanism of action such as e.g. signal transducer proteins [1].
After  its  administration,  a  drug is  absorbed and then  distributed  throughout  the  body,
requiring the coordinated functioning of  various proteins,  including metabolic  enzymes,
trafficking proteins,  receptor  proteins,  and others.  Medication can enter  the  body as  ei‐
ther  active  drugs  or  as  inactive  prodrugs.  Most  drugs  are  metabolized  in  the  liver  to
make  them  more  soluble  for  subsequent  elimination  through  the  kidneys  or  intestines.
Prodrugs require  metabolic  conversion,  also  called biotransformation,  to  liberate  the  ac‐
tive  compound.  Complete  biotransformation  of  any  one  drug  typically  requires  several
different enzymes. [2].  Genetic variability has been described to have effect on drug ab‐
sorption and metabolism and its interactions with the receptors. This forms the basis for
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slow and rapid drug absorption, poor, efficient or ultrarapid drug metabolism and poor
or efficient receptor interactions [3]. The consequences of such variations can lead to ad‐
verse drug reaction and/or terapeutic failure.
In this context, pharmacogenetics is the study of genetic variations associated with individual
variability in drug response, including differences in efficacy, drug-drug interactions, and the
relative risk of an adverse response to drugs. It includes the study of genetic polymorphisms
that could affect the expression or activity of drug transporters, drug metabolizing enzymes
and drug receptors [2-4].
It’s estimated that 99.9% of the human genome sequence between individuals is identical and
genetic differences in polulations are called mutations if they are present in less than 1% and
polymorphisms when present in at least 1% of a population. A single-nucleotide polymor‐
phism (SNP) involves a replacement of one nucleotide base with any one of the other three
and occuring at approximately one out of every 1,000 bases in the human genome [5].
A mutation or polymorphism in genes that encode metabolic enzymes, carriers or receptors
can affect the drug pharmacokinetics and pharmacodinamics leading to undesired therapeutic
effects. The identification of these genetic markers which predicted if a person responds well
or not to a specific drug could help to select the right medication in right dosage, maximizing
the eficacy and preventing or reducing the adverse drug reactions.
2. Problem statement
TB is an important global public health problem but has cure in almost 100% of the new cases
if correct quimiotherapy is applied. The American Thoracic Society (ATS) treatment guidelines
recommend an initial phase for TB treatment which consists of rifampicin 10 mg/kg (maximum
600 mg), isoniazid 5 mg/kg (maximum 300 mg), pyrazinamide 15–30 mg/kg (maximum 2 g),
and ethambutol 15–20 mg/kg (maximum 1.6 g) given daily for 8 weeks, followed by a contin‐
uous phase of isoniazid 15 mg/kg (maximum 900 mg) and rifampicin 10 mg/kg (maximum 600
mg) administered 2–3 times/week for 18 weeks [6]. The use of fixed-dose combination (FDC)
tablets containing anti-TB drugs has been recommended by the World Health Organization
(WHO) as an additional measure to improve treatment adherence by reducing the number of
tablets to be taken. The principal disadvantages of combining three or more drugs in one tablet
include (a) the possibility of overdosage or underdosage resulting from a prescription error,
(b) changes in the bioavailability of rifampicin and (c) difficulties in determining which drug
is responsible for adverse effects [7].
Isoniazid (INH) is an important drug in the TB treatment and was introduced in chemo‐
therapic scheme since 1952. It is the hidrazine of isonicotinic acid and shows cytotoxic ac‐
tivity for Mycobacterium tuberculosis both in rest (during latency) and proliferation phases.
This drug enters easily in macrophague cells to kill bacilli in multiplication and is specif‐
ic for mycobacteria [1].
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INH-induced adverse reactions include fever, nausea, vomiting, hepatotoxicity, skin reactions,
gastrointestinal and neurological disorders. Only in the early 1970s, the occurrence of severe
liver injury as a side effect of this drug was recognized, resulting in the death of some patients
[8]. Among the first-line anti-TB drugs, INH is the main associated with drug-induced
hepatotocixity with a frequency ranging from 1 to 30% in different populations [9]. Other drugs
causing liver injury are mainly reported in combination with INH [10, 11]. Drug-induced
hepatotoxicity is defined as a serum alanine aminotransferase (ALT) level three times greater
than the upper limit of normal (ULN) with clinical symptoms or five times the ULN without
symptoms. In both cases treatment should be interrupted and, generally, a modified or
alternative regimen is introduced [9]. Because these adverse reactions do not only affect
morbidity and mortality rate but also lead to treatment interruptions, failure and relapse,
adverse reactions contribute to the spread of the disease and the emergence of multidrug
resistence (MDR).
Adverse Drug Reactions (ADRs) are common causes of hospitalization and lead to large costs
to society. There are two main financial burdens due to illnesses caused by ADRs: that of
treating and that of avoiding them [12]. The occurrence of serious and fatal ADRs has been
extensively studied in hospitalized patients and a meta-analysis of prospective studies in
approximately forty hospitals in the United States of America (USA) suggests that 6-7% of
hospitalized patients suffer from serious ADRs and 0.32% of patients develop fatal ADRs [13].
This results in approximately 100,000 deaths annually in the U.S. and an annual cost of over a
hundred billion dollars to the society due to prolonged hospitalization and reduced produc‐
tivity [3, 13]. Furthermore, it has been estimated that ADRs are responsible for up to 7% of all
admissions in hospitals in the United Kindown (UK) and 13% in medical clinics in Sweden [3],
which shows the magnitude of this problem in the context of chemotherapy and drug
development. Additionally, in France, a 10-year study in the Liver Unit of Hôpital Beaujon in
Paris showed that among all patients hospitalized with acute hepatitis, 10% were due to
adverse reaction to drugs and the prevalence of drug hepatotoxicity in patients older than fifty
years exceeded 40%. In Japan and other Eastern countries, drugs are responsible for about
10-20% of cases of fulminant hepatitis [14].
Liver injury is the most common ADR and the main complication during chemotherapy since
liver is the central organ for the biotransformation and excretion of most drugs and xenobiotics
[14-17]. There are basically six mechanisms involving primarily the hepatocyte injury. The
reactions of mono-oxygenase cytochrome P450 (CYP450) with certain drugs generate toxic
metabolites that bind to intracellular proteins, leading to calcium homeostasis pump dysfunc‐
tion with consequent disruption of actin fibers and cell lysis. Some drugs affect transport
proteins in the cell membrane interrupting the flow of bile and then causing cholestasis. Several
reactions involving CYP P450 can promote binding of the drug to the enzyme, with consequent
exposure of this complex on the cell surface for recognition by T cells and antibody production
as part of the autoimmune response. Finally, certain drugs may promote hepatic injury
mediated by programmed cell death (apoptosis) or being capable of inhibiting respiration and/
or mitochondrial beta-oxidation [17].
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slow and rapid drug absorption, poor, efficient or ultrarapid drug metabolism and poor
or efficient receptor interactions [3]. The consequences of such variations can lead to ad‐
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and drug receptors [2-4].
It’s estimated that 99.9% of the human genome sequence between individuals is identical and
genetic differences in polulations are called mutations if they are present in less than 1% and
polymorphisms when present in at least 1% of a population. A single-nucleotide polymor‐
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can affect the drug pharmacokinetics and pharmacodinamics leading to undesired therapeutic
effects. The identification of these genetic markers which predicted if a person responds well
or not to a specific drug could help to select the right medication in right dosage, maximizing
the eficacy and preventing or reducing the adverse drug reactions.
2. Problem statement
TB is an important global public health problem but has cure in almost 100% of the new cases
if correct quimiotherapy is applied. The American Thoracic Society (ATS) treatment guidelines
recommend an initial phase for TB treatment which consists of rifampicin 10 mg/kg (maximum
600 mg), isoniazid 5 mg/kg (maximum 300 mg), pyrazinamide 15–30 mg/kg (maximum 2 g),
and ethambutol 15–20 mg/kg (maximum 1.6 g) given daily for 8 weeks, followed by a contin‐
uous phase of isoniazid 15 mg/kg (maximum 900 mg) and rifampicin 10 mg/kg (maximum 600
mg) administered 2–3 times/week for 18 weeks [6]. The use of fixed-dose combination (FDC)
tablets containing anti-TB drugs has been recommended by the World Health Organization
(WHO) as an additional measure to improve treatment adherence by reducing the number of
tablets to be taken. The principal disadvantages of combining three or more drugs in one tablet
include (a) the possibility of overdosage or underdosage resulting from a prescription error,
(b) changes in the bioavailability of rifampicin and (c) difficulties in determining which drug
is responsible for adverse effects [7].
Isoniazid (INH) is an important drug in the TB treatment and was introduced in chemo‐
therapic scheme since 1952. It is the hidrazine of isonicotinic acid and shows cytotoxic ac‐
tivity for Mycobacterium tuberculosis both in rest (during latency) and proliferation phases.
This drug enters easily in macrophague cells to kill bacilli in multiplication and is specif‐
ic for mycobacteria [1].
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INH-induced adverse reactions include fever, nausea, vomiting, hepatotoxicity, skin reactions,
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mediated by programmed cell death (apoptosis) or being capable of inhibiting respiration and/
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Xenobiotics are usually lipophilic and this facilitates their transport in association with
lipoproteins in the blood stream and their penetration of lipid membranes and entrance into
organs. However, physicochemical properties of drug molecules difficult their removal from
the organism by biliary or renal excretion and therefore, these substances require enzymatic
conversion to water soluble compounds [1]. The xenobiotics metabolization, often through
multiple pathways, can generate metabolites that are more toxic than the substrate and through
their interaction with target macromolecules such as DNA, RNA, proteins and receptors,
generate the toxic effects. The organ affected is generally that reponsible for drug metaboli‐
zation or excretion of metabolites [1].
The enzyme systems responsible for the biotransformation of many drugs are located in the
endoplasmic reticulum of the liver (microsomal fraction). Such enzymes are also present in
the kidneys, lungs and gastrointestinal epithelium, although at a lower concentration [1]. The
metabolic modification in biotransformation usually takes place in two consecutive steps and
results in the loss of biological activity. Phase I reactions convert the xenobiotic into a metab‐
olite with higher polarity by oxidation, reduction or hydrolysis and generates a pharmaco‐
logically inactive or less active, or in the case of a pro-drug, more active molecule. This
metabolite is than either eliminated or go through Phase II reactions (so-called synthesis or
conjugation reactions), involving binding to a primary metabolite or endogenous substrate
such as glucuronate, sulfate, acetate, amino acids or glutathione (tripeptide). Such enzymatic
reactions include glucuronidation, methylation, sulfation, acetylation, conjugation with
glutathione and conjugation with glycine [1].
The risk for developing hepatotoxicity is associated both with genetic and acquired factors.
The acquired factors include: age, gender, nutritional habits, drug abuse, pregnancy and
extrahepatic disease. Genetic variations in isoenzymes involved in drug biotransformation can
result in abnormal reactions leading to toxic effects [14,17]. In the case of INH in particular,
advanced age is a risk factor for hepatotoxicity whereas deficiency in the ability of N-acetyla‐
tion represent a genetic risk factor for liver injury.
INH is administered orally and rapidly absorbed through the gastrointestinal tract passing
through the liver by the portal venous system before reaching the general circulation where is
metabolized by a process known as the first pass effect with reduction of its biodiponibility.
About 75% to 95% of the INH is excreted by the kidneys during the first 24 hours, mainly as
the metabolic forms acetyl-isoniazid and isonicotinic acid [1].
In the liver, INH is metabolized to acetylisoniazid by N-acetyltransferase 2 (NAT2), followed
by hydrolysis to acetylhydrazine and then oxidized by cytochrome P4502E1 (CYP2E1) to
hepatotoxic intermediates [18, 19]. These metabolites can destroy hepatocytes either by
interfering with cell homeostasis or by triggering immunologic reactions in which reactive
metabolites that are bound to hepatocyte plasma proteins may act as haptens [17]. The other
metabolic pathway to generate toxic metabolites is direct hydrolysis of INH to hydrazine, a
potent hepatotoxin. NAT2 is also responsible for converting acetylhydrazine to diacetylhy‐
drazine, a nontoxic component [18, 20, 21] (Figure 1). Glutathione S-transferase (GST), an
important phase II detoxification enzyme, is thought to play a protective role as an intracellular
free radical scavenger, which conjugates glutathione with toxic metabolites that are generated
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from CYP2E1 [22]. Sulphydryl conjugation facilitates the elimination of metabolites from the
body and reduces the toxic effect [23] (Figure 1).
Figure 1. Schematic representation of the INH metabolism. The major enzymes involved in this pathway are indicated
in boxes [20, 24].
In the last few years, an increasing number of studies have suggested that genetic polymor‐
phisms in NAT2, CYP2E1 and GST genes would be associated with susceptibility to drug-
induced hepatotoxicity during TB treatment. The present work focused in an overview of the
role of such polymorphisms in occurence of liver injury induced by anti-TB drugs, and by INH
in particular.
3. State of the art
3.1. N-acetyltransferase 2
NAT2, the main enzyme responsible for the metabolism and inactivation of INH in humans,
is a Phase II enzyme that catalyzes the transfer of the acetyl group from the cofactor acetyl
coenzyme A (acetyl-CoA) to the nitrogen terminal of the drug. Variations in activity of NAT2
were discovered over 50 years ago when observing interindividual differences in the metab‐
olism of INH and the level of drug-induced toxicity in TB patients. NAT2 is encoded by the
NAT2 gene and according family genetic studies, variability of NAT2 was directly related to
the emergence of different phenotypes of acetylation [25].
The molecular study of human N-acetyltransferases revealed the presence of three genetic loci,
two very homologous encoding the enzymes NAT1 and NAT2, and a third including the
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coenzyme A (acetyl-CoA) to the nitrogen terminal of the drug. Variations in activity of NAT2
were discovered over 50 years ago when observing interindividual differences in the metab‐
olism of INH and the level of drug-induced toxicity in TB patients. NAT2 is encoded by the
NAT2 gene and according family genetic studies, variability of NAT2 was directly related to
the emergence of different phenotypes of acetylation [25].
The molecular study of human N-acetyltransferases revealed the presence of three genetic loci,
two very homologous encoding the enzymes NAT1 and NAT2, and a third including the
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pseudogene pNAT (Figure 2). These loci are located on chromosome 8 between 170-360Kb at
8p22 [26]. The pNAT is a pseudogene containing a premature stop codon, and is not transcri‐
bed. NAT1 and NAT2 genes consist of 873 bp, are intronless, and encode proteins of 34 kDa.
Protein sequence homology between both enzymes is 81% while that between their respective
genes is 87%. Both enzymes have N-acetylation, O-acetylation and NO-transfer in different
xenobiotics and carcinogens but differ considerably in their tissue distribution and expression
levels during embryonic development [26-28].
Both NAT1 and NAT2 are polymorphic genes and SNPs in their coding region can alter the
enzymatic activity [29, 30] and are the basis of the three major genetically determined pheno‐
types, being rapid, intermediate and slow acetylators, which are inherited as a codominant
trait [31, 32]. The reference NAT2*4 allele (without mutations / wild-type) and 66 variants were
identified and classified in human populations depending on the combination of up to four
SNPs present throughout the NAT2 coding region [33]. So far, over 30 SNPs have been
identified in this region, including several rare mutations described in different populations
[34]. Among these, the seven most frequent are the 191 G>A (R64Q), 282 C>T (silent), 341 T>C
(I114T), 481 C>T (silent), 590 G>A (R197Q), 803 A>G (K268R) and 857 G>A (G286T) SNPs
identified in different human populations [35]. NAT2 alleles containing the 191G>A, 341T>C,
590G>A or 857G>A SNPs are associated with slow acetylator NAT2 alleles [33].
Figure 2. Schematic representation of NAT genes on human chromosome 8p22. Distribution of the seven most com‐
mon SNPs in NAT2. D8S21 represents a polymorphic marker situated in the NAT2 locus [26, 36].
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Presence of different SNPs in NAT2 can be easily determined by genotyping procedures such
as PCR-RFLP [37], allele specific PCR [38] or direct sequencing [39]. To achieve the NAT2
genotype of each individual and predict the phenotype, the haplotype of both chromosomes
is usually reconstructed using the statistic software (PHASEv2.1.1[40, 41]). Using haplotype
data, many studies have reported the frequencies of the different acetylation profiles among
ethnically different populations showing the high diversity around the world. In Asians and
Ameridians, the fast acetylator phenotype is more frequent [42-44] whereas in Euro-descend‐
ants slow acetylators account for 50% of the study population [37,45]. The molecular basis for
such discrepancy is that the most common NAT2 allele in Euro-descendants is very rare in
Asians and may represent a different selective advantage within the gene pools of these
separate populations. Description of new alleles of NAT2 is still ocurring in recent studies [34].
In an attempt to establish an association between acetylation profiles and development of
disease, cohort or case-control studies have been performed using of genotyping and pheno‐
typing tools. Evidence was found for an association between the slow acetylator predicted
phenotype and developing urinary bladder cancer, while rapid acetylators seem more
susceptible to development of colon cancer. For a review, see [27, 46].
For many years, INH has been considered the main cause of hepatotoxicity during TB
treatment and association studies between the acetylation phenotypes and susceptibility to
liver-related ADRs have been performed. Two early studies conducted in oriental populations
investigated the association of the acetylator phenotype with INH induced hepatotoxicity and
observed an increased risk of developing hepatotoxicity by INH among the slow acetilators
[47, 48]. This observation was confirmed in several other studies performed in different
populations [49-52].
Several studies reported the absence of a relationship between acetylation status and hepato‐
toxicity during TB treatment [53-55] but some, suggested the rapid acetylators as more
susceptible to side effects [55, 56]. Reasons for these different findings range from genotyping
methods to ethnicity. In some studies, NAT2 acetylation phenotypes were determined by an
enzymatic method leading to possible misclassification of the acetylation status [53, 56, 57].
Indeed, it is difficult to compare the accuracy of different NAT phenotyping methods or
different cut-off points using the same phenotyping method. In addition, for genotyping,
investigators sometimes select a small number of SNPs to define the acetylation status [54,
55]. Since the frequencies of NAT2 alleles are different among worldwide populations and new
alleles are been identified in some countries, investigators need to characterize such alleles in
their own study population in order to choose appropriate SNPs for genotyping and classify
the acetylation status of individuals, otherwise overestimation of slow acetylators may be
obtained, contributing to a spurious results in the association study.
Recently, a study with an admixed population showed that NAT2 is a genetic factor for
predisposition to anti-TB drug-induced hepatitis. In this case, NAT2 genes were well charac‐
terized by direct sequencing and their genotypes achieved by haplotype reconstruction using
the PHASE software. In addition, functional unknown genotypes were disconsidered and
others confounding variables for hepatotocixity were taken into account. The incidence of
elevated levels of serum transaminases was significantly higher in slow acetylators than those
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obtained, contributing to a spurious results in the association study.
Recently, a study with an admixed population showed that NAT2 is a genetic factor for
predisposition to anti-TB drug-induced hepatitis. In this case, NAT2 genes were well charac‐
terized by direct sequencing and their genotypes achieved by haplotype reconstruction using
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of the rapid/intermediate type. These results corroborate with the current hypothesis that the
acetylator status may be a risk factor for the hepatic side effects of isoniazid [58].
Finally, a meta-analysis was conducted to solve the problem of inadequate statistical power
and controversial results based on accumulated data with small sample size [59]. Data from
14 studies performed between 2000 and 2011 were pooled and showed that TB patients with
a slow acetylator genotype had a higher risk of anti-tuberculosis drug induced hepatotocixity
than patients with rapid or intermediate acetylation (p < 0.001). Moreover, subgroup analyses
indicate that both Asians and non-Asians slow acetylators develop anti-tuberculosis drug
induced hepatotocixity more frequently. Additionally, there were statistically significant
associations between NAT2*5/*7, NAT2*6/*6, NAT2*6/*7 and NAT2*7/*7 and the risk of anti-
TB drug induced hepatotocixity [59].
As a final consideration, NAT acetylates more slowly not only isoniazid but also acetylhydra‐
zine, the immediate precursor of toxic intermediates, to the harmless diacetylhydrazine [60,
61]. This protective acetylation is further suppressed by INH competition. Therefore, slow
acetylators may be prone to higher accumulation rates of INH toxic metabolites. Another
important route to generate toxic intermediates is the direct hydrolysis of unacetylated INH
[62], producing hydrazine that also induces hepatic injury [62, 63]. Pharmacokinetic studies
showed that the serum concentration of hydrazine was significantly higher in slow acetylators
than in rapid acetylators, probably due to the high INH concentration. The high amount of
INH disposed of through this pathway is likely to lead to enhanced hydrolysis to hydrazine,
since the rate of metabolic conversion of INH to acetylisoniazid is lower in slow than in rapid
acetylators [64, 65]. All of these drug-disposal processes may support the finding that slow
acetylators are prone to INH-induced hepatitis. We therefore conclude that screening of
patients for the NAT2 genetic polymorphisms can prove clinically useful for the prediction
and prevention of anti-tuberculosis drug induced hepatotoxicity.
3.2. CYP450
Cytochromes P450 (CYP450) are hemoproteins and form the most important enzymatic group
for Phase I biotransformation. The main activity of isozymes of CYP450 system is oxidation
and they are located in the smooth endoplasmic reticulum, mainly in liver cells. However,
these mono-oxygenases are also localized in the intestine, pancreas, brain, lung, kidney, bone
marrow, skin, ovary and testicles [66]. The CYP450 proteins are clustered into families and
subfamilies according to the similarity between the amino acid sequences: where family
members have ≥ 40% identity in amino acid sequence, members of the same subfamily share
≥ 55% identity [67].
The  CYP450s  are  responsible  for  the  metabolization  of  several  endogenous  substrates
and the synthesis of hydrophobic lipids such as cholesterol, steroid hormones, bile acids
and  fatty  acids.  Moreover,  some  enzymes  of  P450  complex  metabolize  exogenous  sub‐
stances including drugs, environmental chemicals and pollutants as well as products de‐
rived from plants. The metabolism of exogenous substances by CYP450 usually results in
detoxification  of  the  xenobiotic;  however,  the  reactions  triggered  by  such  enzymes  can
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lead to generation of toxic metabolites that contribute to the increased risk of developing
cancers and other toxic effects [68].
The complete sequencing of the human genome revealed the presence of about 115 genes of
CYP450, including 57 active genes and 58 pseudogenes [67]. They belong to families 1-3 and
are responsible for 70-80% of Phase I-dependent metabolism of clinically used drugs. Other
families of CYPs are involved in metabolism of endogenous components [66]. The CYP2
constitutes the largest family of isoenzymes and comprises one third of all human CYPs. Genes
encoding these enzymes are polymorphic and the frequency distribution of allelic variants in
different ethnic groups differs. Overall, four phenotypes based on genotypes can be identified:
(i) poor metabolizers who present low enzymatic activity, (ii) intermediate metabolizers,
usually heterozygous for a defective allele, (iii) rapid metabolizers, who have two normal
alleles and (iv) ultrarapid metabolizers, who have several gene copies [69].
The enzyme CYP2E1 is expressed mainly in the liver but can be found in other organs such as
kidney, gastrointestinal tract and brain and involved in oxidation of substrates such as ethanol
and the metabolism of many drugs and pre-carcinogens. Besides ethanol, CYP2E1 can be
induced by various drugs such as INH but also by hydrocarbons, benzene, chloroform and
various organic solvents [70].
The activity of CYP2E1 is also modulated by polymorphisms in several locations of its gene
and more activity of this enzyme may increase the synthesis of hepatotoxins. Two polymor‐
phisms upstream of the CYP2E1 transcriptional start site are characterized by Pst I and Rsa I
digestion and appear to be in complete linkage disequilibrium (Figure 3). These two poly‐
morphisms are located in a putative HNF-q binding site and thus may play a role in the
regulation of CYP2E1 transcription and subsequent protein expression [71]. Genotypes of
CYP2E1 are classified as being *1A/*1A, *1A/*5 or *5/*5 by Rsa I based restriction analysis. The
polymorphism detectable by Dra I (7632 T>A) is located in intron 6 and characterizes the allelic
variant CYP2E1*6. The other polymorphism is an insertion/deletion of 96 bp (CYP2E1*1D and
*1C alleles) that regulates the expression of the gene [72]. Some studies have shown that allelic
variants CYP2E1 *5, *6 and *1D would increase enzyme activity [71, 73]. However, other
authors did not confirm any relationship with these polymorphisms with CYP2E1 activity [74].
Figure 3. Polymorphic and corresponding restriction enzyme cutting sites at CYP2E1 [24].
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of the rapid/intermediate type. These results corroborate with the current hypothesis that the
acetylator status may be a risk factor for the hepatic side effects of isoniazid [58].
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induced hepatotocixity more frequently. Additionally, there were statistically significant
associations between NAT2*5/*7, NAT2*6/*6, NAT2*6/*7 and NAT2*7/*7 and the risk of anti-
TB drug induced hepatotocixity [59].
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zine, the immediate precursor of toxic intermediates, to the harmless diacetylhydrazine [60,
61]. This protective acetylation is further suppressed by INH competition. Therefore, slow
acetylators may be prone to higher accumulation rates of INH toxic metabolites. Another
important route to generate toxic intermediates is the direct hydrolysis of unacetylated INH
[62], producing hydrazine that also induces hepatic injury [62, 63]. Pharmacokinetic studies
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3.2. CYP450
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The  CYP450s  are  responsible  for  the  metabolization  of  several  endogenous  substrates
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rived from plants. The metabolism of exogenous substances by CYP450 usually results in
detoxification  of  the  xenobiotic;  however,  the  reactions  triggered  by  such  enzymes  can
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lead to generation of toxic metabolites that contribute to the increased risk of developing
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Several studies have described the involvement of polymorphisms in CYP2E1 in cancer
development but results are controversial. The studies showed that the frequency of SNP -1053
C>T in the promoter region varies significantly in different ethnic groups. The mutant allele
is present with a frequency of 2-8% in Euro-descendants but varies in Asia from 25 to 36% [75].
In 2003, Huang and coworkers showed an association of the wild-type genotype *1A/*1A
with risk of developing liver damage induced by isoniazid in adult TB patients,  regard‐
less of their profile of acetylation (OR 2.52;  95% CI 1.26 to 5.05) [76].  Later,  Vuilleumier
and colleagues showed association between this CYP and isoniazid-induced hepatotoxici‐
ty,  without  hepatitis,  during  chemoprophylaxis  for  TB  (OR  3.4;  95%  CI  1.1  to  12;  p  =
0.02).  The  risk  of  having  high  levels  of  liver  enzymes  was  3.4-fold  higher  when  com‐
pared with all  other CYP2E1  genotypes [55].  Another study on Indian children with TB
showed  association  between  risk  of  hepatotoxicity  and  polymorphisms  in  CYP2E1,  de‐
spite of low sample size [77].  However,  a study with on a Korean population found no
relationship  between  hepatic  adverse  effects  with  genotype  *1A/*1A  of  CYP2E1  during
anti-TB treatment [51].  Lack of  association between this  CYP and antituberculosis  drug-
induced  liver  injury  was  also  observed  in  Brazil  [58].  The  discrepancy  of  these  results
may be due to differences in the frequencies of CYP2E1*1A  and CYP2E1*5  alleles among
the populations and the different criteria to define hepatotoxicity used.
Finally, CYP2E1 converts acetyl hydrazine into hepatotoxins like acetyldiazene, ketene and
acetylonium ion. The reaction of acetyl hydrazine (at high levels) with CYP2E1 leads to
covalent binding of these secondary metabolites with intracellular proteins (Figure 1). As a
consequence, intracellular changes occur resulting in loss of ionic gradients and decrease of
ATP levels and consequent disruption of actin followed by cell lysis. Further studies in
different populations and with a larger sample size are needed to determine the true influence
of CYP2E1 gene polymorphisms on the occurrence of liver injury during treatment for TB.
3.3. Glutathione S-transferases
Glutathione S-transferases constitute a superfamily of multifunctional ubiquitous enzymes
that play an important role in cellular detoxification by protecting macromolecules against
reactive electrophilic attack. The GSTs are Phase II enzymes that catalyze the nucleophilic
attack of glutathione (GSH) into components that contain an electrophilic carbon, nitrogen or
sulfur atom. The combination of the GSH with these compounds often leads to formation of
less reactive and more water soluble products, more easily excreted by the body [23, 78].
Glutathione transferases are of great interest to pharmacologists and toxicologists, since they
are drug targets for the treatment of asthma and cancer, in addition to metabolize drugs,
insecticides, herbicides, carcinogens and products of oxidative stress. Polymorphisms in GST
genes are often correlated with susceptibility to various cancers, as well as alcoholic liver
disease [23, 78-81].
In humans, eight gene families of soluble (or cytosolic) GSTs have been described: alpha (α)
located on chromosome 6, mu (μ) on chromosome 1, theta (θ) on chromosome 22, pi (π) on
chromosome 11; zeta (ζ) on chromosome 14, sigma (σ) on chromosome 4; kappa (κ) (chromo‐
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somal location not given) and omega (Ω) on chromosome 10 [80]. This classification is based
on amino acid sequences, substrate specificity, chemical affinity, protein structure and enzyme
kinetics. These enzymes are highly expressed in the liver and constitute up to 4% of total
soluble proteins but can be seen in several other tissues [82]. GSTs have an overlap of specific
substrates and the deficiency in one isoform can be compensated by other isoforms. Gluta‐
thione S-transferase mu (GSTM), glutathione S-transferase theta (GSTT) and glutathione S-
transferase Pi (GSTP) have been the most studied isoform [83-88].
The subfamily GST mu is encoded by five genes arranged in tandem (5_-GSTM4-GSTM2-
GSTM1-GSTM5-GSTM3-_3), forming a 100 kb gene cluster on chromosome 1p13.3 (Figure 4).
Polymorphisms have been identified and clinical consequences of genotypes resulting from
combinations of alleles GSTM1*0, GSTM1*A, and GSTM1*B have been widely investigated [78,
81, 89, 90]. Individuals who possess the homozygous null for GSTM1 (GSTM1*0/GSTM1*0) do
not express this protein. Thus, the absence of this gene can cause an increased accumulation
of reactive metabolites in the body, increasing the interaction with cellular macromolecules
and tumor initiation process. GSTM1*A and GSTM1*B differ in only one base in exon 7 and
encode monomers that form active dimers. The catalytic activity of these enzymes are very
similar [91].
The GSTM1 gene is flanked by two almost identical 4.2-kb regions. GSTM1*0 originates from
homologous recombination between the two repeat regions which results in a 16 Kb deletion
containing the entire gene GSTM1 (Figure 4). GSTM1 is precisely excised leaving the adjacent
GSTM2 and GSTM5 genes intact [78]. In a study of liver specimens of 168 autopsied Japanese
subjects, observed was that the GSTM1*0 null allele was more frequent in livers with hepatitis
and hepatocellular carcinoma compared to control livers [92].
Figure 4. Structural localization of 100 kb gene cluster encoding the GST mu subfamily (chromosome 1p13.3). The
figure indicates the homologous recombination event that can happen causing the null allele (GSTM1*0 - no GSTM1).
Figure adapted from [78].
The subfamily GST theta consists of two genes, GSTT1 and GSTT2, located on chromosome
22q11.2 and separated by approximately 50 Kb (Figure 5). Analysis of the 119 Kb portion
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reactive electrophilic attack. The GSTs are Phase II enzymes that catalyze the nucleophilic
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sulfur atom. The combination of the GSH with these compounds often leads to formation of
less reactive and more water soluble products, more easily excreted by the body [23, 78].
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are drug targets for the treatment of asthma and cancer, in addition to metabolize drugs,
insecticides, herbicides, carcinogens and products of oxidative stress. Polymorphisms in GST
genes are often correlated with susceptibility to various cancers, as well as alcoholic liver
disease [23, 78-81].
In humans, eight gene families of soluble (or cytosolic) GSTs have been described: alpha (α)
located on chromosome 6, mu (μ) on chromosome 1, theta (θ) on chromosome 22, pi (π) on
chromosome 11; zeta (ζ) on chromosome 14, sigma (σ) on chromosome 4; kappa (κ) (chromo‐
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kinetics. These enzymes are highly expressed in the liver and constitute up to 4% of total
soluble proteins but can be seen in several other tissues [82]. GSTs have an overlap of specific
substrates and the deficiency in one isoform can be compensated by other isoforms. Gluta‐
thione S-transferase mu (GSTM), glutathione S-transferase theta (GSTT) and glutathione S-
transferase Pi (GSTP) have been the most studied isoform [83-88].
The subfamily GST mu is encoded by five genes arranged in tandem (5_-GSTM4-GSTM2-
GSTM1-GSTM5-GSTM3-_3), forming a 100 kb gene cluster on chromosome 1p13.3 (Figure 4).
Polymorphisms have been identified and clinical consequences of genotypes resulting from
combinations of alleles GSTM1*0, GSTM1*A, and GSTM1*B have been widely investigated [78,
81, 89, 90]. Individuals who possess the homozygous null for GSTM1 (GSTM1*0/GSTM1*0) do
not express this protein. Thus, the absence of this gene can cause an increased accumulation
of reactive metabolites in the body, increasing the interaction with cellular macromolecules
and tumor initiation process. GSTM1*A and GSTM1*B differ in only one base in exon 7 and
encode monomers that form active dimers. The catalytic activity of these enzymes are very
similar [91].
The GSTM1 gene is flanked by two almost identical 4.2-kb regions. GSTM1*0 originates from
homologous recombination between the two repeat regions which results in a 16 Kb deletion
containing the entire gene GSTM1 (Figure 4). GSTM1 is precisely excised leaving the adjacent
GSTM2 and GSTM5 genes intact [78]. In a study of liver specimens of 168 autopsied Japanese
subjects, observed was that the GSTM1*0 null allele was more frequent in livers with hepatitis
and hepatocellular carcinoma compared to control livers [92].
Figure 4. Structural localization of 100 kb gene cluster encoding the GST mu subfamily (chromosome 1p13.3). The
figure indicates the homologous recombination event that can happen causing the null allele (GSTM1*0 - no GSTM1).
Figure adapted from [78].
The subfamily GST theta consists of two genes, GSTT1 and GSTT2, located on chromosome
22q11.2 and separated by approximately 50 Kb (Figure 5). Analysis of the 119 Kb portion
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containing these genes revealed two regions flanking GSTT1, HA3 and HA5, with more than
90% homology. HA3 and HA5 contain two identical 403-bp repeats and the occurence of
GSTT1*0 allele is probably caused by homologous recombination between the two regions [78].
In humans, GSTT1 is also expressed in erythrocytes and probably plays a global role in early
detoxification of xenobiotics and carcinogens.
Figure 5. Structural localization of gene cluster encoding the GST subfamily theta (chromosome 22q11.2). The GSTT1
null allele (GSTT1*0) arises by homologous recombination of the left and right 403-bp repeats, which results in a 54-
kb deletion containing the entire GSTT1 gene. Figure adapted from [78].
Deficiencies in the GST activity due to the null genotypes of GSTM1 and GSTT1 may modulate
susceptibility to the development of hepatotoxicity induced by drugs and xenobiotics.
Furthermore, it was observed that the frequencies of GSTT1*0 and GSTM1*0 alleles vary within
different ethnic groups [78, 82]. Liver injury induced by INH has been associated with the
depletion of glutathione content and reduction of GST activity in an animal model for
hepatotoxicity by anti-TB drugs [22].
In 2001, Roy and colleagues demonstrated that individuals, homozygous for the null GSTM1,
had a relative risk of 2.12 for developing hepatotoxicity induced by anti-TB drugs. However,
these authors found no association of the GSTT1 null genotype with this side effects [54].
Similarly, another study in the Thai population found that only the GSTM1 null genotype
increases the risk of liver injury (OR 2.23, 95% CI 1.07 to 4.67) [93]. The opposite was observed
by Leiro and colleagues: individuals with the GSTT1 null genotype had an increased risk of
developing hepatotoxicity induced by anti-TB drugs and no significant association was
observed between GSTM1*0/*0 genotype and liver injury [94]. These studies suggest a
protective effect of glutathione S-transferases to the hepatotoxic effects of isoniazid.
On the other hand, recent studies in different population showed no relationship between
GSTM1*0/*0 or GSTT1*0/*0 genotypes and liver injury during anti-TB treatment [58, 95, 96].
In a population-based prospective antituberculosis treatment coort in China, a more robust
case-control study was conducted and there was no statistically significant association between
null genotypes and hepatotoxicity induced by anti-TB drugs [97].
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These controversal results may be due to the small sample size in many studies and the
different frequencies of the null genotypes. New populations should be evaluated with large
sample size to see which of these polymorphisms can be used as genetic markers for the risk
of side effects during anti-TB treatment.
4. Conclusion
The concept of personalized medicine is not really new, but it has been receiving increasing
attention in recent years for improval of drug regulation and medical guidelines. There is
considerable interindividual variability in metabolism, partly due to human differences on a
genetic level. Genetic polymorphisms in drug-metabolizing enzymes can affect enzyme
activity and may cause differences in treatment response or drug toxicity, for example, due to
an increased formation of reactive metabolites. Such polymorphisms may explain differences
in incidence of anti-TB drugs induced hepatotoxicity between different populations.
Genotyping cannot completely predict the phenotype on an individual level because of to the
additional contribution of epigenetic, endogenous and environmental factors. However,
pharmacogenetics is able to add important information in many cases where therapeutic drug
scheme is inappropriate or not sufficient. Nowadays, we can cite three examples of personal‐
ized medicine application in clinical practice, (i) AIDS treatment (abavir / skin hypersensitiv‐
ity / HLA-B*5701), (ii) anticoagulation (warfarin / bleeding / CYP2C9) and (iii) treatment of
acute lymphoblastic leukemia (azathioprine / treatment resistence / TPMT) [98].
Although limited information exists regarding isoniazid concentrations that cause toxic
reactions, it has been proposed to adjust isoniazid dosage depending on individuals acetylator
status: a lower dosage for slow acetylators to reduce the risk of liver injury and a higher
isoniazid dosage for fast acetylators to increase the early bactericidal activity and thereby lower
the probability of treatment failure [50]. However, more robust clinical prospective studies are
needed to evaluate the real contribution of these different polyporphirms in the occurence of
liver side effects during anti-TB treatment. Future studies should include larger sample size,
different ethnic population, simultaneous analysis of different genetic markers, different
degrees of liver injury and consideration of possible confounding factors.
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detoxification of xenobiotics and carcinogens.
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1. Introduction
1.1. Inflammatory process of tuberculosis
When many infectious units of 1-3 bacilli are inhaled, a phenotypically hardy bacillus is likely
to be among them. In addition, the alveolar macrophages apparently vary in their capacity to
destroy bacilli [1]. Staining for acid-fast bacilli is very useful for demonstrating M. tuberculo‐
sis (A). Fig. 1 reveals histologic manifestation of tuberculosis over the time course. Histologi‐
cally, tuberculosis displays exudative inflammation (B), proliferative inflammation (D) and
productive inflammation (C) depending on the time course. Using animal experiments and an
inhalation exposure system, the pathologic condition of the infected animals was followed up
for one year. Exudative inflammation was observed for the first 10 days. Thereafter, granulo‐
mas, which corresponded to foci of proliferative inflammation, were formed. Cavity formation
was not recognized in animal tuberculosis, except for rabbits. Using rabbit models, Dr. Arthur
Dannenberg described the pathology of tuberculosis in detail [2, 3]. There are five stages: onset,
symbiosis, early stages of caseous necrosis, interplay of cell-mediated immunity and tissue
damaging delayed-type hypersensitivity, and liquefaction and cavity formation. In stage 1,
tubercle bacilli are usually destroyed or inhibited by the mature resident alveolar macrophages
that ingest them. If bacilli are not destroyed, they grow and eventually destroy the alveolar
macrophages. In stage 2, bacilli grow logarithmically within the immature nonactivated
macrophages. These macrophages enter a tubercle from the bloodstream. This stage is termed
symbiosis because bacilli multiply locally without apparent damage to the host, and macro‐
phages accumulate and divide. In stage 3, the stage at which caseous necrosis first occurs, the
number of viable bacilli becomes stationary because their growth is inhibited by the immune
response to tuberculin-like antigens released from bacilli. Stage 4 is the stage that usually
determines whether the disease becomes clinically apparent. Cell-mediated immunity plays a
major role in this situation. The cytotoxic delayed- type hypersensitivity immune response
© 2013 Shi and Sugawara; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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kills these macrophages, causing enlargement of the caseous center and progression of the
disease. If good cell-mediated immunity develops, a mantle of highly activated macrophages
surrounds the caseous necrosis. In stage 5, bacilli evade host defenses. When liquefaction of
the caseous center occurs, the bacilli multiply extracellularly, frequently attaining very large
numbers. The high local concentration of tuberculin-like products derived from these bacilli
causes a tissue-damaging delayed-type hypersensitivity response that erodes the bronchial
wall, forming a cavity.
A B
C D
Figure 1. Histologic appearance of tuberculosis A. Staining for acid‐fast bacilli, B. exudative stage, C. productive stage
with cavity formation (→), D. proliferative stage with a multinucleated giant cell.
2. Clinical manifestations
As the cellular processes occur, tuberculosis may develop differently in each patient, according
to the status of the patient’s immune system. Stages include latency, primary disease, primary
progressive disease, and extrapulmonary disease. Each stage has different clinical manifesta‐
tions [4]. M. tb organisms can be enclosed but are difficult to completely eliminate [5]. Persons
with latent tuberculosis have no signs or symptoms of the disease, do not feel sick, and are not
infectious [5]. However, viable bacilli can persist in the necrotic material for years or even a
lifetime [6], and if the immune system later becomes compromised, as it does in many critically
ill patients, the disease can be reactivated. Primary pulmonary tuberculosis is often asympto‐
matic. Although it essentially exists subclinically, some self-limiting findings might be noticed.
Associated paratracheal lymphadenopathy may occur because the bacilli spread from the
lungs through the lymphatic system. Active tuberculosis develops in only 5% to 10% of persons
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exposed to M. tb. Fig. 2 shows typical chest X-ray before (A) and after (B) chemotherapy.
Fatigue, malaise, weight loss, low-grade fever, night sweats, cough, sputum, are the main
symptoms. The sputum may also be streaked with blood. Hemoptysis can be due to destruc‐
tion of a patent vessel located in the wall of the cavity [7]. Extrapulmonary disease occurs in
more than 20% of patients. The most serious location is the central nervous system, where
infection may result in meningitis, which could be fatal in most cases. Another fatal form is
infection of the blood stream by mycobacteria, this form is called disseminated or military
tuberculosis. The most common extrapulmonary tuberculosis is lymphatic tuberculosis. Other
possible locations include bones, joints, pleura, and genitourinary system [4].
A B
Figure 2. Chest X‐ray of pulmonary tuberculosis and cured Tuberculosis A. before chemotherapy with rifampicin, iso‐
niazide, ethambutol and pyrazinamide, B. after chemotherapy. Apical shadow (dotted circle) disappears.
3. T cell activation against Mycobacterium tuberculosis
In human, a TB index case may infect a contact person through cough and expectoration,
so the lung is the primary route of infection and often the main tissue exhibiting TB. Infec‐
tious droplet nuclei are deposited in the alveolar spaces of the contact person where Myco‐
bacterium tuberculosis (M. tb) can be phagocytosed by alveolar macrophages, epithelial cells,
dendritic cells (DC) and neutrophils [8, 9]. Alveolar macrophages and DC are then believed
to transport M. tb to local lymph nodes where T cell activation occurs and expand. Activa‐
tion of the phagocytic host cell is much required to limit growth of M. tb; as in the absence
of activation, disease outcome is extremely poor. Effective phagocyte activation requires a
specific cellular response, as infected hosts lacking specific components of the acquired re‐
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following systemic challenge with M. tb, it is less rapid in the lung. Slow expression of pro‐
tection in the lung allows mycobacteria to grow and modulate the infection site. Until re‐
cently  it  has  not  been  clear  whether  the  slow  response  to  aerosol  delivery  of  bacteria
resulted from limited availability of antigen or inhibition of antigen-presentation by M. tb.
Several  studies  show that  the  first  T  cell  activation  occurs  in  the  draining lymph node
(DLN) of the lung 8–10 days following initial challenge. The activation of T cells correlated
temporally with the arrival of bacteria and availability of antigen in the DLN, however con‐
ditions for T cell activation were unique to the draining lymph nodes as the presence of an‐
tigen-producing bacteria in the lung and spleen did not result in initial activation of T cells
[11, 12]. While delivery of lipopolysaccharide (LPS) to the MTB-infected lung failed to ac‐
celerate T cell priming [11], increasing the bacterial dose did accelerate the response mod‐
estly suggesting that both antigen burden and refractory cells serve to slow the response.
So, protective memory cells will not become activated until they see antigen, i.e. more than
8 days post infection. Once T cells become activated they differentiate into effector T cells
that migrate to the lung. By day 14 of infection, when activated T cells first arrive in the
lung, bacteria are within alveolar macrophages, myeloid DC and neutrophils [11]. T cells
can recognize antigen within the mycobacterially-infected lung but the antigen presenta‐
tion is not optimal. It takes time for the protective T cells to reach sufficient numbers to
stop bacterial growth. T cells can be divided into two subsets, Th1 and Th2, on the basis of
the cytokines they produce. In tuberculosis, Th1 plays a major role in defense against tuber‐
culosis. Th1 cells suppress Th2 cells. CD4 + T cells have unambiguously been identified as
the most important lymphocyte subset for mediating protection.CD4 T lymphocytes differ‐
entiate in the peripheral tissues to adopt a variety of fates such as the Th-1 cells, which pro‐
duce  interferon (IFN)-γ  to  down-regulate  Th2  responses  and Th-2  cells,  which  produce
interleukin  (IL)-4.  CD8  T  lymphocytes  produce  predominantly  IFN-γ.  Though  CD4  re‐
sponse is greater than the CD8 response, the latter can provide protection in the absence of
CD4 help [13]. During active TB there is a local pulmonary immune response characterized
by α/β T cells and strongly enhanced M. tuberculosis antigen-specific Th1 responses, with
large amounts of locally secreted IFN-γ [14].
4. Animal models of tuberculosis
A wide variety of animal models have been used to test new vaccines and drugs [15]. Mice can
harbor high numbers of M. tb within lung tissue without showing clinical signs [16]. Mice do
not cough nor form cavitary lesions, making them a poor model for transmission studies [17].
Fibrous capsules are not observed histologically, which can affect the validity of antibiotic
studies, as M. tb would be more easily accessed by drugs in the mouse lung. In addition,
because of their short life span, mice are poor models for the study of latent infection. Rat TB
also showed similar pathophysiology to murine TB [31]. Guinea pigs develop robust DTH
response to mycobacterial antigens and, after infection with M. tb, reproduce many of the
aspects of human infection, such as caseous and mineralized granulomas, primary and
hemato-genous pulmonary lesions, fibrous capsule formation, and dissemination [19],
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however, pulmonary lesions in guinea pig contain a high proportion of granulocytes, partic‐
ularly eosmophils, which are not common features of human disease [20]. The rabbit is the
only common laboratory animal in which the disease closely resembles the typical chronic
cavitary type found in the majority of human beings [21, 22]. Rabbits infected with M. tb mount
a moderate DTH response and form caseous granulomas and cavitary lesions [23-25]. Rabbits,
including currently available inbred strains, are relatively resistant to M. tb, however, requiring
the inhalation of 500 to 3000 bacilli to form one grossly visible tubercle at 5 weeks postinfection
[23]. Most rabbits will also overcome disease completely, with few culturable bacilli [24]. This
model is useful in the study of latent or paucibacillary TB states, however, without the use of
antibiotics as in the Cornell model. Rabbits do need to be experimentally immunosuppressed
as they will not spontaneously reativate disease [26]. There are minimal immune reagents,
however, for this model, and the larger size of rabbits makes them more costly to use. There
are inbred strains of rabbits, such as the Lurie and Thorbecke rabbits, which are more suscep‐
tible to M. tb infection. This susceptibility has been linked to suppressed macrophage antimy‐
cobacterial activity, decreased MHC Class 2 expression, and impaired development of type 4
hypersensitivity [27]. Other animal models, such as nonhuman primates, which are susceptible
to M. tb and full spectrum of granuloma types can be observed [28], have not been widely used.
Using mycobacterial inoculation into trachea, at necropsy, all unvaccinated monkeys (Macaca
fascicularis and Macaca mulatta) exhibited extensive bilateral lung pathology characterized by
the presence of multiple granulomas. These granulomas exhibited conglomeration to larger
caseous areas, especially in the hilar region [55].
5. Alveolar macrophages in tuberculosis
When tubercle bacilli reach alveoli, they are phagocytosed by resident alveolar macrophages.
Though tubercle bacilli are killed byalveolar macrophages, tubercle bacilli can also kill
macrophages through apoptosis. What is the fate of tubercle bacilli once they enter the
phagosomes of macrophages? Alveolar macrophages of aerially infected guinea pigs were
collected by bronchoalveolar lavage. At 12 days after infection, one out of 10,000 alveolar
macrophages of various sizes contained many tubercle bacilli [31]. This indicates that certain
alveolar macrophages permit M. tuberculosis to replicate in the phagosomes, although most
of tubercle bacilli are killed by activated alveolar macrophages. It will be of great interest to
examine the survival mechanism of M. tuberculosis at the single-cell level, but we still do not
know why macrophages targeted by tubercle bacilli cannot kill the bacilli.
IFN-γ knockout mice were infected with avirulent H37Ra or BCG Pasteur, multinucleated
giant cells were recognized in the granulomatous lesions. The lesions also contained tubercle
bacilli and consisted of multinucleated cell clusters, being immunopositive with anti-Mac-3
antibody. The alveolar macrophages were transformed into multinucleated ginat cells. We
subsequently infected various cytokine-konockout mice with M. tb, but no Langerhans’
multinucleated giant cells were recognized in the granulomas. Therefore, it seems that
formation of multinucleated giant cells requires optimal combinations and concentrations of
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6. Roles of cytokines, neutrophils, NK cells, NKT cells and γδT cells
IFN-γ and TNF have long been implicated as regulators of T cell responses in mycobacterial
disease [29]. The technique of gene targeting (knockout) has swept through biomedical
research. IFN-γ, TNF-α, IRF-1, NF-IL6, NF-κB p50, STAT 1 and STAT 4 knockout mice
succumbed to M. tuberculosis infection over time. There appears to be a cytokine and tran‐
scription factor hierarchy in experimental tuberculosis. The results indicate that these mole‐
cules play major roles in defense against the disease, IFN-γ and TNF-α being the leading
players in this respect [30].
The role of neutrophils in the development of tuberculosis remained unknown for a long time.
We utilized LPS-induced transient neutrophilia in the lungs [31]. LPS (50μg/ml) was admin‐
istered intratracheally to male Fischer rats, which were then infected with M. tuberculosis via
an airborne route. Intratracheal injection of LPS significantly blocked the development of
pulmonary granulomas and significantly reduced the number of pulmonary colony-forming
units (CFU). Treatment with amphotericin B (an LPS inhibitor) or neutralizing anti-rat
neutrophil antibody reversed the development of pulmonary lesions. LPS-induced transient
neutrophilia prevented early mycobacterial infection. The timing of LPS administration was
important. When given intratracheally at least 10 days after aerial infection, LPS did not
prevent the development of tuberculosis. Neutrophils obtained by bronchoalveolar lavage
killed M. tuberculosis bacilli. These results indicate clearly that neutrophils participate actively
in defense against early-phase tuberculosis.
Natural killer (NK) cells are innate lymphocytes which are a first line of defense against
infection. NK cells can kill autologous infected cells without prior sensitization, and are
believed to play a pivotal role in innate immunity to microbial pathogens. In mouse model,
NK cells are activated and produce IFN-γ during the early response to pulmonary tuberculosis
[31] and NK cell-produced IFN-γ regulates the anti-mycobacterial resistance mediated by
neutrophils [32]. However animal models do not give a clear answer to whether NK cells is
important in M. tb infection in vivo. Depletion of NK cells had no effect on bacterial replication
in the lung of immunocompetent mice [33], suggesting that NK cells may be redundant in the
presence of intact adaptive immunity. Surprisingly, IFN-γ knockout mice, which are impaired
in their ability to clear mycobacteria, cleared them as effectively as wild-type mice when NK
cells were depleted, suggesting that NK cells can inhibit protective immunity [34].
Human NK cells use the NKp46, the natural cytotoxicity receptors (NCRs) and NKG2D
receptors to lyse M. tuberculosis-infected monocytes and alveolar macrophages [35], through
damage of infected cells and secretion of cytokines, such as IFN-γ [36]. Inhibitory receptors of
NK cells include killer immunoglobulin-like receptors (KIRs) and the NKG2A:CD94 dimer
and NK cell activation can also be triggered by loss of inhibitory ligands from the cell surface.
In addition, NK cells can also be activated by cytokines, including type I interferons, IL-12 and
IL-18. NK cells are a potent and early source of cytokines, particularly IFN- γ, but they can also
produce Th2-associated cytokines, such as IL-5 and IL-13, and the regulatory cytokine IL-10
[37]. NK cell NKp46 expression and cytotoxicity are reduced in freshly isolated peripheral
blood mononuclear cells (PBMCs) from tuberculosis patients, which may be attributable to
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suppression by monocytes and IL-10. Recent studies have found that NK cells produce IL-22
[38], which was induced by IL-15 and DAP-10, an adaptor protein that is known to be involved
in NK cell activation, in response to M. tuberculosis. Rohan Dhiman et al. also found that IL-22
can restrict growth of M. tuberculosis in macrophages by enhancing phagolysosomal fusion
[39]. Nonetheless to fully understand the importance of NK cells in M. tb infection it may be
necessary to differentiate their contributions at different stages of disease.
Certain T subsets, such as NKT cells and γδ T cells, have features of innate immune cells
including a partially activated phenotype, a rapid response following detection of infected
cells, and the modulation of other cell types. Together with NK cells, these cell subsets are
functionally defined as innate lymphocytes.CD1d-restricted invariant NKT (iNKT) cells are a
conserved subset of T cells that express an invariant T cell receptor (TCR) α chain (Vα24-Jα18
in humans, and Vα14-Jα18 in mice) paired with TCR β chains encoded by one or a few Vβ
gene segments (Vβ11 in humans, and predominantly Vβ2, 7 and 8 in mice). These cells show
different phenotypes and functions [40].Many iNKT cells are CD4+, and they have been mainly
associated with the induction of Th2 cytokines such as IL-4, IL-5, IL-13. This subset is believed
to play a prominent role in suppression of autoimmune or chronic inflammatory diseases, and
in promoting allergic conditions such as asthma. Few iNKT cells are CD8+, and most of those
express only the CD8α subunit, which means that they likely express only CD8αα homodim‐
ers. An additional fraction of iNKT cells are negative for both CD4 and CD8 (DN T cells). They
have been found to produce predominantly IFN-γ and other Th1-associated cytokines. Studies
of human iNKT cells have shown that they have the ability to kill M. tuberculosis organisms
within infected macrophages, possibly through their production of the peptide granulysin [41].
Jin S. Im et al. [42] found that the percentages of iNKT cells among total circulating T cells in
TB patients were not significantly different compared to those in healthy controls. However,
TB patients showed a selective reduction of the proinflammatory CD4−CD8− (DN) iNKT cells
with a proportionate increase in the CD4+ iNKT cells. The mouse model of tuberculosis has
been used by Sada-Ovalle et al to find that iNKT cells have a direct bactericidal effect on M.
tuberculosis, and protect mice against aerosol M.TB infection [43]. Their activation requires
CD1d expression by infected macrophages as well as IL-12 and IL-18. In addition, pharmaco‐
logical activation of iNKT cells with the synthetic ligand aGalCer often enhances host resist‐
ance to infection. iNKT cell use several mechanisms to modify host immunity. These include
induction of DC maturation, secondary activation of effector cells (NK cells) or recruitment of
inflammatory cells to the site of infection [44, 45]. Thus, by being an early producer of IFN-γ
and suppressing intracellular bacterial growth, iNKT cells function as an important part of the
early immune response against M. tb that affect both the innate and the adaptive arms of the
immune response.
Antigen-specific γ/δ T cells represent an early innate defense that may play a role in antimy‐
cobacterial immunity. Studies done in humans and animal models have demonstrated
complex patterns of γ/δ T cell immune responses during early mycobacterial infections and
chronic TB. Like α/β T lymphocytes, γ/δ T cells carry antigen TCR that vary in the physical
properties of their ligand-binding sites. γ/δ T cells are frequently activated by a variety of




6. Roles of cytokines, neutrophils, NK cells, NKT cells and γδT cells
IFN-γ and TNF have long been implicated as regulators of T cell responses in mycobacterial
disease [29]. The technique of gene targeting (knockout) has swept through biomedical
research. IFN-γ, TNF-α, IRF-1, NF-IL6, NF-κB p50, STAT 1 and STAT 4 knockout mice
succumbed to M. tuberculosis infection over time. There appears to be a cytokine and tran‐
scription factor hierarchy in experimental tuberculosis. The results indicate that these mole‐
cules play major roles in defense against the disease, IFN-γ and TNF-α being the leading
players in this respect [30].
The role of neutrophils in the development of tuberculosis remained unknown for a long time.
We utilized LPS-induced transient neutrophilia in the lungs [31]. LPS (50μg/ml) was admin‐
istered intratracheally to male Fischer rats, which were then infected with M. tuberculosis via
an airborne route. Intratracheal injection of LPS significantly blocked the development of
pulmonary granulomas and significantly reduced the number of pulmonary colony-forming
units (CFU). Treatment with amphotericin B (an LPS inhibitor) or neutralizing anti-rat
neutrophil antibody reversed the development of pulmonary lesions. LPS-induced transient
neutrophilia prevented early mycobacterial infection. The timing of LPS administration was
important. When given intratracheally at least 10 days after aerial infection, LPS did not
prevent the development of tuberculosis. Neutrophils obtained by bronchoalveolar lavage
killed M. tuberculosis bacilli. These results indicate clearly that neutrophils participate actively
in defense against early-phase tuberculosis.
Natural killer (NK) cells are innate lymphocytes which are a first line of defense against
infection. NK cells can kill autologous infected cells without prior sensitization, and are
believed to play a pivotal role in innate immunity to microbial pathogens. In mouse model,
NK cells are activated and produce IFN-γ during the early response to pulmonary tuberculosis
[31] and NK cell-produced IFN-γ regulates the anti-mycobacterial resistance mediated by
neutrophils [32]. However animal models do not give a clear answer to whether NK cells is
important in M. tb infection in vivo. Depletion of NK cells had no effect on bacterial replication
in the lung of immunocompetent mice [33], suggesting that NK cells may be redundant in the
presence of intact adaptive immunity. Surprisingly, IFN-γ knockout mice, which are impaired
in their ability to clear mycobacteria, cleared them as effectively as wild-type mice when NK
cells were depleted, suggesting that NK cells can inhibit protective immunity [34].
Human NK cells use the NKp46, the natural cytotoxicity receptors (NCRs) and NKG2D
receptors to lyse M. tuberculosis-infected monocytes and alveolar macrophages [35], through
damage of infected cells and secretion of cytokines, such as IFN-γ [36]. Inhibitory receptors of
NK cells include killer immunoglobulin-like receptors (KIRs) and the NKG2A:CD94 dimer
and NK cell activation can also be triggered by loss of inhibitory ligands from the cell surface.
In addition, NK cells can also be activated by cytokines, including type I interferons, IL-12 and
IL-18. NK cells are a potent and early source of cytokines, particularly IFN- γ, but they can also
produce Th2-associated cytokines, such as IL-5 and IL-13, and the regulatory cytokine IL-10
[37]. NK cell NKp46 expression and cytotoxicity are reduced in freshly isolated peripheral
blood mononuclear cells (PBMCs) from tuberculosis patients, which may be attributable to
Tuberculosis - Current Issues in Diagnosis and Management132
suppression by monocytes and IL-10. Recent studies have found that NK cells produce IL-22
[38], which was induced by IL-15 and DAP-10, an adaptor protein that is known to be involved
in NK cell activation, in response to M. tuberculosis. Rohan Dhiman et al. also found that IL-22
can restrict growth of M. tuberculosis in macrophages by enhancing phagolysosomal fusion
[39]. Nonetheless to fully understand the importance of NK cells in M. tb infection it may be
necessary to differentiate their contributions at different stages of disease.
Certain T subsets, such as NKT cells and γδ T cells, have features of innate immune cells
including a partially activated phenotype, a rapid response following detection of infected
cells, and the modulation of other cell types. Together with NK cells, these cell subsets are
functionally defined as innate lymphocytes.CD1d-restricted invariant NKT (iNKT) cells are a
conserved subset of T cells that express an invariant T cell receptor (TCR) α chain (Vα24-Jα18
in humans, and Vα14-Jα18 in mice) paired with TCR β chains encoded by one or a few Vβ
gene segments (Vβ11 in humans, and predominantly Vβ2, 7 and 8 in mice). These cells show
different phenotypes and functions [40].Many iNKT cells are CD4+, and they have been mainly
associated with the induction of Th2 cytokines such as IL-4, IL-5, IL-13. This subset is believed
to play a prominent role in suppression of autoimmune or chronic inflammatory diseases, and
in promoting allergic conditions such as asthma. Few iNKT cells are CD8+, and most of those
express only the CD8α subunit, which means that they likely express only CD8αα homodim‐
ers. An additional fraction of iNKT cells are negative for both CD4 and CD8 (DN T cells). They
have been found to produce predominantly IFN-γ and other Th1-associated cytokines. Studies
of human iNKT cells have shown that they have the ability to kill M. tuberculosis organisms
within infected macrophages, possibly through their production of the peptide granulysin [41].
Jin S. Im et al. [42] found that the percentages of iNKT cells among total circulating T cells in
TB patients were not significantly different compared to those in healthy controls. However,
TB patients showed a selective reduction of the proinflammatory CD4−CD8− (DN) iNKT cells
with a proportionate increase in the CD4+ iNKT cells. The mouse model of tuberculosis has
been used by Sada-Ovalle et al to find that iNKT cells have a direct bactericidal effect on M.
tuberculosis, and protect mice against aerosol M.TB infection [43]. Their activation requires
CD1d expression by infected macrophages as well as IL-12 and IL-18. In addition, pharmaco‐
logical activation of iNKT cells with the synthetic ligand aGalCer often enhances host resist‐
ance to infection. iNKT cell use several mechanisms to modify host immunity. These include
induction of DC maturation, secondary activation of effector cells (NK cells) or recruitment of
inflammatory cells to the site of infection [44, 45]. Thus, by being an early producer of IFN-γ
and suppressing intracellular bacterial growth, iNKT cells function as an important part of the
early immune response against M. tb that affect both the innate and the adaptive arms of the
immune response.
Antigen-specific γ/δ T cells represent an early innate defense that may play a role in antimy‐
cobacterial immunity. Studies done in humans and animal models have demonstrated
complex patterns of γ/δ T cell immune responses during early mycobacterial infections and
chronic TB. Like α/β T lymphocytes, γ/δ T cells carry antigen TCR that vary in the physical
properties of their ligand-binding sites. γ/δ T cells are frequently activated by a variety of




mice following intravenous challenge with virulent M. tb; however, such a difference has not
been observed following infection by the aerosol route. γ/δ T cells constitute a whole system
of functionally specialized subsets that have been implicated in the innate responses against
tumors and pathogens, the regulation of immune responses, cell recruitment and activation,
and tissue repair [47]. Human alveolar macrophages and monocytes can serve as antigen
presentation cells (APCs) for γ/δ T cells. Furthermore, the predominance of Vγ9Vδ2 T cells in
TB disease has been confirmed [48]. When MTB-activated CD4+ and γ/δ T cells from healthy
tuberculin-positive donors were analyzed for cytokine production in response to MTB-
infected monocytes, both groups secreted large amounts of IFN-γ [49]. Previous studies have
also demonstrated an increased proliferative activity of Vγ9Vδ2 T cells from patients with TB
[50], but reduced production of IFN-γ, compared with that of healthy tuberculin-positive
donors [51]. Additionally, Dieli et al. reported that decrease of Vγ9Vδ2 T cell effector functions
involves not only IFN-γ production but also expression of granulysin [52]. Fig. 3 shows
interaction of cells and cytokines involved in tuberculosis.
neutrophil
Figure 3. Cytokine and cellular network in tuberculosis +. Production of cytokine, ‐. No production of cytokine.
7. Conclusion
Tuberculosis is an international public health problem. It is becoming evident that M. tb
infection is a dynamic state with a wide spectrum of pathology. An improved understanding
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of the immunopathogenesis of TB can facilitate the design of effective vaccines, new drug
candidates and evaluation of their efficacy [53]. Understanding latent tuberculosis can also be
the key to improve diagnostic and novel treatment strategies [54].
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candidates and evaluation of their efficacy [53]. Understanding latent tuberculosis can also be
the key to improve diagnostic and novel treatment strategies [54].
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1. Introduction
Early diagnosis of tuberculosis and drug resistance improves survival and by identifying in‐
fectious cases promotes contact tracing, implementation of institutional cross-infection pro‐
cedures, and other public-health actions. There have been many advances in methodology
for tuberculosis diagnosis [1-3].
For every stages of diagnosis, there are new approaches. New tests are available by level of
laboratory and phase of application.
2. Microscoby
Microscopy has been a diagnostic tool for TB for over a century, and still currently the most
rapid diagnostic method. Standard light microscopy (LM) and fluorescent microscopy (FM)
are common methods. The recent development of light emitting diodes (LED), with the ap‐
propriate fluorescent light output for FM and low power consumption, has led to the devel‐
opment of simple, robust LED FM microscopes, requiring minimal mains or battery power
and no dark room requirement. The WHO has recommended rolling it out as an alternative
to LMs in resource-limited settings, based on studies that have shown comparable perform‐
ance of LM and standard FM systems [4,5].
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3. Culture and drug resistance testing
3.1. Phenotypic methods
Significant effort has been invested into further development of simple, alternative pheno‐
typic methods such as the nitrate reductase assay (NRA), thin-layer agar (TLA), colour test
(Color Test), the microscopic observation drug susceptibility assay (MODS), the colorimetric
redox indicator (CRI) method and phage-based assays, most of which can be set up directly
on specimens [6,7,8]. These methods can detect MTB and resistance to INH and RMP. While
MODS, NRA and CRI have been endorsed by the WHO, current evidence was considered to
be insufficient for recommending the use of TLA or phage-based assays [8].
MODS is an extensively validated method that has almost perfect agreement with conven‐
tional DST for INH, RMP and MDR-TB (100%, 97% and 99%). The results are available with‐
in a median of 7 days; the method is cheap, non-commercial and works well on all types of
primary specimens as well as on isolates. However, it requires relatively long, detailed staff
training. [6,7,9,10]
TLA recently demonstrated a good performance of the MDR-/XDR-TB colour test for the
identification of MTB complex and detection of resistance to INH, RMP and ciprofloxacin in
cultures [11].
3.2. Genotypic methods
Molecular techniques are aimed at the nucleic acid of the mycobacterium as the analyte. Ri‐
bosomal rRNA is useful genetic target for the identification of organisms, since it often con‐
tains spesific sequences and is present in the cells and media in high quantity due to the
growth of the mycobacteria. There are various applications of molecular tecniques for the
detection and identification of MTB.
PCR is the common format of nucleic acid amplification tests (NAAT); other methodologies
include ligase chain reaction, strain displacement amplification, loop-mediated isothermal
amplifi cation (LAMP) and transcription mediated amplification. More recently, real-time
(RT) PCR technologies based on fluorescent- probe detection or melting-curve analysis have
been developed [12-16].
These molecular techniques also aimed detecting resistance genes. Example includes; DNA
probe and DNA sequencing of MTB gene such as catalase (katG) or RNA polymerase
(rpoB). Mutations in these genes have been associated with resistance to isoniazid and ri‐
fampicin respectively. The using of molecular primers in real- time PCR reaction can differ‐
entiate between the presence of the wild- type sequence and mutated sequence associated
with drug resistance. Molecular tests are rapid (within few hours), highly sensitive and spe‐
cific, but expensive, requires expertise and may not differentiate active infection as DNA
from a dead organism during antibiotic treatment can be detected and amplified by PCR
[17]. Genotypic methods are not routinely used in the mycobacterium laboratory; they are
essentially for research purposes [18,19].
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Line-probe assays and XPERT MTB/RIF: Line probe assays (LPAs) are actual molecular
tests. Three main LPAs for the rapid diagnosis of TB and/or rapid detection of RMP resist‐
ance and MDR-/XDR-TB are currently available on the market: INNO-LiPA Rif. TB (Innoge‐
netics, Belgium), GenoType®MTBDR/MTBDRplus and Geno-Type® MTBDRsl (both Hain
Lifescience, Germany). These assays are based on the targeted amplification (PCR) of specif‐
ic fragments of the MTB genome, followed by hybridisation of PCR products to oligonucleo‐
tide probes immobilised on membranes. INNO-LiPA Rif TB detects only RMP resistance,
GenoType MTBDR/MTBDRplus detects both RMP and INH resistance, and GenoType
MTBDRsldetects resistance to flouroquinolons, injectable second-line drugs and ethambutol.
These tests are designed for detection the MTB isolates in respiratory specimens. Xpert®
MTB/RIF (Cepheid Inc, USA) is a fully automated RT-PCR based assay for the detection of
TB bacteria and resistance to RMP in direct clinical specimens [20].
4. Lysis-centrifugation blood culture system
The recovery of mycobacterium from peripheral blood and bone marrow samples may be
improved by lyses- centrifugation blood culture method. In this method, blood is put into a
tube containing an anticoagulant and an agent to effect rupture of both erythrocytes and
neutrophils. Following centrifugation of the tube, the sediment is inoculated into the appro‐
priate culture media. This method has increased both the yield and shortened the time of
recovery of mycobacteria from blood cultures [21].
5. Phage Amplification Technique (PAT)
This is a bacteriophage based test to detect MTB in sputum. Non-pathogenic mycobacteria
(sensor cells) were used for control bacteria in the test. The phage replicate, infect and lyses
the sensor cells leaving zones of clearing (holes) in the agar. The areas of clearing indicates
that the patient sputum contain viable MTB. It is fast with a turnaround time of 2 days. It is
cheap, requires few equipments, sensitive (detection as low as 100 tubercles per ml of spu‐
tum). It can be adapted for sensitivity testing. Limitations are applicability to sputum speci‐
men only and technically demanding [22].
6. Immunological methods
Immunodiagnostic tests can provide indirect evidence current or past infections of MTB. Ex‐
ception of tuberculin skin test, immunodiagnostic tests are of limited application due to
cross reactivity and poor sensitivity.
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6.1. Detection of antibodies
Although the detection of antibodies against MTB in the blood is a relatively simple and
costeffective method, recent meta-analyses and systematic reviews concluded that commer‐
cial serological tests provided inconsistent results [23,24]. As the overall test performance
and data quality of these assays were poor, the WHO currently recommends against their
use for the diagnosis of pulmonary and extrapulmonary TB.
Antibodies against lipoarabinomannans, A60, 38Kd and 16 Kd are mostly studied [25].
6.2. Detection of antigens
Lipoarabinomannan (LAM) was identified as a promising target for antigen detection for TB
diagnosis due to its temperature stability and could be detected in urine. LAM-based assays
are currently being developed by a number of commercial companies, and preliminary re‐
sults indicate their potential applicability in the rapid diagnosis of TB by detecting LAM in a
variety of body fluids, including urine [26]. LAM-based assays are included in the WHO TB
diagnosis re-tooling programme [27] and forma part of a Foundation for Innovative New
Diagnostics (FIND) funded TB Project [19,28].
MTB antigen detection provides direct evidence of TB. Such as LAM, 65Kd, 14 Kd antigens
were widely used. It is very quick and easy to perform. Main limitation is low sensitivity
(detect high levels of antibody). It does not rule out TB in patients with poor antibody re‐
sponse as in HIV and malnutrition and not specific due to cross reactivity with other species
of mycobacteria in the environment [26].
7. Interferon-Gamma Release Assays (IGRA)
Because  of  the  difficulties  with  the  tuberculin  test  interpretation,  the  interferon-gamma
assay test was developed. Two available formats of the interferon-gamma release assays
are; the Quantiferon-TB Gold and T Spot-TB test. The IGRA assay is based on the ability
of the MTB antigens, which includes the Early Secretory Antigen Target 6 (ESAT-6) and
Culture  Filtrate  Protein 10 (CFP-10)  to  stimulate  host  production of  interferon –gamma.
These antigens are not present in NTM or in BCG vaccine, so, these tests can distinguish
latent TB infection from BCG immunization and NTM infections. Requiring a single visit
to  draw  a  blood  sample  and  result  available  within  24  hours  are  main  advantages.  It
does not boost immune response measured by subsequent tests which can happen with
tuberculin skin test.  It  does not  cause to readers bias as  in tuberculin skin test  and not
affected by prior BCG vaccination.  Blood must be processed within 12 hours while leu‐
kocytes are still viable. There are limited data for sensitivity of IGRAs in children young‐
er 17 years of age and immunocompromised patients e.g. HIV/AIDS, diabetics, treatment
with immunosuppressive drugs [29].
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8. The future of TB diagnostics
The rapid technological evolution in the laboratory diagnosis of TB, especially in the ap‐
plication  of  molecular  biology  h  as  diminished the  time  required  for  identification  and
susceptibility  testing.  Continuous effort  endeavor for  increasing reproducibility,  improv‐
ment of performance and cost containment. WHO founded an organisation (FIND-Foun‐
dation for Innovative New Diagnostics) for researching fast, relible and inexpensive tests
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Table 1. WHO projects for TB diagnostic tests. LAMP TB: Loop mediated isothermal amplification (LAMP) for TB
9. Assays being developed/evaluated
Another new approach to diagnosis of TB is biosensing technologies. Variety of portable,
rapid, and sensitive biosensors with immediate “on-the-spot” interpretation have been de‐
veloped for MTB detection based on different biological elements recognition systems and
basic signal transducer principles. Combination of nanotechnology and biosensing technolo‐
gy has very promising.
Transrenal DNA detection provides a challenging new target for molecular TB diagnosis.
No commercial assays are currently available, largely due to the difficulties in the develop‐
ment of TB detection/read-out assays.
Combined high-resolution melting (HRM) curve analysis using a closed-tube RT-PCR is po‐
tentially an ideal screening method with a positive predictive value (PPV) of 100% and neg‐
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kocytes are still viable. There are limited data for sensitivity of IGRAs in children young‐
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ative predictive value (NPV) of at least 99.9%, for screening large specimen numbers in any
TB laboratory.
New amplification methodologies and refinements of ‘molecular beacon’ approaches, such
as linear-after-the exponential PCR, offer future improvements, particularly in drug resist‐
ance analysis [30-32].
MTB urease is a bacterial virulence factor. Isotopcally labelled urea as substrate, Urea tracer
has detected in exaled breath using portable infrared spectrofotometer. Signal correleted
with bacterial load. [33]
A biophotonic detection platform has been developed that utilizes reporter enzyme fluores‐
cence to detect β-lactamase produced by MTB. This innovative new technology is now being
adapted for point of care (POC) use [28]
10. Conclusions and further work
This is an exciting time for new TB diagnostics. This is in part a reflection of the funding and
application of good science, a clear understanding of unmet needs, a commercial sector that
is considering new approaches to a global market, and the complexity of and limited prog‐
ress in new drug and vaccine development, which has encouraged more academic and in‐
dustrial partners to participate in diagnostic development.
Overall, the technology for the diagnosis of TB and RMP resistance in pulmonary specimens
is well advanced, with high specificity and increasingly high sensitivity. Rapid, high-specif‐
icity molecular assays for TB identification and drug resistance cannot replace the standard
diagnostic methods, such as microbiology, clinical and radiological assessments, and con‐
ventional DST for active TB in pulmonary (particularly sputum smear-negative) and extra-
pulmonary TB specimens. Implementation of all of these tools in routine laboratory practice
requires the implementation of appropriate quality assurance systems.
The performance of molecular tools of extra-pulmonary specimens varies and should be
considered separately for each specifi c specimen type. Evidence for the use of these assays
to identify TB and detect drug resistance in TB-HIV co-infected individuals is limited. There
is a need for designed studies among children, including HIV-positive children. There also
remains a need to increase the sensitivity of TB detection among all patients, but especially
among immunocompromised patients and children [20].
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1. Introduction
Tuberculosis is still one of the leading causes of death by infectious diseases with 2 million
deaths per year and 9.2 million new cases of tuberculosis disease annually [1-3]. Besides, more
than 2 milliard people are infected with latent tuberculosis infection (LTBI) [1-3]. Despite
continuous effort in the prevention, monitoring and treatment of tuberculosis, the disease
remains a major health problem in many countries [4-6], particularly in developing countries
like Indonesia [7]. National tuberculosis programs and other programs conducted by foreign
organizations still fail to eliminate the transmission and incidence of tuberculosis. Transmis‐
sion is even on the rise in developing countries despite the availability of effective therapies
for tuberculosis, whereas the spread and the incidence of tuberculosis in Europe and North
America are under control. Several reasons may be responsible for this failure, such us the
difficulty of providing adequate anti-tuberculosis medication in many developing countries
due to cost issues, the emergence of multi-drug resistant (MDR) strains of M. tuberculosis, and
the dramatically high co-incidence of tuberculosis in HIV-infected patients [2, 7]. Another
important issue is delay of diagnosis due to the lack of a proper method to identify tuberculosis
agents [1, 8].
Smear is the cheapest and most widely available detection method for M. tuberculosis. In this
technique, the diagnosis of tuberculosis is based on identification of acid-fast bacilli (AFB) in
a patient`s sputum [9, 10]. Many staining techniques are available for AFB smear, the most
common one of which is the modified Ziehl-Neelsen stain. Unfortunately, the sensitivity and
the specificity of those techniques are low due to difficulty in the identification and differen‐
tiation of the various species of M. tuberculosis [10]. Two studies found that the AFB smear was
positive in only half of patients with subsequent culture positive for M. tuberculosis [9, 10].
Another worldwide available detection method is the conventional culture method on
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Lowenstein-Jensen (LJ) medium. This method is the gold standard in the identification of M.
tuberculosis and still serves as the reference method due to its high sensitivity (89%) and
specificity (98%) [4, 7, 9, 10]. However, this technique requires equipments or materials that
are often unavailable in resource-poor settings. In addition, this technique is time consuming;
the results only can be obtained after 6–12 weeks. In addition, the incidence of other bacterial
contamination on culture tends to be high [7, 11]. Even a modern culture method such as the
BACTEC MGIT 960 culture system, which uses the modified Middlebrook 7H9 broth and a
fluorescent signaling system, allows for earlier detection of growth, but still takes at least 10
days to give any result [9].
The  goal  of  tuberculosis  control  programs  is  to  identify  and  to  cure  as  many  cases  as
possible; therefore the critical role of early diagnosis is obvious [11]. Under-diagnosis may
lead to further spread of the disease because undiagnosed patients can spread the disease
unnoticeably  [11].  Accurate  and  early  diagnosis  is  the  first  important  step  to  effective
management.  Several  new  methods  for  the  identification  of  tuberculosis  are  available,
which including serologic tests and also various molecular methods developed as a result
of  major  advances in understanding the genetic  aspects  of  tuberculosis  [8,  9,  11].  Those
detection methods can be grouped into two types First,  by detection of mycobacteria or
its components directly; second by measurement of immunologic responses to mycobacte‐
rium  infection  [9].  In  this  chapter  we  present  a  short  review  of  some  these  promising
detection methods used in the laboratory to identify tuberculosis.
2. Direct detection methods
The genus mycobacterium consists of almost 100 different species, which all appear similar on
AFB staining and culture [7, 10, 12]. Many of these can be isolated from humans, although
many also can be found in the environment including in animals. It is not easy, however, to
distinguish between pathogen and saprophyte species. Each mycobacterium isolate must be
evaluated individually regarding its potential to cause a disease; therefore identification of
mycobactera is a lengthy and tedious effort. Since the introduction of nucleic acid amplification
assays as diagnostic tool for mycobacteria identification, several probes/gene amplification
systems for tuberculosis have been developed for rapid and specific identification of M.
tuberculosis and other mycobacteria [12, 13]. These techniques allow for the confirmation of
identity of isolates, direct detection of gene sequences from the clinical specimens and also for
molecular detection of drug resistance [12]. Many previous publications have shown the
sensitivity and specificity of several molecular detection assays such as BDProbeTec ET,
(Becton Dickinson), COBAS AMPLICOR (Roche), Amplified M. tuberculosis Direct Test
AMTDT (Gen Probe, USA) for identification of mycobacteria[9].
The use of nucleic-acid probe identification systems was a one step ahead in the rapid
identification of mycobacterium species of M. tuberculosis complex, M. avium complex, M.
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avium, M. intracellulare, M. kansasii, and M. gordonae and also other nontuberculous mycobac‐
teria (NTM) in culture because the result can be obtained after 2 hours [10, 12]. But the
sensitivity and specificity of this probe technology will only approximate 100% if there are
more than 100 mycobacteria present in the sample, except for M. kansasii (87%) [12]. Thus, these
probes are not sensitive enough to be used directly in clinical specimens like sputum. Also, it
still needs to be confirmed by other conventional detection methods such as biochemical test
and molecular tests to able to identify the species identity within the M. tuberculosis complex,
such as for M. microti, M. bovis, M. bovis of BCG,, M. canettii, and M. africanum [10]. There has
been extensive research to design an identification system for ribosomal RNA/DNA finger‐
printing and for development of probes that targeting specific rRNA, ribosomal DNA, spacer
and flanking sequences of various types of mycobacterium species including M. tuberculosis,
M. leprae, M. avium, M. gardonae, etc [12, 13]. Those rRNA targeting probes are 10-100 fold more
sensitive than DNA targeting. However, since the lowest detection limit is still around 100
organisms. it still needs more evaluation before it can be applied to clinical specimens [12].
Several techniques based on polymerase chain reaction (PCR) and isothermal amplification
assay have been developed [7-10, 12]. Various researchers have described the rapid detection
of M. tuberculosis by PCR, and many have reported a high sensitivity in detecting M. tubercu‐
losis in clinical samples by means of DNA amplifications [7, 14]. Such techniques involve
amplification of specific gene regions followed by hybridization with species specific primers,
and also frequently followed by sequencing and or restriction fragment length polymorphism
(RFLP) analysis [12]. RFLP is still most widely used in clinical microbiology laboratories due
to its simplicity and lower costs than PCR Sequencing [12]. Multiplex PCR has been used to
detect M. tuberculosis complex bacteria and other mycobacterium. This technique is based on
the amplification of the most widely used specific insertion sequences IS6110 and 16S [7-9].
Based on our experience, multiplex PCR has sensitivity up to 81.62% with negative predictive
value up to 79.51% [7]. Nevertheless, taking into account the “simple and economical” issue
this technique is probably not suited for most of the countries with a high tuberculosis burden
[11]. Other rapid molecular amplification detection method which is being used in our
laboratory is multiplex PCR-reverse cross blot hybridization, which can be modified to identify
multiple species of mycobacteria at one time by using a specific probe for each species.
Compared to the culture and microscopic method, this technique had a sensitivity of 86.03%,
negative predictive value of 82.41% and it can be applied to detect NTM [7]. The multiplex
PCR reverse cross blot hybridization technique is more complicated than conventional
multiplex PCR; but it can detect considerably more NTM species such as M. avium, M.
intracellulare, M. kansasii, M. fortuitum, M. chelonae, M. genavense and M. smegmatis (Fig. 1) [7].
In term of accuracy and duration time that it  needs to get a result,  Raman spectroscopy
is  one  of  the  most  promising  techniques.  This  vibrational  spectroscopy-based  detection
method  can  detect  and  differentiate  various  molecular  compositions  of  microorganism
[15-18]  and  therefore  is  suitable  to  identify  the  species  and  strains  of  microorganism.
Buijtels et al., demonstrated that Raman spectroscopy differentiated between M. tuberculo‐
sis with NTM with accuracy up to 100% and with 92.5% correct species identification. This
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technique is  also are  much faster;  results  can be obtained within 3  hours  since positive
automated cultured system is  obtained [18].  In view of  the importance of  early diagno‐
sis to prevent further spread of tuberculosis in the community, this time efficiency is the
most significant contribution of Raman spectroscopy.
Figure 1. Multiplex PCR reverse cross blot hybridization assay is able to detect various species of mycobacteria simulta‐
neously. Each column (Col) represents certain species of mycobacteria; Col 1, M. intracellulare; Col 2, M. kansasii ; Col
3-8, 11, 14, 20, 22, 24, 26, 28, 30-33, M. tuberculosis; Col 9, M. fortuitum; Col 10, 12, 13, M. chelonae; Col 15, 16, 18, 19,
23, 25, 27, 29, M. avium; Col 17, M. genavense; Col 21, M. smegmatis ; 34, pool PCR product of mycobacteria. [7]
3. Indirect detection methods
Even those remarkable molecular detection methods are not yet up to the mark when it comes
to in the identification of tuberculosis, particularly latent tuberculosis infection (LTBI). Approx‐
imately 2 milliard people are silent tuberculosis patients, i.e. they have been infected by M.
tuberculosis but show no tuberculosis symptoms [1, 2]. LTBI has been defined by evidence of a
cellular immune response to M. tuberculosis derived antigens. It may be the result of incom‐
plete elimination of M. tuberculosis by the host’s adaptive immune system, resulting in asympto‐
matic infection with almost undetectable bacilli [2]. Thus, the diagnosis of LTBI currently depends
on detecting the host’s immune response to the infection [2]. Affected individuals have little risk
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of progression from LTBI to active tuberculosis, but any disruption of their cellular immunity –
such as in HIV co-infection cases – can considerably increase this risk [2]. Currently, the diagnosis
of LTBI is commonly made with the tuberculosis skin test (TST), which is based on the delayed
hypersensitivity to purified protein derivative (PPD). Unfortunately, patients sensitized to
environmental nontuberculous mycobacteria or patients vaccinated with the bacillus Calmette–
Guérin (BCG) vaccine may have a false positive result. On the other hand, a false negative result
may occur in immunosuppressed patients and also in children [2]. This immunologic re‐
sponse is often not conclusive as antibodies and delayed type hypersensitivity response persist
long after infection or after the diseases has disappeared [12]
Interferon Gamma Release Assays (IGRAs) have been introduced in the clinical setting for the
diagnosis of LTBI [19-21]. These more specific whole-blood tests are based on the principle of
measuring host interferon-y (IFN-y) released by T-cells specific to M. tuberculosis as a marker.
IFN-y is stimulated by early secretory antigen target 6 (ESAT-6) and culture filtrate protein 10
(CFP-10). These are not present in the BCG or in the most of the NTM [2]. There are two types
of IGRAs: The enzyme-linked immunospot assay (ELISpot)-based IGRA, where individual
IFN-y producing T-cells responding to M. tuberculosis antigens stimulation are counted [22],
and the QuantiFERON-TB Gold In-Tube test, an ELISA-based IGRA where the IFN-y produced
by those T-cells is measured after stimulation with M. tuberculosis antigens [2]. Pai et al. showed
that the sensitivity of the ELISpot and ELISA-based approach was around 90% and 70%,
respectively, and that the specificity of both was 93% [2, 20]. As there is still no gold standard
for the diagnosis of LTBI, these assays potentially may serve as routine diagnosis test other
than TST to identify people with LTBI [2].
Cytokine-based detection methods could be useful not only in the detection of LTBI cases but
also of active tuberculosis cases. However, considering the high number of LTBI in the
community, a single cytokine identification method such as IGRAs is not sufficient to detect
active tuberculosis. For this reason the identification of multiple tuberculosis biomarkers-
cytokines seems to be a promising strategy. Several studies have shown the potential useful‐
ness of TNA-a, IL-2, IP-10, MIG along with IF-g simultaneously [23-26]. Using a multiplex
microbead-based assay, Wang et al. showed significant differences in expression of these
cytokines/chemokines between active tuberculosis patients and healthy controls. Regarding
active pulmonary tuberculosis the sensitivity of IFN-y, IP-10 and MIG was 75.3% and the
specificity was 89.7%. They also demonstrated the potential usefulness of this multiplex
microbead-based assay for the detection of new tuberculosis cases by documenting a sensi‐
tivity of 96.3% [23].
Untill now, smear and culture methods are still the gold standard to detect mycobacteria. Based
on our experience, combination of conventional and advanced detection methods would
greatly improve the sensitivity and specificity of the assays. Detection of the mycobacteria
species are quite difficult with culture, therefore we using multiplex PCR as the first confir‐
mation assay to detect the species while it also as confirmation test for negative results from
either smear or culture assay. Hence, to overcome the limitation of multiplex PCR in species
detection, multiplex PCR- reverse cross blot hybridization assay would further expand the
range of mycobacteria species detection (Fig. 2).
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cellular immune response to M. tuberculosis derived antigens. It may be the result of incom‐
plete elimination of M. tuberculosis by the host’s adaptive immune system, resulting in asympto‐
matic infection with almost undetectable bacilli [2]. Thus, the diagnosis of LTBI currently depends
on detecting the host’s immune response to the infection [2]. Affected individuals have little risk
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of progression from LTBI to active tuberculosis, but any disruption of their cellular immunity –
such as in HIV co-infection cases – can considerably increase this risk [2]. Currently, the diagnosis
of LTBI is commonly made with the tuberculosis skin test (TST), which is based on the delayed
hypersensitivity to purified protein derivative (PPD). Unfortunately, patients sensitized to
environmental nontuberculous mycobacteria or patients vaccinated with the bacillus Calmette–
Guérin (BCG) vaccine may have a false positive result. On the other hand, a false negative result
may occur in immunosuppressed patients and also in children [2]. This immunologic re‐
sponse is often not conclusive as antibodies and delayed type hypersensitivity response persist
long after infection or after the diseases has disappeared [12]
Interferon Gamma Release Assays (IGRAs) have been introduced in the clinical setting for the
diagnosis of LTBI [19-21]. These more specific whole-blood tests are based on the principle of
measuring host interferon-y (IFN-y) released by T-cells specific to M. tuberculosis as a marker.
IFN-y is stimulated by early secretory antigen target 6 (ESAT-6) and culture filtrate protein 10
(CFP-10). These are not present in the BCG or in the most of the NTM [2]. There are two types
of IGRAs: The enzyme-linked immunospot assay (ELISpot)-based IGRA, where individual
IFN-y producing T-cells responding to M. tuberculosis antigens stimulation are counted [22],
and the QuantiFERON-TB Gold In-Tube test, an ELISA-based IGRA where the IFN-y produced
by those T-cells is measured after stimulation with M. tuberculosis antigens [2]. Pai et al. showed
that the sensitivity of the ELISpot and ELISA-based approach was around 90% and 70%,
respectively, and that the specificity of both was 93% [2, 20]. As there is still no gold standard
for the diagnosis of LTBI, these assays potentially may serve as routine diagnosis test other
than TST to identify people with LTBI [2].
Cytokine-based detection methods could be useful not only in the detection of LTBI cases but
also of active tuberculosis cases. However, considering the high number of LTBI in the
community, a single cytokine identification method such as IGRAs is not sufficient to detect
active tuberculosis. For this reason the identification of multiple tuberculosis biomarkers-
cytokines seems to be a promising strategy. Several studies have shown the potential useful‐
ness of TNA-a, IL-2, IP-10, MIG along with IF-g simultaneously [23-26]. Using a multiplex
microbead-based assay, Wang et al. showed significant differences in expression of these
cytokines/chemokines between active tuberculosis patients and healthy controls. Regarding
active pulmonary tuberculosis the sensitivity of IFN-y, IP-10 and MIG was 75.3% and the
specificity was 89.7%. They also demonstrated the potential usefulness of this multiplex
microbead-based assay for the detection of new tuberculosis cases by documenting a sensi‐
tivity of 96.3% [23].
Untill now, smear and culture methods are still the gold standard to detect mycobacteria. Based
on our experience, combination of conventional and advanced detection methods would
greatly improve the sensitivity and specificity of the assays. Detection of the mycobacteria
species are quite difficult with culture, therefore we using multiplex PCR as the first confir‐
mation assay to detect the species while it also as confirmation test for negative results from
either smear or culture assay. Hence, to overcome the limitation of multiplex PCR in species
detection, multiplex PCR- reverse cross blot hybridization assay would further expand the
range of mycobacteria species detection (Fig. 2).
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Figure 2. Microbiologic diagnosis of tuberculosis. Multiplex PCR are used to confirm smears results and negative result
of culture assay. Patients with negative multiplex PCR result would be proceed for ELISpot or Tuberculin skin test (TST)
to detect latent tuberculosis (LTBI), while specimen from patient with positive culture result would get final confirma‐
tion by Multiplex PCR reverse cross blot hybridization assay to further detect the mycobacterium species
4. Conclusion
Conventional methods for the diagnosis of tuberculosis, such as the smear and culture methods
have some limitations, particularly the low specificity and sensitivity as well as the time-
consuming nature. Now these limitations have been overcome in some novel and rapid
detection methods. Various gene amplification techniques have demonstrated their usefulness
in the identification of mycobacteria and its various species. The rapid detection of M.
tuberculosis by probes, PCR or other molecular techniques and some newest serologic assays
offer good opportunities to improve the diagnosis and therapy of tuberculosis [2, 7-9, 12, 13].
However despite the availability of diagnostic tools for laboratory identification of tubercu‐
losis at high sensitivity and specificity, the “simple and economically” aspect of those new
methods is still a matter of consideration. The question is whether they can be used in simple
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clinical settings and whether they are economically affordable for developing countries, in
most of which tuberculosis is still rampant [11].
Summary
Tuberculosis still remains a major health problem in many developing countries, despite
continuous long-standing vaccination and surveillance programs, and worldwide availability
of effective anti-tuberculosis drugs. Early detection is of major importance in the control of
tuberculosis. The emergence of multidrug resistant Mycobacterium tuberculosis and the
association of HIV with tuberculosis outbreaks in community both illustrate that rapid
diagnosis is essential. Therefore, a fast and reliable diagnosis of tuberculosis would greatly
improve the control of the tuberculosis. Regrettably, current conventional laboratory diag‐
nostic methods of tuberculosis are still time-consuming. The rapid development of novel
diagnostic methods for the identification of mycobacteria and its species bring new hope,
however, for the diagnosis and management this infectious disease. Meanwhile those techni‐
ques still seem to clash with simplicity and economically affordable issues.
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1. Introduction
Tuberculosis (TB) is caused by infection with Mycobacterium tuberculosis, which is transmitted
through inhalation of aerosolized droplets. TB mainly attacks the lungs, but can also affect
other parts of the body. TB is highly contagious during the active stage of the disease and can
infect an individual through inhalation of as few as 10 Mycobacterium tuberculosis (MTB)
bacteria. After inhalation, these bacteria are mainly captured by the alveolar macrophages, but
they can evade the host immune system and remain in the dormant stage for a long period of
time, at which point they can reactivate to a virulent form under immune-compromised
conditions of the host. This is possible because M. tuberculosis can persist in slow growing as
well as in fast growing stages which makes treatment challenging. Almost all of the antibiotics
that can be used to treat TB work when the bacteria are actively dividing. In the intensive phase
of TB treatment, the antibiotics mainly kill rapidly growing bacteria, which causes rapid
sputum conversion, and the eradication of clinical symptoms. However, in order to kill the
persistent or slow growing strains of MTB, the continuation phase of the treatment is essential.
TB can be treated effectively by using first line drugs (FLD) isoniazid (INH), rifampin (RIF),
pyrazinamide (PZA), ethambutol (EMB) and streptomycin (SM). However, this first line
therapy often fails to cure TB for several reasons. Relapse and the spread of the disease
contribute to the emergence of drug resistant bacteria. The emergence of multidrug resistant
TB (MDR-TB), i.e. which is resistant to at least isoniazid (INH) and rifampicin (RIF), is of great
concern, because it requires the use of second-line drugs that are difficult to procure and are
much more toxic and expensive than FLDs [1]. Therefore, the detection and treatment of drug
susceptible or single drug resistant TB is an important strategy for preventing the emergence
of MDR-TB [2]. M. tuberculosis strains with extensively drug resistant-TB (XDR-TB), that is
resistant to either isoniazid or rifampicin (like MDR tuberculosis), any fluoroquinolone, and
at least one of three second-line antituberculosis injectable drugs—i.e., capreomycin, kanamy‐
cin, and amikacin have also been reported [3].
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First- and second-line drugs, minimum inhibitory concentrations (MICs) and mechanisms of
drug resistance are presented in Table 1 [4]. Antituberculosis drugs are mainly divided into
two parts.
1. First-line antituberculosis drugs- Isoniazid (INH), rifampicin (RIF), ethambutol (EMB),
pyrazinamide (PZA) and streptomycin (SM).
2. Second-line antituberculosis drugs- Sub divided into two
i. Fluoroquinolones- Ofloxacin (OFX), levofloxacin (LEV), moxifloxacin (MOX)
and ciprofloxacin (CIP).
ii. Injectable antituberculosis drugs- Kanamycin (KAN), amikacin (AMK) and
capreomycin (CAP).
iii. Less-effective second-line antituberculosis drugs- Ethionamide (ETH)/Prothio‐
namide (PTH), Cycloserine (CS)/Terizidone, P-aminosalicylic acid (PAS).
Drug MIC (mg/L) Gene Role of gene product
Isoniazid 0.02–0.2 (7H9/7H10) katG catalase/peroxidase
inhA enoyl reductase
ahpC alkyl hydroperoxide reductase
Rifampicin 0.05–0.1 (7H9/7H10) rpoB β-subunit of RNA polymerase
Pyrazinimide 16–50 (LJ) pncA PZase
Streptomycin 2–8 (7H9/7H10) rpsL S12 ribosomal protein
rrs 16S rRNA
gidB 7-methylguanosine methyltransferase
Ethambutol 1–5 (7H9/7H10) embB arabinosyl transferase
Fluoroquinolones 0.5–2.0 (7H9/7H10) gyrA/gyrB DNA gyrase
Kanamycin 2–4 (7H9/7H10) rrs 16S rRNA
eis aminoglycoside acetyltransferase
Amikacin 2–4 (7H9/7H10) rrs 16S rRNA
Capreomycin 2-4 (7H9/7H10) rrs 16S rRNA
tylA rRNA methyltransferase
Ethionamide 2.5–10 (7H11) inhA enoyl reductase
p-aminosalicylic acid 0.5 (LJ) thyA thymidylate synthase A
Table 1. First- and second-line drugs, MICs and mechanisms of drug resistance
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2. First-line antituberculosis drugs
2.1. Isoniazid
Isoniazid (INH) is one of the most effective and specific antituberculosis drugs, which has been
a key to treatment since its introduction in 1952 [5]. M. tuberculosis is highly susceptible to INH
(MIC 0.02–0.2 μg/ml). INH is only active against growing tubercle bacilli, and is not active
against non-replicating bacilli or under anaerobic conditions. INH enters the mycobacterial
cell by passive diffusion [6]. The most significant adverse reactions associated with isoniazid
administration are hepatotoxicity and neurotoxicity.
Resistance to isoniazid is a complex process. Mutations in several genes, including katG,
ahpC, and inhA, have all been associated with isoniazid resistance. INH is a prodrug that is
activated by the mycobacterial enzyme KatG [7]. INH-resistant clinical isolates of M. tubercu‐
losis often lose catalase and peroxidase enzyme encoded by katG [8], especially in high-level
resistant strains (MIC > 5 μg/ml) [9]. Low-level resistant strains (MIC < 1 μg/ml) often still
possess catalase activity [9]. Although mutations in katG have been shown to be responsible
for INH resistance [10], it is not clear whether the regulation of katG expression plays a role in
INH resistance. The katG gene encodes a bifunctional catalase-peroxidase that converts INH
to its active form [7]. Activated INH inhibits the synthesis of essential mycolic acids by
inactivating the NADH-dependent enoyl-acyl carrier protein reductase encoded by inhA [11].
A study by Hazbo´n et al. [12] analysed 240 alleles and found that mutations in katG, inhA and
ahpC were most strongly associated with isoniazid resistance. A decrease in or total loss of
catalase/peroxidase activity as a result of katG mutations are the most common genetic
alterations associated with isoniazid resistance [7]. Ser315Thr is the most widespread katG
mutation in clinical isolates, but there are many mutations that result in inactivation of catalase-
peroxidase, with MICs ranging from 0.2 to 256 mg/L.
Mutations in inhA or its promoter region are usually associated with low-level resistance (MICs
= 0.2 −1 μg/ml) and are less frequent than katG mutations [10, 12]. INH-resistant M. tuberculo‐
sis harboring inhA mutations could have additional mutations in katG, conferring higher levels
of INH resistance [13]. The most common inhA mutation occurs in its promoter region (-15C
→ T) and it has been found more frequently associated with mono-resistant strains [14].
In M. tuberculosis, ahpC codes for an alkyl hydroperoxidase reductase that is implicated in
resistance to reactive oxygen and reactive nitrogen intermediates. It was initially proposed
that mutations in the promoter of ahpC could be used as surrogate markers for the detection
of isoniazid resistance [15]. However, several other studies have found that an increase in the
expression of ahpC seems to be more a compensatory mutation for the loss of catalase/
peroxidase activity rather than the basis for isoniazid resistance [4, 16].
2.2. Rifampicin
Rifampicin (RIF) was introduced in 1972 as an antituberculosis drug and has excellent steriliz‐
ing activity. Rifampicin acts by binding to the β-subunit of RNA polymerase (rpoB) [17], the en‐
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First- and second-line drugs, minimum inhibitory concentrations (MICs) and mechanisms of
drug resistance are presented in Table 1 [4]. Antituberculosis drugs are mainly divided into
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1. First-line antituberculosis drugs- Isoniazid (INH), rifampicin (RIF), ethambutol (EMB),
pyrazinamide (PZA) and streptomycin (SM).
2. Second-line antituberculosis drugs- Sub divided into two
i. Fluoroquinolones- Ofloxacin (OFX), levofloxacin (LEV), moxifloxacin (MOX)
and ciprofloxacin (CIP).
ii. Injectable antituberculosis drugs- Kanamycin (KAN), amikacin (AMK) and
capreomycin (CAP).
iii. Less-effective second-line antituberculosis drugs- Ethionamide (ETH)/Prothio‐
namide (PTH), Cycloserine (CS)/Terizidone, P-aminosalicylic acid (PAS).
Drug MIC (mg/L) Gene Role of gene product
Isoniazid 0.02–0.2 (7H9/7H10) katG catalase/peroxidase
inhA enoyl reductase
ahpC alkyl hydroperoxide reductase
Rifampicin 0.05–0.1 (7H9/7H10) rpoB β-subunit of RNA polymerase
Pyrazinimide 16–50 (LJ) pncA PZase
Streptomycin 2–8 (7H9/7H10) rpsL S12 ribosomal protein
rrs 16S rRNA
gidB 7-methylguanosine methyltransferase
Ethambutol 1–5 (7H9/7H10) embB arabinosyl transferase
Fluoroquinolones 0.5–2.0 (7H9/7H10) gyrA/gyrB DNA gyrase
Kanamycin 2–4 (7H9/7H10) rrs 16S rRNA
eis aminoglycoside acetyltransferase
Amikacin 2–4 (7H9/7H10) rrs 16S rRNA
Capreomycin 2-4 (7H9/7H10) rrs 16S rRNA
tylA rRNA methyltransferase
Ethionamide 2.5–10 (7H11) inhA enoyl reductase
p-aminosalicylic acid 0.5 (LJ) thyA thymidylate synthase A
Table 1. First- and second-line drugs, MICs and mechanisms of drug resistance
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2. First-line antituberculosis drugs
2.1. Isoniazid
Isoniazid (INH) is one of the most effective and specific antituberculosis drugs, which has been
a key to treatment since its introduction in 1952 [5]. M. tuberculosis is highly susceptible to INH
(MIC 0.02–0.2 μg/ml). INH is only active against growing tubercle bacilli, and is not active
against non-replicating bacilli or under anaerobic conditions. INH enters the mycobacterial
cell by passive diffusion [6]. The most significant adverse reactions associated with isoniazid
administration are hepatotoxicity and neurotoxicity.
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mutation in clinical isolates, but there are many mutations that result in inactivation of catalase-
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sis harboring inhA mutations could have additional mutations in katG, conferring higher levels
of INH resistance [13]. The most common inhA mutation occurs in its promoter region (-15C
→ T) and it has been found more frequently associated with mono-resistant strains [14].
In M. tuberculosis, ahpC codes for an alkyl hydroperoxidase reductase that is implicated in
resistance to reactive oxygen and reactive nitrogen intermediates. It was initially proposed
that mutations in the promoter of ahpC could be used as surrogate markers for the detection
of isoniazid resistance [15]. However, several other studies have found that an increase in the
expression of ahpC seems to be more a compensatory mutation for the loss of catalase/
peroxidase activity rather than the basis for isoniazid resistance [4, 16].
2.2. Rifampicin
Rifampicin (RIF) was introduced in 1972 as an antituberculosis drug and has excellent steriliz‐
ing activity. Rifampicin acts by binding to the β-subunit of RNA polymerase (rpoB) [17], the en‐
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zyme  responsible  for  transcription  and  expression  of  mycobacterial  genes,  resulting  in
inhibition of the bacterial transcription activity and thereby killing the organism. An important
characteristic of rifampicin is that it is active against actively growing and slowly metabolizing
(non-growing) bacilli [18]. RIF produces relatively few adverse reactions. It may cause gastro‐
intestinal upset. Hepatotoxicity occurs less frequently than with isoniazid administration.
Rifampicin MICs ranging from 0.05 to 1 μg/ml on solid or liquid media, but the MIC is higher
in egg media (MIC = 2.5–10 μg/ml). Strains with MICs < 1 μg/ml in liquid or agar medium or
MICs < 40 μg/ml in Lowenstein-Jensen (LJ) medium are considered RIF-susceptible. The great
majority of M. tuberculosis clinical isolates resistant to rifampicin show mutations in the gene
rpoB that encodes the β-subunit of RNA polymerase. This results in conformational changes
that determine a low affinity for the drug and consequently the development of resistance [19].
Mutations in a ‘hot-spot’ region of 81 bp of rpoB have been found in about 96% of rifampicin-
resistant M. tuberculosis isolates. This region, spanning codons 507–533 (numbering according
to the Escherichia coli rpoB sequence), is also known as the rifampicin resistance-determining
region (RRDR) [17]. Mutations in codons 531, 526 and 516 (Ser531Leu, His526Tyr, and
Asp516Val) are the most frequently reported mutations in most of the studies [20, 21]. Some
studies have also reported mutations outside of the hot-spot region of rpoB in rifampicin-
resistant M. tuberculosis isolates [22].
2.3. Pyrazinamide
Pyrazinamide (PZA) is an important first-line antituberculosis (anti-TB) drug that is used in
short-course chemotherapy and is one of the cornerstone drugs in the treatment of MDR-TB
[23]. One key characteristic of pyrazinamide is its ability to inhibit semidormant bacilli residing
in acidic environments [23]. Pyrazinamide is a structural analogue of nicotinamide and is a
pro-drug that needs to be converted into its active form, pyrazinoic acid, by the enzyme
pyrazinamidase/nicotinamidase (PZase) [24]. PZA is only active against M. tuberculosis at acid
pH (e.g., 5.5) [25]. Even at acid pH (5.5), PZA activity is quite poor, with MICs in the range of
6.25–50 μg/ml [26]. Hypersensitivity reactions and gastrointestinal upset may occur with PZA
administration.
PZase is encoded in M. tuberculosis by the gene pncA [27]. Mutations in the pncA gene may
cause a reduction in PZase activity which may be the major mechanism of PZA resistance in
MTB [28, 29]. The mutations of the pncA gene in PZA-resistant MTB isolates has been well
characterized, however the correlation varies between different geographical areas including
missense mutations, one or more base insertions or deletions, and complete deletion [28-32].
Despite the highly diverse and scattered distribution of pncA mutations, there is some degree
of clustering of mutations within different regions of the pncA gene such as at amino acid
residues 3–17, 61–85 and 132–142 has been reported [33, 34]. The highly diverse mutation
profile in the pncA gene observed in PZA-resistant strains is unique among drug-resistance
genes in M. tuberculosis [28]. While the reason behind this diversity is still unclear, it is thought
that this could be due to adaptive mutagenesis or due to deficiency in DNA mismatch repair
mechanisms [23]. Most PZA-resistant M. tuberculosis strains (72–97%) have mutations in pncA;
[28, 29, 34, 35] however; some resistant strains do not have pncA mutations.
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2.4. Ethambutol
Ethambutol (EMB) [dextro-2,2’-(ethylenediimino)di-1-butanol], which is an essential first-line
drug in tuberculosis treatment, plays an important role in the chemotherapy of drug-resistant
TB [36]. EMB is also an important antimycobacterial drug as it enhances the effect of other
companion drugs including aminoglycosides, rifamycins and quinolones. The most common
side effects observed with ethambutol are dizziness, blurred vision, color blindness, nausea,
vomiting, stomach pain, loss of appetite, headache, rash, itching, breathlessness, swelling of
the face, lips or eyes, numbness or tingling in the fingers or toes. Patients taking ethambutol
should have their visual acuity and color vision checked at least monthly.
The MICs of EMB for M. tuberculosis are in the range of 0.5–2 μg/ml. EMB is a bacteriostatic
agent that is active for growing bacilli and has no effect on non-replicating bacilli. EMB
interferes with the biosynthesis of cell wall arabinogalactan [37]. It inhibits the polymerization
of cell-wall arabinan of arabinogalactan and of lipoarabinomannan, and induces the accumu‐
lation of D-arabinofuranosyl-P-decaprenol, an intermediate in arabinan biosynthesis [38, 39].
Arabinosyl transferase, encoded by embB, an enzyme involved in the synthesis of arabinoga‐
lactan, has been proposed as the target of EMB in M. tuberculosis [40] and M. avium [41]. In M.
tuberculosis, embB is organized into an operon with embC and embA in the order embCAB. embC,
embB and embA share over 65% amino acid identity with each other and are predicted to encode
transmembrane proteins [40]. Mutations in the embCAB operon, in particular embB, and
occasionally embC, are responsible for resistance to EMB [40]. Point mutations of the em‐
bABC gene commonly occurred in embB codon 306 [40, 42, 43], and mutations in the embB306
codon have been proposed as a marker for EMB resistance in diagnostic tests [44]. However,
point mutations in the embB306 locus occur in only 50 to 60% of all EMB-resistant clinical
isolates [42, 45-47], and embB306 mutations can also occur in EMB-susceptible clinical isolates
[46, 47]. Five different mutations were uncovered in this codon (ATG→ GTG/CTG/ATA, ATC
and ATT), resulting in three different amino acid shifts (Met→ Val, Leu, or Ile) [43]. Although
the association between embB306 mutation and ethambutol resistance or broad drug resistance
has been observed in several groups’ studies with either clinical or laboratorial isolates [48,
49], the exact role of embB306 mutations play in the development of ethambutol resistance and
multidrug resistance in M. tuberculosis is not fully understood. About 35% of EMB-resistant
strains (MIC <10 μg/ml) do not have embB mutations [39, 45], suggesting that there may be
other mechanisms of EMB resistance. Further studies are necessary to identify the potential
new mechanisms of EMB resistance.
2.5. Streptomycin
Streptomycin (SM), an aminocyclitol glycoside antibiotic, was the first drug to be used in the
treatment of TB, in 1948 [50]. SM kills actively growing tubercle bacilli with MICs of 2–4
μg/ml, but it is inactive against non-growing or intracellular bacilli [23]. The drug binds to the
16S rRNA, interferes with translation proofreading, and thereby inhibits protein synthesis [51,
52]. Ototoxicity and nephotoxicity are associated with SM administration. Vestibular dysfunc‐
tion is more common than auditory damage. Renal toxicity occurs less frequently than with
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kanamycin or capreomycin. Hearing and renal function should be monitored in patients
getting SM.
Mutations associated with streptomycin resistance have been identified in the genes encoding
16S rRNA (rrs) [53] and ribosomal protein S12 (rpsL) [54-57]. Ribosomal protein S12 stabilizes
the highly conserved pseudoknot structure formed by 16S rRNA [58]. Amino acid substitu‐
tions in RpsL affect the higher-order structure of 16S rRNA [51] and confer streptomycin
resistance. Alterations in the 16S rRNA structure disrupt interactions between 16S rRNA and
streptomycin, a process that results in resistance [59]. Mutations in rpsL and rrs are the major
mechanism of SM resistance [54, 56, 57], accounting for respectively about 50% and 20% of
SM-resistant strains [54, 56, 57]. The most common mutation in rpsL is a substitution in codon
43 from lysine to arginine [54, 56, 57], causing high-level resistance to SM. Mutation in codon
88 is also common [54, 56, 57]. Mutations of the rrs gene occur in the loops of the 16S rRNA
and are clustered in two regions around nucleotides 530 and 915 [39, 54, 56, 57]. However,
about 20–30% of SM-resistant strains with a low level of resistance (MIC < 32 μg/ml) do not
have mutations in rpsL or rrs [60], which indicates other mechanism(s) of resistance. A
mutation in gidB, encoding a conserved 7-methylguanosine (m(7)G) methyltransferase specific
for 16S rRNA, has been found to cause low-level SM resistance in 33% of resistant M. tubercu‐
losis isolates [61]. A subsequent study showed that while Leu16Arg change is a polymorphism
not involved in SM resistance, other mutations in gidB appear to be involved in low-level SM
resistance [62]. In addition, some low-level SM resistance seems to be caused by increased
efflux as efflux pump inhibitors caused increased sensitivity to SM, although the exact
mechanism remains to be identified [62].
3. Second-line antituberculosis drugs
3.1. Fluoroquinolones
The fluoroquinolones (FQs) have broad-spectrum antimicrobial activity and so are widely
used for the treatment of bacterial infections of the respiratory, gastrointestinal and urinary
tracts, as well as sexually transmitted diseases and chronic osteomyelitis [63]. In contrast to
many other antibiotics used to treat bacterial infections, the FQs have excellent in vitro and in
vivo activity against M. tuberculosis [64, 65]. FQs include ciprofloxacin, ofloxacin, levofloxacin,
and moxifloxacin. So, FQs are currently in use as second-line drugs in the treatment of TB.
Adverse effects are relatively infrequent (0.5–10% of patients) and include gastrointestinal
intolerance, rashes, dizziness, and headache. Most studies of fluoroquinolone side effects have
been based on relatively short-term administration for bacterial infections, but trials have now
shown the relative safety and tolerability of fluoroquinolones administered for months during
TB treatment in adults.
The cellular target of FQs in M. tuberculosis is DNA gyrase, a type II topoisomerase consist‐
ing of two A and two B subunits encoded by gyrA and gyrB genes, respectively [66]. Muta‐
tions in a small region of gyrA, called quinolone resistance-determining region (QRDR) and,
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less frequently, in gyrB are the primary mechanism of FQ resistance in M. tuberculosis [66,
67]. Analysis of QRDR alone by genotypic tests has been suggested as sufficient for rapid
identification of vast majority of FQ-resistant M. tuberculosis strains as additional targeting
of gyrB did not enhance the sensitivity significantly [67, 68].
Mutations within the QRDR of gyrA have been identified in clinical and laboratory-selected
isolates of M. tuberculosis, largely clustered at codons 90, 91 and 94 [69-73], with Asp94 being
relatively frequent [71, 74]. Codon 95 (Ser95Thr) contains a naturally occurring polymor‐
phism that is not related to fluoroquinolone resistance, as it occurs in both fluoroquinolone-
susceptible and fluoroquinolone-resistant strains [75]. A less common involvement is codon
88 [76]. For clinical isolates, gyrB mutations appear to be of much rarer occurrence [72, 73].
Generally, two mutations in gyrA or concomitant mutations in gyrA plus gyrB are required
for the development of higher levels of resistance [69, 77].
3.2. Aminoglycosides (kanamycin, amikacin and capreomycin)
The aminoglycosides amikacin (AMK)/kanamycin (KAN) and the cyclic polypeptide cap‐
reomycin (CAP) are important injectable drugs in the treatment of multidrug-resistant tu‐
berculosis. Although belonging to two different antibiotic families, all exert their activity at
the level of protein translation. Renal toxicity occurs from these drugs. Regular monitoring
of hearing and renal function is recommended.
AMK and KAN are aminoglycosides that have a high level of cross-resistance between them
[78-80]. The cyclic polypeptide CAP is structurally unrelated to the aminoglycosides and
thus is a potential candidate to replace AMK or KAN if resistance to either of them is sus‐
pected [81, 82]. It has been demonstrated that the risk of treatment failure and mortality in‐
crease when CAP resistance emerges among MDR-TB cases [83]. However, cross-resistance
in M. tuberculosis between AMK/KAN and CAP has been observed in both clinical isolates
and laboratory-generated mutants [79, 80, 84, 85].
AMK/KAN and CAP primarily affect protein synthesis in M. tuberculosis and resistance to
these drugs is associated with changes in the 16S rRNA (rrs) [78, 80, 81, 85, 86]. The rrs muta‐
tion A1401G causes high-level AMK/KAN and low-level CAP resistance. C1402T is associat‐
ed with CAP resistance and low-level KAN resistance. G1484T is linked to high-level
AMK/KAN and CAP resistance [79, 80, 84, 86]. Low-level resistance to kanamycin has been
correlated to mutations in the promoter region of the eis gene encoding aminoglycoside ace‐
tyltransferase, the enhanced intracellular survival protein, Eis [87].
Resistance to the cyclic peptide capreomycin has also been associated with mutations in
tlyA  [86].  The gene tlyA  encodes a putative 2’-O-methyltransferase (TlyA) that  has been
suggested to methylate nucleotide C1402 in helix 44 of 16S rRNA and nucleotide C2158 in
helix 69 of 23S rRNA in M. tuberculosis  [81, 88]. Capreomycin binds to the 70S ribosome
and inhibits mRNA–tRNA translocation [89]. It is believed that TlyA methylation enhan‐
ces the antimicrobial activity of capreomycin [81] and that disruption of tlyA leads to cap‐
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The aminoglycosides amikacin (AMK)/kanamycin (KAN) and the cyclic polypeptide cap‐
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ed with CAP resistance and low-level KAN resistance. G1484T is linked to high-level
AMK/KAN and CAP resistance [79, 80, 84, 86]. Low-level resistance to kanamycin has been
correlated to mutations in the promoter region of the eis gene encoding aminoglycoside ace‐
tyltransferase, the enhanced intracellular survival protein, Eis [87].
Resistance to the cyclic peptide capreomycin has also been associated with mutations in
tlyA  [86].  The gene tlyA  encodes a putative 2’-O-methyltransferase (TlyA) that  has been
suggested to methylate nucleotide C1402 in helix 44 of 16S rRNA and nucleotide C2158 in
helix 69 of 23S rRNA in M. tuberculosis  [81, 88]. Capreomycin binds to the 70S ribosome
and inhibits mRNA–tRNA translocation [89]. It is believed that TlyA methylation enhan‐
ces the antimicrobial activity of capreomycin [81] and that disruption of tlyA leads to cap‐
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reomycin resistance because the unmethylated ribosome is insensitive to the drug [81, 86,
88]. The identified mechanism of capreomycin resistance on the basis of in vitro selected
mutants has found that tlyA mutations were common [80, 86] whereas infrequent in clini‐
cal isolates of M. tuberculosis [79, 80].
3.3. Ethionamide/prothionamide
Ethionamide (ETH, 2-ethylisonicotinamide) is a derivative of isonicotinic acid and has been
used as an antituberculosis agent since 1956. The MICs of ETH for M. tuberculosis are 0.5–2 μg/
ml in liquid medium, 2.5–10 μg/ml in 7H11 agar, and 5–20 μg/ml in LJ medium. Ethionamide
and the similar drug prothionamide (PTH, 2-ethyl-4-pyridinecarbothioamide) act as pro-
drugs, like isoniazid. Which is activated by EtaA/EthA (a mono-oxygenase) [90, 91] and inhibits
the same target as INH, the InhA of the mycolic acid synthesis pathway [92]. Once delivered
into the bacterial cell, ethionamide undergoes several changes. Its sulfo group is oxidized by
flavin monooxygenase, and the drug is then converted to 2-ethyl-4-aminopyridine. The
intermediate products formed before 2-ethyl-4-aminopyridine seem to be toxic to mycobac‐
teria, but their structures are unknown (may be highly unstable compounds). Mutants resistant
to ethionamide are cross-resistant to prothionamide. ETH frequently causes gastrointestinal
side effects, such as abdominal pain, nausea, vomiting and anorexia. It can cause hypothyr‐
oidism, particularly if it is used with para-aminosalicyclic acid.
3.4. p-Amino salicylic acid
p-Amino salicylic acid (PAS) was one of the first antibiotics to show anti-TB activity and was
used to treat TB in combination with isoniazid and streptomycin [93]. Later, with the discovery
of other more potent drugs including rifampicin, its use in first line regimens was discontinued.
PAS is still useful as part of a treatment regimen for XDR TB although its benefit is limited and
it is extremely toxic. Thymidylate synthase A, encoded by thyA, an enzyme involved in the
biosynthesis of thymine, has been proposed recently as the target of PAS in M. bovis BCG [94].
Most common mutation in thyA was Thr202Ala, though few susceptible isolates also showed
the same mutation [95]. However, its mechanism of action was never clearly elucidated. The
most common adverse reactions associated with PAS are gastrointestinal disturbances.
3.5. Cycloserine
Cycloserine (CS) is an antibiotic that is used to treat TB. The exact mechanism of action of
cycloserine is unknown, but it is thought to prevent the tuberculosis bacteria from making
substances called peptidoglycans, which are needed to form the bacterial cell wall. This results
in the weakening of bacteria’s cell wall, which then kills the bacteria. Cycloserine possesses
high gastric tolerance (compared with the other drugs) and lacks cross-resistance to other
compounds. But it causes adverse psychiatric effects; [96, 97] which is its main drawback. So,
psychiatric interrogation is necessary before prescribing cycloserine drug. Cycloserine is one
of the cornerstones of treatment for MDR and XDR tuberculosis [96, 97, 98]. Terizidone (a
combination of two molecules of cycloserine) might be less toxic [96, 97], although studies of
this drug are scarce.
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4. Conclusions
Despite all the advances made in the treatment and management, TB still remains as one of
the main public health problems that have plagued mankind for millennia. The challenges
posed by M. tuberculosis infection, through its interaction with the immune system and its
mechanisms for evasion, require many more breakthroughs to make a significant impact on
the worldwide tuberculosis problem. The introduction of MDR and XDR strains of M.
tuberculosis poses several problems in mycobacterial genetics and phthisiotherapy. Among the
response priorities, rapid detection of anti-tuberculosis drug resistance, use of appropriate
regimens for treatment, and new drug development are of paramount importance. However,
regarding the dynamics of TB transmission, and also in view of rational development of new
anti-TB drugs, it is extremely important to extend our knowledge on the molecular basis of
drug resistance and all its complexity. It is necessary to clarify the association between specific
mutations and the development of MDR-TB or the association between drug resistance and
fitness. This would allow better evaluation of the transmission dynamics of resistant strains
and more accurate prediction of a future disease scenario. Adequate monitoring of drug
resistance, especially MDR/XDR-TB in new patients and its transmission, molecular charac‐
terization of the drug-resistant strains, and analysis of patients’ immune status and genetic
susceptibility are also needed to address the problem of the fitness, virulence and transmissi‐
bility of drug-resistant M. tuberculosis strains.
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1. Introduction
An understanding of the epidemiology of multidrug resistant tuberculosis (MDR-TB) and the
extensively drug-resistant tuberculosis (XDR-TB) is critical for effective control of the global
burden of tuberculosis (TB) which is caused by the organisms belonging to the Mycobacterium
tuberculosis complex. Epidemiology of MDR-TB and XDR-TB will be reviewed here.
The history of tuberculosis treatment has observed sequential development of resistance to
anti-tuberculosis drugs over the decades. Para amino salicylic acid (PAS) and isoniazid (INH)
were introduced to reduce the development of streptomycin (SM) resistance, which heralded
the era of combination treatment for tuberculosis [1]. Within 20 years, resistance to both INH
and SM was already a challenge in the use of INH, SM and PAS as the standard anti-tubercu‐
losis regimen. With the discovery of rifampicin (RMP) in 1966 [2] and the expansion of its use
between 1970 and 1990, patients who were already carriers of isoniazid (INH) resistant
Mycobacterium tuberculosis strains became resistant to RMP. This was the start of a progressively
growing problem, multi drug resistant tuberculosis (MDR-TB), which has reached epidemic
proportions in some countries. In the last two decades, with the misuse of other drugs with
anti-tuberculosis action, in particular the fluoroquinolones (FQs), the most effective among the
second-line drugs, resistance has dramatically increased to extensively drug-resistant TB
(XDR-TB) which is defined as resistance to at least RMP and INH (the definition of multidrug-
resistant tuberculosis (MDR-TB)), in addition to any fluoroquinolone, and at least one of the
three injectable anti-tuberculosis (TB) drugs capreomycin, kanamycin and amikacin [3].
1.1. Epidemiology
John Last  has defined epidemiology as “The study of the distribution and determinants
of  health-related  states  or  events  in  specified  populations,  and  the  application  of  this
© 2013 Magana-Arachchi; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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study to the control of health problems” [4]. Epidemiologists are concerned not only with
death,  illness and disability,  but also with more positive health states and,  most impor‐
tantly, with the means to improve health [5]. Epidemiological studies are classified as ei‐
ther  observational  or  experimental.  Various  methods  can  be  used  to  carry  out
epidemiological investigations: surveillance and descriptive studies are used to study dis‐
tribution while analytical studies are used to study determinants.
The two mostly common terms used in epidemiology are the ‘prevalence’ and the ‘incidence’.
The incidence of disease represents the rate of occurrence of new cases arising in a given period
in a specified population, while prevalence is the frequency of existing cases in a defined
population at a given point in time [5]. These are fundamentally different ways of measuring
occurrence, and the relation between incidence and prevalence varies among diseases [5]. [For
a comprehensive study on epidemiology, please refer the World Health Organization (WHO)
manual on Basic Epidemiology].
1.2. Epidemiology of tuberculosis
Despite the availability of highly efficacious treatment for decades, TB remains a major global
health problem. In 1993, WHO declared TB a global public health emergency, at a time when
an estimated 7–8 million cases and 1.3–1.6 million deaths occurred each year. In 2010, there
were an estimated 8.5–9.2 million cases and 1.2–1.5 million deaths from TB [6]. According to
the newest report, has observed a gradual decline in the absolute number of TB cases since
2006 and also in the incidence rates of TB since 2002 [6].
2. Global epidemiology of MDR-TB
2.1. Global epidemiology of MDR-TB (global tuberculosis control: WHO report 2011)
Globally, around 50 000 cases of MDR-TB were notified to WHO in 2010, mostly by Eu‐
ropean countries and South Africa. This represented 18% of the 290 000 (range, 210 000–
380  000)  cases  of  MDR-TB estimated  to  exist  among  patients  with  pulmonary  TB  who
were  notified  in  2010.  The  proportion  of  TB  patients  estimated  to  have  MDR-TB  that
were actually diagnosed was under 10% in all of the 27 high MDR-TB countries outside
the European Region, with the notable exception of South Africa where 81% of estimated
cases were diagnosed. In, 15 high MDR-TB burden countries in the European Region, the
proportion  of  estimated  cases  that  were  diagnosed  ranged  from  24%  (in  Tajikistan)  to
over 90% of cases (in Belarus and Kazakhstan); no data were reported from Lithuania. In
Russian Federation,  which ranks third in terms of  estimated numbers of  cases of  MDR-
TB at the global level, the proportion of estimated cases that were diagnosed was 44% in
2010.  The  numbers  of  patients  diagnosed  with  MDR-TB and started  on  treatment  with
recommended second-line drug regimens in the high MDR-TB burden countries in 2010,
at just under 40 000, was less than the number of cases notified [6]
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2.2. Regimen surveys and definitions of patients registration groups for treatment of
tuberculosis
‘Regimen surveys’ measure first-line and/or second-line drug resistance among a group of
selected patients that cannot be considered representative of a patient population [7]. These
surveys help to determine the predominant patterns of drug resistance, and are useful in
providing guidance on appropriate regimens for MDR-TB treatment for particular patient
groups. These include return cases after treatment failure, chronic cases and symptomatic
contacts of MDR-TB cases. According to WHO, Regimen surveys should be conducted in the
process of developing MDR-TB treatment programmes, or within selected centres or diagnos‐
tic units that regularly address high-risk cases.
The fourth edition of WHO Guidelines for treatment of tuberculosis defines patient registration
groups by history of previous treatment [8]. [For a comprehensive study on definitions, please
refer the document WHO/HTM/TB/2009.420].
2.2.1. New case
For the purpose of surveillance, a ‘new case’ is defined as a newly registered episode of TB in
a patient who, in response to direct questioning denies having had any prior anti-tuberculosis
treatment (for up to one month), and in countries where adequate documentation is available,
for whom there is no evidence of such history. Determining the proportion of drug resistance
among new cases is vital in the assessment of recent transmission.
2.2.2. Previously treated case
For the purpose of surveillance, a ‘previously treated case’ is defined as a newly registered
episode of TB in a patient who, in response to direct questioning admits having been treated
for TB for one month or more, or, in countries where adequate documentation is available,
there is evidence of such history.
2.2.3. Primary resistance
Patients with TB resistant to one or more anti-tuberculosis drugs, but who have never been
previously treated for TB, are said to have “primary resistance” (or “initial resistance”) due to
transmission of a drug-resistant strain.
2.2.4. Acquired resistance
Patients diagnosed with TB who start anti-tuberculosis treatment and subsequently acquire
resistance to one or more of the drugs used during the treatment, are said to have developed
“acquired resistance”. In the past, resistance among previously treated cases (defined as cases
with ≥ one month history of treatment) was used as a proxy for acquired resistance; however,
this patient category is now known to also be comprised of patients who have been re-infected
with a resistant strain, and patients who were primarily infected with a resistant strain and
subsequently failed therapy or relapsed.
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2.2.4. Acquired resistance
Patients diagnosed with TB who start anti-tuberculosis treatment and subsequently acquire
resistance to one or more of the drugs used during the treatment, are said to have developed
“acquired resistance”. In the past, resistance among previously treated cases (defined as cases
with ≥ one month history of treatment) was used as a proxy for acquired resistance; however,
this patient category is now known to also be comprised of patients who have been re-infected
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A patient who has completed a course of anti-TB treatment according to programme protocol
and has at least five consecutive negative cultures from samples collected at least 30 days apart
in the final 12 months of treatment. If only one positive culture is reported during that time,
and there is no concomitant clinical evidence of deterioration, a patient may still be considered
cured, provided that this positive culture is followed by a minimum of three consecutive
negative cultures taken at least 30 days apart.
2.2.6. Failed
Anti-TB treatment will be considered to have failed if two or more of the five cultures recorded
in the final 12 months of therapy are positive, or if any one of the final three cultures is positive.
Treatment will also be considered to have failed if a clinical decision has been made to
terminate treatment early because of poor clinical or radiological response or adverse events.
These latter failures can be indicated separately in order to do sub-analysis.
3. Surveillance studies for the assessment of resistance rates and the
detection of MDR-TB
MDR-TB poses a therapeutic challenge and is associated with increased mortality. Surveillance
studies for the assessment of resistance rates and the detection of MDRTB are therefore crucial
in order to optimize empiric drug therapy and to prevent the dissemination of resistant strains
in a community [9]. The extent of the problem of MDR-TB has been examined by the WHO in
cross-sectional surveys of drug resistance in either clinical series or whole-country cohorts [10].
Cross-sectional surveys almost certainly underestimate the burden and number of cases of
MDR-TB because they do not take into account the numerical burden of TB in the high-burden
countries [11]. When the exercise is repeated with a mathematical modeling design using drug-
resistance estimates and the number of cases of TB, a more accurate picture of the global MDR-
TB burden is claimed [12].
3.1. Global project of drug resistance surveillance
The WHO and the IUATLD (International Union against Tuberculosis and Lung Disease) have
established a global project of drug resistance surveillance that is based on standard epide‐
miological methods and quality control through an extensive network of reference laborato‐
ries. The Global Project has served as a common platform for country, regional and global level
evaluation of the magnitude and trends in anti-tuberculosis drug resistance quantified the
growing global burden of MDR-TB and started to document the spread of XDR-TB. Since its
launch in 1994, the Global Project has collected and analyzed data on drug resistance from
surveys of sampled patients and from national surveillance systems from an ever increasing
number of settings around the world [7].
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The review of Cohn et al, 1997 represented a comprehensive description of worldwide drug
resistance surveys performed during the 1990s. According to the study, resistance to multiple
drugs varied by geographic region and was more common when resistance was acquired
rather than primary. The rate of multidrug resistance (and occasionally other drugs) was low
in most surveys of primary resistance, ranging from 0 to 10.8% (median rate, 0.5%); however,
for acquired resistance, the rate of multidrug resistance ranged from 0 to 48.0% (median rate,
12.2%). For surveys that did not distinguish between primary and acquired resistance, the
range was 0.5% to 14.3% (median rate, 2.3%). In terms of antituberculous drug resistance, they
found a great deal of variability between different countries, and within some countries,
differences between regions or cities [13].
The review of Caminero et al of 2010 [14], broadly discuss the epidemiological data of the
global report, issued in 2008. The report included drug susceptibility data from 90 726 patients
in 83 countries and territories from year 2002 to 2007. The median prevalence of resistance in
new cases of TB was 11.1% for any drug and 1.6% for MDR-TB. The prevalence of MDR-TB in
new TB cases ranged from 0% in eight countries to 22.3% in Baku, Azerbaijan, and 19.4% in
the Republic of Moldova. Of the 20 settings with the highest proportion of MDR-TB in new
cases, 14 were located in countries of the former Soviet Union (between 6.8% and 22.3% in nine
countries, including Moldovia and Azerbaijan) and four in China (7% in two provinces in
China) [15, 16], A trend analysis of the 2008 report shows that between 1994 and 2007 the
prevalence of MDR-TB in new cases (initial resistance) increased substantially in South Korea
and two Russian Oblasts, Tomsk and Orel. By contrast, the prevalence remained stable in
Estonia and Latvia, both of which have high rates of initial MDR-TB. The prevalence of MDR-
TB in all TB cases decreased in Hong Kong and the United States [14].
Of 37 countries and territories that reported representative data on XDR-TB, five countries, all
from the former Soviet Union, each reported 25 or more cases of XDR-TB, with MDR-TB
prevalence ranging from 6.6% to 23.7% [15, 16], data from Eastern Mediterranean countries
showed that the prevalence of initial MDR-TB was higher than previously estimated, with the
exception of Morocco and Lebanon, with rates of respectively 0.5% and 1.1%. Initial MDR-TB
rates in Jordan and Yemen were respectively 5.4% and 2.9%. The Americas, Central Europe
and Africa reported the lowest rates of initial MDR-TB, with the notable exceptions of Peru,
Rwanda and Guatemala, which reported rates of respectively 5.3%, 3.9% and 3.0%. [15, 16].
Data on previously treated cases from the WHO/ Union 2008 report were available for 66
countries and two regions of China [15]. Drug susceptibility testing (DST) results were
available for 12 977 patients. Resistance to at least one anti-tuberculosis drug ranged from 0%
in three European countries to 85.9% in Tashkent, Uzbekistan. The highest proportions of
MDR-TB were reported in Tashkent (60.0%) and Baku, Azerbaijan (55.8%). data from Gujarat
State, India, providing the first reliable descriptions of previously treated cases in India,
showed 17.2% MDR-TB in this group [15].
The 2008 WHO/Union report also included a global estimation of the MDR-TB problem [14].
Based on drug resistance data from 114 countries and two regions of China reporting to this
project, combined with nine other epidemiological factors, the proportion of MDR-TB among
new, previously treated and combined cases was estimated for countries with no survey
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information available. The estimated proportion of MDR-TB for all countries was then applied
to incident TB cases (also based on indirect estimates). It was calculated that 4 89 139 (95%
confidence limits [95%CL] 455 093–614 215) cases emerged in 2006, and that the global
proportion of MDR-TB among all cases was 4.8% (95%CL 4.6–6.0). India, China and the Russian
Federation were estimated to have the highest number of MDR-TB cases: India and China have
approximately 50% of the global burden and the Russian Federation a further 7%. Twenty
seven countries accounted for 86% of the world’s MDRTB burden [14].
Caminero et al, divided the world into four large regions according to the influence of the three
factors i.e., past and present management of TB and transmission of MDR-TB.
1. Countries with an epidemic: high prevalence and incidence of MDR-TB.
2. Countries with high MDR-TB prevalence but low or decreasing incidence.
3. Countries with low prevalence and incidence of MDR-TB and
4. Countries with low prevalence but an increasing incidence of MDR-TB.
The fourth edition of WHO Guidelines for surveillance of drug resistance in tuberculosis is an updat‐
ed version of earlier editions published in 1994, 1997 and 2003. These guidelines incorporate the
2007 WHO Interim recommendations for the surveillance of drug resistance in tuberculosis and the
conclusions of an Expert Committee Meeting on Anti-Tuberculosis Drug Resistance Surveys
held in Geneva in September 2008. In addition experience gained from 15 years of the Global
Project on Anti-Tuberculosis Drug Resistance Surveillance is also included [7].
Given below are some of the updates and clarifications in surveillance methodology that have
been incorporated into the 4th edition:
1. At a minimum, surveillance should evaluate susceptibility to the following drugs:
a. Isoniazid and rifampicin;
b. If resistance is detected to rifampicin, then susceptibility to the fluoroquinolones and
second- line injectable agents most often used in the setting have be tested. Testing for
susceptibility to the first-line drug ethambutol should also be considered.
2. Statistical and epidemiological methodology is a fundamental aspect of designing surveys
that sample patients, and appropriate technical assistance should be received in the early
stages of planning. In particular, for surveys that use cluster-based sampling methods,
results should be adjusted to correct for biases introduced by these sampling techniques.
Missing values should also be accounted for, e.g. using multiple imputation techniques
when possible.
3. MDR-TB management is a component of the Stop TB Strategy and WHO Member States
have committed themselves to achieve universal access to diagnosis and treatment by
2015. Therefore, all drug resistance surveillance activities should be linked to patient
treatment and care. Planning a comprehensive treatment programme for patients
identified during a survey as having drug-resistant TB should run in parallel to planning
the survey itself.
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3.2. MDR-TB and immigration
Gilad et al [9] assessed the incidence of TB in Southern Israel in the period between 1992
and 1997,  and studied the prevalence of  resistance to anti-TB drugs and its  distribution
among the various subpopulations inhabiting that region, with the intention of tailoring
the empirical anti-TB treatment guidelines to those subpopulations. This study described
the  unique epidemiology of  drug-resistant  TB in  Southern Israel,  a  region inhabited by
both native and immigrant populations. Significant differences in age, gender, and resist‐
ance rates were found among the four distinct  subpopulations inhabiting the Negev re‐
gion.  They  attributed  the  observed  differences  to  immigration  from  countries  of  high
prevalence  of  drug-resistant  TB.  According  to  an  earlier  10-year  survey  (1978-  1987)  of
TB in the Negev,  Ethiopian immigrants and Bedouin Arabs comprised 76% of  TB cases
and 33% of them were extrapulmonary TB [17]. However the study of Gilad et al [9], re‐
corded only 20% of  isolates as  extrapulmonary,  and Ethiopian immigrants and Bedouin
Arabs comprised only 40% of the cases. These differences demonstrate how dynamic this
disease might be,  tremendously influenced by immigration, and demonstrate the impor‐
tance of continued surveillance in such a setup [9].
A worldwide survey of drug resistance rates by the WHO [18] demonstrated high rates
of resistance among isolates in the former Soviet  Union,  with the highest  rates detected
in Latvia. The Resistance rates observed rom the study for the immigrants from the for‐
mer  Soviet  Union  (IFSU)  were  much  higher  than  those  encountered  in  the  Russian  re‐
public  for  every  drug  or  drug  combination  [9].  These  rates  were  very  similar  to  those
found in Latvia, and were even higher overall (50% and 41.5%, respectively). In this cur‐
rent  era,  import  of  infectious  diseases  across  international  borders  occurs  much readily
[9].  The studies done in Germany and Canada also had reported an increased incidence
of multidrug resistance due to the immigration [19-21].
These studies have shown the impact of immigration on the incidence and distribution of drug-
resistant TB in a particular country and the importance of continuous surveillance and
immediate therapeutic decisions to prevent the dissemination of such resistant strains to their
general populations [9].
3.3. HIV and MDR-TB
The epidemiological impact of HIV on the epidemic of drug-resistant TB is not known and
may depend on several factors. HIV-positive TB cases are more likely to be smear negative. In
addition, delayed diagnosis of drug resistance and unavailability of treatment (particularly in
previous years) have led to high death rates in people living with HIV. Both of these factors
(smear negativity and short duration of disease due to mortality) may suggest a lower rate of
general transmission. However, HIV-positive cases progress more rapidly to disease and in
settings where MDR-TB is prevalent (either in the general population or in the local population
such as a hospital or a district), this may lead to rapid development of a pool of drug-resistant
TB patients or an outbreak [7].
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According to Cohn et al, 1997 [13], though the association of MDR-TB with AIDS has been well
documented during outbreaks [22-24], the role of HIV infection as a risk factor for the devel‐
opment of drug-resistant TB in other settings was not clear [25]. In Kenya, Malawi, Tanzania,
COte d'Ivoire, and France, drug resistance was not associated with HIV infection [26-30]. In
contrast, in a survey of eight metropolitan areas of the United States, HIV infection was
associated with resistance to antituberculous drugs, both within and outside the New York
City area [31]. The acquired MDR-TB also occurs in largely immunocompetent hosts, which
was seen in India, Korea, Nepal, and Bolivia [32-35].
The  studies  by  Borrell  and  Gagneux  [36]  pointed  out  that,  from  a  scientific  point  of
view, the actual evidence for primary transmission of MDR -TB in HIV-negative individ‐
uals that has been confirmed by molecular methods is very limited, and that more stud‐
ies including molecular data are needed to know the true extent of primary MDR-TB &
XDR –TB in a general population.
3.4. Inadequate treatment and development of MDR and XDR-TB
Multidrug-resistant  tuberculosis  (MDR-TB)  is  a  major  challenge  for  TB  control  world‐
wide.  Inadequate treatment  of  MDR-TB inevitably results  in high mortality  and the de‐
velopment  of  XDR-TB  [37].  The  study  of  Jeon  et  al,  2011  [38],  shows  how  inadequate
treatment has contributed to the high prevalence of MDR and XDR-TB in Korea. Accord‐
ing to  Jeon et  al,  the three TB referral  hospitals  in  the public  sector  are  responsible  for
the management of MDR-TB in the public sector of Korea. This study showed poor out‐
come for  patients  with  MDR-TB at  the  3  TB  hospitals  in  Korea:  low treatment  success
rate (37.1%),  high default  rate (37.1%),  and high all-cause mortality rate (31.2 %) during
the  3-4  yr  after  treatment  initiation.  Since  the  National  Tuberculosis  Program (NTP)  of
Korea has focused on new cases, there have been limited nationwide data about the inci‐
dence and prevalence of MDR-TB and its treatment outcomes. Treatment success rate of
their study was the lowest ever reported among MDR-TB cohorts in Korea [38].
4. Molecular epidemiology of MDR-TB
4.1. Molecular epidemiology
Many different definitions of molecular epidemiology have been published and all mention
the use of molecular tools, but not all explicitly mention epidemiology. Molecular epidemiol‐
ogy is not just molecular taxonomy, phylogeny, or population genetics but the application of
these techniques to epidemiologic problems [39]. Epidemiology attempts to identify factors
that determine disease distribution in time and place, as well as factors that determine disease
transmission, manifestation, and progression. Further, epidemiology is always motivated by
an opportunity or possibility for intervention and prevention [39]. What distinguishes
molecular epidemiology is both the “molecular,” the use of the techniques of molecular biology
to characterize nucleic acid- or amino acid-based content, and the “epidemiology,” the study
of the distribution and determinants of disease occurrence in human populations [39].
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Molecular epidemiology makes use of the genetic diversity within strains of infectious
organisms to track the transmission of these organisms in human populations and to evaluate
the host and parasite -specific risk factors for disease spread.
Therefore molecular epidemiologic techniques can be incorporated into almost any epide‐
miologic assessment to improve exposure and outcome measures
4.2. Molecular epidemiology of TB
The molecular epidemiologic approach to studying tuberculosis epidemiology has identified
several new observations that could not have been obtained by conventional epidemiologic
or laboratory approaches [39]. Mycobacterial strain typing by means of molecular methods
has become an important instrument for tuberculosis surveillance, control and prevention [40].
Among DNA fingerprinting methods which restriction fragment length polymorphism
(RFLP) typing is the most common method used has permitted novel investigations of the
epidemiology and pathogenesis of tuberculosis. The use of IS6110, an insertion sequence which
is present in Mycobacterium tuberculosis, is generally considered to be the gold standard for
tuberculosis molecular epidemiology studies [41], but other molecular typing techniques could
be used as adjuncts in selected circumstances [42].
Spoligotyping is a technique based on the polymorphism of the direct repeat (DR) locus present
in M. tuberculosis DNA. The DR sequences are composed of multiple 36bp copies, interspersed
by short non repetitive sequences [43]. The direct-repeat locus in M. tuberculosis contains 10 to
50 copies of a 36-bp direct repeat, which are separated from one another by spacers that have
different sequences. However, the spacer sequences between any two specific direct repeats
are conserved among strains. Because strains differ in terms of the presence or absence of
specific spacers, the pattern of spacers in a strain can be used for genotyping (spacer oligonu‐
cleotide typing, or "spoligotyping"). Spoligotyping has two advantages over IS6110-based
genotyping. As small amounts of DNA are required, it can be performed on clinical samples
or on strains of M. tuberculosis shortly after their inoculation into liquid culture. In addition
the results of spoligotyping, which are expressed as positive or negative for each spacer, can
be expressed in a digital format. However, spoligotyping has less power to discriminate among
M. tuberculosis strains than does IS6110-based genotyping.
Mycobacterial interspersed repeat units (MIRU) genotyping categorizes the number and size
of the repeats in each of 12 independent MIRUs, with the use of a polymerase-chain-reaction
(PCR) assay, followed by gel electrophoresis to categorize the number and size of repeats in
12 independent loci, each of which has a unique repeated sequence. Two to eight alleles are at
each of the 12 loci, yielding approximately 20 million possible combinations of alleles. The
discriminatory power of MIRU genotyping is almost as great as that of IS6110-based geno‐
typing. Unlike IS6110-based genotyping, MIRU analysis can be automated and can thus be
used to evaluate large numbers of strains, yielding intrinsically digital results that can be easily
catalogued on a computer data base.
The PGRS, the DR and the GTG repeated sequences have mainly been used for sub typ‐
ing strains for which differentiation by IS6110  finger printing appeared insufficient. This
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wide.  Inadequate treatment  of  MDR-TB inevitably results  in high mortality  and the de‐
velopment  of  XDR-TB  [37].  The  study  of  Jeon  et  al,  2011  [38],  shows  how  inadequate
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dence and prevalence of MDR-TB and its treatment outcomes. Treatment success rate of
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4. Molecular epidemiology of MDR-TB
4.1. Molecular epidemiology
Many different definitions of molecular epidemiology have been published and all mention
the use of molecular tools, but not all explicitly mention epidemiology. Molecular epidemiol‐
ogy is not just molecular taxonomy, phylogeny, or population genetics but the application of
these techniques to epidemiologic problems [39]. Epidemiology attempts to identify factors
that determine disease distribution in time and place, as well as factors that determine disease
transmission, manifestation, and progression. Further, epidemiology is always motivated by
an opportunity or possibility for intervention and prevention [39]. What distinguishes
molecular epidemiology is both the “molecular,” the use of the techniques of molecular biology
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Molecular epidemiology makes use of the genetic diversity within strains of infectious
organisms to track the transmission of these organisms in human populations and to evaluate
the host and parasite -specific risk factors for disease spread.
Therefore molecular epidemiologic techniques can be incorporated into almost any epide‐
miologic assessment to improve exposure and outcome measures
4.2. Molecular epidemiology of TB
The molecular epidemiologic approach to studying tuberculosis epidemiology has identified
several new observations that could not have been obtained by conventional epidemiologic
or laboratory approaches [39]. Mycobacterial strain typing by means of molecular methods
has become an important instrument for tuberculosis surveillance, control and prevention [40].
Among DNA fingerprinting methods which restriction fragment length polymorphism
(RFLP) typing is the most common method used has permitted novel investigations of the
epidemiology and pathogenesis of tuberculosis. The use of IS6110, an insertion sequence which
is present in Mycobacterium tuberculosis, is generally considered to be the gold standard for
tuberculosis molecular epidemiology studies [41], but other molecular typing techniques could
be used as adjuncts in selected circumstances [42].
Spoligotyping is a technique based on the polymorphism of the direct repeat (DR) locus present
in M. tuberculosis DNA. The DR sequences are composed of multiple 36bp copies, interspersed
by short non repetitive sequences [43]. The direct-repeat locus in M. tuberculosis contains 10 to
50 copies of a 36-bp direct repeat, which are separated from one another by spacers that have
different sequences. However, the spacer sequences between any two specific direct repeats
are conserved among strains. Because strains differ in terms of the presence or absence of
specific spacers, the pattern of spacers in a strain can be used for genotyping (spacer oligonu‐
cleotide typing, or "spoligotyping"). Spoligotyping has two advantages over IS6110-based
genotyping. As small amounts of DNA are required, it can be performed on clinical samples
or on strains of M. tuberculosis shortly after their inoculation into liquid culture. In addition
the results of spoligotyping, which are expressed as positive or negative for each spacer, can
be expressed in a digital format. However, spoligotyping has less power to discriminate among
M. tuberculosis strains than does IS6110-based genotyping.
Mycobacterial interspersed repeat units (MIRU) genotyping categorizes the number and size
of the repeats in each of 12 independent MIRUs, with the use of a polymerase-chain-reaction
(PCR) assay, followed by gel electrophoresis to categorize the number and size of repeats in
12 independent loci, each of which has a unique repeated sequence. Two to eight alleles are at
each of the 12 loci, yielding approximately 20 million possible combinations of alleles. The
discriminatory power of MIRU genotyping is almost as great as that of IS6110-based geno‐
typing. Unlike IS6110-based genotyping, MIRU analysis can be automated and can thus be
used to evaluate large numbers of strains, yielding intrinsically digital results that can be easily
catalogued on a computer data base.
The PGRS, the DR and the GTG repeated sequences have mainly been used for sub typ‐
ing strains for which differentiation by IS6110  finger printing appeared insufficient. This
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is  useful  when M. tuberculosis  strains contain no or lesser than six copies of  IS6110.  Ac‐
cording to  a  recorded study in  Sri  Lanka,  68% of  the  isolates  had less  than five  copies
which were similar to that of other countries in the Asian region, such as India, Malay‐
sia, Oman and Hong Kong [44].
The study by Ghebremichael et al [45] determined the transmission pattern of TB strains in
Sweden. By MIRU-VNTR 31 (45%) of the 69 patients with Beijing strains were found in
altogether 7 clusters (2–11 per cluster), yielding 45 different patterns. Thus the MIRU-VNTR
typing, with fewer and larger clusters, was less discriminatory than IS6110 RFLP. The two
strains where a possible epidemiological linkage was established differed in one allele and
thus did not cluster in MIRU-VNTR. All strains that clustered by MIRU-VNTR were identical
also by RD deletions, mutT gene polymorphism and Rv3135 gene analysis, but not by
spoligotyping and IS1547. Four of the IS6110 RFLP clusters contained isolates that differed by
MIRU-VNTR. The combination of MIRUVNTR with RFLP resulted in the disappearance of
two clusters, and a reduction of the number of isolates in two clusters, compared to the
clustering observed with IS6110 RFLP clustering alone. In this study they found that patients
with DR Beijing strains have been diagnosed for more than a decade in Sweden. The majority
of the patients were foreign born, and their country of origin reflects areas where the Beijing
genotype is prevalent [45].
4.3. Molecular epidemiology of MDR-TB
A study by Calver et al [46], investigated an outbreak of tuberculosis using a molecular
epidemiologic approach and clinical and epidemiologic data to identify inadequacies in the
implemented DOTS-plus strategy that lead to the emergence of pre–XDR TB and XDR TB in
South Africa. They genotyped the drug-resistant M. tuberculosis isolates using molecular
techniques including insertion sequence (IS) 6110 RFLP, spoligotyping and MIRU typing (12-
loci format). Genotyping results indicated an on-going transmission of drug-resistant TB, and
contact tracing among case-patients in the largest cluster demonstrated multiple possible
points of contact. Phylogenetic analysis demonstrated stepwise evolution of drug resistance,
despite stringent treatment adherence. These findings suggested that existing TB control
measures in South Africa were inadequate to control the spread of drug-resistant TB in their
HIV co-infected population. Diagnosis delay and inappropriate therapy facilitated disease
transmission and drug resistance.
Hsu et al, 2010 [47], investigated the transmission and predominant genotypes of MDR- TB in
Eastern Taiwan using both spoligotyping and MIRU-VNTR. Of the tested MDR isolates of 73
(94%) Spoligotyping, identified the Beijing strain as the predominant genotype (n = 48, 66%),
followed by Haarlem H3 (n = 15, 21%), T1 (n = 3, 4%) and East-African Indian 2 MANILLA (n
= 1, 1%). Six (8%) isolates did not match any spoligotype in the SpolDB4 database. Using MIRU-
VNTR typing, they observed a unique pattern in 27 isolates, and 46 had clustered pattern
strains (10 clusters). According to them by MIRU-VNTR they observed an isolate in cluster 9,
however from spoligotyping, it had a unique pattern and therefore they did not considered it
as a clustered pattern strain. By considering both spoliotyping and MIRU-VNTR into account,
28 (38.4%) isolates were judged to have a unique pattern and 45 (61.6%) were clustered pattern
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strains (classifying into 10 clusters). Assuming that there was one source case in each cluster
and the rest in the cluster were due to transmission, Hsu et al, concluded that 47.9% ([45 − 10]/
73) of the patients had MDR-TB due to recent transmission [47].
To better understand the epidemiology of MDRTB, the New York City Tuberculosis Control
Program began DNA genotyping of MDRTB strains from new cases in 1995 [48]. The objectives
of the study were to provide descriptive molecular epidemiology of MDRTB cases in the city
during 1995–1997 and to identify predominant MDR strains present during the three years, as
well as the extent and risk factors for clustering among the tested cases. Genotyping results
were available for 234 patients; 153 (65.4%) were clustered, 126 (82.3%) of them in eight clusters
of >4 patients. Epidemiologic links were identified for 30 (12.8%) patients; most had been
exposed to patients diagnosed before the study period. From the analysis, the largest cluster
observed was from the “W” strain (59 patients) representing almost 25% of the 241 MDRTB
patients during the 3 years. This strain caused a well-documented multi-institutional outbreak
in New York City from 1990 through 1993 [49-53]. Strain “W1”, which was isolated in seven
patients, is a variant of the W strain. It had an additional IS6110 copy and was a part of the W
strain outbreak [52, 53]. Forty percent (12 of 30) of the epidemiologic links in this cohort were
to patients with these two strains. According to Munsiff et al [48] these strains were likely
transmitted in the early 1990s when MDRTB outbreaks and tuberculosis transmission were
widespread in New York.
To analyze the molecular epidemiology of M. tuberculosis strains at a hospital in Buenos Aires,
Argentina, and mutations related to MDR and XDR-TB, Gonzalo et al [54], conducted a
prospective case –control study. Spoligotyping identified predominance of the Haarlem family
among the MDR TB cases (family responsible for the 1990s [55] outbreak) as well as the LAM
and T families. A similar strain family distribution was reported for the French Departments
of the Americas [56] and Turkey [57]. The Beijing family was seldom encountered in these
areas, which is in line with recent observations in 7 countries in South America, including
Argentina [58]. According to them [54] the MDR TB Haarlem2 strain appears to be more
successful than other circulating MDR- TB strains and also than its susceptible counterpart (of
25 Haarlem2 strains, 20 were MDR TB).
By genotyping all isolates and combining with the mutational results, Perdigão et al [59] were
able to assess the isolates' genetic relatedness and determine possible transmission events.
According to their study strains belonging to family Lisboa, characterized several years ago,
were responsible for the majority of the MDR-TB. Even more alarming was the high prevalence
of extensive drug-resistant tuberculosis (XDR-TB) among the MDR-TB isolates, which was
found to be 53%.
4.4. Transmission of MDR-TB and XDR-TB
Mathematical models predict that the future of the multidrug-resistant (MDR) and extensively
drug-resistant (XDR) tuberculosis (TB) epidemic will depend to a large extent on the trans‐
mission efficiency or relative fitness of drug-resistant Mycobacterium tuberculosis compared to
drug-susceptible strains. Molecular epidemiological studies comparing the spread of drug-
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during 1995–1997 and to identify predominant MDR strains present during the three years, as
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were available for 234 patients; 153 (65.4%) were clustered, 126 (82.3%) of them in eight clusters
of >4 patients. Epidemiologic links were identified for 30 (12.8%) patients; most had been
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observed was from the “W” strain (59 patients) representing almost 25% of the 241 MDRTB
patients during the 3 years. This strain caused a well-documented multi-institutional outbreak
in New York City from 1990 through 1993 [49-53]. Strain “W1”, which was isolated in seven
patients, is a variant of the W strain. It had an additional IS6110 copy and was a part of the W
strain outbreak [52, 53]. Forty percent (12 of 30) of the epidemiologic links in this cohort were
to patients with these two strains. According to Munsiff et al [48] these strains were likely
transmitted in the early 1990s when MDRTB outbreaks and tuberculosis transmission were
widespread in New York.
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among the MDR TB cases (family responsible for the 1990s [55] outbreak) as well as the LAM
and T families. A similar strain family distribution was reported for the French Departments
of the Americas [56] and Turkey [57]. The Beijing family was seldom encountered in these
areas, which is in line with recent observations in 7 countries in South America, including
Argentina [58]. According to them [54] the MDR TB Haarlem2 strain appears to be more
successful than other circulating MDR- TB strains and also than its susceptible counterpart (of
25 Haarlem2 strains, 20 were MDR TB).
By genotyping all isolates and combining with the mutational results, Perdigão et al [59] were
able to assess the isolates' genetic relatedness and determine possible transmission events.
According to their study strains belonging to family Lisboa, characterized several years ago,
were responsible for the majority of the MDR-TB. Even more alarming was the high prevalence
of extensive drug-resistant tuberculosis (XDR-TB) among the MDR-TB isolates, which was
found to be 53%.
4.4. Transmission of MDR-TB and XDR-TB
Mathematical models predict that the future of the multidrug-resistant (MDR) and extensively
drug-resistant (XDR) tuberculosis (TB) epidemic will depend to a large extent on the trans‐
mission efficiency or relative fitness of drug-resistant Mycobacterium tuberculosis compared to
drug-susceptible strains. Molecular epidemiological studies comparing the spread of drug-
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resistant to that of drug-susceptible strains have yielded conflicting results: MDR strains can
be up to 10 times more or 10 times less transmissible than pan-susceptible strains [36].
Experimental work performed with model organisms has highlighted a level of complexity in
the biology of bacterial drug resistance that is generally not considered during standard
epidemiological studies of TB transmission. However, much more work is needed to under‐
stand the detailed molecular mechanisms and evolutionary forces that drive drug resistance
in this pathogen. Such increased knowledge will allow for better epidemiological predictions
and assist in the development of new tools and strategies to fight drug resistant TB [36].
In infectious disease epidemiology, the relevant measure that reflects the reproductive fitness
of a pathogen is the number of secondary cases generated; this measure is also known as the
basic reproductive rate, R0 [60]. In addition to the absolute number of secondary cases (i.e.,
absolute fitness), an often more useful measure is that of ‘relative fitness’, where the success
of a particular pathogen variant is compared to the success of another. For example, the fitness
of a drug-resistant bacterial strain can be expressed relative to the fitness of a drug-susceptible
strain. In addition to epidemiological measures of relative fitness, differences in relative fitness
can be measured experimentally [36].
The results of experimental studies performed with strains resistant to INH, SM or RMP
suggested that, in clinical settings, there was a strong selection pressure for drug resistance-
conferring mutations that cause minimal fitness defects [61]. Although these findings support
the notion that virulence and competitive fitness assays can be predictive of the epidemiology
of drug-resistant TB, they do not capture the overall complexity of the life cycle of M. tuber‐
culosis [36]. Although several mechanisms of compensatory evolution have been described in
other bacteria [62] little work has been done on this topic in M. tuberculosis.
Various molecular tools have been developed to genotype M. tuberculosis strains [63]. These
tools have been applied to molecular epidemiological investigation of TB transmission for
many years. According to the standard concept, patient isolates sharing a particular genotype
or DNA ‘fingerprint’ can be considered epidemiologically linked and represent cases of active
TB transmission (i.e., they are clustered TB cases), whereas strains with distinct or ‘unique’
DNA patterns are thought to reflect reactivation of latent infections. They compared molecular
epidemiological fitness estimates from two previous reviews and more recent studies [60, 64].
Overall, the relative fitness estimates for MDR-TB vary dramatically, ranging from an almost
10-fold increased fitness compared to fully drug-susceptible strains found in a study from
Russia [65] to about 10-fold lower fitness in Mexico [66] other studies have reported that MDR
strains do not cause any secondary cases at all [67]. The reasons for this high variability in
relative fitness of MDR strains have likely to do with the differences in study design and
setting, differences in sample size and different methodologies and also to the variation in the
quality of the TB control programmes [36]. According to Borrell and Gagneux, in addition to
methodological, socio-economic and environmental factors, the variation in MDR fitness also
reflects biological heterogeneity. Current epidemiological evidence for transmission of MDR-
and XDR-TB, particularly compared to pan-susceptible TB, is very inconclusive. This can be
partially explained by the fact that M. tuberculosis is more genetically diverse than is often
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appreciated [68] and because drug-resistant strains can exhibit heterogeneous fitness com‐
pared to drug-susceptible strains [36].
5. Conclusion
An understanding of the epidemiology of multidrug resistant tuberculosis (MDR-TB) and the
extensively drug-resistant tuberculosis (XDR-TB) is critical for effective control of the global
burden of tuberculosis (TB). For a comprehensive study on epidemiology of multidrug
resistant tuberculosis (MDR-TB), please refer the reviews in the reference list.
6. Future studies
Future Studies on Epidemiology
In all epidemiological studies it is essential to have a clear definition of a case of the disease
being investigated by delineating the symptoms, signs or other characteristics indicating that
a person has the disease. A clear definition of an exposed person is also necessary. This
definition must include all the characteristics that identify a person as being exposed to the
factor in question. In the absence of clear definitions of disease and exposure, it is very difficult
to interpret the data from an epidemiological study.
Future Studies on Transmission of TB
Future epidemiological studies on the transmission of drug-resistant TB should incorporate
more comprehensive strain data, including specific drug resistance-conferring mutations and
information on the strain genetic background. These variables, as well as their interaction,
could play an important role in the transmission success of particular drug-resistant variants.
Future Studies on HIV/TB
The investigators who conduct the studies on HIV/ TB need to consider other possible risk
factors for drug resistance such as demographics; prior therapy, socioeconomic status, and
quality of TB control programs, etc.
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1. Introduction
Although major progress has been made to reduce global incidence of drug-susceptible
tuberculosis (TB), the emergence of multidrug-resistant (MDR) and extensively drug-resistant
(XDR) TB over the past decade presents an unprecedented public health challenge to which
countries of concern are responding far too slowly. Indeed, a recent WHO TB surveillance
report indicates the highest global level of drug-resistance ever recorded, which affected
disproportionately developing countries with an estimated 440,000 MDR-TB cases worldwide
resulting in 150,000 deaths in 2009 [1]. Even more troubling is being the recent emergence of
new strains of totally drug-resistant M. tuberculosis (Mtb), currently occurring in densely
populated cities such as Teheran (Iran) [2] and Mumbai (India) [3]. Given that an untreated
TB patient can infect up to 15 contacts in a year in overcrowded areas [4], it is highly likely that
totally drug-resistant TB will continues spreading and one would worry that TB will again
become an incurable disease.
While part of the increase in drug resistance can be attributed to difficulty in treating patients
who are double infected with HIV, which represent about 13% of total TB cases [5], detailed
field studies revealed that the emergence drug-resistant TB is clearly a direct consequence of
misdiagnosis and mismanagement of drug susceptible TB, which result in only a fraction of
TB patients getting correct diagnosis and appropriate therapy ([6,7] and Fig.1). In other words,
“Resistance is man-made, caused by exposure to the wrong treatment, the wrong regimen, the
wrong treatment duration” says TB expert Giovanni Miglio [8]. Therefore, a comprehensive
approach to ensure rapid detection, proper treatment and public health measures needs to be
applied globally to cure TB patients and prevent further transmission of the disease. This
chapter discusses various challenges facing the management of drug resistant TB and presents
the efforts of WHO and its partners for the development of strategies and guidelines for
optimal TB control.
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Figure 1. Misdiagnosis and mismanagement can result in only fraction of TB patients getting correct diagnosis, appro‐
priate therapy, and positive outcomes. Reprinted from Ref. 9 with permission from Dr. Madhukar Pai.
2. Standard treatment for drug-susceptible TB
Symptoms associated with active TB are generally defined as loss of weight and energy, poor
appetite, fever, a productive cough, and night sweats. Although highly suggestive of TB, such
symptoms might easily be assigned to another disease. Therefore accurate diagnosis is
important before initiating drug therapy. The current standard laboratory test consists on the
analysis of 3 sputum specimens for acid-fast bacilli smears and culture, with nucleic acid
amplification performed on at least 1 specimen [10].
In 1994, the WHO introduced the DOTS (Directly Observed Treatment, Short-course) as a
major plan to control TB globally [11]. The DOTS strategy focuses on five main points of action:
1) government commitment to control TB, 2) diagnosis based on sputum-smear microscopy
tests done on patients with TB symptoms, 3) direct observation short-course chemotherapy
treatments, 4) a continuous supply of drugs, and 5) standardized reporting and recording of
cases and treatment outcomes [11]. The standard short course (SSC) treatment recommended
by WHO [12] consists of 2 months of intensive phase of daily oral administration of isoniazid
(INH), rifampicin (RMP), pyrazinamide (PZA) and ethambutol (EMB) followed by 4 months
continuous phase of daily INH and RMP alone.
INH is only active against growing tubercle bacilli [13]. RMP is active against both growing
and stationary phase bacilli with low metabolic activity and is associated with high sterilizing
activity in vivo [14]. PZA plays a unique role in shortening TB treatment from the previous 12
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months to 6 months because it kills the persistent Mtb population in the lung [15]. EMB is
active against growing Mtb but has no effect on dormant bacilli. The combination of drugs
acting at different stages of the Mtb life cycle during SSC therapy has been successful in TB
treatment in most endemic countries when patients adhere to a fairly strict daily regimen. SSC
therapy causes minor or no side effects and is affordable, costing less than $40 for a full course
of treatment. Side effects, if they occur, are manageable and usually do not result in the
interruption of the treatment.
Aproximately 90% of people infected with Mtb develop an efficient immune response that
successfully contains the infection but unfortunately without killing all the bacteria. Surviving
bacteria persist in the lung as non-replicative (i.e. dormant) organisms [16]. In this stage of
latent TB infection (LTBI), people do not exhibit TB symptoms and cannot pass the infection
on to other individuals. However, in weakened immune system conditions (old age, HIV
infection or therapeutic immunosupression), dormant bacteria revert into dividing organisms
leading to TB reactivation [16].
LTBI is highly suspected in individuals previously exposed to those with known active TB,
which would include people in hospitals, homeless shelters and prisons, or people having
recently traveled to countries where TB is highly endemic. The stage of clinical latency is of
surpassing importance for TB control as most cases of active TB arise from the vast reservoir
of the latently infected population [17]. In fact, it estimated that the infection reactivates and
cause active TB in approximately 5 to 10% of latently infected persons [18].
Purified protein derivative (PPD) skin test (also known as the Mantoux test) is the major
diagnostic tool used to identify LTBI patients. A positive skin reaction to the PPD test reflects
a local cellular immune response, which is interpreted as recent or remote exposure to the TB
bacterium. However, despite its usefulness and simplicity, the PPD test have a low predictive
value since false-positive reactions can occur as a result of previous BCG vaccination or
sensitization to environmental mycobacteria [19,20,21]. In fact, the skin test uses a crude mix
of Mtb antigens shared among many mycobacterial species. As a replacement for the PPD test,
new interferon-gamma release assays (IGRAs) have been recently developed and shown to be
more accurate for LTB diagnosis [22]. IGRAs measure ex-vivo production of IFN-gamma by
circulating T cells in whole blood in response to more specific Mtb antigens such as ESAT6,
CFP10 and TB7.7.
Although LTBI is symptom-free and non contagious, many countries have adopted its
treatment in order to reduce the risk of infection progression to active TB and the spread of
the disease to the general population. Six to 9 month treatment with INH alone was proven to
be effective and safe [10]. Unfortunately, if LTBI results from exposure to a person with MDR-
or TB XDR-TB, preventive treatment options are very limited or may not be possible. In both
active and latent TB cases, it is crucial that health care providers make every effort to ensure
that infected persons complete the entire course of treatment. They must explain clearly the
benefit of the treatment and also possible side effects (or drug interactions). Additionally, They
should identify potential barriers to the course of treatment, which will help to establish an
efficient plan to ensure adherence.
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Purified protein derivative (PPD) skin test (also known as the Mantoux test) is the major
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more accurate for LTB diagnosis [22]. IGRAs measure ex-vivo production of IFN-gamma by
circulating T cells in whole blood in response to more specific Mtb antigens such as ESAT6,
CFP10 and TB7.7.
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Understanding the mechanisms of TB latency is crucial to development of better control
strategies. Infection with Mtb occurs initially in alveolar macrophage, in which the bacteria
replicate and induce cytokines that initiate the inflammatory response in the lungs, leading
ultimately to the formation of granuloma [23]. Granuloma is defined as an immune structure
consisting of connective tissue, lymphocytes and activated macrophages, which has a central
necrotic core containing extracellular bacteria. Within the granuloma the bacterium is exposed
to multiple stresses that include, among others, hypoxic, nutrient limiting, oxidative, nitrosa‐
tive and acidic conditions [24,25], which trigger a genetic program controlled by the transcrip‐
tion factor DosR [25]. The later regulates the development of a quiescent physiological state,
which maintains viability of non-dividing bacteria for extended periods of time. The granu‐
loma contains the infection and prevents its spread to other organs [26]. However, dormant
bacteria are capable of reactivation controlled by Rpf (resuscitation promoting factor) genes,
which is associated with reversal of the non-replicating state into a metabolically active
growing and dividing bacteria [27]. Thus, life-long immunity is not gained by a first episode
of active TB disease and the disease may develop again at a later stage, either through relapse
with the same strain or reinfection with a new strain.
Deciphering the molecular basis of dormancy and reactivation is therefore necessary for
developing more efficient TB therapies. Adjuncts of agents that would block transitions
between active growth, dormancy, and resuscitation or kill effectively dormant bacteria can
significantly enhance the efficacy of current treatments for latent infection. Such agents would
also shorten the treatment duration of active TB.
3. Molecular basis of Mtb resistance to SSC drugs
The frequency of spontaneous mutations that confer resistance to an individual TB drugs in
vitro are well known and vary from 1 in 105 (EMB) to 1 in 1010 (RMP) [28].
Resistance to INH: INH is a drug precursor that is activated by Mtb catalase-peroxidase enzyme
(KatG) to generate a range of highly reactive species [29]. Active INH targets essentially enoyl-
acyl carrier protein reductase (InhA enzyme), which is involved in mycolic acid synthesis [29].
Resistance to INH occurs more frequently than for most anti-TB drugs, at a frequency of 1 in
106 bacilli in vitro [13]. Clinical isolates of INH-resistant Mtb often lose catalase and peroxidase
activities due to KatG S315T mutation [30]. Resistance to INH can also occur through mutations
in the promoter region of inhA, causing overexpression of InhA, or by mutations at the InhA
active site, lowering InhA affinity for INH [31]. katG mutation can be associated with inhA
mutations, leading to higher levels of INH resistance [32].
Resistance to RMP: RMP interferes with RNA synthesis by binding to the β subunit of myco‐
bacterial RNA polymerase, which is encoded by rpoB. Mtb resistance to RMP occurs at a
frequency of 10−7 to 10−8 as a result of mutations in rpoB. Mutations at positions 531, 526 and
516 in rpoB are among the most frequent (96%) in RMP-resistant strains [33].
Resistance to PZA: PZA requires conversion to its active form, pyrazinoic acid (POA), by the
pyrazinamidase/nicotinamidase enzyme encoded by Mtb pncA, which then permeates
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through the membrane, disrupts bacterial membrane potential and affects membrane trans‐
port [34]. PZA resistance is linked to defective pyrazinamidase/nicotinamidase activity, which
results from mutations that might occur at different regions (3-17, 61-85 and 132-142) of pncA
[34]. While most PZA-resistant strains (72–97%) have pncA mutations, some do not have pncA
mutations but rather express defective pyrazinamidase/nicotinamidase activity [13], which
suggests possible mutations in a putative pncA regulatory gene, yet to be identified.
Resistance to EMB: Arabinosyl transferase, encoded by embB, an enzyme involved in the
synthesis of cell wall arabinogalactan, has been proposed as the target of EMB in Mtb [35].
Mutation to EMB resistance occurs at a frequency of 10−5 [13]. The embB codon 306 mutation
account for only 68% EMB resistant strains [36], suggesting that there may be other mecha‐
nisms of EMB resistance. Therefore, further studies are needed to identify potential new
mechanisms of EMB resistance.
Because the mutations described above are unlinked, the probability of developing bacillary
resistance to 4 drugs used simultaneously is unlikely. Clinical drug-resistant TB is definitely
the result of genetic mutation amplification through mismanagement of the TB disease. This
includes intermittent therapy due to irregular drug supply, inappropriate drug prescriptions
and most importantly poor patient adherence to treatment [37]. Sequential accumulation of
mutations in different genes involved in individual drug resistance results in the emergence
of multiple drug resistance.
4. Diagnosis of multidrug resistant tuberculosis
Conventional culturing of the etiologic agent combined with drug susceptibility testing (DST)
is the ‘gold standard’ for diagnosing drug resistant TB in order to initiate adequate treatment.
However, this approach is rarely used because it requires 3 to 4 months to produce results.
Indeed, only 7% of all MDR-TB cases are detected globally [1]. Hence, the deficiency in tools
for rapid DST is associated with inadequate treatment regimens, which tragically increase
transmission and spread of drug resistant TB, especially in HIV-infected individuals [38]. This
alarming situation stimulated the development of a great number of rapid culture- and
molecular-based methods that are currently being evaluated in TB diagnosis laboratories. The
Nitrate Reductase Assay (NRA) is based on detection of nitrate reduction into nitrite by Mtb
organisms capable of growth in the presence of the test antibiotic [39]. Whereas the Microscopic
Observation of Drug Susceptibility (MODS) uses inverted microscope to detect the formation
of cord-like structure by Mtb isolates resistant to the test drug [40]. The commercial Mycobac‐
terium Growth Indicator Tube 960 (MGIT 960) is a drug-containing culture system based on
the fluorescence detection of resistant bacteria [41]. The Genotype MTBDRplus is a molecular
line-probe assay that detects simultaneously mutations in the rpoB gene that confers resistance
to RMP as well as mutations in the katG gene and the inhA promoter, which are associated
with resistance to INH [42]. The Alamar blue and resazurin assays are liquid-based colori‐
metric tests [43]; a color change in wells containing drug-exposed bacteria reflects resistance.
The MTT assay relays on the ability of drug-resistant (viable) bacteria to cleave the tetrazolium
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rings of MTT, which produces a violet-purple color [44]. Many of these assays gave excellent
detection of MDR-TB, within a significantly shorter time frame when compared to conven‐
tional culturing methods (Table 1).
The effective implementation of these rapid diagnostic tests for TB and drug resistance will
increase the proportion of patients promptly placed on appropriate therapy, and therefore will
improve substantially management and control of TB disease globally. However a major
limitation to the use of these rapid tests is their affordability and the availability of equipped
laboratories in resource-constrained countries, which unfortunately tend to have the highest
burden of MDR-TB cases. Thus, global initiatives are needed to make new diagnostics
accessible to low-income countries.
MTBDRplus MODS NRA AB Resazurin MTT MGIT 960 LJPM
Average time
to results, days
2 7 7 8 8 8 9 30
Results within
8 days, %
100 90 77 87 87 74 42 -
Results within
10 days, %
100 100 100 100 97 87 81 -
MODS = microscopic observation drug susceptibility; NRA = nitrate reductase assay; AB =Alamar Bbue ; MTT = 3-[4,5-
dimethyl- thiazol-2-yl)-2,5-diphenyltetrazolium bromide; MGIT = Mycobacterium Growth Indicator Tube; LJPM =
Löwenstein-Jensen proportion method.
Table 1. Time to results and percentage of results obtained within 8 and 10 days. Reprinted from Ref. 45 with
permission of the International Union Against Tuberculosis and Lung Disease. Copyright © The Union.
5. Treatment of drug-resistant TB
The emergence of MDR- and XDR-TB has shattered the initial optimism that DOTS based
programmes would progressively eliminate TB. MDR TB is defined as resistance to at least the
two most potent first-line TB drugs—ie, INH and RMP [46,47]. XDR TB strains are resistant to
INH or RMP, any fluoroquinolone, and at least one of three second-line injectable drugs—ie,
capreomycin, kanamycin, and amikacin [46,47]. In order to control the spread of drug resist‐
ant TB, the WHO extended the DOTS programme in 1998 to include the treatment of MDR-TB
(called "DOTS-Plus") [48]. Implementation of DOTS-Plus requires the capacity to perform drug-
susceptibility testing and the availability of second-line agents, in addition to all the require‐
ments for DOTS. Clinical pilot experiences from the past few years showed that high cure rates
of drug resistant TB are achieved in settings where DOTS-Plus has been established [49-51].
Resistance to INH is the most common form of TB drug resistance reported, either in isolation
or in combination with other drugs [13]. INH monoresistant TB is relatively easy to treat with
SCC treatment. Up to 98% cure and less than 5% relapse can be achieved when all four drugs
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INH, RMP, PZA and EMB are used during the 6-month treatment period [52]. RMP-resistant
TB often carries a much more ominous prognosis, as the outcome of SCC treatment is poor in
terms of both disease status at the end of the treatment and relapse [13]. Moreover, RMP
monoresistance in Mtb is rare and usually reflects resistance to INH as well, i.e., MDR-TB [53].
In fact, SCC cures less than 60% of MDR-TB, with a recurrence rate of about 28% among patient
with apparent success [38,54].
The current recommendation for individualized treatment regimens is a combination of at
least four drugs to which the Mtb isolate is likely to be susceptible [55]. Drugs are chosen with
a stepwise selection process through 5 groups of TB drugs (Table 2) on the basis of efficacy
and safety [55]. More than 5 drugs can be used if the sensitivity to a given drug is unclear or
if the regimen contains few bactericidal drugs. The duration of the intensive phase of treatment
(when an injectable drug is given) should be at least 6 months (or 4 months after culture
conversion). The continuation phase (without the injectable drug) should last until 18 months
after culture conversion [55].
Although the effectiveness and feasibility of MDR-TB management in resource-limited
settings have been demonstrated, less than 2% of all estimated MDR-TB patients currently
receive appropriate treatment [5]. Thus, the growing MDR-TB epidemic globally requires
moving beyond the pilot project stage in order to scale up DOTS-plus based TB management
as a routine component of national TB control programmes. However, there are potential
difficulties with implementing DOTS-Plus in low-income countries as it can absorb a large part
of resources dedicated to existing DOTS programmes, and subsequently decrease the overall
standard of care [56]. Note that the emergence of drug resistant TB in these countries is actually
the result of limited resources to implement the simple DOTS programme.
A major barrier to the management of drug resistant TB in low-income countries is the prohibi‐
tive price of second-line drugs. Therefore in an attempt to address this issue, in 2000, the WHO
and its partners established the Green Light Committee (GLC) initiative to facilitate access to
quality-assured second-line TB drugs at reduced prices [57,58]. Evaluation of the first GLC-
endorsed pilot projects of MDR-TB management in five resource-limited countries showed
treatment success rates of 59%–83% [59]. During 2012, the number of patients with MDR-TB
approved for treatment by the GLC Committee was only 42,033 with 13,000 actually starting
treatment. It is clear that these numbers remain small compared to the estimated annual incidence
(440,000 cases) of MDR-TB [1]. Therefore, substantial funding through public-private partner‐
ships is desperately needed to scale up the availability of second line drugs.
Other than the price of second-line drugs, frequent adverse events and the long duration of
the regimen further compromise adherence to TB treatment, even in the most advanced
industrialized countries. These drawbacks have resulted in resurgence in research efforts
during last decade to develop new TB drugs. In recent years, a number of new drug candidates
with novel modes of action and excellent activity against Mtb have entered clinical trials [60].
OPC-67683 (nitro-dihydro-imidazooxazole) and diarylquinoline TMC207 are the most
promising of these new drugs since both are highly active against drug-resistant and suscep‐
tible Mtb strains and possess excellent sterilizing activity [61]. These and other drugs under
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rings of MTT, which produces a violet-purple color [44]. Many of these assays gave excellent
detection of MDR-TB, within a significantly shorter time frame when compared to conven‐
tional culturing methods (Table 1).
The effective implementation of these rapid diagnostic tests for TB and drug resistance will
increase the proportion of patients promptly placed on appropriate therapy, and therefore will
improve substantially management and control of TB disease globally. However a major
limitation to the use of these rapid tests is their affordability and the availability of equipped
laboratories in resource-constrained countries, which unfortunately tend to have the highest
burden of MDR-TB cases. Thus, global initiatives are needed to make new diagnostics
accessible to low-income countries.
MTBDRplus MODS NRA AB Resazurin MTT MGIT 960 LJPM
Average time
to results, days
2 7 7 8 8 8 9 30
Results within
8 days, %
100 90 77 87 87 74 42 -
Results within
10 days, %
100 100 100 100 97 87 81 -
MODS = microscopic observation drug susceptibility; NRA = nitrate reductase assay; AB =Alamar Bbue ; MTT = 3-[4,5-
dimethyl- thiazol-2-yl)-2,5-diphenyltetrazolium bromide; MGIT = Mycobacterium Growth Indicator Tube; LJPM =
Löwenstein-Jensen proportion method.
Table 1. Time to results and percentage of results obtained within 8 and 10 days. Reprinted from Ref. 45 with
permission of the International Union Against Tuberculosis and Lung Disease. Copyright © The Union.
5. Treatment of drug-resistant TB
The emergence of MDR- and XDR-TB has shattered the initial optimism that DOTS based
programmes would progressively eliminate TB. MDR TB is defined as resistance to at least the
two most potent first-line TB drugs—ie, INH and RMP [46,47]. XDR TB strains are resistant to
INH or RMP, any fluoroquinolone, and at least one of three second-line injectable drugs—ie,
capreomycin, kanamycin, and amikacin [46,47]. In order to control the spread of drug resist‐
ant TB, the WHO extended the DOTS programme in 1998 to include the treatment of MDR-TB
(called "DOTS-Plus") [48]. Implementation of DOTS-Plus requires the capacity to perform drug-
susceptibility testing and the availability of second-line agents, in addition to all the require‐
ments for DOTS. Clinical pilot experiences from the past few years showed that high cure rates
of drug resistant TB are achieved in settings where DOTS-Plus has been established [49-51].
Resistance to INH is the most common form of TB drug resistance reported, either in isolation
or in combination with other drugs [13]. INH monoresistant TB is relatively easy to treat with
SCC treatment. Up to 98% cure and less than 5% relapse can be achieved when all four drugs
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INH, RMP, PZA and EMB are used during the 6-month treatment period [52]. RMP-resistant
TB often carries a much more ominous prognosis, as the outcome of SCC treatment is poor in
terms of both disease status at the end of the treatment and relapse [13]. Moreover, RMP
monoresistance in Mtb is rare and usually reflects resistance to INH as well, i.e., MDR-TB [53].
In fact, SCC cures less than 60% of MDR-TB, with a recurrence rate of about 28% among patient
with apparent success [38,54].
The current recommendation for individualized treatment regimens is a combination of at
least four drugs to which the Mtb isolate is likely to be susceptible [55]. Drugs are chosen with
a stepwise selection process through 5 groups of TB drugs (Table 2) on the basis of efficacy
and safety [55]. More than 5 drugs can be used if the sensitivity to a given drug is unclear or
if the regimen contains few bactericidal drugs. The duration of the intensive phase of treatment
(when an injectable drug is given) should be at least 6 months (or 4 months after culture
conversion). The continuation phase (without the injectable drug) should last until 18 months
after culture conversion [55].
Although the effectiveness and feasibility of MDR-TB management in resource-limited
settings have been demonstrated, less than 2% of all estimated MDR-TB patients currently
receive appropriate treatment [5]. Thus, the growing MDR-TB epidemic globally requires
moving beyond the pilot project stage in order to scale up DOTS-plus based TB management
as a routine component of national TB control programmes. However, there are potential
difficulties with implementing DOTS-Plus in low-income countries as it can absorb a large part
of resources dedicated to existing DOTS programmes, and subsequently decrease the overall
standard of care [56]. Note that the emergence of drug resistant TB in these countries is actually
the result of limited resources to implement the simple DOTS programme.
A major barrier to the management of drug resistant TB in low-income countries is the prohibi‐
tive price of second-line drugs. Therefore in an attempt to address this issue, in 2000, the WHO
and its partners established the Green Light Committee (GLC) initiative to facilitate access to
quality-assured second-line TB drugs at reduced prices [57,58]. Evaluation of the first GLC-
endorsed pilot projects of MDR-TB management in five resource-limited countries showed
treatment success rates of 59%–83% [59]. During 2012, the number of patients with MDR-TB
approved for treatment by the GLC Committee was only 42,033 with 13,000 actually starting
treatment. It is clear that these numbers remain small compared to the estimated annual incidence
(440,000 cases) of MDR-TB [1]. Therefore, substantial funding through public-private partner‐
ships is desperately needed to scale up the availability of second line drugs.
Other than the price of second-line drugs, frequent adverse events and the long duration of
the regimen further compromise adherence to TB treatment, even in the most advanced
industrialized countries. These drawbacks have resulted in resurgence in research efforts
during last decade to develop new TB drugs. In recent years, a number of new drug candidates
with novel modes of action and excellent activity against Mtb have entered clinical trials [60].
OPC-67683 (nitro-dihydro-imidazooxazole) and diarylquinoline TMC207 are the most
promising of these new drugs since both are highly active against drug-resistant and suscep‐
tible Mtb strains and possess excellent sterilizing activity [61]. These and other drugs under
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development give hope that a safe and effective TB regimen of shorter duration will be
available within the next few years.
6. Adverse drug reactions to second line TB drugs
The treatment of MDR-TB is a challenging issue due to the adverse events associated with
long-term exposure (18 to 24 months) to second line drugs, all in great contrast to the short
treatment period of drug sensitive TB. Adverse events significantly influence treatment
TB drug group Daily dose

























Group four: less-effective second-line TB drugs (use all possible drugs if necessary)
Ethionamide/Prothionamide
Cycloserine/Terizidone




Group five: less-effective drugs or drugs on which clinical data are sparse (use all necessary drugs if there are less ily
than four from the other groups)
Clofazimine
Amoxicillin with clavulanate (every 12 h)
Linezolid
Imipenem (every 6 h)










Table 2. Categories of TB drugs. Reprinted from Ref. 55 with permission of the International Union Against
Tuberculosis and Lung Disease. Copyright © The Union.
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outcome and patient compliance, leading to acquisition of more resistance and spread of drug-
resistant strains. Initial evidence of the prevalence of adverse events associated with the use
of second-line drugs was deducted from observation of patients enrolled in five DOTS-Plus
sites: Estonia, Latvia, Peru, the Philippines and the Russian Federation. The data collected from
these sites showed that among 818 patients enrolled on MDR-TB 30% required removal of
suspected drugs from the regimen due to adverse events [62] and Table 3.
Adverse events can be distinguished as major or minor and may not be consistently found
among all patients treated for MDR-TB [39]. The major adverse events associated with second
line drugs include auditory toxicity (ototoxicity) and neurologic side effects [63].
Ototoxicity causes damage to the outer hair cells in the cochlea and vestibular labyrinth leading
to permanent hearing loss. Ototoxic hearing loss is common in patients treated with amino‐
glycosides (Streptomycin, Kanamycin and Amikacin). A prospective cohort study of the
incidence of ototoxicity in MDR-TB individuals (with normal hearing) showed that 57% of
aminoglycoside-treated patients developed high-frequency of hearing loss [64]. The same
study showed that HIV-positive patients (70%) were more likely to develop hearing loss than
HIV-negative patients (42%). Susceptibility to hearing loss increases further in patients bearing
mutations in mitochondrial genes [65]. Numerous mutations linked to susceptibility to
ototoxicity have been identified in the mitochondrial MT-RNR1 gene that encodes the human
12S rRNA ribosomal subunit. In particular, the A1555G mutation causes increased binding of
aminoglycosides to the 12S rRNA ribosomal subunit [66], which results in the disruption of
mitochondrial protein synthesis and death of the cell. In this regard, a recent study in South
Africa detected A1555G mutation in a significant proportion of the population (0.9% of Black
and 1.1% of Afrikaner), indicative of high proportion of individuals genetically predisposed
to developing aminoglycoside-induced hearing loss. It is unfortunate that the widespread and
poorly controlled use of aminoglycosides will lead to many individuals suffering from
permanent deafness. Auditory monitoring should be an integral part of the care programme
of MDR-TB patients, particularly in countries where aminoglycosides are still commonly used.
In addition, identification of patients who are genetically predisposed will significantly reduce
the risk of developing ototoxicity.
Patients with neurologic side effects (depression, psychosis and suicidal tendencies) have less
favorable outcome and increased risk of death. Cycloserine is the most significant TB drug
associated with central nervous system (CNS) toxicity. Cycloserine is used as second line drug
in TB treatment based of its structural analogy to D-alanine. Cycloserine competitively inhibits
two necessary enzymes (alanine racemase and alanine ligase) that incorporate alanine into an
alanyl-alanine dipeptide, an essential component of the mycobacterial cell wall [67]. Early
studies revealed that neurological and psychiatric manifestations are present in as many as
33% of patients treated with cycloserine [68]. The principal side effects associated with
cycloserine therapy are convulsions, exacerbations of bipolar states and multiple neurological
symptoms including excitation, dizziness, headaches, insomnia and anxiety [69]. Cycloserine-
mediated neurologic side effects are exacerbated even more when used in combination with
isoniazid [70]. These variable psychotropic responses are related to cycloserine action as an
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development give hope that a safe and effective TB regimen of shorter duration will be
available within the next few years.
6. Adverse drug reactions to second line TB drugs
The treatment of MDR-TB is a challenging issue due to the adverse events associated with
long-term exposure (18 to 24 months) to second line drugs, all in great contrast to the short
treatment period of drug sensitive TB. Adverse events significantly influence treatment
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outcome and patient compliance, leading to acquisition of more resistance and spread of drug-
resistant strains. Initial evidence of the prevalence of adverse events associated with the use
of second-line drugs was deducted from observation of patients enrolled in five DOTS-Plus
sites: Estonia, Latvia, Peru, the Philippines and the Russian Federation. The data collected from
these sites showed that among 818 patients enrolled on MDR-TB 30% required removal of
suspected drugs from the regimen due to adverse events [62] and Table 3.
Adverse events can be distinguished as major or minor and may not be consistently found
among all patients treated for MDR-TB [39]. The major adverse events associated with second
line drugs include auditory toxicity (ototoxicity) and neurologic side effects [63].
Ototoxicity causes damage to the outer hair cells in the cochlea and vestibular labyrinth leading
to permanent hearing loss. Ototoxic hearing loss is common in patients treated with amino‐
glycosides (Streptomycin, Kanamycin and Amikacin). A prospective cohort study of the
incidence of ototoxicity in MDR-TB individuals (with normal hearing) showed that 57% of
aminoglycoside-treated patients developed high-frequency of hearing loss [64]. The same
study showed that HIV-positive patients (70%) were more likely to develop hearing loss than
HIV-negative patients (42%). Susceptibility to hearing loss increases further in patients bearing
mutations in mitochondrial genes [65]. Numerous mutations linked to susceptibility to
ototoxicity have been identified in the mitochondrial MT-RNR1 gene that encodes the human
12S rRNA ribosomal subunit. In particular, the A1555G mutation causes increased binding of
aminoglycosides to the 12S rRNA ribosomal subunit [66], which results in the disruption of
mitochondrial protein synthesis and death of the cell. In this regard, a recent study in South
Africa detected A1555G mutation in a significant proportion of the population (0.9% of Black
and 1.1% of Afrikaner), indicative of high proportion of individuals genetically predisposed
to developing aminoglycoside-induced hearing loss. It is unfortunate that the widespread and
poorly controlled use of aminoglycosides will lead to many individuals suffering from
permanent deafness. Auditory monitoring should be an integral part of the care programme
of MDR-TB patients, particularly in countries where aminoglycosides are still commonly used.
In addition, identification of patients who are genetically predisposed will significantly reduce
the risk of developing ototoxicity.
Patients with neurologic side effects (depression, psychosis and suicidal tendencies) have less
favorable outcome and increased risk of death. Cycloserine is the most significant TB drug
associated with central nervous system (CNS) toxicity. Cycloserine is used as second line drug
in TB treatment based of its structural analogy to D-alanine. Cycloserine competitively inhibits
two necessary enzymes (alanine racemase and alanine ligase) that incorporate alanine into an
alanyl-alanine dipeptide, an essential component of the mycobacterial cell wall [67]. Early
studies revealed that neurological and psychiatric manifestations are present in as many as
33% of patients treated with cycloserine [68]. The principal side effects associated with
cycloserine therapy are convulsions, exacerbations of bipolar states and multiple neurological
symptoms including excitation, dizziness, headaches, insomnia and anxiety [69]. Cycloserine-
mediated neurologic side effects are exacerbated even more when used in combination with
isoniazid [70]. These variable psychotropic responses are related to cycloserine action as an
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agonist of the neuronal NMDA (N-methyl-D-aspartate) receptor for glutamate [71], which is
a major excitatory neurotransmitter in the mammalian CNS [72]. The most dramatic effect of
cycloserine reported so far is the suicide of 2 patients during the postoperative antibiotic
treatment course following pulmonary resection [73]. Because of its neurological toxicities,
cycloserine was prevented very early from being part of first line TB drugs but was recently
reintroduced as one of the cornerstones of treatment for MDR- and XDR-TB [46]. Although co-
administration of pyridoxine (vitamin B6) with cycloserine can reduce partially the neurolog‐
ical side effects, the later should be prescribed after psychiatric evaluation for patients with
apparent convulsions and agitation [55]. Some clinicians favor terizidone (two cycloserine
molecules combined) as they found the side effects associated with it are less severe and more
manageable [55]. However, given the little evidence demonstrating safety and efficacy of
terizidone, it should be used with caution in TB patients intolerant to cycloserine.
Although adverse events associated with second-line drugs are a major obstacle in the
management of MDR-TB, compared with first line treatment, DOTS-Plus programmes have
achieved cure rates of greater than 70% even in resource-poor settings [74,75]. In general, the
Table 3. Frequency of adverse events and suspected agents among 818 patients receiving MDR-TB treatment.PAS:
para-aminosalicyclic acid; TM: thioamides; FQ: fluoroquinolones; CS: cycloserine; AG: aminoglycosides; CM:
capreomycin.. Reprinted from Ref. 62 with permission of the International Union Against Tuberculosis and Lung
Disease. Copyright © The Union.
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main adverse effects of anti-TB drugs occur during the first two to three weeks of treatment.
If they are recognized in time and managed properly, high rates of treatment completion and
cure can be achieved. Proper monitoring should include patient education, clinical examina‐
tion and appropriate laboratory tests. Special training for staff on the various adverse events
associated with second line drugs is essential for successful management. In particular, staff
should consider altering dosages when appropriate, supplementary drugs to treat adverse
events and replacement of drugs when toxicity cannot be managed.
7. Management approaches for the contacts of MDR TB patients
MDR-TB and XDR-TB cases are currently on the increase and it is expected that the number
of their contacts will also increase, especially in densely populated area. Therefore, identifica‐
tion and proper management of these contacts are major components of drug resistant TB
containment. In this regard, WHO recommend the identification of all close contacts of MDR-
TB cases through contact tracing and their evaluation for TB infection.
A contact is defined as an individual who has a risk of acquiring TB because it has been exposed
to Mtb by sharing air space with a person with infectious TB (the source case). The index case
(a person with suspected or confirmed TB disease) is defined as the initial case of TB for a
contact investigation [76]. He is not necessarily identical with the source case [76]. Many
guidance documents focus on the source case and not the index case, as it is the source case
who will have exposed the contacts, not necessarily the index case. Close contacts are those
people sharing common habitation rooms with the source case. This can also include individ‐
uals with evidence of prolonged and frequent exposure to a source case in the workplace,
school, prison, hospital ward, or social settings [77]. Contact tracing is defined as the systematic
finding of contacts of patients with infectious TB disease [77]. The tracing helps identifying
individuals who are particularly at high risk, such as individuals with HIV infection, young
children and elderly.
The management of contacts of drug-resistant TB patients, in term of preventive chemoprophy‐
laxis, remains a complex issue with a significant ethical dimension. In case of drug-susceptible
TB, the provision of preventive INH therapy to suspect LTBI individuals is effective at reduc‐
ing the risk of developing disease among infected contacts [10]. In theory, such a preventive
approach should also work for LTBI individuals exposed to MDR and XDR Mtb strains.
Unfortunately, health care providers cannot predict with certainty the susceptibility pattern of
a contact’s isolate from the source case’s isolate. Indeed, many divergent drug susceptibility test
profiles in source-contact pairs have been reported [78,79], due either to infection of the contact
by another source case or to infection before the source case acquires resistance. Such a scenar‐
io likely occurs in high-burden TB areas where different drug resistant strains may circulate in
homes, schools, and work places. Therefore, the lack of effective drugs with acceptable adverse-
event profile in an otherwise healthy individual is a prominent barrier to the treatment of drug
resistant TB contacts. Indeed, if, to some extent, the occurrence of toxicity is accepted by MDR-
TB patients (since the alternative is high risk of death), convincing healthy contacts to cope with
adverse-events during preventive therapy in is fundamentally different.
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agonist of the neuronal NMDA (N-methyl-D-aspartate) receptor for glutamate [71], which is
a major excitatory neurotransmitter in the mammalian CNS [72]. The most dramatic effect of
cycloserine reported so far is the suicide of 2 patients during the postoperative antibiotic
treatment course following pulmonary resection [73]. Because of its neurological toxicities,
cycloserine was prevented very early from being part of first line TB drugs but was recently
reintroduced as one of the cornerstones of treatment for MDR- and XDR-TB [46]. Although co-
administration of pyridoxine (vitamin B6) with cycloserine can reduce partially the neurolog‐
ical side effects, the later should be prescribed after psychiatric evaluation for patients with
apparent convulsions and agitation [55]. Some clinicians favor terizidone (two cycloserine
molecules combined) as they found the side effects associated with it are less severe and more
manageable [55]. However, given the little evidence demonstrating safety and efficacy of
terizidone, it should be used with caution in TB patients intolerant to cycloserine.
Although adverse events associated with second-line drugs are a major obstacle in the
management of MDR-TB, compared with first line treatment, DOTS-Plus programmes have
achieved cure rates of greater than 70% even in resource-poor settings [74,75]. In general, the
Table 3. Frequency of adverse events and suspected agents among 818 patients receiving MDR-TB treatment.PAS:
para-aminosalicyclic acid; TM: thioamides; FQ: fluoroquinolones; CS: cycloserine; AG: aminoglycosides; CM:
capreomycin.. Reprinted from Ref. 62 with permission of the International Union Against Tuberculosis and Lung
Disease. Copyright © The Union.
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main adverse effects of anti-TB drugs occur during the first two to three weeks of treatment.
If they are recognized in time and managed properly, high rates of treatment completion and
cure can be achieved. Proper monitoring should include patient education, clinical examina‐
tion and appropriate laboratory tests. Special training for staff on the various adverse events
associated with second line drugs is essential for successful management. In particular, staff
should consider altering dosages when appropriate, supplementary drugs to treat adverse
events and replacement of drugs when toxicity cannot be managed.
7. Management approaches for the contacts of MDR TB patients
MDR-TB and XDR-TB cases are currently on the increase and it is expected that the number
of their contacts will also increase, especially in densely populated area. Therefore, identifica‐
tion and proper management of these contacts are major components of drug resistant TB
containment. In this regard, WHO recommend the identification of all close contacts of MDR-
TB cases through contact tracing and their evaluation for TB infection.
A contact is defined as an individual who has a risk of acquiring TB because it has been exposed
to Mtb by sharing air space with a person with infectious TB (the source case). The index case
(a person with suspected or confirmed TB disease) is defined as the initial case of TB for a
contact investigation [76]. He is not necessarily identical with the source case [76]. Many
guidance documents focus on the source case and not the index case, as it is the source case
who will have exposed the contacts, not necessarily the index case. Close contacts are those
people sharing common habitation rooms with the source case. This can also include individ‐
uals with evidence of prolonged and frequent exposure to a source case in the workplace,
school, prison, hospital ward, or social settings [77]. Contact tracing is defined as the systematic
finding of contacts of patients with infectious TB disease [77]. The tracing helps identifying
individuals who are particularly at high risk, such as individuals with HIV infection, young
children and elderly.
The management of contacts of drug-resistant TB patients, in term of preventive chemoprophy‐
laxis, remains a complex issue with a significant ethical dimension. In case of drug-susceptible
TB, the provision of preventive INH therapy to suspect LTBI individuals is effective at reduc‐
ing the risk of developing disease among infected contacts [10]. In theory, such a preventive
approach should also work for LTBI individuals exposed to MDR and XDR Mtb strains.
Unfortunately, health care providers cannot predict with certainty the susceptibility pattern of
a contact’s isolate from the source case’s isolate. Indeed, many divergent drug susceptibility test
profiles in source-contact pairs have been reported [78,79], due either to infection of the contact
by another source case or to infection before the source case acquires resistance. Such a scenar‐
io likely occurs in high-burden TB areas where different drug resistant strains may circulate in
homes, schools, and work places. Therefore, the lack of effective drugs with acceptable adverse-
event profile in an otherwise healthy individual is a prominent barrier to the treatment of drug
resistant TB contacts. Indeed, if, to some extent, the occurrence of toxicity is accepted by MDR-
TB patients (since the alternative is high risk of death), convincing healthy contacts to cope with
adverse-events during preventive therapy in is fundamentally different.
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Given the lack of clear evidence in support of preventive therapy, the WHO does not recom‐
mend universal use of second-line drugs for chemoprophylaxis in MDR-TB contacts. Current
guidance for the management of drug resistant TB contacts are largely based on expert
opinions, which do not reject nor support provision of preventive therapy with the currently
available drugs. In this context a guidance document presenting the most up-to-date evidence
and expert opinion regarding the management of contacts of MDR- and XDR-TB patients has
been recently proposed (March 2012) by the European Centre for Disease Prevention and
Control (ECDC) [76]. Box 1 summarizes key recommendations provided by ECDC document.
Which factors should be evaluated to decide whether to provide preventive therapy to MDR TB contacts
considered to have LTBI?
When evaluating an MDR TB contact and deciding between the two options (to provide preventive therapy and/or
careful clinical observation and information), an overall individual risk assessment should be conducted, taking into
consideration the following: the MDR TB contact’s risk for progression to TB disease; the drug susceptibility pattern of
the source case of infection; and the contact’s risk for adverse drug events if initiating preventive therapy.
Are there any specific risk groups to whom special attention should be paid?
Children below the age of five years and immunocompromised persons in close contact with MDR TB patients and
considered to have LTBI are at particular risk of progressing to TB disease. These risk groups might benefit from
preventive therapy. The preventive therapy may be interrupted if, based on further examination, infection is found to
be unlikely.
Persons over five years of age in close contact with MDR TB patients and considered to have LTBI could also be
considered for preventive therapy if the individual risk assessment indicates this course of action.
If the decision is made to put an individual on preventive therapy, the selection of the drugs should be based on:
the drug susceptibility pattern of the source case’s likely infecting strain;
local patterns of drug resistance;
the potential adverse events in individual patients, taking into account age and other risk factors;
the selection of single or multiple drugs and the duration of treatment will depend on the availability of drugs with
bactericidal activity for the particular infecting strain; alternatively, the decision can follow national guidelines.
Which arrangements should be in place if preventive therapy is considered?
If preventive therapy is considered by the expert physician or other healthcare provider, national legislation should
ensure that the treatment costs for the patient are covered.
If preventive therapy is considered to be relevant for a particular individual, careful clinical monitoring and follow-up is
essential for the detection of drug-adverse events and signs of TB disease if the preventive therapy is not effective.
Specific opinions for XDR TB contacts
As the currently available treatment options are very limited for XDR TB, it is likely that the risks of preventive therapy
outweigh the benefits for contacts of XDR TB patients. Thus, the option to inform and observe the contacts will be
preferable, given the currently available drugs and evidence.
How should health authorities conduct follow-ups for MDR TB and XDR TB contacts suspected to have LTBI?
All MDR TB and XDR TB contacts considered to have LTBI who, after a comprehensive individual risk assessment, are
not given preventive therapy should be followed-up by careful clinical observation.
Follow-ups should be performed according to existing national guidelines.
All persons in contact with MDR TB or XDR TB (after exclusion of TB disease) should be informed about the risks and
symptoms, carefully observed, and provided with easy access to a specialized TB clinic in case of symptoms between
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assessments. No specific time period for follow-up or periodicity of clinical assessments is recommended, but regular
systematic, clinical observation is essential for the early detection of TB disease.
Individuals repeatedly in contact with infectious MDR TB or XDR TB cases (e.g. healthcare workers) should be re-
examined periodically.
Box 1. ECDC expert opinions regarding preventive therapy of MDR- and XDR-TB contacts.
Studies conducted so far on the benefits and adverse events of preventive therapy are not
conclusive in term of optimal treatment and duration for preventive treatment of MDR-TB
contacts [80]. Therefore, well-designed randomized clinical trials for preventive therapy are
urgently needed in settings where MDR-TB therapy and a strong national programme
infrastructure are already in place. Further research is also needed to define the most effective
contact-tracing procedures for contacts and the most effective follow-up procedures in
healthcare workers constantly exposed to drug resistant TB. In addition, specific management
approaches need to be established for children below the age of five years, children with HIV
infection, immunocompromised individuals, pregnant women, and the elderly. Finally,
whether MDR Mtb strains are more or less infectious and/or transmissible than drug-suscep‐
tible strains need to be clarified.
8. Compliance issues from patients and health care providers
The treatment for MDR-TB is long and complex and relies on a handful of antibiotics with
uncertain efficacy. The WHO has launched an 8-point plan to ensure optimal management of
XDR-TB patients with currently available drugs (Box 2). However, guidelines do not always
translate easily into real world practice. In addition to directly observed treatment, what support
can be offered to convince a patient to continue painful treatment? And how should patients
who have exhausted all treatment options with existing second-line drugs be cared for?
1. Strengthen quality of basic TB and HIV/AIDS control
2. Scale up programmatic management of MDR-TB and XDR-TB
3. Strengthen laboratory services
4. Expand MDR-TB and XDR-TB surveillance
5. Develop and implement infection control measures
6. Strengthen advocacy, communication and social mobilization
7. Pursue resource mobilization at all levels
8. Promote research and development of new tools
Box 2. WHO 8-point plan
In many cases, MDR-TB treatment results in poor compliance with subsequent development
of further drug resistance (i.e. XDR-TB), which leaves infected patients, namely HIV positive
individuals, virtually untreatable using currently available drugs. The WHO defines a
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assessments. No specific time period for follow-up or periodicity of clinical assessments is recommended, but regular
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defaulter as being off drugs for more than 8 weeks after completing at least one month of
treatment [81]. It is an operational definition to guide physicians in the decision of using a
retreatment or second line regimen if the patient comes back to the health facility after
defaulting. However it is imperative that health providers understand predictive factors for
treatment default so that they can implement additional measures to target the population at
risk. In this context, a recent review (2010) assessed TB treatment compliance and the factors
predictive for poor adherence based on the analysis of 4 studies performed in Sub-Saharan
Africa in the last 10 years [82]. The review revealed a high proportion of patients defaulting,
which varied between 11.3% and 29.6%. Defaulting appears to be associated with many factors
such as distance from the hospital, not being on the first course of TB medications, lack of
repeated smears, drug-associated side effects, transportation difficulties, absence of family
support and poor knowledge about TB disease and its treatment. Thus it is unfortunate that
health care institutions continue to blame vulnerable and powerless patients who are unable,
for this multitude of reasons, to comply with the treatment. Since distance from health care
centers is a major factor, national programmes should at least consider making drugs more
widely available, by either providing TB treatment in smaller health centers, or organizing
mobile TB clinics, especially in rural areas.
It is time to admit that TB disease is not a ‘patient problem’ by default but rather a social and
community responsibility that requires close cooperation and collaboration at all levels of the
health care system. Forcing a patient to continue an ineffective, toxic regimen that results in
uncertain outcome also raises an ethical issue yet to be resolved. Ereqat and colleagues report‐
ed a recent case of a MDR-TB patient who withdrew from treatment after 2 years while still
sputum-positive [83]. Due to persistent efforts to force compliance, the patient disappeared
carrying with him the potential to infect all people with whom he has contact. The authors suggest
consulting with legal practitioners about the legality of enforced treatment and how patients
who refuse or interrupt treatment can be managed to protect them and their potential con‐
tacts. It is obvious that in the absence of alternative treatment, this approach might end up with
a response to TB without medication (i.e incarceration). For this type of recalcitrant patients,
other TB specialists [84,85] propose directing efforts towards exploring possible regimens with
better chances of cure and securing an appropriate living environment. Indeed, the threat of
incarceration will just encourage patients to disappear and propagate the disease. Providing
supportive accommodation with access to counseling and palliative care, when required, should
reduce the risk of transmission to others [84]. Overall, until newer drugs become available,
management that balances the risk of disease spread with individual human rights is likely to
be more humane and less costly to health services compared with involuntary detention [85]. In
this context, Upshur and Colleagues propose a list of additional considerations to the manage‐
ment of drug resistant TB as moral correlates to the current WHO 8-point plan (Box 3).
A paramount issue in TB management is that in many countries with limited resources most
of the healthcare is provided by the private sector where the number of qualified medical
personnel to prevent and treat drug resistant TB remains very limited. In this regard, the World
Medical Association (WMA, http://www.wma.net) revealed that many doctors are no longer
being taught to diagnose and treat TB. Thus, private physicians make frequent errors in dealing
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with TB cases. They prescribe too few drugs or the wrong drugs, give inadequate doses of
drugs, or prescribe an inadequate duration of treatment [86]. The standardized method of
determining cure is based on bacteriologic laboratory testing for the growth of Mtb on culture
media. However many health care providers rely on clinical observation to determine
treatment outcome [87], either because of shortages in equipment and adequate infrastructure
or because they trust their own observation above test results. Such mismanagement is a major
cause of acquired drug resistance and treatment failure. On the other hand, on many occasions
lung cancer was misdiagnosed and treated as sputum negative TB, a medical error due to high
TB prevalence and radiological similarities [88].
It is therefore important that healthcare personnel at the forefront in the fight against TB
acquire appropriate and state-of-the art training on TB management. In this regards, the WMA
launched in its website a new online refresher course for care providers in many languages.
The course provides basic clinical care information for TB including the latest diagnostics,
treatment and information about multidrug-resistant TB. It also provides information on how
to ensure patient adherence and infection control and includes many aspects of TB care and
management. Dr. Julia Seyer, medical adviser at the WMA, said: ‘When we started an online
MDR-TB training course in 2006, we discovered that many physicians were missing the most
basic knowledge about normal TB’.
In summary, both the lack of patient adherence to treatment and deficiencies in programme
managements are compromising the effectiveness of MDR TB treatment and the interaction
of these two issues raises further the barrier to achieving efficient TB control. From the various
opinions on the issue of non-compliance it can be concluded that:
• Addressing therapy-related adverse events should contribute positively in improving
patient’s compliance. Therefore, potential adverse effects must be carefully evaluated when
designing the therapy plan. Alternative plans should be discussed with the patients to
minimize the possibility of therapeutic barriers.
• Healthcare system quality is significantly related to compliance. Long waiting times and
unhappy experiences during clinic visits are frequent complains from TB patients. A
healthcare system that considers patient satisfaction would enhance patient adherence to
TB treatment.
• Compliance is also affected by the characteristics of TB disease. While non-adherence is not
a major issue when treating short duration infections, this is not the case for TB, a chronic
1. Adherence research
2. Building the evidence-base for infection control practices
3. Supporting communities
4. Enhancing public health response while addressing the social determinants of health
5. Embracing palliative care
6. Advocacy for research
Box 3. Additional considerations to the WHO 8-point plan
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disease by definition. Therefore, special effort should be made to explain the nature of the
disease with a particular focus on the asymptomatic stage of TB.
• Healthcare expenditures are a very important factor that affects compliance. TB patients
often feel that the cost of long-term treatment would be a financial burden, which definitely
threatens therapy compliance. Therefore, health care personnel should discuss the patient’s
resources and help identifying sources that might provide financial assistance to low-
income patients.
Overall providing care centered on patient needs and expectations is a key component for the
success of TB control programmes.
9. Programmatic management of drug resistant TB
Policies, strategies, protocols and guidelines for TB management are well explained and
articulated on the paper. However, their implementation in resource-limited sittings remains
challenging due to weak case finding strategies, unclear patient tracing mechanisms (espe‐
cially defaulters), a lack of MDR-TB rapid diagnostic tools, absence of childhood TB case
finding approaches and inadequate patient support services. Furthermore, specialized drug
resistant TB services are limited to locations that often exclude many patients living in remote
areas from receiving adequate health care. Recording systems, mainly paper-based, are time
consuming for health care providers, and therefore reduces time for quality care. Addressing
these many challenges requires collaboration from different components of national TB control
programmes. These components include case detection, treatment, prevention, surveillance,
and adequate monitoring/evaluation of the programme’s performance. Such objectives are the
backbone of DOTS-Plus management programme introduced by the WHO in 1998 [48]. Many
DOTS-plus pilot projects provided evidence base for this strategy in the management of drug
resistant TB [59,89,90]. Based on the success of pilot projects, the WHO issued in 2006 guide‐
lines for what is now called programmatic management of drug-resistant TB (PMDT), which
were recently updated with extra focus on the detection and treatment of drug-resistant TB in
resources limited settings [91]. Priority topics identified in the new WHO document are:
• Case-finding through use of rapid molecular tests; investigation of contacts and other high-
risk groups;
• Regimens for MDR-TB and their duration in HIV-positive and HIV-negative patients;
• Monitoring during treatment;
• Models of care.
PMDT is currently highly supported by funding for MDR-TB treatment, which has dramati‐
cally increased in the past few years. Multi-billion dollar funds are now available through
governments and donors, including the Global Fund to Fight AIDS, Tuberculosis and Malaria,
UNITAID and the GLC committee [90]. Such fund was essential to demonstrate the feasibility
and effectiveness of PMDT in many resource-limited settings, where it is needed most [92].
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The current status of MDR-TB epidemic requires urgent moving of PMDT beyond this pilot
project stage in order to respond to the call of Stop TB for the treatment of 1.6 million MDR-
TB patients in the near future [93].
Although the last WHO document on TB control provides comprehensive guidelines for good
PMDT, The WHO recognizes that many crucial management issues remain to be addressed.
Thus, during the development of the recent PMDT document, a review published in 2008 [92]
revealed some important gaps in knowledge that need to be addressed in order to optimize
PMDT:
• Lack of high quality evidence from randomized controlled trials for optimizing treatment
regimens in patients with MDR-TB, including the best combination of drugs and treatment
duration;
• Very limited information about treatment and management of pediatric MDR-TB;
• Identification of the most effective chemoprophylaxis for contacts of MDR-TB cases;
• The therapy for symptomatic relief from adverse reactions linked to second-line TB drugs.
It is also important to note that social stigma and discrimination are still major obstacles for access
to TB care services in many countries [94,95]. Similarly, financial issues and geographical
accessibility is also a barrier for the continuation of treatment [96,97]. Misconceptions about TB
are highly prevalent, which discourages seeking help in time or encourage those with TB to seek
help from traditional healers [98]. Therefore national TB programmes must also include specific
strategies to combat these issues in order to optimize the implementation of good PMDT.
Diversity in the epidemiology of MDR-TB poses a challenge for its management in various
settings [99]. Ideally, TB management approaches need to be adapted to each particular setting.
However it is possible to build a minimal package that could be adapted to specific countries
wishing to implement proper TB management approaches. Accordingly, in 2003 a Stop TB
Working Group on DOTS-Plus for MDR-TB identified key research questions to be answered
in order to scale up the management of all forms of drug-resistant TB and to maximize its
public health impact [99]. The working group felt that evidence is needed to address the
following questions:
• How can regimens be selected (either at the programme or at the individual patient level)
based on standardized and reproducible DST that adequately reflects in vivo responsiveness
to treatment?
• How can setting specific treatment strategies be optimized with respect to effectiveness,
complexity (dosing, eligibility, duration, and monitoring of outcome and side effects),
safety, adherence, and affordability?
• What is the minimum infrastructure needed to scale-up PMDT, in terms of:
◦ laboratory and treatment provision
◦ efficient and equitable patient selection
◦ prevention of transmission to other patients and health care workers
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• How should infected contacts of DR-TB patients be managed?
Ensuring that these research questions are addressed is the responsibility of all parties involved
in the management of MDR-TB. If adequately addressed, they will generate a solid evidence-
base to support existing WHO guidelines.
The integration of PMDT into existing TB control programmes beyond the limited pilot project
phase has become a critical emergency in order to respond to the increasing spread of MDR/
XDR-TB worldwide. However, analysis of current WHO strategies by many experts in the field
of TB management [100] suggest that successful PMDT will still require:
• New and improved tools for drug resistance testing;
• Clinical trials to test the efficacy and effectiveness of simplified and shorter second-line
treatment regimens as well as of candidate second-line drugs;
• New and improved strategies for identifying patients with drug-resistant disease, promot‐
ing treatment adherence, and improving infection control;
• Better epidemiological data to explain geographic variations in occurrence of drug resist‐
ance and to identify the greatest contributors to development of drug resistance in specific
settings;
• Clinical trials to test the efficacy and effectiveness of new regimens for prophylactic
treatment of contacts of patients with DR-TB.
10. Patient centered care approach
Acquiring adequate care for TB is becoming increasingly complex and costly when patients
are infected with drug resistant Mtb. This problem is further amplified when patient access to
health care centers is limited and adequate patient-clinician relationships are absent. To
address this issue Stop TB included patient centered approach as one of its important under‐
lying principles. It insists on respect for patients right as individuals and as partners in TB care
and control. Therefore what are usually characterized as ‘patient problems’ need to be
reconfigured into solidarity with patients and programmatic challenges. Patient-centeredness
can be traced back to the adoption of the right to health as part of the International Human
right declaration in 1948 [101], but it is only in the 1990s, as result of the community reaction
to the AIDS epidemic, that its importance has been perceived. Since then, the rise in prevalence
of all forms of TB in HIV individuals has become one of the major stimulating factors for
implementation of patient-centered approaches in TB care.
Promoting patient-centered case management involves assessing each TB patient's needs and
identifying a treatment plan that ensures the completion of therapy. Policies and guidelines
for patient-centered approaches are currently widely distributed. Unfortunately, their
application in the field is progressing very slowly. Applying a patient-centered approach takes
time and requires effort at many levels. It is a new way of thinking, teaching, providing care,
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prevention and communication [102]. Therefore, many countries will continue to experience
substantial difficulties in treating drug resistant TB patients at high risk of defaulting.
A systematic review of factors that contribute to non-adherence [103] indicate that many social
and economic barriers prevent patients from successfully completing their treatment. A wide
range of interacting factors impact on the patient behavior, which is subject to changes during
the course of treatment. According to Doctor Without Borders [104], one of the major chal‐
lenges faced by drug resistant TB patients is the long and arduous treatment period, which
can involve large numbers of tablets each day, as well as injectables, both expensive and not
always easily available or accessible. Low-income patients living in remote area often struggle
to reach specialized TB clinics, in particular when the harsh winter weather affect severely the
country’s road network and compromises the transportation system. Therefore, in the absence
of efficient patient-centered approaches, it is almost impossible to convince patients to continue
this forceful effort every day for up to two years.
In the Russian Federation, the proportion of MDR-TB patients defaulting from treatment has
increased from 12% in 2001 to almost 30% in 2004 [105], despite the expansion of the DOTS
programme to include the treatment of drug resistant TB in 2000. This failure to control drug
resistant TB was mainly attributed to the absence of patient-centered strategies adapted to
many risk factors for non-adherence such as poverty, unemployment, homelessness, alcohol‐
ism, drug abuse and mental illness, to name a few [105]. In response to the alarming proportion
of defaulters, a novel patient-centered TB treatment delivery programme (Sputnik) was
introduced in Tomsk City [106]. Sputnik care providers accompanied patients through
treatment by remaining responsible for patients from the time of enrollment in the programme
until the end of treatment (Box 4). The programme paid a particular attention to care giving.
In addition to clinical preparation, nurses received a comprehensive training on how to care
for patients facing a myriad of biosocial challenges. Indeed, a review of the emotional support
that nurses provide to patients living with MTR-TB [107] concluded that nursing of TB patients
could be improved with an integrated approach where the nurses are responsible for treating
not only the patient, but also ambient factors that affect health, such as family and community.
A high nurse-to patient ratio (2:15),
More staff time per patient to facilitate bonding and defaulter searching
Provision of portable phones to nurses, which increases flexibility
Easier access to specialists
Expanded social and psychological support, which included clothing and assistance with
procuring documentation required to access social services
Box 4. Sputnik programme package
The application of the Sputnik programme led to a mean adherence of 79.0% and a cure rate
of 71.1%, indicating that adapted patient-centered approaches contributed significantly to
improving TB patient adherence.
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• How should infected contacts of DR-TB patients be managed?
Ensuring that these research questions are addressed is the responsibility of all parties involved
in the management of MDR-TB. If adequately addressed, they will generate a solid evidence-
base to support existing WHO guidelines.
The integration of PMDT into existing TB control programmes beyond the limited pilot project
phase has become a critical emergency in order to respond to the increasing spread of MDR/
XDR-TB worldwide. However, analysis of current WHO strategies by many experts in the field
of TB management [100] suggest that successful PMDT will still require:
• New and improved tools for drug resistance testing;
• Clinical trials to test the efficacy and effectiveness of simplified and shorter second-line
treatment regimens as well as of candidate second-line drugs;
• New and improved strategies for identifying patients with drug-resistant disease, promot‐
ing treatment adherence, and improving infection control;
• Better epidemiological data to explain geographic variations in occurrence of drug resist‐
ance and to identify the greatest contributors to development of drug resistance in specific
settings;
• Clinical trials to test the efficacy and effectiveness of new regimens for prophylactic
treatment of contacts of patients with DR-TB.
10. Patient centered care approach
Acquiring adequate care for TB is becoming increasingly complex and costly when patients
are infected with drug resistant Mtb. This problem is further amplified when patient access to
health care centers is limited and adequate patient-clinician relationships are absent. To
address this issue Stop TB included patient centered approach as one of its important under‐
lying principles. It insists on respect for patients right as individuals and as partners in TB care
and control. Therefore what are usually characterized as ‘patient problems’ need to be
reconfigured into solidarity with patients and programmatic challenges. Patient-centeredness
can be traced back to the adoption of the right to health as part of the International Human
right declaration in 1948 [101], but it is only in the 1990s, as result of the community reaction
to the AIDS epidemic, that its importance has been perceived. Since then, the rise in prevalence
of all forms of TB in HIV individuals has become one of the major stimulating factors for
implementation of patient-centered approaches in TB care.
Promoting patient-centered case management involves assessing each TB patient's needs and
identifying a treatment plan that ensures the completion of therapy. Policies and guidelines
for patient-centered approaches are currently widely distributed. Unfortunately, their
application in the field is progressing very slowly. Applying a patient-centered approach takes
time and requires effort at many levels. It is a new way of thinking, teaching, providing care,
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prevention and communication [102]. Therefore, many countries will continue to experience
substantial difficulties in treating drug resistant TB patients at high risk of defaulting.
A systematic review of factors that contribute to non-adherence [103] indicate that many social
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this forceful effort every day for up to two years.
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not only the patient, but also ambient factors that affect health, such as family and community.
A high nurse-to patient ratio (2:15),
More staff time per patient to facilitate bonding and defaulter searching
Provision of portable phones to nurses, which increases flexibility
Easier access to specialists
Expanded social and psychological support, which included clothing and assistance with
procuring documentation required to access social services
Box 4. Sputnik programme package
The application of the Sputnik programme led to a mean adherence of 79.0% and a cure rate
of 71.1%, indicating that adapted patient-centered approaches contributed significantly to
improving TB patient adherence.
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In 1998, the Centers for Disease Control and Prevention (CDC) and the Institute of Medicine
of the National Academy of Sciences conducted a study to determine if TB eradication in the
United State was feasible. The resulting report “Ending Neglect: The Elimination of Tuberculosis
in the United States” concluded that TB elimination would require “aggressive and decisive
action beyond what was in effect.” One of the top objectives of the new CDC plan is to ensure
that patient-centered case management and monitoring of treatment outcomes are the
standard of care for all TB patients [108]. In particular, the CDC guidelines recommend all
patients with active TB must be tested for HIV infection and that all patients double infected
with Mtb and HIV infection must be appropriately and adequately treated. To ensure adher‐
ence to treatment, the CDC recommend the inclusion of multiple enablers (e.g., transportation
vouchers and housing for the homeless) and incentives that will motivate the patient (e.g., food
coupons), and other treatment enhancers such as alternative treatment delivery sites, and
strategies to overcome social and cultural barriers.
Addressing social and economic barriers definitely increases patient access to adequate TB
care. However, health education would also strengthen patient-centered approaches. Under‐
standing an illness and how it affects ones life, as well as available treatment options, are
necessary for a patient and community to take an active role in TB management. With input
from community health professionals from several countries, a literacy tool kit “Within Our
Reach: A TB Literacy Toolkit” was developed in 2009 for health educators, outreach workers,
counselors, and supervisors who provide services to TB patients [109] and (Box 5).
Increasing knowledge about TB, the link between TB and HIV, TB treatment, and TB
transmission
Raising awareness that TB is a serious but treatable disease
Giving patients confidence that they can complete TB treatment and be cured
Educating caregivers and families about how to support TB patients
Reducing stigma attached to TB and HIV
Box 5. Supporting objectives of the TB Literacy Toolkit
The tools are designed to educate TB and HIV patients, their caregivers, and their communities
about TB and what it takes to complete a full course of TB treatment. The kit developers suggest
that individual sessions should be conducted with flipcharts between the health provider and
patient, and videos should be played in a waiting area or during community education events.
Patient-centeredness has become a central approach towards realizing universal access for all
patients to efficient TB care. However scaling up this approach is progressing slowly in high
TB-burden countries and is mainly challenged by the socio-economic determinants of knowl‐
edge and attitudes about TB among health care providers and the general population.
Therefore optimal patient-centeredness approach requires collaborative efforts between all
organizations serving TB patients to ensure that health care providers, policy makers, com‐
munity leaders and the public are knowledgeable about TB disease.
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11. Drug resistant TB infection (tansmission) in the community and
hospitals
TB is a highly contagious disease, acquired mainly through inhalation of airborne aerosols.
Infection can occur by inhaling as few as 5-10 living bacteria. People with active TB infection
spread the bacterium not only by coughing and sneezing but also by spitting, speaking, singing
or laughing. The infectiousness of a TB patient is directly related to the number of droplet
nuclei carrying Mtb that are expelled into the air. These droplets rapidly evaporated to form
tiny particle nuclei, which could remain airborne for several days [110]. Given this mode of
propagation, a person with active TB can spread the germs to up to 15 people in a year, if left
untreated [4]. Therefore the process of TB spread also needs to be controlled in order to
successfully combat the TB epidemic. In this regards, Nardell recommend the term “trans‐
mission control of TB” instead of “infection control of TB”, since a third of the world’s
population is already infected with TB, a situation that appear to be stationary [111].
Because MDR strains carry mutations in major metabolic activities, in particular INH resistant
strains lacking catalase activity [112], some researchers have suggested that they may be less
virulent and less transmissible [113]. Contrasting with this hypothesis, the epidemic that
occurred in New York City in the 1990s [114,115], which affected mainly HIV-infected persons,
proved that MDR strains are highly virulent and transmissible. Current data on MDR TB
prevalence in Africa, Eastern Europe and Asia [116] provides further evidence of this phe‐
nomenon. Drug resistant TB can be transmitted in virtually any setting but healthcare settings,
correctional institutions and homeless shelters have an increased risk of transmission. The level
of drug resistance TB in hospital settings varies according to local TB prevalence. For instance
an university hospitals in Paris (France), reported MDR rates of respectively 1.2% among TB
cases [117], while in university hospitals in Manila (Philippine), this figure was an alarming
53.5% [118].
It is generally thought that the emergence of drug-resistant TB (usually termed acquired)
occurs in settings where patients fail to adhere to proper treatment regimens or receive
inadequate treatment. It is difficult to assign the current magnitude of the epidemic to acquired
resistance alone. Another mechanism for the perpetuation of resistance, which has largely been
neglected in the development of TB control programmes, is the direct transmission of drug-
resistant strains (called primary or transmitted resistance) [119]. In the 2006 XDR-TB outbreak
in KwaZulu-Natal (South Africa), 52 of 53 people who contracted the disease (all of them HIV
infected) died within weeks [120]. This outbreak received international attention because 85
percent of infected patients had genetically similar XDR strain, indicating that resistance was
likely transmitted rather than acquired. Consistent with these findings, a study conducted in
Tomsk (Siberia) –a setting where HIV infection is not widespread and effective TB treatment
is available– to identify factors leading to increases in MDR-TB cases [121], revealed that a
patient was six times more likely to develop MDR-TB if hospitalized for drug-susceptible TB
than if not hospitalized. These results strongly suggest that nosocomial transmission of TB
rather than resistance (acquired predominantly by nonadherence) is increasingly responsible
for the rising MDR TB case rates in Russia and probably in many other places.
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Worthy of note is that nosocomial transmission of TB is a risk not only to inpatients but also
health care workers (HCWs). In fact, early studies revealed transmission of MDR-TB from
patient  to  patient  and  from  patient  to  HCWs  [122].  A  systematic  review  by  Joshi  and
colleagues [123] demonstrated that TB is a significant occupational problem among HCWs
in many low- and middle-income countries and that most health care facilities in these sittings
lack  resources  to  prevent  nosocomial  transmission  of  TB.  HIV-infected  HCWs  have  a
particularly high risk of TB, which may be fatal if the disease is caused by a drug-resistant
strain [124].  Indeed, dramatic nosocomial outbreaks of MDR TB occurred the late 1980s,
largely in HIV infected HCWs, and caused many deaths [110]. This situation increased the
concern  of  HCWs about  the  safety  of  working  in  institutions  with  a  large  numbers  of
admissions for active TB. Indeed, it is estimated that 1% to 10% of HCWs are infected annually
in hospitals with more than 200 admissions per year for TB [110]. The risk of TB transmis‐
sion to HCWs is particularly high in certain areas of the hospital, such as emergency rooms
and units that admit patients with active TB [125].
A review of several reports of TB outbreaks with transmission to HCWs in industrialized
countries revealed that many factors contribute to nosocomial transmission, such as delayed
diagnosis, poor ventilation with positive pressure in isolation rooms, aerosolization of bacilli
through mechanical ventilation, bronchoscopy and dressing change [110]. There was also
strong evidence that technicians involved in cough-inducing procedures, histologic prepara‐
tions and autopsies are at high risk, even in institutions caring for few patients with TB [126].
These outbreaks revealed many deficiencies in the knowledge of TB and its transmission as
well as strategies used to control the disease. Therefore, various health authorities have
implemented effective control programmes based on the early detection of TB and the prompt
isolation and treatment of persons with TB in addition to introducing strong measures to
prevent nosocomial transmissions of TB. For instance, the US Centers for Disease Control
(CDC) [127] recommended the following levels of controls: 1. Administrative controls, which
reduce risk of exposure. 2. Environmental controls, which prevent spread and reduce
concentration of droplet nuclei. 3. Respiratory-protection controls, which further reduce risk
of exposure in special areas and circumstances. (Box 6).
Implementation of a full hierarchy of these measures lead to a significant reduction in
nosocomial transmission of TB in the United States [128]. Whereas the extent of the epidemics
in low and middle income countries is still attributed, in large part, to ineffective transmission
control strategies. In these countries, double infection with TB and HIV has further accelerated
the transmission of drug resistant TB and increased the spread of HIV. Such a dramatic
situation blocks the efforts of both the Stop TB Partnership and anti-retroviral therapy
programmes. It is regrettable that many health care institutions continue to house HIV positive
individuals with patients who have drug-resistant TB, thus leading to nosocomial transmission
with subsequent community transmission. In this regards, health authorities in Haiti imple‐
mented an effective community-based transmission control programme with a baseline triage
and separation strategy [111]. Patients are admitted to either the general medical ward, a TB
pavilion, or very basic isolation rooms based on smear results and HIV status (Fig. 2).
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Figure 2. Community-based TB treatment triage strategy in Haiti. The general medical ward has natural ventila‐
tion and UV air disinfection. The TB ward has natural ventilation with fenestrated brick and more UV fixtures to disin‐
fect the air than the general ward has. The six isolation rooms are off a common corridor, and each has a large exhaust
fan built into the wall that draws air into the room from the corridor, as well as a UV fixture. Reprinted from Ref. 111
with permission of the International Union Against Tuberculosis and Lung Disease. Copyright © The Union
Although this simple baseline strategy is not sufficient, Nardell considers that its implement‐
ing in other resource-poor settings would contribute significantly to reduce the burden of TB
epidemic [111].
Administrative Controls
• Assign responsibility for TB infection control • Conduct TB risk assessment • Develop and institute a written TB
infection-control plan • Ensure the timely availability of recommended laboratory processing, testing, and reporting of
results
• Implement effective work practices for the management of patients with suspected or confirmed TB disease •
Ensure proper cleaning and sterilization or disinfection of potentially contaminated equipment • Train and educate
health-care workers • Test and evaluate health-care workers for TB infection and disease • Apply epidemiology-based
prevention principles • Use posters and signs demonstrating and advising respiratory hygiene and cough etiquette •
Coordinate efforts with the local or state health department.
Environmental Controls
Reduce concentration of infectious droplet nuclei through the following technologies:
• Ventilation technologies (Natural ventilation and Mechanical ventilation) • High efficiency particulate air filtration •
Ultraviolet germicidal irradiation
Respiratory Protection Controls
• Implement a respiratory-protection programme • Train health-care workers on respiratory protection • Educate
patients on respiratory hygiene and the importance of covering their cough • Test HCWs for mask fit and functionality
Box 6. TB Infection-Control Programme: Level of Controls
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Founded in 2001, the goal of The Stop TB Partnership for 2015 was to reduce the global burden
of TB disease (deaths and prevalence) by 50% relative to 1990 levels. The reality of the global
incidence of all forms of TB in 2012 indicates that this timetable is unrealistic. Despite billions
of dollars already spent on TB control programs, less than 2% of drug resistant TB cases
currently receive appropriate treatment in high burden countries allowing the disease to
spread faster than the implementation of adequate management programs. This dramatic
situation severely attenuates global efforts to control TB.
One of the major challenges now is to develop innovative approaches to expand the detection
and treatment of drug resistant cases globally. To achieve this goal, substantial funding and
development of extensive human resources is needed. Among the response priorities, the
following are of paramount importance: 1) developing tools for rapid detection of drug
resistance; 2) clinical trials to test simplified, safe and shorter second-line treatment regimens;
3) developing approaches to enhance treatment adherence; 4) clinical trials to test the efficacy
of new prophylactic treatment regimens for contacts of patients; and finally 5) developing safe
and more efficient second-line drugs.
However, even with increased detection and treatment of drug resistant TB, focusing on the
care of TB and neglecting living conditions in low-income countries has little chance of
completely reversing the burden of TB. The severity of the TB epidemic in the Western world
during the 19th century was largely due to the low living standards prevalent among the poor
during the industrial revolution. As living standards improved, TB mortality began to decrease
long before any vaccinations or specific therapy was introduced. Reminiscent of the 19th
century situation is the persistence of TB in poor and marginalized populations in most modern
cities of the world. As the British historian Thomas Mc-Keown said in 1976, “the overall health
of the population is less related to medical advances than to standards of living and nutrition”
[101]. Thus the control and eventual eradication of the TB epidemic will need support and
cooperation from multiple levels within the medical and scientific community, as well as all
levels of government worldwide in order to address living standards and develop better drugs
and therapeutic tools for the clinic.
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3) developing approaches to enhance treatment adherence; 4) clinical trials to test the efficacy
of new prophylactic treatment regimens for contacts of patients; and finally 5) developing safe
and more efficient second-line drugs.
However, even with increased detection and treatment of drug resistant TB, focusing on the
care of TB and neglecting living conditions in low-income countries has little chance of
completely reversing the burden of TB. The severity of the TB epidemic in the Western world
during the 19th century was largely due to the low living standards prevalent among the poor
during the industrial revolution. As living standards improved, TB mortality began to decrease
long before any vaccinations or specific therapy was introduced. Reminiscent of the 19th
century situation is the persistence of TB in poor and marginalized populations in most modern
cities of the world. As the British historian Thomas Mc-Keown said in 1976, “the overall health
of the population is less related to medical advances than to standards of living and nutrition”
[101]. Thus the control and eventual eradication of the TB epidemic will need support and
cooperation from multiple levels within the medical and scientific community, as well as all
levels of government worldwide in order to address living standards and develop better drugs
and therapeutic tools for the clinic.
Acknowledgements
This work was supported by operating grants from the Canadian Institutes of Health Research
and BC Lung Association. The author is supported by scholar awards from the Michael Smith
Foundation for Health Research, and the TB Vets Charitable Foundation. The author thanks
Alice Lau and Jeffrey Helm for their editing help.
Tuberculosis - Current Issues in Diagnosis and Management226
Author details
Zakaria  Hmama
Division of Infectious diseases, Department of Medicine, University of British Columbia, BC,
Canada
References
[1] WHO. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 Global Report
on Surveillance and Response. Available at: http://www.who.int/tb/publications/
2010/978924599191/en/index.html
[2] Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emer‐
gence of new forms of totally drug-resistant tuberculosis bacilli: super extensively
drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest 2009 Aug;
136(2):420-425.
[3] Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis
in India. Clin Infect Dis 2012 Feb 15;54(4):579-581.
[4] WHO. Tuberculosis Fact sheet N°104. 2012. Available at: http://www.who.int/media‐
centre/factsheets/fs104/en/
[5] WHO report 2008. Global tuberculosis control - surveillance, planning, financing.
Available at: http://www.who.int/tb/publications/global_report/2008/summary/en/
index.html
[6] Jain A, Dixit P. Multidrug-resistant to extensively drug resistant tuberculosis: what is
next? J Biosci 2008 Nov;33(4):605-616.
[7] Jain A, Mondal R. Extensively drug-resistant tuberculosis: current challenges and
threats. FEMS Immunol Med Microbiol 2008 Jul;53(2):145-150.
[8] Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in
Italy resistant to all tested drugs. Euro Surveill 2007 May 17;12(5):E070517.1.
[9] Bhargava A, Pinto L, Pai M. Mismanagement of tuberculosis in India: Causes, conse‐
quences, and the way forward. Hypothesis 2011;9:e7.
[10] Sia IG, Wieland ML. Current concepts in the management of tuberculosis. Mayo Clin
Proc 2011 Apr;86(4):348-361.
[11] Elzinga G, Raviglione MC, Maher D. Scale up: meeting targets in global tuberculosis
control. Lancet 2004 Mar 6;363(9411):814-819.
Management of Drug-Resistant TB
http://dx.doi.org/10.5772/55531
227
[12] Treatment of Tuberculosis Guidelines, 4th edition. 2010. Available at: http://whqlib‐
doc.who.int/publications/2010/9789241547833_eng.pdf
[13] Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis.
Int J Tuberc Lung Dis 2009 Nov;13(11):1320-1330.
[14] Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy.
Tubercle 1985 Sep;66(3):219-225.
[15] Wade MM, Zhang Y. Anaerobic incubation conditions enhance pyrazinamide activi‐
ty against Mycobacterium tuberculosis. J Med Microbiol 2004 Aug;53(Pt 8):769-773.
[16] Kaufmann SH, McMichael AJ. Annulling a dangerous liaison: vaccination strategies
against AIDS and tuberculosis. Nat Med 2005 04;11(4):S33-S44.
[17] Ernst JD. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012 Jul
13;12(8):581-591.
[18] Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A
prospective study of the risk of tuberculosis among intravenous drug users with hu‐
man immunodeficiency virus infection. N Engl J Med 1989 Mar 2;320(9):545-550.
[19] Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J,
et al. Predictive value of interferon-gamma release assays for incident active tubercu‐
losis: a systematic review and meta-analysis. Lancet Infect Dis 2012 Jan;12(1):45-55.
[20] Horowitz HW, Luciano BB, Kadel JR, Wormser GP. Tuberculin skin test conversion
in hospital employees vaccinated with bacille Calmette-Guerin: recent Mycobacteri‐
um tuberculosis infection or booster effect? Am J Infect Control 1995 Jun;23(3):
181-187.
[21] Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what
is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung
Dis 2006 Nov;10(11):1192-1204.
[22] Long SS. Interferon-gamma release assay for evaluation of latent tuberculosis infec‐
tion. J Pediatr 2012 Oct;161(4):A3.
[23] Gengenbacher M, Kaufmann SH. Mycobacterium tuberculosis: success through dor‐
mancy. FEMS Microbiol Rev 2012 May;36(3):514-532.
[24] Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient star‐
vation model of Mycobacterium tuberculosis persistence by gene and protein expres‐
sion profiling. Mol Microbiol 2002 Feb;43(3):717-731.
[25] Boon C, Dick T. How Mycobacterium tuberculosis goes to sleep: the dormancy sur‐
vival regulator DosR a decade later. Future Microbiol 2012 Apr;7(4):513-518.
[26] Flynn JL, Chan J. Tuberculosis: latency and reactivation. Infect Immun 2001 Jul;69(7):
4195-4201.
Tuberculosis - Current Issues in Diagnosis and Management228
[27] Chao MC, Rubin EJ. Letting sleeping dos lie: does dormancy play a role in tuberculo‐
sis? Annu Rev Microbiol 2010;64:293-311.
[28] David HL. Probability distribution of drug-resistant mutants in unselected popula‐
tions of Mycobacterium tuberculosis. Appl Microbiol 1970 Nov;20(5):810-814.
[29] Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and iso‐
niazid resistance of Mycobacterium tuberculosis. Nature 1992 Aug 13;358(6387):
591-593.
[30] Hazbon MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, Var‐
ma-Basil M, et al. Population genetics study of isoniazid resistance mutations and
evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents
Chemother 2006 Aug;50(8):2640-2649.
[31] Rozwarski DA, Grant GA, Barton DH, Jacobs WR,Jr, Sacchettini JC. Modification of
the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science
1998 Jan 2;279(5347):98-102.
[32] Heym B, Alzari PM, Honore N, Cole ST. Missense mutations in the catalase-peroxi‐
dase gene, katG, are associated with isoniazid resistance in Mycobacterium tubercu‐
losis. Mol Microbiol 1995 Jan;15(2):235-245.
[33] Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of
rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993 Mar
13;341(8846):647-650.
[34] Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotina‐
midase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacil‐
lus. Nat Med 1996 Jun;2(6):662-667.
[35] Telenti A, Philipp WJ, Sreevatsan S, Bernasconi C, Stockbauer KE, Wieles B, et al. The
emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to
ethambutol. Nat Med 1997 May;3(5):567-570.
[36] Ramaswamy SV, Amin AG, Goksel S, Stager CE, Dou SJ, El Sahly H, et al. Molecular
genetic analysis of nucleotide polymorphisms associated with ethambutol resistance
in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother
2000 Feb;44(2):326-336.
[37] Vareldzis BP, Grosset J, de Kantor I, Crofton J, Laszlo A, Felten M, et al. Drug-resist‐
ant tuberculosis: laboratory issues. World Health Organization recommendations.
Tuber Lung Dis 1994 Feb;75(1):1-7.
[38] Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, et al. Stand‐
ard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes
in 6 countries. JAMA 2000 May 17;283(19):2537-2545.
Management of Drug-Resistant TB
http://dx.doi.org/10.5772/55531
229
[12] Treatment of Tuberculosis Guidelines, 4th edition. 2010. Available at: http://whqlib‐
doc.who.int/publications/2010/9789241547833_eng.pdf
[13] Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis.
Int J Tuberc Lung Dis 2009 Nov;13(11):1320-1330.
[14] Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy.
Tubercle 1985 Sep;66(3):219-225.
[15] Wade MM, Zhang Y. Anaerobic incubation conditions enhance pyrazinamide activi‐
ty against Mycobacterium tuberculosis. J Med Microbiol 2004 Aug;53(Pt 8):769-773.
[16] Kaufmann SH, McMichael AJ. Annulling a dangerous liaison: vaccination strategies
against AIDS and tuberculosis. Nat Med 2005 04;11(4):S33-S44.
[17] Ernst JD. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012 Jul
13;12(8):581-591.
[18] Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A
prospective study of the risk of tuberculosis among intravenous drug users with hu‐
man immunodeficiency virus infection. N Engl J Med 1989 Mar 2;320(9):545-550.
[19] Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J,
et al. Predictive value of interferon-gamma release assays for incident active tubercu‐
losis: a systematic review and meta-analysis. Lancet Infect Dis 2012 Jan;12(1):45-55.
[20] Horowitz HW, Luciano BB, Kadel JR, Wormser GP. Tuberculin skin test conversion
in hospital employees vaccinated with bacille Calmette-Guerin: recent Mycobacteri‐
um tuberculosis infection or booster effect? Am J Infect Control 1995 Jun;23(3):
181-187.
[21] Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what
is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung
Dis 2006 Nov;10(11):1192-1204.
[22] Long SS. Interferon-gamma release assay for evaluation of latent tuberculosis infec‐
tion. J Pediatr 2012 Oct;161(4):A3.
[23] Gengenbacher M, Kaufmann SH. Mycobacterium tuberculosis: success through dor‐
mancy. FEMS Microbiol Rev 2012 May;36(3):514-532.
[24] Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient star‐
vation model of Mycobacterium tuberculosis persistence by gene and protein expres‐
sion profiling. Mol Microbiol 2002 Feb;43(3):717-731.
[25] Boon C, Dick T. How Mycobacterium tuberculosis goes to sleep: the dormancy sur‐
vival regulator DosR a decade later. Future Microbiol 2012 Apr;7(4):513-518.
[26] Flynn JL, Chan J. Tuberculosis: latency and reactivation. Infect Immun 2001 Jul;69(7):
4195-4201.
Tuberculosis - Current Issues in Diagnosis and Management228
[27] Chao MC, Rubin EJ. Letting sleeping dos lie: does dormancy play a role in tuberculo‐
sis? Annu Rev Microbiol 2010;64:293-311.
[28] David HL. Probability distribution of drug-resistant mutants in unselected popula‐
tions of Mycobacterium tuberculosis. Appl Microbiol 1970 Nov;20(5):810-814.
[29] Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and iso‐
niazid resistance of Mycobacterium tuberculosis. Nature 1992 Aug 13;358(6387):
591-593.
[30] Hazbon MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, Var‐
ma-Basil M, et al. Population genetics study of isoniazid resistance mutations and
evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents
Chemother 2006 Aug;50(8):2640-2649.
[31] Rozwarski DA, Grant GA, Barton DH, Jacobs WR,Jr, Sacchettini JC. Modification of
the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science
1998 Jan 2;279(5347):98-102.
[32] Heym B, Alzari PM, Honore N, Cole ST. Missense mutations in the catalase-peroxi‐
dase gene, katG, are associated with isoniazid resistance in Mycobacterium tubercu‐
losis. Mol Microbiol 1995 Jan;15(2):235-245.
[33] Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of
rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993 Mar
13;341(8846):647-650.
[34] Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotina‐
midase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacil‐
lus. Nat Med 1996 Jun;2(6):662-667.
[35] Telenti A, Philipp WJ, Sreevatsan S, Bernasconi C, Stockbauer KE, Wieles B, et al. The
emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to
ethambutol. Nat Med 1997 May;3(5):567-570.
[36] Ramaswamy SV, Amin AG, Goksel S, Stager CE, Dou SJ, El Sahly H, et al. Molecular
genetic analysis of nucleotide polymorphisms associated with ethambutol resistance
in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother
2000 Feb;44(2):326-336.
[37] Vareldzis BP, Grosset J, de Kantor I, Crofton J, Laszlo A, Felten M, et al. Drug-resist‐
ant tuberculosis: laboratory issues. World Health Organization recommendations.
Tuber Lung Dis 1994 Feb;75(1):1-7.
[38] Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, et al. Stand‐
ard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes
in 6 countries. JAMA 2000 May 17;283(19):2537-2545.
Management of Drug-Resistant TB
http://dx.doi.org/10.5772/55531
229
[39] Furin JJ, Mitnick CD, Shin SS, Bayona J, Becerra MC, Singler JM, et al. Occurrence of
serious adverse effects in patients receiving community-based therapy for multi‐
drug-resistant tuberculosis. Int J Tuberc Lung Dis 2001 Jul;5(7):648-655.
[40] Moore DA, Evans CA, Gilman RH, Caviedes L, Coronel J, Vivar A, et al. Microscop‐
ic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006
Oct 12;355(15):1539-1550.
[41] Reisner BS, Gatson AM, Woods GL. Evaluation of mycobacteria growth indicator
tubes for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifam‐
pin. Diagn Microbiol Infect Dis 1995 Aug;22(4):325-329.
[42] Levine ML, Moskowitz GW, Dorf BS, Bank S. Pneumatic dilation in patients with
achalasia with a modified Gruntzig dilator (Levine) under direct endoscopic control:
results after 5 years. Am J Gastroenterol 1991 Nov;86(11):1581-1584.
[43] Martin A, Portaels F, Palomino JC. Colorimetric redox-indicator methods for the rap‐
id detection of multidrug resistance in Mycobacterium tuberculosis: a systematic re‐
view and meta-analysis. J Antimicrob Chemother 2007 Feb;59(2):175-183.
[44] Montoro E, Lemus D, Echemendia M, Martin A, Portaels F, Palomino JC. Compara‐
tive evaluation of the nitrate reduction assay, the MTT test, and the resazurin micro‐
titre assay for drug susceptibility testing of clinical isolates of Mycobacterium
tuberculosis. J Antimicrob Chemother 2005 Apr;55(4):500-505.
[45] Bwanga F, Joloba ML, Haile M, Hoffner S. Evaluation of seven tests for the rapid de‐
tection of multidrug-resistant tuberculosis in Uganda. Int J Tuberc Lung Dis 2010 Jul;
14(7):890-895.
[46] Caminero JA, World Health Organization, American Thoracic Society, British Thora‐
cic Society. Treatment of multidrug-resistant tuberculosis: evidence and controver‐
sies. Int J Tuberc Lung Dis 2006 Aug;10(8):829-837.
[47] Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, et al. Comprehensive
treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008 Aug 7;359(6):
563-574.
[48] Iseman MD. MDR-TB and the developing world--a problem no longer to be ignored:
the WHO announces 'DOTS Plus' strategy. Int J Tuberc Lung Dis 1998 Nov;2(11):867.
[49] Tupasi TE, Gupta R, Quelapio MI, Orillaza RB, Mira NR, Mangubat NV, et al. Feasi‐
bility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort
study in the Philippines. PLoS Med 2006 Sep;3(9):e352.
[50] Tupasi TE, Quelapio MI, Orillaza RB, Alcantara C, Mira NR, Abeleda MR, et al.
DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance
urgently needed. Tuberculosis (Edinb) 2003;83(1-3):52-58.
Tuberculosis - Current Issues in Diagnosis and Management230
[51] Riekstina V, Leimane V, Holtz TH, Leimans J, Wells CD. Treatment outcome cohort
analysis in an integrated DOTS and DOTS-Plus TB program in Latvia. Int J Tuberc
Lung Dis 2007 May;11(5):585-587.
[52] Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy
for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research
Council. Am Rev Respir Dis 1987 Dec;136(6):1339-1342.
[53] O'Riordan P, Schwab U, Logan S, Cooke G, Wilkinson RJ, Davidson RN, et al. Rapid
molecular detection of rifampicin resistance facilitates early diagnosis and treatment
of multi-drug resistant tuberculosis: case control study. PLoS One 2008 Sep
9;3(9):e3173.
[54] Becerra MC, Freeman J, Bayona J, Shin SS, Kim JY, Furin JJ, et al. Using treatment
failure under effective directly observed short-course chemotherapy programs to
identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2000
Feb;4(2):108-114.
[55] Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-
resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010 Sep;
10(9):621-629.
[56] Sterling TR, Lehmann HP, Frieden TR. Impact of DOTS compared with DOTS-plus
on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ
2003 Mar 15;326(7389):574.
[57] Gupta R, Cegielski JP, Espinal MA, Henkens M, Kim JY, Lambregts-Van Weezenbeek
CS, et al. Increasing transparency in partnerships for health--introducing the Green
Light Committee. Trop Med Int Health 2002 Nov;7(11):970-976.
[58] Gupta R, Kim JY, Espinal MA, Caudron JM, Pecoul B, Farmer PE, et al. Public health.
Responding to market failures in tuberculosis control. Science 2001 Aug 10;293(5532):
1049-1051.
[59] Nathanson E, Lambregts-van Weezenbeek C, Rich ML, Gupta R, Bayona J, Blondal
K, et al. Multidrug-resistant tuberculosis management in resource-limited settings.
Emerg Infect Dis 2006 Sep;12(9):1389-1397.
[60] Grosset JH, Singer TG, Bishai WR. New drugs for the treatment of tuberculosis: hope
and reality. Int J Tuberc Lung Dis 2012 Aug;16(8):1005-1014.
[61] Rivers EC, Mancera RL. New anti-tuberculosis drugs in clinical trials with novel
mechanisms of action. Drug Discov Today 2008 Dec;13(23-24):1090-1098.
[62] Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, Tupasi TE, et al.
Adverse events in the treatment of multidrug-resistant tuberculosis: results from the
DOTS-Plus initiative. Int J Tuberc Lung Dis 2004 Nov;8(11):1382-1384.
Management of Drug-Resistant TB
http://dx.doi.org/10.5772/55531
231
[39] Furin JJ, Mitnick CD, Shin SS, Bayona J, Becerra MC, Singler JM, et al. Occurrence of
serious adverse effects in patients receiving community-based therapy for multi‐
drug-resistant tuberculosis. Int J Tuberc Lung Dis 2001 Jul;5(7):648-655.
[40] Moore DA, Evans CA, Gilman RH, Caviedes L, Coronel J, Vivar A, et al. Microscop‐
ic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006
Oct 12;355(15):1539-1550.
[41] Reisner BS, Gatson AM, Woods GL. Evaluation of mycobacteria growth indicator
tubes for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifam‐
pin. Diagn Microbiol Infect Dis 1995 Aug;22(4):325-329.
[42] Levine ML, Moskowitz GW, Dorf BS, Bank S. Pneumatic dilation in patients with
achalasia with a modified Gruntzig dilator (Levine) under direct endoscopic control:
results after 5 years. Am J Gastroenterol 1991 Nov;86(11):1581-1584.
[43] Martin A, Portaels F, Palomino JC. Colorimetric redox-indicator methods for the rap‐
id detection of multidrug resistance in Mycobacterium tuberculosis: a systematic re‐
view and meta-analysis. J Antimicrob Chemother 2007 Feb;59(2):175-183.
[44] Montoro E, Lemus D, Echemendia M, Martin A, Portaels F, Palomino JC. Compara‐
tive evaluation of the nitrate reduction assay, the MTT test, and the resazurin micro‐
titre assay for drug susceptibility testing of clinical isolates of Mycobacterium
tuberculosis. J Antimicrob Chemother 2005 Apr;55(4):500-505.
[45] Bwanga F, Joloba ML, Haile M, Hoffner S. Evaluation of seven tests for the rapid de‐
tection of multidrug-resistant tuberculosis in Uganda. Int J Tuberc Lung Dis 2010 Jul;
14(7):890-895.
[46] Caminero JA, World Health Organization, American Thoracic Society, British Thora‐
cic Society. Treatment of multidrug-resistant tuberculosis: evidence and controver‐
sies. Int J Tuberc Lung Dis 2006 Aug;10(8):829-837.
[47] Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, et al. Comprehensive
treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008 Aug 7;359(6):
563-574.
[48] Iseman MD. MDR-TB and the developing world--a problem no longer to be ignored:
the WHO announces 'DOTS Plus' strategy. Int J Tuberc Lung Dis 1998 Nov;2(11):867.
[49] Tupasi TE, Gupta R, Quelapio MI, Orillaza RB, Mira NR, Mangubat NV, et al. Feasi‐
bility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort
study in the Philippines. PLoS Med 2006 Sep;3(9):e352.
[50] Tupasi TE, Quelapio MI, Orillaza RB, Alcantara C, Mira NR, Abeleda MR, et al.
DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance
urgently needed. Tuberculosis (Edinb) 2003;83(1-3):52-58.
Tuberculosis - Current Issues in Diagnosis and Management230
[51] Riekstina V, Leimane V, Holtz TH, Leimans J, Wells CD. Treatment outcome cohort
analysis in an integrated DOTS and DOTS-Plus TB program in Latvia. Int J Tuberc
Lung Dis 2007 May;11(5):585-587.
[52] Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy
for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research
Council. Am Rev Respir Dis 1987 Dec;136(6):1339-1342.
[53] O'Riordan P, Schwab U, Logan S, Cooke G, Wilkinson RJ, Davidson RN, et al. Rapid
molecular detection of rifampicin resistance facilitates early diagnosis and treatment
of multi-drug resistant tuberculosis: case control study. PLoS One 2008 Sep
9;3(9):e3173.
[54] Becerra MC, Freeman J, Bayona J, Shin SS, Kim JY, Furin JJ, et al. Using treatment
failure under effective directly observed short-course chemotherapy programs to
identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2000
Feb;4(2):108-114.
[55] Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-
resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010 Sep;
10(9):621-629.
[56] Sterling TR, Lehmann HP, Frieden TR. Impact of DOTS compared with DOTS-plus
on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ
2003 Mar 15;326(7389):574.
[57] Gupta R, Cegielski JP, Espinal MA, Henkens M, Kim JY, Lambregts-Van Weezenbeek
CS, et al. Increasing transparency in partnerships for health--introducing the Green
Light Committee. Trop Med Int Health 2002 Nov;7(11):970-976.
[58] Gupta R, Kim JY, Espinal MA, Caudron JM, Pecoul B, Farmer PE, et al. Public health.
Responding to market failures in tuberculosis control. Science 2001 Aug 10;293(5532):
1049-1051.
[59] Nathanson E, Lambregts-van Weezenbeek C, Rich ML, Gupta R, Bayona J, Blondal
K, et al. Multidrug-resistant tuberculosis management in resource-limited settings.
Emerg Infect Dis 2006 Sep;12(9):1389-1397.
[60] Grosset JH, Singer TG, Bishai WR. New drugs for the treatment of tuberculosis: hope
and reality. Int J Tuberc Lung Dis 2012 Aug;16(8):1005-1014.
[61] Rivers EC, Mancera RL. New anti-tuberculosis drugs in clinical trials with novel
mechanisms of action. Drug Discov Today 2008 Dec;13(23-24):1090-1098.
[62] Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, Tupasi TE, et al.
Adverse events in the treatment of multidrug-resistant tuberculosis: results from the
DOTS-Plus initiative. Int J Tuberc Lung Dis 2004 Nov;8(11):1382-1384.
Management of Drug-Resistant TB
http://dx.doi.org/10.5772/55531
231
[63] Baghaei P, Tabarsi P, Dorriz D, Marjani M, Shamaei M, Pooramiri MV, et al. Adverse
effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a
report from Iran. Am J Ther 2011 Mar-Apr;18(2):e29-34.
[64] Harris T, Bardien S, Schaaf HS, Petersen L, De Jong G, Fagan JJ. Aminoglycoside-in‐
duced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculo‐
sis patients. S Afr Med J 2012 May 8;102(6):363-366.
[65] Human H, Hagen CM, de Jong G, Harris T, Lombard D, Christiansen M, et al. Inves‐
tigation of mitochondrial sequence variants associated with aminoglycoside-induced
ototoxicity in South African TB patients on aminoglycosides. Biochem Biophys Res
Commun 2010 Mar 19;393(4):751-756.
[66] Qian Y, Guan MX. Interaction of aminoglycosides with human mitochondrial 12S
rRNA carrying the deafness-associated mutation. Antimicrob Agents Chemother
2009 Nov;53(11):4612-4618.
[67] Lambert MP, Neuhaus FC. Mechanism of d-Cycloserine Action: Alanine Racemase
from Escherichia coli W1. J Bacteriol 1972 Jun;110(3):978-987.
[68] Helmy B. Side effects of cycloserine. Scand J Respir Dis Suppl 1970;71:220-225.
[69] Pasargiklian M, Biondi L. Neurologic and behavioural reactions of tuberculous pa‐
tients treated with cycloserine. Scand J Respir Dis Suppl 1970;71:201-208.
[70] Villar TG. Personal experience with cycloserine in 206 patients with pulmonary tu‐
berculosis. Scand J Respir Dis Suppl 1970;71:196-200.
[71] Wood PL, Emmett MR, Rao TS, Mick S, Cler J, Iyengar S. In vivo modulation of the
N-methyl-D-aspartate receptor complex by D-serine: potentiation of ongoing neuro‐
nal activity as evidenced by increased cerebellar cyclic GMP. J Neurochem 1989 Sep;
53(3):979-981.
[72] Weinberg RJ. Glutamate: an excitatory neurotransmitter in the mammalian CNS.
Brain Res Bull 1999 Nov-Dec;50(5-6):353-354.
[73] Esteves Pinto E. Suicide of two patients during the postoperative course after pulmo‐
nary resection: possible effect of cycloserine. Scand J Respir Dis Suppl
1970;71:256-258.
[74] Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcantara F, et al. Community-based
therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003 Jan
9;348(2):119-128.
[75] Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, et al.
Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in
Latvia: a retrospective cohort study. Lancet 2005 Jan 22-28;365(9456):318-326.
Tuberculosis - Current Issues in Diagnosis and Management232
[76] ECDC Guidance. Management of contacts of MDR TB and XDR TB patients. 2012.
Available at: http://www.ecdc.europa.eu/en/publications/Publications/201203-Guid‐
ance-MDR-TB-contacts.pdf
[77] Duarte R, Neto M, Carvalho A, Barros H. Improving tuberculosis contact tracing: the
role of evaluations in the home and workplace. Int J Tuberc Lung Dis 2012 Jan;16(1):
55-59.
[78] Kritski AL, Marques MJ, Rabahi MF, Vieira MA, Werneck-Barroso E, Carvalho CE, et
al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant
tuberculosis. Am J Respir Crit Care Med 1996 Jan;153(1):331-335.
[79] Furin JJ, Becerra MC, Shin SS, Kim JY, Bayona J, Farmer PE. Effect of administering
short-course, standardized regimens in individuals infected with drug-resistant My‐
cobacterium tuberculosis strains. Eur J Clin Microbiol Infect Dis 2000 Feb;19(2):
132-136.
[80] van der Werf MJ, Langendam MW, Sandgren A, Manissero D. Lack of evidence to
support policy development for management of contacts of multidrug-resistant tu‐
berculosis patients: two systematic reviews. Int J Tuberc Lung Dis 2012;16(3):288-296.
[81] TB Case Definitions. Revision May 2011. Available at: http://www.stoptb.org/wg/gli/
assets/documents/TBcasedefinitions_20110506b.pdf
[82] Castelnuovo B. A review of compliance to anti tuberculosis treatment and risk fac‐
tors for defaulting treatment in Sub Saharan Africa. Afr Health Sci 2010 Dec;10(4):
320-324.
[83] Ereqat S, Spigelman M, Bar-Gal GK, Ramlawi A, Abdeen Z. MDR tuberculosis and
non-compliance with therapy. Lancet Infect Dis 2011 Sep;11(9):662.
[84] Cox H, Hughes J, Ford N, London L. MDR tuberculosis and non-compliance with
therapy. Lancet Infect Dis 2012 Mar;12(3):178; author reply 178-9.
[85] Upshur R, Singh J, Ford N. Apocalypse or redemption: responding to extensively
drug-resistant tuberculosis. Bull World Health Organ 2009 Jun;87(6):481-483.
[86] Rao SN, Mookerjee AL, Obasanjo OO, Chaisson RE. Errors in the treatment of tuber‐
culosis in Baltimore. Chest 2000 Mar;117(3):734-737.
[87] Alexy ER, Podewils LJ, Mitnick CD, Becerra MC, Laserson KF, Bonilla C. Concord‐
ance of programmatic and laboratory-based multidrug-resistant tuberculosis treat‐
ment outcomes in Peru. Int J Tuberc Lung Dis 2012;16(3):364-369.
[88] Singh VK, Chandra S, Kumar S, Pangtey G, Mohan A, Guleria R. A common medical
error: lung cancer misdiagnosed as sputum negative tuberculosis. Asian Pac J Cancer
Prev 2009 Jul-Sep;10(3):335-338.
Management of Drug-Resistant TB
http://dx.doi.org/10.5772/55531
233
[63] Baghaei P, Tabarsi P, Dorriz D, Marjani M, Shamaei M, Pooramiri MV, et al. Adverse
effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a
report from Iran. Am J Ther 2011 Mar-Apr;18(2):e29-34.
[64] Harris T, Bardien S, Schaaf HS, Petersen L, De Jong G, Fagan JJ. Aminoglycoside-in‐
duced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculo‐
sis patients. S Afr Med J 2012 May 8;102(6):363-366.
[65] Human H, Hagen CM, de Jong G, Harris T, Lombard D, Christiansen M, et al. Inves‐
tigation of mitochondrial sequence variants associated with aminoglycoside-induced
ototoxicity in South African TB patients on aminoglycosides. Biochem Biophys Res
Commun 2010 Mar 19;393(4):751-756.
[66] Qian Y, Guan MX. Interaction of aminoglycosides with human mitochondrial 12S
rRNA carrying the deafness-associated mutation. Antimicrob Agents Chemother
2009 Nov;53(11):4612-4618.
[67] Lambert MP, Neuhaus FC. Mechanism of d-Cycloserine Action: Alanine Racemase
from Escherichia coli W1. J Bacteriol 1972 Jun;110(3):978-987.
[68] Helmy B. Side effects of cycloserine. Scand J Respir Dis Suppl 1970;71:220-225.
[69] Pasargiklian M, Biondi L. Neurologic and behavioural reactions of tuberculous pa‐
tients treated with cycloserine. Scand J Respir Dis Suppl 1970;71:201-208.
[70] Villar TG. Personal experience with cycloserine in 206 patients with pulmonary tu‐
berculosis. Scand J Respir Dis Suppl 1970;71:196-200.
[71] Wood PL, Emmett MR, Rao TS, Mick S, Cler J, Iyengar S. In vivo modulation of the
N-methyl-D-aspartate receptor complex by D-serine: potentiation of ongoing neuro‐
nal activity as evidenced by increased cerebellar cyclic GMP. J Neurochem 1989 Sep;
53(3):979-981.
[72] Weinberg RJ. Glutamate: an excitatory neurotransmitter in the mammalian CNS.
Brain Res Bull 1999 Nov-Dec;50(5-6):353-354.
[73] Esteves Pinto E. Suicide of two patients during the postoperative course after pulmo‐
nary resection: possible effect of cycloserine. Scand J Respir Dis Suppl
1970;71:256-258.
[74] Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcantara F, et al. Community-based
therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003 Jan
9;348(2):119-128.
[75] Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, et al.
Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in
Latvia: a retrospective cohort study. Lancet 2005 Jan 22-28;365(9456):318-326.
Tuberculosis - Current Issues in Diagnosis and Management232
[76] ECDC Guidance. Management of contacts of MDR TB and XDR TB patients. 2012.
Available at: http://www.ecdc.europa.eu/en/publications/Publications/201203-Guid‐
ance-MDR-TB-contacts.pdf
[77] Duarte R, Neto M, Carvalho A, Barros H. Improving tuberculosis contact tracing: the
role of evaluations in the home and workplace. Int J Tuberc Lung Dis 2012 Jan;16(1):
55-59.
[78] Kritski AL, Marques MJ, Rabahi MF, Vieira MA, Werneck-Barroso E, Carvalho CE, et
al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant
tuberculosis. Am J Respir Crit Care Med 1996 Jan;153(1):331-335.
[79] Furin JJ, Becerra MC, Shin SS, Kim JY, Bayona J, Farmer PE. Effect of administering
short-course, standardized regimens in individuals infected with drug-resistant My‐
cobacterium tuberculosis strains. Eur J Clin Microbiol Infect Dis 2000 Feb;19(2):
132-136.
[80] van der Werf MJ, Langendam MW, Sandgren A, Manissero D. Lack of evidence to
support policy development for management of contacts of multidrug-resistant tu‐
berculosis patients: two systematic reviews. Int J Tuberc Lung Dis 2012;16(3):288-296.
[81] TB Case Definitions. Revision May 2011. Available at: http://www.stoptb.org/wg/gli/
assets/documents/TBcasedefinitions_20110506b.pdf
[82] Castelnuovo B. A review of compliance to anti tuberculosis treatment and risk fac‐
tors for defaulting treatment in Sub Saharan Africa. Afr Health Sci 2010 Dec;10(4):
320-324.
[83] Ereqat S, Spigelman M, Bar-Gal GK, Ramlawi A, Abdeen Z. MDR tuberculosis and
non-compliance with therapy. Lancet Infect Dis 2011 Sep;11(9):662.
[84] Cox H, Hughes J, Ford N, London L. MDR tuberculosis and non-compliance with
therapy. Lancet Infect Dis 2012 Mar;12(3):178; author reply 178-9.
[85] Upshur R, Singh J, Ford N. Apocalypse or redemption: responding to extensively
drug-resistant tuberculosis. Bull World Health Organ 2009 Jun;87(6):481-483.
[86] Rao SN, Mookerjee AL, Obasanjo OO, Chaisson RE. Errors in the treatment of tuber‐
culosis in Baltimore. Chest 2000 Mar;117(3):734-737.
[87] Alexy ER, Podewils LJ, Mitnick CD, Becerra MC, Laserson KF, Bonilla C. Concord‐
ance of programmatic and laboratory-based multidrug-resistant tuberculosis treat‐
ment outcomes in Peru. Int J Tuberc Lung Dis 2012;16(3):364-369.
[88] Singh VK, Chandra S, Kumar S, Pangtey G, Mohan A, Guleria R. A common medical
error: lung cancer misdiagnosed as sputum negative tuberculosis. Asian Pac J Cancer
Prev 2009 Jul-Sep;10(3):335-338.
Management of Drug-Resistant TB
http://dx.doi.org/10.5772/55531
233
[89] Van Deun A, Salim MA, Das AP, Bastian I, Portaels F. Results of a standardised regi‐
men for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004
May;8(5):560-567.
[90] Mukherjee JS, Rich ML, Socci AR, Joseph JK, Viru FA, Shin SS, et al. Programmes and
principles in treatment of multidrug-resistant tuberculosis. Lancet 2004 Feb
7;363(9407):474-481.
[91] WHO. Guidelines for the programmatic management of drug-resistant tuberculosis.
2011. Available at: http://whqlibdoc.who.int/publications/
2011/9789241501583_eng.pdf.
[92] Cobelens FG, Heldal E, Kimerling ME, Mitnick CD, Podewils LJ, Ramachandran R, et
al. Scaling up programmatic management of drug-resistant tuberculosis: a priori‐
tized research agenda. PLoS Med 2008 Jul 8;5(7):e150.
[93] WHO. The Global MDR-TB & XDR-TB Response Plan 2007-2008. 2007. Available at:
http://whqlibdoc.who.int/hq/2007/who_htm_tb_2007.387_eng.pdf.
[94] Shanks L, Masumbuko EW, Ngoy NM, Maneno M, Bartlett S, Thi SS, et al. Treatment
of multidrug-resistant tuberculosis in a remote, conflict-affected area of the Demo‐
cratic Republic of Congo. Int J Tuberc Lung Dis 2012 Aug;16(8):1066-1068.
[95] Daftary A, Padayatchi N. Social constraints to TB/HIV healthcare: Accounts from co‐
infected patients in South Africa. AIDS Care 2012 Dec;24(12):1480-1486.
[96] Mauch V, Woods N, Kirubi B, Kipruto H, Sitienei J, Klinkenberg E. Assessing access
barriers to tuberculosis care with the tool to Estimate Patients' Costs: pilot results
from two districts in Kenya. BMC Public Health 2011 Jan 18;11:43.
[97] Lin X, Chongsuvivatwong V, Geater A, Lijuan R. The effect of geographical distance
on TB patient delays in a mountainous province of China. Int J Tuberc Lung Dis 2008
Mar;12(3):288-293.
[98] Ngang PN, Ntaganira J, Kalk A, Wolter S, Ecks S. Perceptions and beliefs about
cough and tuberculosis and implications for TB control in rural Rwanda. Int J Tuberc
Lung Dis 2007 Oct;11(10):1108-1113.
[99] Gupta R, Espinal M, Stop TB Working Group on DOTS-Plus for MDR-TB. A priori‐
tised research agenda for DOTS-Plus for multidrug-resistant tuberculosis (MDR-TB).
Int J Tuberc Lung Dis 2003 May;7(5):410-414.
[100] Zellmer E, Zhang Z, Greco D, Rhodes J, Cassel S, Lewis EJ. A homeodomain protein
selectively expressed in noradrenergic tissue regulates transcription of neurotrans‐
mitter biosynthetic genes. J Neurosci 1995 Dec;15(12):8109-8120.
[101] Cueto M. The origins of primary health care and selective primary health care. Am J
Public Health 2004 Nov;94(11):1864-1874.
Tuberculosis - Current Issues in Diagnosis and Management234
[102] TB CTA. Patient Centered Approach Strategy. Available at: http://www.tbcare1.org/
publications/toolbox/tools/access/PCA_Booklet.pdf.
[103] Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence
to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007
Jul 24;4(7):e238.
[104] Doctors without borders. Tuberculosis, 2012. Available at: http://www.doctorswi‐
thoutborders.org/news/issue.cfm?id=2404.
[105] Jakubowiak WM, Bogorodskaya EM, Borisov SE, Danilova ID, Kourbatova EV. Risk
factors associated with default among new pulmonary TB patients and social sup‐
port in six Russian regions. Int J Tuberc Lung Dis 2007 Jan;11(1):46-53.
[106] Gelmanova IY, Taran DV, Mishustin SP, Golubkov AA, Solovyova AV, Keshavjee S.
'Sputnik': a programmatic approach to improve tuberculosis treatment adherence
and outcome among defaulters. Int J Tuberc Lung Dis 2011 Oct;15(10):1373-1379.
[107] Chalco K, Wu DY, Mestanza L, Munoz M, Llaro K, Guerra D, et al. Nurses as provid‐
ers of emotional support to patients with MDR-TB. Int Nurs Rev 2006 Dec;53(4):
253-260.
[108] US Centers for Disease Control. Tuberculosis (TB). 2012; Available at: http://
www.cdc.gov/tb/publications/reportsarticles/iom/iomresponse/goal1.h tm. Guide‐
lines, 2012.
[109] C-Hub. Within Our Reach: A TB Literacy Toolkit, 2012. Available at: http://
www.fhi360.org/en/HIVAIDS/pub/res_TBLiteracy_Toolkit.htm.
[110] Menzies D, Fanning A, Yuan L, Fitzgerald M. Tuberculosis among health care work‐
ers. N Engl J Med 1995 Jan 12;332(2):92-98.
[111] Nardell E, Dharmadhikari A. Turning off the spigot: reducing drug-resistant tuber‐
culosis transmission in resource-limited settings. Int J Tuberc Lung Dis 2010 Oct;
14(10):1233-1243.
[112] Wilson TM, de Lisle GW, Collins DM. Effect of inhA and katG on isoniazid resistance
and virulence of Mycobacterium bovis. Mol Microbiol 1995 Mar;15(6):1009-1015.
[113] Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance
in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998;79(1):3-29.
[114] US Centers for Disease Control. Transmission of multidrug-resistant tuberculosis
among immunocompromised persons in a correctional system--New York, 1991.
MMWR Morb Mortal Wkly Rep 1992 Jul 17;41(28):507-509.
[115] US Centers for Disease Control. Outbreak of multidrug-resistant tuberculosis at a
hospital--New York City, 1991. MMWR Morb Mortal Wkly Rep 1993 Jun 11;42(22):
427, 433-4.
Management of Drug-Resistant TB
http://dx.doi.org/10.5772/55531
235
[89] Van Deun A, Salim MA, Das AP, Bastian I, Portaels F. Results of a standardised regi‐
men for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004
May;8(5):560-567.
[90] Mukherjee JS, Rich ML, Socci AR, Joseph JK, Viru FA, Shin SS, et al. Programmes and
principles in treatment of multidrug-resistant tuberculosis. Lancet 2004 Feb
7;363(9407):474-481.
[91] WHO. Guidelines for the programmatic management of drug-resistant tuberculosis.
2011. Available at: http://whqlibdoc.who.int/publications/
2011/9789241501583_eng.pdf.
[92] Cobelens FG, Heldal E, Kimerling ME, Mitnick CD, Podewils LJ, Ramachandran R, et
al. Scaling up programmatic management of drug-resistant tuberculosis: a priori‐
tized research agenda. PLoS Med 2008 Jul 8;5(7):e150.
[93] WHO. The Global MDR-TB & XDR-TB Response Plan 2007-2008. 2007. Available at:
http://whqlibdoc.who.int/hq/2007/who_htm_tb_2007.387_eng.pdf.
[94] Shanks L, Masumbuko EW, Ngoy NM, Maneno M, Bartlett S, Thi SS, et al. Treatment
of multidrug-resistant tuberculosis in a remote, conflict-affected area of the Demo‐
cratic Republic of Congo. Int J Tuberc Lung Dis 2012 Aug;16(8):1066-1068.
[95] Daftary A, Padayatchi N. Social constraints to TB/HIV healthcare: Accounts from co‐
infected patients in South Africa. AIDS Care 2012 Dec;24(12):1480-1486.
[96] Mauch V, Woods N, Kirubi B, Kipruto H, Sitienei J, Klinkenberg E. Assessing access
barriers to tuberculosis care with the tool to Estimate Patients' Costs: pilot results
from two districts in Kenya. BMC Public Health 2011 Jan 18;11:43.
[97] Lin X, Chongsuvivatwong V, Geater A, Lijuan R. The effect of geographical distance
on TB patient delays in a mountainous province of China. Int J Tuberc Lung Dis 2008
Mar;12(3):288-293.
[98] Ngang PN, Ntaganira J, Kalk A, Wolter S, Ecks S. Perceptions and beliefs about
cough and tuberculosis and implications for TB control in rural Rwanda. Int J Tuberc
Lung Dis 2007 Oct;11(10):1108-1113.
[99] Gupta R, Espinal M, Stop TB Working Group on DOTS-Plus for MDR-TB. A priori‐
tised research agenda for DOTS-Plus for multidrug-resistant tuberculosis (MDR-TB).
Int J Tuberc Lung Dis 2003 May;7(5):410-414.
[100] Zellmer E, Zhang Z, Greco D, Rhodes J, Cassel S, Lewis EJ. A homeodomain protein
selectively expressed in noradrenergic tissue regulates transcription of neurotrans‐
mitter biosynthetic genes. J Neurosci 1995 Dec;15(12):8109-8120.
[101] Cueto M. The origins of primary health care and selective primary health care. Am J
Public Health 2004 Nov;94(11):1864-1874.
Tuberculosis - Current Issues in Diagnosis and Management234
[102] TB CTA. Patient Centered Approach Strategy. Available at: http://www.tbcare1.org/
publications/toolbox/tools/access/PCA_Booklet.pdf.
[103] Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence
to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007
Jul 24;4(7):e238.
[104] Doctors without borders. Tuberculosis, 2012. Available at: http://www.doctorswi‐
thoutborders.org/news/issue.cfm?id=2404.
[105] Jakubowiak WM, Bogorodskaya EM, Borisov SE, Danilova ID, Kourbatova EV. Risk
factors associated with default among new pulmonary TB patients and social sup‐
port in six Russian regions. Int J Tuberc Lung Dis 2007 Jan;11(1):46-53.
[106] Gelmanova IY, Taran DV, Mishustin SP, Golubkov AA, Solovyova AV, Keshavjee S.
'Sputnik': a programmatic approach to improve tuberculosis treatment adherence
and outcome among defaulters. Int J Tuberc Lung Dis 2011 Oct;15(10):1373-1379.
[107] Chalco K, Wu DY, Mestanza L, Munoz M, Llaro K, Guerra D, et al. Nurses as provid‐
ers of emotional support to patients with MDR-TB. Int Nurs Rev 2006 Dec;53(4):
253-260.
[108] US Centers for Disease Control. Tuberculosis (TB). 2012; Available at: http://
www.cdc.gov/tb/publications/reportsarticles/iom/iomresponse/goal1.h tm. Guide‐
lines, 2012.
[109] C-Hub. Within Our Reach: A TB Literacy Toolkit, 2012. Available at: http://
www.fhi360.org/en/HIVAIDS/pub/res_TBLiteracy_Toolkit.htm.
[110] Menzies D, Fanning A, Yuan L, Fitzgerald M. Tuberculosis among health care work‐
ers. N Engl J Med 1995 Jan 12;332(2):92-98.
[111] Nardell E, Dharmadhikari A. Turning off the spigot: reducing drug-resistant tuber‐
culosis transmission in resource-limited settings. Int J Tuberc Lung Dis 2010 Oct;
14(10):1233-1243.
[112] Wilson TM, de Lisle GW, Collins DM. Effect of inhA and katG on isoniazid resistance
and virulence of Mycobacterium bovis. Mol Microbiol 1995 Mar;15(6):1009-1015.
[113] Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance
in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998;79(1):3-29.
[114] US Centers for Disease Control. Transmission of multidrug-resistant tuberculosis
among immunocompromised persons in a correctional system--New York, 1991.
MMWR Morb Mortal Wkly Rep 1992 Jul 17;41(28):507-509.
[115] US Centers for Disease Control. Outbreak of multidrug-resistant tuberculosis at a
hospital--New York City, 1991. MMWR Morb Mortal Wkly Rep 1993 Jun 11;42(22):
427, 433-4.
Management of Drug-Resistant TB
http://dx.doi.org/10.5772/55531
235
[116] Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, et al. Surveil‐
lance of anti-tuberculosis drug resistance in the world: an updated analysis,
2007-2010. Bull World Health Organ 2012 Feb 1;90(2):111-119D.
[117] Robert J, Trystram D, Truffot-Pernot C, Cambau E, Jarlier V, Grosset J. Twenty-five
years of tuberculosis in a French university hospital: a laboratory perspective. Int J
Tuberc Lung Dis 2000 Jun;4(6):504-512.
[118] Mendoza MT, Gonzaga AJ, Roa C, Velmonte MA, Jorge M, Montoya JC, et al. Nature
of drug resistance and predictors of multidrug-resistant tuberculosis among patients
seen at the Philippine General Hospital, Manila, Philippines. Int J Tuberc Lung Dis
1997 Feb;1(1):59-63.
[119] Van Rie A, Warren R, Richardson M, Gie RP, Enarson DA, Beyers N, et al. Classifica‐
tion of drug-resistant tuberculosis in an epidemic area. Lancet 2000 Jul 1;356(9223):
22-25.
[120] Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively
drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculo‐
sis and HIV in a rural area of South Africa. Lancet 2006 Nov 4;368(9547):1575-1580.
[121] Gelmanova IY, Keshavjee S, Golubchikova VT, Berezina VI, Strelis AK, Yanova GV,
et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation:
non-adherence, default and the acquisition of multidrug resistance. Bull World
Health Organ 2007 Sep;85(9):703-711.
[122] Pearson ML, Jereb JA, Frieden TR, Crawford JT, Davis BJ, Dooley SW, et al. Nosoco‐
mial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to pa‐
tients and health care workers. Ann Intern Med 1992 Aug 1;117(3):191-196.
[123] Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in
low- and middle-income countries: a systematic review. PLoS Med 2006 Dec;
3(12):e494.
[124] O'Donnell MR, Jarand J, Loveday M, Padayatchi N, Zelnick J, Werner L, et al. High
incidence of hospital admissions with multidrug-resistant and extensively drug-re‐
sistant tuberculosis among South African health care workers. Ann Intern Med 2010
Oct 19;153(8):516-522.
[125] Biscotto CR, Pedroso ER, Starling CE, Roth VR. Evaluation of N95 respirator use as a
tuberculosis control measure in a resource-limited setting. Int J Tuberc Lung Dis 2005
May;9(5):545-549.
[126] Kantor HS, Poblete R, Pusateri SL. Nosocomial transmission of tuberculosis from un‐
suspected disease. Am J Med 1988 May;84(5):833-838.
[127] US Centers for Disease Control. TB elimination. Infection control in health care sit‐
tings. Available at: http://www.cdc.gov/tb/publications/factsheets/prevention/
ichcs.pdf.
Tuberculosis - Current Issues in Diagnosis and Management236
[128] Maloney SA, Pearson ML, Gordon MT, Del Castillo R, Boyle JF, Jarvis WR. Efficacy
of control measures in preventing nosocomial transmission of multidrug-resistant tu‐
berculosis to patients and health care workers. Ann Intern Med 1995 Jan 15;122(2):
90-95.
Management of Drug-Resistant TB
http://dx.doi.org/10.5772/55531
237
[116] Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, et al. Surveil‐
lance of anti-tuberculosis drug resistance in the world: an updated analysis,
2007-2010. Bull World Health Organ 2012 Feb 1;90(2):111-119D.
[117] Robert J, Trystram D, Truffot-Pernot C, Cambau E, Jarlier V, Grosset J. Twenty-five
years of tuberculosis in a French university hospital: a laboratory perspective. Int J
Tuberc Lung Dis 2000 Jun;4(6):504-512.
[118] Mendoza MT, Gonzaga AJ, Roa C, Velmonte MA, Jorge M, Montoya JC, et al. Nature
of drug resistance and predictors of multidrug-resistant tuberculosis among patients
seen at the Philippine General Hospital, Manila, Philippines. Int J Tuberc Lung Dis
1997 Feb;1(1):59-63.
[119] Van Rie A, Warren R, Richardson M, Gie RP, Enarson DA, Beyers N, et al. Classifica‐
tion of drug-resistant tuberculosis in an epidemic area. Lancet 2000 Jul 1;356(9223):
22-25.
[120] Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively
drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculo‐
sis and HIV in a rural area of South Africa. Lancet 2006 Nov 4;368(9547):1575-1580.
[121] Gelmanova IY, Keshavjee S, Golubchikova VT, Berezina VI, Strelis AK, Yanova GV,
et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation:
non-adherence, default and the acquisition of multidrug resistance. Bull World
Health Organ 2007 Sep;85(9):703-711.
[122] Pearson ML, Jereb JA, Frieden TR, Crawford JT, Davis BJ, Dooley SW, et al. Nosoco‐
mial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to pa‐
tients and health care workers. Ann Intern Med 1992 Aug 1;117(3):191-196.
[123] Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in
low- and middle-income countries: a systematic review. PLoS Med 2006 Dec;
3(12):e494.
[124] O'Donnell MR, Jarand J, Loveday M, Padayatchi N, Zelnick J, Werner L, et al. High
incidence of hospital admissions with multidrug-resistant and extensively drug-re‐
sistant tuberculosis among South African health care workers. Ann Intern Med 2010
Oct 19;153(8):516-522.
[125] Biscotto CR, Pedroso ER, Starling CE, Roth VR. Evaluation of N95 respirator use as a
tuberculosis control measure in a resource-limited setting. Int J Tuberc Lung Dis 2005
May;9(5):545-549.
[126] Kantor HS, Poblete R, Pusateri SL. Nosocomial transmission of tuberculosis from un‐
suspected disease. Am J Med 1988 May;84(5):833-838.
[127] US Centers for Disease Control. TB elimination. Infection control in health care sit‐
tings. Available at: http://www.cdc.gov/tb/publications/factsheets/prevention/
ichcs.pdf.
Tuberculosis - Current Issues in Diagnosis and Management236
[128] Maloney SA, Pearson ML, Gordon MT, Del Castillo R, Boyle JF, Jarvis WR. Efficacy
of control measures in preventing nosocomial transmission of multidrug-resistant tu‐
berculosis to patients and health care workers. Ann Intern Med 1995 Jan 15;122(2):
90-95.




Drug-Resistant Tuberculosis – Diagnosis, Treatment,
Management and Control: The Experience in Thailand
Attapon  Cheepsattayakorn
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/54852
1. Introduction
Multidrug-resistant tuberculosis (MDR-TB) is defined as TB bacilli revealing resistance to at
least isoniazid and rifampicin whereas extensively drug-resistant tuberculosis (XDR-TB) is TB
bacilli that develops resistance to at least isoniazid and rifampicin as well as to any quinolone
drug and at least one of the second-line anti-TB injectable drug : kanamycin, amikacin, or
capreomycin. Report from the World Health Organization (WHO)/International Union
Against Tuberculosis and Lung Disease (IUATLD) Global Project on Drug Resistance Surveil‐
lance revealed that the prevalence of the primary multidrug-resistant tuberculosis during
1996-1999 ranged between 0-14.1 % [1]. In 1994, the first WHO-IUATLD global anti-TB drug
resistance surveillance was carried out in 35 countries and subsequently, the second, third and
fourth surveillances occurred in 1996-1999, 1999-2002 and 2002-2007, respectively. The
emergence of clinically significant MDR-TB was in the early 1990s. Reports of Primary Drug-
Resistance Surveillance in Thailand during 1997-1998, 2001-2002, and 2005-2006 were 2.02 %
[2], 0.93 % [3], and 1.65 % [4], respectively while the secondary drug-resistance in 2005-2006
revealed 34.54 % [4]. However, number of patients with MDR-TB demonstrated in 2008 Annual
Report of the Bureau of Tuberculosis, Thailand were only 294 while the WHO’ s estimated
number of patients were 2,774 [5]. The prevalence of primary plus secondary MDR-TB among
prisoners in Thailand in 2002-2003 was 5.3 % while the prevalence of primary MDR-TB was
5.9 % [6]. Report from the 10th Zonal Tuberculosis and Chest Disease Centre, Chiang Mai,
Thailand, 10th office of Disease prevention and Control, Department of Disease Control,
Ministry of Public Health, Thailand in 2011 revealed only 88 patients who registered with
MDR-TB at hospitals in northern Thailand [7] while only 16.3 %, 18.6 % and 18.6 % of 43 patients
with laboratory confirmation were cure, completeness of treatment, and dead, respectively in
2009 report [8]. Findings from the Bureau of Tuberculosis of Thailand ‘ s 2007-2009 Research
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Project on Anti-tuberculosis Drug Resistance Surveillance in Thailand (Situation of Multidrug-
Resistant Tuberculosis in Thailand : Fiscal Year 2007-2009) that studied in 126 hospitals
countrywide showed 877 patients with laboratory-confirmed MDR-TB and 64 patients with
laboratory-confirmed XDR-TB while 21.5 % were dead and 12.74 % of these MDR/XDR-TB
patients had human immunodeficiency virus (HIV) infection /acquired immunodeficiency
syndrome (AIDS) compared to 21.57% of probable or presumptive MDR-TB patients co-
infected with HIV/AIDS [9]. Only 18.2% of the studied data sources came from TB registered
book for MDR-TB patients and most of them came from the hospital medical registry [9]. A
previous study by Scano F et al. revealed 52 of the 53 patients with XDR-TB died [10]. The
median survival time from collection of specimen to death of these patients was 16 days [10].
The prevalence of XDR-TB among all MDR-TB patient was as the following : 10.3% in Germany
and 14.3% in Italy (1993-2004) ; 1.5% in Asia, 15.4% in Republic of Korea, 13.6% in Russia, 0.6%
in Africa and Middle East, 6.5% in industrialized countries, and 6.6% overall worldwide
(2000-2004); 12% in Hong Kong (2004); 10.9% in Iran (2006); 7.3% in India; and 4% in France
(2006) [11]. The WHO notified that Thailand possibly underreported of MDR/XDR-TB
prevalence due to delaying of transportation of the specimens for anti-tuberculosis drug
susceptibility testing to the specialized centres and processes of unstandardized data collecting
of the country [9]. More than 400,000 new MDR-TB cases globally occur each year while
approximately half of a million cases occurred in 2007 and accounted for more than 5% of the
annually global cases of TB disease. The emerging of drug-resistant TB is a global health
problem, although emphasis has been placed on several “ hotspots ” (higher than 3% of its
prevalence) worldwide because of lacking of good global data reported to the WHO. The
emergence of MDR-TB and XDR-TB is a real health threat to achieve TB elimination.
2. Epidemiology
Development of anti-tuberculosis drug resistance can occur due to Mycobacterium tuberculo‐
sis genetic factor, previous anti-tuberculosis treatment-related factors and many other factors
[11]. The mechanism of drug-resistance is shown in Figure 1. There is a constant rate of
spontaneous mutation of 0.0033 mutations/deoxyribonucleic acid (DNA) replication that is
unique for a diverse spectrum of prokaryotic organisms [12]. The average rates of spontaneous
mutation for rifampicin, isoniazid, pyrazinamide, streptomycin, and ethambutol are 2.25 x
10-10, 2.56 x 10-8, 1 x 10-3, 2.95 x 10-8, and 1.0 x 10-7, respectively [13]. A previous study in India
revealed 3.4% and 25% of primary and acquired MDR-TB, respectively [14] which were higher
than the primary MDR-TB and acquired MDR-TB prevalence previously surveyed in Thailand
[2,3,4]. Liu CH et al. reported their study in China which presented 19.4% of MDR-TB, 1.3% of
XDR-TB, 19.8% of poly-resistant TB, and 47.1% of any anti-tuberculosis drug resistance [15].
A surveillance data in 2007 from the WHO demonstrated 4.8% of MDR-TB cases among new
TB cases worldwide [16] compared to the study from MDR-TB surveillance in Thailand
between 2007-2009 revealed the MDR-TB prevalence of 0-0.21% (average 0.08%) which was
highest in the central part of Thailand [9]. The prevalence among patients with previously TB
treatment from the same surveillance project was between 1.58-58.72% (average 8.49%, higher
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than the percentage of hotspot of MDR-TB prevalence set by the WHO (3%, an indicator for
implementation of DOTS (Directly Observed Treatment, Short Course)-Plus programmes)
which was also found highest in the central part of Thailand while the northern part of Thailand
was the second [9]. This Thailand’s serious MDR-TB situation needs urgently management
such as implementation of DOTS-Plus programmes. In 2006, Gandhi NR et al. firstly reported
of XDR-TB co-infected with HIV/AIDS which had been studied in Kwazulu Natal, South Africa
(KZN) [11]. XDR-TB epidemic in South Africa appears to be the primary mechanism through
the acquisition of 63-75% of XDR-TB cases [11] whereas the strain of Mycobacterium tuberculo‐
sis infected among a large number of XDR-TB cases in KZN was F15/LAM4/KZN [11].
Generally, individual who is infected with Mycobacterium tuberculosis has approximately 5-10%
lifetime risk of developing TB disease, but in an individual with HIV-infection/AIDS the risk
is 5-15% a year [11]. This can contribute HIV-infection/AIDS to facilitate the control of
outbreaks of MDR-TB and XDR-TB, although it has contributed to outbreaks of drug-resistant
TB [17]. The patients with MDR-TB and HIV/AIDS co-infection will have exceedingly high
mortality [16]. Gandhi NR et al. recently reported their study on risk factors for mortality
among MDR/XDR-TB patients with HIV/AIDS co-infection which revealed that 80% of XDR-
TB patients died whereas 63% of MDR-TB patients were dead following the diagnosis [18].
The CD4-T cell count less than 50 cells/mm3 was the strongest independent factor for mortality
among both patient groups [18]. History of TB treatment is the most significant predictor of
development of MDR-TB [19]. High prevalence of HIV/AIDS co-infection and inadequate
resources for case detection and management have contributed to the emergence of untreatable
XDR-TB [20]. Unfortunately, the presence of XDR-TB in non—HIV-infected patients with
MDR-TB is independent poor prognostic factors [11]. Prevalence of XDR-TB is globally
accounted for approximately 5.4% of MDR-TB prevalence [21]. Drug-resistant TB and drug-
resistant gram-negative bacterial infection and disease are associated with the most serious
health problems in developing countries [22]. Estimated 81,000 patients with MDR-TB (18.4%
of the estimated MDR-TB patients worldwide in 2011) live in the 53 countries of the WHO
European Region [23]. This European MDR-TB problem contributed to launching of a new
WHO Regional Office for Europe Action Plan to fight MDR-TB to contain the spread of drug-
resistant TB in the region by the end of 2015 [23]. The new action plan set the targets to be
achieved by the end of 2015, are : 1) decreasing 20% of the proportion of MDR-TB cases among
previously treated patients 2) diagnosis of at least 85% of the estimated MDR-TB cases and 3)
treating successfully at least 75% of notified MDR-TB cases [23]. If this plan is fully imple‐
mented and expected, by 2015, to successfully treat 127,000 MDR-TB cases, and to prevent the
emergence of 250,000 new MDR-TB cases and 13,000 new XDR-TB cases [23]. This would
interrupt the transmission of MDR-TB and save 120,000 lives in this region [23].
3. Systematic management of MDR/XDR-TB
Diagnostic and treatment consultation networks for MDR/XDR-TB which set by the 10th Zonal
Tuberculosis and Chest Disease Centre, Chiang Mai, 10th Office of Disease Prevention and
Control, Department of Disease Control, Ministry of Public Health, Thailand beyond the year
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laboratory-confirmed XDR-TB while 21.5 % were dead and 12.74 % of these MDR/XDR-TB
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syndrome (AIDS) compared to 21.57% of probable or presumptive MDR-TB patients co-
infected with HIV/AIDS [9]. Only 18.2% of the studied data sources came from TB registered
book for MDR-TB patients and most of them came from the hospital medical registry [9]. A
previous study by Scano F et al. revealed 52 of the 53 patients with XDR-TB died [10]. The
median survival time from collection of specimen to death of these patients was 16 days [10].
The prevalence of XDR-TB among all MDR-TB patient was as the following : 10.3% in Germany
and 14.3% in Italy (1993-2004) ; 1.5% in Asia, 15.4% in Republic of Korea, 13.6% in Russia, 0.6%
in Africa and Middle East, 6.5% in industrialized countries, and 6.6% overall worldwide
(2000-2004); 12% in Hong Kong (2004); 10.9% in Iran (2006); 7.3% in India; and 4% in France
(2006) [11]. The WHO notified that Thailand possibly underreported of MDR/XDR-TB
prevalence due to delaying of transportation of the specimens for anti-tuberculosis drug
susceptibility testing to the specialized centres and processes of unstandardized data collecting
of the country [9]. More than 400,000 new MDR-TB cases globally occur each year while
approximately half of a million cases occurred in 2007 and accounted for more than 5% of the
annually global cases of TB disease. The emerging of drug-resistant TB is a global health
problem, although emphasis has been placed on several “ hotspots ” (higher than 3% of its
prevalence) worldwide because of lacking of good global data reported to the WHO. The
emergence of MDR-TB and XDR-TB is a real health threat to achieve TB elimination.
2. Epidemiology
Development of anti-tuberculosis drug resistance can occur due to Mycobacterium tuberculo‐
sis genetic factor, previous anti-tuberculosis treatment-related factors and many other factors
[11]. The mechanism of drug-resistance is shown in Figure 1. There is a constant rate of
spontaneous mutation of 0.0033 mutations/deoxyribonucleic acid (DNA) replication that is
unique for a diverse spectrum of prokaryotic organisms [12]. The average rates of spontaneous
mutation for rifampicin, isoniazid, pyrazinamide, streptomycin, and ethambutol are 2.25 x
10-10, 2.56 x 10-8, 1 x 10-3, 2.95 x 10-8, and 1.0 x 10-7, respectively [13]. A previous study in India
revealed 3.4% and 25% of primary and acquired MDR-TB, respectively [14] which were higher
than the primary MDR-TB and acquired MDR-TB prevalence previously surveyed in Thailand
[2,3,4]. Liu CH et al. reported their study in China which presented 19.4% of MDR-TB, 1.3% of
XDR-TB, 19.8% of poly-resistant TB, and 47.1% of any anti-tuberculosis drug resistance [15].
A surveillance data in 2007 from the WHO demonstrated 4.8% of MDR-TB cases among new
TB cases worldwide [16] compared to the study from MDR-TB surveillance in Thailand
between 2007-2009 revealed the MDR-TB prevalence of 0-0.21% (average 0.08%) which was
highest in the central part of Thailand [9]. The prevalence among patients with previously TB
treatment from the same surveillance project was between 1.58-58.72% (average 8.49%, higher
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TB patients died whereas 63% of MDR-TB patients were dead following the diagnosis [18].
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resistant TB in the region by the end of 2015 [23]. The new action plan set the targets to be
achieved by the end of 2015, are : 1) decreasing 20% of the proportion of MDR-TB cases among
previously treated patients 2) diagnosis of at least 85% of the estimated MDR-TB cases and 3)
treating successfully at least 75% of notified MDR-TB cases [23]. If this plan is fully imple‐
mented and expected, by 2015, to successfully treat 127,000 MDR-TB cases, and to prevent the
emergence of 250,000 new MDR-TB cases and 13,000 new XDR-TB cases [23]. This would
interrupt the transmission of MDR-TB and save 120,000 lives in this region [23].
3. Systematic management of MDR/XDR-TB
Diagnostic and treatment consultation networks for MDR/XDR-TB which set by the 10th Zonal
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2000 have been firstly initiated at tertiary care hospitals in northern Thailand. Data collecting
on MDR/XDR-TB control has been tracked through the special project paper-based recording
and reporting systems set by the 10th Zonal Tuberculosis and Chest Disease Centre which
separated from the routine DOTS recording and reporting systems. Currently, a new computer
programme has been developed by staff of this centre to efficiently record and report the MDR/
XDR-TB data in the area of northern Thailand and attempt to gradually extend the use of this
computer programme throughout the country.
4. Presumptive diagnosis of MDR-TB
The Thailand’ s 2012 National Tuberculosis Management Guidelines [24] set the criteria for
probable or suspected MDR-TB, are :
1. patients with history of TB retreatment, especially within 6 months after completeness of
treatment or cure,
2. patients with interruption of 6 month-short course chemotherapy (2HRZE/4HR, H=iso‐
niazid, R=rifampicin, Z=pyrazinamide, E=ethambutol) and having continuously positive-
sputum smear examinations after treatment interruption,
3. patients with history of multiple TB treatments, irregular anti-TB drug taking, and
persistently positive-sputum smear examinations,
4. patients having positive-sputum smear examinations at the end of second and fifth
months of the 6-month short course chemotherapy (2HRZE/4HR),
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treatment  is  the  most  significant  predictor  of  development  of  MDR-TB [19].  
High  prevalence  of  HIV/AIDS  co-infection  and  inadequate  resources  for  case  
detection  and  management  have  contributed  to  the  emergence  of  untreatable  
XDR-TB [20].   Unfortunately, the presence  of  XDR-TB  in  non—HIV-infected  
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of  2015, are : 1)  decreasing  20%  of  the  proportion  of  MDR-TB  cases  among  
previously  treated  patients  2)  diagnosis  of  at  least  85%  of  the  estimated  MDR-
TB  cases  and  3)  treating  successfully  at  least  75%  of  notified  MDR-TB  cases 
[23].  If  this  plan  is  fully  implemented  and  expected , by  2015, to  successfully  
treat  127,000  MDR-TB  cases, and  to  prevent  the  emergence  of  250,000  new  
MDR-TB  cases  and  13,000  new  XDR-TB  cases [23].  This  would  interrupt  the  
transmission  of  MDR-TB  and  save  120,000  lives  in  this  region [23].            
                                                         
                                                                                                     
                             
                                                                                                                               
                                              














Figure 1. Mechanism of development of anti-tuberculosis drug resistance
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5. patients with evidence of HIV co-infection/AIDS before the 6-month short course chemo‐
therapy starting,
6. general TB patients with history of MDR-TB patient exposure, including health or medical
personnel with TB disease who have history of MDR-TB patient exposure, and
7. other high-risk patients of MDR-TB, such as general TB patient with huge lung cavity,
diabetic patients, prisoners with TB disease, and TB patients who live in the cross-
borderline areas.
5. Laboratory investigations for MDR-TB
Several plans have been announced for the WHO Stop TB Department to collaborate with the
Foundation for Innovative New Diagnostics (FIND) to initiate and introduce rapid-culture
technology and new rapid drug-resistant tests in the southern African countries and the world
including the international standards for the second-line drug-susceptibility testing [11]. The
Thailand’ s 2012 National Tuberculosis Management Guidelines [24] set the laboratory
investigations for MDR-TB which are direct acid-fast bacilli (AFB)-sputum smear examina‐
tions with sputum culture and drug susceptibility testing (DST). For reduction of the diagnosis
time for unrecognized drug-resistant TB, new rapid diagnostic technologies for drug resistance
from sputum smear or positive culture for smear-negative and extra-pulmonary TB must be
prioritized [10]. All TB control programmes in moderate- and high-MDR TB prevalent settings
should consider the promotion of culture and DST including implementation of use of
algorithms for the diagnosis of pulmonary and extra-pulmonary TB [10]. Rapid DST is
preferred to the conventional DST due to 1-2 days of resulting. Recently, the 2011 WHO
Guidelines recommends “ Xpert MTB/RIF® ” and line-probe assay which are new molecular
diagnostic technologies and can detect drug resistance to both isoniazid and rifampicin or only
rifampicin [24], but their disadvantage is inability to detect the resistance to every drugs used
in MDR-TB treatment for detecting probable XDR-TB, required expertise and expensive
technologies/equipments which limit their wider uses [25]. The conventional DST takes 1-3
months of the results that take markedly longer than the new molecular methods and is labor-
intensive [24]. Other alternative phenotypic methods based on the Mycobacterium tuberculosis
metabolism such as CO2 (carbon dioxide) production, oxygen uptake, ATP (adenosine
triphosphate) bioluminescence, etc. have been experimented and demonstrated promising in
overcoming this obstacle of longer time resulting [25]. These methods also have impressive
sensitivity and specificity compared to the conventional DST [25]. Currently, molecular line
probe assays and automated liquid culture systems are recommended by the WHO as the gold
standard for the first-line and second-line DSTs. Liquid culture DST has been demonstrated
to have relatively good reliability and reproducibility for aminoglycosides, fluoroquinolones,
and polypeptides for detecting XDR-TB [26]. However, liquid culture DST for other second-
line drugs such as para-aminosalisylic acid, linezolid, clarithromycin, amoxicillin-clavulanate,
cycloserine, clofazimine, terizidone, ethionamide, and prothionamide is not recommended by
the WHO [26]. A recent study reported the use of spoligotyping and sequence 6110 restriction
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personnel with TB disease who have history of MDR-TB patient exposure, and
7. other high-risk patients of MDR-TB, such as general TB patient with huge lung cavity,
diabetic patients, prisoners with TB disease, and TB patients who live in the cross-
borderline areas.
5. Laboratory investigations for MDR-TB
Several plans have been announced for the WHO Stop TB Department to collaborate with the
Foundation for Innovative New Diagnostics (FIND) to initiate and introduce rapid-culture
technology and new rapid drug-resistant tests in the southern African countries and the world
including the international standards for the second-line drug-susceptibility testing [11]. The
Thailand’ s 2012 National Tuberculosis Management Guidelines [24] set the laboratory
investigations for MDR-TB which are direct acid-fast bacilli (AFB)-sputum smear examina‐
tions with sputum culture and drug susceptibility testing (DST). For reduction of the diagnosis
time for unrecognized drug-resistant TB, new rapid diagnostic technologies for drug resistance
from sputum smear or positive culture for smear-negative and extra-pulmonary TB must be
prioritized [10]. All TB control programmes in moderate- and high-MDR TB prevalent settings
should consider the promotion of culture and DST including implementation of use of
algorithms for the diagnosis of pulmonary and extra-pulmonary TB [10]. Rapid DST is
preferred to the conventional DST due to 1-2 days of resulting. Recently, the 2011 WHO
Guidelines recommends “ Xpert MTB/RIF® ” and line-probe assay which are new molecular
diagnostic technologies and can detect drug resistance to both isoniazid and rifampicin or only
rifampicin [24], but their disadvantage is inability to detect the resistance to every drugs used
in MDR-TB treatment for detecting probable XDR-TB, required expertise and expensive
technologies/equipments which limit their wider uses [25]. The conventional DST takes 1-3
months of the results that take markedly longer than the new molecular methods and is labor-
intensive [24]. Other alternative phenotypic methods based on the Mycobacterium tuberculosis
metabolism such as CO2 (carbon dioxide) production, oxygen uptake, ATP (adenosine
triphosphate) bioluminescence, etc. have been experimented and demonstrated promising in
overcoming this obstacle of longer time resulting [25]. These methods also have impressive
sensitivity and specificity compared to the conventional DST [25]. Currently, molecular line
probe assays and automated liquid culture systems are recommended by the WHO as the gold
standard for the first-line and second-line DSTs. Liquid culture DST has been demonstrated
to have relatively good reliability and reproducibility for aminoglycosides, fluoroquinolones,
and polypeptides for detecting XDR-TB [26]. However, liquid culture DST for other second-
line drugs such as para-aminosalisylic acid, linezolid, clarithromycin, amoxicillin-clavulanate,
cycloserine, clofazimine, terizidone, ethionamide, and prothionamide is not recommended by
the WHO [26]. A recent study reported the use of spoligotyping and sequence 6110 restriction
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fragment length polymorphism insertion analysis of genomic DNA which demonstrated that
MDR-TB cases (74.0%) were more likely to be identified in clusters than anti-TB drug suscep‐
tible cases (33.6%) [27]. Xpert MTB/RIF assay recently has been introduced which meets the
requirements of effective diagnosis of pulmonary TB as the following : allowing detection of
both the Mycobacterium tuberculosis complex and resistance to the principal anti-TB drugs,
especially rifampicin (RIF or R), availability on a global scale with standardized-easy use and
robust diagnostic tools recently has been introduced [28]. This assay is a nucleic acid amplifi‐
cation test for detection of rifampicin resistance-associated mutations of the rpoB gene and
Mycobacterium tuberculosis complex DNA in sputum [28]. It can be designed for use with other
systems to automate and integrate sample processing, nucleic acid amplification, and detection
of target sequences using reverse transcriptase polymerase chain reaction (PCR) and real-time
PCR [28]. Between 2007-2009, the WHO has approved several drug-resistant TB diagnostic
tests such as liquid culture (MGIT®, an automated liquid culture, developed by BD Diagnostic
Systems, 2007) which has been used at the 10th Zonal Tuberculosis and Chest Disease Centre,
Chiang Mai, Thailand, line-probe assays (INNO-Lipa®, line-probe assay that requires culture,
developed by Innogenetics, 2008), noncommercial culture and drug susceptibility testing
(Microscopic Observation Drug Susceptibility (MODS), developed by Academic Laboratories,
2009; Nitrate reductase assay, developed by Academic Laboratories, 2009; and Colorimetric
drug susceptibility testing, developed by Academic Laboratories, 2009) [29]. GeneXpert MTB/
RIF®, a new automated nucleic acid amplification technique which was developed by
Cepheid, The Foundation for Innovative New Diagnostics (FIND) and University of Medicine
and Dentistry of New Jersey (UMDNJ) was reviewed by the WHO in 2011 [29] and currently
has been recommended to measure the Mycobacterium tuberculosis DNA and the rifampicin-
resistance sequence worldwide. This new technique has been set in Thailand at least 6 sets
including the one set at the 10th Zonal Tuberculosis and Chest Disease Centre, Chiang Mai,
Thailand in collaboration with the Unites States Centres for Disease Control and Prevention
(US-CDC) for reference laboratories in Thailand. GeneXpert test’s sensitivity is moderate at
67.2% in AFB-smear negative cases at one-time smear staining of the specimens, and increases
to 80% when is performed three times [28]. This test provides the results within two hours and
requires minimal training of the laboratory workers [29]. The limitations of the test are
requirement of a consistent source of electricity that will limit its use outside of the settings
where a regular electric power supply can be guaranteed, its expensive cost of the instrument,
and cost per test cartridge [29]. Mishra B et al. used the automated BACTEC 460 TB system in
study the emergence of drug-resistant TB at an urban tertiary care hospital in South India
which revealed that 37.2% were MDR-TB isolates whereas 42% of the pulmonary Mycobacte‐
rium tuberculosis isolates and 20.4% of extra-pulmonary isolates were MDR [30]. Phenotypic
and genotypic detections of anti-TB drug resistance are described as the following [31- 49]:
1. Phenotypic detection
1.1 Slide DST
This method has less equiptment, suitable for decentralization, 93% rifampicin susceptibility
at 88% predictive value of resistance.
1.2 Mycobacteria Growth Indicator Tube (MGIT) Systems
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This test has sensitivities of 100% for rifampicin, isoniazid, ethambutol and streptomycin,
specificity of 100% for rifampicin, 97.7% for isoniazid, 98.0% for ethambutol and 89.8%% for
streptomycin.
1.3 Microscopic observation broth-drug susceptibility assay (MODS)
This method has sensitivity of 72.7% and specificity of 99.7% for rifampicin, 72.6% and 97.9%
for isoniazid, and 77.8% and 99.7% for MDR-TB.
1.4 Mycobacteriophage-based method
1.4.1 Commercial FASTPlaque assay (FASTPlaque TB test and FastPlaque TB-
RIFTM (rifampicin DST) (Biotech Labs Ltd, Ipswich, UK))
This test has sensitivity and specificity of 31.2% and 94.9%, respectively in all anti-TB drug-
susceptible and resistant TB patients, sensitivity and specificity of 33.3% and 93.9%, respec‐
tively in all anti-TB drug-susceptible and resistant TB patients with HIV-infection/AIDS.
1.4.2 Fluoromycobacteriophage assay (Figures 2, 3)
This method has 94% sensitivities for rifampicin and isoniazid and 98% sensitivity for
streptomycin and specificities of 97% for isoniazid, 95% for rifampicin, and 98% for strepto‐
mycin (resazurin microplate technique), sensitivity of 94% for all three anti-TB drugs (rifam‐
picin, isoniazid, and streptomycin) (EGFP-phage technique) and specificities of 93% for
rifampicin, 90% for isoniazid and 95% for streptomycin (EGFP-phage technique).
1.4.3 Luciferase reporter phage assay
This test has 100% sensitivity and 89-100% specificity for culture isolates.
1.5 Nitrate reductase assay
This method has sensitivity and specificity of 100% and 100% for rifampicin, 93% and 100%
for isoniazid, 76% and 100% for streptomycin, and 55% and 99% for ethambutol, respectively.
1.6 Microcolony method (Thin-layer agar (TLA) method)
This test has sensitivities and specificities of 100% for both rifampicin and ofloxacin, and
sensitivity of 100% and specificity of 98.7% for kanamycin, 100% overall accuracy for rifam‐
picin and isoniazid resistance.
1.7 Colorimetric redox indicator methods
This method has sensitivities of 100% for rifampicin, ofloxacin, kanamycin and capreomycin
and 99.1% for isoniazid, specificity of 100% for rifampicin, isoniazid, ofloxacin and kanamycin,
and 97.9% for capreomycin, overall accuracy of 98.4% for rifampicin, 96.6% for isoniazid, 96.7%
for ofloxacin, 98.3% for kanamycin and 90% for capreomycin.
2. Genotypic detection (Nucleic Acid Amplification)
2.1 Line-probe assay (LPA)
2.1.1 INNO-LiPA Rif.TB® assay (Innogenetics, Ghent, Belgium)
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fragment length polymorphism insertion analysis of genomic DNA which demonstrated that
MDR-TB cases (74.0%) were more likely to be identified in clusters than anti-TB drug suscep‐
tible cases (33.6%) [27]. Xpert MTB/RIF assay recently has been introduced which meets the
requirements of effective diagnosis of pulmonary TB as the following : allowing detection of
both the Mycobacterium tuberculosis complex and resistance to the principal anti-TB drugs,
especially rifampicin (RIF or R), availability on a global scale with standardized-easy use and
robust diagnostic tools recently has been introduced [28]. This assay is a nucleic acid amplifi‐
cation test for detection of rifampicin resistance-associated mutations of the rpoB gene and
Mycobacterium tuberculosis complex DNA in sputum [28]. It can be designed for use with other
systems to automate and integrate sample processing, nucleic acid amplification, and detection
of target sequences using reverse transcriptase polymerase chain reaction (PCR) and real-time
PCR [28]. Between 2007-2009, the WHO has approved several drug-resistant TB diagnostic
tests such as liquid culture (MGIT®, an automated liquid culture, developed by BD Diagnostic
Systems, 2007) which has been used at the 10th Zonal Tuberculosis and Chest Disease Centre,
Chiang Mai, Thailand, line-probe assays (INNO-Lipa®, line-probe assay that requires culture,
developed by Innogenetics, 2008), noncommercial culture and drug susceptibility testing
(Microscopic Observation Drug Susceptibility (MODS), developed by Academic Laboratories,
2009; Nitrate reductase assay, developed by Academic Laboratories, 2009; and Colorimetric
drug susceptibility testing, developed by Academic Laboratories, 2009) [29]. GeneXpert MTB/
RIF®, a new automated nucleic acid amplification technique which was developed by
Cepheid, The Foundation for Innovative New Diagnostics (FIND) and University of Medicine
and Dentistry of New Jersey (UMDNJ) was reviewed by the WHO in 2011 [29] and currently
has been recommended to measure the Mycobacterium tuberculosis DNA and the rifampicin-
resistance sequence worldwide. This new technique has been set in Thailand at least 6 sets
including the one set at the 10th Zonal Tuberculosis and Chest Disease Centre, Chiang Mai,
Thailand in collaboration with the Unites States Centres for Disease Control and Prevention
(US-CDC) for reference laboratories in Thailand. GeneXpert test’s sensitivity is moderate at
67.2% in AFB-smear negative cases at one-time smear staining of the specimens, and increases
to 80% when is performed three times [28]. This test provides the results within two hours and
requires minimal training of the laboratory workers [29]. The limitations of the test are
requirement of a consistent source of electricity that will limit its use outside of the settings
where a regular electric power supply can be guaranteed, its expensive cost of the instrument,
and cost per test cartridge [29]. Mishra B et al. used the automated BACTEC 460 TB system in
study the emergence of drug-resistant TB at an urban tertiary care hospital in South India
which revealed that 37.2% were MDR-TB isolates whereas 42% of the pulmonary Mycobacte‐
rium tuberculosis isolates and 20.4% of extra-pulmonary isolates were MDR [30]. Phenotypic
and genotypic detections of anti-TB drug resistance are described as the following [31- 49]:
1. Phenotypic detection
1.1 Slide DST
This method has less equiptment, suitable for decentralization, 93% rifampicin susceptibility
at 88% predictive value of resistance.
1.2 Mycobacteria Growth Indicator Tube (MGIT) Systems
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This test has sensitivities of 100% for rifampicin, isoniazid, ethambutol and streptomycin,
specificity of 100% for rifampicin, 97.7% for isoniazid, 98.0% for ethambutol and 89.8%% for
streptomycin.
1.3 Microscopic observation broth-drug susceptibility assay (MODS)
This method has sensitivity of 72.7% and specificity of 99.7% for rifampicin, 72.6% and 97.9%
for isoniazid, and 77.8% and 99.7% for MDR-TB.
1.4 Mycobacteriophage-based method
1.4.1 Commercial FASTPlaque assay (FASTPlaque TB test and FastPlaque TB-
RIFTM (rifampicin DST) (Biotech Labs Ltd, Ipswich, UK))
This test has sensitivity and specificity of 31.2% and 94.9%, respectively in all anti-TB drug-
susceptible and resistant TB patients, sensitivity and specificity of 33.3% and 93.9%, respec‐
tively in all anti-TB drug-susceptible and resistant TB patients with HIV-infection/AIDS.
1.4.2 Fluoromycobacteriophage assay (Figures 2, 3)
This method has 94% sensitivities for rifampicin and isoniazid and 98% sensitivity for
streptomycin and specificities of 97% for isoniazid, 95% for rifampicin, and 98% for strepto‐
mycin (resazurin microplate technique), sensitivity of 94% for all three anti-TB drugs (rifam‐
picin, isoniazid, and streptomycin) (EGFP-phage technique) and specificities of 93% for
rifampicin, 90% for isoniazid and 95% for streptomycin (EGFP-phage technique).
1.4.3 Luciferase reporter phage assay
This test has 100% sensitivity and 89-100% specificity for culture isolates.
1.5 Nitrate reductase assay
This method has sensitivity and specificity of 100% and 100% for rifampicin, 93% and 100%
for isoniazid, 76% and 100% for streptomycin, and 55% and 99% for ethambutol, respectively.
1.6 Microcolony method (Thin-layer agar (TLA) method)
This test has sensitivities and specificities of 100% for both rifampicin and ofloxacin, and
sensitivity of 100% and specificity of 98.7% for kanamycin, 100% overall accuracy for rifam‐
picin and isoniazid resistance.
1.7 Colorimetric redox indicator methods
This method has sensitivities of 100% for rifampicin, ofloxacin, kanamycin and capreomycin
and 99.1% for isoniazid, specificity of 100% for rifampicin, isoniazid, ofloxacin and kanamycin,
and 97.9% for capreomycin, overall accuracy of 98.4% for rifampicin, 96.6% for isoniazid, 96.7%
for ofloxacin, 98.3% for kanamycin and 90% for capreomycin.
2. Genotypic detection (Nucleic Acid Amplification)
2.1 Line-probe assay (LPA)
2.1.1 INNO-LiPA Rif.TB® assay (Innogenetics, Ghent, Belgium)
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This test has higher than 95% sensitivity and 100% specificity, sensitivity of 82.2% and
specificity of 66.7% for MDR-TB detection.
2.1.2 GenoType® MTBDRplus kit (Hain Lifescience, Nehren, Germany)
This method has nearly 91% sensitivity for MDR-TB, possibly detects rifampicin and isoniazid
resistance and confirms TB infection simultaneously.
2.1.3 Genotype MTBDRsl assay
This test has ethambutol, 89% sensitivity for ofloxacin, 87% sensitivity for capreomycin, 75%
sensitivity for amikacin.
2.2 Real-time PCR
This technique has sensitivity of 89% and specificity of 99% (molecular beacons), overall
sensitivity of 98-100% with 72% sensitivity in smear-negative specimens and specificity of
100% for Xpert MTB/RIF assay (Cepheid Xpert MTB/RIF®, Sunyvale, CA).
2.3 PCR sequencing
This technique has sensitivities of 96.7% for rifampicin-resistant isolates (rpoB gene), 64% for
isoniazid-resistant isolates (katG gene) and 70% of ofloxacin-resistant isolates (gyrA gene) (PCR
pyrosequencing).
2.4 DNA Microarrays (DNA biochip)
This technique has specificity of 97% and 95% for rifampicin, 91% and 60% for isoniazid,
96%  and  67%  for  kanamycin,  93%  and  73%  for  streptomycin,  and  98%  and  89%  for
ethambutol,  respectively,  simultaneous detection of  multiple  genetic  sequences (oligonu‐
cleotide microarray).
Although genotypic methods have potentially fastest results, the massive cross-contamination
is still the main risk. To prevent its, strict internal controls, special technique, and separation
of working areas are required. The reproducibility of the results of the Xpert MTB/RIF assay
under actual field conditions, the strength of the laboratories, and the manner and extent of
its introduction are the impact of this new assay. The sources of error for genotypic methods
are incomplete coverage of rifampicin-resistance gene-core region and mixtures (multiple
mutations, wild-type strain/emerging mutant) and silent mutations. These sources of error
may contribute to 1% false-resistant and 5% false-susceptible results [31].
Schematic  representation of  phAE87  :  hsp60-EGFP  construction.  Shuttle  phasmid phAE87
is  a  conditionally  replicating  derivative  of  phage  TM4  in  which  the  cosmid  moiety  is
flanked by Pac I restriction sites. A plasmid derivative of pYUB854  containing the EGFP
gene (pMP14) was used to replace the cosmid in phAE87  followed by lambda packaging
and recovery in E. coli.
Tuberculosis - Current Issues in Diagnosis and Management246
Source : Rondo′n L, Piuri M, Jacobs WR Jr, Waard Jde, Hatfull GF, Takiff HE. Evaluation of fluoromycobacteriophages
for detecting drug resistance in Mycobacterium tuberculosis. J Clin Microbiol 2011; 49 (5) : 1838-1842.
Figure 3. A, B). Two strains of Mycobacterium tuberculosis were incubated separately in 7H9-OAD with 2 µg of rifam‐
picin/ml for 24 hours, infected with the EGFP-phage, killed with paraformaldehyde, and then fixed on microscope
slides. The images, obtained with a fluorescence microscope, show a susceptible-to-rifampicin strain (A) and a resist‐
ant-to-rifampicin strain (B).
Source : Piuri M, Jacobs WR Jr, Hatfull GF. Fluoromycobacteriophages for rapid, specific, and sensitive antibiotic sus‐
ceptibility testing of Mycobacterium tuberculosis. PLoS ONE 2009; 4(3) : e4870. doi: 10.1371/journal.pone.0004870
Figure 2. Fluoromycobacteriophages construction
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This test has higher than 95% sensitivity and 100% specificity, sensitivity of 82.2% and
specificity of 66.7% for MDR-TB detection.
2.1.2 GenoType® MTBDRplus kit (Hain Lifescience, Nehren, Germany)
This method has nearly 91% sensitivity for MDR-TB, possibly detects rifampicin and isoniazid
resistance and confirms TB infection simultaneously.
2.1.3 Genotype MTBDRsl assay
This test has ethambutol, 89% sensitivity for ofloxacin, 87% sensitivity for capreomycin, 75%
sensitivity for amikacin.
2.2 Real-time PCR
This technique has sensitivity of 89% and specificity of 99% (molecular beacons), overall
sensitivity of 98-100% with 72% sensitivity in smear-negative specimens and specificity of
100% for Xpert MTB/RIF assay (Cepheid Xpert MTB/RIF®, Sunyvale, CA).
2.3 PCR sequencing
This technique has sensitivities of 96.7% for rifampicin-resistant isolates (rpoB gene), 64% for
isoniazid-resistant isolates (katG gene) and 70% of ofloxacin-resistant isolates (gyrA gene) (PCR
pyrosequencing).
2.4 DNA Microarrays (DNA biochip)
This technique has specificity of 97% and 95% for rifampicin, 91% and 60% for isoniazid,
96%  and  67%  for  kanamycin,  93%  and  73%  for  streptomycin,  and  98%  and  89%  for
ethambutol,  respectively,  simultaneous detection of  multiple  genetic  sequences (oligonu‐
cleotide microarray).
Although genotypic methods have potentially fastest results, the massive cross-contamination
is still the main risk. To prevent its, strict internal controls, special technique, and separation
of working areas are required. The reproducibility of the results of the Xpert MTB/RIF assay
under actual field conditions, the strength of the laboratories, and the manner and extent of
its introduction are the impact of this new assay. The sources of error for genotypic methods
are incomplete coverage of rifampicin-resistance gene-core region and mixtures (multiple
mutations, wild-type strain/emerging mutant) and silent mutations. These sources of error
may contribute to 1% false-resistant and 5% false-susceptible results [31].
Schematic  representation of  phAE87  :  hsp60-EGFP  construction.  Shuttle  phasmid phAE87
is  a  conditionally  replicating  derivative  of  phage  TM4  in  which  the  cosmid  moiety  is
flanked by Pac I restriction sites. A plasmid derivative of pYUB854  containing the EGFP
gene (pMP14) was used to replace the cosmid in phAE87  followed by lambda packaging
and recovery in E. coli.
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for detecting drug resistance in Mycobacterium tuberculosis. J Clin Microbiol 2011; 49 (5) : 1838-1842.
Figure 3. A, B). Two strains of Mycobacterium tuberculosis were incubated separately in 7H9-OAD with 2 µg of rifam‐
picin/ml for 24 hours, infected with the EGFP-phage, killed with paraformaldehyde, and then fixed on microscope
slides. The images, obtained with a fluorescence microscope, show a susceptible-to-rifampicin strain (A) and a resist‐
ant-to-rifampicin strain (B).
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6. Radiological features in patients with MDR/XDR-TB
A recent study in South Korea showed 100% of lung nodules, 60% of lung consolidation,
and 47% of lung cavities that were mainly located in the upper and middle lung zones
in XDR-TB patients whereas less frequent lung nodules and ground-glass opacity lesions
were found in XDR-TB patients  compared to the patients  with anti-TB drug-susceptible
pulmonary TB [50]. More frequent multiple lung cavities, lung nodules, and bronchial di‐
latation  were  found  in  both  MDR-TB  and  XDR-TB  patients  compared  to  the  patients
with  anti-TB  drug-susceptible  pulmonary  TB  [50].  There  was  no  different  radiological
findings between MDR-TB and XDR-TB patients [50]. Another recent study in South Ko‐
rea  revealed  that  micronodules  and tree-in-bud appearance  were  found in  100% of  the
pulmonary  XDR-TB  patients  whereas  lung  consolidations,  lung  cavities,  bronchiectasis,
lobar consolidations were found in 85%, 85%, 80%, and 70%, respectively [51]. This study
showed  a  significantly  larger  extent  of  tree-in-bud  appearance  and  lung  consolidations
compared to the MDR-TB patients [51]. In childhood patients, chest radiological features
at the time of diagnosis demonstrates lobar opacification, intrathoracic lymphadenopathy,
particular  hilar  lymph nodes,  and airway narrowing [52].  Chest  radiological  features  of
three patients with MDR-TB who attended the 10th Zonal Tuberculosis and Chest Disease
Centre,  Chiang Mai,  Thailand are shown in the Figure 4  (A,B,C) which demonstrated a
single cavity at the upper lung zone in two patients and no lung cavity in another one.
These  three  patients  possibly  attended  the  10th  Zonal  Tuberculosis  and  Chest  Disease
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Figure 4. First-attendance chest radiological features of the three patients (A,B,C) with MDR-TB at the 10th Zonal Tu‐
berculosis and Chest Disease Centre, Chiang Mai, Thailand A : Showing bilaterally diffuse lung infiltration with a cavity
in the left upper lung zone, B : Showing fibrotic infiltration with surrounding new infiltration at the right upper lung
zone with bilaterally diffuse emphysematous lung changes, C : Showing bilaterally diffuse infiltration with a cavity in
the right upper lung zone with left pleural effusion.
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7. Regimens used in treating patients with drug-resistant tuberculosis
A recent study on MDR-TB treatment revealed that use of later generation quinolones
(moxifloxacin, gatifloxacin, sparfloxacin, levofloxacin), ofloxacin or ethionamide/prothiona‐
mide, use of four or more likely effective drugs in the initial intensive phase, and three or more
likely effective drugs in the continuation phase was associated with the treatment success
compared to the treatment failure or relapse [53]. The duration of initial phase up to 7.1-8.5
months and the total duration of treatment up to 18.6-21.5 months increased the chances of
treatment success [53]. In 2011, the WHO recommended the regimens containing a fluoroqui‐
nolone, pyrazinamide, ethionamide (or prothionamide), para-aminosalicylic acid (or cyclo‐
serine), and a second-line injectable drug with more than 20 months of treatment duration [54].
Five MDR-TB control projects with used DST results and previous treatment history were
conducted among 1,047 MDR-TB patients in 5 resource-limited settings with well-established
DOTS programmes (Manila, Estonia, Latvia, Lima, and Tomsk) in 1999 for Lima and Manila,
2000 for Tomsk and Latvia, and 2001 for Estonia [55]. At least 4 drug (ethambutol, pyrazina‐
mide, cycloserine, clofazimine, para-aminosalicylic acid, ethionamide, or prothionamide,
augmentin, clarithromycin or thiacetazone) including an injectable drug (kanamycin, amika‐
cin, capreomycin, or streptomycin) and a fluoroquinolone (ofloxacin, ciprofloxacin, or
levofloxacin) were administered for the duration of treatment (18-24 months) except for the
injectable drug, which was administered for a specified interval after the patient’ s specimens
were culture-negative [55]. Monthly sputum-AFB smear and culture were monitored [55].
Every 6-months (Manila and Lima) and 3-months chest radiographs (Tomsk, Latvia, and
Estonia) were performed [55]. The treatment outcomes among new and previously treated
MDR-TB patients revealed 74.8% and 68.3% cured patients, 2.5% and 0.3% completed treat‐
ment patients, 4.2% and 7.0% failed treatment patients, 3.4% and 14.2% dead patients, and
77.3% and 66.6% treatment success rates (cure rate + completed treatment rate), respectively
[55]. The results showed worsen outcomes among previously treated patients. Report from
the 10th Zonal Tuberculosis and Chest Disease Centre, Chiang Mai, Thailand, in 2011 which
had been collected from the data of laboratory-confirmed 254 MDR-TB patients (72.8% of all
probable MDR-TB cases) among 349 totally suspected-MDR-TB cases with 15.8% of HIV co-
infection in northern Thailand between 2005-2010 gradually increased from 62.2% of probable
MDR-TB cases in 2005 to 78.3% in 2010 and revealed 3.2% treatment-denial patients, 75.2%
treatment-registered patients, 30.2% died before starting the second-line drug treatment
regimens (pyrazinamide, ethambutol, ofloxacin, para-aminosalicylic acid administered for
18-24 months and one injectable drug (kanamycin, or amikacin) administered 5 days per week
for the initial 6-month phase), 25.4% default-treatment patients (continuous interruption of
treatment more than 2 months), 54.8% treatment success rate, and 22.2% unavailable-data
patients [7]. Among 19 cases with pre-treatment death, 10 cases (52.63%) demonstrated HIV
co-infection. Extra-pulmonary cases accounted for 2.4% of the laboratory-confirmed cases
which was lower than percentage of susceptible extra-pulmonary TB cases in the same area
[56]. Four cases with laboratory-confirmed MDR-TB emerged as XDR-TB during treatment [7].
A previous study on outcomes of a daily supervised-MDR-TB treatment regimen which
consisted of initial phase of 6-9 months with kanamycin, ofloxacin, cycloserine, ethionamide,
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6. Radiological features in patients with MDR/XDR-TB
A recent study in South Korea showed 100% of lung nodules, 60% of lung consolidation,
and 47% of lung cavities that were mainly located in the upper and middle lung zones
in XDR-TB patients whereas less frequent lung nodules and ground-glass opacity lesions
were found in XDR-TB patients  compared to the patients  with anti-TB drug-susceptible
pulmonary TB [50]. More frequent multiple lung cavities, lung nodules, and bronchial di‐
latation  were  found  in  both  MDR-TB  and  XDR-TB  patients  compared  to  the  patients
with  anti-TB  drug-susceptible  pulmonary  TB  [50].  There  was  no  different  radiological
findings between MDR-TB and XDR-TB patients [50]. Another recent study in South Ko‐
rea  revealed  that  micronodules  and tree-in-bud appearance  were  found in  100% of  the
pulmonary  XDR-TB  patients  whereas  lung  consolidations,  lung  cavities,  bronchiectasis,
lobar consolidations were found in 85%, 85%, 80%, and 70%, respectively [51]. This study
showed  a  significantly  larger  extent  of  tree-in-bud  appearance  and  lung  consolidations
compared to the MDR-TB patients [51]. In childhood patients, chest radiological features
at the time of diagnosis demonstrates lobar opacification, intrathoracic lymphadenopathy,
particular  hilar  lymph nodes,  and airway narrowing [52].  Chest  radiological  features  of
three patients with MDR-TB who attended the 10th Zonal Tuberculosis and Chest Disease
Centre,  Chiang Mai,  Thailand are shown in the Figure 4  (A,B,C) which demonstrated a
single cavity at the upper lung zone in two patients and no lung cavity in another one.
These  three  patients  possibly  attended  the  10th  Zonal  Tuberculosis  and  Chest  Disease
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Figure 4. First-attendance chest radiological features of the three patients (A,B,C) with MDR-TB at the 10th Zonal Tu‐
berculosis and Chest Disease Centre, Chiang Mai, Thailand A : Showing bilaterally diffuse lung infiltration with a cavity
in the left upper lung zone, B : Showing fibrotic infiltration with surrounding new infiltration at the right upper lung
zone with bilaterally diffuse emphysematous lung changes, C : Showing bilaterally diffuse infiltration with a cavity in
the right upper lung zone with left pleural effusion.
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7. Regimens used in treating patients with drug-resistant tuberculosis
A recent study on MDR-TB treatment revealed that use of later generation quinolones
(moxifloxacin, gatifloxacin, sparfloxacin, levofloxacin), ofloxacin or ethionamide/prothiona‐
mide, use of four or more likely effective drugs in the initial intensive phase, and three or more
likely effective drugs in the continuation phase was associated with the treatment success
compared to the treatment failure or relapse [53]. The duration of initial phase up to 7.1-8.5
months and the total duration of treatment up to 18.6-21.5 months increased the chances of
treatment success [53]. In 2011, the WHO recommended the regimens containing a fluoroqui‐
nolone, pyrazinamide, ethionamide (or prothionamide), para-aminosalicylic acid (or cyclo‐
serine), and a second-line injectable drug with more than 20 months of treatment duration [54].
Five MDR-TB control projects with used DST results and previous treatment history were
conducted among 1,047 MDR-TB patients in 5 resource-limited settings with well-established
DOTS programmes (Manila, Estonia, Latvia, Lima, and Tomsk) in 1999 for Lima and Manila,
2000 for Tomsk and Latvia, and 2001 for Estonia [55]. At least 4 drug (ethambutol, pyrazina‐
mide, cycloserine, clofazimine, para-aminosalicylic acid, ethionamide, or prothionamide,
augmentin, clarithromycin or thiacetazone) including an injectable drug (kanamycin, amika‐
cin, capreomycin, or streptomycin) and a fluoroquinolone (ofloxacin, ciprofloxacin, or
levofloxacin) were administered for the duration of treatment (18-24 months) except for the
injectable drug, which was administered for a specified interval after the patient’ s specimens
were culture-negative [55]. Monthly sputum-AFB smear and culture were monitored [55].
Every 6-months (Manila and Lima) and 3-months chest radiographs (Tomsk, Latvia, and
Estonia) were performed [55]. The treatment outcomes among new and previously treated
MDR-TB patients revealed 74.8% and 68.3% cured patients, 2.5% and 0.3% completed treat‐
ment patients, 4.2% and 7.0% failed treatment patients, 3.4% and 14.2% dead patients, and
77.3% and 66.6% treatment success rates (cure rate + completed treatment rate), respectively
[55]. The results showed worsen outcomes among previously treated patients. Report from
the 10th Zonal Tuberculosis and Chest Disease Centre, Chiang Mai, Thailand, in 2011 which
had been collected from the data of laboratory-confirmed 254 MDR-TB patients (72.8% of all
probable MDR-TB cases) among 349 totally suspected-MDR-TB cases with 15.8% of HIV co-
infection in northern Thailand between 2005-2010 gradually increased from 62.2% of probable
MDR-TB cases in 2005 to 78.3% in 2010 and revealed 3.2% treatment-denial patients, 75.2%
treatment-registered patients, 30.2% died before starting the second-line drug treatment
regimens (pyrazinamide, ethambutol, ofloxacin, para-aminosalicylic acid administered for
18-24 months and one injectable drug (kanamycin, or amikacin) administered 5 days per week
for the initial 6-month phase), 25.4% default-treatment patients (continuous interruption of
treatment more than 2 months), 54.8% treatment success rate, and 22.2% unavailable-data
patients [7]. Among 19 cases with pre-treatment death, 10 cases (52.63%) demonstrated HIV
co-infection. Extra-pulmonary cases accounted for 2.4% of the laboratory-confirmed cases
which was lower than percentage of susceptible extra-pulmonary TB cases in the same area
[56]. Four cases with laboratory-confirmed MDR-TB emerged as XDR-TB during treatment [7].
A previous study on outcomes of a daily supervised-MDR-TB treatment regimen which
consisted of initial phase of 6-9 months with kanamycin, ofloxacin, cycloserine, ethionamide,
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ethabutol, and pyrazinamide demonstrated that in cases of persistent culture positive at fourth
month, the initial phase was extended for additional 3 months. Then ofloxacin, cycloserine,
ethionamide, and ethambutol were continued for 18 months [57]. The results of the study
revealed that 82% of cases demonstrated time to culture conversion at the second month or
before. The culture conversion rates at third month and sixth month were 84% and 87%,
respectively. The cure rate was 66%. At 24 months, 79% of the patients remained culture
negative for more than 18 months. Adverse drug reactions were reported among 58% of cases
and 2 failure cases emerged as XDR-TB during treatment [57]. A recent study on comparison
between traditional hospital-based treatment-model of MDR-TB patient care and community-
based model in rural areas of South Africa revealed that median times to starting the treatment
and sputum smear conversion were shorter for community-based model (84 days versus 106.5
days and 59 days versus 92 days, respectively) [58]. Lack of sputum culture conversion at
month 9 was a predictor of pulmonary MDR-TB treatment failure with 84% of sensitivity and
94% of specificity [59]. A recent study by Dheda K et al. demonstrated that the number of XDR-
TB deaths was not significantly different compared between patients with and without HIV
co-infection [60] whereas Well CD recently reported that lower cure rates and higher death
rates were found in MDR-TB patients with HIV co-infection compared to the patients without
HIV co-infection [61]. Survival of XDR-TB patients with HIV co-infection was associated with
absence of biomarkers indicative of multiorgan dysfunction, less advanced stage of both
diseases at time of diagnosis, and antiretrovirals provision [62]. Previous culture-proven MDR-
TB, number of drug used in a MDR-TB treatment regimen, and treatment with moxifloxacin
were independent predictors of death [60] while some previous reports showed that treatment
success rates were poor (30-50%) in XDR-TB patients with HIV co-infection [63] and the MDR/
XDR-TB prevalence was substantially precipitated by the HIV epidemic [64, 65]. In children
with MDR-TB, the treatment guidelines are the same principles, using the same drugs as in
adult patients with strict and prolonged supervision by expert pediatricians [66]. HIV co-
infection are particular challenges and requires early starting of antiretroviral therapy with
careful monitoring for drug-adverse side-effects [66]. Children with close contact with MDR-
TB patients should be tested with tuberculin skin testing or interferon-gamma release assays,
direct AFB-smear examinations, cultures, and DST and taking the chest radiological exami‐
nations [24]. Cases with close contact should be at least 2-year followed up [24]. If they are
diagnosed MDR-TB, they must be treated with the empirical MDR-TB regimen [24]. Empirical
MDR-TB treatment regimen is not recommended for MDR-TB chemoprophylaxis [24]. MDR-
TB chemoprophylaxis for children with at least 2 second-line drugs for 6-12 months and
reflecting the susceptibility profile of the source case’ s isolate with daily supervision should
be considered [52, 67]. The knowledge of mechanisms of the second-line drugs for children is
necessary for ensuring the treatment adherence and long-term control of the disease.
A previous study on the second-line drug susceptibility among 40 MDR-TB strains in Turkey
revealed mono-resistant to ethionamide 25%, amikacin 10.0%, kanamycin 2.5%, ofloxacin
2.5%, amikacin 0%, and clofazimine 0%, any resistant to ethionamide 37.5%, capreomycin
25.0%, kanamycin 5.0%, ofloxacin 5.0%, amikacin 5.0%, and clofazimine 2.5%, resistant to both
ethionamide + capreomycin 5.0%, both capreomycin + clofazimine 2.5%, ofloxacin + ethiona‐
mide + capreomycin 2.5%, amikacin + ethionamide + capreomycin 2.5%, and kanamycin +
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amikacin + ethionamide + capreomycin 2.5% [68]. Currently, the data of the second-line drug
resistance are not available [9].
The Thailand’ s 2012 National Tuberculosis Management Guidelines [24] recommends the
guidelines for both pulmonary and extra-pulmonary MDR-TB treatment as the following flow
diagram : 15 
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Figure 5. Flow Diagram of Management of Patient with Probable/Suspected MDR-TB
Currently, in Thailand, patients with persistent AFB-smear and/or culture positive after
completeness of MDR-TB treatment will be prescribed isoniazid alone for lifelong while no
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ethabutol, and pyrazinamide demonstrated that in cases of persistent culture positive at fourth
month, the initial phase was extended for additional 3 months. Then ofloxacin, cycloserine,
ethionamide, and ethambutol were continued for 18 months [57]. The results of the study
revealed that 82% of cases demonstrated time to culture conversion at the second month or
before. The culture conversion rates at third month and sixth month were 84% and 87%,
respectively. The cure rate was 66%. At 24 months, 79% of the patients remained culture
negative for more than 18 months. Adverse drug reactions were reported among 58% of cases
and 2 failure cases emerged as XDR-TB during treatment [57]. A recent study on comparison
between traditional hospital-based treatment-model of MDR-TB patient care and community-
based model in rural areas of South Africa revealed that median times to starting the treatment
and sputum smear conversion were shorter for community-based model (84 days versus 106.5
days and 59 days versus 92 days, respectively) [58]. Lack of sputum culture conversion at
month 9 was a predictor of pulmonary MDR-TB treatment failure with 84% of sensitivity and
94% of specificity [59]. A recent study by Dheda K et al. demonstrated that the number of XDR-
TB deaths was not significantly different compared between patients with and without HIV
co-infection [60] whereas Well CD recently reported that lower cure rates and higher death
rates were found in MDR-TB patients with HIV co-infection compared to the patients without
HIV co-infection [61]. Survival of XDR-TB patients with HIV co-infection was associated with
absence of biomarkers indicative of multiorgan dysfunction, less advanced stage of both
diseases at time of diagnosis, and antiretrovirals provision [62]. Previous culture-proven MDR-
TB, number of drug used in a MDR-TB treatment regimen, and treatment with moxifloxacin
were independent predictors of death [60] while some previous reports showed that treatment
success rates were poor (30-50%) in XDR-TB patients with HIV co-infection [63] and the MDR/
XDR-TB prevalence was substantially precipitated by the HIV epidemic [64, 65]. In children
with MDR-TB, the treatment guidelines are the same principles, using the same drugs as in
adult patients with strict and prolonged supervision by expert pediatricians [66]. HIV co-
infection are particular challenges and requires early starting of antiretroviral therapy with
careful monitoring for drug-adverse side-effects [66]. Children with close contact with MDR-
TB patients should be tested with tuberculin skin testing or interferon-gamma release assays,
direct AFB-smear examinations, cultures, and DST and taking the chest radiological exami‐
nations [24]. Cases with close contact should be at least 2-year followed up [24]. If they are
diagnosed MDR-TB, they must be treated with the empirical MDR-TB regimen [24]. Empirical
MDR-TB treatment regimen is not recommended for MDR-TB chemoprophylaxis [24]. MDR-
TB chemoprophylaxis for children with at least 2 second-line drugs for 6-12 months and
reflecting the susceptibility profile of the source case’ s isolate with daily supervision should
be considered [52, 67]. The knowledge of mechanisms of the second-line drugs for children is
necessary for ensuring the treatment adherence and long-term control of the disease.
A previous study on the second-line drug susceptibility among 40 MDR-TB strains in Turkey
revealed mono-resistant to ethionamide 25%, amikacin 10.0%, kanamycin 2.5%, ofloxacin
2.5%, amikacin 0%, and clofazimine 0%, any resistant to ethionamide 37.5%, capreomycin
25.0%, kanamycin 5.0%, ofloxacin 5.0%, amikacin 5.0%, and clofazimine 2.5%, resistant to both
ethionamide + capreomycin 5.0%, both capreomycin + clofazimine 2.5%, ofloxacin + ethiona‐
mide + capreomycin 2.5%, amikacin + ethionamide + capreomycin 2.5%, and kanamycin +
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amikacin + ethionamide + capreomycin 2.5% [68]. Currently, the data of the second-line drug
resistance are not available [9].
The Thailand’ s 2012 National Tuberculosis Management Guidelines [24] recommends the
guidelines for both pulmonary and extra-pulmonary MDR-TB treatment as the following flow
diagram : 15 
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Figure 5. Flow Diagram of Management of Patient with Probable/Suspected MDR-TB
Currently, in Thailand, patients with persistent AFB-smear and/or culture positive after
completeness of MDR-TB treatment will be prescribed isoniazid alone for lifelong while no
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standardized treatment is recommended yet. Types of patients with MDR-TB, patient moni‐
toring during MDR-TB treatment and assessment of sputum conversion, and classification of
treatment outcomes are shown in the Table 1, 2, and 3, respectively [24].
Type Description
New case
patient who does not take any anti-TB drugs before or take any anti-TB drugs less than 1 month
duration and the DST results show resistance to at least rifampicin and isoniazid
Relapse case




patient who continuously interrupts the TB treatment more than 2 months and the DST results
before treatment interruption demonstrates MDR-TB
After failure of the
first- TB treatment
patient’ s AFB examinations show positive results at the end of the fifth month and the DST
results at the end of the second or fifth month reveal MDR-TB
After failure of
retreatment
patient who treated with the retreatment regimen (2 months of streptomycin, rifampicin,
isoniazid, pyrazinamide, and ethambutol, followed by 1 month of rifampicin, isoniazid,
pyrazinamide, and ethambutol , and then followed by 5 months of isoniazid, pyrazinamide, and
ethambutol for relapse cases) and the DST results at the end of third or fifth month demonstrate
MDR-TB
Transfer in
patient who is referred from one setting to the other setting for further diagnosis, treatment,
and management, transferred setting must report the outcome of treatment to the referred
setting (first setting) for discharge registration as “ transfer in ”
Other
other patients who cannot be registered as the above 6 patient-registration types including
patients who treated with empirical MDR-TB treatment regimen at the non-NTP settings (not
registered as the above 6 patient-registration types)
Table 1. Registration of the patients with MDR-TB [24]
Patient monitoring during MDR-TB treatment Assessment of sputum conversion
Direct AFB-smear examinations and cultures will be
performed at month : 0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, , 14,
16, 18, and 20.
Results of 2 consecutively direct-AFB-smear negative and
culture negative with 30-day intervals will indicate sputum
conversion. Mostly, patients with sputum conversion will
converse the positive to the negative results within the first 6-
month of treatment duration.
Chest radiological examinations will be performed at
month : 0, 3, 6, 12, and 18.
Table 2. Patient monitoring during MDR-TB treatment and Assessment of sputum conversion [24]
8. Patient monitoring after completeness of the MDR-TB treatment [24]
For assessment of the MDR-TB relapse rate, direct AFB-smear examinations and cultures are
performed and assessed every 3 months in the first 6-month completeness of treatment and
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then every 6 months for 18 months. Chest radiological examinations are preformed when
indicated.
Cured
patient who treated with MDR-TB treatment regimen following the Thailand’ s 2012 National
Tuberculosis Control Management (or NTP) Guidelines with consecutively 5- negative results of the
30 day-interval AFB smear examinations and cultures of the last 12 months of treatment duration
Treatment
completed
patient with completeness of the MDR-TB treatment following the Thailand’ s 2012 NTP
Guidelines but no consecutively AFB-smear examination and culture results during the last 12-
month treatment duration
Died
patient with any cause of death during MDR-TB treatment following the Thailand’ s 2012 NTP
Guidelines
Failed
patient treated with MDR-TB regimen following the Thailand’ s 2012 NTP Guidelines with 2
positive results of the 5 consecutive AFB-smear examinations and cultures during the last 12
months of treatment duration or patient with 1 positive-culture result of the last 3 consecutive
cultures or patient with physician’ s decision to stop the MDR-TB treatment due to clinical
unresponsiveness or various adverse-drug reactions
Default
patient with continuous interruption of the MDR-TB treatment following the Thailand’ s 2012 NTP
Guidelines
Transfer out
partially MDR-TB treated patient with referring from (Transferring out) one setting to another
setting with unknown treatment outcomes will be registered as “ Transfer out ”
Table 3. Classification of treatment outcomes [24]
9. MDR-TB management and treatment outcomes in Thailand between
2007-2009
The prevalence of laboratory-confirmed MDR-TB was 0.08%. Highest prevalence (0.21%) was
found in the central part of Thailand. MDR-TB was mostly diagnosed and treated at the
secondary care settings or general hospitals (31.5% and 31.14%), 24.3% and 25.08% of cases
were diagnosed at the tertiary care settings and only 6.9% and 6.7% of the patients were
diagnosed at the university hospitals, respectively [9]. The majority of the patients (63.82%)
were registered as “ after failure of the first-TB treatment ” [9]. In Thailand, numbers of the
secondary care settings or general hospitals are more than that of the tertiary care hospitals,
this may reflex the above figures. Only 33.5% of cases were referred to the well-facilitated
setting for directly observed treatment (DOT) [9]. Only 60.6% of MDR-TB cases were prescri‐
bed 4 oral second-line drugs and an injectable aminoglycoside drug [9] which recommended
by the Thailand’ s 2012 National Tuberculosis Management Guidelines while the rests were
prescribed various treatment regimens [24]. Only 57.5% of cases had completed treatment
adherence [9]. Low DOT implementation can contribute to high default rates, high treatment
failure rates, high death rates, and low cured rates. There was 24.2 % of patients with com‐
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standardized treatment is recommended yet. Types of patients with MDR-TB, patient moni‐
toring during MDR-TB treatment and assessment of sputum conversion, and classification of
treatment outcomes are shown in the Table 1, 2, and 3, respectively [24].
Type Description
New case
patient who does not take any anti-TB drugs before or take any anti-TB drugs less than 1 month
duration and the DST results show resistance to at least rifampicin and isoniazid
Relapse case




patient who continuously interrupts the TB treatment more than 2 months and the DST results
before treatment interruption demonstrates MDR-TB
After failure of the
first- TB treatment
patient’ s AFB examinations show positive results at the end of the fifth month and the DST
results at the end of the second or fifth month reveal MDR-TB
After failure of
retreatment
patient who treated with the retreatment regimen (2 months of streptomycin, rifampicin,
isoniazid, pyrazinamide, and ethambutol, followed by 1 month of rifampicin, isoniazid,
pyrazinamide, and ethambutol , and then followed by 5 months of isoniazid, pyrazinamide, and
ethambutol for relapse cases) and the DST results at the end of third or fifth month demonstrate
MDR-TB
Transfer in
patient who is referred from one setting to the other setting for further diagnosis, treatment,
and management, transferred setting must report the outcome of treatment to the referred
setting (first setting) for discharge registration as “ transfer in ”
Other
other patients who cannot be registered as the above 6 patient-registration types including
patients who treated with empirical MDR-TB treatment regimen at the non-NTP settings (not
registered as the above 6 patient-registration types)
Table 1. Registration of the patients with MDR-TB [24]
Patient monitoring during MDR-TB treatment Assessment of sputum conversion
Direct AFB-smear examinations and cultures will be
performed at month : 0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, , 14,
16, 18, and 20.
Results of 2 consecutively direct-AFB-smear negative and
culture negative with 30-day intervals will indicate sputum
conversion. Mostly, patients with sputum conversion will
converse the positive to the negative results within the first 6-
month of treatment duration.
Chest radiological examinations will be performed at
month : 0, 3, 6, 12, and 18.
Table 2. Patient monitoring during MDR-TB treatment and Assessment of sputum conversion [24]
8. Patient monitoring after completeness of the MDR-TB treatment [24]
For assessment of the MDR-TB relapse rate, direct AFB-smear examinations and cultures are
performed and assessed every 3 months in the first 6-month completeness of treatment and
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then every 6 months for 18 months. Chest radiological examinations are preformed when
indicated.
Cured
patient who treated with MDR-TB treatment regimen following the Thailand’ s 2012 National
Tuberculosis Control Management (or NTP) Guidelines with consecutively 5- negative results of the
30 day-interval AFB smear examinations and cultures of the last 12 months of treatment duration
Treatment
completed
patient with completeness of the MDR-TB treatment following the Thailand’ s 2012 NTP
Guidelines but no consecutively AFB-smear examination and culture results during the last 12-
month treatment duration
Died
patient with any cause of death during MDR-TB treatment following the Thailand’ s 2012 NTP
Guidelines
Failed
patient treated with MDR-TB regimen following the Thailand’ s 2012 NTP Guidelines with 2
positive results of the 5 consecutive AFB-smear examinations and cultures during the last 12
months of treatment duration or patient with 1 positive-culture result of the last 3 consecutive
cultures or patient with physician’ s decision to stop the MDR-TB treatment due to clinical
unresponsiveness or various adverse-drug reactions
Default
patient with continuous interruption of the MDR-TB treatment following the Thailand’ s 2012 NTP
Guidelines
Transfer out
partially MDR-TB treated patient with referring from (Transferring out) one setting to another
setting with unknown treatment outcomes will be registered as “ Transfer out ”
Table 3. Classification of treatment outcomes [24]
9. MDR-TB management and treatment outcomes in Thailand between
2007-2009
The prevalence of laboratory-confirmed MDR-TB was 0.08%. Highest prevalence (0.21%) was
found in the central part of Thailand. MDR-TB was mostly diagnosed and treated at the
secondary care settings or general hospitals (31.5% and 31.14%), 24.3% and 25.08% of cases
were diagnosed at the tertiary care settings and only 6.9% and 6.7% of the patients were
diagnosed at the university hospitals, respectively [9]. The majority of the patients (63.82%)
were registered as “ after failure of the first-TB treatment ” [9]. In Thailand, numbers of the
secondary care settings or general hospitals are more than that of the tertiary care hospitals,
this may reflex the above figures. Only 33.5% of cases were referred to the well-facilitated
setting for directly observed treatment (DOT) [9]. Only 60.6% of MDR-TB cases were prescri‐
bed 4 oral second-line drugs and an injectable aminoglycoside drug [9] which recommended
by the Thailand’ s 2012 National Tuberculosis Management Guidelines while the rests were
prescribed various treatment regimens [24]. Only 57.5% of cases had completed treatment
adherence [9]. Low DOT implementation can contribute to high default rates, high treatment
failure rates, high death rates, and low cured rates. There was 24.2 % of patients with com‐
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pleteness of treatment, 29.1% cured, 20.5% default, 2.2% treatment failure, and 21.5% died [9].
Treatment failure and treatment default rates were higher among new case compared to the
patients with previous TB treatment whereas higher death rates were found among the
patients with previous TB treatment. This could be due to inadequately strict- and intensive-
health education provision to the new cases and more severe disease at the time of diagnosis
among the patients with previous TB treatment. Only 27.5% of cases with completed treatment
were followed up more than 2 months [9].
A recent study in South Korea revealed that the treatment regimen was individualized based
on the history of anti-TB drugs taken by the patient and the most DST result [69]. Three to
seven anti-TB drugs were self-administered except injectable drugs during hospitalization
[69]. Injectable drugs were prescribed for 6-7 months [69]. The total treatment duration was at
least 18 months after sputum culture conversion [69]. If the medical treatment was expected
to fail or had failed in patients with localized lung cavities, or bilateral lesions and anticipated
adequate postoperative lung function, surgical resection was considered [69]. The treatment
outcomes showed that 37.1% of patients had treatment success, and 4.5% of them died of all
causes during the 3-4 years after treatment initiation [69]. The independent predictors of all-
cause mortality were age, history of MDR-TB treatment, XDR-TB, and prothionamide resist‐
ance [69]. Currently, there is no DOTS programme implementation in South Korea [69] while
Thailand has been implemented several years ago, but the treatment outcomes were better
than that of Thailand [9, 69]. These different results of both projects should be intensively
investigated and explained. Kliiman K et al. recently demonstrated that predictors of poor
treatment outcomes in MDR-TB were previous TB treatment, ofloxacin resistance, positive-
AFB smear, and HIV-infection/AIDS [70].
The criteria for capacity of establishment of the specialized MDR-TB centre that recommended
by the Thailand’ s 2012 NTP guidelines [24] are as the following : 1.authorized persons’
recognition of the MDR-TB threats 2.good laboratory networks and good patient-referral
system 3.good DOT system, and 4.consistently continuous care for MDR-TB patients.
10. XDR-TB treatment
A previous study in Peru by Mitnick CD et al. demonstrated that 48 (7.4%) of 651 tested-isolate
patients had XDR-TB [71]. The results showed various individualized regimens prescribed for
47 patients with XDR-TB as the following : 1) 14.9% of the patients included ethambutol, 2)
34.0% included pyrazinamide, 3) 38.3% included streptomycin, 4) 19.1% included amikacin,
5) 53.2% included capreomycin, 6) 17.0% included kanamycin, 7) 21.3% included ciprofloxacin,
8) 12.8% included ofloxacin, 9) 42.6% included levofloxacin, 10) 2.1% included spafloxacin, 11)
72.3% included moxifloxacin, 12) 100% included cycloserine, 13) 66.0% included ethionamide,
14) 95.7% included para-aminosalicylic acid, 15) 100% included amoxicillin-clavulanate, 16)
44.7% included clarithromycin, 17) 97.9% included clofazimine, 18) 17.0% included rifabutin,
19) number of drugs in regimen (number without documented resistance or prior exposure
for more than 1 month) : 19.1) 5.3 +/- 1.3 agents among all available agents, 19.2) 3.2 +/- 1.2
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agents among 12 agents or classes for which routine DST was performed, 20) median duration
of treatment with injectable agents : 15.4 months, and 21) median duration of treatment ranged
8.0- 24.9 months, median duration from treatment initiation to surgery : 11.6 months, and
median duration of treatment for patients undergoing surgery : 31.2 months [70]. The median
duration of follow-up was 19.4 months [71]. Treatment outcomes revealed that 60.4% of
patients were cured or completed treatment [71]. This study is currently the up-to-date
information of XDR-TB treatment. Positive AFB-smear, and urban residence could be predic‐
tors of poor treatment outcomes in XDR-TB [70]. For patients with mono/poly-resistant drug
(s) TB, the recommended treatment regimens are shown in the Table 4 (13).
Mono/Poly-resistant Drug (s) Regimen
Rifampicin mono-resistance
initial 2 months of isoniazid, pyrazinamide, and ethambutol, and followed by
10-16 months of isoniazid, ethambutol and a fluoroquinolone +/- initial 6
months of an injectable drug
Isoniazid mono-resistance
initial 2 months of rifampicin, pyrazinamide, and ethambutol, and followed
by 4-7 months of rifampicin, and a fluoroquinolone (750-1,000 mg of
levofloxacin or 400 mg of moxifloxacin substituted for isoniazid in the
standard 6-month short-course regimen)
Rifampicin and pyrazinamide (+/-
streptomycin) resistance
at least the initial 2-3 months of isoniazid, ethambutol, a fluoroquinolone,
and an injectable drug (initial 6 months if extensive disease) for 18 months of
total treatment duration
Rifampicin and ethambutol (+/-
streptomycin) resistance
at least the initial 2-3 months of isoniazid, pyrazinamide, a fluoroquinolone,
and an injectable drug (initial 6 months if extensive disease) for 18 months of
total treatment duration
Isoniazid and pyrazinamide resistance
9-12 months of rifampicin, ethambutol,and a fluoroquinolon (longer if
extensive disease)
Isoniazid and ethambutol resistance
9-12 months of rifampicin, pyrazinamide, and a fluoroquinolone (longer if
extensive disease)
Isoniazid, pyrazinamide, and ethambutol
(+/- streptomycin) resistance
at least the initial 2-3 months (6 months if extensive disease) of rifampicin, a
fluoroquinolone, an oral second-line drug, an injectable drug for 18 months
of total treatment duration
Table 4. Treatment of patients with mono-drug resistant and poly-drug resistant tuberculosis [13]
11. MDR/XDR-TB treatment-pipeline agents or compounds in clinical
trials and related innovative researches
Currently, drugs in phase III clinical trials are moxifloxacin, gatifloxacin, and meropenem [72].
Heteronemin, nephalsterol, litosterol, and kahalalides are other interesting compounds which
are in pre-clinical stage [72]. Okada M et al. conducted a study on granulysin and a new DNA
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pleteness of treatment, 29.1% cured, 20.5% default, 2.2% treatment failure, and 21.5% died [9].
Treatment failure and treatment default rates were higher among new case compared to the
patients with previous TB treatment whereas higher death rates were found among the
patients with previous TB treatment. This could be due to inadequately strict- and intensive-
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among the patients with previous TB treatment. Only 27.5% of cases with completed treatment
were followed up more than 2 months [9].
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seven anti-TB drugs were self-administered except injectable drugs during hospitalization
[69]. Injectable drugs were prescribed for 6-7 months [69]. The total treatment duration was at
least 18 months after sputum culture conversion [69]. If the medical treatment was expected
to fail or had failed in patients with localized lung cavities, or bilateral lesions and anticipated
adequate postoperative lung function, surgical resection was considered [69]. The treatment
outcomes showed that 37.1% of patients had treatment success, and 4.5% of them died of all
causes during the 3-4 years after treatment initiation [69]. The independent predictors of all-
cause mortality were age, history of MDR-TB treatment, XDR-TB, and prothionamide resist‐
ance [69]. Currently, there is no DOTS programme implementation in South Korea [69] while
Thailand has been implemented several years ago, but the treatment outcomes were better
than that of Thailand [9, 69]. These different results of both projects should be intensively
investigated and explained. Kliiman K et al. recently demonstrated that predictors of poor
treatment outcomes in MDR-TB were previous TB treatment, ofloxacin resistance, positive-
AFB smear, and HIV-infection/AIDS [70].
The criteria for capacity of establishment of the specialized MDR-TB centre that recommended
by the Thailand’ s 2012 NTP guidelines [24] are as the following : 1.authorized persons’
recognition of the MDR-TB threats 2.good laboratory networks and good patient-referral
system 3.good DOT system, and 4.consistently continuous care for MDR-TB patients.
10. XDR-TB treatment
A previous study in Peru by Mitnick CD et al. demonstrated that 48 (7.4%) of 651 tested-isolate
patients had XDR-TB [71]. The results showed various individualized regimens prescribed for
47 patients with XDR-TB as the following : 1) 14.9% of the patients included ethambutol, 2)
34.0% included pyrazinamide, 3) 38.3% included streptomycin, 4) 19.1% included amikacin,
5) 53.2% included capreomycin, 6) 17.0% included kanamycin, 7) 21.3% included ciprofloxacin,
8) 12.8% included ofloxacin, 9) 42.6% included levofloxacin, 10) 2.1% included spafloxacin, 11)
72.3% included moxifloxacin, 12) 100% included cycloserine, 13) 66.0% included ethionamide,
14) 95.7% included para-aminosalicylic acid, 15) 100% included amoxicillin-clavulanate, 16)
44.7% included clarithromycin, 17) 97.9% included clofazimine, 18) 17.0% included rifabutin,
19) number of drugs in regimen (number without documented resistance or prior exposure
for more than 1 month) : 19.1) 5.3 +/- 1.3 agents among all available agents, 19.2) 3.2 +/- 1.2
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agents among 12 agents or classes for which routine DST was performed, 20) median duration
of treatment with injectable agents : 15.4 months, and 21) median duration of treatment ranged
8.0- 24.9 months, median duration from treatment initiation to surgery : 11.6 months, and
median duration of treatment for patients undergoing surgery : 31.2 months [70]. The median
duration of follow-up was 19.4 months [71]. Treatment outcomes revealed that 60.4% of
patients were cured or completed treatment [71]. This study is currently the up-to-date
information of XDR-TB treatment. Positive AFB-smear, and urban residence could be predic‐
tors of poor treatment outcomes in XDR-TB [70]. For patients with mono/poly-resistant drug
(s) TB, the recommended treatment regimens are shown in the Table 4 (13).
Mono/Poly-resistant Drug (s) Regimen
Rifampicin mono-resistance
initial 2 months of isoniazid, pyrazinamide, and ethambutol, and followed by
10-16 months of isoniazid, ethambutol and a fluoroquinolone +/- initial 6
months of an injectable drug
Isoniazid mono-resistance
initial 2 months of rifampicin, pyrazinamide, and ethambutol, and followed
by 4-7 months of rifampicin, and a fluoroquinolone (750-1,000 mg of
levofloxacin or 400 mg of moxifloxacin substituted for isoniazid in the
standard 6-month short-course regimen)
Rifampicin and pyrazinamide (+/-
streptomycin) resistance
at least the initial 2-3 months of isoniazid, ethambutol, a fluoroquinolone,
and an injectable drug (initial 6 months if extensive disease) for 18 months of
total treatment duration
Rifampicin and ethambutol (+/-
streptomycin) resistance
at least the initial 2-3 months of isoniazid, pyrazinamide, a fluoroquinolone,
and an injectable drug (initial 6 months if extensive disease) for 18 months of
total treatment duration
Isoniazid and pyrazinamide resistance
9-12 months of rifampicin, ethambutol,and a fluoroquinolon (longer if
extensive disease)
Isoniazid and ethambutol resistance
9-12 months of rifampicin, pyrazinamide, and a fluoroquinolone (longer if
extensive disease)
Isoniazid, pyrazinamide, and ethambutol
(+/- streptomycin) resistance
at least the initial 2-3 months (6 months if extensive disease) of rifampicin, a
fluoroquinolone, an oral second-line drug, an injectable drug for 18 months
of total treatment duration
Table 4. Treatment of patients with mono-drug resistant and poly-drug resistant tuberculosis [13]
11. MDR/XDR-TB treatment-pipeline agents or compounds in clinical
trials and related innovative researches
Currently, drugs in phase III clinical trials are moxifloxacin, gatifloxacin, and meropenem [72].
Heteronemin, nephalsterol, litosterol, and kahalalides are other interesting compounds which
are in pre-clinical stage [72]. Okada M et al. conducted a study on granulysin and a new DNA
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vaccine against MDR/XDR-TB and revealed that agglutinating virus of Japan/Heat-Shock-
Protein65DNA+Interleukin-12-12DNA vaccine provided strong therapeutic efficacy in killing
MDR/XDR-TB bacilli in mice and monkey models [73]. A recent experiment using MDR-TB
monkey models which received normal and genetically altered Bacilli Calmette Gue′rin (BCG)
vaccines demonstrated that these 2 groups of monkeys survived well compared to the control
group [74]. Another study in XDR-TB mice model showed ability of interleukin-7 to kill the
bacilli [74].
12. Totally drug-resistant tuberculosis
Totally drug-resistant tuberculosis (TDR-TB or XXDR-TB) was recently defined as TB bacilli
which resist to all first-line and the 6 second-line drugs (para-aminosalicylic acid, fluoroqui‐
nolones, aminoglycosides, thiamines, polypeptides, and cycloserine) [75]. Meanwhile, a recent
report from the US-CDC listed 7 challenges that should be addressed before new terminology
of TDR-TB should be considered for adopting [76], following are the challenges:
1. The definition should not hinge on resistance to all drugs tested, because the number of
drugs tested varies widely between laboratories.
2. In vitro testing data suggest cross-resistance among different drugs within a class of drugs
or closely related classes of drugs (e.g., polypeptides and aminoglycosides) is not 100%.
3. Research and reference laboratories in many countries do not test for resistance to the
third-line drugs (linezolid, thioridazine, other phenothiazines, monobactams (merope‐
nem, imipenem), macrolides, metronidazole and other imidazoles, clofazimine, and
amoxicillin/clavulanic acid).
4. DST for several anti-TB drugs is not sufficiently reliable or reproducible; retesting the
same isolate provides a different result in many cases.
5. There are several new anti-TB agents in development pipeline that will be prototypes for
new classes of antimycobacterial drugs or add new chemical entities to existing class.
6. Avoiding the unintended implication that patients with TDR-TB should not or cannot be
treated.
7. Global laboratory capacity for DST of Mycobacterium tuberculosis isolates remains limited
[75]. Two cases of TDR-TB with controversies of terminology and treatment occurred in
2003 in Italy and firstly reported in 2007 [77]. Currently, in Thailand, patients with all anti-
TB drug-resistance will be prescribed isoniazid alone for lifelong whereas no standardized
treatment is recommended yet. During 21-22 March 2012, the WHO had convened a
technical consultation to discuss the feasibility and implications of a definition to cover
more advanced patterns of TB resistance than XDR-TB [78]. The WHO concluded that
reports of severe patterns of anti-TB drug resistance ( worse than XDR-TB alone) are
increasing whereas a new definition of anti-TB drug resistance beyond XDR-TB is not
recommended [78]. This undefined resistance patterns contributed to technical difficulties
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with DST of several anti-TB agents, the lack of standardized DST methods for several
present and new investigational drugs, and insufficient evidence to link such DST results
to patients’ treatment outcomes [78]. No DST methods for group 5 and new investigational
agents currently exist [78]. Molecular DST for the second-line drugs cannot yet replace
phenotypic methods [78]. Collaboration between the national TB control programme,
Ministries of Public Health, and the pharmaceutical companies will be required to resolve
the limitations of treatment options by the compassionate use of new anti-TB agents [78].
The WHO will be the lead in ensuring that better patient data provide a more robust
information for future policy decision [78].
13. Conclusion
As countries are purchasing and using second-line drugs, the likelihood of misuse and
developing of TB-resistant strains increases. Currently, WHO and its partners have reached
the phase of expanding MDR-TB control as a component of a comprehensive TB control
programme. Launching in 2002, the Global Fund to Fight AIDS, Tuberculosis and Malaria
(GFATM) expected that requests for second-line drugs for MDR-TB management should go
through the Green Light Committee to prevent their misuse. The number of Green Light
Committee-approved MDR-TB control programme is increasing rapidly as a result of main
streaming of MDR-TB management into general TB control efforts. Expanding projects and
accelerating evidence gathering are essential to further develop international policies. The TB-
endemic countries themselves and the ability of the technical agencies, as well as the donor
community are the factors of future success to expand MDR-TB control programmes.
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1. Introduction
Tuberculosis (TB) has traditionally been one of the major causes of pleural disease and until
the earlier decades of the past century held as a principal paradigm of “pleuritis”. Indeed in
the presence of a distinctly exudative effusion and a compatible clinical presentation the widely
used term “pleuritis exudativa” insinuated a tuberculous aetiology and has therefore been
understood to be synonymous with “pleuritis exudativa tuberculosa”. Whilst in the era of TB
decline in the Western hemisphere the term “pleuritis exudativa” (which actually is a tautol‐
ogy!) has largely survived but should now describe exudative effusions in general, the full and
precise term “pleuritis exudativa tuberculosa” is therefore suggested whenever the possibility
of a tuberculous background is addressed. Otherwise the term “tuberculous pleurisy” or
“tuberculous pleuritis” is used to describe this entity, in some countries also the term “specific
pleurisy” is common. Apart from acute pleuritis exudative tuberculosa, TB of the pleura may
however rarely present as a rather chronic disease state in terms of caseous pleurisy or specific
(i. e. tuberculous) empyema, respectively. The following chapter reviews the different features
and mechanisms of tuberculous pleural involvement as well as their diagnostic and thera‐
peutic implications.
2. Epidemiology
In many regions of the world tuberculous effusion maintains its role as the leading inflam‐
matory pleural disease. With the worldwide unabated HIV epidemic and related immune
deficiency syndrome this state of affairs is likely to continue or being even aggravated within
least in certain high risk populations. On a global scale the current significance of human
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of approximately 13 % by the year 2009 [1, 2]. Conversely it is assumed, that 33 % to 50 % of
HIV infected individuals are co-infected with M. tuberculosis [2]. The MTB/HIV-association
however shows a huge intercontinental and regional variance, with the highest rate of HIV-
pleural tuberculosis-coincidence being reported in Zimbabwe where 95 % of Patients with
tuberculosis pleurisy were HIV positive [3]. In Burundi and Tansania a HIV-coinfection was
found in 60 % of all cases of tuberculous pleurisy [4]. One of the lowest rates is reported from
Spain with 10 % [5]. Am example of the impact of a high HIV-endemic environment on the
incidence of tuberculous pleurisy is also given in a series from Ruanda, where TB accounted
for as much as 86 % of all diagnosed pleural effusions [4]. Pleurisy incidence obviously and
essentially parallels variability of global TB prevalence with an overwhelming share of 95 %
occurring in developing countries. In TB-patients as a whole, pleural involvement varies
between ~ 3-5 % in Western Europe and the USA vs. ~ 30 % in developing, HIV-high-preva‐
lence-countries [6, 7, 8]. The differences clearly underline the modifying role of immunological
determinants, stage and severity of the disease, general health status and nutritional factors.
The effect of HIV on the occurrence of pleural involvement in a given TB-patient is illustrated
by a study reporting a 38 % pleurisy incidence in AIDS-associated TB as compared with 20 %
in matched HIV-negative TB patients [5]. On the basis of the presented data according to even
conservative WHO estimates the TB-pleurisy incidence throughout the current decade is
expected to remain grossly unchanged compared to the past decade, i. e. 18.2 – 62/100.000 in
the developing countries vs. 0.42-0.77/100.000 in Western countries [6, 7, 10]. When the
epidemiology of pleurisy (or pleural effusion in general) is analysed in terms of the magnitude
of TB-contribution, a probably still valid estimate in Western countries is as low as 0.1 – 0.2 %
and remains distinctly < 1 % even when referring to pleurisy in a strict sense (i. e. exudates)
[11]. By comparison the previously reported percentages of 30-86 % in developing countries
are – and remain – indeed dramatically different.
3. Pathophysiology and natural history
3.1. Immunological and microbiological factors
MTB may affect the pleura at different stages of pulmonary or systemic disease and by a
number of different mechanisms. Thus pleural involvement occurs in primary, postprimary
and reactivated TB alike and is basically believed to arise directly from contiguous macroscopic
or microscopic lung lesions or else lymphogenic or hematogenic spread, but probably also via
immunogenic mechanisms. Pleuritis exudativa tuberculosa is by far the most common clinical
variety and has been classically interpreted as an early delayed-hypersensitivity-type phe‐
nomenon rather than direct organ involvement [12, 13]. Many clinical observations and
experimental findings are in favour of this hypothesis such as:
• its frequent association with known primary infection and a typical 6-12 weeks latency,
• an often striking absence of significant pulmonary or systemic TB-lesions,
• an often culturally negative or paucibacillary effusion [14],
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• the sometimes abundant isolation of specifically purified protein derivative (PPD)- protein
sensitized T-lymphocytes from pleural fluid [15] and
• more recently the inducible pleurisy in previously PPD-sensitized animals when exposed
to intra-pleural mycobacterial protein.
Also the vigorous expression of inflammatory mediators interleukins (IL) like interferon (IFN)
γ, IL-1 and IL-8 observed in this model (or conversely their suppression by antilymphocyte
serum) support this view [16, 17].
On the other hand there is also strong evidence, that infectious invasion of the pleural space
actually occurs at a substantial, albeit variable degree. At thoracoscopy, even with negative
fluids studies, extensive inflammatory granuloma formation and fibrin deposits with unex‐
pected abundant mycobacteria recovery are a common finding (see also section on invasive
endoscopic-bioptic studies) [18]. The increasingly emerging evidence of a preferred association
of TB-pleurisy with reactivated TB in Western populations clearly points to infectious as well
as immunological mechanisms being interrelated and operative in a complex manner. Direct
infectious invasion however clearly prevails in chronic tuberculous involvement of the pleura
as in specific empyema.
According to present views and based on experimental evidence the sequence of immunologi‐
cal processes involved in TB-pleuritis appears to follow a three stage pattern of cellular reactions
and granuloma formation as a topic variant of general interaction mechanisms between MTB
and the human immune system. A schematic representation is given in figure 1 [19, 20].
Any trigger-mechanism that allows access of mycobacterial protein to the pleura will set off a
rapid mesothelial cell initiated and IL-8 mediated polymorphonuclear neutrophil (PMN)
influx within a few hours [21]. In addition macrophages and blood-borne monocytes deter‐
mine this IL-1, IL-6 and tumor necrosis factor (TNF)-α-orchestrated early stage reaction.
Within roughly 3 days, in the following intermediate stage lymphocyte subpopulations, mainly
of CD4+ helper cells but also a substantial CD8+ cytotoxic (natural killer cells) fraction
dominate the scene resulting in a CD4+/CD8+-ratio of ~ 4.3 [22]. A minor contribution includes
so-called T-cell receptor double negative (DN) αβ-T-cells and γδ-T-cells which appear to have
regulatory functions. More recently in tuberculous pleural fluid another unique CD4+CD25+
T-cell-class could be demonstrated being specifically involved in the down-regulation of auto-
reactive IFN-γ-producing T-cells, thus preventing inflammatory overshoot [23]. IFN-γ a strong
promoter of macrophage activation and granuloma formation (together with TNF-α) is the
predominant interleukin in this stage. IFN-γ-producing cells have been phenotypically
indentified as CDW29+ subpopulation and make up a substantial portion of the granuloma
core structure [24].
The  late  phase  is  characterised  by  an  equilibrated  and  sustained  CD4+/CD8+  cell-based
response  with  continued  IFN-γ  release  and  prolonged  granuloma  formation.  Several
modulating interleukins are involved in this process such as T-helper-cells (CD4+)-support‐
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Results of HIV and AIDS research also emphasize the importance of T-cell response. Several
working groups have shown, that the prevalence of tuberculous pleurisy in HIV-infected patients
with TB is strikingly correlated with their CD4+ blood lymphocyte count. In one series pleuri‐
sy prevalence in individuals with a count of > 200 cells/ml was 27 % as compared to 10 % in those
with a count of < 200 cells/ml [25]. The data support the view, that the clinical expression of
exudative pleural effusion requires a largely intact cellular immune system and features pleurisy
as a high activity response in a still immunocompetent individual. In epidemiologic terms one
would conclude that pleural effusion should be more frequent in the still immunocompetent
host than in patients with AIDS. In reality however in most HIV-high-prevalence countries like
South Africa, Uganda and Zimbabwe the percentage of thoracic TB-patients with pleural effusion
is reportedly higher in HIV+ patients [26]. As an explanation the situation is probably blurred
by a variable and poorly defined immune status in HIV+ individuals.
Figure 1. Mechanisms and immunogenesis of tuberculous pleurisy: the three stages of protective immune response.
IFN: interferon; TNF: tumor necrosis factor; IL: interleukin; PMN: polymorphonuclear granulocyte; X: undefined cell;
MΦ: macrophage, MTB: mycobacterium tuberculosis; PPD purified protein derivative
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3.2. Other factors
The mechanisms of fluid accumulation and of abundant protein leakage to the pleura with
often extensive fibrin deposits in tuberculous pleurisy have so far not been fully elucidated.
In actual fact pleuritis exudativa tuberculosa generally presents with the highest protein levels
commonly seen in exudative conditions. The intensity of inflammation and a proportionately
increased vascular permeability would provide a satisfying explanation [25, 27] although at
least in animal models, no such significantly altered vascular permeability could be demon‐
strated [12]. Current opinion holds that grossly impeded lymphatic protein clearance from the
pleura due to altered parietal lymphatic channels is probably of tantamount importance.
Again the entry mechanism of mycobacteria to the pleura has remained unclear. It is usually
assumed that the release of infectious material from a ruptured subpleural TB-lesion is the
most common mechanism. While this is likely to occur in more or less extensive pulmonary
TB, it would not explain the frequent association of tuberculous pleuritis with an – at least
radiographically – unaffected lung. There are also no convincing data yet to quantify the
contribution of a purported hematogenous or lymphogenous contribution. One might
reasonably speculate that different patterns of pleural tuberculous involvement are operative
which might correspond to the different clinical settings of primary, post-primary and
reactivated TB.
Caseous tuberculous pleuritis or specific empyema is nowadays a rare condition which is believed
to be the result of longstanding or chronic infection of the pleura, when either caseous material
gains access to the pleura or chronic pleuritis develops on the background of impaired local
defence such as pre-existing fibrous damage of the pleura or as a sequel and complication of
artificial pneumothorax, oleothorax or other TB-specific surgery dating back to the pre-
chemotherapy era. Correspondingly there is usually an extremely long history often with a
remarkable paucity or even absence of symptoms. Penetration to deeper chest wall structures
(specific abscess) and ultimately transcutaneous discharge (empyema necessitans) or creation
of a specific bronchopleural fistula, as not infrequently seen in the pre-chemotherapeutic era,
may complicate this condition [27]. Putrid discharge from a thoracic mass or putrid expecto‐
ration with or without haemoptysis may ultimately advert to the condition.
4. Clinical manifestations and natural course
Tuberculous pleurisy may occur as an acute, subacute or rather chronic disease. At times the
course is also surprisingly oligosymtomatic. Therefore duration of symptoms or major illness
prior to hospital admission and diagnosis varies considerably from < 1 week (31 %) to < 1months
(62 %) or even longer (7 %) [28]. These data refer to the pre-HIV era and would not apply for HIV-
seropositive patients and elderly populations, which both tend to have a particularly long
symptomatic or else oligosymtomatic period. An infectious, i. e. febrile illness is nevertheless by
far the most common clinical presentation. As a general rule, an acute febrile illness is the more
likely to occur the younger and the more immunocompetent a given patient is. In developing,
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thirties, whereas in industrialized countries with a major contribution of reactivated TB it has
shifted to about 50 yrs [29]. But still the age-related incidence peak of tuberculous pleuritis is
distinctly lower than of parenchymal pulmonary TB which used to peak around 55 yrs [30].
Implicitly by the same statement in Western populations TB-pleurisy was historically more
symptomatic than is currently the case. In a representative series from the 1960-1970s ~ 60 % of
patients developed an acute illness mimicking bacterial (pleuro)-pneumonia with cough (70 %),
chest pain (75 %) and low- to high-grade fever (86 %) as the most frequent symptoms [31, 32].
Other symptoms include those commonly occurring in various TB disease states such as weight
loss, malaise and night sweat. Severe or even live threatening disease, defined as persistent high-
grade fever > 38,3°C over > 2 weeks or respiratory distress has been in reported in a more recent
series in only 7 % [31], whereas an oligosymptomatic or a febrile course is described in 14-33 %
[32]. Tuberculous pleurisy usually involves one hemithorax only (90-95 %) and is of limited size
(roughly up to one-half of the hemithorax volume). In a major series (n=254) effusions occupy‐
ing more than 2/3 of a hemithorax were noted in only 18 % [33]. Rarely effusion will occupy the
entire hemithorax and will almost never reveal compressive or displacing features [31]. Basically
there are no specific clinical clues to tuberculous etiology in pleurisy unless some TB-contact is
revealed or suspected. An HIV-related background may be suspected in a compatible clinical
and history setting or when there is a long preclinical period, unusual additional symptoms like
diarrhea and more hepato(spleno)-megaly or lymphadenopathy as might be attributed to the
tuberculous condition. Untreated, lone pleuritis exudativa tuberculosa in the short term seems
to be a self-limited inflammatory process in most instances, terminating in complete or incom‐
plete resolution within weeks or month. Frequently observed otherwise unexplained diaphrag‐
matic adhesions may be a late sequel of clinical silent or oligosymtomatic TB pleurisy. Importantly
however progression or reactivation to active pleuropulmonary or extrapulmonary TB occurs
in an important fraction. In one follow-up study the recurrence rate within 1 year was 5 %, where
TB did not relapse earlier than 8 month after the onset of pleurisy. Within a 4-5 yr period however
the rate was dramatically higher and in initially culture positive and culture negative subjects
with 65 % and 60 % respectively roughly alike [27]. One major outcome determinant clearly is
the presence and the extent of pulmonary involvement. At a similar therapeutic intensity in a
very recent major clinical study from Taiwan, 51 (24,9 %) out of 205 hospitalised patients having
been identified to have isolated (lone) pleuritis had a significantly better outcome, shorter hospital
stay and less comorbidity than the patients with pleuropulmonary disease [34].
5. Diagnosis
5.1. Clinical findings
5.1.1. Signs at physical examination
Physical examination clearly will provide only non-specific signs of pleural effusion in general
including dullness to percussion and the occasional demonstration of a pleural rub at auscul‐
tation (“snow-ball-crunching sign”) in particular in the presence of chest pain. Signs of a
trapped or loculated rather than free flowing fluid collection may suggest a tuberculous
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aetiology, but this observation holds also true for “plain” parapneumonic pleurisy. Usual signs
of systemic infection, as mentioned above, that should be looked for, may alert to the possibility
of a HIV-related background.
5.1.2. Imaging studies
Imaging techniques are engaged in the evaluation of tuberculous pleurisy following general
diagnostic pathway recommendations for effusion. Conventional chest radiography (CRX) requires
fluid amounts of at least 150 ml to become clearly detectable as blunting of the costodiaphrag‐
matic angle in standard projections. Profuse effusion with opacification of an entire hemithor‐
ax would rather favour differential diagnoses like malignancy in the elderly and afebrile patient
[35]. Free flowing effusion may be easily identified, but one should look specifically for signs of
loculation, pleural thickening or adhesions and in profuse effusion for compressive signs
interfering with the respiratory performance. Apart from pleural changes pulmonary infil‐
trates, nodules, lymphnodes and other suggestive signs of TB like encapsulated or cavitary
lesions must be carefully looked for using routine CT-imaging. CT-based prevalence of lung
perenchymal tuberculous lesions in mixed populations appears to be significantly higher than
previously assessed based on conventional radiography. In one recent series from Korea
comprising 106 patients with an age distribution from 16-89 yrs (mean 53) with 86% a remarka‐
ble high rate of parenchymal changes was found, presumed to represent active tuberculosis in
59 % [36]. Most of these lesions revealed features of reactivated rather than primary tuberculo‐
sis. Sonography (Ultrasound, US) using innovative technical achievements like high frequency
(5-7.5 MHz) – US and convex or sector scanners allow extended exploration of the chest wall
structures, the diaphragm and the anterior mediastinum up to a penetration depth of ~ 25 cm.
Specific advantages of US are a more precise fluid volumetry than by CRX, precise localisation
of septae, membranes and chambers as well as pleural thickening along with its particular
versatility for bedside diagnosis. On demand guidance for interventions such as thoracentesis
is a particular asset of US.. Examples are shown in figure 2, 3. Magnetic-resonance imaging (MRI)
is a highly refined, not generally available technique, which will rarely be required but does have
differential diagnostic merits in the analysis of critical borderline relationships i. e. distinguish‐
ing between inflammatory- infiltrative and malignant-destructive pleural processes via different
T-weighted sequences [37]. Very recently a role of PET-CT has also been described. PET-
imaging may indeed provide differently extensive focal and impressing laminar changes which
however remain indistinguishable from malignant lesions [38].
5.2. Immunologic tests
5.2.1. Tuberculin skin reaction
The tuberculin skin reaction is traditionally considered an indispensable tool in the diagnosis
of tuberculosis in general and likewise in tuberculous pleurisy although it is less reliable than
in pulmonary TB. The rate of false negative reactions to PPD has been given as high 30 % of
cases but even figures up to < 41 % have been reported [31, 32, 33], the variability possibly
reflecting non-standardised test doses. Still however there remains an amazing false negative
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aetiology, but this observation holds also true for “plain” parapneumonic pleurisy. Usual signs
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cases but even figures up to < 41 % have been reported [31, 32, 33], the variability possibly
reflecting non-standardised test doses. Still however there remains an amazing false negative




Figure 3. Ultrasound detection of multiple chambers in pleuritis exudativa tuberculosa
Figure 2. Ultrasound detection of inflammatory visceral membranes and consecutively trapped lung in pleuritis exu‐
dativa tuberculosa
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ocal experimental evidence. It appears a valid speculation to consider a local pooling of
sensitised T-lymphocytes at the site of infection responsible. Animal experiments and clinical
investigations have shown sequestration of PPD-sensitized lymphocytes to the pleural
compartment actually to occur in the early phase of infection leading to their systemic
depletion [39]. As a presumptive additional mechanism the presence of adhering suppressor
cells to blood lymphocytes has been demonstrated in PPD-anergic patients [39]. While the
explanatory evidence may remain scanty, it should be emphasised that in clinical practice the
phenomenon appears to be transitory and restricted to the early phase of tuberculous infection.
It might thus be associated with the pre-allergic phase of tuberculous infection, since conver‐
sion of skin reactivity has been subsequently observed within a 6-8 weeks delay [27]. As a
reverse conclusion in the framework of discussed hypotheses the observation of a delayed
PPD-conversion might be interpreted as a clue to primary infection to have occurred. Persisting
anergy would then point to other immune-modulating factors like advanced age, certain drug
interference or immune-compromising comorbidity.
5.2.2. Interferon-γ-release assays
In Europe commercially available Interferon-γ-release assays (IGRA) are the QuantiFERON-
TB-Gold-Test and the T-Spot-TB-Test. Both use the MTB-RD1-region antigen sequences CFP10
and ESAT 6 and measure the specific lymphocyte-induced quantitative IFN-γ-response or the
sensitized IFN-γ-producing lymphocyte response, respectively. There has been elaborated a
body of clinical data in practical use highlighting both the assets and pitfalls of the investiga‐
tion. In summary and in general there is distinct superiority to the PPD-skin-test with an overall
sensitivity of ~ 85 % and a high specificity well > 90 % [40]. The concordance of the PPD-test
and IFN-γ-release assays is in the order of 60-85 % [41]. However in the identification of active
clinical tuberculosis blood-based IFN-γ-release assays also have revealed a considerable rate
of false negative findings. In several studies including pulmonary a well as pleural tubercu‐
losis, sensitivity was limited to 60-64 % [42, 43, 44]. There have also been a number of incon‐
sistent and equivocal reports where the results obviously vary with different TB-prevalence
settings (i. e. pretest probability). In a number of studies the variability of sensitivity ranges
between 96 % in low prevalence settings down to 58 % in studies featuring high prevalence
areas, also specificity setbacks are reported [45]. Blood-based IGRA´s therefore seem to share
the limitations of PPD-testing. Since they cannot distinguish latent from active TB, in conclu‐
sion, the diagnostic value for identification of tuberculous pleurisy in high prevalence settings
is very low and has even only limited value in industrialized countries.
5.3. Pleural fluid analysis
5.3.1. Biochemical parameters
When there is enough effusion to allow safe puncture and TB is suspected, thoracentesis is a
mandatory diagnostic step. The effusion will be invariably and markedly exudative with a
(unless in tuberculous empyema) clear, straw- to amber-coloured appearance and a mean
protein content above 5.0 g/dl, in one series (n=83) it was 5.2 g/dl (range 3.5 – 7.0) [32]. Glucose
and pH-values have traditionally believed to be characteristically low in TB. It appears
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ence these values are not substantially different from exudates due to other aetiologies. SAHN
[46] found pH-values < 7.29 and glucose values < 30 mg/dl in only 20% of patients and this has
been confirmed by others [47]. Interestingly however, if low values actually occur, they appear
to correlate with the pleural bacillary load and are to some extent predictive of cultural results.
In one thoracoscopic study positive pleural fluid culture yield was 59 % when the glucose level
was < 50 mg/dl but only 25 % when the glucose values were > 50 mg/dl (p<0.005) [18]. Lactic
dehydrogenase (LDH) is a non-specific marker of pleural inflammation, which may be
excessively elevated in tuberculous pleurisy, although with a mean value of 423 IU/ml (range
43 – 1.575) as reported in a representative series again does not discriminate TB from para‐
pneumonic and not even from malignant effusion [32]. Adenosine deaminase (ADA) has been
a promising and much hailed semispecific biochemical parameter. ADA is an inflammatory
enzyme expressed predominantly by sensitized and activated T-lymphocytes. Isoenzymes
(ADA2) in addition reflect to some extent monocyte/macrophage activation. Thus increased
ADA-activity in general indicates various T cell/macrophage interactive inflammatory
processes like granulomatous disease but also empyema and collagen vascular disease. It
appears however particularly sensitive to TB. In a key study (n=129) in patients < 35 yrs a
receiver operating characteristics (ROC) –derived cut-off level of 47 U/ml allowed distinction
of tuberculous effusion from empyema, rheumatic and neoplastic disease with a 100 %
sensitivity and 87.5 specificity. When empyema was eliminated, specificity and the positive
predictive value even attained 100 % [48]. There are important limitations to the interpretation
of these results and their clinical relevance:
• the data reflect the afore mentioned age group only, in more heterogenous groups both
sensitivity and specificity have to be (down)-corrected to 95 % and 90 % respectively [22,
49, 50].
• the results strictly apply to high TB prevalence settings only and do not allow for different
pre-test prohabilities [3].
• also immune suppression like in AIDS endemic areas may interfere with inflammatory
ADA-release and invalidate diagnostic conclusions [3, 51].
Nevertheless, based on the most accepted cut-off level of 40 IU/l and provided its critical use
in areas of at least intermediate TB-prevalence ADA determination must be regarded as a true
diagnostic enrichment. An era of successful ADA-use has been recently summarized and
confirmed by a large size metaanalysis (63 studies, 5297 tuberculous and non-tuberculous
effusions) resulting in a sensitivity and specificity of 92 % and 90 % respectively [52].
5.3.2. Cytological analysis
Based on the immunological processes involved, a marked lymphocytosis is the predicted and
characteristic feature of TB-pleurisy along with significantly increased total white cell counts
as reflected in one representative study with a mean count of 2.309/mm3 (range 30 – 24.009
mm3) [32]. Usually 90 – 95 % of pleural fluid cells are T-lymphocytes, the remainder being B-
lymphocytes and (mostly) activated mesothelial cells. Only exceptionally (in ~ 5 %) lympho‐
cyte counts < 50 % may occur [27]. Thus when an 80 % lymphocyte reference line is chosen,
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pleuritis tuberculosa exudativa is by far the most frequent cause of pleural lymphocytosis [46].
Rarely, in particular in the early phase of inflammation fluid cytology may reveal neutrophil
leucocyte (PMN) predominance. Expansion of the eosinophil compartment would be an
extremely unusual finding. In the presence of significant numbers of eosinophils (> 5 %)
differential diagnoses should be considered.
5.3.3. Microbiological studies
The microbiological yield from diagnostic (low volume) thoracentesis as far the smear is
concerned is very low unless the whole effusion or large amounts are being centrifuged or the
patient has a tuberculous empyema [14, 29]. In HIV positive individuals, particularly in those
with CD4 cell counts < 200 x 106/l significantly higher yields are being reported amounting in
one study to 37 % vs. 0 % in non HIV-patients [53]. In a comprehensive study on microbiologic
smear findings in pleural fluid specimens in non-selected HIV negative out-patients, the
positive acid fast smear yield (n=232) again was actually zero [54]. Cultures should be obtained
both from the sputum and pleural fluid. The positive cultural yield from pleural fluid has been
given in collective reviews with 10 – 35 %, being ~ 25 % in the mean [14, 30]. In one of the largest
series (n=100] the sensitivity of pleural fluid culture was 28 % [18, 55]. The use of radiometric
or non-radiometric liquid culture systems (BACTEC, MB/BacT, MGIT) will markedly acceler‐
ate results and possibly lead to an enhanced yield (~ 50 %), when bedside instead of laboratory
inoculation is used [56]. The yield of sputum cultures in tuberculous effusion is expectedly
largely dependent on the extent and nature of pulmonary involvement and may mount up to
~ 50 %. In the non-expectorating patient the use of induced sputum is advised [57]. The positive
yield is also believed to be higher in HIV-infected patients [53, 57]. In the complete absence of
pulmonary lesions according to most sources the sensitivity will be no more than 4-7 % [30].
Only exceptionally a surprisingly high figure of 31 % for induced sputum has been reported
[57].
5.3.4. Immunological and molecular studies
Immunological studies of pleural fluid in TB-pleurisy focus on the measurement and analysis
of chemokins and interleukins that are characteristically associated with the tuberculous
immune response. TNFα and IFNγ revealed at a cut-off 140 pg/ml a sensitivity of 94 % and a
specificity of 85 % [58,60]. Similarly as for ADA the major confounders were bacterial empyema
and parapneumonic effusion respectively. Interestingly TNFα did not attain enough discrim‐
inatory power to separate TB from various inflammatory conditions and is no more considered
a valid option in the diagnosis of TB. More recent meta analysis-derived collective data from
22 studies resulted in an overall sensitivity of 89 % at a 97 % specificity [61]. Thus at present
IFNγ-determination in pleural fluid – contrasting to systemic IGRA-application – would
appear a useful diagnostic test with a sensitivity and discriminatory power comparable to that
of ADA-determination if one was to accept the significantly higher costs and disregard more
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Molecular mycobacterial identification methods employing a variety of nucleic acid amplifica‐
tion techniques (NAAT) have been applied in TB pleurisy with considerable enthusiasm and
expectations ever since their first application in TB in 1989 [62]. The techniques that have been
used include target amplification (polymerase chain reaction, PCR), strand displacement
amplification (SDA), transcription mediated amplification (TMA), probe/primer amplification
(ligand chain reaction, LCR) and Q-Beta replicase amplification mostly with the IS 6110, 16S
recombinant ribonucleic acid (rRNA) and 65 XD target sequence [63-66]. So far published data,
both biopsy- and pleural fluid-based have shown considerable variance of diagnostic yield,
which ranged from 20-81 % as to sensitivity with an expectedly high specificity in the order of
98-100 % (table 1). When analyzing the sources of this high variance, apart from technical
factors like contamination-related “carry over” or amplification inhibitors, the most important
determinant appeared to be the number of bacilli in the pleura fluid or specimen sample [31].
Although theoretically requiring the presence of merely one microorganism to trigger
amplification, similar to sputum anlysis, failed to detect pleural MTB in particular when the
pleurisy was paucibacillar, correlating with cultural negativity. In addition to fluid samples
numerous studies have evaluated the value of various nucleic acid extraction and amplifica‐
tions techniques in formalin-fixed and paraffin-embedded pleural tissue specimen [67-71].
With the use of commercial kits of both DNA amplicons (ligand chain MTB assay, LCxMTB
or AMPLICOR MTB) or RNA amplicons (amplified MTB direct test, AMTDT) according to the
latest currently available sources, the sensitivity of each single technique did not exceed 63.2
% albeit at an expected 100 % specificity [71]. The so far largest meta-analysis including 40
studies and featuring commercial as well as in-house (“home-brew”) tests, confirms a low and
heterogeneous sensitivity (in the mean 62 %) and high specificity of 98 % [72]. Thus there is
no convincing evidence, that generally and especially in the critical issue of paucibacillar
(cultural negative) pleurisy, NAATs perform substantially better in tissue than in effusion
specimens (table 1). Although in-house assays have been reported to be slightly superior [73],
there remain significant sensitivity set backs both in liquid- and tissue-derived specimen. In
summary NAATs may offer certain advantages like quick results within hours or added
specificity. They may also improve sensitivity in combined and parallel use with conventional
methods and multiple amplicors (diagnostic confirmation), but can certainly not replace or
obviate the need for conventional tools in the diagnosis of TB pleurisy.
5.3.5. Invasive bioptic and endoscopic studies
Bioptic techniques in the evaluation of tuberculous effusions incorporate closed blind or
imaging guided needle biopsy and medical (video)-thoracoscopy. Only exceptionally, if ever,
surgical  diagnostic  efforts  including  video-assisted  surgical  thoracoscopy (VATS)  would
appear appropriate. Invasive techniques are indicated when clinical investigation and pleural
fluid analysis provide only ambiguous or conflicting results and this is particularly true if
relevant differential diagnoses like malignancy need to be reliably excluded. Needle biopsy
may be considered a first step. There are no clear preferences as to the type of needle to be
used, although in the author´s opinion the Tru-Cut or Raja-system may be preferable to the
older  Abrams-  or  Ramel-needle  by  providing  a  larger  specimen along with  easier  han‐
dling. It is recommended, that at least six biopsies are obtained, since they will not regular‐
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ly contain a representative parietal pleural sample [74]. With this premise and the expected
yield of at least two valid samples closed needle biopsy should be diagnostic in tubercu‐
lous pleurisy in ~ 60 % of cases, when histology and tissue-, as well as fluid-culture are being
combined. In a major series (n=100 %) a 61 % positive yield was composed of 51 % biopsy
yield and 28 % positive fluid culture (figure 4) [18, 55]. Distinctly higher yields have also
been reported in the literature, leading in a collective review to an average sensitivity of 69
% (range 28-88 %) [75]. The difference and wide range is likely to be due to technical disparities
and inclusion of data originating from largely different prevalence areas. In one study from
a high prevalence area (South Africa) comprising 51 patients with undiagnosed pleurisy the
positive closed needle yield in tuberculous pleurisy (histology+AFB-stain+culture) was 79%,
when combined with pleural fluid ADA-determination and a lymphocyte/neutrophil ratio >
0.75 sensitivity increased to 93% at a specificity of 100% [76]. Thus with the parallel use of
less invasive parameters needle biopsy approaches the diagnostic potency of more inva‐
sive techniques and would appear the second best diagnostic option in areas with limited
medical logistics and resources.
Medical thoracoscopy as a “window to the pleural space” [77] is the gold standard procedure in the
evaluation of exudative pleural effusion, hence also pleural pleurisy. The current and future
role of thoracoscopy needs to be redefined for its diagnostic and interventional efficacy in the
light of its close historical affiliation with TB. In fact tuberculosis was already a major focus of
medical thoracoscopy or “pleuroscopy” as referred to and initiated by JACOBAEUS back in
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yield of at least two valid samples closed needle biopsy should be diagnostic in tubercu‐
lous pleurisy in ~ 60 % of cases, when histology and tissue-, as well as fluid-culture are being
combined. In a major series (n=100 %) a 61 % positive yield was composed of 51 % biopsy
yield and 28 % positive fluid culture (figure 4) [18, 55]. Distinctly higher yields have also
been reported in the literature, leading in a collective review to an average sensitivity of 69
% (range 28-88 %) [75]. The difference and wide range is likely to be due to technical disparities
and inclusion of data originating from largely different prevalence areas. In one study from
a high prevalence area (South Africa) comprising 51 patients with undiagnosed pleurisy the
positive closed needle yield in tuberculous pleurisy (histology+AFB-stain+culture) was 79%,
when combined with pleural fluid ADA-determination and a lymphocyte/neutrophil ratio >
0.75 sensitivity increased to 93% at a specificity of 100% [76]. Thus with the parallel use of
less invasive parameters needle biopsy approaches the diagnostic potency of more inva‐
sive techniques and would appear the second best diagnostic option in areas with limited
medical logistics and resources.
Medical thoracoscopy as a “window to the pleural space” [77] is the gold standard procedure in the
evaluation of exudative pleural effusion, hence also pleural pleurisy. The current and future
role of thoracoscopy needs to be redefined for its diagnostic and interventional efficacy in the
light of its close historical affiliation with TB. In fact tuberculosis was already a major focus of
medical thoracoscopy or “pleuroscopy” as referred to and initiated by JACOBAEUS back in




1910 [78]. Anticipating modern minimally invasive surgical techniques, now all included
under the heading video-assisted thoracic surgery (VATS), his pioneering approach to thoraco‐
scopy was basically interventional with the intention to optimize pneumolysis and to break
strands for artificial pneumothorax induction in pulmonary TB (“Jacobaeus operation”).
However the ability to visualize major portions of the pleural surface, to intervene in the
presence of membranes, adhesions and septae with the option of numerous dedicated biopsies
also ensures optimum diagnostic results that are reflected in a yield of 94-99 % as confirmed
in decades of clinical experience [18, 77-81]. At thoracoscopy tuberculous pleurisy usually
appeals to the experienced investigator with characteristic and fairly diagnostic inflammatory
patterns.
• One may present with abundant fibrinous membranes, septae, loculations and diffuse
inflammatory thickening of the parietal and visceral pleura as the prevailing pattern. An
example of this endoscopic pattern is shown in figure 5.
• A second characteristic feature is a more or less intensive seeding of the pleural surface with
solid or caseous, sago-like nodules and only scanty fibrin deposits as shown in figure 6.
Although usually fairly small, major nodules as also shown in figure 6 may easily be
confused with malignant lesions.
• Tuberculous empyema as exemplified in figure 7 may be visually indistinguishable from non-
specific bacterial empyema unless calcifications, irreversible lung trapping or suspect
pulmonary lesions suggest a tuberculous origin.
Similarly to closed needle biopsy a sufficient number of biopsies – at least three- should be
obtained to warrant optimum and representative results. This may often require mechanical
debridement of membranes and septae to gain access to the inflamed pleura. When thoraco‐
Figure 4: Single and cumulated yield (%) of various microbiological and   
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scopic results are combined with aforementioned techniques positive results may be aug‐
mented to virtually 100 % (fig. 2) [18].
Thoracoscopy also provides a number of additional advantages:
• With the reasonable diagnostic certainty of visual findings combined with an immedi‐
ate  histological  yield  of  >  90  %  it  allows  instant  implementation  of  antituberculous
chemotherapy
• The percentage of positive TB-cultures obtained from biopsies and fibrous membranes may
be twice as high (78 %) as from needle biopsies and pleural fluid combined (39 %) [77]. This
in turn provides superior opportunity for drug susceptibility testing.
• Complete removal and subsequent drainage of pleural fluid with pulmonary re-expansion
provides instant relief to the patients and warrants better healing and outcome options (see
section on therapy).
Male 48 years, pleuritis tuberculosa exsudativa
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• In addition thoracoscopy may be easily expanded to an adjuvant therapeutic intervention
by breaking adhesions and debridement of membranes as also discussed in the section on
therapy.
In the overall assessment of biopsy techniques the experienced investigator will therefore
bypass closed needle biopsy and prefer thoracoscopy. Closed needle biopsy however will
remain the second best alternative if
• there is no logistic option for thoracoscopy or
• in the presence of clinical obstacles such as contraindications or mal-detachment of the lung
due to adhesions or advanced obliteration of the pleural space.
In summary, for the diagnosis of tuberculous pleurisy it appears and remains a well-founded
clinical policy to push for the recovery of biopsy specimens whenever possible and to combine
these with less invasive test results to ensure optimum management of the condition.
Male 24 years, pleuritis exsudativa tuberculosa
Figure 6. Typical thoracoscopic aspect of sago-type disseminated small and larger nodules both of the parietal and
visceral pleura giving rise to confusion with malignancy
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6. Therapy options
6.1. Systemic therapy
Basically systemic therapy of tuberculous pleurisy in the moderately ill patient neither differs
in intensity nor duration from antituberculous chemotherapy of pulmonary and other organ
tuberculosis in general. Current short term recommendations for non-complicated pulmonary
and extrapulmonary organ tuberculosis call for a quadruple drug therapy in the 2-month acute
phase in the combination of 5 mg/kg Isoniacid (INH), 10 mg/kg Rifampicin (RMP), 30-35 mg/
kg Pyrazinamid (PZA) and 20-25 mg/kg Ethambutol (EMB) or 15 mg/kg Streptomycin (SM),
where daily alternation of the SM and EMB component may be preferable [82]. In the second
4-month stabilizing phase a INH/RMP dual therapy is recommended. Until the 1990-years a
triple therapy in the initial phase for Tb was considered safe enough in view of a low incidence
of primary drug resistance. The quadruple therapy recommendation is therefore an amend‐
ment to a meanwhile globally changed drug susceptibility situation. Thus in an un-clarified
clinical setting the extent of drug resistance expectation will modify treatment strategies. The
Male patient, 48 yrs
Figure 7. Typical thoracoscopic aspect of tuberculous („specific“) empyema showing putrid parietal coverings includ‐
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current policy in the case of tuberculous pleurisy therefore holds, that in lone and paucibacillar
pleurisy (without lung parenchymal lesions) after immediate quadruple therapy a down-
grading to a historical triple scheme is safe enough, provided full drug susceptibility is
warranted. In the presence of lung parenchymal involvement the full standard scheme would
however apply. The current average drug resistance probability is reflected in one major series
(n=78) with a rate of 6.4 %, being probably representative for Middle Europe [55].
The addition of an oral or parenteral steroid regimen to antituberculous drug therapy has been
discussed controversially. The rationale put forward for this approach focuses on
• the assumption of a shorter, attenuated clinical course in the severely ill patient,
• improved outcome by prevention of sequels in terms of pulmonary encasement and
fibrothorax.
Three valid clinical studies employing a randomized, double-blind controlled design may be
considered to have basically settled the issue [83, 84, 85]. These studies consistently showed,
that a tapering steroid therapy for 4 and up to 12 weeks starting with 0.5, 0.75 and 1.0 mg/kg/
day prednisone added to a standard antituberculous drug regimen, although mitigating and
shortening the clinical course to a moderate extent in two studies, did not alter any of the
outcome endpoints (clinical status, effusion resolution, pleural sequelae, lung volume and gas
exchange). In conclusion from these data, steroids would generally not appear indicated in
TB-pleurisy, a reasonable practice however would be a temporary use in the presence of a
severe febrile and consumptive clinical course. Their long term use for the prevention of fibrotic
sequels would appear obsolete.
6.2. Local therapy
Local therapy is an option, which is usually directly derived from a thoracoscopic approach
to the management of the condition. First of all it needs to be emphasized that the (possibly
complete) evacuation of pleural effusion is already an important topic treatment approach.
While this can basically be achieved by non-endoscopic techniques like simple thoracentesis
and small bore catheters as well, there is no doubt, that thoracoscopy will be disparately more
effective due to the ability of visual guided optimum positioning and the use of large bore
drains. In addition there is ample clinical evidence, that expert medical thoracoscopy can open
intrapleural loculations and chambers, completely evacuate sequestrated effusion compart‐
ments and also to some extent produce effective debridement of membranes. Although no
controlled study has so far proven the value of such efforts, from the view of the expert
endoscopist it would appear a straightforward and convincing approach. Together with the
early induction of antituberculous chemotherapy it might be responsible for the fact that in
our institution over more than two decades of experience none of the patients needed decor‐
tication subsequently.
Another more recently discussed approach in topical therapy would be, by a rationale
analogue to non-specific bacterial empyema, the use of fibrinolysis (streptokinase) which even
need not necessarily be linked to an endoscopic protocol. There is so far only scanty experience
[85]. However one fairly comprehensive study from Taiwan using a non-endoscopic pigtail
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catheter technique and comparing a loculated streptokinase group (n=22) with a loculated
normal saline irrigation group (n=22), reported significantly better outcome both in clinical
terms of imaging and functional criteria [86]. Additional future evidence provided, this would
seem an encouraging step towards further improvement in acute tuberculous pleurisy
management.
Surgery in the era of antituberculous chemotherapy is only exceptionally required in the
management of tuberculous involvement of the pleura. Remaining indications refer to rare
instances of previously mentioned tuberculous empyema and in particular its complications.
Specific issues in this context would be excessive membrane formation with trapped lung and
significant long term pulmonary encasement due to fibrothorax. Due to the scarcity of
pertinent cases and studies (at least in the western hemisphere) there are no generally accepted
surgical guidelines for the management of these conditions. Surgical decisions must be created
in an individual case-determined approach. A reasonable policy would appear to perform lone
or combined empyemectomy/pleurectomy, also termed early decortication in clinically severe
and functionally disabling conditions refractory to medical efforts. These indications may be
amenable to video-assisted thoracic surgery (VATS)-based interventions. Formal thoracotomy
would however be required if it comes to additional lung parenchymal resection or thoraco‐
plasty in rare complicated cases e.g. with persisting pyopneumothorax with or without
trapped lung due to a large, medically intractable broncho-pleural fistula.
A different issue is severe, chronically trapped lung due to fibrothorax. A reserved approach to
surgical strategies is generally advised because unexpected long term remission of inflammato‐
ry peels is sometimes impressing. Although decortication has been performed as early as 6 weeks
after the precipitating insult (empyema), the indication to late decortication is basically dis‐
cussed in the context of definitely and irreversibly trapped lung (fibrothorax) i.e. when at least
6 months have elapsed. With a focus on repair of lung function and prevention of chest deformity
most investigators agree that the indication requires a significant decrement of lung function
(TLC < 60% pred., reduction of perfusion > 50%) and level of deformity in the absence of significant
calcifications (pleuritis calcarea). Even then with extensive fibrotic fusion of both pleural sheaths
not only will surgery be fraught with considerable technical problems but also the certainty and
extent of functional improvement may not be predictable and warranted.
6.3. Sequels and prognosis
There are largely diverging data as to the prevalence of fibrothorax and permanent pleural
thickening as the most important sequel of pleural TB. In one source based on standard
radiographs in pleuritis exudative tuberculosa a percentage as high as 49 % has been given
[32]. With the strict definition of fibrothorax as a pleural membrane of at least 5 mm thickness
extending across major portions of the hemithorax and persisting > 8 weeks after initiation of
therapy a figure of ~ 5 % is a more likely and widely accepted rate of this complication. The
intensity of pleural inflammation expressed as interleukin levels and derangement of bio‐
chemical parameters is assumed to be to some extent predictive for this complication. In one
study residual pleural thickening was indeed significantly correlated with the magnitude of
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Caseous tubercus pleurisy and specific empyema respectively is in its natural course and in
prognostic terms an entirely different entity. These patients will invariably and typically
develop an extensive calcified fibrothorax (pleuritis calcarea) with or without concomitant
chest deformity. Also chronic non-specific lung disease (COPD) with or without bronchiecta‐
sis, late TB-exacerbations and internal or external fistulisation (specific empyema necessitans)
may develop. Anecdotical occurrence of non-HODGKIN lymphomas arising from long term
smouldering encasements has also been described.
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1. Introduction
The incidence and mortality of tuberculosis (TB), the most common opportunistic infection in
HIV patients has drastically increased with the emergence of the HIV pandemic
The HIV infection supported the re-emergence of TB as well as two major changes in the natural
history of TB, namely it has increased the frequency of extrapulmonary TB and the mycobac‐
terial multidrug resistance. The extrapulmonary TB involvement is present in up to 40% of the
HIV cases and includes respiratory, digestive, lymphatic and neurologic localizations. Of these
neurotuberculosis (NTB) is probably the most devastating extrapulmonary form of TB. The
risk of acquiring NTB in HIV patients has been reported as 10 times higher than in non-HIV
individuals and its related mortality exceeds 50%. The prognosis is further worsened by the
HIV related progressive immunodeficiency which leads to the reactivation of opportunistic
infections and the development of malignancies. The early diagnosis of NTB in HIV positive
patients improves the short and long term prognosis of these patients and increases their life
expectancy. Unfortunately the complexity of the clinical presentation and the variability of the
bacteriological results accounts for significant difficulties in the diagnostic confirmation of
NTB. Therefore treatment in these patients is often empirical. Moreover the antituberculous
treatment is of long duration with serious adverse effects. Ensuing complications during
treatment include the immune reconstitution inflammatory syndrome (IRIS) - a complication
that is characteristic for HIV patients undergoing treatment for TB. Furthermore the multiple
drug interactions between the antituberculous and antiretroviral treatment require close
supervision of these patients.
This chapter summarizes the epidemiological, pathogenic, clinic and therapeutic challenges
of NTB in HIV patients.
This chapter summarizes the epidemiological, pathogenic, clinic and therapeutic challenges
of NTB in HIV patients.
© 2013 Iacob and Iacob; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
[81] Harris, R. J, & Kavuru, M. S. Mehta ACThe impact of thoracoscopy on the manage‐
ment of pleural disease Chest (1996). , 107, 845-852.
[82] Blumberg, H. M, Burman, W. J, Chaisson, R. E, et al. American Thoracic Society/
Centers for Disease Control and Prevention / Infectious Disease Society of America:
treatment of tuberculosis Am J Respir Crit Care Med (2003). , 167, 603-662.
[83] Lee, C. H, & Wang, C. J. Lan RS Corticosteroids in the treatment of tuberculous
pleurisy: a double-blind, placebo-controlled, randomised study Chest (1988). , 94,
1256-1259.
[84] Wyser, C, & Walzl, G. Smedema JP Corticosteroids in the treatment of tuberculous
pleurisy: a double-blind, placebo-controlled, randomised study. Chest (1996). , 110,
333-338.
[85] Galarza, I, Canete, C, & Granados, A. Randomised trial of corticosteroids in the treat‐
ment of tuberculous pleurisy Thorax (1999). , 50, 1305-1307.
[86] Chung, C. L, Chen, C. L, Yeh, C. Y, et al. Early effective drainage in the treatment of
loculated tuberculous pleurisy Eur Respir J (2008). , 31, 1261-1267.
[87] Pablo de AVillena V., Echave-Sustaeta L., Encuentra AL Are pleural fluid parameters
related to the development of residual pleural thickening in tuberculosis? Chest
(1997). , 112, 1293-1297.
[88] Iuchi K, Aozasa K, Yamamoto S et al. Non-Hodgkin´s lymphoma of the pleural cavi‐
ty developing from longstanding pyothorax. Summary of clinical and pathological
findings in thirty-seven cases Jpn J Clin Oncol (1989) 19(3):249-57
Tuberculosis - Current Issues in Diagnosis and Management292
Chapter 15
Neurotuberculosis and HIV Infection
Simona Alexandra  Iacob and Diana Gabriela  Iacob
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/54631
1. Introduction
The incidence and mortality of tuberculosis (TB), the most common opportunistic infection in
HIV patients has drastically increased with the emergence of the HIV pandemic
The HIV infection supported the re-emergence of TB as well as two major changes in the natural
history of TB, namely it has increased the frequency of extrapulmonary TB and the mycobac‐
terial multidrug resistance. The extrapulmonary TB involvement is present in up to 40% of the
HIV cases and includes respiratory, digestive, lymphatic and neurologic localizations. Of these
neurotuberculosis (NTB) is probably the most devastating extrapulmonary form of TB. The
risk of acquiring NTB in HIV patients has been reported as 10 times higher than in non-HIV
individuals and its related mortality exceeds 50%. The prognosis is further worsened by the
HIV related progressive immunodeficiency which leads to the reactivation of opportunistic
infections and the development of malignancies. The early diagnosis of NTB in HIV positive
patients improves the short and long term prognosis of these patients and increases their life
expectancy. Unfortunately the complexity of the clinical presentation and the variability of the
bacteriological results accounts for significant difficulties in the diagnostic confirmation of
NTB. Therefore treatment in these patients is often empirical. Moreover the antituberculous
treatment is of long duration with serious adverse effects. Ensuing complications during
treatment include the immune reconstitution inflammatory syndrome (IRIS) - a complication
that is characteristic for HIV patients undergoing treatment for TB. Furthermore the multiple
drug interactions between the antituberculous and antiretroviral treatment require close
supervision of these patients.
This chapter summarizes the epidemiological, pathogenic, clinic and therapeutic challenges
of NTB in HIV patients.
This chapter summarizes the epidemiological, pathogenic, clinic and therapeutic challenges
of NTB in HIV patients.
© 2013 Iacob and Iacob; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
2. Epidemiological data on the HIV/TB co-infection
TB is preventable and curable and its eradication was considered possible before the spread
of the HIV pandemic. Since then the pathogenic mechanisms of HIV and TB have been closely
entwined. Such is the complementary evolution of HIV and TB that the HIV/TB co-infection
has been referred to as a ‘’syndemic’’ by some authors [1]. The term ‘’syndemic’’ reflects the
similar social, epidemiological and pathological settings of both diseases. The close interrela‐
tion between HIV and tuberculosis overcomes by far the interactions between other commun‐
ity acquired infections. Thus epidemiological studies suggest that as many as 50% of the HIV
patients develop mycobacterial infections. The rate of extrapulmonary TB could account for
more than 50% of cases presenting with HIV and TB coinfection. In the pre-AIDS era the
immunodeficiency status incriminated in the pathogenesis of extrapulmonary TB was induced
by autoimmune diseases, aging, diabetes, alcoholism, malnutrition, malignancies or immu‐
nosuppressive chemotherapy. However the total amount of extrapulmonary TB in non-HIV
immunosupressed patients did not exceed 15% of all TB cases. In addition meningitis and other
forms of NTB represented less than 1% of all TB cases in non-HIV patients [2,3] but presently
account for 10% of all TB cases in HIV patients [4]. Tuberculous meningitis (TBM) occurs in
5%-8% of the HIV patients [5,6] but tuberculomas and abscesses are also a common finding in
late stages of AIDS [7]. Regarding the CNS infection with non-tuberculous mycobacteria one
of the most important risk factors is the progressive immunodeficiency induced by HIV
infection.
Co-infection with HIV not only increases the risk for central nervous system (CNS) TB [17] but
also alters the clinical signs, delays the diagnosis and worsens the prognosis [8]. Thus the
mortality of HIV patients with TBM is as high as 63% and nearly half of deaths occur in the
first 21 days [9].
3. Pathogenic mechanisms of NTB
TB is a respiratory infection with a generally latent course. The immunodeficiency status favors
the extrapulmonary dissemination of mycobacteria leading to inflammatory granulomas with
diverse localisations. Some granulomas arise adjacent to the meninges or to the brain paren‐
chyma and become the last station before the CNS invasion. Disruption of these granulomas
into the subarachnoid space is followed by the cerebrospinal fluid (CSF) invasion with
mycobacteria and meningeal infection.Release of mycobacteria from these granulomas is
mainly associated with the severe depletion of macrophages and lymphocytes along with the
imbalance of local cytokines. The CSF inflammatory reaction induced by mycobacteria
antigens leads to a lymphocyte and fibrin-rich subarachnoid exudate which progressively
envelops the blood vessels and cranial nerves. The expansion and intensity of this inflamma‐
tory exudate induces multiple complications including: the obliterative vasculitis followed by
cerebral infarctions, the CSF obstruction and emerging hydrocephalus and the spinal extension
of TB and chronic arachnoiditis. Some of the CNS granulomas could evolve as cerebral or spinal
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masses further developing into tuberculomas or tuberculous abscesses [ 10,11,12]. In addition
HIV patients characteristically present several TB cerebral lesions evolving simultaneously.
Below we enlisted the factors involved in the clinical progression and persistent CNS invasion
with mycobacteria in HIV patients.
1. The cellular immunosuppression in TB and HIV infection.
The site of extrapulmonary mycobacterial infections and especially the CNS invasion
depend on the efficacy of cell-mediated immunity. Both the HIV infection and TB trigger
complex mechanisms which increase the cellular immunosuppresion.
On the other hand humoral immnity is increased but inefficient. The high titres of antimyco‐
bacterial antibodies are not protective and could instead result in numerous complications.
The most important mechanism behind the cellular immunosuppression in the HIV-TB co-
infection is the severe depletion of macrophage and lymphocyte cells.
Macrophage and lymphocyte cells. Macrophages play a crucial role in both HIV and mycobac‐
terial infections. As phagocytes of the innate immunity they are considered the main cells
involved in the immune response against mycobacteria.Infected macrophages recruit addi‐
tional immune cells such as dendritic cells and T cell lymphocytes and release numerous
chemokines and cytokines to form granulomas. The latter are specific stable inflammatory
structures limiting the growth of mycobacteria. At the same time mycobacteria could devel‐
op inside macrophages from granulomas thus ensuring their persistence. In addition macro‐
phages infected with Mycobacterium tuberculosis (M. tbc) augment the expression of the C-
C chemokine receptor type 5, also known as CCR5, the most important HIV coreceptor [13].
Therefore infected macrophages perform a significant role in the protection and transport of
mycobacteria and HIV to other tissues including the brain.
With the passing of time some of the macrophages infected with mycobacteria suffer apoptosis
leading to a numeric decrease of the most important cells involved in the defence against
mycobacteria invasion. Moreover HIV is directly responsible for the depletion of CD4+ T
lymphocytes through its cytopathic effect and anti-gp120 antibodies. The depletion of CD4+
T lymphocytes raises the susceptibility to TB and most notably towards neurologic forms of
TB [14]. In this respect the decreasing CD4+ T cell count was proven to vary inversely with the
incidence of NTB. Most patients with HIV and NTB display a CD4+ T cell count below 200
cells/ mm3 unlike patients with pulmonary TB who commonly present with a CD4+T cell count,
between 250 and 550 cells/ mm3. In conclusion in the late stages of infection the main pathogenic
mechanisms of invasion with mycobacteria and HIV are closely interwined.
The Cytokine dysregulation.  Both HIV and mycobacteria are intracellular pathogens.  Their
presence stimulates the release of cytokines by macrophages and Th1 cells which in turn regulate
the cells involved in the immune response. The stability of the granuloma is usually ensured by
a high number of CD4+ T and CD8+ lymphocytes along with a Th1 cytokine profile represent‐
ed by IFN -γ and TNF-α. [15].TNF-α is a pro-inflammatory cytokine released at high levels by
CD4+T cells and macrophages coinfected with mycobacteria and HIV. The role of TNF-α in the
clinical outcome of the 2 diseases is contradictory. Regarding its role in the control of tuberculo‐
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sis a high level of TNF-α stimulates the apoptosis of infected macrophages and the cellular
activation [16,17]. On the other hand the use of TNF-α neutralizing antibodies in inflammato‐
ry diseases has been associated with an increased risk of extrapulmonary TB including TBM
[18].CD4-T-cell deficient mice [19] as well as mice able to neutralize endogenous TNf- α [20] or
the gene for IFN-γ [21] are subjected to fatal TB. Nevertheless an in vitro experiment on human
monocytes noted that higher levels of TNF-α could be associated with more virulent or faster
growing mycobacterial strains [22].The contradictory effect of TNF-α was also observed in the
HIV infection. Studies conducted by Lane and Osborn proved that TNF-α is a potent inhibitor
over the primary HIV infection of the macrophages but enhances the HIV replication in latent
HIV infections [23,24 ]. This finding could explain why mycobacteria infections which pro‐
mote the synthesis of TNF-α could also augment HIV replication in chronic infected individu‐
als. The level of TNF-α in the blood of patients infected with mycobacteria and HIV was
documented to be 3 to 10 times higher than in non-HIV patients [25] showing a major imbal‐
ance in the release of this proinflammatory cytokine. TNF- α also plays a central role in the CNS
localizations of mycobacteria. The excessive amount of TNF-α could accelerate the disruption
of rich tuberculous foci adjacent to the CNS. Increased levels of TNF-α as well as IFN-γ were
found in the CSF of patients with TBM at the disease onset [26] as well as several months after
the acute episode [27] Experimental studies on rabbits proved that the excess of TNF- α acts as
a persistent trigger of the inflammatory response and as a procoagulant factor associated with
both the mycobacteria CNS invasion as well as cerebral vascular complications. [28]. The
therapeutic use of TNF-α inhibitors in severe forms of TBM, tuberculoma and cerebral tubercu‐
lous abscesses was linked to a decreased inflammatory response and noticeable clinical recovery
[29-31]. The major role of TNF-α in the progression of TBM was also proved in murine models
by Tsenova as well [28,33]. Studies on HIV patients with TBM also emphasized the signifi‐
cance of increased levels of CSF TNF-α and of IFN-γ in advanced TBM stages [34].
In conclusion all these studies proved that important variations of the Th1 cytokine profile and
especially of those involving the release of TNF-α represent one of the pathogenic mechanisms
that aggravate the outcome of NTB in the HIV infection. Understanding these changes could
be the first step towards the development of efficient complementary therapies in NTB to
reduce the excessive inflammatory response. Thus TNF-α inhibition could be used as an
antiinflammatory therapy in NTB with severe complications but should not be recommended
in other forms of TB.
2. The persistent activation of microglial cells.
A significant role in the pathogenic mechanisms of CNS infections was assigned to the
activation of microglial cells, the resident macrophages of the CNS. Microglial cells are
involved in the local phagocytosis and play a central role in the pathogenesis of infections
and inflammatory diseases [35]. These cells also represent the main target of both HIV and
mycobacteria infection [36,37]. Thus the activation of microglial cells by mycobacteria
induces the release of proinflammatory cytokines, some of which are able to add to the
stability of cerebral granulomas. A moderate level of CXCL9 and CXCL10 chemokines
released by microglial cells regulates the influx of inflammatory cells to the brain and
interferes with the chemotaxis of monocytes/macrophages and T cells thus assisting the
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formation of granulomas. However since microglial cells are the main source of cerebral
TNF-α these could also induce an aggresive inflammatory response with severe menin‐
geal  inflammation,  brain  edema,  protein  accumulation,  endarteritis  and  intracranial
hypertension accounting for most of the complications described in NTB [28,38]. There‐
fore a balanced activation of microglial cells is critical against the CNS mycobacterial
invasion. On the other hand the intracellular HIV replication in microglial cells leads to their
activation, neuroinflammation and release of neurotoxins that cause AIDS associated neural
dysfunctions. The complex role of the microglia in cerebral HIV/TB co-infection is ex‐
plained by the rich number of HIV receptors and co-receptors expressed by these cells such
as CD4, CCR5, CXCR4 as well as other receptors involved in the inflammatory response
including IFN-γ, TNF-α,CD14 and MHC class I and II receptors [39].The CD14 receptor
promotes the uptake of both HIV and nonopsonized M.tbc strains in microglial cells [40]
while CD4 and CCR5/CXCR4 co-receptors interfere with HIV cell attachment. As a result
microgial cells are the main target of HIV and mycobacteria once these enter the CNS.
Therapies  directed  towards  reducing  the  inflammatory  response  in  the  HIV/TB co-
infection include the blockage of certain receptors (such as CD14),  the use of CCR5
antagonists and TNF-α blockers (as thalidomide). Another alternative is dexametasone
recommended in most forms of CNS TB. The clinical benefits of dexametazone were inspired
by in vitro studies proving a potent inhibitory effect on the release of cytokines from
microglia [39].
In conclusion simultaneous infection of the microglia with HIV and mycobacteria increases the
meningeal inflammatory response, the fundamental pathogenic step in all forms of CNS TB.
The synthesis of excessive inflammatory infiltrate is responsible for the clinical findings and
possibly irreversible complications in NTB, such as hydrocephalus and vasculitis [41].
Moreover the excessive inflammatory response triggered in the HIV/TB co-infection could
induce the immune reconstitution inflammatory syndrome – a complication that is specific for
this patient category.
4. Pathogenesis of the immune reconstitution inflammatory syndrome
The Immune Reconstitution Inflammatory Syndrome (IRIS) is an uncommon inflammatory
response encountered in those cases of severe immunosuppression in which the rapid adminis‐
tration of specific treatment abruptly restores the immune response. The HIV infection is the
most frequent cause of immunodeficiency predisposing to IRIS. In addition TB is the most
common opportunistic infection related to HIV-associated IRIS. The antiretroviral and antituber‐
culous treatments rapidly restore the immune response. Such a rapid treatment response may
sometimes lead to an aggressive lymphoproliferative reaction and massive release of proinflam‐
matory cytokines. There are 2 clinical presentations of IRIS known as the paradoxical IRIS and
unmasking IRIS. IRIS manifestations in HIV patients with NTB follow two possible scenarios:
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a. A paradoxical reaction emerging in patients with NTB correctly diagnosed and appro‐
priately treated in which HIV infection is subsequently detected and also treated but new
severe neurological manifestations arise during treatment (paradoxical NeuroIRIS-TB).
b. An unmasking reaction appears in patients with HIV and latent unknown NTB in which
the successful antiretroviral treatment unexpectedly induces neurological manifestations
of TB (unmasked NeuroIRIS-TB)
The neurologic manifestation of IRIS-TB are rare (19% of the total cases) but with a mortality risk
that is three times higher than other IRIS localisations [42]. The specific features related to
NeuroIRIS-TB reside in the excessive CNS inflammatory reactions generated by the activation
of microglia. The excessive inflammatory response is linked to the abundance of mycobacteri‐
al antigens and their high immunogenicity. Various studies have approached the immunolog‐
ic mechanisms and risk factors for IRIS in HIV-TB patients.
The observations below on the pathogenesis of IRIS-TB were selected according to the potential
clinical application.
• The release of multiple mycobacterial antigens in the first 2 months of antituberculous
therapy and concurrent wide distribution of sequestered CD45RO memory lymphocytes in
the bloodstream during HIV antiretroviral treatment are the principal mechanisms inducing
an excessive inflammatory response. To avoid the overlap of these events the current WHO
recommendations advocate an initial antituberculous treatment followed at a minimum
interval of 2 weeks by the antiretroviral treatment in patients with a low level of Th CD4+
cells [43]
• The pathological overproduction of Th1 cytokines particularly IFN-γ was noticed in IRIS-
TB/ HIV co-infection [44,45].Taking into account the experimentally increased levels of IFN-
γ in IRIS the blood interferon-gamma (IFN-γ) release assays (IGRA) could be implemented
to monitor IRIS evolution in the future. In addition the pathological overproduction of
chemokines CXCL9 and CXCL10 induced by IFN-γ was observed in IRIS-TB/HIV co-
infection [46]. The development of therapeutic strategies which could reduce the intracere‐
bral level of these chemokines are essential to prevent and decrease ensuing granulomas
thus protecting against IRIS.[47,48]
• The excessive release of IgG antibodies to PPD was observed in patients with IRIS-TB/HIV
co-infection [45] Nonetheless the level of antibodies against the phenolic glycolipid antigen
(PGL-TB1) was lower in IRIS hosts. The IgG anti PPD and especially the intrathecal synthesis
of IgG/PPD could provide additional information on the humoral immune response in
NeuroIRIS – TB [49].
• The restoration of a delayed type of hypersensitivity to mycobacterial antigens was reported
in HIV patients with latent TB after starting the antiretroviral therapy [50,51]. All the same
recent studies cast doubt on the tuberculin-specific Th1-responses in prompting IRIS [52]
• The profile of cytokines differs between the 2 types of IRIS as well as between TB infection
and IRIS-TB. Hence certain cytokines (IFN-γ,TNF-α and IL-6) are more elevated in IRIS-TB
than compared with patients presenting only TB. [53,54]. This finding could help distinguish
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TB from IRIS-TB. Other studies have also investigated different profiles of immunological
markers which could aid in the above distinction. Conradie et al. have identified a profile
of makers including IL8, active NK cells, C reactive protein and lymphocyte count that is
related to unmasking IRIS-TB. This profile could be further used in the differential diagnosis
of the 2 manifestations or as a prediction of unmasking IRIS-TB [55].
5. Etiological data on the mycobacterial strains in HIV/TB co-infection
HIV patients are frequently infected by virulent strains of M.tbc. The virulence of a particular
strain depends on the genetic composition of M.tbc. Thus the Beijing genotype of M.tbc mostly
found in Asia is considered the most aggressive genotype and has been associated with CSF
dissemination and multidrug resistance to antituberculous agents in HIV patients [56].
Infections with M. bovis are rare and occur mostly in HIV Hispanic patients. Despite the high
environmental exposure to nontuberculous mycobacteria CNS involvement is rare even in
AIDS patients and usually occurs at a CD4+ count under 10 cells/mm3. The pathogenic
mechanisms behind the interactions established between the host and virulent mycobacteria
are less documented. The infection with Mycobacterium avium complex (MAC) remains the
most studied and most frequent nontuberculous mycobacteria accounting for the atypical
tuberculous manifestations in the advanced stages of AIDS infection [57]. The Mycobacterium
avium intracellulare (MAI) serotypes 4 and 8 are the most prevalent in AIDS patients [58].
Sporadic cases of NTB with other mycobacteria have also been recorded in AIDS patients
following disseminated infection [59]. MAC is an ubiquitary environmental mycobacteria
which colonizes the gastrointestinal and respiratory tract but is also able to invade the
epithelial cells and the intestinal wall [60]. Virulent strains isolated from AIDS patients are able
to penetrate the mucosal barriers and resist intracellular killing by macrophages resulting in
a disseminated infection. Further studies on the interaction between M. avium and the HIV-
infected cells confirmed the inhibition of several cytokines secreted by the Th1 CD4+cells,
natural killer cells and macrophages.These ultimately favour the intracellular survival of M.
avium and even accelerate its growth rate [61,62]. The neurologic involvement due to MAC in
advanced stages of AIDS generally presents as TBM following a disseminated infection with
prolonged bacteremia [63-66]. The comparative aspects of the CNS invasions with M.tbc and
nontuberculous mycobacteria in HIV hosts are presented in table 1
6. Clinical data on NTB in HIV patients
NTB is frequent in HIV patients compared with non-HIV patients. Reactivation of latent forms
of TB is accelerated in HIV patients with a 10% annual risk of progression to active infection
compared with 10-20% lifetime risk of developing TB in non-HIV patients. Literature data is
contradictory as to the role of HIV on the clinical presentation or evolution of NTB. Although
some studies found significant differences between HIV and non-HIV NTB [67-69] others
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a. A paradoxical reaction emerging in patients with NTB correctly diagnosed and appro‐
priately treated in which HIV infection is subsequently detected and also treated but new
severe neurological manifestations arise during treatment (paradoxical NeuroIRIS-TB).
b. An unmasking reaction appears in patients with HIV and latent unknown NTB in which
the successful antiretroviral treatment unexpectedly induces neurological manifestations
of TB (unmasked NeuroIRIS-TB)
The neurologic manifestation of IRIS-TB are rare (19% of the total cases) but with a mortality risk
that is three times higher than other IRIS localisations [42]. The specific features related to
NeuroIRIS-TB reside in the excessive CNS inflammatory reactions generated by the activation
of microglia. The excessive inflammatory response is linked to the abundance of mycobacteri‐
al antigens and their high immunogenicity. Various studies have approached the immunolog‐
ic mechanisms and risk factors for IRIS in HIV-TB patients.
The observations below on the pathogenesis of IRIS-TB were selected according to the potential
clinical application.
• The release of multiple mycobacterial antigens in the first 2 months of antituberculous
therapy and concurrent wide distribution of sequestered CD45RO memory lymphocytes in
the bloodstream during HIV antiretroviral treatment are the principal mechanisms inducing
an excessive inflammatory response. To avoid the overlap of these events the current WHO
recommendations advocate an initial antituberculous treatment followed at a minimum
interval of 2 weeks by the antiretroviral treatment in patients with a low level of Th CD4+
cells [43]
• The pathological overproduction of Th1 cytokines particularly IFN-γ was noticed in IRIS-
TB/ HIV co-infection [44,45].Taking into account the experimentally increased levels of IFN-
γ in IRIS the blood interferon-gamma (IFN-γ) release assays (IGRA) could be implemented
to monitor IRIS evolution in the future. In addition the pathological overproduction of
chemokines CXCL9 and CXCL10 induced by IFN-γ was observed in IRIS-TB/HIV co-
infection [46]. The development of therapeutic strategies which could reduce the intracere‐
bral level of these chemokines are essential to prevent and decrease ensuing granulomas
thus protecting against IRIS.[47,48]
• The excessive release of IgG antibodies to PPD was observed in patients with IRIS-TB/HIV
co-infection [45] Nonetheless the level of antibodies against the phenolic glycolipid antigen
(PGL-TB1) was lower in IRIS hosts. The IgG anti PPD and especially the intrathecal synthesis
of IgG/PPD could provide additional information on the humoral immune response in
NeuroIRIS – TB [49].
• The restoration of a delayed type of hypersensitivity to mycobacterial antigens was reported
in HIV patients with latent TB after starting the antiretroviral therapy [50,51]. All the same
recent studies cast doubt on the tuberculin-specific Th1-responses in prompting IRIS [52]
• The profile of cytokines differs between the 2 types of IRIS as well as between TB infection
and IRIS-TB. Hence certain cytokines (IFN-γ,TNF-α and IL-6) are more elevated in IRIS-TB
than compared with patients presenting only TB. [53,54]. This finding could help distinguish
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TB from IRIS-TB. Other studies have also investigated different profiles of immunological
markers which could aid in the above distinction. Conradie et al. have identified a profile
of makers including IL8, active NK cells, C reactive protein and lymphocyte count that is
related to unmasking IRIS-TB. This profile could be further used in the differential diagnosis
of the 2 manifestations or as a prediction of unmasking IRIS-TB [55].
5. Etiological data on the mycobacterial strains in HIV/TB co-infection
HIV patients are frequently infected by virulent strains of M.tbc. The virulence of a particular
strain depends on the genetic composition of M.tbc. Thus the Beijing genotype of M.tbc mostly
found in Asia is considered the most aggressive genotype and has been associated with CSF
dissemination and multidrug resistance to antituberculous agents in HIV patients [56].
Infections with M. bovis are rare and occur mostly in HIV Hispanic patients. Despite the high
environmental exposure to nontuberculous mycobacteria CNS involvement is rare even in
AIDS patients and usually occurs at a CD4+ count under 10 cells/mm3. The pathogenic
mechanisms behind the interactions established between the host and virulent mycobacteria
are less documented. The infection with Mycobacterium avium complex (MAC) remains the
most studied and most frequent nontuberculous mycobacteria accounting for the atypical
tuberculous manifestations in the advanced stages of AIDS infection [57]. The Mycobacterium
avium intracellulare (MAI) serotypes 4 and 8 are the most prevalent in AIDS patients [58].
Sporadic cases of NTB with other mycobacteria have also been recorded in AIDS patients
following disseminated infection [59]. MAC is an ubiquitary environmental mycobacteria
which colonizes the gastrointestinal and respiratory tract but is also able to invade the
epithelial cells and the intestinal wall [60]. Virulent strains isolated from AIDS patients are able
to penetrate the mucosal barriers and resist intracellular killing by macrophages resulting in
a disseminated infection. Further studies on the interaction between M. avium and the HIV-
infected cells confirmed the inhibition of several cytokines secreted by the Th1 CD4+cells,
natural killer cells and macrophages.These ultimately favour the intracellular survival of M.
avium and even accelerate its growth rate [61,62]. The neurologic involvement due to MAC in
advanced stages of AIDS generally presents as TBM following a disseminated infection with
prolonged bacteremia [63-66]. The comparative aspects of the CNS invasions with M.tbc and
nontuberculous mycobacteria in HIV hosts are presented in table 1
6. Clinical data on NTB in HIV patients
NTB is frequent in HIV patients compared with non-HIV patients. Reactivation of latent forms
of TB is accelerated in HIV patients with a 10% annual risk of progression to active infection
compared with 10-20% lifetime risk of developing TB in non-HIV patients. Literature data is
contradictory as to the role of HIV on the clinical presentation or evolution of NTB. Although
some studies found significant differences between HIV and non-HIV NTB [67-69] others
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argued that the HIV co-infection does not influence the clinical evolution [70]. Nevertheless
the differential diagnosis between NTB and numerous systemic and neurologic nontubercu‐
lous complications emerging in AIDS is difficult. Thus the clinical presentation of NTB in HIV
patients could be influenced by numerous factors such as:
• various neurological manifestations caused by HIV itself;
• other opportunistic infections with CNS tropism, mainly toxoplasma, criptococcus, papil‐
loma or herpes viruses infections;
• concurrent cerebral tumors : non-Hodkin cerebral lymphoma, Kaposi sarcoma;
• simultaneous evolution of various forms of NTB (meningitis, tuberculoma)- a characteristic
finding in HIV patients;
• extra-neurological infections or malignancies related to HIV.
All these interfering factors could explain the variable descriptions of the clinical presentation,
CSF manifestations or imaging aspects in the numerous studies on NTB in HIV patients.
NTB in HIV patients encompasses the following forms: TBM, disseminated TB of the nevrax,
tuberculoma, and tuberculous abcess. En plaque tuberculoma, chronic spinal pahymeningitis
and serous TBM are rare forms of TB not described in HIV patients.
6.1. Tuberculous meningitis in HIV patients
The  real  frequency  of  TBM  in  HIV  patients  is  hard  to  assess  as  the  various  clinical
presentations  related  to  immunodepression  could  be  confused  with  other  neurologic
manifestations.  The  epidemiological  data  on  the  subject  is  contradictory.  Current  statis‐
tics  in  areas  with  an  increased  prevalence  of  TB  disclose  M.  tbc  as  the  most  frequent
etiologic  agent  of  meningitis  in  HIV patients  [71].  Moreover  TBM was  recorded as  the
M. tbc Nontuberculous mycobacteria
Mycobacteria strain M tbc, rarely M bovis 98% MAC, rarely other mycobacteria
Primary infection Usually respiratory Gastrointestinal or respiratory
Frequency Moderate Low/very low
CD4+ T cell count < 200 cells/mm3 <10% cells/mm3 ( usually)
Clinical forms Meningitis, Tuberculoma, Abscess Disseminated, Abscess
Diagnosis Established diagnosis criteria No standard diagnosis criteria
CSF mycobacteria
detection
Essential to diagnosis confirmation Not essential to diagnosis confirmation
Mycobacteria detection
(other than CSF)
In blood In faeces (frequently), in blood (if
disseminated infections)
Prognosis Reserved Terminal infections (frequently)
Table 1. Comparative aspects of the CNS invasions with M. tbc and nontuberculous mycobacteria in HIV hosts
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initial presentation of AIDS in 42% of cases. A study performed in Kenya, a state with an
increasing incidence of TB and HIV, revealed that 80% of the necropsies performed on HIV
patients  exhibited disseminated TB and 26% of  these also displayed meningeal  involve‐
ment [72].On the other hand the frequency of disseminated tuberculosis based on clinical
and  bacteriological  criteria  only  did  not  exceed  14,5%  of  cases  [73-74].  The  conclusion
arising from these studies is that the extent of the CNS invasion is highly variable and a
large number of disseminated TB in AIDS probably remains undiagnosed.
Neurological presentation. TBM is the most frequent form of NTB in HIV patients. The
neurological manifestations differ according to the degree of immunodeficiency.
• TBM in the early stages of HIV immunodepression. The onset of TBM is insidious. Fever and
meningeal signs develop progressively (7-30 days) paralleling the changes in the cognitive
status and mental state. Once the meningeal syndrome is established the evolution is rapid.
The meningeal syndrome is intense and progressive. Under such circumstances the
diagnosis could be aided by recognizing the paralysis of certain cranial nerves (mostly
involving the sixth cranial nerve but also the second, third, fourth and eighth nerves) as well
as the signs of hydrocephalus or cerebral edema (headache, convulsions, pyramidal or
cerebellar signs). Encephalitic forms display an altered level of consciousness with progres‐
sive evolution to coma. In forms with major spinal involvement (TB spinal meningitis, spinal
arachnoiditis ) the inflammatory exudate surrounds the spinal cord and induces radicular
compression. As a result radicular pains develop along with sings of transverse mielitis
(paraplegia and urine retention).
• TBM in advanced stage of HIV immunodepression. In advanced stage of immunodepression the
inflammatory exudate is decreased and the clinical presentation is atypical. Fever could be
absent in these patients. The meningeal sings are discrete or missing [75]. Hydrocephalus is
delayed. Tuberculous vasculopathy prompts frequent complications following thrombosis,
or hemorrhagic infarcts. Focal lesions related to the vasculopathy are common. The cogni‐
tive dysfunction is severe [76] with a rapid evolution to profound coma [8].In this advanced
stage of AIDS NTB rarely evolves as a solitary finding. Usually other infections or tumors are
also associated with NTB and the wide spectrum of clinical manifestations implies various
neurological patterns with focal, perypheral or central nervous signs.
CSF data. The aspect of the initial CSF could be suggestive disclosing lymphocytic pleocytosis,
elevated proteins and low glucose levels. Nevertheless the etiologic confirmation is based on
bacteriological criteria only. In patients with severe immunodeficiency the CSF white cell count
is usually only slightly increased but could also be normal [67] The low number of lymphocytes
in HIV could modify the differential count in the CSF to a predominant number of neutrophils
[67] causing confusion with bacterial meningitis. Elevated proteins are a typical finding in TBM
in non-HIV patients. However 43% of the HIV reported cases presented low or even normal
protein values [5,8]. The most difficult cases are those in which the CSF is reported as normal,
a common finding in patients with severe immunodeficiency. In the absence of a strong
inflammatory response acid-fast bacilli smear retrieves positive results [67] in up to 67% of
cases and the cultures are positive in 40 – 87,9% of cases [76,77].High rates of smear and culture
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argued that the HIV co-infection does not influence the clinical evolution [70]. Nevertheless
the differential diagnosis between NTB and numerous systemic and neurologic nontubercu‐
lous complications emerging in AIDS is difficult. Thus the clinical presentation of NTB in HIV
patients could be influenced by numerous factors such as:
• various neurological manifestations caused by HIV itself;
• other opportunistic infections with CNS tropism, mainly toxoplasma, criptococcus, papil‐
loma or herpes viruses infections;
• concurrent cerebral tumors : non-Hodkin cerebral lymphoma, Kaposi sarcoma;
• simultaneous evolution of various forms of NTB (meningitis, tuberculoma)- a characteristic
finding in HIV patients;
• extra-neurological infections or malignancies related to HIV.
All these interfering factors could explain the variable descriptions of the clinical presentation,
CSF manifestations or imaging aspects in the numerous studies on NTB in HIV patients.
NTB in HIV patients encompasses the following forms: TBM, disseminated TB of the nevrax,
tuberculoma, and tuberculous abcess. En plaque tuberculoma, chronic spinal pahymeningitis
and serous TBM are rare forms of TB not described in HIV patients.
6.1. Tuberculous meningitis in HIV patients
The  real  frequency  of  TBM  in  HIV  patients  is  hard  to  assess  as  the  various  clinical
presentations  related  to  immunodepression  could  be  confused  with  other  neurologic
manifestations.  The  epidemiological  data  on  the  subject  is  contradictory.  Current  statis‐
tics  in  areas  with  an  increased  prevalence  of  TB  disclose  M.  tbc  as  the  most  frequent
etiologic  agent  of  meningitis  in  HIV patients  [71].  Moreover  TBM was  recorded as  the
M. tbc Nontuberculous mycobacteria
Mycobacteria strain M tbc, rarely M bovis 98% MAC, rarely other mycobacteria
Primary infection Usually respiratory Gastrointestinal or respiratory
Frequency Moderate Low/very low
CD4+ T cell count < 200 cells/mm3 <10% cells/mm3 ( usually)
Clinical forms Meningitis, Tuberculoma, Abscess Disseminated, Abscess
Diagnosis Established diagnosis criteria No standard diagnosis criteria
CSF mycobacteria
detection
Essential to diagnosis confirmation Not essential to diagnosis confirmation
Mycobacteria detection
(other than CSF)
In blood In faeces (frequently), in blood (if
disseminated infections)
Prognosis Reserved Terminal infections (frequently)
Table 1. Comparative aspects of the CNS invasions with M. tbc and nontuberculous mycobacteria in HIV hosts
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initial presentation of AIDS in 42% of cases. A study performed in Kenya, a state with an
increasing incidence of TB and HIV, revealed that 80% of the necropsies performed on HIV
patients  exhibited disseminated TB and 26% of  these also displayed meningeal  involve‐
ment [72].On the other hand the frequency of disseminated tuberculosis based on clinical
and  bacteriological  criteria  only  did  not  exceed  14,5%  of  cases  [73-74].  The  conclusion
arising from these studies is that the extent of the CNS invasion is highly variable and a
large number of disseminated TB in AIDS probably remains undiagnosed.
Neurological presentation. TBM is the most frequent form of NTB in HIV patients. The
neurological manifestations differ according to the degree of immunodeficiency.
• TBM in the early stages of HIV immunodepression. The onset of TBM is insidious. Fever and
meningeal signs develop progressively (7-30 days) paralleling the changes in the cognitive
status and mental state. Once the meningeal syndrome is established the evolution is rapid.
The meningeal syndrome is intense and progressive. Under such circumstances the
diagnosis could be aided by recognizing the paralysis of certain cranial nerves (mostly
involving the sixth cranial nerve but also the second, third, fourth and eighth nerves) as well
as the signs of hydrocephalus or cerebral edema (headache, convulsions, pyramidal or
cerebellar signs). Encephalitic forms display an altered level of consciousness with progres‐
sive evolution to coma. In forms with major spinal involvement (TB spinal meningitis, spinal
arachnoiditis ) the inflammatory exudate surrounds the spinal cord and induces radicular
compression. As a result radicular pains develop along with sings of transverse mielitis
(paraplegia and urine retention).
• TBM in advanced stage of HIV immunodepression. In advanced stage of immunodepression the
inflammatory exudate is decreased and the clinical presentation is atypical. Fever could be
absent in these patients. The meningeal sings are discrete or missing [75]. Hydrocephalus is
delayed. Tuberculous vasculopathy prompts frequent complications following thrombosis,
or hemorrhagic infarcts. Focal lesions related to the vasculopathy are common. The cogni‐
tive dysfunction is severe [76] with a rapid evolution to profound coma [8].In this advanced
stage of AIDS NTB rarely evolves as a solitary finding. Usually other infections or tumors are
also associated with NTB and the wide spectrum of clinical manifestations implies various
neurological patterns with focal, perypheral or central nervous signs.
CSF data. The aspect of the initial CSF could be suggestive disclosing lymphocytic pleocytosis,
elevated proteins and low glucose levels. Nevertheless the etiologic confirmation is based on
bacteriological criteria only. In patients with severe immunodeficiency the CSF white cell count
is usually only slightly increased but could also be normal [67] The low number of lymphocytes
in HIV could modify the differential count in the CSF to a predominant number of neutrophils
[67] causing confusion with bacterial meningitis. Elevated proteins are a typical finding in TBM
in non-HIV patients. However 43% of the HIV reported cases presented low or even normal
protein values [5,8]. The most difficult cases are those in which the CSF is reported as normal,
a common finding in patients with severe immunodeficiency. In the absence of a strong
inflammatory response acid-fast bacilli smear retrieves positive results [67] in up to 67% of
cases and the cultures are positive in 40 – 87,9% of cases [76,77].High rates of smear and culture
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positivity facilitate the diagnosis in patients with an atypical clinical presentation and normal
CSF exam.
Neuroradiological findings. The classic CT neuroradiological findings in TBM include basal
meningeal enhancement, hydrocephalus, and infarctions in the supratentorial brain paren‐
chyma and brainstem [78]. The concurrent finding of basal meningeal enhancement, tubercu‐
loma or both on CT scans could disclose a sensitivity of 89% and 100% specificity for TBM in
non-HIV patients [79]. In HIV patients contrast-enhanced MRI is generally considered superior
to CT results [78]. Some MRI studies indicated that meningeal enhancement and cerebral
infarctions were more common in HIV-infected individuals with TBM by comparison with
non-HIV patients [5,70]. However the basal meningeal enhancement and hydrocephalus rarely
occur in advanced stages of AIDS with reduced inflammatory response [76]. On the other hand
cerebral infarctions and focal mass lesions are frequently encountered in late stages of AIDS
[80-82]. In addition to the previous aspects imaging studies also disclose cerebral atrophy due
to HIV infection. Tubeculomas also were reported in 15-24% of cases [5].
6.1.1. The diagnosis of TBM in HIV infected patients
The diagnosis is urgent and extensive including all tuberculous lesions, HIV status and other
HIV associated lesions, bacteriological confirmation and neurological complications. It is
based on clinical features, CSF analysis and MRI imaging. (table 2). A belated diagnosis
increases the mortality, complications and the risk of relapse.
Clinical diagnostic criteria. Clinical features in HIV patients with TBM reflect the atypical
inflammatory response and the extensive vasculopathy. The meningeal sings are inconstant
and discrete especially in patients with severe immunodepression. The signs of encephalitis
emerge from the onset and could be the first significant manifestation of the disease. The
gravity of the altered level of consciousness parallels the increased mortality [8].Cerebral nerve
paralysis is a common finding but could be also induced by other associated conditions such
as HIV neurotoxicity, the cerebral reactivation of opportunistic infections (toxoplasma, JS
virus, Herpes simplex virus) or cerebral malignancies (Non-Hodgkin lymphoma, Kaposi
sarcoma). These patients particularly exhibit multiple extraneurologic manifestations. The
presence of other active lesions like pulmonary TB or other extrameningeal sites of TB is highly
suggestive for the CNS TB diagnosis [5,67,81]. Thus the presentation of HIV patients unlike
non-HIV patients often includes peripheral, intrathoracic and intraabdominal adenopathies.
The etiology of these adenopathies does not always imply a diagnosis of TB. The differential
diagnosis for adenopathies should always include other lymphotropic opportunistic infections
with neurologic manifestations (toxoplasma, CMV, syphilis). The tuberculous origin of
adenopathies could be overestimated in the clinical diagnosis if the histological confirmation
is not obtained. The histological examination is thus a prerequisite for a correct diagnosis of
these adenopathies. Hepatosplenomegaly is commonly reported but could also occur as a
result of other HIV associated infections (B or C hepatitis, CMV infections).To conclude no
clinical criteria is highly suggestive for CNS TB in HIV patients. Moreover any neurologic or
extraneurologic finding should prompt a thorough differential diagnosis that includes any
other HIV related affections.
Tuberculosis - Current Issues in Diagnosis and Management302
Laboratory diagnostic criteria. The degree of immunodeficiency in HIV patients with NTB
could be assessed using the CD4+T cell count. Most studies on TBM disclose a CD4+T cell
count between 32-200 /mm3 [5,81,82].Other findings including a lower hematocrit, periph‐
eral low neutrophils, lower plasma sodium level [76] and moderate to severe anemia Hb
< 8 gm/dl [69] were not constantly present in all  studies and could be mostly related to
the HIV infection than to TB. Moreover hyponatremia in patients with HIV-TB co-infec‐
tion could arise due to the following: a) cerebral salt wasting syndrome observed in 65%
of  patients  with  numerous  cerebral  lesions,  including  patients  with  TBM  [83];  b)  the
syndrome  of  inappropriate  release  of  antidiuretic  hormone  secretion;  c)  hypothalamus
pituitary-adrenal axis suppresion. Hyponatremia is  a marker of the disease severity and
the mortality in this patient group is significantly higher than that of patients with normal
sodium levels (36,5% versus 19.7%) [84].
The CSF exam is decisive for the diagnosis. The specificity of the bacteriological diagnosis is
100% but its implication in the final diagnosis is quite low since the Ziehl-Neelsen stain is
positive in less than 20% of cases and Lowenstein culture confirmation although positive in
73% of cases is tardy [85]. Methods of improving the sensibility of Ziehl-Neelsen stain have
been described [86] but are less implemented. Tuberculin skin test and Interferon-gamma
release assays if positive do not distinguish between latent TB and active disease. As well
negative results should be evaluated with caution in severely immunodepressed patients.
Several complementary diagnostic tools were explored in certain studies like specific antigens
and antibodies detection, adenosine deaminase detection, PCR techniques, detection of
tuberculostearic acid or IFN-γ levels in the CSF. However their use is limited due to discordant
results or other inconveniences related to the cost, cross-reactivity, specificity or sensibility
[87-90]. Recently the improvement of nucleic acid amplification assay techniques, particularly
polymerase chain reaction (PCR) assay (especially nested PCR assay technique) increased the
diagnostic sensitivity and specificity but its use in AIDS related CNS TB is still unconfirmed
[91]. All in all the bacteriological confirmation is difficult and belated but remains the only
diagnostic tool in AIDS related CNS TB.
Imaging diagnostic criteria. Imaging studies are required in the evaluation of neurological
complications of TBM, in the treatment follow-up and differential diagnosis. Contrast en‐
hanced MRI and Positron emission computed tomography – computed tomography (PET-CT)
display the highest sensibility. Unfortunately most literature studies are based on the more
inexpensive CT scans. No aspects are definitely characteristic to CNS TB in HIV patients.
Atypical results showing the absence or minimal meningeal enhancement [8] or the absence
of communicating hydrocephalus were reported on the CT scan in 69% of AIDS cases [5,8].
Nevertheless other studies found no significant radiological differences between HIV and non-
HIV patients.
*In addition to the clinical, CSF and radiologic criteria, a medical history of TB and positive
tuberculin skin test could help raise the diagnostic suspicion of a tuberculous infection.
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positivity facilitate the diagnosis in patients with an atypical clinical presentation and normal
CSF exam.
Neuroradiological findings. The classic CT neuroradiological findings in TBM include basal
meningeal enhancement, hydrocephalus, and infarctions in the supratentorial brain paren‐
chyma and brainstem [78]. The concurrent finding of basal meningeal enhancement, tubercu‐
loma or both on CT scans could disclose a sensitivity of 89% and 100% specificity for TBM in
non-HIV patients [79]. In HIV patients contrast-enhanced MRI is generally considered superior
to CT results [78]. Some MRI studies indicated that meningeal enhancement and cerebral
infarctions were more common in HIV-infected individuals with TBM by comparison with
non-HIV patients [5,70]. However the basal meningeal enhancement and hydrocephalus rarely
occur in advanced stages of AIDS with reduced inflammatory response [76]. On the other hand
cerebral infarctions and focal mass lesions are frequently encountered in late stages of AIDS
[80-82]. In addition to the previous aspects imaging studies also disclose cerebral atrophy due
to HIV infection. Tubeculomas also were reported in 15-24% of cases [5].
6.1.1. The diagnosis of TBM in HIV infected patients
The diagnosis is urgent and extensive including all tuberculous lesions, HIV status and other
HIV associated lesions, bacteriological confirmation and neurological complications. It is
based on clinical features, CSF analysis and MRI imaging. (table 2). A belated diagnosis
increases the mortality, complications and the risk of relapse.
Clinical diagnostic criteria. Clinical features in HIV patients with TBM reflect the atypical
inflammatory response and the extensive vasculopathy. The meningeal sings are inconstant
and discrete especially in patients with severe immunodepression. The signs of encephalitis
emerge from the onset and could be the first significant manifestation of the disease. The
gravity of the altered level of consciousness parallels the increased mortality [8].Cerebral nerve
paralysis is a common finding but could be also induced by other associated conditions such
as HIV neurotoxicity, the cerebral reactivation of opportunistic infections (toxoplasma, JS
virus, Herpes simplex virus) or cerebral malignancies (Non-Hodgkin lymphoma, Kaposi
sarcoma). These patients particularly exhibit multiple extraneurologic manifestations. The
presence of other active lesions like pulmonary TB or other extrameningeal sites of TB is highly
suggestive for the CNS TB diagnosis [5,67,81]. Thus the presentation of HIV patients unlike
non-HIV patients often includes peripheral, intrathoracic and intraabdominal adenopathies.
The etiology of these adenopathies does not always imply a diagnosis of TB. The differential
diagnosis for adenopathies should always include other lymphotropic opportunistic infections
with neurologic manifestations (toxoplasma, CMV, syphilis). The tuberculous origin of
adenopathies could be overestimated in the clinical diagnosis if the histological confirmation
is not obtained. The histological examination is thus a prerequisite for a correct diagnosis of
these adenopathies. Hepatosplenomegaly is commonly reported but could also occur as a
result of other HIV associated infections (B or C hepatitis, CMV infections).To conclude no
clinical criteria is highly suggestive for CNS TB in HIV patients. Moreover any neurologic or
extraneurologic finding should prompt a thorough differential diagnosis that includes any
other HIV related affections.
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Laboratory diagnostic criteria. The degree of immunodeficiency in HIV patients with NTB
could be assessed using the CD4+T cell count. Most studies on TBM disclose a CD4+T cell
count between 32-200 /mm3 [5,81,82].Other findings including a lower hematocrit, periph‐
eral low neutrophils, lower plasma sodium level [76] and moderate to severe anemia Hb
< 8 gm/dl [69] were not constantly present in all  studies and could be mostly related to
the HIV infection than to TB. Moreover hyponatremia in patients with HIV-TB co-infec‐
tion could arise due to the following: a) cerebral salt wasting syndrome observed in 65%
of  patients  with  numerous  cerebral  lesions,  including  patients  with  TBM  [83];  b)  the
syndrome  of  inappropriate  release  of  antidiuretic  hormone  secretion;  c)  hypothalamus
pituitary-adrenal axis suppresion. Hyponatremia is  a marker of the disease severity and
the mortality in this patient group is significantly higher than that of patients with normal
sodium levels (36,5% versus 19.7%) [84].
The CSF exam is decisive for the diagnosis. The specificity of the bacteriological diagnosis is
100% but its implication in the final diagnosis is quite low since the Ziehl-Neelsen stain is
positive in less than 20% of cases and Lowenstein culture confirmation although positive in
73% of cases is tardy [85]. Methods of improving the sensibility of Ziehl-Neelsen stain have
been described [86] but are less implemented. Tuberculin skin test and Interferon-gamma
release assays if positive do not distinguish between latent TB and active disease. As well
negative results should be evaluated with caution in severely immunodepressed patients.
Several complementary diagnostic tools were explored in certain studies like specific antigens
and antibodies detection, adenosine deaminase detection, PCR techniques, detection of
tuberculostearic acid or IFN-γ levels in the CSF. However their use is limited due to discordant
results or other inconveniences related to the cost, cross-reactivity, specificity or sensibility
[87-90]. Recently the improvement of nucleic acid amplification assay techniques, particularly
polymerase chain reaction (PCR) assay (especially nested PCR assay technique) increased the
diagnostic sensitivity and specificity but its use in AIDS related CNS TB is still unconfirmed
[91]. All in all the bacteriological confirmation is difficult and belated but remains the only
diagnostic tool in AIDS related CNS TB.
Imaging diagnostic criteria. Imaging studies are required in the evaluation of neurological
complications of TBM, in the treatment follow-up and differential diagnosis. Contrast en‐
hanced MRI and Positron emission computed tomography – computed tomography (PET-CT)
display the highest sensibility. Unfortunately most literature studies are based on the more
inexpensive CT scans. No aspects are definitely characteristic to CNS TB in HIV patients.
Atypical results showing the absence or minimal meningeal enhancement [8] or the absence
of communicating hydrocephalus were reported on the CT scan in 69% of AIDS cases [5,8].
Nevertheless other studies found no significant radiological differences between HIV and non-
HIV patients.
*In addition to the clinical, CSF and radiologic criteria, a medical history of TB and positive
tuberculin skin test could help raise the diagnostic suspicion of a tuberculous infection.




Clinical investigations (assessing the risk of tuberculosis, neurological manifestations, other manifestations)
History of tuberculosis (TB antecedents, risk of exposure)
Physical examination disclosing:
1. Signs of menigeal irritation (suggesting meningitis or a meningeal reaction to localized cerebral lesions)
2. Neurologic examination (mental status, sensory and motor exam, focal signs, intracranial hypertension)
3. Other manifestations suggesting TB and nontuberculous lesions induced by HIV activity, opportunistic infections
or malignancies like lymphadenopathy (given attention to lymphoma, syphilis, toxoplasmosis), pleural or pericardial
effusion (given attention to Kaposi sarcoma), pulmonary lesion (given attention to pneumocystosis, Kaposi
sarcoma, fungal pneumonia,CMV pneumonia, lymphocytic interstitial pneumonitis), skin lesions (given attention to
Kaposi sarcoma, Moluscum contagiosum, fungal lesions, meningococcal purpura)
Laboratory data assessing the immune status, HIV activity, risk of opportunistic infections or malignancies
Complete blood count (pancytopenia suggests medullar invasion with mycobacteria but also invasive malignancies
or drug toxicities)
Biochemical evaluation of liver and renal function; indicate associated co-morbidities; important for drug regimen
recomandation,
Serum sodium level (hyponatremia is linked to disseminated mycobacteriosis and cerebral lesions/ it corelates with
the mortality risk)
Immune status: CD4+ T cell count (CD4<200 cells/mm3 is related to the risk of NTB and major HIV-related
opportunistic infections; CD4< 50 cells/mm3 is related to the risk of nontuberculous mycobacteriosis or to the risk of
IRIS)
HIV viral status: blood/CSF RNA HIV viral load (if positive it point to the antiretroviral failure and needing to swich
the regimen)
Serologic assays: serum specific antibodies IgG and IgM related to other HIV-opportunistic infections,mainly
toxoplasma, CMV, syphilis.
Imaging studies: cerebral or spinal CT/MRI; (important in localized NTB and other cerebral opportunistic infections
or malignancies
Eye fundus examination : shows choroid tubercles in disseminated tuberculosis
Neurotuberculosis confirmation
Lumbar puncture (if the MRI does not indicate mass lesions!): CSF analysis: cytochemistry, stains*, culture **, or
complementary exams ***!
Other specimens analysis: sputum, pleural fluid, blood, urine, tissue specimens (lymph node, hepatic or cerebral
biopsy): stains*, culture** other examination***
, human immunodeficiency virus; CSF, cerebrospinal fluid; TB, tuberculosis; NTB, neurotuberculosis; MRI, magnetic
resonance imaging;CMV, citomegalvirus; * stains: Ziehl Neelsen (acid-fast bacilli), India ink (fungi), Gram smear (bacteria);
** culture on specific media: Lowestein or Bactec(mycobacteria), Sabourraud (fungi), blood agar (bacteria); ***
PCR,polymerase chain reaction, detection of ADA activity, detection of antigens/ antibodies for toxoplasma, CMV,
criptococcus, meningococcus, pneumococcus
Table 2. Neurotuberculosis diagnosis in HIV patients
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6.1.2. The evolution of TBM in HIV patients
In the HIV-TB co-infection TBM is frequently associated with pulmonary TB or tuberculous
lymphadenopathies. The risk of a relapse is considered 23%. The most important risk of relapse
is the lack of adherence to the antituberculous and antiretroviral treatment. CSF blood glucose
ratio and the presence of pulmonary TB could also be linked with the risk of relapse according
to a study performed in Vietnam [92]. The mortality rate is high; the survival rate is difficult to
evaluate taking into account the increased mortality of HIV patients due to other opportunistic
infections or specific complications. Risk factors for death during hospitalization for TBM
included: a) the CD4+ count lower than 50 cells/mm3; b) the presence of advanced neurologic
signs or hydrocephalus on admission; c) a diagnosis and treatment delay with more than 3
days [80];d) the absence of the antiretroviral treatment or failure of the highly active antire‐
troviral therapy (HAART) [93].TBM relapsing forms and multidrug resistant mycobacteria are
linked to a high mortality rate. IRIS prognosis is generally good.
6.1.3. Conclusion
TBM comprises variable manifestations in HIV patients. Early stages of immunodepression in
HIV patients usually set the same diagnostic difficulties as in non-HIV patients as a result of
the variable clinical presentations and delayed bacteriological results. In the advanced stages
of HIV the clinical presentation is atypical and the CSF cytochemical profile could be within
normal parameters. Other concurrent lesions of active TB could ease the diagnosis. The
differential diagnosis should always include other HIV-associated manifestations, other
opportunistic infections or malignancies. The bacteriological exam is still the only tool able to
confirm the diagnosis. The prognosis of TBM in HIV patients is shadowed by numerous
diagnostic difficulties, increased risk of relapse and associated HIV pathology.
Below are NTB diagnosis criteria (table 2) and imaging aspects found in our clinical practice
in patients with HIV and NTB: meningoencephalitis (figure 1), cerebral tuberculoma (figure
2) and cerebral tuberculoma in context of IRIS (figure 3)
6.2. CNS disseminated TB
CNS disseminated TB (CNS milliary TB, cerebrospinal granulia) is a form of cerebral milliary
frequently associated with disseminated TB. It is rarely limited to the CNS. The diagnosis is
usually based on findings at the necropsy or MRI results. Constitutional symptoms develop
progressively even in the absence of neurologic signs; mycobacteria could also be isolated in other
pathological products than the CSF (most frequently from the blood). The eye fundus exam could disclose
characteristic choroid tubercles. A classical miliary pattern on chest radiograph frequently
complements the aspects of cerebral miliary. Postconstrast MR brain images reveal intense
nodular enhancing granulomas located at cortico-medulary junction and throughout the brain
parenchyma. The differential diagnosis of cerebral military should include other opportunistic
disseminated infections or secondary metastatic lesions. It is possible to underestimate this
form of CNS TB as a result of the diagnostic difficulties and required expensive imaging
studies.
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usually based on findings at the necropsy or MRI results. Constitutional symptoms develop
progressively even in the absence of neurologic signs; mycobacteria could also be isolated in other
pathological products than the CSF (most frequently from the blood). The eye fundus exam could disclose
characteristic choroid tubercles. A classical miliary pattern on chest radiograph frequently
complements the aspects of cerebral miliary. Postconstrast MR brain images reveal intense
nodular enhancing granulomas located at cortico-medulary junction and throughout the brain
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disseminated infections or secondary metastatic lesions. It is possible to underestimate this
form of CNS TB as a result of the diagnostic difficulties and required expensive imaging
studies.
Neurotuberculosis and HIV Infection
http://dx.doi.org/10.5772/54631
305
6.3. Intracranial mass lesions in HIV patients with CNS TB
6.3.1. Tuberculoma
CNS tuberculomas develop insidiously in the cerebral parenchyma following either the
reactivation of local granulomas [94] or a paradoxical response to the antituberculous therapy
(figure 2,3). The lesions could be solitary or multiple and their localisations are diverse.
Cerebral localisations are more frequent than spinal ones. Data on HIV patients presenting
tuberculomas is scarce [95,96]. The diagnosis is probably underestimated in low income
countries taking into account the expensive CT/MRI importance in the confirmation. The
clinical presentation is pseudotumoral with fever and headaches. The neurologic signs vary
according to localisation and may be absent. HIV patients rarely present signs of intracranial
hypertension or convulsions. On the other hand tuberculomas could be associated with other
(A) (B) 
(C) (D) 
Figure 1. A-D. Cranio-cerebral MR: axial (A), coronal (B and C), and saggital (D) images showing tuberculous meningi‐
tis, cerebral thrombosis and hidrocephalus in a 23-year-old patient with AIDS. He had been receiving antiretroviral treatment
for 3 months prior to the present hospitalization. He was admitted with milliary TB and meningoencephalitis associated
with oral HCV infection, candidiosis and reactivated CMV infection. The clinical evolution was complicated by toxic hepatitis
due to antituberculous treatment and cerebral thrombosis. On admission the CD4 count was 244/mm3 and the RNA HIV
load was 239 copies/ml. Contrast MRI before and after the administration of intravenous gadolinium and angioMRI(sag
3D PC phlebography) show: hyperintense lesions on FLAIR sequences and T2 weighted images, appearing hypointense
on T1 with no contrast enhancement, located in the medial part of the lentiform nucleus and the head of the caudate
nucleus; contrast filling of the basal cisterns extending to the sylvian fissure (more proeminent on the left side), the floor
of the third ventricule and the infundibular area (involving the optic nerves, chiasm and optic tracts); asymmetric profound
venous system with bilateral amputation of the superios talamostriate veins without the visualisation of the anterior left
vein of the pellucid septum; enlargement of the ventricular system with no median shift or transependimar resorbtion.
Conclusions: post ischemic sequelae, thrombosis of the profound venous system, basal meningeal contrast enhance‐
ment suggestive for meningitis and dilation of the ventricular system.
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manifestations of TB such as TBM, pulmonary TB or other signs suggestive for CNS TB such
as tuberculous vasculitis. The CSF usually displays no changes or few cytochemical abnormal
findings (low glucose, elevated proteins); the acid-fast bacilli smear and culture are frequently
negative. The aspect on the CT suggestive for a tuberculoma presents as isodense or lightly
hypodense lesions with annular contrast enhancement and the ‘’target sign’’ as a result of
central calcifications. Nevertheless these aspects are not pathognomonic and the diagnosis
requires a cerebral biopsy with histological and bacteriological confirmation. The histopatho‐
logical examination usually discloses a central region of caseous necrosis surrounded by a
capsule with a granulomatous structure. This aspect evolves dynamically as follows: 1)
noncaseating granuloma; 2) caseating granuloma with a solid center; 3) caseating granuloma
with a liquid center. This dynamics could also be detected at the contrast enhanced MRI or
MRI spectroscopy as opposed to the images induced by a cerebral abscess. The MRI exami‐
nation indicates a correspondent evolution with the histopatological examination as: 1)
hypointense lesions on T1-weighted images (T1W) and hyperintense T2W lesions with
nodular enhancemen postgadolinium administration; 2) hypointense lesions on T1W and T2W
with peripheral rim enhancement postgadolinium ;3) hypointense T1W and hyperintense T2W
with hypointense rim postgadolinium. Difussion weigthed images indicate diffusion restric‐
tion within the tuberculoma. The lesions are surrounded by edema. The lesions in HIV patients
often appear as ring-enhancement lesions under 1 cm and the mass effect is rarely seen [97].
The CT/MRI aspect should be distinguished from other ring-enhancing lesions including






Figure 2. Cranio-cerebral MR images showing cerebelous tuberculoma in a 41 year-old patient with a 5 year history of
HIV infection nonadherent to the antiretroviral treatment.The patient was admitted with a cerebellous tuberculoma
and acute ischemic stroke.The laboratory data on admission disclosed a CD4 count of 145cells/mm3 and RNA HIV load
240000 copies/ml.Axial T1 weighted images shows (A): Focal enchancing triangular lesion in the anterolateral right‐
side of the pons of 5×9 mm with FLAIR hyperintensity, difussion restriction, no significant changes in the apparent
diffusion coefficient (ADC) and no contrast enhancement (the aspect is suggestive for acute ischemia); a right focal
cortico-subcortical cerebellous lesion with peripheral ring enhancement on T1 weighted images and mass effect (the
aspect is compatible with a tuberculoma). Coronal T1 weighted images shows (B): symmetrical enlargement of the
ventricular system with no midline shift; transependimar circumferential resorbtion edema is present adjacent to the
ventricular wall; no intraventricular obstruction or contrast enhancement. Conclusions: acute ischemic stroke in the an‐
terolateral right side of the pons; focalinferolateral parenchymal lesion suggestive for a tuberculoma; significant hy‐
drocephalus with no intraventricular obstruction.
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Figure 3. Cranio-cerebral MRI, showing left pontine tuberculoma in a 16 year-old patient previously diagnosed and
undergoing treated for lymph node TB for the past 2 months and recently diagnosed with HIV infection.The patient
also associated HBV and CMV infection and oral candidiosis.On admission the patient was in coma. The laboratory
data displayed a CD4 count of 24 cells/mm3 and RNA HIV 1064973copies/ml. Final diagnosis was NeuroIRIS TB (tuber‐
culoma).The CSF disclosed no changes.The clinical evolution was favourable. A: coronal T1 weighted image demon‐
strating left pontine paramedian nodular lesion of 4 mm surrounded by perilesional edema (discrete hyposignal). B:
coronal section T1 postcontrast shows hypersignal; C- coronal section T2 and D- axial FLAIR section show intense con‐
trast uptake and no diffusion restriction.
6.3.2.Tuberculous abscess
The tuberculous abscess represents a purulent collection delineated by a capsule with a
granulomatous structure. This is a rare finding in immunocompetent patients as well as in the
early stages of AIDS but common in severe immunodeficiency states with CD4+T cell count
under 100/mm3 [96]. The tuberculous abscess results from the liquefaction of tuberculomas
[13] or from the necrotic evolution of granulomas in the setting of severe immunodeficiency
[98].The necrotic centre is invaded by mycobacteria. The CSF is unchanged. The evolution is
more acute than tuberculomas with neurologic deficit, fever and headaches [96, 99-100]. The
CT/MRI aspect resembles the images in caseous tuberculomas but the lesion is larger (>3cm),
multilobulated, surrounded by a thick capsule and ring enhancement. The perilesional edema
and the mass effect are the most important features. The histological and bacteriological exam
the cerebral biopsy confirm the diagnosis. The differential diagnosis includes other intracranial
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space-occupying lesions especially cerebral toxoplasmosis and lymphoma [19].In such cases
PCR techniques could increase the diagnostic yield [101,102].
7. Infections with non-tuberculous mycobacteria in HIV patients
Nontuberculous mycobacteria induce CNS lesions especially in AIDS patients with advanced
stages of immunodepression. Sporadic cases triggered by M. avium, M. kanssasi, M. fortui‐
tum, M gordonae, M. genavense and M. terrae were reported [105,106]. As a rule CNS infec‐
tions with non-tuberculous mycobacteria are the result of MAC infection. Nevertheless infection
with MAC shows no predilection for the CNS as it frequently colonises the respiratory and
gastrointestinal tract. Disseminated infections occur as a result of a severe immune dysfunc‐
tion at a CD4 count under 60 cells/mm3 [57]. Under 10 cells/ mm3 the neurological dissemina‐
tion is also possible [107]. However a case study reported by Fletcher disclosed a cerebral abscess
with a double etiology involving M tbc and MAC in an AIDS patient with a CD+4 count of 140
cells/mm3 [108]. Higher values of the CD4+ count were also found in cases of MAC–related IRIS
in the absence of a systemic infection [109]. Most MAC neurologic manifestations in HIV infected
patients are cerebral abscesses and meningoencephalitis. Localized mass lesions (including
single or multiple abscesses) contain a large number of mycobacteria in the absence of the typical
granulomatous structure. These findings are frequently accompanied by pleocytosis and an
occasionally high protein level on CSF examination. The diagnosis should be confirmed by a
histological exam (in cerebral localized forms) or by using minimum 2 hemocultures (in
disseminated forms). MAC was also isolated in the CSF in disseminated forms. NeuroIRIS-
MAC associated manifestations were sporadically reported in HIV patients [110].
8. The treatment of NTB in HIV patients
The treatment of NTB in HIV patients should be combined, controlled and individualized.
1. The antituberculous and antiretroviral medication must be combined according to the
synergistic drug interactions; the doses in the combined scheme must be adjusted to
prevent treatment resistance.
2. The drug regimen must be controlled for adherence, drug interactions, toxicities, clinical
response and treatment resistance
3. Treatment must be individualized and adapted to other co-morbidities, associated therapies
and hypersensitivity reactions of the patient
The main antituberculous and antiretroviral classes, their corresponding representative drugs,
pharmacological interactions, adverse reactions and treatment efficacy are shown in table 3. The
NTB treatment principles in HIV patients are presented in accordance with the European AIDS
Clinical Society guidelines, CDC and American Thoracic Society recomandations [111-113].
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space-occupying lesions especially cerebral toxoplasmosis and lymphoma [19].In such cases
PCR techniques could increase the diagnostic yield [101,102].
7. Infections with non-tuberculous mycobacteria in HIV patients
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stages of immunodepression. Sporadic cases triggered by M. avium, M. kanssasi, M. fortui‐
tum, M gordonae, M. genavense and M. terrae were reported [105,106]. As a rule CNS infec‐
tions with non-tuberculous mycobacteria are the result of MAC infection. Nevertheless infection
with MAC shows no predilection for the CNS as it frequently colonises the respiratory and
gastrointestinal tract. Disseminated infections occur as a result of a severe immune dysfunc‐
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tion is also possible [107]. However a case study reported by Fletcher disclosed a cerebral abscess
with a double etiology involving M tbc and MAC in an AIDS patient with a CD+4 count of 140
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and hypersensitivity reactions of the patient
The main antituberculous and antiretroviral classes, their corresponding representative drugs,
pharmacological interactions, adverse reactions and treatment efficacy are shown in table 3. The
NTB treatment principles in HIV patients are presented in accordance with the European AIDS
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8.1. The antituberculous treatment
Treatment of tuberculous meningitis. TBM is a curable disease. Response to treatment in
patients with NTB and HIV is similar to patients diagnosed with TB only. The elevated
mortality is a result of the belated diagnosis, resistant mycobacteria and severe immunodefi‐
ciency
• The main characteristics of the antituberculous treatment in HIV patients with NTB
1. Treatment should be urgently started based on clinical and biological data, CSF modifi‐
cations, the history of TB, other tuberculous lesions and imaging studies. The CSF
specimens should be collected for culture and for resistance detection before treatment
starting. The bacteriological confirmation should not delay the treatment as the treatment
delay accounts for a poor prognosis. Advanced stages of the disease with irreversible
complications (hydrocephalia, adherences, cerebral infarcts) are related to high mortality
rates.
2. The antituberculous therapy must have increased CSF penetration (table 3) [114-120].
3. Corticosteroid therapy should be initiated as early as possible and continued for 6–8
weeks.
4. A long course of therapy for a minimum of 12 months is strong recomended.
• Factors to consider
1. Combined treatment must include an initial phase of 2 months, with 4 first-line antitubercu‐
lous drugs having high CSF penetration (ussualy isoniazid, rifampicin, pyrazinamide,
ethambutol) administered daily; the initial phase is followed by a second phase of another
10 months with only 2 first-line antituberculous drugs (isoniazid, rifampicin) adminis‐
tered 3 times per week [121]
2. Controlled treatment should approach:
• treatment adherence
• drug interactions and toxicities taking into consideration the followings (see table 3):a) the
side effects to the antituberculous treatment are three times more frequent in HIV than non
HIV patients; b) the interactions between the antituberculous and antiretroviral therapy may
impede the administration of the most efficient regimen or a simultaneous therapy; the most
important interaction involves the protease inhibitors (important class of antiretrovirals)
and rifampicin (first line antituberculous drug). Rifampicin accelerates the hepatic metab‐
olism of protease inhibitors decreasing their blood levels and increasing the risk of HIVdrug
resistance. In addition protease inhibitors delay the metabolism of rifampicin increasing its
serum concentration and toxicity. Izoniazid and rifampicin also decrease the concentration
of fluconazole, an antifungal frequently used in the HIV patients. Additionally there are
many other interactions between rifampicin and antiretrovirals, corticosteroids or trimeto‐
prim/sulfamethoxazole (table 3). For this reason rifabutin is preferred to rifampicin in HIV
patients along with a prolonged treatment.
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• neurological/extraneurological complications
Monitoring for ensuing complications includes a complete physical examination, laboratory
data, CSF aspects and imaging studies. It is important to consider the followings: a) neuro‐
logical complications are more frequent in HIV patients (mostly due to immune exacerbation
as tuberculous vasculopathy or IRIS); b) neurological complications may occur during
treatment: hydrocephalus and arachnoiditis could sometimes occur even in the presence of a
correct treatment; c) complications are frequently associated with other undetected TB
localizations.
• drug resistance.
The risk of resistance is increased in non-adherent patients, large bacillary load and patients
who start less efficient regimens. The glucocorticoid therapy reestablishes the low permeability
of the blood-brain barrier and could therefore decrease the CSF diffusion of antibiotics.
Inadequate doses of antituberculous therapy or low CSF antituberculous concentration may
induce drug resistance. An unfavourable clinical evolution and decreasing CD4+T cell count
require repeated CSF collection for culture and drug resistance. Close surveillance for drug
resistance is essential throughout the entire course of therapy.
3. Individualized treatment. The patient’s co-morbidities (like viral hepatitis or other risk
factors for hepatotoxicity, ocular diseases, renal failure, allergic reactions,other medica‐
tions and pregnancy) must be investigated before establishing the drug regimen and
should continue to be closely monitored.
Treatment of tuberculomas. Cerebral tuberculomas are potentially curable tumor-like masses.
There is a low number of tuberculoma cases reported in HIV patients [94- 95, 122-125].
Treatment is based on the same principles as TBM but with the following mentions:
• The perilesional granulomatous vasculitis decreases the penetration of antituberculous
drugs; the lesions heal progressively and require 12 to 30 months of antituberculous
treatment, or even longer;
• The recommended regimen is based on rifampicin, izoniazid and pirazinamide for 4 to 5
months and then rifampicin and izoniazid for 12 to 16 additional months. Other active drugs
include rifabutin, fluoroquinolones, kanamycin, ethionamide;
• Surgical treatment is rarely needed; it is indicated in tuberculomas with mass effect,
increased intracranial hypertension and hydrocephalus. The antituberculous treatment
should be started before surgery. The recurrence after surgical ablation is unsual.
• Glucocorticoid therapy is an important part of the treatment regimen as it reduces the edema
and improves the clinical manifestations. It should be maintained for at least 4 to 8 weeks.
Treatment monitoring requires the clinical and radiological follow-up on the long term. The
evolution of other tuberculous localizations if present should also remain under observation.
Response to therapy is favorable despite large lesions or immunodeficiency.
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Treatment of tuberculous abscesses requires surgical and pharmacological treatment similar
to the regimen recommended in tuberculoma but for an interval of 18 months to 2 years.
The prognosis is unfavourable due to severe imunodeficiency and large lesions [99, 101 ].
Treatment of NTB with resistant strains of M.tbc. The risk of resistance is higher in geo‐
graphic areas with high prevalence of resistant mycobacteria and in the case of recent TB
improperly treated. Resistance could occur against one or more antituberculous drugs. The
association between HIV and multidrug resistance (MDR-TB) or extensive drug resistance
(XDR-TB) is not well documented [126,127].The antituberculous treatment should be under‐
taken according to the advice of an experienced specialist only and should include at least 4
antituberculous drugs with an increased diffusion in the CSF [128].
Treatment of CNS TB with nontuberculous myobacteria. Data related to infections with
nontuberculous mycobacteria is scarce and insufficient for establishing definite treatment
guidelines. Therefore treatment regimens are largely undefined and the subsequent outcome
remains disappointing. The severity of the evolution appears to be related to the variable
sensitivity to the antituberculous antibiotics and the advanced stages of immunodeficiency
which predispose to a disseminated disease. Therapeutic regimens should be individualized
to include complex drug associations (5-6 drugs) on longer periods of time. A close consultation
with an experienced specialist is required. Mycobacteria belonging to the MAC display
increased resistance against most antituberculous drugs and therefore a large variety of
therapeutic regimens was evaluated. The repeated therapeutic failure is apparently linked to
the diverse sensitivity to antituberculous drugs associated with M. avium species. Moreover
there is the alternative that some HIV patients could be simultaneously infected with more
than one species of M avium. Macrolides proved efficient but cannot penetrate to the CSF.
Chlaritromycin is involved in several drug interactions with the antiretroviral therapy.
Considering the increased risk for disseminated forms induced by the MAC it is recommended
to add azithromycin, ethambutol and rifabutin to therapy. Other drugs that could be associated
in such cases include fluoroquinolones, streptomycin, amikacin. Treatment should always be
based on the results of susceptibility testing. After 12 months of treatment, prophylaxis with
macrolides is recommended until the CD4+ count raises above 100/mm3.M. scrofulaceum, M.
simiae, M. malmoense reveal the same sensitivity pattern as MAC. In the case of M. kansasii
recommended drugs include: rifabutin, streptomycin, HIN, ethambutol, amikacin.
Treatment during Pregnancy. The antituberculous treatment is urgently instituted according
to classic treatment regimens. Among prohibited drugs are streptomycin, fluoroquinolones
and ethionamide.
Treatment of NeuroIRIS-TB. Neurologic TB-IRIS is a rare manifestation of TB-IRIS. It
generally occurs within 2-3 months after initiating the combination of antiretroviral and the
antituberculous therapy [42].The risk of IRIS increases with the early starting and high efficacy
of antiretroviral therapy. Delaying the antiretroviral therapy with a minimum of 2 weeks after
antituberculous therapy is recommended to avoid IRIS complication. Usually IRIS is self-
limited and requires symptomatic or anti-inflammatory treatment without stopping the
antiretroviral treatment. Severe forms benefit from treatment with prednisone or methylpred‐
nisolone 1 mg/g gradually tapered within the 2 following weeks [129,130]
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8.2. The antiretroviral therapy
The antiretroviral (ARV) treatment ought to be started as soon as possible after the antituber‐
culous treatment. The urgency of the ARV therapy increases with the degree of immunodefi‐
ciency. Three important studies (CAMELIA performed in Cambodgia, SAPiT conducted in
South Africa and STRIDE a multinational study) established that an earlier start of the ARV
therapy significantly decreases the mortality in AIDS patients and especially in patients in
which the CD4+ cell count is below <50 cells /mm3. Although the development of IRIS is more
frequent if the ARV treatment is more precocious, the gravity of the IRIS manifestations in the
3 studies above cannot justify a longer delay of the antiretroviral therapy. Most guidelines
recommended that HIV patients start the antiretroviral treatment at least 2 weeks after the
antituberculous treatment if the CD4+ count is below 50 cells per mm3 ; the antiretroviral
treatment can be delayed until 4 weeks if the CD4+ count > 50 cells/mm3. Note that NTB in
HIV patients could be shadowed by the possible reactivation of other neurotropic agents
(cytomegalovirus, toxoplasma, JV virus) or cerebral tumors (cerebral lymphoma, Kaposi
sarcoma).The diagnosis in these cases could be difficult and if these associations are not
excluded from diagnosis, treatment should also address these conditions with the risk of
multiple drug interactions. Such is the case of cerebral toxoplasmosis.
• The main characteristics of antiretroviral treatment in HIV patients with NTB
◦ Therapeutic regimens must contain antiretroviral drugs with a high penetration in the
CSF. The main ARV drugs used in the co-infection with TB are listed in table 3 along with
their adverse reacions.
◦ The antiretroviral therapy in NTB is based on reverse transcriptase inhibitors represented
by 2 important classes: nucleoside reverse transcriptase inhibitors (NRTI) and non-
nucleoside reverse transcriptase inhibitors (NNRTI). The highest drug penetration into
the CSF is assigned to zidovudine, abacavir, nevirapine, delavirdine. Although efavirenz
(a NNRTI) does not display high levels in the CSF some studies advocate a very good
response in the treated adults [131]. Protease inhibitors should not be used due to their
interaction with rifampicin and low diffusion in the CSF. If their use is required (as a
result of resistance or toxicity to other antiretrovirals) rifampicin is to be replaced with
rifabutin with similar results.
◦ The doses of antiretrovirals should be changed according to the antituberculous drug
interference.
• Factors to consider
1. Combined treatment includes 3 NNRTIs with a preferred option for trizivir (combination
of zidovudine, abacavir and lamivudine) or 2 NRTIs + 1 NNRTI (ussualy efavirenz).
2. Controlled treatment should approach:
• The adherence (especially if a large number of drugs are introduced at the same time) [132].
Nevertheless adherence to trizivir is high (the number of capsules is low, there are few
adverse reactions).
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• Drug interactions and toxicities (see table 3). The clinician should recognize the overlapping
toxicities, drug interactions and also the occurrence of IRIS (paradoxical reactions) [133].The
interactions between NNRTI or NRTI and antituberculous drugs are few. The risk of toxicity
is minimal but adverse reactions are possible with some NRTIs (see table 3). Regarding the
toxicity the ARV could interfere not only with antituberculous drugs but also with other
drugs used in the prophylaxis or treatment of other opportunistic infections (such as
fluconazol for Candida or Criptococcus neoformans or sulphametoxazole/trimethoprim for
Penumocystis jirovecii).
• The efficiency and complications of treatment. The efficiency is to be monitored on a clinical,
virologic and immunological basis. The best control in HIV infections is the virologic (RNA
HIV viral load) and immunologic control (CD4+ cell count).Treatment control could be
undertaken at 14 days, one month, three and six months respectively. If the HIV RNA load
does not become undetectable after 3 months of treatment virologic failure should be
considered. If this is the case investigations on the underlying cause should focus on the
lack of adherence, acquired resistance (especially to NNRTIs) or a wrong treatment regimen
(doses, antagonistic associations or the lack of drug penetration to the CSF). Nevertheless
the intracerebral load of HIV could be hard to evaluate since the viral load detection in the
serum does not always reflect the intracerebral levels of HIV.
• Drug resistance. In case of virologic failure drug-resistance testing should be obtained
during treatment with the failing ARV regimen or within 4 weeks of treatment discontinu‐
ation. Resistance to antiretrovirals generally applies to most compounds in the same class.A
new regimen with other fully active drugs preferably from other new classes must be
restarted.
3. Individualized treatment: the treatment options should address other opportunistic
infections and the patient’s medical history. A CD4+ count under 200 cells/mm3 urges the
prophylaxis against fungal infections (cryptococcus, pneumocytsis). Prophylaxis against
toxoplasmosis should be started at a CD4+ cell count under 100 cells/mm3 due to an
increased risk of reactivation. Pregnant patients require urgent ARV treatment after 14
days of antituberculous treatment.
9. Conclusion
The failure of the antituberculous/antiretroviral treatment is generally a result of the low
compliance, inadequate treatment regimen (length, doses, low penetration into the CSF,
adverse reactions impeding the use of certain efficacious drugs), delays in the diagnosis or
treatment resistance. Any changes in the clinical examination, imaging studies and CSF aspect
during treatment or at follow-up require further investigations. Despite the immunodeficiency
the prognosis of CNS TB in HIV patients resembles that of non-HIV patients.
Tuberculosis - Current Issues in Diagnosis and Management314
ANTITUBERCULOUS DRUGS
Drug Pharmacologic aspects Drug interactions/Adverse reactions
Isoniazid (NIH)***
(first-line agent)
Interferes with mycolic acids synthesis. Bactericidal to
rapidly-dividing extracellular mycobacteria,
bacteriostatic against the slow-growing intracellular
mycobacteria. CSF peak concentrations exceed 30
times the minimal inhibitory concentration
Peripheral neuropathy (requires pyridoxine
supplementation). Hepatotoxicity (reversible)
depending on the dose and association with
rifampicin and alcohol consumption. Rare cases







is a semi-synthetic rifamycin
derivate with longer half-time
(not recommended in HIV
patients)
Rifampicin acts against intra and extracellular bacilli,
especially on slow-growing mycobacteria
(bactericidal). The metabolism is primarily hepatic;
because of its ability to induce certain microsomal
hepatic enzymes (CYP3A4) it interferes with the
metabolism of other drugs. Poorly penetrates the CSF
in the absence of meningeal inflammation. In
meningitis CSF level is up to 10-20% of the serum
levels. Rapid emergence of resistant mycobacteria.
Rifabutin is bactericidal.The level of rifabutin in the
serum is 7-10 times lower than the concentration of
rifampicin. It easily diffuses through the uninflammed
meninges.
Renal failure. Digestive and allergic reactions.
Hepatotoxicity (cholestatic hepatitis) especially
in drug associations. Hemorrhagic
manifestations due to thrombocytopenia.
Sulfamethoxazole/ trimethoprim enhances the
effect of rifampicin and could increase its
toxicity. Corticosteroids decrease the level of
rifampicin. Rifampicin could singnificantly
reduce the plasma concentrations of most PIs
and some NNRTIs; it could be associated with
NRTI and some NNRTIs.
Adverse reactions to rifabutin mirror those of
rifampicin; in addition rifabutin could induce
uveitis, arthralgias, leucopenia, asymptomatic
hepatitis. Rifabutin does not interact with PIs.
Because rifabutin is a less potent inducer, it is
generally considered a reasonable alternative to
rifampicin. Doses should be adjusted in the
coadministration with an PI ; underdosing of
rifabutin can result in selection of rifamycin
resistance, whereas overdosing of rifabutin
might result in toxicities.
Pyrazinamide***
(first-line agent)
Active against intracellular bacilli only at acid pH.
Bactericidal/bacteriostatic (dose dependent). Is well
absorbed and crosses the blood-brain barrier leading






Bactericidal with low activity. Ethambutol could
increase the activity of other antituberculous drugs
affecting the cellular permeability of MAC strains and
possibly of multiresistant M.tbc strain. Low CSF level
(moderate rise above the minimum bactericidal
concentration)
Optic neuropathy especially after prolonged
treatments. Rarely triggers allergic reactions and
hyperuricemia. No hepatotoxicity reactions.
Streptomycin*
(second-line drug)
Belongs to aminoglycosides class. Bactericidal. Active
only on replicating extracellular bacilli. Poor CSF level
even in patients with meningitis. High rate of
resistance
Nephrotoxicity. Neurotoxicity. Ototoxicity.




Belongs to the class of aminoglycosides. The same
characteristics as streptomycin. Low CSF
concentrations
Less toxic than streptomycin.Contraindicated in
pregnancy
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the intracerebral load of HIV could be hard to evaluate since the viral load detection in the
serum does not always reflect the intracerebral levels of HIV.
• Drug resistance. In case of virologic failure drug-resistance testing should be obtained
during treatment with the failing ARV regimen or within 4 weeks of treatment discontinu‐
ation. Resistance to antiretrovirals generally applies to most compounds in the same class.A
new regimen with other fully active drugs preferably from other new classes must be
restarted.
3. Individualized treatment: the treatment options should address other opportunistic
infections and the patient’s medical history. A CD4+ count under 200 cells/mm3 urges the
prophylaxis against fungal infections (cryptococcus, pneumocytsis). Prophylaxis against
toxoplasmosis should be started at a CD4+ cell count under 100 cells/mm3 due to an
increased risk of reactivation. Pregnant patients require urgent ARV treatment after 14
days of antituberculous treatment.
9. Conclusion
The failure of the antituberculous/antiretroviral treatment is generally a result of the low
compliance, inadequate treatment regimen (length, doses, low penetration into the CSF,
adverse reactions impeding the use of certain efficacious drugs), delays in the diagnosis or
treatment resistance. Any changes in the clinical examination, imaging studies and CSF aspect
during treatment or at follow-up require further investigations. Despite the immunodeficiency
the prognosis of CNS TB in HIV patients resembles that of non-HIV patients.
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ANTITUBERCULOUS DRUGS
Drug Pharmacologic aspects Drug interactions/Adverse reactions
Isoniazid (NIH)***
(first-line agent)
Interferes with mycolic acids synthesis. Bactericidal to
rapidly-dividing extracellular mycobacteria,
bacteriostatic against the slow-growing intracellular
mycobacteria. CSF peak concentrations exceed 30
times the minimal inhibitory concentration
Peripheral neuropathy (requires pyridoxine
supplementation). Hepatotoxicity (reversible)
depending on the dose and association with
rifampicin and alcohol consumption. Rare cases







is a semi-synthetic rifamycin
derivate with longer half-time
(not recommended in HIV
patients)
Rifampicin acts against intra and extracellular bacilli,
especially on slow-growing mycobacteria
(bactericidal). The metabolism is primarily hepatic;
because of its ability to induce certain microsomal
hepatic enzymes (CYP3A4) it interferes with the
metabolism of other drugs. Poorly penetrates the CSF
in the absence of meningeal inflammation. In
meningitis CSF level is up to 10-20% of the serum
levels. Rapid emergence of resistant mycobacteria.
Rifabutin is bactericidal.The level of rifabutin in the
serum is 7-10 times lower than the concentration of
rifampicin. It easily diffuses through the uninflammed
meninges.
Renal failure. Digestive and allergic reactions.
Hepatotoxicity (cholestatic hepatitis) especially
in drug associations. Hemorrhagic
manifestations due to thrombocytopenia.
Sulfamethoxazole/ trimethoprim enhances the
effect of rifampicin and could increase its
toxicity. Corticosteroids decrease the level of
rifampicin. Rifampicin could singnificantly
reduce the plasma concentrations of most PIs
and some NNRTIs; it could be associated with
NRTI and some NNRTIs.
Adverse reactions to rifabutin mirror those of
rifampicin; in addition rifabutin could induce
uveitis, arthralgias, leucopenia, asymptomatic
hepatitis. Rifabutin does not interact with PIs.
Because rifabutin is a less potent inducer, it is
generally considered a reasonable alternative to
rifampicin. Doses should be adjusted in the
coadministration with an PI ; underdosing of
rifabutin can result in selection of rifamycin
resistance, whereas overdosing of rifabutin
might result in toxicities.
Pyrazinamide***
(first-line agent)
Active against intracellular bacilli only at acid pH.
Bactericidal/bacteriostatic (dose dependent). Is well
absorbed and crosses the blood-brain barrier leading






Bactericidal with low activity. Ethambutol could
increase the activity of other antituberculous drugs
affecting the cellular permeability of MAC strains and
possibly of multiresistant M.tbc strain. Low CSF level
(moderate rise above the minimum bactericidal
concentration)
Optic neuropathy especially after prolonged
treatments. Rarely triggers allergic reactions and
hyperuricemia. No hepatotoxicity reactions.
Streptomycin*
(second-line drug)
Belongs to aminoglycosides class. Bactericidal. Active
only on replicating extracellular bacilli. Poor CSF level
even in patients with meningitis. High rate of
resistance
Nephrotoxicity. Neurotoxicity. Ototoxicity.




Belongs to the class of aminoglycosides. The same
characteristics as streptomycin. Low CSF
concentrations
Less toxic than streptomycin.Contraindicated in
pregnancy








Belongs to fluorochinolones class. Bactericidal. Active
on rapidly multiplying bacilli. Acts on nontuberculous
mycobacteria. Good CSF penetrations. except for
ciprofloxacin
Rare adverse reactions. To be avoided in
pregnancy. Interferes with antiacids
Azithromycin Clarithromycin Belongs to macrolides class. Bacteriostatic. Active on
nontuberculous mycobacteria. High intracellular
levels Do not cross the blood brain barrier.
Clarithromycin interfers with PIs and efavirenz;




Bacteriostatic/bactericidal (dose depending). Effect
on extra/intra cellular bacilli. Good CSF penetration
(equal to those in serum).Active on resistant
mycobacteria.





Bactericidal/bacteriostatic (dose depending). Effect
on intra and extracellular bacilli, including resistant
mycobacteria. Good CSF penetration
Neuropsy-chic reactions. Rash. Not
recommended with efavirenz. No
hepatotoxicity; indicated in patients with acute




Belongs to the entry inhibitor class (chemokine
receptor antagonist); it blocks HIV entry into the host
cell.
Substrate of CYP3A enzymes.
Hepatotoxicity. Rash. Caution and dose
adjustment is necessary when MVC is used in
combination with CYP3A inducers agents (such
as EFV or rifampin).
Fusion inhibitor: enfuvirtide
(EFV) *
Belongs to the entry inhibitor class. It is not affected
by the CYP enzymes
Hypersensitivity reactions. Can be used with the
rifamycins
Integrase inhibitor: RAL** HIV-1 integrase inhibitor. Blood-brain-barrier restrict
RAL entry; meningeal inflammation enhances drug
entry.
Hypersensitivity reactions. Rifampin and




AMP ***; IDV***; LPV***;
NFV*;RTV*; TPV*
Interfere with the protease enzyme that HIV uses to
produce infectious viral particles.
PI are CYP P450 inducer and substrate
Hepatotoxicity (requires monitoring of hepatic
enzymes). Rash. Prolonged QT interval. PIs are
not recommended with rifampicin. Adjust the





NNRTI bind to revers transcriptase, interfering with its
ability to convert the HIV RNA into HIV DNA
The NNRTIs are also substrates of CYP3A4 and can act
as an inducer/inhibitor or mixt
NNRTIs are related with an increased risk of resistance
if the therapeutic regimen is not respected.
Hepatotoxicity. Hypersensitivity reactions. Fewer
interactions with RIF; nevirapine does not affect
the levels of RIF; efavirenz or nevirapine-based
regimen are preffered when using associated
therapy with RIF; etravirine not recommended
with RIF. Adjust the doses in the combination of
EFV and rifabutin /rifampicine
Nucleos(t)ide reverse
transcriptase inhibitors (NRTI):
ZDV***; 3TC** ABC ***; d4T
** ddI* ; FTC**TDF*; ZAL*
Interfere with reverse transcription and conversion of
HIV RNA to HIV-DNA. Do not use the CYP metabolic
pathway. No significant interaction with rifampicin or
rifabutin
Hepatitis. Neuropathy (only stavudine,
didanosine). Optic neuritis (didanosine)
***very  good ability  to  cross  the  blood-brain  barrier;  **  moderate  ability  to  cross  the  blood-brain  barrier;  *  low
ability to cross the blood-brain barrier
Table 3. The most important antituberculous and antiretroviral drugs used in the treatment of CNS tuberculosis
[113-118]
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1. Introduction
Tuberculosis (TB) is a contagious infectious disease caused byspecies belonging to the Mycobac‐
terium tuberculosis complex. At present, it is a re-emerging disease, due to co-infection with the
Human Immunodeficiency Virus (HIV), but also to global bacterial resistance, and lack of
adequate treatment in some places in the world. Approximately one third of the world’s
population is infected with M. tuberculosis, and out of these people, about 1.1 million people die
every year of TB [1], making this disease the main cause of bacterial infectious death in adoles‐
cents and adults all around the world. In 2010 there was an estimation of 8.8 million incident
cases and 12.0 million prevalent cases of TB worldwide. M. tuberculosis drug-resistant isolates
have appeared giving origin to multidrug-resistant (MDR) and extensively drug-resistant (XDR)
strains. XDR-TB has been identified in every continent of the planet. By 2010, the World Health
Organization (WHO) was notified of the existence of 53.018 cases of multi-drug resistant TB
(MDR-TB) worldwide; figure that only represents 18% of the TB-MDR estimated cases among
reported pulmonary TB cases around the world [1]. Currently, there is global alarm since the
infection with these strains is cured only in 66% of MDR cases and in 60% of the XDR cases [2].
More than sixty years ago, the introduction of the first anti-TB drugs for the treatment of TB
(streptomycin (STR), p-aminosalcylic acid (PAS), isoniazid (INH) and then later ethambutol
(EMB) and rifampicin (RIF)) gave optimism to the medical community, and it was believed
that the disease would be completely eradicated soon. After a 30-year halt of anti-TB drug
Research & Development pipeline, the Global Alliance for TB Drug Development (TB Alliance)
started to fill the gap between the existing chemotherapeutics and the clinical need. Despite
the efforts carried out with candidates in clinical trials such as PA-824 and bedaquiline, there
is an urgent need of in-depth medicinal chemistry discovery studies for assuring enough leads
© 2013 Guzman et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
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and reproduction in any medium, provided the original work is properly cited.
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and candidates feeding the pipeline within the next decade[3]. Emerging chemical entities
must shorten the time of treatment, be potent and safe while effective facing resistant strains
and non-replicative, latent forms, and not interfere in the antiretroviral therapy [4]. In this
review, we explore why we require to work continuously on the development of novel anti-
TB agents, the stages necessary for the development of new anti-TB agents, breakthroughs in
the discovery of new active principles and targets, the preclinical and clinical development of
drugs, as well as the new approaches for the search of anti-TB active principles.
2. Targets and action mode of active principles currently used in the
treatment of TB
Current TB chemotherapy is based on the combination of four anti-TB drugs which inhibit the
bacterial metabolism, particularly the cell wall synthesis [5]. During the therapy, the goal of this
drug combination strategy is to prevent effectively the mutational events [6]. According to their
action mode, first and second line anti-TB drugs are grouped into cell wall inhibitors (INH, EMB,
ethionamide (ETH), and cycloserine (DCS)), protein synthesis inhibitors (RIF, fluoroquino‐
lones, STR, kanamycin (KAN)), and membrane energy metabolism inhibitors (PZA).
Current chemotherapy principally inhibits cell processes such as cell wall biosynthesis and
DNA replication, and they only turn to be active regarding bacteria in active growth [5]. This
implies that the chemotherapeutic agents in use are efficient bactericides but are poor steri‐
lizers, not able to kill “dormant” M. tuberculosis which persists in macrophages after the death
of the active bacteria [5]. RIF and PZAhave a partial sterilizing activity and they play an
important role in the decrease of therapy from 18 to 6 months, even though there is a persistent
population surviving these two agents. Consequently the current therapy ensures a clinical
cure but fails to obtain a bacteriological cure [5].
3. Why we need new active anti-TB agents?
Whereas it is true that TB can be cured with the current active principles, treatment is complex
and long, involving four drugs for two months and two drugs for four months more as a
minimum.
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Table 1. Reported MIC and molecular targets drugs of first and second-line drugs used in the treatment of TB [7].
Since the start of chemotherapeutic era, physicians have realized the slowness and difficulty
of achieving effective cure. McDermott et al proved in 1956 that the in vitroefficacy of first-line
TB drugsdo not correlate to their in vivo efficacy [5]. Cultures of M. tuberculosis in exponential
growth are sterilized in vitro in a few days by firstline agents such as INH and RIF, while the
same combination requires months to achieve the same result in host tissue. It has been stated
that mycobacterial persistency is due to the physiologic heterogeneity of bacillus in the tissues,
the existence of subpopulations with completely different rate-determining factors. Despite
an urgent need for new therapies targeting persistent bacteria, our knowledge of bacterial
metabolism throughout the course of infection remains rudimentary [8].Mitchison and
colleagues proposed in 1979 that, in lesions, M. tuberculosisexists under at least four different
population stages listed below [9] and showed in Figure 1:
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Since the start of chemotherapeutic era, physicians have realized the slowness and difficulty
of achieving effective cure. McDermott et al proved in 1956 that the in vitroefficacy of first-line
TB drugsdo not correlate to their in vivo efficacy [5]. Cultures of M. tuberculosis in exponential
growth are sterilized in vitro in a few days by firstline agents such as INH and RIF, while the
same combination requires months to achieve the same result in host tissue. It has been stated
that mycobacterial persistency is due to the physiologic heterogeneity of bacillus in the tissues,
the existence of subpopulations with completely different rate-determining factors. Despite
an urgent need for new therapies targeting persistent bacteria, our knowledge of bacterial
metabolism throughout the course of infection remains rudimentary [8].Mitchison and
colleagues proposed in 1979 that, in lesions, M. tuberculosisexists under at least four different
population stages listed below [9] and showed in Figure 1:
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1. Bacteria in active growth, susceptible to INH.
2. Bacteria with intermittent metabolism period, susceptible to RIF.
3. Low metabolic activity bacteria residing in acidic pH, susceptible to PZA.
4. “Dormant” or “persistent” bacteria, non susceptible to any current active principle.
Figure 1. Spectrum of M. tuberculosisphysiology.Extent of variation of physiological cell subpopulations of M. tu‐
berculosis on an in vivo environment. Notice that first-line drugs mainly inhibit actively dividing bacteria, while there is
not a single agent targeting the lower physiologically active stages.
During the initial chemotherapy phase (2 months), actively dividing bacilli rapidly die mostly
because of INH bactericidal activity. Thereafter bacilli of low metabolic activity suffer from a
slow death under the effects of RIF and PZA. There is evidence that persistentbacillarpopula‐
tion existing in the lesions usually determines the duration oftherapy [9]. Therefore efforts
need to be made to target every physiological state of M. tuberculosis thus shortening the time
of therapy and the appearance of drug resistance.
That brings us to the second reason why we need new anti-TB drugs. Drug resistance has
emerged as a phantom from the dark, threatening today every corner of the world. RIF-
resistance often correlates to MDR category (resistant to INH and RIF). XDR M. tuberculosis is
an MDR strain also resistant to any fluoroquinolone and at least one injectable agent. Prognosis
is less favorable for patients harboring XDR-bacilly compared to patients with MDR, with five
times higher risk of death, require longer hospitalization or treatment times. However it has
been shown that within an aggressive treatment, XDR-TB patients have been successfully
cured in 60% [10,11]. Treatment of M/XDR-TB usually takes more than two years, and requires
the use of more toxic, less effective and more expensive drugs. In resource-limiting countries,
supplies of second-line drugs cannot be guaranteed. In an attempt to improve the conditions
for millions of patients, Jim Yong Kim and Paul Farmer from Partners in Health brought down
the price of second-line drugs has by more than 80%. Unfortunately the latest reports from
Italy, India and Iran, facing the extremely (XXDR) or totally (TDR) super-bug, have made
imperious the essential necessity of new drugs targeting novel mechanisms of action [12].
TB infection in immune-compromisedpopulation leads tosevere cases,possibly affecting other
parts of the body, such as the pleura, meninges, the lymphatic system, the genitourinary
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system, and the bones [13]. It has been estimated that HIV infected patients are 100 times more
likely to develop TB [14]. Although the studies support a decrease of mortality for TB patients
after the introduction of antiretroviral therapy, evidence of the existence of interactions
between Highly active antiretroviral therapy (HAART)and TB chemotherapy. HAAR is based
on a combination therapynormally involving two reverse-transcriptase inhibitors and a non-
inhibitor [15]. P450 Cytochrometypicallymetabolizes reverse-transcriptase inhibitors,however
this cytochrome is also induced by RIF. TB chemotherapy may reduce significantly the
concentrations of anti-retroviral drugs which may lead to treatment failure or resistance. An
increase of the nevirapine dose to compensate for this interaction increases the risk of toxic
effects and hepatotoxicity in patients who already present a low body mass index and high
level of CD4 lymphocytes [16]. Physicians prefer to avoid the concomitant use of nevirapine
and RIF; consequently there is a clinical need for mycobactericidal agents devoid of P450
catabolism.
4. A 50-year wait
Antibiotic discovery began in the early 1930s when different classes were discovered [17]. At
the end of the 1950 decade, the combined regime was established and was thought to eradicate
the disease completely. In the following thirty years after the introduction of the last first-line
anti-TB drug, RIF, the regimen remained unchanged. The landscape changed in 1993 when
the WHO declared TB a global health emergency [18]. Until recently, research in development
of new anti-TB drugs was poor. These days, the TB Alliance has emerged as a non-profit
organization promoting and funding anti-TB drug development by creating consortia over a
defined project involving oftenbig pharmacompanies, institutes of research, and universities.
Interest in drug discovery has placed on both phenotypic and target-based approaches to set
in motion strong pipeline. With the joint effort of the Working Group on New TB Drugs, Stop
TB Partnership and other societies.gatifloxacin, delamanib, PA824, rifapentine, sutezolid,
SQ-109, bedaquiline and linezolid are candidatesin clinical trial [19]. There are other promising
compounds (CPZEN-45, BTZ043, AZD5847, DC-159a and others), but a handful ofscientists
believe that the gap is large and there is no certainty whether there will be a full new regimen
in the next decade [3].
Neglected diseases affect mostly the poorest population on Earth, predominantly those who
live in remote, rural areas, in depressed urban settings, or in regions of conflict. Together with
malaria, leishmaniasis,filariasis and Chagas disease, TB makes part of the high impact
neglected diseases, which unfortunately represent an insufficient market to attract enough
investment on research by the pharma industry [20]. Whereas the most advanced societies
have increased their life expectation thanks to technological development of medicine, in
developing countries these diseases (some of which are preventable, treatable, and curable)
still devastate the frailest populations. However, governments, multilateral organizations, and
foundations spend billions of dollars in the procurement of treatments; and with the current
situation of the disease, world health care organisms applaud recent efforts to develop new
anti-TB drugs, even though the panorama is not that promising yet [3,21].
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5. Platform for the development of active principles in the treatment of TB
Both basic and clinical pharmacology have contributed to the progress in the discovery of drugs
applying their experience to the development and validation of hypotheses of new action targets
in order to produce novel drugs. In this sense, researchers need to be innovative and they must
have a wide vision over the interpretation of the results [20]. The choice of a therapeutic candidate
is probably the most important decision to make in the discovery and development of a
medication. The chemical structure of a drug confers its biologic, pharmacokinetic, physicochem‐
ical, and toxicological properties [22]. On the other hand, the discovery and development of new
drugs is a complex and costly process requiring large amount of resources and time. The cost of
launching a new drug to the market ranges from US$ 800 million and 1000 million, and it may
take between 8 and 17 years depending on the disease and the treatment (Figure 2) [23].
Figure 2. TB drug pipeline.From the discovery bench through preclinical and clinical studies for novel anti-TB agents,
a process that could last more than 15 years.
The term “hit” is used to describe a small number of structurally related molecules possessing
an established biologic (antituberculosis) activity [24,25]. The term “lead” is defined as a
molecule belonging to a series, which shows a substantial structure – activity improvement
around a determined “hit”, and from which other important factors have been obtained such
as evidence of selectivity and pharmacokinetic data or in vivo activity [24].
Once these terms are defined it is important to knowthe biochemical target on which a certain
structural type of a chemical compound exerts a biological action. The determination of the
mechanism can be carried out in vitro by generating drug-resistant mutants which are
examined on their whole-genome sequences analysis. The transcriptional profile using cutting
edge mycobacterial microarrays or qPCR) can be interrogated among the whole transcriptome
for potentially distinguishing a defined set of genes involved in the response against chemical
injury. Once a determined protein or receptor has been identified, cloning, over-expressing
and purifying the proteins is usually performed with the aim of examining its biochemistry
and its possibility of affinity or interaction in the tube test is always possible option. Gene
deletions and over-expressing systems in Mycobacterium are also used for confirming the
mechanism of action of a defined candidate [26].Ideally, an antibacterial agent must show
bactericidal activity often impeding an essential function for the survival of the microorganism.
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Another more classical possibility is monitoring of microbiologic parameters such as growth
rate, CFU counting and chemical analysis of metabolites in the treatment with sib MIC, MIC
and over-MIC values of the agent. Currently, many active principles are identified as the result
of a rational design, supported by genomics inspired hypotheses or from another perspective,
by automated high-throughput screening (HTS) using compounds libraries [23].
6. Discovery of active compounds
The parameter most commonly determined to examine the in vitro antibacterial activity of a
specific moleculeis the minimum inhibitory concentration (MIC) which represents the
concentration required to inhibit 99.9% of the growth of bacilli The main limitations of these
trials is that do not describe the percentage of dead bacteria (which critically depends on cell
density) or the metabolic state of the bacteria, if we aim to examine the persistent antimicrobial
effects of a certain drug [27]. Most publications include at least a compound with a MIC lower
than 6.25 mg/Ll [24,26]. It is recommended that active compounds under a colorimetric assay
(Resazurin, Alamar Blue, MTT) are reconfirmed usingagar-based techniques or MGIT. A
simple and easy to use, agar-based method using Middlebrook 7H10 was introduced in 2004
by Bhakta et al for measuring MIC values [28,29]. The spot culture growth inhibition assay
(SPOTi) has now being used to screen more at least more than 1000 compounds. Simultane‐
ously, the cytotoxicity in different type of mammalian and/or macrophages is carried out. The
selectivity index (SI) is determined by dividing the growth inhibitory concentration 50 (GIC50)
corresponding to the concentration of compound capable of killing half of the mammalian
cellsby the MIC using the same concentration units. If the SI is larger than 10, infection of a
macrophage with a selected strain of mycobacteria and treating with the drug candidate can
help to determine its intracellular potential (Figure3)[26].
Figure 3. Research and development of new TB active compounds.In an attempt to promote quickly pre-clinical
studies of early leads, Orme propose this rapid diagram based on the selectivity ration between a bacteria and mam‐
malian cell line [26].
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The macrophage infectionmodel offers the possibility of evaluating the compound in a
physiologically challenging intracellular space. By plotting a viability curve fordifferent
concentrations of the active principle, The EC90, EC99 and EC99.9values of are determined
verifying the concentration that is able to reduce the bacterial load by 1, 2 and 3 logarithmic
units. MIC is most usually defined as EC99.(or EC95). Bactericidal compounds are generally
associated with a 3-fold reduction in CFU logarithmic units. In addition the infection assay
determines the activity of a compound in an intracellular medium which does not always
correlate with in vitro media-based inhibition measurements. For instance, transport mecha‐
nisms in the cell may influence the intracellular concentration of the drug regardless of the
external fluid concentration [30].
The success of a discovery program of antibacterial principles is founded on three factors:
identification of key elements contributing to pathogenicity of the microorganism, the
understanding of the existing relationships between the microbe and the host, and important‐
ly, the properties of the chemical compound [30]. Two pathways have been traced with the
aim of discovering active principles. One is the empirical pathway, mainly based on chemistry
and phenotypic screening; and the more modern is the mechanistic, based on genomics,
biochemistry and molecular biology. The former begins with the identification of an active
principle with potent antimicrobial activity on in vitro conditions. The active principle is
discovered by chance or by random screening. Then, it is subject to trial on rigoroustoxico‐
logical assays before using animal models. Some candidates may eventually beselected for
human trials. The limitation of the empirical pathway is the lack of information on the specific
target or the action mode, sometimes this lack of understanding can led to high failure rates
mostly for toxicity problems [30]. On the other hand,the mechanistic pathway started with the
age of molecular biology and genomics which allowed the identification of specific targets of
the microbe, absent or structurally different in human hosts. This strategy can be upgradeto
high-throughput screening (HTS) platform and to evaluate a large amount a substances in little
time. Crystallization of the target proteins and X-ray diffraction spectroscopy, together with
an analysis of the active site in the presence of the natural substrate and inhibitors allow the
detailed study of the crucial structural interactions.
In  the  mechanistic  approach  discovery  usually  involves  firstly  the  identification  and
validation of amycobacterial target macromolecule to be inhibited or interrupted. Obtain‐
ing the small molecules which inhibit such a target is another story. Large collections of
compounds can be screened directly against the protein if a high-throughput method of assay
is available. Alternatively if there is structural information it is possible to computationally
interrogate the target against a defined set of computer-based compounds (docking). The
preferred targets are generally the ones ocurring in M. tuberculosis and not represented in
the human genome. By means of comparative genomics, the targets are present in the human
genome.  For  example,  nicotinamide adenine dinucleotide (NAD)is  generated in humans
either  by de  novobiosynthesis,  or  by DNA and RNA degradation.  HoweverM. tuberculo‐
siscan only synthesize NAD using thede novo synthesis. This allows to rationally explorequi‐
nolinatephosphoribosyltransferase  (QAPRTase)  inhibition  (de  novo  pathway)  for  the
developing of microbial selective inhibitors [30].
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Targets existing in M. tuberculosiswhileabsent in other bacteria would seem ideal since active
compounds against this target will be harmless to bacteria beneficial for the human being.
However, selecting targets complying with this requisite leads to restrict extensively the likely
targets: for the most of it only the biosynthesis of the mycobacterial cell- wall or those implied
in specific mycobacterial process (virulence, detoxification, others).
The validation of a target, involves the examination of bacterial viability when decreasingthe
protein expression. If reducing the enzyme level,led to lose in bacterial viability, then the target
is known as “vulnerable”, and it is meant to be attacked [30]. The elimination or knockout of
the gene that codifies an essential protein is difficult (or impossible) to produce by homologous
recombination if the gene is essential in the conditions of growth, and therefore inducible
promoters are a better chance to show the effect of tightly reducing its expression. Over-
expression of the target is also possible, the growth of the over-expressed mutant being rescued
under higher concentrations of inhibitor. These studied have led to many targets that have
been identified and validated. The studies of Sasettiet al identified which enzymes were
essential in vitro and in vivo using a transposon site hybridization analysis (TraSH) using both
in vitro or in vivo [31,32].
Another approach is related to the genomics of virulence. Some mycobacterial genes are only
expressed in granulomabut not inside the macrophages. Isocitratelyase enzyme is fundamen‐
tal in the persistence of bacilli in chronic infection in mice and its function is related to obtaining
carbon during its persistence in the host [8,33]. The extracellular repetition protein (Erp) is
another essential protein involved in M. tuberculosis virulence that was the first discovered
virulence factor. The mutant Δ-erp that does not express correctly the extracellular repetition
protein does not show any alteration in standard in vitro culture, but maintains an essential
function for in vivo survival [34,35]. This protein is also a potential target for the development
of anti-TB active principles. Two independent proteins (fadD28 and mmpL7) have been
identified contributing to the early growth of M. tuberculosis in mice lungs and are related to
the synthesis and transport of a complex lipid associated to the cell wall, i.e. phthioceroldi‐
mycocerosate (PDIM) [34]. Although the function of this lipid is unknown, it is suspected that
itplays a role in the decrease of the host’s immune response. There is no doubt about the
remarkable progress that the sequencing of theM. tuberculosisgenomehas brought to the anti-
TB drug discovery area of research. The functional annotation of all these genes remains a
considerable amount of experimental work. Sequencing of other related organisms such as M.
marinum, M. leprae, M. aurumand othersoffer often clues about the essentiality of specific set of
genes and operon distribution.
7. Target or compound type in discovery stage
Analogues of thiolactomycin: Thiolactomycinwas the first natural thiolactonedisplaying
antibiotic activity. The compound showed moderate in vitro activity of 56 μM against M.
tuberculosis[36]. Thiolactomycin analogues have been synthesized and some hits were found
[5]. Analogues of thiolactomycin seem to inhibit mycolatesynthetase, an enzyme involved in
the cell wall biosynthesis.
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of anti-TB active principles. Two independent proteins (fadD28 and mmpL7) have been
identified contributing to the early growth of M. tuberculosis in mice lungs and are related to
the synthesis and transport of a complex lipid associated to the cell wall, i.e. phthioceroldi‐
mycocerosate (PDIM) [34]. Although the function of this lipid is unknown, it is suspected that
itplays a role in the decrease of the host’s immune response. There is no doubt about the
remarkable progress that the sequencing of theM. tuberculosisgenomehas brought to the anti-
TB drug discovery area of research. The functional annotation of all these genes remains a
considerable amount of experimental work. Sequencing of other related organisms such as M.
marinum, M. leprae, M. aurumand othersoffer often clues about the essentiality of specific set of
genes and operon distribution.
7. Target or compound type in discovery stage
Analogues of thiolactomycin: Thiolactomycinwas the first natural thiolactonedisplaying
antibiotic activity. The compound showed moderate in vitro activity of 56 μM against M.
tuberculosis[36]. Thiolactomycin analogues have been synthesized and some hits were found
[5]. Analogues of thiolactomycin seem to inhibit mycolatesynthetase, an enzyme involved in
the cell wall biosynthesis.
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Nitrofuranilamides:M. tuberculosishas been found to be susceptible to compounds containing
a nitro group. Nitrofuranilamide was identified in a screening for inhibitors of UDP-galacto‐
semutase [5]. A set of compounds structurally related to nitrofuranilamides was synthesized
and tested for antimicrobial activity. All resulted active both to sensitive and resistant strains
with a MIC ranging from 0.0004 – 0.05 mg/L [37]. Four nitrofuranilamide type compounds
showed significant activity in the tuberculous infection in mice models [37].
Figure 4. Development of new active compounds targeting M. tuberculosis
Analogues of nitroimidazole: While the PA-824 product is developed, the TB Alliance started
a project to maximize the potential of this class, by identifying the improved versions of PA-824
[38,39].
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Dihydrolipoamideacetyltransferase inhibitors: Dihydrolipoamideacetyltransferase (dlaT)
enzyme of M. tuberculosis is a potential target for TBdrug discovery [5]. This enzyme is a
component of the pyruvate dehydrogenase sub-unit, an enzyme catalyzing acetyl-CoA
synthesis and also contributes to peroxinitritereductase, adefense enzyme against oxidative/
nitrosative stress. Some heterocyclic compounds have been found to be inhibitors of the dlaT
enzyme, displaying non-replicative bacterial killing [40].
“Focused Screening”: TB Alliance is helping to develop a set of projects identify chemical
compounds which are active against specific molecular targets including DNA gyrase
inhibitors (fluoroquinolones targets), peptidedeformylase inhibitors, and quinone-analogous
electron transport inhibitors [5].
InhA inhibitors: InhA is the well-known enoyl-reductase of M. tuberculosisbeing an essential‐
biocatalyst forlong chain fatty acids biosynthesis (FAS-II) [41]. INH resistance is mainly
mediated by mutations on KatG, the enzyme activating the prodrug. Consequently, InhA
inhibitors that do not require activation by KatGcould be interesting candidates. The main goal
of the screening is directInhA inhibition. Some compounds of the biphenylether type have
proven to be inhibitory of InhAin a degree correlatingwithin vitro growth inhibition [42]. A
possible limitation of this class is the possibility of cross resistance with INH and potentially
with ETH [5].
Isocitratelyase inhibitors: The isocitratelyase enzyme (ICL) has been found to be essential for
the long term persistence of M. tuberculosis in mice but not in culture medium or under hypoxia
conditions. McKinney and colleagues have proved recently that inhibition of the ICL1 and
ICL2 isoforms block bacterial growth and survival in macrophages [8]. The absence of
orthologues in mammals for this enzyme, makes it a good target for the development of
inhibitors [5]. A screening of more than 900,000 compounds has been performed without
satisfactory results. The potential of traditional Chinese medicine has also been researched in
obtaining specific inhibitors of this enzyme [43].
Pleuromutilins: Pleuromutilins represent a new kind of antibiotics derived from pleuromu‐
tiline, a bioactive diterpene initially isolated from edible Clitopilusscyphoidesfungus [44]. These
molecules interfere with protein synthesis associating to the 23S rRNA unit. Despite the
structural novelty of these compounds, recent studies have pointed out cross-resistance among
pleuromutilins and oxazolidinones[5]. Pleuromutilins have proved to inhibit M. tuberculosis
growth of in vitro.
Macrolides: This project aimed to optimize the anti-TB activity of the macrolide class through
the synthesis of modified derivates of erythromycin [5]. Derivatives of erythromycin such as
11, 12-diol, 11, 12-carbamates, and 11, 12-carbazates have been found to be to most promissory
[45].
Quinolones and DNA gyrase inhibitors. The goal of this projectwasto synthesize and assess
the potential of novel quinolones trying to decrease the time of treatment. More than 450
compounds were synthesized and assessed [5]. The 2-pyridones class has proven to be active
DNA gyrase of M. tuberculosis, being KR1-10018 an interesting lead for the development of
anti-TBdrugs [46].
Research and Development of New Drugs Against Tuberculosis
http://dx.doi.org/10.5772/54278
341
Nitrofuranilamides:M. tuberculosishas been found to be susceptible to compounds containing
a nitro group. Nitrofuranilamide was identified in a screening for inhibitors of UDP-galacto‐
semutase [5]. A set of compounds structurally related to nitrofuranilamides was synthesized
and tested for antimicrobial activity. All resulted active both to sensitive and resistant strains
with a MIC ranging from 0.0004 – 0.05 mg/L [37]. Four nitrofuranilamide type compounds
showed significant activity in the tuberculous infection in mice models [37].
Figure 4. Development of new active compounds targeting M. tuberculosis
Analogues of nitroimidazole: While the PA-824 product is developed, the TB Alliance started
a project to maximize the potential of this class, by identifying the improved versions of PA-824
[38,39].
Tuberculosis - Current Issues in Diagnosis and Management340
Dihydrolipoamideacetyltransferase inhibitors: Dihydrolipoamideacetyltransferase (dlaT)
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biocatalyst forlong chain fatty acids biosynthesis (FAS-II) [41]. INH resistance is mainly
mediated by mutations on KatG, the enzyme activating the prodrug. Consequently, InhA
inhibitors that do not require activation by KatGcould be interesting candidates. The main goal
of the screening is directInhA inhibition. Some compounds of the biphenylether type have
proven to be inhibitory of InhAin a degree correlatingwithin vitro growth inhibition [42]. A
possible limitation of this class is the possibility of cross resistance with INH and potentially
with ETH [5].
Isocitratelyase inhibitors: The isocitratelyase enzyme (ICL) has been found to be essential for
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conditions. McKinney and colleagues have proved recently that inhibition of the ICL1 and
ICL2 isoforms block bacterial growth and survival in macrophages [8]. The absence of
orthologues in mammals for this enzyme, makes it a good target for the development of
inhibitors [5]. A screening of more than 900,000 compounds has been performed without
satisfactory results. The potential of traditional Chinese medicine has also been researched in
obtaining specific inhibitors of this enzyme [43].
Pleuromutilins: Pleuromutilins represent a new kind of antibiotics derived from pleuromu‐
tiline, a bioactive diterpene initially isolated from edible Clitopilusscyphoidesfungus [44]. These
molecules interfere with protein synthesis associating to the 23S rRNA unit. Despite the
structural novelty of these compounds, recent studies have pointed out cross-resistance among
pleuromutilins and oxazolidinones[5]. Pleuromutilins have proved to inhibit M. tuberculosis
growth of in vitro.
Macrolides: This project aimed to optimize the anti-TB activity of the macrolide class through
the synthesis of modified derivates of erythromycin [5]. Derivatives of erythromycin such as
11, 12-diol, 11, 12-carbamates, and 11, 12-carbazates have been found to be to most promissory
[45].
Quinolones and DNA gyrase inhibitors. The goal of this projectwasto synthesize and assess
the potential of novel quinolones trying to decrease the time of treatment. More than 450
compounds were synthesized and assessed [5]. The 2-pyridones class has proven to be active
DNA gyrase of M. tuberculosis, being KR1-10018 an interesting lead for the development of
anti-TBdrugs [46].
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Survey of natural products: Natural products represent an alternative for the search of new
compounds. Different research institutescontinuously carry out screening of natural products
(products from plants, fungi, and bacteria) with the hope of identifying compounds with anti-
TB activity [5]. Some natural substances have shown significant anti-TB activity: saringosterol
24-epimers, esgosterol-5,8-endoperoxide, micromolide, ascididemin, the manzamines, and
engelhardione, among others; however, there is lack of more research regarding selectivity
and toxicity [47-50].
Plants: Drugs based on plants extracts have been used worldwide for the treatment of several
diseases from ancient times.A great interest in phytomedicine and natural product structures
are screened in order to measure their pharmacologic activity. In Colombia, there has been a
resurgent interest in the discovery of novel natural anti-TB drugs [50-54].
Natural sea products: oceans are outstanding sources of natural products, not only in inverte‐
brate species such as sponges, mollusks, bryozoos, but also in marine bacteria and marine
sediments. The alkaloid (+)-8-hydroxymanzamine A was initially isolated from the Pachypelli‐
nasp sponge [55]. In the same way, irciniol A was found in sponges from the Indian Pacific proving
to be a good candidate for further studies [56]. Aerothiononine isolated from the marine sponge
Aplysinagerardogreenimarine sponge was active against clinical isolates of MDR-TB, despite of
the resistance patterns, with MIC from 6.5 to 25 mg/L [57]. The alkaloid (+)-8-hydroxymanza‐
mine A alkaloid showed potent inhibitory activity against M. tuberculosis H37Rv [58].
Insects. The immune system of invertebrates and vertebrates is made up by cytolitic peptides
which act as antimicrobial agents during the invasion of eukaryotes and prokaryotes micro‐
organisms. Poison from arachnids (spiders and scorpions) contains toxic peptides of high
molecular weight (2 – 12 kDa) with high specificity against prokaryote cells [59]. This type of
compounds may be very promising as a drug in the treatment of tuberculosis.
Microorganisms.Most of the major antibiotics drugs have been isolated frommicroorganisms.
Streptomycin,the first effective anti-TB drug was identified in Streptomyces griseus. Besides
streptomycin, aminogyicosides kanamycin, amikacin, and capreomycinhave been very
important therapeutically as second-line agents [59]. Other important anti-TB drugs in TB
treatment are the rifamycins, which constitute a group of semi-synthetic antibiotics isolated
from Streptomyces mediterrani[59].
8. Preclinical and clinical development for new anti-tuberculosis drugs
8.1. Preclinical development of anti-TB active principles
Preclinical tests involve the use of animal models to prove the efficacy and safety of a given
candidate before being tested in humans. Because of its management in terms of size, offer,
maintenance, strength, and reproducibility, the mouse constitutes the preferred animal model
for in vivo research of the TB infection [60]. Other possible animal models include rats, guinea
pigs, and macaques. The amounts of viable mycobacteria and mortality and the possibility of
organomegaly in the pulmonary tissue are evaluated during therapy, at the end of therapy
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and in the post-therapy period. Post antibiotic effect, relapses, and resistance development are
examined. Antagonists, additives, or synergistic effects are also evaluated when the compound
is administered in combination with other active principles, as well as its capability to sterilize
lesions in experimentally infected animals. Finally, toxicological studies, which must be highly
controlled and documented, are carried out forthe determination of the safety window in order
to perform the subsequent clinical trials in humans [60].
The drugs regime must be administered for several months, using commonly between 100 –
150 mice per test, therefore requiring large amounts of space and resources for maintaining
the animals. Model in mice is more effective regarding the cost-benefit relation, and most of
the data obtained can be reproduced in clinical studies. The model of infection by TB in mice
has served to predict the sterilizing potential of new compounds, the effectiveness of the
combination of drugs, success in intermittent therapy and the duration of therapy necessary
to avoid relapse. The effectiveness of the active principle is measured mainly the reduction of
the colony forming units (CFU) in the lung and spleen. Several varieties of mice have been
used in laboratories conducting this type of test and, to this date, no comparisons have been
reported [61].
Genetically modified mice have been used in the in bioassay of compounds with anti-
mycobacterial activity [62]. A mouse that does not express the interferon-γ gene (knock-out)
is incapable of producing cytokine Th1 and therefore suffers a more acute infection. Bioassay
with this mouse allows determining the initial efficacy of a chemical compound in six days.
Because of their statistical power, substances with low antimycobacterial activity can be
detected by a small decrease in the CFU count. The model has great usefulness in initial trials,
when there is a limited amount of the chemical compound. Another model, still under
development, has been proposed to study relapse. An animal that cannot produce the
granulocyte-macrophage-colony stimulation factor (GM-CSF) is used.
Wayne’s model, which indicates the effect of compounds against persistent bacilli, has also
been used. Bacilli under anoxia conditions are used and they are directly inoculated in the
mouse. The guinea pig model also allows observing the destruction of tissue by caseous
necrosis where there is not oxygen contribution and bacteria go into a hypoxia state [61].
Pharmacokinetics and pharmacodynamics range from in vitro tests, in vivo tests in animal
models, and finally clinical trials in humans [57]. The simplest pharmacodynamic measure is
determining the MIC in vitro, used widely in the primary discovery of active principles. This
measure can be roughly related to the maximum cut point of the active principle concentration
in plasma (Cmax) and can aid in the prediction of in vivo pharmacodynamics among a series of
structurally related agents. However, it does not represent the concentration at which the
growth ceases, and, as we have already seen, does not allow distinguishing between bacteri‐
cide and bacteriostatic activity. Moreover, it does not allow obtaining information regarding
the dynamic relationships in vivo either, since the growth conditions do not represent the ones
of persistent organisms in the living tissue.
Animal models enable to evaluate the in vivo efficacy of novel active principles regimens.
Protection experiments using monotherapyfor a certain amount of time and then performing
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examined. Antagonists, additives, or synergistic effects are also evaluated when the compound
is administered in combination with other active principles, as well as its capability to sterilize
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Wayne’s model, which indicates the effect of compounds against persistent bacilli, has also
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determining the MIC in vitro, used widely in the primary discovery of active principles. This
measure can be roughly related to the maximum cut point of the active principle concentration
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the dynamic relationships in vivo either, since the growth conditions do not represent the ones
of persistent organisms in the living tissue.
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lethal intravenous or aerosol inoculation can prove the efficacy and selection of a preliminary
dose. Studies on the short term using colonies count in different homogenized organs allow
estimating the bactericide capability of a medication or a combination of drugs, as well as the
likely appearance of resistance [57]. However, in order to describe the sterilizing activity of a
given compound, a larger study time is required as well as other techniques since negative
cultures finalizing the therapy do not necessarily indicate that there was sterilization. Three
months are required after the end of treatment to determine a durable cure and success of the
sterilization. Cornell’s mouse model uses an intensive therapy in order to obtain negative cultures
and then evaluate the ability of individual active principles or their combinations to prevent
relapse when the mouse is left untreated or when it is maintained immunocompromised[57].
The following are the PK and PD parameters which are calculated in the trial with mice: the
C/MIC quotient, defined as the ratio of the serum maximum concentration (Cmax) over the MIC;
the AUC/MIC quotient, defined as the ratio of the area below the concentration-time curve
(AUC) over the MIC in the serum during the total time of treatment(144 h) divided by 6 in
order to obtain a daily value (AUC24/MIC); and the percentage of time above the MIC (T > MIC)
estimated by the first order kinetic equation C = C0 e-kt, where C0 is the concentration to time
0, k is the constant and t the time, and it is defined as the percentage of the 144-hour time in
which the medication concentration surpasses the MIC in the serum [63].
Recent studies of the PK and PD parameters for INH, RIF, and fluoroquinolones have
improved the understanding of PK and PD properties of these drugs. Although the PK and
PD parameters are characterized for antibacterial agents, a clear description of the efficacy is
still lacking [63]. The parameter that best describes the bactericidal activity of anti-TB drugs
in the mice model is AUC24 / MIC, with a correlation of 0.83. For INH when the value of
AUC24 / MIC reaches 500, the maximum effect is observed with a decrease of 1.3 log CFU per
mouse lung. In other words, the INH effect was the same when the total doses were admin‐
istered into 6, 12, or 18 doses divided equally during one week [63]. Mitchison observed that
the administration of a single total dose of INH in infected guinea pigs had the same effect
than if administered daily, every other day, or every four days during a six-week period.
Therefore, the efficacy of INHwas dependent on the size of the doses but not on the regime
[63]. Preclinical trials that establish pharmacodynamic and pharmacokinetic properties enable
to obtain information regarding the optimal doses and regimens.
Despite of the large use of the mouse model,this rodentdoes not develop the typical human
lesions observed in pulmonary TB such as caseous necrosis or cavitations[57]. Also, one has
to be very prudent conducting escalation in the doses of the agents between the mouse and
the human due to the metabolic differences and possible pharmacokinetic interactions. The
histological characteristics of guinea pigs in a TB infection are more similar to human pathol‐
ogy; but there is little experience in the chemotherapeutical use of this model. Preliminary
studies suggest that the guinea pig model is capable of differentiating the sterilizing activities
of INH and RIF [57].
A good model to study latent forms of TB is the cynomolgus macaque (Macacafascicularis) [61,
64]. All primates infected by bronchial instillation developed the infection, based on the
tuberculin test and immune responses to M. tuberculosis antigens. Differences in the progres‐
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sion of the disease for the 17 macaques studied were observed. Between 50 – 60% of infected
primates developed active and chronic infection, characterized by clear signs of disease in
thoracic x-rays and other tests. Approximately 40% of the initially infected macaques did not
develop the disease in the 20 months of study. These primates showed clinical signs of latent
TB. In summary, the study proves that it is possible to use the cynomolgus macaque in infection
by M. tuberculosis because it presents the complete spectrum of infection in humans (rapid and
lethal infection, chronic infection, and latent infection). This animal model is the only one that
enables to study the latent forms of the infection. Its great advantage is the high pathologic
similarity of the infection in macaques and humans, whereas the disadvantages are the cost
and maintenance of the animals, particularly since they require facilities with Biosafety Level
3 [64]. This model has been proposed in final preclinical trials for the development of active
principles for latent forms of TB [61].The following are examples of promising compounds in
preclinical phase. Some of these substances are protected by patents and therefore access to
information is restricted.
The following are examples of promising compounds in preclinical phase. Some of these
substances are protected by patents and therefore access to information is restricted.
SQ609 dipiperidine: this compound is a completely novel anti-TB active principle. It acts by
interrupting the biosynthesis ofcell wall, but its specific mechanism is unknown [5]. It
demonstratedantymycobacterial activity in anin vivo mouse model.
FAS20013 synthetase ATP inhibitor: Inhibition of bacterial fatty acids synthesis (FASII) still
represents a valid, target for the discovery of anti-TBdrugs. However, this novel compound
was identified by Fasgen and it has as action target the inhibition of enzymes for biosynthesis
of fatty acids in Mycobacterium [65]. It belongs to the β-sulfonylcarboxamides class.
Translocase inhibitors SQ641: The pharmaindustryis developing a series of translocase
inhibitors for the treatment of TB. The mycobacterial translocase I is an enzyme required for
the biosynthesis of the cell wall, and the SQ641 compound has been reported as a selective
inhibitor of this enzyme [66,67].
8.2. Clinical development of anti-TB active principles
Identifying new anti-TB is a complex and highly regulated process carried out around a critical
moment: when the new compound is tested in humans [5]. Currently, clinical images offer a
support method for generation of drugs which enables to establish information about the bio-
distribution of the molecule, interaction of the target, and pharmacokinetics[68]. Clinical
development of a promising substance is usually divided into four phases. The first phase is
carried out in healthy human beings and it provides information regarding the chemical
compound pharmacokinetic profile, and some preliminary information regarding safety [69].
Phase I trials are conducted in a small size, usually 15 to 30 subjects, and can be of single or
multiple doses. Besides the phase I trials, researchers may consider incorporating the phar‐
macokinetics and safety studies to a wider population size (200 to 300 subjects). Phase II studies
are conducted on patients diagnosed with active TB. The efficacy in monotherapy and
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C/MIC quotient, defined as the ratio of the serum maximum concentration (Cmax) over the MIC;
the AUC/MIC quotient, defined as the ratio of the area below the concentration-time curve
(AUC) over the MIC in the serum during the total time of treatment(144 h) divided by 6 in
order to obtain a daily value (AUC24/MIC); and the percentage of time above the MIC (T > MIC)
estimated by the first order kinetic equation C = C0 e-kt, where C0 is the concentration to time
0, k is the constant and t the time, and it is defined as the percentage of the 144-hour time in
which the medication concentration surpasses the MIC in the serum [63].
Recent studies of the PK and PD parameters for INH, RIF, and fluoroquinolones have
improved the understanding of PK and PD properties of these drugs. Although the PK and
PD parameters are characterized for antibacterial agents, a clear description of the efficacy is
still lacking [63]. The parameter that best describes the bactericidal activity of anti-TB drugs
in the mice model is AUC24 / MIC, with a correlation of 0.83. For INH when the value of
AUC24 / MIC reaches 500, the maximum effect is observed with a decrease of 1.3 log CFU per
mouse lung. In other words, the INH effect was the same when the total doses were admin‐
istered into 6, 12, or 18 doses divided equally during one week [63]. Mitchison observed that
the administration of a single total dose of INH in infected guinea pigs had the same effect
than if administered daily, every other day, or every four days during a six-week period.
Therefore, the efficacy of INHwas dependent on the size of the doses but not on the regime
[63]. Preclinical trials that establish pharmacodynamic and pharmacokinetic properties enable
to obtain information regarding the optimal doses and regimens.
Despite of the large use of the mouse model,this rodentdoes not develop the typical human
lesions observed in pulmonary TB such as caseous necrosis or cavitations[57]. Also, one has
to be very prudent conducting escalation in the doses of the agents between the mouse and
the human due to the metabolic differences and possible pharmacokinetic interactions. The
histological characteristics of guinea pigs in a TB infection are more similar to human pathol‐
ogy; but there is little experience in the chemotherapeutical use of this model. Preliminary
studies suggest that the guinea pig model is capable of differentiating the sterilizing activities
of INH and RIF [57].
A good model to study latent forms of TB is the cynomolgus macaque (Macacafascicularis) [61,
64]. All primates infected by bronchial instillation developed the infection, based on the
tuberculin test and immune responses to M. tuberculosis antigens. Differences in the progres‐
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sion of the disease for the 17 macaques studied were observed. Between 50 – 60% of infected
primates developed active and chronic infection, characterized by clear signs of disease in
thoracic x-rays and other tests. Approximately 40% of the initially infected macaques did not
develop the disease in the 20 months of study. These primates showed clinical signs of latent
TB. In summary, the study proves that it is possible to use the cynomolgus macaque in infection
by M. tuberculosis because it presents the complete spectrum of infection in humans (rapid and
lethal infection, chronic infection, and latent infection). This animal model is the only one that
enables to study the latent forms of the infection. Its great advantage is the high pathologic
similarity of the infection in macaques and humans, whereas the disadvantages are the cost
and maintenance of the animals, particularly since they require facilities with Biosafety Level
3 [64]. This model has been proposed in final preclinical trials for the development of active
principles for latent forms of TB [61].The following are examples of promising compounds in
preclinical phase. Some of these substances are protected by patents and therefore access to
information is restricted.
The following are examples of promising compounds in preclinical phase. Some of these
substances are protected by patents and therefore access to information is restricted.
SQ609 dipiperidine: this compound is a completely novel anti-TB active principle. It acts by
interrupting the biosynthesis ofcell wall, but its specific mechanism is unknown [5]. It
demonstratedantymycobacterial activity in anin vivo mouse model.
FAS20013 synthetase ATP inhibitor: Inhibition of bacterial fatty acids synthesis (FASII) still
represents a valid, target for the discovery of anti-TBdrugs. However, this novel compound
was identified by Fasgen and it has as action target the inhibition of enzymes for biosynthesis
of fatty acids in Mycobacterium [65]. It belongs to the β-sulfonylcarboxamides class.
Translocase inhibitors SQ641: The pharmaindustryis developing a series of translocase
inhibitors for the treatment of TB. The mycobacterial translocase I is an enzyme required for
the biosynthesis of the cell wall, and the SQ641 compound has been reported as a selective
inhibitor of this enzyme [66,67].
8.2. Clinical development of anti-TB active principles
Identifying new anti-TB is a complex and highly regulated process carried out around a critical
moment: when the new compound is tested in humans [5]. Currently, clinical images offer a
support method for generation of drugs which enables to establish information about the bio-
distribution of the molecule, interaction of the target, and pharmacokinetics[68]. Clinical
development of a promising substance is usually divided into four phases. The first phase is
carried out in healthy human beings and it provides information regarding the chemical
compound pharmacokinetic profile, and some preliminary information regarding safety [69].
Phase I trials are conducted in a small size, usually 15 to 30 subjects, and can be of single or
multiple doses. Besides the phase I trials, researchers may consider incorporating the phar‐
macokinetics and safety studies to a wider population size (200 to 300 subjects). Phase II studies
are conducted on patients diagnosed with active TB. The efficacy in monotherapy and
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combination therapy is evaluated. One of the objectives of trials in phase I/II is to determine
the optimal dose for the phase III studies.
Early Bactericidal Activity (EBA) is one of the fundamental parameters to determine the clinical
efficacy of active principles [70]. It consists on a large trial conducted on patients recently
diagnosed with pulmonary TB who are treated with active principles or combinations for a
period of 2 to 14 days. Patients must not have used anti-TB drugs previously. During the
treatment period, the amount of viable bacilli appearing in sputum samples is determined
quantitatively. The traditional EBA unit is the logarithmic decrease of colony forming units
(CFU/mL sputum/day during the first 48 hours). EBA studies have shown that there are
differences between the fall of viable bacteria counts in the first two days of treatment in
comparison with the following twelve [71]. Differences among several treatments were also
more significant during the first two days. In the early therapy, the activity of INH was superior
and dominant regarding the other active principles administered in combination. Any
addition of INH to a regime leads to an increase of EBA but never higher than INH on its own.
The addition of PZA to a regime of STR, INH, and RIF increased 0-2 days EBA from 0.415 to
0.472 [71]. The greatest disadvantage of determining the EBA is its inability to detect sterilizing
activity. Some researchers have concluded that extended EBA trials (2 to 14 days) do not
correlate to the sterilizing activity [72]. For example, the potent sterilizing activity of PZA was
not detected in an extended EBA trial. STR showed potent activity in extended EBA, and it is
known it has a very low sterilizing activity in randomized clinical trials. In extended EBA,
EMB appears as antagonist; however, there is no clinical evidence that this drug interferes with
the sterilizing effects of RIF and PZA [72].
In order to determine the sterilizing activity of the anti-TB active principles, and 8-week study
has been proposed, and the ratio of patients whose sputum be negative is determined; this
parameter correlates to the ratio of patients who suffer relapse after the treatment [73]. In these
studies, frequent counts of the number of viable bacilli are carried out being known as “serial
sputum CFU counts” or SSCC. This method enables to distinguish between differences in the
organisms that divide rapidly from the persistent ones.These studies turn out to be appropriate
to determine the possibility of a regime to decrease the time of treatment [73].
Phase III clinical trials are carried out at large scale; they are randomized and they are
conducted to demonstrate the improved or equivalent efficacy of a new treatment against
standard treatments [60]. Around 1000 patients are enrolled per study for TB and the cure on
treated patients is bacteriologically observed during certain amount of time as well as the ratio
of relapse. The accepted end point to demonstrate efficacy is 2 years. The experimental design
of Phase III trials must be designed cautiously clearly definingcritical primary and secondary
end points, the size of the sample, the intervalsof confidence, and the statistical methods that
will be used to obtain the data [60]. It is fundamental that microbiologic assessments are being
conducted during an appropriate time, with the aim of determining the real activity of the
researched agent. To ensure a sufficient population in Phase III studies, trials may be conducted
in countries with high incidence rate of TB. Countries possessing a robust and expansive TB
control program that provides essential information such as annual incidence (location of the
disease, comorbility, resistance) are preferred. A reference laboratory is required for most of
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the trials, but there is also need to extend duplicates to local laboratories. Finally, validated
relapse markers, which provide evidence of the sterilizing activity of an active principle or
regime, are used. To this end, the most used method is determining the ratio of patients who
have a negative sputum culture, 8 weeks after the beginning of the treatment compared to the
standard treatment. Molecular methods using relapse markers require greater study and
validation in order to be employed successfully [60].
Phase IV studies include product development efforts such as patents, description of biologic
activity, toxicity, safety profile in humans and demonstrated clinical efficacy. Best manufac‐
turing practices studies are conducted, as well as laboratory and clinical practice to ensure the
marketing needs of the product. Post-marketing studies duringPhase IV are typically assess‐
ment of new regimens in comparison to thenormally used, and surveillance of likely adverse
effects, including the development of resistance. The acceptance for use of the new active
principle must be subscribed by the patient, and the economic benefits of the new drug must
also be established [60].
SQ109 diamine: The lead was identified in a screening conducted in 2003 using a combinatory
library based on EMB as pharmacophore. It shows an MIC value of 0.11 μg/ml. t remains
equally active as EMB at 100 mg/kg when administered in the mouse model at a dose of 1 mg/
kg. However, SQ109 did not increase its effectiveness at higher doses (10 mg/kg, 25 mg/kg)
and it was clearly less effective than INH[5]. Its effectiveness has been proved against MDR
Figure 5. Pharmacological activity of RIF, INH and PZA targeting M. tuberculosis subpopulations. Differential
population of M. tuberculosis in the lesions, observed after 6 months of treatment.as log CFU in sputum
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sputum CFU counts” or SSCC. This method enables to distinguish between differences in the
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to determine the possibility of a regime to decrease the time of treatment [73].
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conducted to demonstrate the improved or equivalent efficacy of a new treatment against
standard treatments [60]. Around 1000 patients are enrolled per study for TB and the cure on
treated patients is bacteriologically observed during certain amount of time as well as the ratio
of relapse. The accepted end point to demonstrate efficacy is 2 years. The experimental design
of Phase III trials must be designed cautiously clearly definingcritical primary and secondary
end points, the size of the sample, the intervalsof confidence, and the statistical methods that
will be used to obtain the data [60]. It is fundamental that microbiologic assessments are being
conducted during an appropriate time, with the aim of determining the real activity of the
researched agent. To ensure a sufficient population in Phase III studies, trials may be conducted
in countries with high incidence rate of TB. Countries possessing a robust and expansive TB
control program that provides essential information such as annual incidence (location of the
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Tuberculosis - Current Issues in Diagnosis and Management346
the trials, but there is also need to extend duplicates to local laboratories. Finally, validated
relapse markers, which provide evidence of the sterilizing activity of an active principle or
regime, are used. To this end, the most used method is determining the ratio of patients who
have a negative sputum culture, 8 weeks after the beginning of the treatment compared to the
standard treatment. Molecular methods using relapse markers require greater study and
validation in order to be employed successfully [60].
Phase IV studies include product development efforts such as patents, description of biologic
activity, toxicity, safety profile in humans and demonstrated clinical efficacy. Best manufac‐
turing practices studies are conducted, as well as laboratory and clinical practice to ensure the
marketing needs of the product. Post-marketing studies duringPhase IV are typically assess‐
ment of new regimens in comparison to thenormally used, and surveillance of likely adverse
effects, including the development of resistance. The acceptance for use of the new active
principle must be subscribed by the patient, and the economic benefits of the new drug must
also be established [60].
SQ109 diamine: The lead was identified in a screening conducted in 2003 using a combinatory
library based on EMB as pharmacophore. It shows an MIC value of 0.11 μg/ml. t remains
equally active as EMB at 100 mg/kg when administered in the mouse model at a dose of 1 mg/
kg. However, SQ109 did not increase its effectiveness at higher doses (10 mg/kg, 25 mg/kg)
and it was clearly less effective than INH[5]. Its effectiveness has been proved against MDR
Figure 5. Pharmacological activity of RIF, INH and PZA targeting M. tuberculosis subpopulations. Differential
population of M. tuberculosis in the lesions, observed after 6 months of treatment.as log CFU in sputum
Research and Development of New Drugs Against Tuberculosis
http://dx.doi.org/10.5772/54278
347
strains. Preclinical toxicology studies have been completed and further phase II clinical studies
are underway [67].
TMC-207 diarylquinoline: This agent is a promising agent as a new kind of antimycobacterial
agent. Twenty diarylquinolines have been reported on the series with MIC lower than 0.5 mg/L
against H37Rv. Antimycobacterial activity was confirmed in vivo for three compounds of this
class. The most effective agent was TMC-207, which had a MIC of 0.06 mg/L against H37Rv and
its spectrum was unique in specificity against mycobacteria [74]. TMC-207 inhibits the ATP
synthetase leading to a decrease of ATP and a pH imbalance. This compound has a potent EBA
in the murine infection model, superior or similar to INH. The combinations TMC-207, INH,
and PZA cleansed the bacilli present in the lungs of all mice after two months. Trials have also
been conducted in mice with combinations of second line agents. Preliminary studies have
proved in vivo sterilizing activity in the mice model, and decrease in the treatment time. Currently
it is in phase IIa. Therefore, it is the most promising drug candidate in the last 30 years.
Gatifloxacin: It has been reported bactericidal activity in vitro and in vivo against M. tubercu‐
losis to this compound. Its MIC has been reported between 0.25 mg/L and 0.03 mg/L against
H37Rv [76]. In an in vitro study on bacilli in stationary phase, gatifloxacin showed the greatest
bactericidal activity in the first two days, but none afterwards. In mice studies, the combination
of gatifloxacin with EMB and PZA cleansed the lungs of infected animals after two months of
treatment. Currently, gatifloxacin is under phase III to prove the efficacy and safety of a four-
month regime for the treatment of pulmonary TB supervised by the European Commission
Oflotub Consortium, WHO-TDR, Tuberculosis Research Unit (TBRU), National Institute of
Allergy and Infectious Diseases (NIAID), Tuberculosis Research Centre [5,67].
Moxifloxacin: Moxifloxacin is the most promising fluorquinolone against M. tuberculosis. Its
activity in vitro seems to affect bacilli unaffected by RIF. Its MIC reported in vitro is 0.5 mg/L
[77]. It seems that moxifloxacin interferes with the protein synthesis on bacteria with low
metabolic activity by a mechanism different to the one of RIF. However, the specific action
mechanism is unknown. In the mouse model, the effectiveness of moxifloxacin is comparable
to INH. When administered in combination with PZA, moxifloxacin has a greater bactericidal
activity tan the INH + RIF + PZA regime. In fact, the combination RIF + moxifloxacin + PZA
decreases completely bacilli count within four months, whereas the combination RIF + INH +
PZA requires 6 months. It is likely that there is synergism among the three drugs, and the
alternative regime replacing INH by moxifloxacin has been proposed. Moxifloxacin is under
phase III [67]. Clinical studies have not proved a greater sterilizing activity of a regime
containing moxifloxacin in comparison with the standard regime; however, it has increased
activity in early points [5,75].
Nitroimidazole PA-824: This bicyclical nitroimidazole is under development by the TB
Alliance, which has the proprietary rights. The in vitro MIC of the PA-824 compound is between
0.15 and 0.3 μg/ml [78].After an activation by the F420 factor of M. tuberculosis, the PA-824
compound inhibits biosynthesis of the cell wall components by means of mechanisms still to
be established. It has proved bactericidal activity against replicative and static bacilli in vitro.
Although PA-824 was more efficient than INH or moxifloxacin, during the continuation phase
it was not better than the RIF + INHH combination. On the long term, the 12-month treatment
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did not achieve total eradication in any of the mice treated. The 6-month regime of PA-824 in
combination with RIF, INH, and PZA in mice proved to be superior to the standard regime
regarding quickness of eradication and lower relapse rate. This compound has been widely
evaluated in animals and humans; currently it is under phase II clinical trials as part of an
initial scheme (PA-824, moxifloxacin, and PZA) containing new anti-TB drugs[79].
Nitroimidazole-oxazol OPC67683:There is very little public information regarding this
compound. It belongs to a subclass of mycolic acids synthesis inhibitors. It has shown in
vitro activity against standard and resistant strains, showing a MICof 12 ng/ml [80]. It has not
shown cross resistance with any other medication. The compound shown activity against
bacilli residing within human macrophages and type II pneumocytes. The chronic TB trial in
mice demonstrated an activity 6 – 7 times more effective than the one observed for first line
INH and RIFdrugs. Favorable oral absorption and distribution have been reported. Currently
it is under phase II clinical trials.
Pyrrole LL-3858: Some pyrroles derivatives have been found to have in vitro activity against
M. tuberculosis. The MIC of pyrrole LL-3858 is between 0.025 and 0.12 μg/ml. The LL-3858
derivate identified by Lupin Limited showed greater bactericidal activity in the lungs of mice
infected in monotherapy than INH. The trial of LL-3858 in combination with INH and RIF, or
with INH, RIF, and PZA sterilized the totality of mice in 3 months [5]. Currently, the compound
is under phase II clinical trials [67].
8.3. New approaches for the development of anti-TB active principles
In the dawn of the 21st century, pathogenesis of the infectious disease appears as a competition
between the host and the pathogen involving short term adaptations and co evolution of the
genomes [81]. The pathogen and the host constantly exercise selective pressure over each other,
making the environment in test tube completely different from that within the host.
In latent tuberculous infection (LTBI), most of bacilli are not replicating, whereas in a phase of
active disease most of the population is on active growth. Chemotherapy must take this
metabolic adversity to favor the host.A durable cure must eliminate both the replicative and
the persistent bacilli.Eradication of the persistent bacilli onchemotherapylasting between 6 –
24 months has been proposed in order to avoid relapse. However, such a long treatment is
difficult to sustain and there is always resistance-associated risks in interrupted regimens
[81].A philosophy of mycobacterial infection states that the essential genes for infection in mice
include genes that are not essential in vitro.
The proteasome of M. tuberculosis is a set of proteins that provide a quick adaptation to
changing conditions [82]. Two genes, mpa (Mycobacterium proteosomal ATPase) and pafA
(proteasome accessory factor) were identified as important in the survival of M. tuberculosisto
exposure against reactive nitrogen species (RNS) in vitro and required for active disease in
vivo [82]. These genes codify for proteins involved in the bacteria proteasomal function.
Proteasomes are barrel-shaped proteases consisting of 14 α units and 14 β units [82]. Mpa is
similar to ATPases found in the proteosome of eukaryotes cells, and chemical inhibition of the
protease activity of the M. tuberculosis proteosome causes sensitization of the wild strain to
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compound inhibits biosynthesis of the cell wall components by means of mechanisms still to
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In the dawn of the 21st century, pathogenesis of the infectious disease appears as a competition
between the host and the pathogen involving short term adaptations and co evolution of the
genomes [81]. The pathogen and the host constantly exercise selective pressure over each other,
making the environment in test tube completely different from that within the host.
In latent tuberculous infection (LTBI), most of bacilli are not replicating, whereas in a phase of
active disease most of the population is on active growth. Chemotherapy must take this
metabolic adversity to favor the host.A durable cure must eliminate both the replicative and
the persistent bacilli.Eradication of the persistent bacilli onchemotherapylasting between 6 –
24 months has been proposed in order to avoid relapse. However, such a long treatment is
difficult to sustain and there is always resistance-associated risks in interrupted regimens
[81].A philosophy of mycobacterial infection states that the essential genes for infection in mice
include genes that are not essential in vitro.
The proteasome of M. tuberculosis is a set of proteins that provide a quick adaptation to
changing conditions [82]. Two genes, mpa (Mycobacterium proteosomal ATPase) and pafA
(proteasome accessory factor) were identified as important in the survival of M. tuberculosisto
exposure against reactive nitrogen species (RNS) in vitro and required for active disease in
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reactive nitrogen species (RNS). The PafA protein does not share homology with any protein
of known function [82]. Two specific proteasomeinhibitors, epoxomicin and a peptidic-
boronate prevented the growth of M. tuberculosis and turned out to be bactericidal during the
recovery of the mycobacterium against exposure to RNS [81]. The operon that codifies for the
proteasome was knocked out by using conditional gene silencing and it was proved that
bacteria require it to survive during the chronic infection in mice and its silencing allowed the
mouse to be free of the persistent infection [83]. Whereas the proteasome of the mycobacterium
is essential for the infection of a host, it is not required to grow in a rich and aerated medium
such as Middlebrook 7H9 broth [81].
Unlike other bacteria, M. tuberculosis possesses a unique defense system that relates the
antioxidant and metabolic activities [81]. The system includes a peroxyredoxin, the C subunit
of an alkylhydroperoxy-reductase (AhpC), a thioredoxin type protein (AhpD), dihydrolipoa‐
mideacyltransferase (DlaT), and lipoamide dehydrogenase (Lpd), and the four enzymes
together work as peroxydases and peroxynitroreductases and peroxynitroreductasesdepend‐
ant of NADH [81]. The dual functionality of these enzymes is interesting as potential targets
for the development of anti-TB active principles.
Moreover, the DosRsystem,discovered 15 years ago, regulates the development of a form of non-
eplicative survival without morphologic differentiation in M. tuberculosis (known as latency
state). This state of physiologic quiescence maintained viable the microorganism for long periods
of time, contributing with two key characteristicsof TB: the symptom-free latent infection state
and the persistence of the active disease of the tubercular infection in spite of the prolonged
therapy time. Due to the importance of the bacilli latency state in the pathophysiology and
chemotherapy of the disease, researchers have set their interest in the DosR system. Drugs that
attack the latent state of the bacterium not only would be the key for eradication of the latent
infection, but also shortening the time of treatment of active infection [84].
9. A new approach to research processes
Traditionally, the focus of research is the evaluation of a single drugin extensive and costly
trials. This process may take a lot of time and reduces the possibility of developing a combi‐
nation of new drugs that is effective. For this reason, a new approach to research has been led
by the Critical Path to TB Drug Regimens (CPTR) organization created in March 2010 by the
Bill & Melinda Gates Foundations, the Critical Path Institute, and the TB Alliance. This strategic
partnership has the strength of reducing the time necessary to develop a new TB treatment
scheme, as well as reducing significantly the research costs. This initiative has been endorsed
by the US Food and Drug Administration and other regulatory entities, as well as the World
Health Organization [67].
As a result of the 41st Union World Conference in Berlin, Germany, on November 2010, the
TB Alliance announced the launch of the first clinical phase to test a new TB treatment scheme
which expedites the treatment of patients. The combination of three drugs has been promising
for the treatment of drug sensitive (DS-TB) and MDR-TB, thus changing the course of the TB
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pandemics through simplification and shortening in the treatment time of the disease world‐
wide. The combination is currently in phase II of clinical trials and contains PA-824 and
moxifloxacin together with PZA. Researchers have reported that preclinical data reveal a
decrease in the treatment time both for DS-TB and MDR-TB patients, and possibly XDR-TB
ones with a simple three-drug treatment scheme [67].
10. Nano-particles: A projection towards the future
Nanoparticles can create new directions in the diagnosis, treatment, and prevention of TB. A
significant application in the progress of this technology is using drug carriers.This system has
been found to be advantageous, as it gives high stability of the drug, high load capacity (many
molecules of the medication can be incorporated in the matrix of the particle), easiness to
incorporate hydrophilic and hydrophobic substances, possibility of being administered orally
or via inhalation. Perhaps more importantly, the anti-TB drug release in a controlled manner
from the matrix enables to improve the bioavailability and reduction of the doses frequency.
Load or delivery systems such as liposome or microspheres have been developed for the
sustained release of anti-TB drugs, and better chemotherapeutical efficacy has been found
when the system is researched in animal models (e.g. mice) [85,86].In 2005, the efficacy of
nanoparticles was assessed in the distribution of anti-TBdrugs administered every 10 days
versus the non capsulated form of aerosol administration of drugs against M. tuberculosis in
guinea pigs; in both cases the treatments reduced the bacteria count. These findings suggest
that the distribution of drugs by nanoparticles has a great potential in the treatment of TB [86].
11. Conclusions
Currently, devastating diseases in the world such as tuberculosis get the attention of author‐
ities with the aim of supporting breakthroughs which provide alternatives for their control.
The development of active principles against M. tuberculosis is nowadays a worldwide priority
due to the appearance of strains resistant to medications used in current therapeutic schemes,
thus existing the need to articulate in an expedite manner the basic research looking for new
therapeutic choices, along with clinical research and its articulation with the industry in order
to guarantee a quick production of novel alternatives which overcome the limitations of
current treatment schemes.
The concern in many sectors devoted to tuberculosis control is that there are not sufficient
alternatives that can join rapidly the treatment against tuberculosis, and they convey discour‐
aging estimations regarding the degree of resistance that each one of these molecules will have
at the moment of entering the therapeutic scheme deduced from natural resistant bacilli. These
justifications have promoted research around the world towards finding new molecules, based
on investigations of natural sources such as plants, insects, marine microorganisms, synthetic
molecules deduced from the modification or substitutions made on the structure of already
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reactive nitrogen species (RNS). The PafA protein does not share homology with any protein
of known function [82]. Two specific proteasomeinhibitors, epoxomicin and a peptidic-
boronate prevented the growth of M. tuberculosis and turned out to be bactericidal during the
recovery of the mycobacterium against exposure to RNS [81]. The operon that codifies for the
proteasome was knocked out by using conditional gene silencing and it was proved that
bacteria require it to survive during the chronic infection in mice and its silencing allowed the
mouse to be free of the persistent infection [83]. Whereas the proteasome of the mycobacterium
is essential for the infection of a host, it is not required to grow in a rich and aerated medium
such as Middlebrook 7H9 broth [81].
Unlike other bacteria, M. tuberculosis possesses a unique defense system that relates the
antioxidant and metabolic activities [81]. The system includes a peroxyredoxin, the C subunit
of an alkylhydroperoxy-reductase (AhpC), a thioredoxin type protein (AhpD), dihydrolipoa‐
mideacyltransferase (DlaT), and lipoamide dehydrogenase (Lpd), and the four enzymes
together work as peroxydases and peroxynitroreductases and peroxynitroreductasesdepend‐
ant of NADH [81]. The dual functionality of these enzymes is interesting as potential targets
for the development of anti-TB active principles.
Moreover, the DosRsystem,discovered 15 years ago, regulates the development of a form of non-
eplicative survival without morphologic differentiation in M. tuberculosis (known as latency
state). This state of physiologic quiescence maintained viable the microorganism for long periods
of time, contributing with two key characteristicsof TB: the symptom-free latent infection state
and the persistence of the active disease of the tubercular infection in spite of the prolonged
therapy time. Due to the importance of the bacilli latency state in the pathophysiology and
chemotherapy of the disease, researchers have set their interest in the DosR system. Drugs that
attack the latent state of the bacterium not only would be the key for eradication of the latent
infection, but also shortening the time of treatment of active infection [84].
9. A new approach to research processes
Traditionally, the focus of research is the evaluation of a single drugin extensive and costly
trials. This process may take a lot of time and reduces the possibility of developing a combi‐
nation of new drugs that is effective. For this reason, a new approach to research has been led
by the Critical Path to TB Drug Regimens (CPTR) organization created in March 2010 by the
Bill & Melinda Gates Foundations, the Critical Path Institute, and the TB Alliance. This strategic
partnership has the strength of reducing the time necessary to develop a new TB treatment
scheme, as well as reducing significantly the research costs. This initiative has been endorsed
by the US Food and Drug Administration and other regulatory entities, as well as the World
Health Organization [67].
As a result of the 41st Union World Conference in Berlin, Germany, on November 2010, the
TB Alliance announced the launch of the first clinical phase to test a new TB treatment scheme
which expedites the treatment of patients. The combination of three drugs has been promising
for the treatment of drug sensitive (DS-TB) and MDR-TB, thus changing the course of the TB
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pandemics through simplification and shortening in the treatment time of the disease world‐
wide. The combination is currently in phase II of clinical trials and contains PA-824 and
moxifloxacin together with PZA. Researchers have reported that preclinical data reveal a
decrease in the treatment time both for DS-TB and MDR-TB patients, and possibly XDR-TB
ones with a simple three-drug treatment scheme [67].
10. Nano-particles: A projection towards the future
Nanoparticles can create new directions in the diagnosis, treatment, and prevention of TB. A
significant application in the progress of this technology is using drug carriers.This system has
been found to be advantageous, as it gives high stability of the drug, high load capacity (many
molecules of the medication can be incorporated in the matrix of the particle), easiness to
incorporate hydrophilic and hydrophobic substances, possibility of being administered orally
or via inhalation. Perhaps more importantly, the anti-TB drug release in a controlled manner
from the matrix enables to improve the bioavailability and reduction of the doses frequency.
Load or delivery systems such as liposome or microspheres have been developed for the
sustained release of anti-TB drugs, and better chemotherapeutical efficacy has been found
when the system is researched in animal models (e.g. mice) [85,86].In 2005, the efficacy of
nanoparticles was assessed in the distribution of anti-TBdrugs administered every 10 days
versus the non capsulated form of aerosol administration of drugs against M. tuberculosis in
guinea pigs; in both cases the treatments reduced the bacteria count. These findings suggest
that the distribution of drugs by nanoparticles has a great potential in the treatment of TB [86].
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to guarantee a quick production of novel alternatives which overcome the limitations of
current treatment schemes.
The concern in many sectors devoted to tuberculosis control is that there are not sufficient
alternatives that can join rapidly the treatment against tuberculosis, and they convey discour‐
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existing molecules with the aim of potentiate their effect; or from new sources such as
nanoparticles, computing studies, among many others.
The results expected at the end of each process producing a new alternative of treatment
against tuberculosis is that these drugs may shorten the duration of the current treatment, be
active against resistant strains and non-replicative conditions of M. tuberculosis as well as not
interfering with HIV antiretroviral therapy, reduce adverse side effects, and that it is of easy
administration to facilitate the patient’s compliance. For the management of tuberculosis as a
public health event worldwide, these new drugs must be produced easily in large amounts;
they must be stable under minimum storage conditions, and they must be of low cost so that
all governments may guarantee access of all the diseased population.
For these expectations to become true in the short term, more basic and applied research is
required to generate new ideas in the development of anti-tuberculosis drugs, as well as
stronger financial support in research and greater commitment from the pharmaceutical
industry and public health entities.
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1. Introduction
Since its creation in the middle of the 20th century, the Internet has become the universal
language of the digital world. All the capabilities it offers, such as electronic mail systems,
information distribution, file sharing, multimedia streaming services and online social
networking, have already been of service to billions of people around the world. In fact, if the
Internet were to disappear tomorrow, most people would struggle to manage their lives
without it.
By providing millions of people with information that is constantly updated (24 hours a day,
seven days a week) Internet has become the second source of information for the whole world,
television still being the first one in most countries. It has also provided a unique way of
communication, where a person in an isolated geographical location can instantly be in touch
with thousands and maybe millions of other individuals around the world.
Scientists were among the first ones to explore all these capabilities. Now, we talk about data
mining, terabytes and petabytes, algorithms – terms related to what we call “Big Data”, the
large volume of information generated by a variety of new technologies, ranging from
Astronomy (telescope data), the Internet itself (more and more Facebook users every day) to
Biology (cheaper and more efficient DNA sequencing technologies), among other areas of
study and research. Some technologies and experiments, like the Large Hadron Collider at
CERN, Switzerland (perhaps the most important scientific tool ever built), produce an
incredible volume of information, on the order of terabytes per second.
Databases containing DNA and protein sequences were created; institutions around the world
developed websites to expose their work to the world; scientific magazines started their online
versions. The world is connected as never before. This connection transcend the virtual realm
© 2013 Catanho and de Miranda; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
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of the Internet: today, it is possible to travel from one side of the world to the other in just one
day. Unfortunately, this has presented us a negative side: infectious agents may also cross the
world in just about the same time.
Tuberculosis is a global disease, with an estimated one-third of all people in the world
contaminated by the bacillus, Mycobacterium tuberculosis. Although treatable, the large period
of treatment (many abandon the therapy as soon as they feel better) together with the indis‐
criminate use of antibiotics is causing the spread of new, drug-resistant strains. Actually, as
those familiar with epidemiology have already noticed, that is a remarkable similarity between
the patterns of an epidemic or outbreak with the spread of a new piece of information
throughout the internet.
However, there has also been a revolution in other areas: new high-throughput technologies,
like genomics, transcriptomics and proteomics, offer a new, more integrated view of the
metabolism and genetics of the organism studied, and of course M. tuberculosis was among the
first to have its genome sequenced. Today, more than 30 different strains have been sequenced,
as well as other organisms from the Mycobacterium genus. By comparing the genomes of
virulent and non-virulent strains of TB, scientists may pinpoint particular genes and/or
polymorphisms involved in this process; by examining transcriptome data, researchers may
have an idea of the effects of a given drug in the bacillus’ metabolism.
The purpose of this chapter is by no means to offer an exhaustive list of all the resources
available on the Internet about TB, the topic of this book. This would be a massive and perhaps
futile work, since the evolution of the internet occurs at a very fast pace. Rather, this chapter
concentrates on a selection of the most important, relevant and stable websites with relevance
to several aspects of TB, such as research, treatment, main Institutions, funding, and special‐
ized platforms. We think this should complement all the other information already presented
in this book, offering the reader a more integrated view of the disease, and also access to new
platforms and systems specialized in the analysis of data generated by a series of new
technologies such as DNA sequencing.
2. Tuberculosis facts information and treatment research
Most of the selected sites presented in this section have information about several aspects of
TB, like history, epidemiology, transmission and pathogenesis, diagnosis, treatment, infection
control, besides offering other services such as courses, guidelines, fact sheets and links to
related sites. We have chosen an alphabetical classification to avoid conveying a false impres‐
sion of importance to some sites in detriment of others. In fact, we think that every effort is
worthy in this global battle against this terrible disease.
Centers for Disease Control and Prevention. The mission of the Division of Tuberculosis
Elimination (DTBE) is to promote health and quality of life by preventing, controlling, and
eventually eliminating tuberculosis from the United States, and by collaborating with other
countries and international partners in controlling global tuberculosis. URL: <http://
www.cdc.gov/tb/>
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Global Tuberculosis Institute. Located at the New Jersey Medical School, the institute
provides expertise in program development, education, training and research to ministers of




American Lung Association (ALA) Lung
Disease Programs
http://www.lung.org/
American Public Health Association http://www.apha.org/
Bill & Melinda Gates Foundation http://www.gatesfoundation.org/
CREATE: Consortium to Respond to the
AIDS/TB Epidemic
http://www.tbhiv-create.org/
Food and Drug Administration (FDA) http://www.fda.gov/default.htm
Institute for Tuberculosis Research http://www.tuberculosisdrugresearch.org/
National Institute of Allergy and Infectious
Diseases (NIAID)
http://www.niaid.nih.gov/
National Library of Medicine, PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
Tuberculosis Net http://tuberculosis.net/
Africa
AllAfrica.com: TB News from Africa http://allafrica.com/tuberculosis/
Desmond Tutu TB Centre
http://sun025.sun.ac.za/portal/page/portal/
Health_Sciences/English/Centres/dttc
South African Tuberculosis Vaccine Initiative http://www.satvi.uct.ac.za/
Asia and
Oceania
JATA - Research Institute of Tuberculosis http://www.jata.or.jp/eindex/home.html
National Institute for Research in Tuberculosis http://www.trc-chennai.org/
Pakistan Anti TB Association http://www.patba.org/
TBC India http://www.tbcindia.nic.in/
Europe





International Union Against Tuberculosis and
Lung Disease (UNION)
http://www.theunion.org/
Max Planck Institute for Infection Biology http://www.mpiib-berlin.mpg.de/
Pasteur Institute http://www.pasteur.fr
Table 1. Additional websites covering tuberculosis facts information and treatment research
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2. Tuberculosis facts information and treatment research
Most of the selected sites presented in this section have information about several aspects of
TB, like history, epidemiology, transmission and pathogenesis, diagnosis, treatment, infection
control, besides offering other services such as courses, guidelines, fact sheets and links to
related sites. We have chosen an alphabetical classification to avoid conveying a false impres‐
sion of importance to some sites in detriment of others. In fact, we think that every effort is
worthy in this global battle against this terrible disease.
Centers for Disease Control and Prevention. The mission of the Division of Tuberculosis
Elimination (DTBE) is to promote health and quality of life by preventing, controlling, and
eventually eliminating tuberculosis from the United States, and by collaborating with other
countries and international partners in controlling global tuberculosis. URL: <http://
www.cdc.gov/tb/>
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Global Tuberculosis Institute. Located at the New Jersey Medical School, the institute
provides expertise in program development, education, training and research to ministers of




American Lung Association (ALA) Lung
Disease Programs
http://www.lung.org/
American Public Health Association http://www.apha.org/
Bill & Melinda Gates Foundation http://www.gatesfoundation.org/
CREATE: Consortium to Respond to the
AIDS/TB Epidemic
http://www.tbhiv-create.org/
Food and Drug Administration (FDA) http://www.fda.gov/default.htm
Institute for Tuberculosis Research http://www.tuberculosisdrugresearch.org/
National Institute of Allergy and Infectious
Diseases (NIAID)
http://www.niaid.nih.gov/
National Library of Medicine, PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
Tuberculosis Net http://tuberculosis.net/
Africa
AllAfrica.com: TB News from Africa http://allafrica.com/tuberculosis/
Desmond Tutu TB Centre
http://sun025.sun.ac.za/portal/page/portal/
Health_Sciences/English/Centres/dttc
South African Tuberculosis Vaccine Initiative http://www.satvi.uct.ac.za/
Asia and
Oceania
JATA - Research Institute of Tuberculosis http://www.jata.or.jp/eindex/home.html
National Institute for Research in Tuberculosis http://www.trc-chennai.org/
Pakistan Anti TB Association http://www.patba.org/
TBC India http://www.tbcindia.nic.in/
Europe





International Union Against Tuberculosis and
Lung Disease (UNION)
http://www.theunion.org/
Max Planck Institute for Infection Biology http://www.mpiib-berlin.mpg.de/
Pasteur Institute http://www.pasteur.fr
Table 1. Additional websites covering tuberculosis facts information and treatment research
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Pan American Health Organization (PAHO). Serving as the regional office for WHO, PAHO
has been working for more than one century to improve health and the living standards of the
countries of the Americas, being recognized as part of the United Nations’ system. URL:
<http://new.paho.org/hq/>
StopTB Partnership. The StopTb Partnership operates through a secretariat hosted by the
World Health Organization (WHO) in Geneva, Switzerland, and seven working groups whose
role is to accelerate progress on access to TB diagnosis and treatment, research and develop‐
ment for new TB diagnostics, drugs and vaccines, and tackling drug resistant- and HIV-
associated TB. URL: <http://www.stoptb.org/>
Tb Alliance. Established in the year 2000, its main objective is to discover and develop better,
faster-acting, and affordable drugs to fight tuberculosis. Today, the organization and its
partners manage a portfolio of new anti-Tb drugs. URL: <http://www.tballiance.org>
World Health Organization (WHO). Created in 1948, WHO is the directing and coordinating
authority in international health within the United Nations’ system, composed of 193 countries
and two associate members. It supports and promotes health research in several areas, Tb being
one of them. URL: <http://who.int/topics/tuberculosis/en/>
3. Tuberculosis databases and platforms
Since the emergence of Bioinformatics and Computational Biology back in the 1960’s, numer‐
ous databases and computational tools have been created in order to provide the scientific
community the necessary means to access and interpret a range of biological data.
Actually, the contribution of these disciplines became particularly evident in the 1990’s and
2000’s, when the development of supercomputers, powerful personal computers, and com‐
puter networks at global scale, as well as of high-throughput technologies, collectively referred
as omics – e.g., genomics, transcriptomics, and proteomics –, revolutionized the field of Biology.
Nowadays, a number of web resources are publicly available aiming to organize, integrate,
and provide efficient access to the ever-increasing amount of biological information produced
over decades of research, particularly in recent years, with numerous projects applying the
aforementioned high-throughput technologies worldwide. Accordingly, diverse options to
visualize, search, retrieve and analyze this wealth of data are offered, providing the opportu‐
nity to acquire more detailed knowledge about genomes and their respective organisms,
among many others opportunities.
However, the creation and maintenance of such web resources is a challenge by itself, not only
because they usually have to deal with large amounts of data, but mostly because they require
the designing of schemes and frameworks that accurately represent the complexity of biolog‐
ical systems, which is frequently a hard task to be accomplished. Another difficulty is the
development of efficient data retrieval systems, implemented in user-friendly interfaces and
intended for complex and massive database searching. It is worth noting that, in many
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circumstances, the authors and curators of such resources receive little or no remuneration for
their productive efforts, and the access to financial support for creation and maintenance of
biological databases is still a difficult task.
In this section we present the main web resources fully or partially dedicated to mycobacterial
species with relevance for readers interested in TB. Each database or platform, categorized
according to its purpose and functionality, is quickly reviewed, and references to the original
paper describing it, as well as its electronic site, are provided, serving as a guideline for
researches or students working on TB. Notably, the computational resources presented here
are all publicly available as online services and can potentially be applied to the identification
of new drug targets, vaccine antigens, or diagnostics for TB, among many others applications.
3.1. Generic and multifunctional
MyBASE. The Mycobacterial Database [1] is an integrated platform for functional and
evolutionary genomic study of the genus Mycobacterium, comprising extensive literature
review and data annotation on mycobacterial genome polymorphism, virulence factors, and
essential genes. URL: <http://mybase.psych.ac.cn/>
TBDB. The TB Database [2] provides a comprehensive genomic data repository for M.
tuberculosis and related bacteria, combining (in silico) genome sequence and annotation data
and (experimental) gene-expression data. It also provides an analysis platform with suitable
computational tools to assist (comparative) genomic and gene-expression studies of these
microorganisms. Annotated features of genes and genomes, predicted orthologous groups,
operons and synteny blocks, as well as predicted and curated immunological epitopes and
gene-expression patterns are available. URL: <http://www.tbdb.org/>
The MycoBrowser portal. The Mycobacterial Browser portal [3] is an extensive genomic and
proteomic data repository for four related mycobacteria: M. tuberculosis H37Rv, M. leprae TN,
M. marinum M, and M. smegmatis MC2. The system provides in silico generated and manually
reviewed information on the complete genome sequence of these organisms. As part of this
portal, the TubercuList database [4] integrates a range of information on the M. tuberculosis
genome, such as genomic and protein annotations and features, drug and transcriptome data,
mutant and operon annotation, and comparative genomics. It represents a complete redesign
of the database with the same name provided by the GenoList genome browser (also described
in this chapter). URL: <http://mycobrowser.epfl.ch/>
3.2. Genomic mapping and data mining
TubercuList, BoviList, BCGList. The GenoList [5] is a collection of databases dedicated to
microbial genome analysis, providing a complete data set of protein and nucleotide sequences
for selected species, as well as annotation and functional classification of these sequences. The
TubercuList, BoviList, and BCGList databases are devoted to collect and integrate various
aspects of the genomic information of M. tuberculosis H37Rv, M. bovis AF2122/97, and M.
bovis BCG Pasteur 1173P2, respectively. URL: <http://genolist.pasteur.fr/>
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Pan American Health Organization (PAHO). Serving as the regional office for WHO, PAHO
has been working for more than one century to improve health and the living standards of the
countries of the Americas, being recognized as part of the United Nations’ system. URL:
<http://new.paho.org/hq/>
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World Health Organization (WHO) in Geneva, Switzerland, and seven working groups whose
role is to accelerate progress on access to TB diagnosis and treatment, research and develop‐
ment for new TB diagnostics, drugs and vaccines, and tackling drug resistant- and HIV-
associated TB. URL: <http://www.stoptb.org/>
Tb Alliance. Established in the year 2000, its main objective is to discover and develop better,
faster-acting, and affordable drugs to fight tuberculosis. Today, the organization and its
partners manage a portfolio of new anti-Tb drugs. URL: <http://www.tballiance.org>
World Health Organization (WHO). Created in 1948, WHO is the directing and coordinating
authority in international health within the United Nations’ system, composed of 193 countries
and two associate members. It supports and promotes health research in several areas, Tb being
one of them. URL: <http://who.int/topics/tuberculosis/en/>
3. Tuberculosis databases and platforms
Since the emergence of Bioinformatics and Computational Biology back in the 1960’s, numer‐
ous databases and computational tools have been created in order to provide the scientific
community the necessary means to access and interpret a range of biological data.
Actually, the contribution of these disciplines became particularly evident in the 1990’s and
2000’s, when the development of supercomputers, powerful personal computers, and com‐
puter networks at global scale, as well as of high-throughput technologies, collectively referred
as omics – e.g., genomics, transcriptomics, and proteomics –, revolutionized the field of Biology.
Nowadays, a number of web resources are publicly available aiming to organize, integrate,
and provide efficient access to the ever-increasing amount of biological information produced
over decades of research, particularly in recent years, with numerous projects applying the
aforementioned high-throughput technologies worldwide. Accordingly, diverse options to
visualize, search, retrieve and analyze this wealth of data are offered, providing the opportu‐
nity to acquire more detailed knowledge about genomes and their respective organisms,
among many others opportunities.
However, the creation and maintenance of such web resources is a challenge by itself, not only
because they usually have to deal with large amounts of data, but mostly because they require
the designing of schemes and frameworks that accurately represent the complexity of biolog‐
ical systems, which is frequently a hard task to be accomplished. Another difficulty is the
development of efficient data retrieval systems, implemented in user-friendly interfaces and
intended for complex and massive database searching. It is worth noting that, in many
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circumstances, the authors and curators of such resources receive little or no remuneration for
their productive efforts, and the access to financial support for creation and maintenance of
biological databases is still a difficult task.
In this section we present the main web resources fully or partially dedicated to mycobacterial
species with relevance for readers interested in TB. Each database or platform, categorized
according to its purpose and functionality, is quickly reviewed, and references to the original
paper describing it, as well as its electronic site, are provided, serving as a guideline for
researches or students working on TB. Notably, the computational resources presented here
are all publicly available as online services and can potentially be applied to the identification
of new drug targets, vaccine antigens, or diagnostics for TB, among many others applications.
3.1. Generic and multifunctional
MyBASE. The Mycobacterial Database [1] is an integrated platform for functional and
evolutionary genomic study of the genus Mycobacterium, comprising extensive literature
review and data annotation on mycobacterial genome polymorphism, virulence factors, and
essential genes. URL: <http://mybase.psych.ac.cn/>
TBDB. The TB Database [2] provides a comprehensive genomic data repository for M.
tuberculosis and related bacteria, combining (in silico) genome sequence and annotation data
and (experimental) gene-expression data. It also provides an analysis platform with suitable
computational tools to assist (comparative) genomic and gene-expression studies of these
microorganisms. Annotated features of genes and genomes, predicted orthologous groups,
operons and synteny blocks, as well as predicted and curated immunological epitopes and
gene-expression patterns are available. URL: <http://www.tbdb.org/>
The MycoBrowser portal. The Mycobacterial Browser portal [3] is an extensive genomic and
proteomic data repository for four related mycobacteria: M. tuberculosis H37Rv, M. leprae TN,
M. marinum M, and M. smegmatis MC2. The system provides in silico generated and manually
reviewed information on the complete genome sequence of these organisms. As part of this
portal, the TubercuList database [4] integrates a range of information on the M. tuberculosis
genome, such as genomic and protein annotations and features, drug and transcriptome data,
mutant and operon annotation, and comparative genomics. It represents a complete redesign
of the database with the same name provided by the GenoList genome browser (also described
in this chapter). URL: <http://mycobrowser.epfl.ch/>
3.2. Genomic mapping and data mining
TubercuList, BoviList, BCGList. The GenoList [5] is a collection of databases dedicated to
microbial genome analysis, providing a complete data set of protein and nucleotide sequences
for selected species, as well as annotation and functional classification of these sequences. The
TubercuList, BoviList, and BCGList databases are devoted to collect and integrate various
aspects of the genomic information of M. tuberculosis H37Rv, M. bovis AF2122/97, and M.
bovis BCG Pasteur 1173P2, respectively. URL: <http://genolist.pasteur.fr/>
Web Resources on TB: Information, Research, and Data Analysis
http://dx.doi.org/10.5772/53949
363
TBrowse. The TBrowse [6] is a genomic data resource, based on the Generic Model Organism
Database (a collection of open source computational tools for creating and managing genome-
scale biological databases); the browse provides the scientific community an integrative
genomic map of M. tuberculosis with millions of data-points representing different genomic
features and computational predictions systematically collected from online resources and
publications, including gene/operon predictions, orthologs, gene expression data, non-coding
RNA, pathway/networks, regulatory elements, variation and repeats, subcellular localization,
among others. URL: <http://tbrowse.osdd.net>
3.3. Comparative genomics
GenoMycDB. The GenoMycDB [7] is a relational database for large-scale comparative analysis
of completely sequenced mycobacterial genomes based on their predicted protein content.
Currently, the database comprises six mycobacteria – M. tuberculosis (strains H37Rv and
CDC1551), M. bovis AF2122/97, M. avium subsp. paratuberculosis K10, M. leprae TN, and M.
smegmatis MC2 155 – providing for each of their encoded protein sequences the predicted
subcellular localization, the assigned cluster of orthologous groups (COGs), features of the
corresponding gene, and links to several important databases; in addition, pairs or groups of
homologs between selected species/strains can be dynamically inferred based on user-defined
criteria. URL: <http://www.dbbm.fiocruz.br/GenoMycDB.html>
MycoDB. The xBASE [8] is another collection of databases, this one dedicated to bacterial
comparative genome analyses. It provides precomputed data of comparative genome analyses
among selected bacterial genera, as well as inferred orthologous groups and functional
annotations. It also provides precomputed analyses of codon usage, base composition, codon
adaptation index (CAI), hydropathy, and aromaticity of the protein coding sequences in these
bacteria. As part of this multi-microbial system, the MycoDB currently comprises comparative
data from 61 completely sequenced or unfinished mycobacterial genomes, including 40 strains
of M. tuberculosis, M. bovis AF2122/97, M. bovis BCG strains Pasteur 1173P2 and Tokyo 172,
among others mycobacteria. URL: <http://www.xbase.ac.uk/>
Mycobacterium  tuberculosis  Comparative  Database.  This  Broad  Institute’s  database
comprises precomputed comparative genome analyses data of eight M. tuberculosis patient
isolates  with  relevant  clinical  phenotypes  and  disease  epidemiology  (varied  degree  of
spread,  drug  resistance,  and  clinical  severity):  M.  tuberculosis  F11,  M. tuberculosis  Haar‐
lem, M. tuberculosis KZN 4207 (DS), M. tuberculosis KZN 1435 (MDR), M. tuberculosis KZN
605 (XDR), M. tuberculosis C, M. tuberculosis 98-R604 INH-RIF-EM, and M. tuberculosis W-148.
Among the comparative data provided by this TB resource we can cite: inferred families
of  orthologous  genes,  genomic  two-dimensional  dot  plot  matrices,  comparative  genome
mapping  and  browsing,  and  several  comparative  gene  annotations  and  features.  URL:
<http://www.broadinstitute.org/annotation/genome/mycobacterium_tuberculosis_spp/
MultiHome.html>
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3.4. Genetic diversity and epidemiology
MGDD. The Mycobacterial Genome Divergence Database [9] comprises a data repository of
genetic variations among different organisms belonging to the M. tuberculosis complex. The
MGDD system provides quick searches for precomputed single nucleotide polymorphisms
(SNPs), insertions/deletions, repeat expansions, and divergent sequences (inversions, dupli‐
cations, and changes in synteny) in genomic regions of fully sequenced M. tuberculosis complex
species and strains genomes. URL: <http://mirna.jnu.ac.in/mgdd/>
MIRU-VNTRplus. The Mycobacterial Interspersed Repetitive Unit – Variable Number
Tandem Repeat (MIRU-VNTR) database [10,11] comprises a collection of 186 well character‐
ized strains representing the major M. tuberculosis complex in which, for each strain, species,
lineage, and epidemiologic information are provided together with 24 MIRU loci, Spoligotype
patterns, Regions of Difference (RD) profiles, Single Nucleotide Polymorphisms (SNPs),
susceptibility data, and IS6110 Restriction Fragment Length Polymorphism (RFLP) fingerprint
images. The system enables users to analyze genotyping data of their own strains alone or in
comparison with the reference strains in the database; analyses and comparisons of genotypes
can be based on Multiple Locus VNTR Analysis (MLVA), Spoligotypes, Large Sequence
Polymorphism (LSP) and SNPs data, or on a weighted combination of these markers. Tools
for data analysis include: search for similar strains, creation of phylogenetic and minimum
spanning trees and mapping of geographic information. URL: <http://www.miru-
vntrplus.org>
MTCID. The M. tuberculosis Clinical Isolate Genetic Polymorphism Database [12] consists in
a repository of genetic polymorphisms, providing Single Nucleotide Polymorphism (SNPs)
and Spoligotype profiles of clinical isolates of M. tuberculosis, based on published literature
and manual curation. URL: <http://ccbb.jnu.ac.in/Tb/>
SITVITWEB. The SITVITWEB [13] is a multi-marker database, comprising three major types
of molecular markers: Spoligotypes, Mycobacterial Interspersed Repetitive Units (MIRUs) and
Variable Number Tandem Repeat (VNTRs); this webserver is dedicated to the investigation
of M. tuberculosis genetic diversity and molecular epidemiology. Currently, this international
resource provides genotyping information on 62,582 M. tuberculosis complex clinical isolates
from 153 countries of patient origin. URL: <http://www.pasteur-guadeloupe.fr:8081/
SITVIT_ONLINE/>
Additionally, a few relevant computational tools are currently available as web services
dedicated to analyze the genetic diversity of M. tuberculosis complex strains and characterize
TB dynamics using molecular epidemiological data:
The spolTools [14] comprise a collection of browser programs designed to manipulate and
analyze Spoligotype data of the M. tuberculosis complex, consisting in an online repository of
Spoligotype isolates collected from various published data sets (currently, 1179 Spoligotypes
and 6278 isolates across 30 datasets), and online tools for manipulating and analyzing these
data (computation of basic population genetic quantities; visualization of clusters of Spoligo‐
type patterns based on an estimated evolutionary history; and a procedure to predict emerging
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of completely sequenced mycobacterial genomes based on their predicted protein content.
Currently, the database comprises six mycobacteria – M. tuberculosis (strains H37Rv and
CDC1551), M. bovis AF2122/97, M. avium subsp. paratuberculosis K10, M. leprae TN, and M.
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homologs between selected species/strains can be dynamically inferred based on user-defined
criteria. URL: <http://www.dbbm.fiocruz.br/GenoMycDB.html>
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annotations. It also provides precomputed analyses of codon usage, base composition, codon
adaptation index (CAI), hydropathy, and aromaticity of the protein coding sequences in these
bacteria. As part of this multi-microbial system, the MycoDB currently comprises comparative
data from 61 completely sequenced or unfinished mycobacterial genomes, including 40 strains
of M. tuberculosis, M. bovis AF2122/97, M. bovis BCG strains Pasteur 1173P2 and Tokyo 172,
among others mycobacteria. URL: <http://www.xbase.ac.uk/>
Mycobacterium  tuberculosis  Comparative  Database.  This  Broad  Institute’s  database
comprises precomputed comparative genome analyses data of eight M. tuberculosis patient
isolates  with  relevant  clinical  phenotypes  and  disease  epidemiology  (varied  degree  of
spread,  drug  resistance,  and  clinical  severity):  M.  tuberculosis  F11,  M. tuberculosis  Haar‐
lem, M. tuberculosis KZN 4207 (DS), M. tuberculosis KZN 1435 (MDR), M. tuberculosis KZN
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Among the comparative data provided by this TB resource we can cite: inferred families
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species and strains genomes. URL: <http://mirna.jnu.ac.in/mgdd/>
MIRU-VNTRplus. The Mycobacterial Interspersed Repetitive Unit – Variable Number
Tandem Repeat (MIRU-VNTR) database [10,11] comprises a collection of 186 well character‐
ized strains representing the major M. tuberculosis complex in which, for each strain, species,
lineage, and epidemiologic information are provided together with 24 MIRU loci, Spoligotype
patterns, Regions of Difference (RD) profiles, Single Nucleotide Polymorphisms (SNPs),
susceptibility data, and IS6110 Restriction Fragment Length Polymorphism (RFLP) fingerprint
images. The system enables users to analyze genotyping data of their own strains alone or in
comparison with the reference strains in the database; analyses and comparisons of genotypes
can be based on Multiple Locus VNTR Analysis (MLVA), Spoligotypes, Large Sequence
Polymorphism (LSP) and SNPs data, or on a weighted combination of these markers. Tools
for data analysis include: search for similar strains, creation of phylogenetic and minimum
spanning trees and mapping of geographic information. URL: <http://www.miru-
vntrplus.org>
MTCID. The M. tuberculosis Clinical Isolate Genetic Polymorphism Database [12] consists in
a repository of genetic polymorphisms, providing Single Nucleotide Polymorphism (SNPs)
and Spoligotype profiles of clinical isolates of M. tuberculosis, based on published literature
and manual curation. URL: <http://ccbb.jnu.ac.in/Tb/>
SITVITWEB. The SITVITWEB [13] is a multi-marker database, comprising three major types
of molecular markers: Spoligotypes, Mycobacterial Interspersed Repetitive Units (MIRUs) and
Variable Number Tandem Repeat (VNTRs); this webserver is dedicated to the investigation
of M. tuberculosis genetic diversity and molecular epidemiology. Currently, this international
resource provides genotyping information on 62,582 M. tuberculosis complex clinical isolates
from 153 countries of patient origin. URL: <http://www.pasteur-guadeloupe.fr:8081/
SITVIT_ONLINE/>
Additionally, a few relevant computational tools are currently available as web services
dedicated to analyze the genetic diversity of M. tuberculosis complex strains and characterize
TB dynamics using molecular epidemiological data:
The spolTools [14] comprise a collection of browser programs designed to manipulate and
analyze Spoligotype data of the M. tuberculosis complex, consisting in an online repository of
Spoligotype isolates collected from various published data sets (currently, 1179 Spoligotypes
and 6278 isolates across 30 datasets), and online tools for manipulating and analyzing these
data (computation of basic population genetic quantities; visualization of clusters of Spoligo‐
type patterns based on an estimated evolutionary history; and a procedure to predict emerging
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strains/genotypes associated with elevated transmission). URL: <http://
www.emi.unsw.edu.au/spolTools/>
The TB-Insight [15] is a collection of computational methods (based on different models and
datasets) for both lineage classification of M. tuberculosis complex strains, and for visualization
of genetic diversity in M. tuberculosis complex population and distribution by lineage, as well
as visual representation of associations between patient and strain groups, providing percep‐
tion on differences in phenotypic characteristics, and phylogeographic associations of M.
tuberculosis complex strains with host populations. URL: <http://tbinsight.cs.rpi.edu/>
3.5. Gene expression and regulation
MTBRegList. The MTBRegList [16] is dedicated to the analysis of gene expression and
regulation data in M. tuberculosis, containing predicted and characterized regulatory motifs
cross-referenced with their respective transcription factor(s), experimentally identified
transcription start sites, and DNA binding sites. URL: <http://www.usherbrooke.ca/vers/
MtbRegList>
MycoperonDB. The MycoperonDB [17] is a repository of known and computationally
predicted operons and transcriptional units of (currently) five different mycobacteria – M.
tuberculosis (strains H37Rv and CDC1551), M. bovis AF2122/97, M. avium subsp. paratuberculo‐
sis K10, and M. leprae TN – whose genomes have been completely sequenced. Presently, it
comprises 18,053 genes organized as 8,256 predicted operons and transcriptional units,
providing literature links for experimentally characterized operons, and access to known
promoters and related information. URL: <http://cdfd.org.in/mycoperondb/home.html>
MTBreg. The MTBreg is part of the online services provided by the UCLA-DOE Institute for
Genomics and Proteomics (http://www.doe-mbi.ucla.edu/), and consists in a repository of
conditionally regulated proteins in M. tuberculosis grown under several different conditions
mimicking infection; the database provides information on proteins that are regulated by
selected transcription factors or other regulatory proteins, as well as on the experimental
condition, the experimental dataset and a literature reference. URL: <http://www.doe-
mbi.ucla.edu/Services/MTBreg/>
MycoRegDB. The Mycobacterial Promoter and Regulatory Elements Database [18] is part of
a user-friendly web interface (RegAnalyst) that integrates a motif prediction program (MoPP),
a pattern detection tool (MyPatternFinder), and a database of promoter and regulatory
elements from various mycobacterial species (MycoRegDB). Currently, the MycoRegDB
comprises the following species: M. tuberculosis (strains H37Rv and CDC1551), M. bovis BCG,
M. leprae, M. smegmatis, M. avium subsp. paratuberculosis, M. marinum, M. ulcerans, M. gilvum,
and M. vanbaalenii. For each database entry, a variety of useful information is provided, such
as, gene annotation, CDS positions, promoter/regulatory sequence (with Transcription Start
Point (TSP) or binding site explicitly marked), TSP-CDS/Motif-CDS distance, among others.
The first release of MycoRegDB contained 290 annotated DNA motifs (174 promoters and 116
transcription factor binding sites) described in 81 research papers, according to the authors..
URL: <http://www.nii.ac.in/~deepak/RegAnalyst/MycoRegDB>
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3.6. Structural biology
MtbSD. The M. tuberculosis Structural Database [19] is a resource dedicated to 3D protein
structures of M. tuberculosis, providing relevant information on description, reaction catalyzed,
domains, active sites, structural homologs and similarities between bound and cognate
ligands. Currently, the database comprises 876 structures for 332 mycobacterial genes. URL:
<http://bmi.icmr.org.in/mtbsd/MtbSD.php>
3.7. Drug targets and resistance
TDR Targets database. The Tropical Disease Research (TDR/WHO) Targets database [20]
comprises extensive genetic, biochemical and pharmacological data related to tropical disease
pathogens, including M. tuberculosis, as well as computationally predicted druggability for
potential targets and compound desirability information; the goal is to exploit the availability
of diverse datasets to facilitate the identification and prioritization of drugs and drug targets
in neglected disease pathogens, such as the tubercle bacillus. URL: <http://tdrtargets.org/>
TB Drug Resistance Mutation Database. The Tuberculosis Drug Resistance Mutation
Database [21] is a comprehensive database that catalogs mutations associated with TB drug
resistance and the frequency of the most common mutations associated with resistance to
specific drugs, providing a resource for the development of molecular diagnostics for TB, as
well as structural mapping of mutations to investigate mechanisms of resistance for drug
discovery purposes. URL: <http://www.tbdreamdb.com/>
4. Conclusion
As outlined in this chapter, Informatics has acquired a great importance not only in the
biological sciences, but in all areas of knowledge. Internet has become one of the most
important tools for most people, from a dedicated researcher interested in the latest advances
in his/her particular field of work to the teenager trying to contact his friends. Companies,
industries and research institutes developed sites, where they expose their work to laymen.
The large number of publicly available databases and computational tools that have been
developed, dedicated to organize, integrate, and provide efficient access to the ever-increasing
amount of biological information produced over decades of research, have benefited research‐
ers all over the world, especially those from low-income countries.
One important drawback, that still has to be overcome, is that the wealth of biological
information available is presently fragmented, dispersed across numerous computational
resources, and is redundant in many circumstances, clearly requiring unification in order to
provide a global and integral picture of the biological systems they are dedicated to.
Ideally, the upcoming databases and computational tools should offer: data integration,
providing multi-perspective analyses; combine in silico generated and manually curated data,
improving the quality of our research; present efficient data structure, storage and processing,
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strains/genotypes associated with elevated transmission). URL: <http://
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conditionally regulated proteins in M. tuberculosis grown under several different conditions
mimicking infection; the database provides information on proteins that are regulated by
selected transcription factors or other regulatory proteins, as well as on the experimental
condition, the experimental dataset and a literature reference. URL: <http://www.doe-
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Point (TSP) or binding site explicitly marked), TSP-CDS/Motif-CDS distance, among others.
The first release of MycoRegDB contained 290 annotated DNA motifs (174 promoters and 116
transcription factor binding sites) described in 81 research papers, according to the authors..
URL: <http://www.nii.ac.in/~deepak/RegAnalyst/MycoRegDB>
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3.6. Structural biology
MtbSD. The M. tuberculosis Structural Database [19] is a resource dedicated to 3D protein
structures of M. tuberculosis, providing relevant information on description, reaction catalyzed,
domains, active sites, structural homologs and similarities between bound and cognate
ligands. Currently, the database comprises 876 structures for 332 mycobacterial genes. URL:
<http://bmi.icmr.org.in/mtbsd/MtbSD.php>
3.7. Drug targets and resistance
TDR Targets database. The Tropical Disease Research (TDR/WHO) Targets database [20]
comprises extensive genetic, biochemical and pharmacological data related to tropical disease
pathogens, including M. tuberculosis, as well as computationally predicted druggability for
potential targets and compound desirability information; the goal is to exploit the availability
of diverse datasets to facilitate the identification and prioritization of drugs and drug targets
in neglected disease pathogens, such as the tubercle bacillus. URL: <http://tdrtargets.org/>
TB Drug Resistance Mutation Database. The Tuberculosis Drug Resistance Mutation
Database [21] is a comprehensive database that catalogs mutations associated with TB drug
resistance and the frequency of the most common mutations associated with resistance to
specific drugs, providing a resource for the development of molecular diagnostics for TB, as
well as structural mapping of mutations to investigate mechanisms of resistance for drug
discovery purposes. URL: <http://www.tbdreamdb.com/>
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in his/her particular field of work to the teenager trying to contact his friends. Companies,
industries and research institutes developed sites, where they expose their work to laymen.
The large number of publicly available databases and computational tools that have been
developed, dedicated to organize, integrate, and provide efficient access to the ever-increasing
amount of biological information produced over decades of research, have benefited research‐
ers all over the world, especially those from low-income countries.
One important drawback, that still has to be overcome, is that the wealth of biological
information available is presently fragmented, dispersed across numerous computational
resources, and is redundant in many circumstances, clearly requiring unification in order to
provide a global and integral picture of the biological systems they are dedicated to.
Ideally, the upcoming databases and computational tools should offer: data integration,
providing multi-perspective analyses; combine in silico generated and manually curated data,
improving the quality of our research; present efficient data structure, storage and processing,
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providing dynamic, flexible and fast data visualization, data searching, data retrieval and data
analysis, via user-friendly graphical interfaces; implement a consistent and controlled
vocabulary to describe the data and standardized data formats, providing full data inter‐
changing and integration with other data sources. We believe that only in this way, a fruitful
field for interactions and cooperation among researches from distinct areas might emerge,
providing the required support to interpret and analyze this wealth of data according to a truly
multidisciplinary approach.
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1. Introduction
Until recently, tuberculosis (TB) had become a neglected disease, particularly in children. It
was after the emergence of multi drug resistant TB, and the complications brought about by
the HIV/AIDS coinfection, that TB took centre stage again. The common perception has been
that children rarely develop severe forms of TB and that they do not contribute much to the
spread of the epidemic. Although this could be the case in non-endemic areas, where diligent
contact tracing is enforced, in children from endemic areas it is a different story as revealed by
an autopsy study conducted in Zambia which demonstrated that tuberculosis was a major
cause of death from respiratory disease (Chintu et al., 2002).
Children are particularly vulnerable to more rapid development of severe disease and death
after infection, and those with latent infection become the reservoir of disease reactivation in
adulthood, fueling the future epidemic (Nicol et al., 2011). Since focus has been on reducing
transmission, previous TB control strategies have not prioritized childhood TB (Zar and Pai,
2011). Due to the difficulty in establishing an accurate diagnosis of childhood tuberculosis, the
true extent of the tuberculosis-related morbidity and mortality suffered by children in endemic
areas is rarely appreciated (Chintu et al., 2002). For example, Regional Data from the WHO in
2007 showed that smear-positive TB in children aged under 14 years accounted for 0.6–3.6%
of reported cases but since about 95% of cases in children under 12 years of age are smear
negative, these data underestimate the true burden of TB. Furthermore, in countries with a
high prevalence of HIV infection, there has been a marked increase in the incidence and a
decrease in the peak age prevalence of infectious TB; thus, most cases now occur in young
adults, who are often parents of young children (WHO Report, 2009). This finding suggests
that children in developing countries will emerge as a group at high risk. In industrialized
countries, most childhood TB cases are detected through contact tracing and have good
outcomes. This is in contrast to the situation in low- and middle-income countries, where
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childhood TB is closely associated with poverty, overcrowding, and malnutrition, with
consequently higher death and lower treatment success rates (Nelson and Wells, 2010).
Studies have revealed that children contribute a significant proportion to the disease burden
and suffer severe tuberculosis-related morbidity and mortality, particularly in endemic areas.
TB is now among the 10 major causes of mortality among children, with a global estimate of
130,000 deaths per year (WHO Report, 2009). Mortality has a strong correlation with socioe‐
conomic status, underlying nutritional status and immunocompetence (Palme, 2002). TB has
also been reported to be the third most common cause of death in HIV-infected children with
a clinical diagnosis of acute severe pneumonia (Palme, 2002). With roughly a million cases
estimated globally each year (Walls and, Shingadia, 2004) and a much higher risk of severe
disease and death among young children than adults, paediatric TB remains a public health
emergency and this is particularly evident in developing countries with poor public health
infrastructure.
As in adults, the majority of cases occur in the 22 high burden countries, where a combination
of high transmission rates and a large proportion of the population under the age of 15 years
mean children account for up to 25-40% of cases, with incidence rates for paediatric TB ranging
from 60-600 per 100,000 per year (Nelson and Wells, 2004). Increasing rates of childhood TB
have also been reported in Eastern Europe in the wake of the explosive TB epidemic which
followed the break up of the Soviet Union (Walls and Shingadia, 2007). Even traditionally low-
burden countries have seen a rise in cases, mainly due to immigration from TB endemic areas.
In most countries of Western Europe and North America, where children account for 4-7%
cases, paediatric incidence rates vary from about 1 to 15 per 100,000 per year, although much
higher rates are observed in some cities, such as London (Newton et al., 2008).
Despite this huge disease burden, children's access to anti-tuberculosis treatment in most
endemic areas remains poor, as tuberculosis control programs focus predominantly on the
treatment of sputum smear–positive adults (Starke, 2002). Recent technological advancements
in diagnosis of TB in adults have not been validated in children and, similarly, trials of new
drugs and development of pediatric formulations of standard first- and second-line drugs are
lagging behind. As a result both research and surveillance data in the field of childhood TB
have been greatly limited. Further research into the epidemiology, immune mechanisms,
diagnosis, treatment and prevention of childhood TB is urgently needed to enhance our
understanding of TB in children which may provide wider insights and opportunities to
facilitate efforts to control TB in the population.
Another problem is that most programs for TB control are limited because they target and treat
only active cases (Graham, et al., 2004) when most TB cases in children present as latent
tuberculosis infection (LTBI) with active disease occurring mainly in developing countries
(Dogra, et al., 2007). Without treatment, the majority of infants aged under 1 year die due to
TB. Even with effective antimicrobial therapy, severe TB continues to occur in young children
(Ávalos and Montes de Oca, 2012). Priorities for future research should, therefore, enhance
collaborations between developing and developed nations.
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This chapter addresses some of the unique features of TB in children; presents existing and
novel diagnostic, therapeutic and preventative measures; and outlines important areas of
future research. The main challenges for future research are highlighted and in conclusion it
is emphasized that well-targeted interventions, improved resources, and improved political
commitment, may lead to a dramatic reduction in tuberculosis-related morbidity and mortality
among children.
2. Epidemiology of paediatric TB
2.1. Global disease burden of paediatric TB
Poor case ascertainment, lack of resources for active case finding in most settings, and limited
paediatric surveillance data from TB control programs all hamper efforts to define accurately
the global burden of childhood TB (Nelson and Wells, 2004). Until recently, under the WHO
Directly Observed Treatment Short Course (DOTS) strategy, only smear positive cases were
being reported for children, yet smears are seldom performed in many high burden settings
and most disease in children is smear negative.
Although limited surveillance data prevent reliable estimates of the contribution of TB to
childhood mortality, available data indicate that pneumonia is the commonest cause of
childhood death globally (Nelson et al., 2004) an implication that TB, being an important cause
of pneumonia in many settings (Scott et al., 2008), may contribute significantly to these global
childhood deaths. A necropsy study in Zambia found evidence of TB in 18% of HIV-positive
and 26% of HIV-negative children dying of pneumonia (Chintu et al., 2002) although more
robust regional data on the epidemiology of childhood TB are urgently needed to define the
true burden of disease, and to characterize current transmission rates and circulating strains.
2.2. Pathophysiology of TB in children
2.2.1. Natural history of TB in children
The natural history of TB in children and pediatric patients follows a series of steps in which
phase 1 occurs after an incubation period of 3–8 weeks after primary infection. This is followed
by appearance of well-defined signs that include fever, erythema nodosum, a positive
tuberculin skin test response, and formation of the primary complex visible on chest radiog‐
raphy. Phase 2 occurs 1–3 months after the phase 1 in which period, the bacillus can migrate
to other parts of the body via the blood and this represents the period of the highest risk for
the development of tuberculous meningitis and miliary tuberculosis in young children. This
is the phase where dissemination of the bacillus most frequently occurs. Phase 3 occurs 3–7
months after primary infection and is the period of pleural effusions in children greater than
5 years old and bronchial disease in children less than 5 years. Phase 4 presents after 1–3 years
after phase 1 and is during which the osteoarticular tuberculosis in children 5 years and below,
appears. Phase 5 occurs up to 3 years after phase 1 and it is presented after calcification has
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childhood TB is closely associated with poverty, overcrowding, and malnutrition, with
consequently higher death and lower treatment success rates (Nelson and Wells, 2010).
Studies have revealed that children contribute a significant proportion to the disease burden
and suffer severe tuberculosis-related morbidity and mortality, particularly in endemic areas.
TB is now among the 10 major causes of mortality among children, with a global estimate of
130,000 deaths per year (WHO Report, 2009). Mortality has a strong correlation with socioe‐
conomic status, underlying nutritional status and immunocompetence (Palme, 2002). TB has
also been reported to be the third most common cause of death in HIV-infected children with
a clinical diagnosis of acute severe pneumonia (Palme, 2002). With roughly a million cases
estimated globally each year (Walls and, Shingadia, 2004) and a much higher risk of severe
disease and death among young children than adults, paediatric TB remains a public health
emergency and this is particularly evident in developing countries with poor public health
infrastructure.
As in adults, the majority of cases occur in the 22 high burden countries, where a combination
of high transmission rates and a large proportion of the population under the age of 15 years
mean children account for up to 25-40% of cases, with incidence rates for paediatric TB ranging
from 60-600 per 100,000 per year (Nelson and Wells, 2004). Increasing rates of childhood TB
have also been reported in Eastern Europe in the wake of the explosive TB epidemic which
followed the break up of the Soviet Union (Walls and Shingadia, 2007). Even traditionally low-
burden countries have seen a rise in cases, mainly due to immigration from TB endemic areas.
In most countries of Western Europe and North America, where children account for 4-7%
cases, paediatric incidence rates vary from about 1 to 15 per 100,000 per year, although much
higher rates are observed in some cities, such as London (Newton et al., 2008).
Despite this huge disease burden, children's access to anti-tuberculosis treatment in most
endemic areas remains poor, as tuberculosis control programs focus predominantly on the
treatment of sputum smear–positive adults (Starke, 2002). Recent technological advancements
in diagnosis of TB in adults have not been validated in children and, similarly, trials of new
drugs and development of pediatric formulations of standard first- and second-line drugs are
lagging behind. As a result both research and surveillance data in the field of childhood TB
have been greatly limited. Further research into the epidemiology, immune mechanisms,
diagnosis, treatment and prevention of childhood TB is urgently needed to enhance our
understanding of TB in children which may provide wider insights and opportunities to
facilitate efforts to control TB in the population.
Another problem is that most programs for TB control are limited because they target and treat
only active cases (Graham, et al., 2004) when most TB cases in children present as latent
tuberculosis infection (LTBI) with active disease occurring mainly in developing countries
(Dogra, et al., 2007). Without treatment, the majority of infants aged under 1 year die due to
TB. Even with effective antimicrobial therapy, severe TB continues to occur in young children
(Ávalos and Montes de Oca, 2012). Priorities for future research should, therefore, enhance
collaborations between developing and developed nations.
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This chapter addresses some of the unique features of TB in children; presents existing and
novel diagnostic, therapeutic and preventative measures; and outlines important areas of
future research. The main challenges for future research are highlighted and in conclusion it
is emphasized that well-targeted interventions, improved resources, and improved political
commitment, may lead to a dramatic reduction in tuberculosis-related morbidity and mortality
among children.
2. Epidemiology of paediatric TB
2.1. Global disease burden of paediatric TB
Poor case ascertainment, lack of resources for active case finding in most settings, and limited
paediatric surveillance data from TB control programs all hamper efforts to define accurately
the global burden of childhood TB (Nelson and Wells, 2004). Until recently, under the WHO
Directly Observed Treatment Short Course (DOTS) strategy, only smear positive cases were
being reported for children, yet smears are seldom performed in many high burden settings
and most disease in children is smear negative.
Although limited surveillance data prevent reliable estimates of the contribution of TB to
childhood mortality, available data indicate that pneumonia is the commonest cause of
childhood death globally (Nelson et al., 2004) an implication that TB, being an important cause
of pneumonia in many settings (Scott et al., 2008), may contribute significantly to these global
childhood deaths. A necropsy study in Zambia found evidence of TB in 18% of HIV-positive
and 26% of HIV-negative children dying of pneumonia (Chintu et al., 2002) although more
robust regional data on the epidemiology of childhood TB are urgently needed to define the
true burden of disease, and to characterize current transmission rates and circulating strains.
2.2. Pathophysiology of TB in children
2.2.1. Natural history of TB in children
The natural history of TB in children and pediatric patients follows a series of steps in which
phase 1 occurs after an incubation period of 3–8 weeks after primary infection. This is followed
by appearance of well-defined signs that include fever, erythema nodosum, a positive
tuberculin skin test response, and formation of the primary complex visible on chest radiog‐
raphy. Phase 2 occurs 1–3 months after the phase 1 in which period, the bacillus can migrate
to other parts of the body via the blood and this represents the period of the highest risk for
the development of tuberculous meningitis and miliary tuberculosis in young children. This
is the phase where dissemination of the bacillus most frequently occurs. Phase 3 occurs 3–7
months after primary infection and is the period of pleural effusions in children greater than
5 years old and bronchial disease in children less than 5 years. Phase 4 presents after 1–3 years
after phase 1 and is during which the osteoarticular tuberculosis in children 5 years and below,
appears. Phase 5 occurs up to 3 years after phase 1 and it is presented after calcification has
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been completed. It is after this stage that manifestations of classical adult tuberculosis appear
(Marais et al., 2004).
Extrapulmonary tuberculosis or miliary TB is a complication of primary TB in young children.
It includes peripheral lymphadenopathy, TB meningitis, skeletal TB, and other organ involve‐
ment. Other unusual sites for TB include the middle ear, gastrointestinal (GI) tract, skin,
kidneys, and ocular structures (Marais et al., 2006). Lymph node involvement typically occurs
6-9 months following initial infection by the tubercle bacilli. More superficial lymph nodes
commonly are involved. Frequent sites of involvement include the anterior cervical, subman‐
dibular, and supraclavicular nodes. TB of the skeletal system may lead to involvement of the
inguinal, epitrochlear, or axillary lymph nodes. Typically, infected lymph nodes are firm and
non- tender with non erythematous overlying skin. The nodes are initially non-fluctuant.
Suppuration and spontaneous drainage of the lymph nodes may occur with caseation and the
development of necrosis (Marais et al., 2006).
Bone or joint TB or skeletal TB may present acutely or sub-acutely. Vertebral disease may go
unrecognized for months to years because of its indolent nature. Common sites involved
include the large weight-bearing bones or joints, including the vertebrae (50%), hip (15%), and
knee (15%). Destruction of the bones with deformity is a late sign of TB. Manifestations for
skeletal TB may include angulation of the spine (gibbus deformity) and/or Pott disease (severe
kyphosis with destruction of the vertebral bodies). Cervical spine involvement may result in
allantoaxial subluxation, which may lead to paraplegia or quadriplegia.
2.2.2. TB risk factors
Following infection children have a higher risk not only of progression to disease, but also of
extrapulmonary dissemination and death. Infants have a particularly high morbidity and
mortality from TB (WHO, 2007). While many factors including host genetics, microbial
virulence and underlying conditions that impair immune competence (as is the case with
malnutrition and HIV infection) determine the outcome of infection, it is likely that the high
rate of progressive TB seen in young children is largely a reflection of the immaturity of the
immune response. Risk factors for the acquisition of tuberculosis (TB) are usually exogenous
to the patient. Thus, the likelihood of being infected depends on the environment and the
features of the index case. However, the development of TB disease depends on inherent
immunologic status of the host. For example, tuberculosis has been reported in patients treated
for arthritis, inflammatory bowel disease, and other conditions with tumor necrosis factor
(TNF)-alpha blockers/antagonists.
2.2.3. Factors for acquiring paediatric TB disease
Neonatal CD4 cells appear intrinsically deficient in their capacity to express Th1 effector
function, partially attributed to hypermethylation of the proximal promoter of the IFN-γ gene,
(White et al., 2002) and this results in a highly restricted pattern of IFN-γ response to a variety
of stimuli (Kampmann et al., 2006). CD154 (CD40 ligand) expression is also significantly
reduced compared with adult cells. These findings of generally impaired cell-mediated
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immune responses in the neonate and young children raise the question of whether antigen-
specific immune responses to mycobacteria are equally affected. Delayed type hypersensitivity
(DTH) to purified protein derivative (PPD) may be absent in up to 40% of HIV negative
children presenting with extrapulmonary TB, (van der Weert et al., 2006) compounding the
difficulties of diagnosis in young children. However, studies measuring responses to neonatal
vaccination with M. bovis BCG demonstrate potent Th1 responses, possibly related to the
activating properties of BCG vaccine on the potent antigen-presenting cells (APC). Indeed
while the long term efficacy of BCG vaccination may be limited, it does offer protection against
disseminated disease in infants and young children. The risk of serious and potentially
devastating disease is nevertheless still high in the first two years of life, underscoring the need
for a better understanding of the determinants of host protection particularly in this vulnerable
age group.
In the natural history of childhood intrathoracic TB, primary infection before 2 years of age
frequently progresses to disease within the first 12 months (Marais, et al., 2004). Young age
and HIV infection are the most important risk factors for severe or disseminated disease; the
risk of disease progression decreases during childhood, least at 5–10 years of age, and increases
again during adolescence. Pulmonary parenchymal disease and intrathoracic adenopathy are
the most common clinical manifestations of pediatric TB, accounting for 60%–80% of all cases
(Jensen, 2002). Among extra-pulmonary manifestations, lymphadenopathy is the most
common (67%), followed by central nervous system involvement (13%) and pleural (6%),
disseminated (5%), and skeletal (4%) TB (Marais, 2006). Disseminated disease and TB menin‐
gitis are usually found in very young children (age, under 3 years) and/or HIV-infected
children (Starke, 2003). More research is required to identify better strategies for case detection
and contact tracing, especially in high-burden settings, and to study the role of genetic and
nutritional factors that protect children from TB infection and disease.
HIV-infected children are at risk of both atypical pulmonary presentation and extra-pul‐
monary  disease,  which  comprises  up  to  60%  of  TB  in  this  population  (Starke,  2003).
Symptom-based diagnostic approaches perform poorly, because other HIV-related condi‐
tions, such as lymphocytic interstitial pneumonitis, broncho-ectasis, and respiratory infec‐
tions  (including  viral  pneumonitis),  mimic  the  clinical  and  radiographic  features  of  TB
(Marais,  2007).  Lymphocytic interstitial  pneumonitis tends to occur in children aged less
than  two  years,  presents  with  recurrent  respiratory  symptoms,  and  is  associated  with
clubbing and generalized lymphadenopathy and a miliary TB-like picture on chest radio‐
graph.  Although these patients  improve temporarily with antibiotic  therapy,  antiretrovi‐
ral treatment is required for sustained benefit and to avoid development of chronic lung
disease.  In  the  short  term,  there  is  little  prospect  of  achieving  a  widely  available  gold
standard diagnosis of TB in children either by means of culture, microscopy, PCR, or se‐
rological testing. Consequently, clinicians must rely on clinical criteria, chest radiography,
and tuberculin testing,  and attempts must  be made to improve the predictive power of
available tools (Swaminathan and Rekha, 2010).
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been completed. It is after this stage that manifestations of classical adult tuberculosis appear
(Marais et al., 2004).
Extrapulmonary tuberculosis or miliary TB is a complication of primary TB in young children.
It includes peripheral lymphadenopathy, TB meningitis, skeletal TB, and other organ involve‐
ment. Other unusual sites for TB include the middle ear, gastrointestinal (GI) tract, skin,
kidneys, and ocular structures (Marais et al., 2006). Lymph node involvement typically occurs
6-9 months following initial infection by the tubercle bacilli. More superficial lymph nodes
commonly are involved. Frequent sites of involvement include the anterior cervical, subman‐
dibular, and supraclavicular nodes. TB of the skeletal system may lead to involvement of the
inguinal, epitrochlear, or axillary lymph nodes. Typically, infected lymph nodes are firm and
non- tender with non erythematous overlying skin. The nodes are initially non-fluctuant.
Suppuration and spontaneous drainage of the lymph nodes may occur with caseation and the
development of necrosis (Marais et al., 2006).
Bone or joint TB or skeletal TB may present acutely or sub-acutely. Vertebral disease may go
unrecognized for months to years because of its indolent nature. Common sites involved
include the large weight-bearing bones or joints, including the vertebrae (50%), hip (15%), and
knee (15%). Destruction of the bones with deformity is a late sign of TB. Manifestations for
skeletal TB may include angulation of the spine (gibbus deformity) and/or Pott disease (severe
kyphosis with destruction of the vertebral bodies). Cervical spine involvement may result in
allantoaxial subluxation, which may lead to paraplegia or quadriplegia.
2.2.2. TB risk factors
Following infection children have a higher risk not only of progression to disease, but also of
extrapulmonary dissemination and death. Infants have a particularly high morbidity and
mortality from TB (WHO, 2007). While many factors including host genetics, microbial
virulence and underlying conditions that impair immune competence (as is the case with
malnutrition and HIV infection) determine the outcome of infection, it is likely that the high
rate of progressive TB seen in young children is largely a reflection of the immaturity of the
immune response. Risk factors for the acquisition of tuberculosis (TB) are usually exogenous
to the patient. Thus, the likelihood of being infected depends on the environment and the
features of the index case. However, the development of TB disease depends on inherent
immunologic status of the host. For example, tuberculosis has been reported in patients treated
for arthritis, inflammatory bowel disease, and other conditions with tumor necrosis factor
(TNF)-alpha blockers/antagonists.
2.2.3. Factors for acquiring paediatric TB disease
Neonatal CD4 cells appear intrinsically deficient in their capacity to express Th1 effector
function, partially attributed to hypermethylation of the proximal promoter of the IFN-γ gene,
(White et al., 2002) and this results in a highly restricted pattern of IFN-γ response to a variety
of stimuli (Kampmann et al., 2006). CD154 (CD40 ligand) expression is also significantly
reduced compared with adult cells. These findings of generally impaired cell-mediated
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immune responses in the neonate and young children raise the question of whether antigen-
specific immune responses to mycobacteria are equally affected. Delayed type hypersensitivity
(DTH) to purified protein derivative (PPD) may be absent in up to 40% of HIV negative
children presenting with extrapulmonary TB, (van der Weert et al., 2006) compounding the
difficulties of diagnosis in young children. However, studies measuring responses to neonatal
vaccination with M. bovis BCG demonstrate potent Th1 responses, possibly related to the
activating properties of BCG vaccine on the potent antigen-presenting cells (APC). Indeed
while the long term efficacy of BCG vaccination may be limited, it does offer protection against
disseminated disease in infants and young children. The risk of serious and potentially
devastating disease is nevertheless still high in the first two years of life, underscoring the need
for a better understanding of the determinants of host protection particularly in this vulnerable
age group.
In the natural history of childhood intrathoracic TB, primary infection before 2 years of age
frequently progresses to disease within the first 12 months (Marais, et al., 2004). Young age
and HIV infection are the most important risk factors for severe or disseminated disease; the
risk of disease progression decreases during childhood, least at 5–10 years of age, and increases
again during adolescence. Pulmonary parenchymal disease and intrathoracic adenopathy are
the most common clinical manifestations of pediatric TB, accounting for 60%–80% of all cases
(Jensen, 2002). Among extra-pulmonary manifestations, lymphadenopathy is the most
common (67%), followed by central nervous system involvement (13%) and pleural (6%),
disseminated (5%), and skeletal (4%) TB (Marais, 2006). Disseminated disease and TB menin‐
gitis are usually found in very young children (age, under 3 years) and/or HIV-infected
children (Starke, 2003). More research is required to identify better strategies for case detection
and contact tracing, especially in high-burden settings, and to study the role of genetic and
nutritional factors that protect children from TB infection and disease.
HIV-infected children are at risk of both atypical pulmonary presentation and extra-pul‐
monary  disease,  which  comprises  up  to  60%  of  TB  in  this  population  (Starke,  2003).
Symptom-based diagnostic approaches perform poorly, because other HIV-related condi‐
tions, such as lymphocytic interstitial pneumonitis, broncho-ectasis, and respiratory infec‐
tions  (including  viral  pneumonitis),  mimic  the  clinical  and  radiographic  features  of  TB
(Marais,  2007).  Lymphocytic interstitial  pneumonitis tends to occur in children aged less
than  two  years,  presents  with  recurrent  respiratory  symptoms,  and  is  associated  with
clubbing and generalized lymphadenopathy and a miliary TB-like picture on chest radio‐
graph.  Although these patients  improve temporarily with antibiotic  therapy,  antiretrovi‐
ral treatment is required for sustained benefit and to avoid development of chronic lung
disease.  In  the  short  term,  there  is  little  prospect  of  achieving  a  widely  available  gold
standard diagnosis of TB in children either by means of culture, microscopy, PCR, or se‐
rological testing. Consequently, clinicians must rely on clinical criteria, chest radiography,
and tuberculin testing,  and attempts must  be made to improve the predictive power of
available tools (Swaminathan and Rekha, 2010).
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2.2.4. Host genetic susceptibility to paediatric TB
The immunological responses to MTB are due to the interaction between the immature
immune system in children, the host, bacterial and environmental factors (Meya and McAdam,
2007). Genetic as well as acquired defects in host immune response pathways greatly increase
the risk of progressive disease (Kampmann et al., 2005). Results from genome wide linkage
studies suggest that TB disease susceptibility is highly likely to be polygenic, with contribu‐
tions from many minor loci (Hill, 2006) and a large number of TB susceptibility markers have
been identified from candidate gene studies as ‘disease-causing’ genes which include TIRAP,
HLA DQB1, VDR, IL-12β, IL12Rβ1, IFN-γ, SLC11A1 and MCP-1. However, to date the greatest
evidence to support an underlying genetic basis for TB has come from the discovery of single
gene defects predisposing to disseminated and often lethal mycobacterial disease. Most
observations were initially made in children with reduced ability to activate macrophage
antimycobacterial mechanisms through defects in the IFN-γ (Kampmann et al., 2005) /IL-12
pathway resulting in severe mycobacterial infection. However, subsequent studies have led
to description of mutations in five susceptibility genes (Ottenhoff et al., 2005) confirming that
up-regulation of the macrophage through the IL-12/23-IFN-γ pathway is a fundamental step
in the containment of infection with mycobacteria. However, despite a growing adult literature
on the role of candidate genes from this pathway, data from children is scarce. This is surprising
given the marked differences in TB pathophysiology in children, which may also reflect
differences in genetic factors. Further studies of TB genetics in well-defined paediatric
populations are therefore needed.
2.3. Impact of HIV epidemic paeditric TB
Studies demonstrating a higher risk of TB among HIV- children (Jeena et al., 2002) highlight
the essential role of cell mediated immunity (CMI) in preventing mycobacterial dissemination
(Tena et al., 2003). Poor CMI in HIV co-infection often results in disseminated disease,
especially in advanced stages of HIV-infection, resulting in poorer survival compared to HIV-
negative children (Palme et al., 2002). Risk of active TB in HIV co-infected children is related
to both CD4 count and more indirectly also to viral load (Elenga et al., 2005).Conversely,
restoration of cellular immunity with anti-retroviral therapy partially reverses TB susceptibil‐
ity (Kampmann et al., 2006).
The impact of the Human Immunodeficiency Virus (HIV) epidemic on the burden of childhood
TB has been less well characterized than for adults (Corbett et al., 2003). However, the observed
shift in disease burden to younger adults it has caused, suggests that children are at particularly
high risk of exposure as well as disease (Graham et al, 2001). Reported prevalence of HIV co-
infection among children with TB range from below 5%, in industrialized settings, to over 50%
in some high burden African settings (Nelson and Wells, 2004). However, it is often difficult
to draw reliable inferences about the effect of HIV on TB incidence or risk from these obser‐
vational data due to ascertainment bias or diagnostic bias; incomplete ascertainment of HIV
status and because denominator population data on the proportion of all children infected
with HIV are usually lacking. (For example, children with HIV are more likely to be investi‐
gated for TB and diagnosis is unreliable because it is affected by HIV status). Nevertheless an
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increased TB incidence and poorer outcome have been observed among HIV infected children
in a variety of settings (Palme et al., 2002) including an estimated 20-fold increased TB incidence
associated with HIV infection in a study from South Africa. Methodological constraints in some
studies may explain why this has not been a universal finding (Marais et al., 2007).
2.4. Nutrition and paediatric TB
Several observational studies from adults and children show an association between mal‐
nutrition  and  TB,  (Cegielski  and  McMurray,  2004)  although  proving  the  direction  of  a
causal link is challenging, as TB in itself causes wasting. Diagnosis is further complicated
by frequently false negative TST in malnutrition, reverting to positivity only once nutri‐
tion has improved. Nevertheless these observational data, coupled with experimental ani‐
mal data and impaired CMI observed in malnutrition, support its role as a risk factor for
childhood TB (Cegielski and McMurray, 2004). However the effect of differing types and
degrees of  malnutrition,  and the population at  risk due to  malnutrition in communities
where both are endemic, are yet to be defined.
Among micronutrients, vitamin D deficiency has been most extensively studied, and shown
to be associated with TB in UK immigrants. Its active metabolite 1-alpha, 25-dihydroxy-
vitamin D modulates the host response to TB infection in numerous ways, including the
induction of antimicrobial peptides such as Cathelicidin LL-37 (Martineau et al., 2007).
2.5. Host-pathogen interactions in paediatric TB
The relationship between MTB strain genotype and clinical manifestation of disease is poorly
documented in children. A study in the Western Cape Province of South Africa demonstrated
that the Beijing and Haarlem genotype families are significantly associated with drug resistant
TB in children (Marais et al., 2006). The high prevalence of Beijing and Latin American
Mediterranean (LAM) strains in children reflects considerable transmission of these genotype
families in this setting (Marais et al., 2006).
Genetic markers of virulence and transmissibility, (Lopez et al., 2003) and the ability to
modulate host cellular immunity have been described for the Beijing strain, HN878 (Reed, et
al., 2004). Similarly the East African-Indian lineage is characterized by an LSP (Large Sequence
Polymorphism) conferring an immune subverting phenotype that contributes to its persistence
and outbreak potential of this lineage (Newton et al., 2006). Strain differences in immunoge‐
nicity may result in reduced detection by TST (Anderson et al., 2006) as documented in a
London school contact tracing investigation - an extremely worrying phenomenon which may
lead to underestimates of the true global burden of TB and underscores the need for new
diagnostics. Most studies of strain-specific responses are derived from adult TB cases, and it
remains to be established whether results are equally applicable to children. Further research
to characterize strain differences in pathogenicity and induction of immune responses should
include children as well as adults.
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2.2.4. Host genetic susceptibility to paediatric TB
The immunological responses to MTB are due to the interaction between the immature
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2007). Genetic as well as acquired defects in host immune response pathways greatly increase
the risk of progressive disease (Kampmann et al., 2005). Results from genome wide linkage
studies suggest that TB disease susceptibility is highly likely to be polygenic, with contribu‐
tions from many minor loci (Hill, 2006) and a large number of TB susceptibility markers have
been identified from candidate gene studies as ‘disease-causing’ genes which include TIRAP,
HLA DQB1, VDR, IL-12β, IL12Rβ1, IFN-γ, SLC11A1 and MCP-1. However, to date the greatest
evidence to support an underlying genetic basis for TB has come from the discovery of single
gene defects predisposing to disseminated and often lethal mycobacterial disease. Most
observations were initially made in children with reduced ability to activate macrophage
antimycobacterial mechanisms through defects in the IFN-γ (Kampmann et al., 2005) /IL-12
pathway resulting in severe mycobacterial infection. However, subsequent studies have led
to description of mutations in five susceptibility genes (Ottenhoff et al., 2005) confirming that
up-regulation of the macrophage through the IL-12/23-IFN-γ pathway is a fundamental step
in the containment of infection with mycobacteria. However, despite a growing adult literature
on the role of candidate genes from this pathway, data from children is scarce. This is surprising
given the marked differences in TB pathophysiology in children, which may also reflect
differences in genetic factors. Further studies of TB genetics in well-defined paediatric
populations are therefore needed.
2.3. Impact of HIV epidemic paeditric TB
Studies demonstrating a higher risk of TB among HIV- children (Jeena et al., 2002) highlight
the essential role of cell mediated immunity (CMI) in preventing mycobacterial dissemination
(Tena et al., 2003). Poor CMI in HIV co-infection often results in disseminated disease,
especially in advanced stages of HIV-infection, resulting in poorer survival compared to HIV-
negative children (Palme et al., 2002). Risk of active TB in HIV co-infected children is related
to both CD4 count and more indirectly also to viral load (Elenga et al., 2005).Conversely,
restoration of cellular immunity with anti-retroviral therapy partially reverses TB susceptibil‐
ity (Kampmann et al., 2006).
The impact of the Human Immunodeficiency Virus (HIV) epidemic on the burden of childhood
TB has been less well characterized than for adults (Corbett et al., 2003). However, the observed
shift in disease burden to younger adults it has caused, suggests that children are at particularly
high risk of exposure as well as disease (Graham et al, 2001). Reported prevalence of HIV co-
infection among children with TB range from below 5%, in industrialized settings, to over 50%
in some high burden African settings (Nelson and Wells, 2004). However, it is often difficult
to draw reliable inferences about the effect of HIV on TB incidence or risk from these obser‐
vational data due to ascertainment bias or diagnostic bias; incomplete ascertainment of HIV
status and because denominator population data on the proportion of all children infected
with HIV are usually lacking. (For example, children with HIV are more likely to be investi‐
gated for TB and diagnosis is unreliable because it is affected by HIV status). Nevertheless an
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increased TB incidence and poorer outcome have been observed among HIV infected children
in a variety of settings (Palme et al., 2002) including an estimated 20-fold increased TB incidence
associated with HIV infection in a study from South Africa. Methodological constraints in some
studies may explain why this has not been a universal finding (Marais et al., 2007).
2.4. Nutrition and paediatric TB
Several observational studies from adults and children show an association between mal‐
nutrition  and  TB,  (Cegielski  and  McMurray,  2004)  although  proving  the  direction  of  a
causal link is challenging, as TB in itself causes wasting. Diagnosis is further complicated
by frequently false negative TST in malnutrition, reverting to positivity only once nutri‐
tion has improved. Nevertheless these observational data, coupled with experimental ani‐
mal data and impaired CMI observed in malnutrition, support its role as a risk factor for
childhood TB (Cegielski and McMurray, 2004). However the effect of differing types and
degrees of  malnutrition,  and the population at  risk due to  malnutrition in communities
where both are endemic, are yet to be defined.
Among micronutrients, vitamin D deficiency has been most extensively studied, and shown
to be associated with TB in UK immigrants. Its active metabolite 1-alpha, 25-dihydroxy-
vitamin D modulates the host response to TB infection in numerous ways, including the
induction of antimicrobial peptides such as Cathelicidin LL-37 (Martineau et al., 2007).
2.5. Host-pathogen interactions in paediatric TB
The relationship between MTB strain genotype and clinical manifestation of disease is poorly
documented in children. A study in the Western Cape Province of South Africa demonstrated
that the Beijing and Haarlem genotype families are significantly associated with drug resistant
TB in children (Marais et al., 2006). The high prevalence of Beijing and Latin American
Mediterranean (LAM) strains in children reflects considerable transmission of these genotype
families in this setting (Marais et al., 2006).
Genetic markers of virulence and transmissibility, (Lopez et al., 2003) and the ability to
modulate host cellular immunity have been described for the Beijing strain, HN878 (Reed, et
al., 2004). Similarly the East African-Indian lineage is characterized by an LSP (Large Sequence
Polymorphism) conferring an immune subverting phenotype that contributes to its persistence
and outbreak potential of this lineage (Newton et al., 2006). Strain differences in immunoge‐
nicity may result in reduced detection by TST (Anderson et al., 2006) as documented in a
London school contact tracing investigation - an extremely worrying phenomenon which may
lead to underestimates of the true global burden of TB and underscores the need for new
diagnostics. Most studies of strain-specific responses are derived from adult TB cases, and it
remains to be established whether results are equally applicable to children. Further research
to characterize strain differences in pathogenicity and induction of immune responses should
include children as well as adults.
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2.6. Clinical spectrum of paediatric TB disease
The clinical spectrum of childhood TB also reflects differences in the balance between the
pathogen and the host immune response, with more severe disease resulting from either poor
or ‘over-exuberant’ attempts to contain the disease. Many cases of primary TB infection in
children are asymptomatic, self-healing and remain completely unnoticed or accidentally
discovered at a later stage (Marais et al., 2004). In previously healthy children, what determines
the differences in the host/pathogen interactions that lead to successful containment as
opposed to progressive disease remains largely unknown. However, age and immunodefi‐
ciency are important factors. Thus, while an exuberant immune response, in immunocompe‐
tent adolescents, tends to result in adult-type, cavitating disease, (Marais et al., 2005) in young
children and/or HIV co-infection, poor CMI is thought to allow unrestrained proliferation of
bacilli with progressive parenchymal lung damage (with or without cavity formation)
dissemination (Marais et al., 2005)
While dissemination can occur to almost any site, TB meningitis (TBM) is one of the commonest
consequences of extra-pulmonary TB and develops three to six months after primary infection
(Donald and Schoeman, 2004). It is also the most severe and potentially devastating form of
childhood TB with mortality or significant long term neurological sequelae occurring in almost
50% of cases (Thwaites and Tran, 2005). Anatomical differences in children, compared with
adults, also modify the presentation of TB. Complications arising from enlarging lymph nodes
and small airways are common in children less than five years of age (Marais, et al., 2004;
Marais et al., 2005). Post-primary TB can result in upper-lobe pulmonary consolidation and
cavitation with highly infectious patients, more likely to be seen in older children.
HIV infection often mimics TB associated signs and symptoms, such as weight loss, failure to
thrive and chronic pulmonary symptoms, corroborating the diagnostic difficulties (reviewed
in references (Marais et al., 2007). In turn, the treatment of HIV with ART can result in
unmasking signs and symptoms of underlying LTBI or active TB in the form of immune
reconstitution disease (IRD) (Walters et al., 2006) in young children is largely a reflection on
the immaturity of the immune response.
2.7. Differences in childhood immune responses to TB
The alveolar macrophage is the first line of defense in the innate immune response to TB
and  plays  a  critical  role  in  amplifying  the  response  to  infection.  Studies  in  the  animal
and human host have consistently demonstrated reduced microbial killing and diminish‐
ed monocyte recruitment to the site of infection in infants compared to adults. Thus im‐
pairment  of  innate  pulmonary  defenses  in  the  neonate  and  infant  may  allow
mycobacteria  to  overwhelm the effects  of  the innate immune system prior  to  the initia‐
tion of an antigen-specific immune response.
Antigen presentation by dendritic cells (DC), the major antigen-presenting cell (APC) in the
lung, and the efficiency with which naïve T cells respond to antigen, also appears less effective
in infants and may contribute to the delay in initiating an appropriate antigen-specific
response, resulting in development of active disease. Blood derived DCs are functionally
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immature at birth relative to adult DCs and continue to express a less differentiated phenotype
throughout early childhood (Upham et al., 2006). Some studies also suggest that neonatal APCs
lack the capacity to deliver important Th1 polarising signals to T-cells. Their capacity to
synthesise interleukin (IL)-12, a key APC-derived cytokine, matures slowly during childhood
(Upham et al., 2002) and neonatal, monocyte-derived DCs have a specific defect in IL-12p35
expression (Goriely et al., 2001). IL-12 is critical for the initial phases of Th1 polarisation and
also for maintaining the efficiency of the interferon (IFN)-γ transcription machinery in Th1
effector cells (Goriely et al., 2001).
2.8. Latent tuberculosis in children
2.8.1. Detection of the infection
Transmission within a community is measured by the Annual Risk of Infection (ARI) (Rieder,
2005). Infection rates rise with increased exposure in toddlers, around the ages of school entry
and with increased social mobility in late teens and early adulthood (Marais et al., 2004). ARI
is traditionally estimated using childhood tuberculin surveys, although this has limitations
due to the poor specificity of the tuberculin skin test (TST), particularly where Bacille Calmette
Guerin (BCG) vaccine is given at birth and non-tuberculous mycobacteria (NTM) are endemic.
T-cell based interferon gamma release assays (IGRAs) may offer a more specific alternative
(Dinnes et al., 2007), but have not yet found a use in this context due to their cost, ethical
concerns about venepuncture in healthy children (Rieder, 2005), and uncertainty about the
significance of a positive result for later development of active disease. Threfore, differences
in the pathophysiology and clinical presentation of TB in children make diagnosis more
challenging than in adults (Shingadia and Novelli, 2003) and the definitions of latent infection
and disease, are less clear cut (Marais et al., 2004).
2.8.2. Activation from infection to disease
Following infection, several factors appear to influence the balance of risk between latent TB
infection (LTBI) or progression to active disease, including age (Marais et al., 2004) and
nutritional (Cegielski and McMurray, 2004), vaccination and immune status (Chen, 2004).
Children are at much higher risk of progression to active disease than adults. This risk is
greatest for infants and children under 2 years of age (Marais et al., 2004). Active surveillance
data from the pre-chemotherapy era suggest that the majority of children develop radiological
abnormalities following infection, including 60-80% of children less than two years. However,
less than 10% of those are notified, suggesting the disease is controlled by the host immune
response in most cases (Marais et al., 2004). This has implications for case definitions based on
radiological findings. Overall the risk of disease is highest among infants and in late teens,
with the lowest risk between 5 and 10 years - the so-called “safe school years” (Marais et al.,
2004). Most disease occurred in the first year following infection (Marais et al., 2004). Thus
because disease in young children reflects recent infection, rather than secondary reactivation,
the paediatric disease burden potentially provides a useful measure of current transmission
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2.6. Clinical spectrum of paediatric TB disease
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ed monocyte recruitment to the site of infection in infants compared to adults. Thus im‐
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mycobacteria  to  overwhelm the effects  of  the innate immune system prior  to  the initia‐
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Antigen presentation by dendritic cells (DC), the major antigen-presenting cell (APC) in the
lung, and the efficiency with which naïve T cells respond to antigen, also appears less effective
in infants and may contribute to the delay in initiating an appropriate antigen-specific
response, resulting in development of active disease. Blood derived DCs are functionally
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also for maintaining the efficiency of the interferon (IFN)-γ transcription machinery in Th1
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is traditionally estimated using childhood tuberculin surveys, although this has limitations
due to the poor specificity of the tuberculin skin test (TST), particularly where Bacille Calmette
Guerin (BCG) vaccine is given at birth and non-tuberculous mycobacteria (NTM) are endemic.
T-cell based interferon gamma release assays (IGRAs) may offer a more specific alternative
(Dinnes et al., 2007), but have not yet found a use in this context due to their cost, ethical
concerns about venepuncture in healthy children (Rieder, 2005), and uncertainty about the
significance of a positive result for later development of active disease. Threfore, differences
in the pathophysiology and clinical presentation of TB in children make diagnosis more
challenging than in adults (Shingadia and Novelli, 2003) and the definitions of latent infection
and disease, are less clear cut (Marais et al., 2004).
2.8.2. Activation from infection to disease
Following infection, several factors appear to influence the balance of risk between latent TB
infection (LTBI) or progression to active disease, including age (Marais et al., 2004) and
nutritional (Cegielski and McMurray, 2004), vaccination and immune status (Chen, 2004).
Children are at much higher risk of progression to active disease than adults. This risk is
greatest for infants and children under 2 years of age (Marais et al., 2004). Active surveillance
data from the pre-chemotherapy era suggest that the majority of children develop radiological
abnormalities following infection, including 60-80% of children less than two years. However,
less than 10% of those are notified, suggesting the disease is controlled by the host immune
response in most cases (Marais et al., 2004). This has implications for case definitions based on
radiological findings. Overall the risk of disease is highest among infants and in late teens,
with the lowest risk between 5 and 10 years - the so-called “safe school years” (Marais et al.,
2004). Most disease occurred in the first year following infection (Marais et al., 2004). Thus
because disease in young children reflects recent infection, rather than secondary reactivation,
the paediatric disease burden potentially provides a useful measure of current transmission
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within a community, Marais et al., 2005) including multi-drug resistant (MDR) (Schaaf et al.,
2006) and extensively drug resistant (XDR) strains.
3. Challenges presented by paediatric TB in the field of diagnosis and
treatment
3.1. Concepts from the natural history of disease
The pre-chemotherapy literature documented the natural history of tuberculosis in children.
Unfortunately, clinicians and researchers have limited access to these important studies as they
were conducted before 1950 and are not included in modern electronic databanks. Since the
discovery of safe and effective antituberculosis treatment, conducting studies on the natural
history of disease became unethical and therefore these historic disease descriptions remain
invaluable today. The pre-chemotherapy literature provides a strong body of evidence;
multiple studies monitored large cohorts of children for prolonged periods of time and
carefully documented the development of disease after primary infection with Mycobacterium
tuberculosis. A critical review of the natural history of disease identified three central concepts
that are important to consider when addressing current and/or future challenges in the field
of childhood tuberculosis: (1) the need for accurate case definitions, (2) the importance of risk
stratification, and (3) the diverse spectrum of disease pathology, which necessitates accurate
disease classification (Marais et al., 2004).
3.2. Challenge of case definition
Accurate case definition revolves mainly around the ability to differentiate primary infection
from active disease. Primary infection is believed to occur when a previously uninfected child
inhales a single infectious aerosol droplet, which may contain fewer than five bacilli that
penetrate into a terminal airway. A localized pneumonic process, referred to as the primary
parenchymal (Ghon) focus, results at the site of organism deposition. For the first 4–6 weeks,
unrestrained multiplication occurs within the Ghon focus and bacilli drain via local lymphatics
to the regional lymph nodes and beyond. The upper lobes drain to ipsilateral–paratracheal
nodes, whereas the rest of the lung drains to perihilar and subcarinal nodes, with dominant
lymph flow from left to right (Marais et al., 2006). The Ghon complex is represented by both
the Ghon focus, with or without some overlying pleural reaction, and the affected regional
lymph nodes (Marais et al., 2006).
Occult dissemination frequently occurs during this early proliferative phase before cell-
mediated immunity is fully activated. Bacteriologic cultures collected at this time may be
positive; Wallgren demonstrated in the 1930s that M. tuberculosis is sometimes recovered from
recently infected children who are not diseased. Therefore, with active contact tracing and
aggressive screening that includes the collection of mycobacterial cultures in asymptomatic
children it is not unexpected to find some positive cultures in recently infected children who
are not diseased. This illustrates the overlap that exists between recent primary infection and
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case definitions of disease that rely exclusively on bacteriology. It is important to consider this
overlap when case definitions are formulated for research purposes, particularly within the
contact setting, although it is less relevant in everyday practice where there is no reason to
obtain cultures from completely asymptomatic children.
Uncomplicated hilar adenopathy remains the most common disease manifestation in children
and is usually regarded as the hallmark of primary tuberculosis. However, the prechemother‐
apy literature documented transient hilar adenopathy in the majority (50–60%) of children
after recent primary pulmonary infection, of whom only a few progressed to disease (Marais
et al., 2004). The natural history of disease illustrates that progression to disease is indicated
by the onset of persistent, nonremitting symptoms, referred to as the breakpoint of clinical
significance whereas the complete absence of symptoms usually indicates good organism
containment (Marais et al., 2004). By convention, asymptomatic hilar adenopathy is currently
treated as active disease, although early experience with isoniazid alone demonstrated that
one-drug therapy was sufficient in these cases. In terms of pathophysiology, microbiology,
and natural history, asymptomatic hilar adenopathy is more indicative of recent primary
infection than active disease (Marais et al., 2004).
This indicates that radiologic signs should be interpreted with caution in the absence of clinical
data. The entity of so-called asymptomatic tuberculosis, where the case definition rests
exclusively on radiographic criteria, is a case in point. High-resolution computed tomography
is the most sensitive tool available to detect hilar adenopathy (Andronikou et al., 2004), as
demonstrated by the fact that in children with recent M. tuberculosis infection and a normal
chest radiograph, prominent intrathoracic nodes are frequently demonstrated by high-
resolution computed tomography. Particular caution is required when interpreting the
relevance of these radiologic signs in the absence of clinical data. It is important to point out
that there is no role for high-resolution computed tomography in the evaluation of asympto‐
matic, immune-competent children exposed to M. tuberculosis.
In reality, differences in patient selection may result in the use of different functional case
definitions even though the definitions appear similar on paper. In non-endemic areas where
active contact tracing is diligently enforced, more children with transient radiologic signs
indicative of recent primary infection will be identified, and those with active disease will be
diagnosed at an earlier, less advanced stage. Active contact tracing is rarely enforced in
endemic areas and children usually present to health care facilities with suspicious symptoms
and more advanced disease (Marais et al., 2006). Unlike asymptomatic contacts in which visible
radiologic signs probably indicate recent primary infection only, radiologic signs in sympto‐
matic children indicate active disease. From a research perspective it is important to be aware
of these differences, as inconsistent case definitions may confound the scientific interpretation
of results. In everyday practice, distinguishing between the signs and symptoms of recent
primary infection and active disease is less relevant in high-risk children (less than 3 years of
age and/or immune compromised) in whom infection frequently progresses to disease,
sometimes with rapid disease progression.
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penetrate into a terminal airway. A localized pneumonic process, referred to as the primary
parenchymal (Ghon) focus, results at the site of organism deposition. For the first 4–6 weeks,
unrestrained multiplication occurs within the Ghon focus and bacilli drain via local lymphatics
to the regional lymph nodes and beyond. The upper lobes drain to ipsilateral–paratracheal
nodes, whereas the rest of the lung drains to perihilar and subcarinal nodes, with dominant
lymph flow from left to right (Marais et al., 2006). The Ghon complex is represented by both
the Ghon focus, with or without some overlying pleural reaction, and the affected regional
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Occult dissemination frequently occurs during this early proliferative phase before cell-
mediated immunity is fully activated. Bacteriologic cultures collected at this time may be
positive; Wallgren demonstrated in the 1930s that M. tuberculosis is sometimes recovered from
recently infected children who are not diseased. Therefore, with active contact tracing and
aggressive screening that includes the collection of mycobacterial cultures in asymptomatic
children it is not unexpected to find some positive cultures in recently infected children who
are not diseased. This illustrates the overlap that exists between recent primary infection and
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case definitions of disease that rely exclusively on bacteriology. It is important to consider this
overlap when case definitions are formulated for research purposes, particularly within the
contact setting, although it is less relevant in everyday practice where there is no reason to
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Uncomplicated hilar adenopathy remains the most common disease manifestation in children
and is usually regarded as the hallmark of primary tuberculosis. However, the prechemother‐
apy literature documented transient hilar adenopathy in the majority (50–60%) of children
after recent primary pulmonary infection, of whom only a few progressed to disease (Marais
et al., 2004). The natural history of disease illustrates that progression to disease is indicated
by the onset of persistent, nonremitting symptoms, referred to as the breakpoint of clinical
significance whereas the complete absence of symptoms usually indicates good organism
containment (Marais et al., 2004). By convention, asymptomatic hilar adenopathy is currently
treated as active disease, although early experience with isoniazid alone demonstrated that
one-drug therapy was sufficient in these cases. In terms of pathophysiology, microbiology,
and natural history, asymptomatic hilar adenopathy is more indicative of recent primary
infection than active disease (Marais et al., 2004).
This indicates that radiologic signs should be interpreted with caution in the absence of clinical
data. The entity of so-called asymptomatic tuberculosis, where the case definition rests
exclusively on radiographic criteria, is a case in point. High-resolution computed tomography
is the most sensitive tool available to detect hilar adenopathy (Andronikou et al., 2004), as
demonstrated by the fact that in children with recent M. tuberculosis infection and a normal
chest radiograph, prominent intrathoracic nodes are frequently demonstrated by high-
resolution computed tomography. Particular caution is required when interpreting the
relevance of these radiologic signs in the absence of clinical data. It is important to point out
that there is no role for high-resolution computed tomography in the evaluation of asympto‐
matic, immune-competent children exposed to M. tuberculosis.
In reality, differences in patient selection may result in the use of different functional case
definitions even though the definitions appear similar on paper. In non-endemic areas where
active contact tracing is diligently enforced, more children with transient radiologic signs
indicative of recent primary infection will be identified, and those with active disease will be
diagnosed at an earlier, less advanced stage. Active contact tracing is rarely enforced in
endemic areas and children usually present to health care facilities with suspicious symptoms
and more advanced disease (Marais et al., 2006). Unlike asymptomatic contacts in which visible
radiologic signs probably indicate recent primary infection only, radiologic signs in sympto‐
matic children indicate active disease. From a research perspective it is important to be aware
of these differences, as inconsistent case definitions may confound the scientific interpretation
of results. In everyday practice, distinguishing between the signs and symptoms of recent
primary infection and active disease is less relevant in high-risk children (less than 3 years of
age and/or immune compromised) in whom infection frequently progresses to disease,
sometimes with rapid disease progression.
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3.3. Problems of risk stratification
The natural history of disease demonstrates that age is the most important variable that
determines the risk to progress to disease after primary M. tuberculosis infection in immune-
competent children (Marais et al., 2004). Infants are at the highest risk (Marais et al., 2004) and
the risk drops but stays appreciable in the second year of life, to reach its lowest level in children
infected between 5 and 10 years of age (Marais et al., 2004). Children with human immuno‐
deficiency virus (HIV) infection and/or other forms of immune compromise, such as severe
malnutrition, seem to experience a similar high risk as the very young (less than 2 years of
age), immune-immature children (Marais et al., 2004). The vast majority (more than 95%) of
children who progress to disease do so within 12 months of primary infection and, therefore,
it seems prudent to categorize all children less than 3 years of age and/or immune-compro‐
mised children as high-risk. Because of the frequency and rapidity with which disease
progression may occur, exposure to and/or infection with M. tuberculosis warrants treatment
intervention in this high-risk group (Marais et al., 2004).
Immune-competent children of at least 3 years of age are at low risk of progression to disease
after primary infection. However, as the vast majority of children in endemic areas become
infected after 2 to 3 years of age, these low-risk children still contribute a significant percentage
to the total disease burden. In addition, although these children are at low risk to progress to
disease, latent infection with M. tuberculosis does pose the risk of future reactivation of the
disease. In non-endemic areas, where transmission rates are low and eradicating the pool of
latent infection is an achievable aim, the provision of preventive therapy to these low-risk
children is warranted. In endemic areas, where the majority of disease in immune-competent
adults results from ongoing transmission and not from reactivation (Saiman et al., 2001), the
provision of preventive therapy after exposure and/or infection becomes less relevant. The
major diagnostic challenge in this low-risk group is the differentiation between latent infection
and active disease (Marais et al., 2004). Fortunately, active disease is accompanied by persis‐
tent, non-remitting symptoms and disease progression is slow, which provides a window of
opportunity for symptom-based diagnosis (Marais et al., 2004).
3.4. Difficulties in classifying disease diversity
Childhood tuberculosis is often reported as a single disease entity, although it represents a
diverse spectrum of pathology (Marais et al., 2004), and one of the obstacles has been the lack
of standard descriptive terminology. Accurate disease classification is important, because of
its prognostic significance and to facilitate scientific communication and optimal case man‐
agement. Within the Ghon focus, containment is usually successful, but disease progression
may result from either poor or “excessive” containment. Poor containment and unrestrained
organism proliferation may cause progressive parenchymal damage, with ultimate break‐
down of the Ghon focus. Infants (Dinnes et al., 2007) and HIV-positive children (Pai et al.,
2004), who have poor cell-mediated immune responses, are most vulnerable to this type of
cavitation. In contrast, immune-competent adolescents seem to mount an “excessive” (dam‐
aging) immune response in an attempt to contain the organism. The exact immune mechanisms
underlying adult-type disease remain uncertain, but it is a striking observation that it emerges
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only as children enter into puberty (Marais et al., 2004). It is important to remember that
children with adult-type disease are frequently sputum smear–positive and that they do
contribute to disease transmission (Cegielski and McMurray, 2004), particularly in congregate
settings such as schools.
Complications that arise from affected lymph nodes are most common in children less than 5
years old, because of exuberant lymph node enlargement and small airway size (Marais et al.,
2004). Extraluminal compression results when the airway is encircled by enlarged lymph
nodes and associated inflammatory edema (Marais et al., 2004). Intraluminal obstruction
results from polyps or granulomatous tissue that develops secondary to inflammatory changes
in the bronchial wall, or when caseous material is deposited into an airway after lymph node
eruption (Marais et al., 2004). Radiologic signs vary from segmental or lobar hyperinflation
with partial obstruction and a check-valve effect (Marais et al., 2004), to segmental or lobar
collapse with total obstruction and resorption of distal air (Marais et al., 2004). The pathology
that results from the aspiration of caseous material is influenced by the dose and virulence of
the bacilli aspirated. The pathology may range from transient parenchymal consolidation,
resulting from a pure hypersensitivity response to dead bacilli and/or toxic products, to an
expansile pneumonic process with progressive caseating pneumonia in the affected segment
or lobe (Marais et al., 2004). Expansible caseating pneumonia frequently leads to parenchymal
destruction and cavity formation.
Thus, cavitary disease in children may result from three distinct pathologic processes: (1) poor
containment at the site of organism deposition (very young and/or immune-compromised
children); (2) aspiration of live bacilli when a diseased lymph node erupts into an airway, with
destructive caseating pneumonia in the distal segment or lobe (children less than 5 year of
age); and (3) adult-type disease (mainly children greater than 10 year of age). The fact that
immune-competent children 5 to 10 yr of age experience the lowest risk to progress to disease
after primary infection with M. tuberculosis is an interesting immunologic phenomenon that
is poorly understood. A better understanding of age-related differences in the immune
response to M. tuberculosis may provide important insight into immune correlates of disease
and protection.
Disseminated disease occurs predominantly in very young (immune-immature) and/or
immune-compromised children, such as the HIV-infected or severely malnourished (Pai et al.,
2004; Shingadia and Chen, 2004). These children have suboptimal cellular immune responses
and demonstrate poor containment of the organism, both within the regional lymph nodes
and at the multiple sites of occult dissemination. TB meningitis (TBM) is the most dangerous
complication of disseminated disease, occurring in 20 to 30% of cases (Chen, 2004).
3.5. Challenges in diagnosis
3.5.1. Overview of diagnostic challenges
Diagnostic difficulties pose the greatest challenge to childhood TB management (Marais and
Pai, 2007). There are diagnostic complications because: (i) TB can mimic many common child‐
hood diseases, including pneumonia, generalized bacterial and viral infections, malnutrition,
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children with adult-type disease are frequently sputum smear–positive and that they do
contribute to disease transmission (Cegielski and McMurray, 2004), particularly in congregate
settings such as schools.
Complications that arise from affected lymph nodes are most common in children less than 5
years old, because of exuberant lymph node enlargement and small airway size (Marais et al.,
2004). Extraluminal compression results when the airway is encircled by enlarged lymph
nodes and associated inflammatory edema (Marais et al., 2004). Intraluminal obstruction
results from polyps or granulomatous tissue that develops secondary to inflammatory changes
in the bronchial wall, or when caseous material is deposited into an airway after lymph node
eruption (Marais et al., 2004). Radiologic signs vary from segmental or lobar hyperinflation
with partial obstruction and a check-valve effect (Marais et al., 2004), to segmental or lobar
collapse with total obstruction and resorption of distal air (Marais et al., 2004). The pathology
that results from the aspiration of caseous material is influenced by the dose and virulence of
the bacilli aspirated. The pathology may range from transient parenchymal consolidation,
resulting from a pure hypersensitivity response to dead bacilli and/or toxic products, to an
expansile pneumonic process with progressive caseating pneumonia in the affected segment
or lobe (Marais et al., 2004). Expansible caseating pneumonia frequently leads to parenchymal
destruction and cavity formation.
Thus, cavitary disease in children may result from three distinct pathologic processes: (1) poor
containment at the site of organism deposition (very young and/or immune-compromised
children); (2) aspiration of live bacilli when a diseased lymph node erupts into an airway, with
destructive caseating pneumonia in the distal segment or lobe (children less than 5 year of
age); and (3) adult-type disease (mainly children greater than 10 year of age). The fact that
immune-competent children 5 to 10 yr of age experience the lowest risk to progress to disease
after primary infection with M. tuberculosis is an interesting immunologic phenomenon that
is poorly understood. A better understanding of age-related differences in the immune
response to M. tuberculosis may provide important insight into immune correlates of disease
and protection.
Disseminated disease occurs predominantly in very young (immune-immature) and/or
immune-compromised children, such as the HIV-infected or severely malnourished (Pai et al.,
2004; Shingadia and Chen, 2004). These children have suboptimal cellular immune responses
and demonstrate poor containment of the organism, both within the regional lymph nodes
and at the multiple sites of occult dissemination. TB meningitis (TBM) is the most dangerous
complication of disseminated disease, occurring in 20 to 30% of cases (Chen, 2004).
3.5. Challenges in diagnosis
3.5.1. Overview of diagnostic challenges
Diagnostic difficulties pose the greatest challenge to childhood TB management (Marais and
Pai, 2007). There are diagnostic complications because: (i) TB can mimic many common child‐
hood diseases, including pneumonia, generalized bacterial and viral infections, malnutrition,
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and HIV (Marais and Pai, 2007); (ii) the absence of a practical reference test or gold standard
(Marais et al., 2006); (iii) of the inability of child patients to expectorate sputum (Nelson and
Wells, 2004) (iv) of the nonspecific clinical presentation (Nicol. et al., 2009); (v) of the lower ba‐
cillary load in children which is often smear negative (Detjen et al., 2007) (vi) confirmation by
culture of Mycobacterium tuberculosis, usingthe gold standard of diagnosis in adult TB, rare‐
ly exceeds 30–40% sensitivity (although it may be considerably higher in children with ad‐
vanced disease) (Hesseling et al., 2002) even when using gastric aspirates, induced sputum,
liquid media, and polymerase chain reaction (PCR) (Edwards et al., 2007); vii) distinguishing
between recent primary infection and active disease is highly difficult (Gomez-Pastrana et al.,
2001); viii) gastric aspirates continue to be the best specimens for testing for suspected pulmo‐
nary TB in children (Ling et al., 2011) with 30–40% sensitivity (Hesseling et al., 2002).
Bacteriologic confirmation, the accepted gold standard, is of limited use in children because
of the paucibacillary nature of their disease and poor bacteriologic yields. Sputum smear
microscopy, often the only diagnostic test available in endemic areas, is positive in less than
10 to 15% of children with probable tuberculosis (Schaaf et al., 2006). However, the yield is
high in children with adult-type disease and sputum smear microscopy has definite diagnostic
value in older children (more than 10 year of age) (Cegielski and McMurray, 2004). Culture
yields are also low; reported yields in children with probable tuberculosis are less than 30 to
40% (Schaaf et al., 2006). However, the bacteriologic yield depends on the specific intrathoracic
disease manifestation. A study from South Africa reported a yield of 77% in children with
advanced intrathoracic disease, whereas the yield in those with uncomplicated hilar adenop‐
athy was only 35% (odds ratio, 6.3; 95% confidence interval, 3.2–12.8) (Graham et al., 2001).
This indicates the potential value of sensitive bacteriology-based diagnostic approaches,
particularly in endemic areas where children frequently present with advanced disease.
Most children with TB are classified as smear-negative pulmonary TB (PTB) for the reasons
mentioned above, which is an inappropriate term as a smear or culture has not usually been
done. This leads to difficulties in determining the true extent of PTB in children in different
areas and circumstances. Extrapulmonary TB (EPTB) accounts for up to 20–30% of the total
caseload of TB in children, and the diagnosis is usually easier than PTB because of the
characteristic clinical features like lymphadenopathy with or without scrofula, spinal deform‐
ity, disseminated disease, meningitis, effusions (pleural or pericardial), or painless ascite
(Lewinsohn et al., 2004). The isolation of Mycobacterium tuberculosis takes several weeks.
Consequently, the diagnosis of TB in children is often supported only by epidemiological,
clinical, and radiographic findings in the presence of a positive tuberculin skin test (López
Ávalos and Montes de Oca, 2012).
The value of the classic diagnostic is based on: (1) exposure to an adult index case; (2) chronic
respiratory symptoms that do not respond to broad-spectrum antibiotics; (3) documented
weight loss or failure to thrive; (4) a positive tuberculin skin test (TST); (5) the presence of
suggestive signs on the chest radiograph (CXR), which is greatly reduced in endemic areas
where exposure to and/or infection with M. tuberculosis is common (Marais et al., 2006). These
criteria are less helpful in endemic areas where a positive TST result is common and exposure
to M. tuberculosis is often undocumented (Hesseling et al., 2002). For all these reasons, many
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children with TB are never diagnosed or registered as cases of TB (Nelson and Wells, 2004).
Furthermore, the consequences of missed diagnosis in children are severe, as untreated
children have a high probability of developing active TB, usually within two years of infection
(López Ávalos and Montes de Oca, 2012).
The difficulty to obtain samples for TB diagnosis in children has led researchers to create smart
approaches as “la cuerda dulce” (sweet string), reported by Chow et al., (2006). They provide
a technique which consists of a coiled nylon string inside a gel capsule. The string unravels
through a hole in the end of the weighted capsule as it descends into the stomach and the
capsule then dissolves in it, allowing the string to become coated with gastrointestinal
secretions containing whatever pathogens are present. After about four hours, the capsule is
passed in the feces. This methodology is well tolerated by children and is less invasive than
the gastrointestinal lavage (López Ávalos and Montes de Oca, 2012).
In addition to poor bacteriologic yields, the collection of bacteriologic specimens is often
problematic. Two or three fasting gastric aspirates collected on consecutive days, usually
requiring hospital admission, are routinely performed in young children who cannot cough
up phlegm. A retrospective study from California compared the bacteriologic yield achieved
in gastric aspirates collected from hospitalized and nonhospitalized children. Although the
yield in hospitalized children was higher (percentage of positive cultures, 48 compared to
37%), this difference was not statistically significant, which suggests that hospitalization may
not be a prerequisite for the collection of a good gastric aspirate specimen. Bronchoalveolar
lavage, using flexible fiberoptic bronchoscopy, has additive value when used in combination
with gastric lavage, but this technique is highly specialized and is unavailable in most endemic
areas. In a study from Peru, midmorning nasopharyngeal aspiration was compared with early
morning gastric aspiration; gastric aspiration provided a slightly better yield than nasophar‐
yngeal aspiration (38 compared to 30%), but the results were comparable (Nelson et al., 2004).
Nasopharyngeal aspiration is minimally invasive, does not require hospitalization or fasting,
and can be performed any time of the day. A study from South Africa demonstrated that a
single specimen, using hypertonic saline–induced sputum collection, may provide the same
yield as three gastric aspirate specimens (Corbett et al., 2003). However, the overall yield in
this study remained poor (15% with one and 20% with three induced sputum specimens) and
the technique has not been used outside the hospital setting. Additional studies are awaited
to confirm the feasibility and diagnostic value of collecting induced sputum specimens in
primary health care settings.
Because of the difficulty in achieving bacteriologic confirmation, the diagnosis of childhood
tuberculosis in non- endemic areas is usually based on (1) known contact with an adult index
case (frequently within the household), (2) a positive tuberculin skin test (TST), and (3)
suggestive signs on the chest radiograph. This triad provides a fairly accurate diagnosis in
settings where exposure to M. tuberculosis is rare and well documented. However, its
diagnostic accuracy is greatly reduced in endemic areas where exposure to M. tuberculosis is
common and often undocumented, as exposure frequently occurs outside the household.
Despite reservations about the specificity of the TST response after Bacille Calmette-Guérin
(BCG) vaccination and/or exposure to environmental mycobacteria, a positive TST reaction
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2001); viii) gastric aspirates continue to be the best specimens for testing for suspected pulmo‐
nary TB in children (Ling et al., 2011) with 30–40% sensitivity (Hesseling et al., 2002).
Bacteriologic confirmation, the accepted gold standard, is of limited use in children because
of the paucibacillary nature of their disease and poor bacteriologic yields. Sputum smear
microscopy, often the only diagnostic test available in endemic areas, is positive in less than
10 to 15% of children with probable tuberculosis (Schaaf et al., 2006). However, the yield is
high in children with adult-type disease and sputum smear microscopy has definite diagnostic
value in older children (more than 10 year of age) (Cegielski and McMurray, 2004). Culture
yields are also low; reported yields in children with probable tuberculosis are less than 30 to
40% (Schaaf et al., 2006). However, the bacteriologic yield depends on the specific intrathoracic
disease manifestation. A study from South Africa reported a yield of 77% in children with
advanced intrathoracic disease, whereas the yield in those with uncomplicated hilar adenop‐
athy was only 35% (odds ratio, 6.3; 95% confidence interval, 3.2–12.8) (Graham et al., 2001).
This indicates the potential value of sensitive bacteriology-based diagnostic approaches,
particularly in endemic areas where children frequently present with advanced disease.
Most children with TB are classified as smear-negative pulmonary TB (PTB) for the reasons
mentioned above, which is an inappropriate term as a smear or culture has not usually been
done. This leads to difficulties in determining the true extent of PTB in children in different
areas and circumstances. Extrapulmonary TB (EPTB) accounts for up to 20–30% of the total
caseload of TB in children, and the diagnosis is usually easier than PTB because of the
characteristic clinical features like lymphadenopathy with or without scrofula, spinal deform‐
ity, disseminated disease, meningitis, effusions (pleural or pericardial), or painless ascite
(Lewinsohn et al., 2004). The isolation of Mycobacterium tuberculosis takes several weeks.
Consequently, the diagnosis of TB in children is often supported only by epidemiological,
clinical, and radiographic findings in the presence of a positive tuberculin skin test (López
Ávalos and Montes de Oca, 2012).
The value of the classic diagnostic is based on: (1) exposure to an adult index case; (2) chronic
respiratory symptoms that do not respond to broad-spectrum antibiotics; (3) documented
weight loss or failure to thrive; (4) a positive tuberculin skin test (TST); (5) the presence of
suggestive signs on the chest radiograph (CXR), which is greatly reduced in endemic areas
where exposure to and/or infection with M. tuberculosis is common (Marais et al., 2006). These
criteria are less helpful in endemic areas where a positive TST result is common and exposure
to M. tuberculosis is often undocumented (Hesseling et al., 2002). For all these reasons, many
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children with TB are never diagnosed or registered as cases of TB (Nelson and Wells, 2004).
Furthermore, the consequences of missed diagnosis in children are severe, as untreated
children have a high probability of developing active TB, usually within two years of infection
(López Ávalos and Montes de Oca, 2012).
The difficulty to obtain samples for TB diagnosis in children has led researchers to create smart
approaches as “la cuerda dulce” (sweet string), reported by Chow et al., (2006). They provide
a technique which consists of a coiled nylon string inside a gel capsule. The string unravels
through a hole in the end of the weighted capsule as it descends into the stomach and the
capsule then dissolves in it, allowing the string to become coated with gastrointestinal
secretions containing whatever pathogens are present. After about four hours, the capsule is
passed in the feces. This methodology is well tolerated by children and is less invasive than
the gastrointestinal lavage (López Ávalos and Montes de Oca, 2012).
In addition to poor bacteriologic yields, the collection of bacteriologic specimens is often
problematic. Two or three fasting gastric aspirates collected on consecutive days, usually
requiring hospital admission, are routinely performed in young children who cannot cough
up phlegm. A retrospective study from California compared the bacteriologic yield achieved
in gastric aspirates collected from hospitalized and nonhospitalized children. Although the
yield in hospitalized children was higher (percentage of positive cultures, 48 compared to
37%), this difference was not statistically significant, which suggests that hospitalization may
not be a prerequisite for the collection of a good gastric aspirate specimen. Bronchoalveolar
lavage, using flexible fiberoptic bronchoscopy, has additive value when used in combination
with gastric lavage, but this technique is highly specialized and is unavailable in most endemic
areas. In a study from Peru, midmorning nasopharyngeal aspiration was compared with early
morning gastric aspiration; gastric aspiration provided a slightly better yield than nasophar‐
yngeal aspiration (38 compared to 30%), but the results were comparable (Nelson et al., 2004).
Nasopharyngeal aspiration is minimally invasive, does not require hospitalization or fasting,
and can be performed any time of the day. A study from South Africa demonstrated that a
single specimen, using hypertonic saline–induced sputum collection, may provide the same
yield as three gastric aspirate specimens (Corbett et al., 2003). However, the overall yield in
this study remained poor (15% with one and 20% with three induced sputum specimens) and
the technique has not been used outside the hospital setting. Additional studies are awaited
to confirm the feasibility and diagnostic value of collecting induced sputum specimens in
primary health care settings.
Because of the difficulty in achieving bacteriologic confirmation, the diagnosis of childhood
tuberculosis in non- endemic areas is usually based on (1) known contact with an adult index
case (frequently within the household), (2) a positive tuberculin skin test (TST), and (3)
suggestive signs on the chest radiograph. This triad provides a fairly accurate diagnosis in
settings where exposure to M. tuberculosis is rare and well documented. However, its
diagnostic accuracy is greatly reduced in endemic areas where exposure to M. tuberculosis is
common and often undocumented, as exposure frequently occurs outside the household.
Despite reservations about the specificity of the TST response after Bacille Calmette-Guérin
(BCG) vaccination and/or exposure to environmental mycobacteria, a positive TST reaction
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remains a fairly accurate measure of M. tuberculosis infection in immune-competent children.
Current U.S. guidelines recommend the use of three different cutoff points to define a positive
TST reaction. In endemic areas a positive TST is not uncommon in randomly selected healthy
children (Jeena et al., 2002), which limits its diagnostic value. Consequently, the diagnosis of
tuberculosis in children from endemic areas depends mainly on clinical features and the
subjective interpretation of the chest radiograph (Marais et al., 2007). However, chest radiog‐
raphy is unavailable in many endemic areas and it has well-known limitations that may result
in both under- and overdiagnosis of disease (Brent et al., 2007). Despite these limitations it
provides an accurate diagnosis in the majority of symptomatic children with tuberculosis and
the interpretation of the chest radiograph remains the most widely used diagnostic criterion
in clinical practice (Palme et al., 2002).
Various clinical scoring systems have been developed. A critical review of these clinical scoring
systems concluded that they are limited by a lack of standard symptom definitions and
adequate validation (Walls and Shingadia, 2007). Developing standard symptom definitions
through consensus of expert opinion is a difficult and subjective exercise; better guidance may
be provided by objectively measuring the potential diagnostic value of different symptom
definitions. A community-based survey demonstrated that the poorly defined symptoms
traditionally associated with tuberculosis (such as a cough greater than 3 weeks in duration)
are frequently reported in a random selection of healthy children (Bryce et al., 2005). Of 1,397
children without tuberculosis, 253 (26.4%) reported a cough during the preceding 3 months
and 66 (6.9%) reported a cough greater than 3 weeks in duration (Bryce et al., 2005). In addition,
nearly 50% of children with visible hilar adenopathy on the chest radiograph (diagnosed with
tuberculosis) reported no symptoms at all (Bryce et al., 2005). These observations demonstrate
the limited diagnostic value of poorly defined symptoms and the need for improved symptom
and case definitions. In a follow-on study the use of well-defined symptoms with a persistent,
nonremitting character showed greatly improved diagnostic accuracy (Scot et al., 2008).
However, the potential diagnostic value offered by the use of these well-defined symptoms
requires further validation in a prospective, community-based study that includes children
from all relevant risk groups. It is expected that symptom-based diagnostic approaches would
have less value in high-risk children (less than 3 years of age and/or immune compromised)
where disease progression may occur rapidly, emphasizing the need for preventive chemo‐
therapy and early diagnosis of disease in this group (Chintu, et al., 2002). Other diagnostic
modalities may hold promise, but have not shown convincing results to date (WHO, 2006).
Serologic tests are currently unable to diagnose childhood tuberculosis with accuracy, and
sputum-based polymerase chain reaction (PCR) tests have shown variable results and limited
utility (WHO, 2007). Good results were reported with the use of a heminested PCR technique
in Peru, but the study used uninfected children as the control group and therefore could not
evaluate the ability of this novel PCR-based test to differentiate latent infection from active
disease (Upham et al., 2006), which is important, as specific concerns have been raised
regarding the specificity of PCR-based tests.
The diagnostic dilemma is even more pronounced in HIV-infected children. The specificity of
symptom-based diagnostic approaches is reduced by the presence of chronic HIV-related
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symptoms, while the potential window for symptom-based diagnosis is limited by the rapidity
with which disease progression may occur. Chest radiograph interpretation is complicated by
HIV-related comorbidity and atypical disease presentation. These difficulties increase the
potential diagnostic value of sensitive bacteriology-based approaches, to identify HIV-infected
children with tuberculosis (Upham et al., 2002). However, as HIV-infected children are in the
high-risk group the detection of M. tuberculosis infection is also highly relevant. Disease
progression may occur soon (less than 12 months) after primary or reinfection, or latent
infection may be reactivated at a later date because of a decline in immunity. The traditional
TST has poor sensitivity to detect M. tuberculosis infection in HIV-infected children; 50% or
less of HIV-infected children with bacteriologically confirmed tuberculosis are TST positive,
despite using an induration size of at least 5 mm (Upham et al., 2002). This is a major limitation
and development of a more reliable measure of infection will be valuable to identify HIV-
infected children who may benefit from preventive chemotherapy; it may also provide
supportive evidence to establish a diagnosis of active tuberculosis.
3.5.2. Challenges presented by diagnosis of latent infection in children
LTBI, in children as in adults, lacks a diagnostic gold standard. The diagnosis is usually
pursued after a documented household exposure, or to evaluate if chemoprophylactic therapy
is indicated in the context of immunosuppression. In this setting, pre-existing MTB specific
host immune responses are measured to confirm previous infection. Data in adults have
confirmed that IGRA are more sensitive and specific than the TST (Pai et al., 2004; Ferrara et
al., 2006) in this context. Preliminary data suggest IGRA also perform better in children but
age-related data are still sparse. Longitudinal studies assessing their positive predictive value
for the development of active TB are required in both TB-endemic and low-incidence countries,
as the continued exposure in TB endemic settings might yield very different results, compared
to the “one-off” exposure more typically encountered in non-endemic countries.
3.6. Challenges presented by drug resistance
There were an estimated 0.5 million adult cases of MDR-TB in 2007. By the end of 2008, 55
countries and territories had reported at least 1 case of extensively drug-resistant TB (WHO
Report, 2009). Latest research reports published in The Lancet at the end of August 2012,
indicate that researchers have found rates of both multi drug-resistant TB (MDR-TB) and
extensively drug-resistant TB (XDR-TB) higher than previously thought and that they are
threatening global efforts to curb the spread of TB. They contend that most international
recommendations for TB control have been developed for MDR-TB prevalence of up to around
5 percent but that now the world faces a prevalence up to 10 times higher in some places, where
almost half of the patients are transmitting MDR strains. The Researchers who studied rates
of the disease in Estonia, Latvia, Peru, the Philippines, Russia, South Africa, South Korea, and
Thailand are reported to have found that almost 44 percent of cases of MDR TB were also
resistant to at least one second-line drug outline goes here (Dalton et al., 2012)
Comprehensive studies on resistance to anti-TB drugs in children are lacking, because they
are not included in global surveys. Surveillance of anti-TB drug resistance during 1995–2007
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raphy is unavailable in many endemic areas and it has well-known limitations that may result
in both under- and overdiagnosis of disease (Brent et al., 2007). Despite these limitations it
provides an accurate diagnosis in the majority of symptomatic children with tuberculosis and
the interpretation of the chest radiograph remains the most widely used diagnostic criterion
in clinical practice (Palme et al., 2002).
Various clinical scoring systems have been developed. A critical review of these clinical scoring
systems concluded that they are limited by a lack of standard symptom definitions and
adequate validation (Walls and Shingadia, 2007). Developing standard symptom definitions
through consensus of expert opinion is a difficult and subjective exercise; better guidance may
be provided by objectively measuring the potential diagnostic value of different symptom
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traditionally associated with tuberculosis (such as a cough greater than 3 weeks in duration)
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and 66 (6.9%) reported a cough greater than 3 weeks in duration (Bryce et al., 2005). In addition,
nearly 50% of children with visible hilar adenopathy on the chest radiograph (diagnosed with
tuberculosis) reported no symptoms at all (Bryce et al., 2005). These observations demonstrate
the limited diagnostic value of poorly defined symptoms and the need for improved symptom
and case definitions. In a follow-on study the use of well-defined symptoms with a persistent,
nonremitting character showed greatly improved diagnostic accuracy (Scot et al., 2008).
However, the potential diagnostic value offered by the use of these well-defined symptoms
requires further validation in a prospective, community-based study that includes children
from all relevant risk groups. It is expected that symptom-based diagnostic approaches would
have less value in high-risk children (less than 3 years of age and/or immune compromised)
where disease progression may occur rapidly, emphasizing the need for preventive chemo‐
therapy and early diagnosis of disease in this group (Chintu, et al., 2002). Other diagnostic
modalities may hold promise, but have not shown convincing results to date (WHO, 2006).
Serologic tests are currently unable to diagnose childhood tuberculosis with accuracy, and
sputum-based polymerase chain reaction (PCR) tests have shown variable results and limited
utility (WHO, 2007). Good results were reported with the use of a heminested PCR technique
in Peru, but the study used uninfected children as the control group and therefore could not
evaluate the ability of this novel PCR-based test to differentiate latent infection from active
disease (Upham et al., 2006), which is important, as specific concerns have been raised
regarding the specificity of PCR-based tests.
The diagnostic dilemma is even more pronounced in HIV-infected children. The specificity of
symptom-based diagnostic approaches is reduced by the presence of chronic HIV-related
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symptoms, while the potential window for symptom-based diagnosis is limited by the rapidity
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children with tuberculosis (Upham et al., 2002). However, as HIV-infected children are in the
high-risk group the detection of M. tuberculosis infection is also highly relevant. Disease
progression may occur soon (less than 12 months) after primary or reinfection, or latent
infection may be reactivated at a later date because of a decline in immunity. The traditional
TST has poor sensitivity to detect M. tuberculosis infection in HIV-infected children; 50% or
less of HIV-infected children with bacteriologically confirmed tuberculosis are TST positive,
despite using an induration size of at least 5 mm (Upham et al., 2002). This is a major limitation
and development of a more reliable measure of infection will be valuable to identify HIV-
infected children who may benefit from preventive chemotherapy; it may also provide
supportive evidence to establish a diagnosis of active tuberculosis.
3.5.2. Challenges presented by diagnosis of latent infection in children
LTBI, in children as in adults, lacks a diagnostic gold standard. The diagnosis is usually
pursued after a documented household exposure, or to evaluate if chemoprophylactic therapy
is indicated in the context of immunosuppression. In this setting, pre-existing MTB specific
host immune responses are measured to confirm previous infection. Data in adults have
confirmed that IGRA are more sensitive and specific than the TST (Pai et al., 2004; Ferrara et
al., 2006) in this context. Preliminary data suggest IGRA also perform better in children but
age-related data are still sparse. Longitudinal studies assessing their positive predictive value
for the development of active TB are required in both TB-endemic and low-incidence countries,
as the continued exposure in TB endemic settings might yield very different results, compared
to the “one-off” exposure more typically encountered in non-endemic countries.
3.6. Challenges presented by drug resistance
There were an estimated 0.5 million adult cases of MDR-TB in 2007. By the end of 2008, 55
countries and territories had reported at least 1 case of extensively drug-resistant TB (WHO
Report, 2009). Latest research reports published in The Lancet at the end of August 2012,
indicate that researchers have found rates of both multi drug-resistant TB (MDR-TB) and
extensively drug-resistant TB (XDR-TB) higher than previously thought and that they are
threatening global efforts to curb the spread of TB. They contend that most international
recommendations for TB control have been developed for MDR-TB prevalence of up to around
5 percent but that now the world faces a prevalence up to 10 times higher in some places, where
almost half of the patients are transmitting MDR strains. The Researchers who studied rates
of the disease in Estonia, Latvia, Peru, the Philippines, Russia, South Africa, South Korea, and
Thailand are reported to have found that almost 44 percent of cases of MDR TB were also
resistant to at least one second-line drug outline goes here (Dalton et al., 2012)
Comprehensive studies on resistance to anti-TB drugs in children are lacking, because they
are not included in global surveys. Surveillance of anti-TB drug resistance during 1995–2007
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among children from South Africa showed a significant increase in resistance to INH or RIF
from 6.9% to 15.1% and an increase in multidrug resistance from 2.3% to 6.7% (Schaaf et al.,
2009). Drug resistance among children has been documented in clinical trials of both pulmo‐
nary and extrapulmonary TB (Rekha and Swaminathan, 2007). Management of MDR-TB is a
challenge, because it requires prolonged treatment for 24 months with second-line drugs,
which are more toxic and expensive than first-line drugs. According to the 2006 WHO
guidelines for programmatic management of MDR-TB, an optimal regimen should include a
fluoroquinolone, an injectable (capreomycin, kanamycin, or amikacin), and at least 2 of the
following drugs: cycloserine, thiomides, para-amino salicylic acid, and first-line agents other
than INH and RIF (WHO, 2008). Experience with second-line TB drugs in children is limited;
38 children in Peru were treated with supervised, individualized regimens consisting of 5
drugs in the national program. Despite half of these children being anemic and malnourished,
treatment was well tolerated and resulted in a 95% cure rate (Drobac et al., 2006).
There is little published information on optimal treatment of latent TB infection in children in
contact with patients with MDR-TB. In a 30-month follow-up of contacts of patients with MDR-
TB, 5% of children who received appropriate chemoprophylaxis and 20% of those who did not
receive prophylaxis developed disease (Schaaf et al., 2007). Regimens used included INH, PZA,
and ethionamide or EMB. Currently, the best approach may be to perform a complete risk
assessment and clinical evaluation and to individualize therapy, while keeping these children
under close observation. Multicentric trials are urgently required to determine the most
effective drug combinations and optimal duration of chemoprophylaxis for contacts of patients
with MDR-TB.
TB is often not considered in the differential diagnosis in children, especially in low endemic
settings. TB can mimic many common childhood diseases, including pneumonia, generalised
bacterial and viral infections, malnutrition and HIV. However, the main impediment to the
accurate diagnosis of active TB is the paucibacillary nature (containing just a few bacilli) of the
disease in children. Younger children also produce smaller amounts of sputum, which is
usually swallowed rather than expectorated. Bacteriological samples may be collected by
conducting early morning gastric washings, a fairly unpleasant procedure that requires
hospital admission and overnight-fast for up to three consecutive nights. Consequently
bacteriological confirmation is the exception rather than the rule with only 10-15 % of sputum
samples revealing acid fast bacilli (AFB) and culture remaining negative in around 70% of
cases with probable TB (Zar et al., 2005). Without a definitive diagnosis treatment is therefore
often initiated on clinical judgment, aided by algorithms based on exposure history, clinical
features, chest x-ray (CXR) and TST (Marais et al., 2006). Several approaches have been taken
to improve the diagnosis (Marais and Pai, 2007).
3.7. Improving bacteriological detection and rapid resistance analysis
Recent advances in bacteriological and molecular methods for the detection of MTB in patient
samples aim to identify drug-resistance in parallel with detection of MTB. These include the
Microscopic Observation Drug Susceptibility assay (MODS) (Moore et al., 2006), more
sensitive PCR techniques (Sarmiento et al., 2003) or phage-based tests such as FASTPlaque
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(Kalantri et al., 2005). This represents laudable progress, particularly in the context of increas‐
ing drug resistance. Calorimetric culture systems such as the TK medium (Kocagoz et al.,
2004) and electronic-nose technology (Fend et al., 2006) are also under investigation. Among
adults MODS appears to be at least as sensitive as gold standard liquid culture methods (Moore
et al., 2006), Data comparing its performance in children is more limited, but MODS has been
evaluated in a paediatric hospital setting and found to be more sensitive than solid media in
one study (Oberhelman et al., 2006). Data validating other new methods in paediatric speci‐
mens are also lacking, yet performance may be affected by the paucibacillary nature of
childhood TB. The lowest limit of detection of TB by the electronic nose for example has been
reported to be 104 CFU/ml of sputum for example which is just within the range of the expected
bacillary burden in paediatric specimens (Fend et al., 2006). Validation of these assays on
paediatric samples is a research priority (López Ávalos G G and Montes de Oca, 2012). The
introduction of GeneXpert which includes use of integrated DNA extraction and amplification
systems and utilizes real-time PCR (rt-PCR) technology to both diagnose TB and detect
rifampicin resistance, has given a ray of hope with paediatric TB diagnosis and rifampicin
resistance (Gordetsov et al., 2008).
4. Diagnosis and treatment: Current state of affairs
4.1. Classical diagnosis
4.1.1. Clinical symptoms approach
The use of well-defined symptoms improves diagnostic accuracy of pulmonry tuberculo‐
sis  (PTB)  (Imaz  et  al.,  2001).  With  clinical  symptoms  approach  only,  the  status  can  be
classified in two; suspected TB or probable TB. Two situations lead the clinician to sus‐
pect that a child has tuberculosis. The first is a history of chronic illness with clear symp‐
toms: cough and/or fever, weight loss or failure to thrive, an inability to return to normal
health after measles or whooping cough, fatigue, and wheezing; second, is when one or
more of the following: malnutrition, lymphadenopathy, chest signs, hepatomegaly and/or
splenomegaly, meningeal signs, and/or ascites is/are observed. For probable TB, in addi‐
tion  to  suspected  TB,  the  child  presents  with  a  positive  TST,  a  suggestive  radiological
chest  appearing  as  pleural  effusion,  caseation  of  biopsy  material,  poor  response  to  2
weeks  of  antibiotic  treatment,  and/or  favourable  response  to  antituberculous  treatment
(weight gain and loss of signs) (Hesseling et al., 2002).
In pediatric TB, the most common symptoms are pulmonary parenchymal disease and
intrathoracic adenopathy accounting for 60–80% of all cases. Among extrapulmonary mani‐
festations, lymphadenopathy is the most common (67%), followed by central nervous system
involvement (13%), pleural (6%), miliary and/or disseminated TB (5%), and skeletal TB form
(4%). Disseminated disease and TB meningitis are usually found in very young children who
are below the age of 3 years, and/or HIV-infected children (Nelson et al., 2004). TB meningitis
occurs when the child has contact with a suspected or confirmed case.
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among children from South Africa showed a significant increase in resistance to INH or RIF
from 6.9% to 15.1% and an increase in multidrug resistance from 2.3% to 6.7% (Schaaf et al.,
2009). Drug resistance among children has been documented in clinical trials of both pulmo‐
nary and extrapulmonary TB (Rekha and Swaminathan, 2007). Management of MDR-TB is a
challenge, because it requires prolonged treatment for 24 months with second-line drugs,
which are more toxic and expensive than first-line drugs. According to the 2006 WHO
guidelines for programmatic management of MDR-TB, an optimal regimen should include a
fluoroquinolone, an injectable (capreomycin, kanamycin, or amikacin), and at least 2 of the
following drugs: cycloserine, thiomides, para-amino salicylic acid, and first-line agents other
than INH and RIF (WHO, 2008). Experience with second-line TB drugs in children is limited;
38 children in Peru were treated with supervised, individualized regimens consisting of 5
drugs in the national program. Despite half of these children being anemic and malnourished,
treatment was well tolerated and resulted in a 95% cure rate (Drobac et al., 2006).
There is little published information on optimal treatment of latent TB infection in children in
contact with patients with MDR-TB. In a 30-month follow-up of contacts of patients with MDR-
TB, 5% of children who received appropriate chemoprophylaxis and 20% of those who did not
receive prophylaxis developed disease (Schaaf et al., 2007). Regimens used included INH, PZA,
and ethionamide or EMB. Currently, the best approach may be to perform a complete risk
assessment and clinical evaluation and to individualize therapy, while keeping these children
under close observation. Multicentric trials are urgently required to determine the most
effective drug combinations and optimal duration of chemoprophylaxis for contacts of patients
with MDR-TB.
TB is often not considered in the differential diagnosis in children, especially in low endemic
settings. TB can mimic many common childhood diseases, including pneumonia, generalised
bacterial and viral infections, malnutrition and HIV. However, the main impediment to the
accurate diagnosis of active TB is the paucibacillary nature (containing just a few bacilli) of the
disease in children. Younger children also produce smaller amounts of sputum, which is
usually swallowed rather than expectorated. Bacteriological samples may be collected by
conducting early morning gastric washings, a fairly unpleasant procedure that requires
hospital admission and overnight-fast for up to three consecutive nights. Consequently
bacteriological confirmation is the exception rather than the rule with only 10-15 % of sputum
samples revealing acid fast bacilli (AFB) and culture remaining negative in around 70% of
cases with probable TB (Zar et al., 2005). Without a definitive diagnosis treatment is therefore
often initiated on clinical judgment, aided by algorithms based on exposure history, clinical
features, chest x-ray (CXR) and TST (Marais et al., 2006). Several approaches have been taken
to improve the diagnosis (Marais and Pai, 2007).
3.7. Improving bacteriological detection and rapid resistance analysis
Recent advances in bacteriological and molecular methods for the detection of MTB in patient
samples aim to identify drug-resistance in parallel with detection of MTB. These include the
Microscopic Observation Drug Susceptibility assay (MODS) (Moore et al., 2006), more
sensitive PCR techniques (Sarmiento et al., 2003) or phage-based tests such as FASTPlaque
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(Kalantri et al., 2005). This represents laudable progress, particularly in the context of increas‐
ing drug resistance. Calorimetric culture systems such as the TK medium (Kocagoz et al.,
2004) and electronic-nose technology (Fend et al., 2006) are also under investigation. Among
adults MODS appears to be at least as sensitive as gold standard liquid culture methods (Moore
et al., 2006), Data comparing its performance in children is more limited, but MODS has been
evaluated in a paediatric hospital setting and found to be more sensitive than solid media in
one study (Oberhelman et al., 2006). Data validating other new methods in paediatric speci‐
mens are also lacking, yet performance may be affected by the paucibacillary nature of
childhood TB. The lowest limit of detection of TB by the electronic nose for example has been
reported to be 104 CFU/ml of sputum for example which is just within the range of the expected
bacillary burden in paediatric specimens (Fend et al., 2006). Validation of these assays on
paediatric samples is a research priority (López Ávalos G G and Montes de Oca, 2012). The
introduction of GeneXpert which includes use of integrated DNA extraction and amplification
systems and utilizes real-time PCR (rt-PCR) technology to both diagnose TB and detect
rifampicin resistance, has given a ray of hope with paediatric TB diagnosis and rifampicin
resistance (Gordetsov et al., 2008).
4. Diagnosis and treatment: Current state of affairs
4.1. Classical diagnosis
4.1.1. Clinical symptoms approach
The use of well-defined symptoms improves diagnostic accuracy of pulmonry tuberculo‐
sis  (PTB)  (Imaz  et  al.,  2001).  With  clinical  symptoms  approach  only,  the  status  can  be
classified in two; suspected TB or probable TB. Two situations lead the clinician to sus‐
pect that a child has tuberculosis. The first is a history of chronic illness with clear symp‐
toms: cough and/or fever, weight loss or failure to thrive, an inability to return to normal
health after measles or whooping cough, fatigue, and wheezing; second, is when one or
more of the following: malnutrition, lymphadenopathy, chest signs, hepatomegaly and/or
splenomegaly, meningeal signs, and/or ascites is/are observed. For probable TB, in addi‐
tion  to  suspected  TB,  the  child  presents  with  a  positive  TST,  a  suggestive  radiological
chest  appearing  as  pleural  effusion,  caseation  of  biopsy  material,  poor  response  to  2
weeks  of  antibiotic  treatment,  and/or  favourable  response  to  antituberculous  treatment
(weight gain and loss of signs) (Hesseling et al., 2002).
In pediatric TB, the most common symptoms are pulmonary parenchymal disease and
intrathoracic adenopathy accounting for 60–80% of all cases. Among extrapulmonary mani‐
festations, lymphadenopathy is the most common (67%), followed by central nervous system
involvement (13%), pleural (6%), miliary and/or disseminated TB (5%), and skeletal TB form
(4%). Disseminated disease and TB meningitis are usually found in very young children who
are below the age of 3 years, and/or HIV-infected children (Nelson et al., 2004). TB meningitis
occurs when the child has contact with a suspected or confirmed case.
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In general, there is a sense of skepticism regarding the potential diagnostic value of symptom-
based approaches but nevertheless, the natural history of childhood tuberculosis demonstrates
that symptoms may have diagnostic value if appropriate risk stratification is applied. Marais
et al., (2005), evaluated whether well-defined symptoms have a diagnosis value in children
and a standard symptom-based questionnaire was completed and reported symptoms were
individually characterized. A tuberculin skin test (TST) and chest radiograph (CXR) were
performed in all children. In this study,well-defined symptoms had excellent diagnostic value.
4.1.2. Radiologic studies
Radiography became available after the First World War, and since that time, PTB detection
became easier (Marais et al., 2004). Evidence of pulmonary TB in chest radiographs varies, but
usually radiographs show enlargement of hilar, mediastinal, or subcarinal lymph nodes and
lung parenchymal changes with hilar lymphodenopathy with or without a focal parenchymal
lesion. The most common findings are segmental hyperinflation then atelectasis, alveolar
consolidation, interstitial densities, pleural effusion, and, rarely, a focal mass. Cavitation is rare
in young children but is more common in adolescents, who may develop reactivation disease
similar to that seen in adults (Marais. and Pai, 2007). High-resolution computed tomography
is the most sensitive tool currently available to detect hilar adenopathy and/or early cavitation
(Hesseling et al., 2002).
4.1.3. Diagnostic algorithms
These are point-scoring systems to make diagnostic classifications. Diagnostic algorithms were
developed to deal with these diagnostic difficulties and provide the health care worker with
a rational, stepwise tool to identify children in need of treatment. They are very helpful and
very easy to use in countries with restricted technology, but only few of them are available
especially in resource limited countries (Edwards et al., (2007). Although the natural history
of tuberculosis (TB) in children follows a continuum, the American Thoracic Society (ATS)
definition of stages is useful (Blumberg, et al., 2003). According to the ATS the stages are as
follows:
Stage 1: Exposure has occurred, implying that the child has had recent contact with an adult
who has contagious TB. The child has no physical signs or symptoms and has a negative
tuberculin skin test (TST) result. Chest radiography does not reveal any changes at this stage.
However, not all patients who are exposed become infected, and the TST result may not be
positive for 3 months. Unfortunately, children younger than 5 years may develop disseminated
TB in the form of miliary disease or TB meningitis before the TST result becomes positive. Thus,
a very high index of suspicion is required when a young patient has a history of contact.
Stage 2: This second stage is heralded by a positive TST result. No signs and symptoms occur,
although an incidental chest radiograph may reveal the primary complex.
Stage 3: In stage 3, TB disease occurs and is characterized by the appearance of signs and
symptoms depending on the location of the disease. Radiographic abnormalities may al‐
so be seen.
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Stage 4: Stage 4 is defined as TB with no current disease. This implies that the patient has a
history of previous episodes of TB or abnormal, stable radiographic findings with a significant
reaction to the TST and negative bacteriologic studies. No clinical findings suggesting current
disease are present.
Stage 5: TB is suspected, and the diagnosis is pending. Any patient with pneumonia, pleural
effusion, or a cavitary or mass lesion in the lung that does not improve with standard anti‐
bacterial therapy should be evaluated for tuberculosis (TB). Also, patients with fever of
unknown origin, failure to thrive, significant weight loss, or unexplained lymphadenopathy
should be evaluated for TB (Marais et al., 2006).
4.1.4. Mycobacterial detection and isolation
Microbiological confirmation of TB in young children is not routinely attempted in many high
burden settings due to the difficulty in obtaining samples and the poor performance of smear
microscopy (Nicol and Zar, 2011). Diagnosis of TB still relies primarily on examination of Acid-
Fast Bacilli- (AFB-) stained smears from clinical specimens in adults, however, children with
pulmonary TB usually do not cough up voluntarily, either because they do not produce
sputum or because it produces discomfort. When sputum samples cannot be obtained, gastric
aspirate samples are used for detection and isolation of M. Tuberculosis. Most of the current
TB diagnostic methods were developed over a century ago. In 1898, Neunier became the first
person to culture stomach contents for the evidence of tuberculosis in children (Marais and
Pai, 2007; Lalvani and Millington, 2007), so even with this method, fewer than 20% of children
with TB have a positive AFB smear of sputum or gastric aspirate.
For many years, the collection of three consecutive early morning gastric lavages or gastric
aspirate samples has been the accepted method for attempting microbiological confirmation
even as the yield is very low and that in many populations cannot be performed due to the
lack of infrastructure. In addition low pH is known to kill tuberculous bacilli, indicating that
stomach pH may inhibit TB survival for subsequent culture (Marais. and Pai, 2007). More
recently, a number of less invasive alternative methods have been proposed, including induced
sputum (administration of an inhaled bronchodilator followed by nebulized hypertonic 3–5%
saline and then collecting nasopharyngeal aspiration or expectoration of mucus from lower
respiratory tract). In the nasopharyngeal aspiration, a cannula elicits a cough reflex and the
sweet string test mentioned above (Nicol and Zar, 2011). One of the methods that can be used
to collect samples for microbiological analysis is the string test. This is a non-invasive collection
method and is reported to be well tolerated by children as young as 4 years (Chow et al.,
2006). Inducing sputum after hypertonic saline nebulization has also been shown to be feasible
for young children, although the most widely used procedure is still the early-morning gastric
aspiration or lavage. However, all these procedures involve hospitalization, trained personnel,
and attention to infection control.
All of these alternative ways of sampling have been made to increase yield because a positive
culture is regarded as the “gold standard test” to establish a definitive diagnosis of TB in a
symptomatic child (Hesseling et al., 2002). If culture is negative, diagnosis is made on the basis
of a positive TST. With clinical and radiographic findings suggestive of TB, and history of
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In general, there is a sense of skepticism regarding the potential diagnostic value of symptom-
based approaches but nevertheless, the natural history of childhood tuberculosis demonstrates
that symptoms may have diagnostic value if appropriate risk stratification is applied. Marais
et al., (2005), evaluated whether well-defined symptoms have a diagnosis value in children
and a standard symptom-based questionnaire was completed and reported symptoms were
individually characterized. A tuberculin skin test (TST) and chest radiograph (CXR) were
performed in all children. In this study,well-defined symptoms had excellent diagnostic value.
4.1.2. Radiologic studies
Radiography became available after the First World War, and since that time, PTB detection
became easier (Marais et al., 2004). Evidence of pulmonary TB in chest radiographs varies, but
usually radiographs show enlargement of hilar, mediastinal, or subcarinal lymph nodes and
lung parenchymal changes with hilar lymphodenopathy with or without a focal parenchymal
lesion. The most common findings are segmental hyperinflation then atelectasis, alveolar
consolidation, interstitial densities, pleural effusion, and, rarely, a focal mass. Cavitation is rare
in young children but is more common in adolescents, who may develop reactivation disease
similar to that seen in adults (Marais. and Pai, 2007). High-resolution computed tomography
is the most sensitive tool currently available to detect hilar adenopathy and/or early cavitation
(Hesseling et al., 2002).
4.1.3. Diagnostic algorithms
These are point-scoring systems to make diagnostic classifications. Diagnostic algorithms were
developed to deal with these diagnostic difficulties and provide the health care worker with
a rational, stepwise tool to identify children in need of treatment. They are very helpful and
very easy to use in countries with restricted technology, but only few of them are available
especially in resource limited countries (Edwards et al., (2007). Although the natural history
of tuberculosis (TB) in children follows a continuum, the American Thoracic Society (ATS)
definition of stages is useful (Blumberg, et al., 2003). According to the ATS the stages are as
follows:
Stage 1: Exposure has occurred, implying that the child has had recent contact with an adult
who has contagious TB. The child has no physical signs or symptoms and has a negative
tuberculin skin test (TST) result. Chest radiography does not reveal any changes at this stage.
However, not all patients who are exposed become infected, and the TST result may not be
positive for 3 months. Unfortunately, children younger than 5 years may develop disseminated
TB in the form of miliary disease or TB meningitis before the TST result becomes positive. Thus,
a very high index of suspicion is required when a young patient has a history of contact.
Stage 2: This second stage is heralded by a positive TST result. No signs and symptoms occur,
although an incidental chest radiograph may reveal the primary complex.
Stage 3: In stage 3, TB disease occurs and is characterized by the appearance of signs and
symptoms depending on the location of the disease. Radiographic abnormalities may al‐
so be seen.
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Stage 4: Stage 4 is defined as TB with no current disease. This implies that the patient has a
history of previous episodes of TB or abnormal, stable radiographic findings with a significant
reaction to the TST and negative bacteriologic studies. No clinical findings suggesting current
disease are present.
Stage 5: TB is suspected, and the diagnosis is pending. Any patient with pneumonia, pleural
effusion, or a cavitary or mass lesion in the lung that does not improve with standard anti‐
bacterial therapy should be evaluated for tuberculosis (TB). Also, patients with fever of
unknown origin, failure to thrive, significant weight loss, or unexplained lymphadenopathy
should be evaluated for TB (Marais et al., 2006).
4.1.4. Mycobacterial detection and isolation
Microbiological confirmation of TB in young children is not routinely attempted in many high
burden settings due to the difficulty in obtaining samples and the poor performance of smear
microscopy (Nicol and Zar, 2011). Diagnosis of TB still relies primarily on examination of Acid-
Fast Bacilli- (AFB-) stained smears from clinical specimens in adults, however, children with
pulmonary TB usually do not cough up voluntarily, either because they do not produce
sputum or because it produces discomfort. When sputum samples cannot be obtained, gastric
aspirate samples are used for detection and isolation of M. Tuberculosis. Most of the current
TB diagnostic methods were developed over a century ago. In 1898, Neunier became the first
person to culture stomach contents for the evidence of tuberculosis in children (Marais and
Pai, 2007; Lalvani and Millington, 2007), so even with this method, fewer than 20% of children
with TB have a positive AFB smear of sputum or gastric aspirate.
For many years, the collection of three consecutive early morning gastric lavages or gastric
aspirate samples has been the accepted method for attempting microbiological confirmation
even as the yield is very low and that in many populations cannot be performed due to the
lack of infrastructure. In addition low pH is known to kill tuberculous bacilli, indicating that
stomach pH may inhibit TB survival for subsequent culture (Marais. and Pai, 2007). More
recently, a number of less invasive alternative methods have been proposed, including induced
sputum (administration of an inhaled bronchodilator followed by nebulized hypertonic 3–5%
saline and then collecting nasopharyngeal aspiration or expectoration of mucus from lower
respiratory tract). In the nasopharyngeal aspiration, a cannula elicits a cough reflex and the
sweet string test mentioned above (Nicol and Zar, 2011). One of the methods that can be used
to collect samples for microbiological analysis is the string test. This is a non-invasive collection
method and is reported to be well tolerated by children as young as 4 years (Chow et al.,
2006). Inducing sputum after hypertonic saline nebulization has also been shown to be feasible
for young children, although the most widely used procedure is still the early-morning gastric
aspiration or lavage. However, all these procedures involve hospitalization, trained personnel,
and attention to infection control.
All of these alternative ways of sampling have been made to increase yield because a positive
culture is regarded as the “gold standard test” to establish a definitive diagnosis of TB in a
symptomatic child (Hesseling et al., 2002). If culture is negative, diagnosis is made on the basis
of a positive TST. With clinical and radiographic findings suggestive of TB, and history of
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contact with an adult source case, the child may be diagnosed with positive TB based on
symptomatology. This measure was taken because the yields in children are less than 50%.
Zar et al., (2000), investigated whether sputum induction could be successfully performed in
infants and young children with and without HIV and determined the utility of salbutamol-
induced sputum compared to gastric lavage (GL) for the diagnosis of pulmonary tuberculosis.
They concluded that sputum induction can be effectively performed and is well tolerated and
safe even in infants and this induction is better than GL for the isolation of M. tuberculosis in
both HIV-infected and uninfected infants and children.
Although culture on Lowenstein-Jensen medium is considered to be the gold standard, liquid
culture systems (commercial and non commercial) offer the possibility of more rapid and more
sensitive diagnosis of active TB and drug susceptibility but are not widely available in
resource-poor settings (Brittle et al., 2009) compared mycobacterial yields and time to detection
in pediatric clinical samples with use of mycobacterial growth-indicator tubes with those with
use of solid Lowenstein-Jensen slants and found that the yield was substantially higher with
use of mycobacterial growth-indicator tubes (11% compared to 1.6%). Furthermore, the mean
time to detection could be reduced from 18.5 days to 12.4 days with use of a nutrient broth
supplement; newer approaches, such as the colorimetric culture systems and phage-based tests
are of interest, but limited data are available for children.
4.1.5. Smear microscopy
Advances have been done in the performance of smear microscopy for the rapid detection of
MTB, for example, the concentration of specimens by centrifugation or the change of the
staining of carbol fuchsin (Ziehl-Neelsen or Kinyoun) for a fluorescent dyes (auramine-
rhodamine), which both increases sensitivity and reduces the time for screening (Bakir et al.,
2008). However, even under optimal circumstances, the sensitivity of smear microscopy for
the diagnosis of childhood TB remains less than 15%, except in older children with adult-like
disease (Nicol and Zar, 2011).
4.1.6. Tuberculin skin test (TST)
This is one of the major classes of tests that are currently used to detect Latent TB. Tuberculin
which is also called purified protein derivative or PPD is a standardised killed extract of
cultured TB, which is injected into the skin to estimate an individual’s immune response to
TB. There are three methods of testing: the Mantoux test, the Heaf test and the Tine test but
not all of them are currently available for use and some countries prefer one over the other.
The Heaf test is no loner available because its continued manufacture was not economically
viable.
The Tuberculin skin test, or Mantoux TST, is based on the detection of a cutaneous delayed-
type hypersensitivity response to purified protein derivative, a poorly defined mixture of
antigens present in M. tuberculosis, Mycobacterium bovis Bacille Calmette-Guerin (BCG) and
several nontuberculous mycobacteria (Nicol et al., 2011). TST is the standard method for
detecting infection by M. tuberculosis. The reaction is measured as millimeters of induration
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after 48 to 72 hours. This test was the only method available for the diagnosis of latent
tuberculosis infection (LTBI) until very recently.
The Heaf test uses what is called a Heaf gun which uses disposable single-use heads, each head
having six needles arranged in a circle. The device has standard heads and pediatric heads -
the standard head being used on all patients aged 2 years and older while the pediatric head
is for infants under the age of 2. For the standard head, its needles protrude 2 mm when the
gun is actuated while for the pediatric heads, the needles protrude only 1 mm. Before appli‐
cation, the skin is cleaned with alcohol, then 100,000 units/ml (equivalent to about 0.1 ml) of
tuberculin is evenly smeared on the skin and the gun applied to the skin and fired. The excess
of the solution is then wiped off and a waterproof ink mark is drawn around the injection site
as an indicator of the site of administration and the test read 2 to 7 days later. The results of
the test are interpreted as follows:
Grade 0: no reaction, or induration of 3 or less puncture points;Grade 1: induration of four or
more puncture points; Grade 2: induration of the six puncture points coalesce to form a circle;
Grade 3: induration of 5 mm; or more and Grade 4: induration of 10 mm or more, or ulceration.
There is not much difference between the Heaf and Mantoux test, but the two tests can be
related as follows: Heaf grade 0 and 1 approximately equivalent Mantoux less than 5 mm; Heaf
grade 2 approximatley equivalent to Mantoux 5–14 mm and Heaf grade 3 & 4 being approxi‐
mately equivalent to Mantoux 15 mm or greater, To avoid cases of false positives and false
negatives, the tuberculin used for Heaf tests is 1000 times more concentrated than that used
for Mantoux tests. In countries where both tests are used, use of the correct concentration
avoids false positive and false negative results.
The recommended Tuberculin Skin Test (TST), which has now been standardised by the WHO
to contain 0.1 ml of tuberculin (100 units/ ml), is the Mantoux test (CDC, 2010). The dosage of
0.1 ml containing 5 tuberculin units [TU] of purified protein derivative (PPD) should be
injected intradermally into the volar aspect of the forearm using a 27-gauge needle. A detergent
called Tween 80 to prevent loss of efficacy on contact and adsorption by glass stabilizes the
PPD. A wheal should be raised and should measure approximately 6-10 mm in diameter.
Skilled personnel should always read the test 48-72 hours after administration. Measure the
amount of induration and not erythema. This should be measured transverse to the long axis
of the forearm. Multiple puncture tests such as Tine test and Heaf test lack sensitivity and
specificity and hence are not recommended in this situation (Marais et al., 2006).
Subcutaneous injection should be avoided because it results in false negative results. The site
of administration is indicated by a water-proof ink mark drawn around the site of injection to
serve as an indicator for the site. The reading, which is done two to seven days involves
measuring area of induration transversely (left to right) across the forearm and recorded to
the nearest millimetre. It should be borne in mind that the induration (dermal thickening
causing the cutaneous surface to feel thicker and firmer) should not be confused with erythema
(redness of the skin) caused by hyperemia of the capillaries in the lower layers of the skin.
If a patient who has previously had a negative tuberculin skin test develops a positive
tuberculin skin test at a later date, tuberculin conversion is said to have occurred. When such
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contact with an adult source case, the child may be diagnosed with positive TB based on
symptomatology. This measure was taken because the yields in children are less than 50%.
Zar et al., (2000), investigated whether sputum induction could be successfully performed in
infants and young children with and without HIV and determined the utility of salbutamol-
induced sputum compared to gastric lavage (GL) for the diagnosis of pulmonary tuberculosis.
They concluded that sputum induction can be effectively performed and is well tolerated and
safe even in infants and this induction is better than GL for the isolation of M. tuberculosis in
both HIV-infected and uninfected infants and children.
Although culture on Lowenstein-Jensen medium is considered to be the gold standard, liquid
culture systems (commercial and non commercial) offer the possibility of more rapid and more
sensitive diagnosis of active TB and drug susceptibility but are not widely available in
resource-poor settings (Brittle et al., 2009) compared mycobacterial yields and time to detection
in pediatric clinical samples with use of mycobacterial growth-indicator tubes with those with
use of solid Lowenstein-Jensen slants and found that the yield was substantially higher with
use of mycobacterial growth-indicator tubes (11% compared to 1.6%). Furthermore, the mean
time to detection could be reduced from 18.5 days to 12.4 days with use of a nutrient broth
supplement; newer approaches, such as the colorimetric culture systems and phage-based tests
are of interest, but limited data are available for children.
4.1.5. Smear microscopy
Advances have been done in the performance of smear microscopy for the rapid detection of
MTB, for example, the concentration of specimens by centrifugation or the change of the
staining of carbol fuchsin (Ziehl-Neelsen or Kinyoun) for a fluorescent dyes (auramine-
rhodamine), which both increases sensitivity and reduces the time for screening (Bakir et al.,
2008). However, even under optimal circumstances, the sensitivity of smear microscopy for
the diagnosis of childhood TB remains less than 15%, except in older children with adult-like
disease (Nicol and Zar, 2011).
4.1.6. Tuberculin skin test (TST)
This is one of the major classes of tests that are currently used to detect Latent TB. Tuberculin
which is also called purified protein derivative or PPD is a standardised killed extract of
cultured TB, which is injected into the skin to estimate an individual’s immune response to
TB. There are three methods of testing: the Mantoux test, the Heaf test and the Tine test but
not all of them are currently available for use and some countries prefer one over the other.
The Heaf test is no loner available because its continued manufacture was not economically
viable.
The Tuberculin skin test, or Mantoux TST, is based on the detection of a cutaneous delayed-
type hypersensitivity response to purified protein derivative, a poorly defined mixture of
antigens present in M. tuberculosis, Mycobacterium bovis Bacille Calmette-Guerin (BCG) and
several nontuberculous mycobacteria (Nicol et al., 2011). TST is the standard method for
detecting infection by M. tuberculosis. The reaction is measured as millimeters of induration
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after 48 to 72 hours. This test was the only method available for the diagnosis of latent
tuberculosis infection (LTBI) until very recently.
The Heaf test uses what is called a Heaf gun which uses disposable single-use heads, each head
having six needles arranged in a circle. The device has standard heads and pediatric heads -
the standard head being used on all patients aged 2 years and older while the pediatric head
is for infants under the age of 2. For the standard head, its needles protrude 2 mm when the
gun is actuated while for the pediatric heads, the needles protrude only 1 mm. Before appli‐
cation, the skin is cleaned with alcohol, then 100,000 units/ml (equivalent to about 0.1 ml) of
tuberculin is evenly smeared on the skin and the gun applied to the skin and fired. The excess
of the solution is then wiped off and a waterproof ink mark is drawn around the injection site
as an indicator of the site of administration and the test read 2 to 7 days later. The results of
the test are interpreted as follows:
Grade 0: no reaction, or induration of 3 or less puncture points;Grade 1: induration of four or
more puncture points; Grade 2: induration of the six puncture points coalesce to form a circle;
Grade 3: induration of 5 mm; or more and Grade 4: induration of 10 mm or more, or ulceration.
There is not much difference between the Heaf and Mantoux test, but the two tests can be
related as follows: Heaf grade 0 and 1 approximately equivalent Mantoux less than 5 mm; Heaf
grade 2 approximatley equivalent to Mantoux 5–14 mm and Heaf grade 3 & 4 being approxi‐
mately equivalent to Mantoux 15 mm or greater, To avoid cases of false positives and false
negatives, the tuberculin used for Heaf tests is 1000 times more concentrated than that used
for Mantoux tests. In countries where both tests are used, use of the correct concentration
avoids false positive and false negative results.
The recommended Tuberculin Skin Test (TST), which has now been standardised by the WHO
to contain 0.1 ml of tuberculin (100 units/ ml), is the Mantoux test (CDC, 2010). The dosage of
0.1 ml containing 5 tuberculin units [TU] of purified protein derivative (PPD) should be
injected intradermally into the volar aspect of the forearm using a 27-gauge needle. A detergent
called Tween 80 to prevent loss of efficacy on contact and adsorption by glass stabilizes the
PPD. A wheal should be raised and should measure approximately 6-10 mm in diameter.
Skilled personnel should always read the test 48-72 hours after administration. Measure the
amount of induration and not erythema. This should be measured transverse to the long axis
of the forearm. Multiple puncture tests such as Tine test and Heaf test lack sensitivity and
specificity and hence are not recommended in this situation (Marais et al., 2006).
Subcutaneous injection should be avoided because it results in false negative results. The site
of administration is indicated by a water-proof ink mark drawn around the site of injection to
serve as an indicator for the site. The reading, which is done two to seven days involves
measuring area of induration transversely (left to right) across the forearm and recorded to
the nearest millimetre. It should be borne in mind that the induration (dermal thickening
causing the cutaneous surface to feel thicker and firmer) should not be confused with erythema
(redness of the skin) caused by hyperemia of the capillaries in the lower layers of the skin.
If a patient who has previously had a negative tuberculin skin test develops a positive
tuberculin skin test at a later date, tuberculin conversion is said to have occurred. When such
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a reaction occurs, it provides strong evidence for significant exposure to TB. Different countries
have different standards about the time interval between tests. The UK recommendation is
that the two tests have to be done at least six weeks apart; while in the U.S. the recommendation
is that the two tests can be done one week apart.
Another phenomenon associated with tuberculin skin test is what is called boosting, which
occurs when people who have had some traces of infection with M. tuberculosis and/or
previous exposure to BCG vaccination against tuberculosis, are given repeated tuberculin skin
tests. In these cases, the first test revives or primes the immune response so that on repeat
testing, the response is much stronger and the patient now appears to have a positive reaction.
The second tuberculin skin test result is what is taken to be the correct one. Again, the
guidelines on how to approach the phenomenon of boosting are different in different countries
with the U.S. guidelines emphasising that, ignoring previous immunisation with BCG would
lead to a person showing the phenomenon of boosting, being falsely described as a tuberculin
converter. On the other hand, UK guidelines advocate two tuberculin skin tests one week apart,
if boosting is suspected, taking the result of the second test as being the true result. The
phenomenon of boosting can occur up to two years after the first Mantoux test.
According to the American Academy of Pediatrics (AAP) immediate skin testing is indicated
for the following children: 1)Those who have been in contact with persons with active or
suspected TB; 2) Immigrants from TB-endemic countries or children with travel histories to
these countries; 3) Those who have radiographic or clinical findings suggestive of TB. 4)
Children who are infected with human immunodeficiency virus (HIV) or those living in a
household with persons infected with HIV and; 5) Incarcerated adolescents.
Testing at 2-year to 3-year intervals is indicated if the child has been exposed to high-risk
individuals including those who are homeless, institutionalized adults who are infected with
HIV, users of illicit drugs, residents of nursing homes, and incarcerated adolescents or adults.
Testing when children are aged 4-6 years and 11-16 years is indicated for the following
children:1) Children without risk factors residing in high-prevalence areas; 2) Children whose
parents emigrated from regions of the world with a high prevalence of TB or who have
continued potential exposure by travel to the endemic areas and/or household contact.
Performing an initial TST before the initiation of immunosuppressive therapy is recommended
in any patient (AAP, 1996).
Wit regard to administering the TST to previous recipients of the Bacille Calmette-Guérin
(BCG) several problems are encountered when it comes to interpreting the results of the test.
Immunization with BCG is not a contraindication to the TST but differentiating tuberculin
reactions caused by vaccination with BCG versus reactions caused by infection with M
tuberculosis is difficult. History of contact with a person with contagious TB or emigration
from a country with a high prevalence of TB suggests that the positive results are due to
infection with M tuberculosis. However, multiple BCG vaccinations may increase the likeli‐
hood that the positive TST result is due to the BCG vaccination. The positive reactivity caused
by BCG vaccination generally wanes with the passage of time. With the administration of TST,
this positive tuberculin reactivity may be boosted. However, previous BCG vaccination does
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not affect interpretation of a TST result for a person who is symptomatic or in whom TB is
strongly suspected (Marais et al., 2006).
For the UK the guidelines for interpreting tuberculin skin tests are formulated according to
the Heaf test. For patients who have had BCG previously, latent TB is diagnosed if the Heaf
test is grade 3 or 4 and have no signs or symptoms of active; if the Heaf test is grade 0 or 1,
then the test is repeated and, in patients who have not had BCG previously, latent TB isiag‐
nosed if the Heaf test if grade 2, 3 or 4, and have no signs or symptoms of active TB. Repeat
Heaf testing is not done in patients who have had BCG of the phenomenon of boosting.
The Centers for Disease Control and Prevention (CDC) and the AAP provided recommenda‐
tions regarding the size of the induration created by the TST that is considered a positive result
and indicative of disease [http://www.cdc.gov/tb/]. The TST is interpreted on the basis of 3 "cut
points": 5 mm, 10 mm, and 15 mm. Induration of 5 mm or more is considered a positive TST
result in the following children: 1) Children having close contact with known or suspected
contagious cases of the disease, including those with household contacts with active TB whose
treatment cannot be verified before exposure; 2) Children with immunosuppressive conditions
(such as HIV) or children who are on immunosuppressive medications; 3) Children who have
an abnormal chest radiograph finding consistent with active TB, previously active TB, or
clinical evidence of the disease.
Induration of 10 mm or more is considered a positive TST result in the following children: 1)
Children who are at a higher risk of dissemination of TB disease, including those younger than
5 years or those who are immunosuppressed because of conditions such as lymphoma,
Hodgkin disease, diabetes mellitus, and malnutrition; 2) Children with increased exposure to
the disease, including those who are exposed to adults in high-risk categories (such as
homeless, HIV infected, users of illicit drugs, residents of nursing homes, incarcerated or
institutionalized persons); 3) those who were born in or whose parents were born in high-
prevalence areas of the world; and those with travel histories to high-prevalence areas of the
world. Induration of 15 mm or more is considered a positive TST result in children aged 5
years or older without any risk factors for the disease.
False-positive reactions and false-negative results are common and can be due to various
causes. False-positive reactions are often attributed to asymptomatic infection by environ‐
mental non-TB mycobacteria (due to cross-reactivity). False-negative results, on the other
hand, may be due to vaccination with live-attenuated virus, anergy, immunosuppression,
immune deficiency, or malnutrition. In cases of anergy, a lack of reaction by the body's defence
mechanisms when it comes into contact with foreign substances, the tuberculin reaction will
occur weakly, thus compromising the value of Mantoux testing. For example, anergy is present
in AIDS, a disease which strongly depresses the immune system. Therefore, anergy testing is
advised in cases where suspicion is warranted that it is present. However, routine anergy skin
testing is not recommended. Other factors that may cause a false-negative result include
improper administration (such as subcutaneous injection, injection of too little antigen),
improper storage, and contamination. PPD has been recognized to have an initial false-
negative rate of 29% (Marais et al., 2006).
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a reaction occurs, it provides strong evidence for significant exposure to TB. Different countries
have different standards about the time interval between tests. The UK recommendation is
that the two tests have to be done at least six weeks apart; while in the U.S. the recommendation
is that the two tests can be done one week apart.
Another phenomenon associated with tuberculin skin test is what is called boosting, which
occurs when people who have had some traces of infection with M. tuberculosis and/or
previous exposure to BCG vaccination against tuberculosis, are given repeated tuberculin skin
tests. In these cases, the first test revives or primes the immune response so that on repeat
testing, the response is much stronger and the patient now appears to have a positive reaction.
The second tuberculin skin test result is what is taken to be the correct one. Again, the
guidelines on how to approach the phenomenon of boosting are different in different countries
with the U.S. guidelines emphasising that, ignoring previous immunisation with BCG would
lead to a person showing the phenomenon of boosting, being falsely described as a tuberculin
converter. On the other hand, UK guidelines advocate two tuberculin skin tests one week apart,
if boosting is suspected, taking the result of the second test as being the true result. The
phenomenon of boosting can occur up to two years after the first Mantoux test.
According to the American Academy of Pediatrics (AAP) immediate skin testing is indicated
for the following children: 1)Those who have been in contact with persons with active or
suspected TB; 2) Immigrants from TB-endemic countries or children with travel histories to
these countries; 3) Those who have radiographic or clinical findings suggestive of TB. 4)
Children who are infected with human immunodeficiency virus (HIV) or those living in a
household with persons infected with HIV and; 5) Incarcerated adolescents.
Testing at 2-year to 3-year intervals is indicated if the child has been exposed to high-risk
individuals including those who are homeless, institutionalized adults who are infected with
HIV, users of illicit drugs, residents of nursing homes, and incarcerated adolescents or adults.
Testing when children are aged 4-6 years and 11-16 years is indicated for the following
children:1) Children without risk factors residing in high-prevalence areas; 2) Children whose
parents emigrated from regions of the world with a high prevalence of TB or who have
continued potential exposure by travel to the endemic areas and/or household contact.
Performing an initial TST before the initiation of immunosuppressive therapy is recommended
in any patient (AAP, 1996).
Wit regard to administering the TST to previous recipients of the Bacille Calmette-Guérin
(BCG) several problems are encountered when it comes to interpreting the results of the test.
Immunization with BCG is not a contraindication to the TST but differentiating tuberculin
reactions caused by vaccination with BCG versus reactions caused by infection with M
tuberculosis is difficult. History of contact with a person with contagious TB or emigration
from a country with a high prevalence of TB suggests that the positive results are due to
infection with M tuberculosis. However, multiple BCG vaccinations may increase the likeli‐
hood that the positive TST result is due to the BCG vaccination. The positive reactivity caused
by BCG vaccination generally wanes with the passage of time. With the administration of TST,
this positive tuberculin reactivity may be boosted. However, previous BCG vaccination does
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not affect interpretation of a TST result for a person who is symptomatic or in whom TB is
strongly suspected (Marais et al., 2006).
For the UK the guidelines for interpreting tuberculin skin tests are formulated according to
the Heaf test. For patients who have had BCG previously, latent TB is diagnosed if the Heaf
test is grade 3 or 4 and have no signs or symptoms of active; if the Heaf test is grade 0 or 1,
then the test is repeated and, in patients who have not had BCG previously, latent TB isiag‐
nosed if the Heaf test if grade 2, 3 or 4, and have no signs or symptoms of active TB. Repeat
Heaf testing is not done in patients who have had BCG of the phenomenon of boosting.
The Centers for Disease Control and Prevention (CDC) and the AAP provided recommenda‐
tions regarding the size of the induration created by the TST that is considered a positive result
and indicative of disease [http://www.cdc.gov/tb/]. The TST is interpreted on the basis of 3 "cut
points": 5 mm, 10 mm, and 15 mm. Induration of 5 mm or more is considered a positive TST
result in the following children: 1) Children having close contact with known or suspected
contagious cases of the disease, including those with household contacts with active TB whose
treatment cannot be verified before exposure; 2) Children with immunosuppressive conditions
(such as HIV) or children who are on immunosuppressive medications; 3) Children who have
an abnormal chest radiograph finding consistent with active TB, previously active TB, or
clinical evidence of the disease.
Induration of 10 mm or more is considered a positive TST result in the following children: 1)
Children who are at a higher risk of dissemination of TB disease, including those younger than
5 years or those who are immunosuppressed because of conditions such as lymphoma,
Hodgkin disease, diabetes mellitus, and malnutrition; 2) Children with increased exposure to
the disease, including those who are exposed to adults in high-risk categories (such as
homeless, HIV infected, users of illicit drugs, residents of nursing homes, incarcerated or
institutionalized persons); 3) those who were born in or whose parents were born in high-
prevalence areas of the world; and those with travel histories to high-prevalence areas of the
world. Induration of 15 mm or more is considered a positive TST result in children aged 5
years or older without any risk factors for the disease.
False-positive reactions and false-negative results are common and can be due to various
causes. False-positive reactions are often attributed to asymptomatic infection by environ‐
mental non-TB mycobacteria (due to cross-reactivity). False-negative results, on the other
hand, may be due to vaccination with live-attenuated virus, anergy, immunosuppression,
immune deficiency, or malnutrition. In cases of anergy, a lack of reaction by the body's defence
mechanisms when it comes into contact with foreign substances, the tuberculin reaction will
occur weakly, thus compromising the value of Mantoux testing. For example, anergy is present
in AIDS, a disease which strongly depresses the immune system. Therefore, anergy testing is
advised in cases where suspicion is warranted that it is present. However, routine anergy skin
testing is not recommended. Other factors that may cause a false-negative result include
improper administration (such as subcutaneous injection, injection of too little antigen),
improper storage, and contamination. PPD has been recognized to have an initial false-
negative rate of 29% (Marais et al., 2006).
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With a TST, it is not possible to assert or deny the presence of TB, but it only indicates infection
with a mycobacterium. In a child who has not been BCG-vaccinated, a TST has been defined
as positive when the diameter of skin induration is greater than 10 mm, and in a BCG-
vaccinated child, when the diameter of induration is greater than 15 mm. A negative TST does
not exclude TB and some induration (5–14 mm) could be supportive if the clinical features and
contact history are suggestive (Lewinsohn et al., 2004). Furthermore, the utility of this con‐
ventional test is hampered by technical and logistical problems: potential for false-positive and
false-negative results; problems in administration and interpretation; difficulty in separating
true infection from the effects of prior BCG vaccination, infection due to nontuberculous
mycobacteria (Dogra et al., 2007). In children with debilitating or immunosuppressive
illnesses, malnutrition, or viral (as HIV) and certain bacterial infections, the yield is unknown,
but it is certainly higher than 10%. Moreover, false-positive reactions to TST are often attributed
to asymptomatic infection by environmental nontuberculous mycobacteria (Nicol et al., 2011).
Given that the US guidelines recommend that previous BCG vaccination be ignored in the
interpretation of tuberculin skin tests, false positives are possible. People who have previously
had BCG, will falsely appear to be tuberculin converters and this may lead to treating more
people than necessary, with the possible risk of those patients suffering adverse drug reactions.
However, considering the fact that BCG vaccine is not 100% effective, and that it is less
protective in adults than pediatric patients, not treating these patients could lead to a possible
infection which tennds to justify the current US policy. The U.S. guidelines also allow for
tuberculin skin testing in immunosuppressed patients whereas the UK guidelines recommend
that tuberculin skin tests should not be used for such patients because it is unreliable
4.2. New approaches in TB diagnostics
4.2.1. Polymerase chain reaction (PCR)
Diagnostic PCR is a technique of in vitro DNA amplification that uses specific DNA sequences
(oligonucleotides) as effective fishhooks for the DNA/cDNA of microorganisms. In theory, this
technique can detect a single organism in a lot of specimens such as sputum, gastric aspirate,
pleural fluid, cerebrospinal fluid, blood, and urine. Various PCR assays, mostly using the
mycobacterial insertion element IS6110 as the DNA marker for M. tuberculosis-complex
organisms, have a sensitivity and specificity greater than 90% for detecting pulmonary TB in
adults. This is a rapid, sensitive, specific, and reasonable-cost (Montenegro et al., 2003) method
for the detection of M. tuberculosis in clinical samples. The PCR may be used to (a) diagnose
tuberculosis in difficult samples with negative microscopic examination, negative culture, or
with scarce sample; (b) determine if the organisms in the sample are M. tuberculosis or atypical
mycobacteria; (c) identify the presence of genetic variations like a mutations or deletions
known to be associated with resistance to some antimycobacterial agents (Marais et al., 2005).
Studies in children have obtained better sensitivity by PCR than by culture. In 2001, Gomez-
Pastrana et al., (2001) reported a comparison between sensitivity of culture and PCR showing
higher sensitivity for the latter. PCR may have a special role in the diagnosis of extrapulmonary
TB and pulmonary TB in children since sputum smears are usually unrevealing in these cases.
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However, these tests are not performed correctly in all clinical laboratories. The cost involved,
the need for sophisticated equipment, the limitations in their specificity, the need to obtain
multiple samples to optimize yield and scrupulous technique to avoid cross-contamination of
specimens preclude the use of PCR techniques in many developing countries (Montenegro et
al., 2003).The sensitivity of PCR of gastric lavage/bronchoalveolar lavage has been found to be
56.8% in children with clinically active disease. Authors conclude that nested PCR is a rapid
and sensitive method for the early diagnosis of TB in children. Additionally, other unique
sequences of M. tuberculosis have been suggested as diagnostic test for TB, because they are
absent in M. africanum, M. microti, M. bovis, and M. bovis BCG (Liang et al., 2008).
4.2.2. In-house nucleic acid amplification (NAA) assays
These assays are highly dependent on the operator’s skills. Performance is also influenced by
the choice of target sequence and DNA extraction method. Interpretation of the performance
of these assays in pediatric TB suspects is hindered by the lack of a sensitive and specific
reference standard. When compared with culture, the sensitivity of NAA for the diagnosis of
childhood TB is typically low (40–83%). However, it appears, at least from some reports, that
NAA identified a group of children who are clinically diagnosed with TB but in whom
mycobacterial culture is negative. This means that with a proper technique it could be done
efficiently (Nicol and Zar, 2011 ).
4.2.3. Adenosine deaminase
Adult studies have shown increased levels of adenosine deaminase (ADA) in pleural TB
and TB-caused meningitis,  both  paucibacillary  forms of  TB,  and have  advocated for  its
use  in  diagnosis.  Due  to  this  evidence,  a  serum ADA has  already been  evaluated  in  a
childhood population with a very high sensitivity (100%) and specificity (90.7%) for pul‐
monary TB. This study demonstrated the great potential of this technique because it has
significant difference in serum ADA levels  between children with disease and infection.
However, there were several weaknesses in the study design, including unclear case defi‐
nition, exclusion of nontuberculous patients, and a relatively small TB patient population
(20 with active disease) (Marais. and Pai, 2007).
In the case of extrapulmonary TB, ADA measurement can be helpful, but its sensitivity and
specificity varies widely and has been lower than multiplex PCR using primers for IS6110,
dnaJ, and hsp65. Specifically, a meta-analysis of 63 studies of ADA in tuberculous pleuritis
reveals that the sensitivity of the test is of 0.92 (95% CI 0.90–0.93) and specificity of 0.90 (95%
CI 0.89–0.91) (Lawn and Nicol, 2011).
4.2.4. Serology and antigen detection
In absence of good diagnostic method for tuberculosis, the interest in serodiagnosis has been
increased (Marais et al., 2005). Serological tests vary in a number of features, including antigen
composition (38 kDa, Ag 60, and lipoarabinomannan, LAM), antigen source (native or
recombinant), chemical composition (protein or lipid), extent of antigen(s) purification, and
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With a TST, it is not possible to assert or deny the presence of TB, but it only indicates infection
with a mycobacterium. In a child who has not been BCG-vaccinated, a TST has been defined
as positive when the diameter of skin induration is greater than 10 mm, and in a BCG-
vaccinated child, when the diameter of induration is greater than 15 mm. A negative TST does
not exclude TB and some induration (5–14 mm) could be supportive if the clinical features and
contact history are suggestive (Lewinsohn et al., 2004). Furthermore, the utility of this con‐
ventional test is hampered by technical and logistical problems: potential for false-positive and
false-negative results; problems in administration and interpretation; difficulty in separating
true infection from the effects of prior BCG vaccination, infection due to nontuberculous
mycobacteria (Dogra et al., 2007). In children with debilitating or immunosuppressive
illnesses, malnutrition, or viral (as HIV) and certain bacterial infections, the yield is unknown,
but it is certainly higher than 10%. Moreover, false-positive reactions to TST are often attributed
to asymptomatic infection by environmental nontuberculous mycobacteria (Nicol et al., 2011).
Given that the US guidelines recommend that previous BCG vaccination be ignored in the
interpretation of tuberculin skin tests, false positives are possible. People who have previously
had BCG, will falsely appear to be tuberculin converters and this may lead to treating more
people than necessary, with the possible risk of those patients suffering adverse drug reactions.
However, considering the fact that BCG vaccine is not 100% effective, and that it is less
protective in adults than pediatric patients, not treating these patients could lead to a possible
infection which tennds to justify the current US policy. The U.S. guidelines also allow for
tuberculin skin testing in immunosuppressed patients whereas the UK guidelines recommend
that tuberculin skin tests should not be used for such patients because it is unreliable
4.2. New approaches in TB diagnostics
4.2.1. Polymerase chain reaction (PCR)
Diagnostic PCR is a technique of in vitro DNA amplification that uses specific DNA sequences
(oligonucleotides) as effective fishhooks for the DNA/cDNA of microorganisms. In theory, this
technique can detect a single organism in a lot of specimens such as sputum, gastric aspirate,
pleural fluid, cerebrospinal fluid, blood, and urine. Various PCR assays, mostly using the
mycobacterial insertion element IS6110 as the DNA marker for M. tuberculosis-complex
organisms, have a sensitivity and specificity greater than 90% for detecting pulmonary TB in
adults. This is a rapid, sensitive, specific, and reasonable-cost (Montenegro et al., 2003) method
for the detection of M. tuberculosis in clinical samples. The PCR may be used to (a) diagnose
tuberculosis in difficult samples with negative microscopic examination, negative culture, or
with scarce sample; (b) determine if the organisms in the sample are M. tuberculosis or atypical
mycobacteria; (c) identify the presence of genetic variations like a mutations or deletions
known to be associated with resistance to some antimycobacterial agents (Marais et al., 2005).
Studies in children have obtained better sensitivity by PCR than by culture. In 2001, Gomez-
Pastrana et al., (2001) reported a comparison between sensitivity of culture and PCR showing
higher sensitivity for the latter. PCR may have a special role in the diagnosis of extrapulmonary
TB and pulmonary TB in children since sputum smears are usually unrevealing in these cases.
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However, these tests are not performed correctly in all clinical laboratories. The cost involved,
the need for sophisticated equipment, the limitations in their specificity, the need to obtain
multiple samples to optimize yield and scrupulous technique to avoid cross-contamination of
specimens preclude the use of PCR techniques in many developing countries (Montenegro et
al., 2003).The sensitivity of PCR of gastric lavage/bronchoalveolar lavage has been found to be
56.8% in children with clinically active disease. Authors conclude that nested PCR is a rapid
and sensitive method for the early diagnosis of TB in children. Additionally, other unique
sequences of M. tuberculosis have been suggested as diagnostic test for TB, because they are
absent in M. africanum, M. microti, M. bovis, and M. bovis BCG (Liang et al., 2008).
4.2.2. In-house nucleic acid amplification (NAA) assays
These assays are highly dependent on the operator’s skills. Performance is also influenced by
the choice of target sequence and DNA extraction method. Interpretation of the performance
of these assays in pediatric TB suspects is hindered by the lack of a sensitive and specific
reference standard. When compared with culture, the sensitivity of NAA for the diagnosis of
childhood TB is typically low (40–83%). However, it appears, at least from some reports, that
NAA identified a group of children who are clinically diagnosed with TB but in whom
mycobacterial culture is negative. This means that with a proper technique it could be done
efficiently (Nicol and Zar, 2011 ).
4.2.3. Adenosine deaminase
Adult studies have shown increased levels of adenosine deaminase (ADA) in pleural TB
and TB-caused meningitis,  both  paucibacillary  forms of  TB,  and have  advocated for  its
use  in  diagnosis.  Due  to  this  evidence,  a  serum ADA has  already been  evaluated  in  a
childhood population with a very high sensitivity (100%) and specificity (90.7%) for pul‐
monary TB. This study demonstrated the great potential of this technique because it has
significant difference in serum ADA levels  between children with disease and infection.
However, there were several weaknesses in the study design, including unclear case defi‐
nition, exclusion of nontuberculous patients, and a relatively small TB patient population
(20 with active disease) (Marais. and Pai, 2007).
In the case of extrapulmonary TB, ADA measurement can be helpful, but its sensitivity and
specificity varies widely and has been lower than multiplex PCR using primers for IS6110,
dnaJ, and hsp65. Specifically, a meta-analysis of 63 studies of ADA in tuberculous pleuritis
reveals that the sensitivity of the test is of 0.92 (95% CI 0.90–0.93) and specificity of 0.90 (95%
CI 0.89–0.91) (Lawn and Nicol, 2011).
4.2.4. Serology and antigen detection
In absence of good diagnostic method for tuberculosis, the interest in serodiagnosis has been
increased (Marais et al., 2005). Serological tests vary in a number of features, including antigen
composition (38 kDa, Ag 60, and lipoarabinomannan, LAM), antigen source (native or
recombinant), chemical composition (protein or lipid), extent of antigen(s) purification, and
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immunoglobulin detected. The majority are based on the enzyme-linked immunosorbent
assay (ELISA) rapid versions and use various immunochromatographic formats, with lateral
flow being the most popular.
A recent review of serological tests concluded that commercial antibody detection tests for
extrapulmonary TB have no role in clinical care or case detection (Steingart et al., 2007). The
search for novel biomarkers in blood or urine that can reliably distinguish active from latent
TB in children with and without other co-infections remains an important global goal. Well-
defined cohorts of paediatric patients in TB-endemic and non-endemic settings will be essential
for initial screening and future validation of such potential markers. In the meantime, the
diagnosis of TB in children in resource-poor countries continues to rely on practical algorithms,
which lack standard symptom definitions and adequate validation (Marais et al., 2006). This
poses an increased challenge in the context of HIV infection
Imaz et al., (2001) reported the importance of the recombinant 16-kDa antigen (re-Ag16) of M.
tuberculosis in the serodiagnosis of tuberculosis (TB) in children measuring the values of IgA,
IgM, and IgG and an increased mean antibody response to reAg16 was observed in contact
children compared with nonmycobacterial disease patient with a 95% of specificity. A
combining result of the IgG and IgA assays led to 43% positivity in children with active TB
(Trilling. et al., 2011).
Mycobacterial antigen detection has been evaluated in adults, but rarely in children. Serology
has found little place in the routine diagnosis of tuberculosis in children, even though it is
rapid and does not require specimen from the site of disease. Sensitivity and specificity depend
on the antigen used, gold standard for the diagnosis of tuberculosis, and the type of tubercular
infection. Though most of these tests have high specificity, their sensitivity is poor because
several factors can alter the results such as age, exposure to other mycobacteria, and BCG
vaccination (Marais et al., 2005).
4.2.5. In vitro interferon-γ (IFN-γ) release assays (IGRAs) and antigen-testing
In addition to the traditional TST, which is known to lack both sensitivity and specificity, blood
based assays have recently become available. These T-cell assays rely on stimulation of host
blood cells with MTB specific antigens and measure production of IFN-γ. Numerous published
studies compare the two available commercial assays, T Spot TB (Oxford Immunotec) and
Quantiferon-Gold IT (Cellestis), with the TST for both detection of active disease and LTBI
(Ferrara et al., 2006). T-cell assays have proven to be more specific than the TST, (Arend et al.,
2007) but they are still unable to distinguish between active disease and LTBI. Interpretation
therefore remains dependent on the clinical context. Some few studies have presented
paediatric data but none have provided an assessment of age-related performance of these
assays, and reservations remain regarding their performance in very young children and in
immunocompromised populations, such as those with HIV (Clark et al., 2007).
There is still a lot of on going research aimed at establishing the proper role of gamma
interferon tests and the guidelines ar still under constant review. The interferon-γ release
assays (IGRAs) currently commercially available include QuantiFERON-TB Gold (QFT-G),
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Quanti FERON-TB Gold In-Tube and T-SPOT.TB. These tests are aimed at he body's response
to specific TB antigens not present in other forms of mycobacteria and BCG (ESAT-6). The tests
are not affected by prior BCG vaccination, and despite their being new, these are now becoming
available globally and CDC recommends that QFT-G may be used in all circumstances in which
the TST is currently used, including contact investigations, evaluation of recent immigrants,
and sequential-testing surveillance programs for infection control such as those for health-care
workers. Health Protection Agency (HPA) recommends the use of IGRA testing in health care
workers, if available, in view of the importance of detecting latently infected staff that may go
on to develop active disease and come into contact with immunocompromised patients and
the logistical simplicity of IGRA testing.
4.2.6. GeneXpert MTB/RIF system
GeneXpert includes the development of integrated DNA extraction and amplification systems.
This requires minimal manipulation of sample and operator training. It utilizes real-time PCR
(rt-PCR) technology to both diagnose TB and detect rifampicin resistance. The test amplifies
a region of the rpoB gene of M. tuberculosis. Mutations of this region give rise to 95% of
rifampicin resistance. Resistant strains contain mutations localized within the 81 bp core region
of the bacterial RNA polymerase rpoB gene, which encodes the active site of the enzyme. In
addition, the rpoB core region is flanked by Mycobacterium tuberculosis-specific DNA
sequences. Thus, it is possible to test for M. tuberculosis and for rifampicin resistance simul‐
taneously. The simplicity for the user makes this an assay that could feasibly be widely
implemented outside centralized laboratories and potentially impacts on TB control (Gordet‐
sov et al., (2008). The Xpert system has some advantages over the cultivation, mainly in
specificity and a shorter time to get results (Imaz. et al., 2001).
Recently, Nicol et al., (2011), reported the application of this method in 452 hospitalized
children from South Africa, with or without HIV, with a median age of 19.4 months, and
suspected of having TB. Two Xpert tests doubled the case detection rate compared with smear
microscopy (76% versus 38%), identifying all smear-positive and 61% of smear-negative cases,
the specificity was 98.8%. The sensitivities for smear-negative TB were 33.3% and 61.1% when
testing one or two samples, respectively. The samplings were induced sputum and they
detected three quarters of culture-confirmed tuberculosis with very high specificity; the yield
of this method was twice that of smear microscopy. This could suggest the possibility of
replacing the microscopy for this type of methodology which has greater sensitivity especially
with a second sample (Rachow et al., 2011).
4.2.7. Gas sensor array electronic nose (electronic nose)
The potential to detect different Mycobacterium species in the headspaces of cultures and
sputum samples is another innovative approach that is currently in development. The array
uses 14 sensors to profile a “smell” by assessing the change in each sensor’s electrical properties
when exposed to a specific odour mixture. In an initial study using sputum samples from
patients with culture-confirmed tuberculosis and those without tuberculosis, the E-Nose
correctly predicted 89% of culture-positive patients with a specificity of 91% (Imaz. et al.,
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has found little place in the routine diagnosis of tuberculosis in children, even though it is
rapid and does not require specimen from the site of disease. Sensitivity and specificity depend
on the antigen used, gold standard for the diagnosis of tuberculosis, and the type of tubercular
infection. Though most of these tests have high specificity, their sensitivity is poor because
several factors can alter the results such as age, exposure to other mycobacteria, and BCG
vaccination (Marais et al., 2005).
4.2.5. In vitro interferon-γ (IFN-γ) release assays (IGRAs) and antigen-testing
In addition to the traditional TST, which is known to lack both sensitivity and specificity, blood
based assays have recently become available. These T-cell assays rely on stimulation of host
blood cells with MTB specific antigens and measure production of IFN-γ. Numerous published
studies compare the two available commercial assays, T Spot TB (Oxford Immunotec) and
Quantiferon-Gold IT (Cellestis), with the TST for both detection of active disease and LTBI
(Ferrara et al., 2006). T-cell assays have proven to be more specific than the TST, (Arend et al.,
2007) but they are still unable to distinguish between active disease and LTBI. Interpretation
therefore remains dependent on the clinical context. Some few studies have presented
paediatric data but none have provided an assessment of age-related performance of these
assays, and reservations remain regarding their performance in very young children and in
immunocompromised populations, such as those with HIV (Clark et al., 2007).
There is still a lot of on going research aimed at establishing the proper role of gamma
interferon tests and the guidelines ar still under constant review. The interferon-γ release
assays (IGRAs) currently commercially available include QuantiFERON-TB Gold (QFT-G),
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the TST is currently used, including contact investigations, evaluation of recent immigrants,
and sequential-testing surveillance programs for infection control such as those for health-care
workers. Health Protection Agency (HPA) recommends the use of IGRA testing in health care
workers, if available, in view of the importance of detecting latently infected staff that may go
on to develop active disease and come into contact with immunocompromised patients and
the logistical simplicity of IGRA testing.
4.2.6. GeneXpert MTB/RIF system
GeneXpert includes the development of integrated DNA extraction and amplification systems.
This requires minimal manipulation of sample and operator training. It utilizes real-time PCR
(rt-PCR) technology to both diagnose TB and detect rifampicin resistance. The test amplifies
a region of the rpoB gene of M. tuberculosis. Mutations of this region give rise to 95% of
rifampicin resistance. Resistant strains contain mutations localized within the 81 bp core region
of the bacterial RNA polymerase rpoB gene, which encodes the active site of the enzyme. In
addition, the rpoB core region is flanked by Mycobacterium tuberculosis-specific DNA
sequences. Thus, it is possible to test for M. tuberculosis and for rifampicin resistance simul‐
taneously. The simplicity for the user makes this an assay that could feasibly be widely
implemented outside centralized laboratories and potentially impacts on TB control (Gordet‐
sov et al., (2008). The Xpert system has some advantages over the cultivation, mainly in
specificity and a shorter time to get results (Imaz. et al., 2001).
Recently, Nicol et al., (2011), reported the application of this method in 452 hospitalized
children from South Africa, with or without HIV, with a median age of 19.4 months, and
suspected of having TB. Two Xpert tests doubled the case detection rate compared with smear
microscopy (76% versus 38%), identifying all smear-positive and 61% of smear-negative cases,
the specificity was 98.8%. The sensitivities for smear-negative TB were 33.3% and 61.1% when
testing one or two samples, respectively. The samplings were induced sputum and they
detected three quarters of culture-confirmed tuberculosis with very high specificity; the yield
of this method was twice that of smear microscopy. This could suggest the possibility of
replacing the microscopy for this type of methodology which has greater sensitivity especially
with a second sample (Rachow et al., 2011).
4.2.7. Gas sensor array electronic nose (electronic nose)
The potential to detect different Mycobacterium species in the headspaces of cultures and
sputum samples is another innovative approach that is currently in development. The array
uses 14 sensors to profile a “smell” by assessing the change in each sensor’s electrical properties
when exposed to a specific odour mixture. In an initial study using sputum samples from
patients with culture-confirmed tuberculosis and those without tuberculosis, the E-Nose
correctly predicted 89% of culture-positive patients with a specificity of 91% (Imaz. et al.,
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2001). In a further development applying advanced data extraction and linear discriminant
function analysis, obtained sensitivities were of 68% and 75%, and specificities of 75% and 67%
for Rob and Walter electronic noses, respectively (Imaz. et al., 2001). Further applications of
this test, including its potential value in the diagnosis of child tuberculosis, are needed.
4.3. Diagnosing congenital TB
Congenital TB is rare but symptoms typically develop during the second or third week of life
and include poor feeding, poor weight gain, cough, lethargy, and irritability. Other symptoms
include fever, ear discharge, and skin lesions. The principles in place are that for one to make
a definitive diagnosis of congenital TB, the infant should have proven TB lesions and that it
should have at least one of the following: 1) skin lesions during the first week of life, including
papular lesions (ulcerated areas of the skin) or petechiae (bleeding into the skin); 2) documen‐
tation of TB infection of the placenta or the maternal genital tract; 3) presence of a primary
complex in the liver and 4) the possibility of postnatal transmission should be ruled out. Signs
of congenital TB include failure to thrive, icterus (jaundice or yellow skin), hepatosplenome‐
galy (enlargement of both the liver and spleen), tachypnea (rapid breathing), and lympha‐
denopathy (involving inflammation of lymphnodes) (Marais et al., 2006). Patients with
asymptomatic infection have a positive tuberculin skin test (TST) result, but they do not have
any clinical or radiographic manifestations. Children with asymptomatic infection may be
identified on a routine healthy-child physical examination, or they may be identified subse‐
quent to TB diagnosis in household or other contacts ( for example, children who recently have
immigrated or adopted children). Primary TB is characterized by the absence of any signs on
clinical evaluation. As discussed above, these patients are identified by a positive TST result.
Tuberculin hypersensitivity may be associated with erythema nodosum and phlyctenular
conjunctivitis (Marais et al., 2006).
Endobronchial TB with lymphadenopathy, which is the disease with enlargement of lymph
nodes, is the most common variety of pulmonary TB. Symptoms are the result of impingement
on various structures by the enlarged lymph nodes. Enlargement of lymph nodes and
persistent cough may result in signs suggestive of bronchial obstruction or hemi-diaphrag‐
matic paralysis, whereas difficulty in swallowing may result from esophageal compression.
Vocal cord paralysis may be suggested by hoarseness or difficulty breathing and may occur
as a result of local nerve compression. Dysphagia (swallowing problems) due to esophageal
compression may also be observed. Pleural effusions due to TB may also occur and usually
occur in older children and are rarely associated with miliary disease. The typical history
reveals an acute onset of fever, chest pain that increases in intensity on deep inspiration, and
shortness of breath. Fever usually persists for 14-21 days. Signs include: tachypnea, respiratory
distress, decreased breath sounds, and, occasionally, features of mediastinal shift (moving of
the tissues and organs that comprise the mediastinum) (Marais et al., 2006).
Progression of the pulmonary parenchymal component of TB leads to enlargement of the
caseous area (caseated = cheese-like necrotised tissue) and may lead to pneumonia, atelectasis
(collapse of lung tissue), and air trapping. This is more likely to occur in young children than
in adolescents. The child usually appears ill with symptoms of fever, cough, malaise, and
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weight loss. This condition presents with classic signs of pneumonia, including tachypnea,
nasal flaring, grunting, dullness to percussion, egophony or egobronchophony (increased
resonance of voice sounds, with a high-pitched bleating quality, heard especially over lung
tissue compressed by pleural effusion); decreased breath sounds, and crackles (Marais et al.,
2006). Reactivation of TB disease usually has a sub-acute presentation with weight loss, fever,
cough, and, rarely, hemoptysis (coughing up of blood or bloody sputum from the lungs or
airway). This condition typically occurs in older children and adolescent and is more common
in patients who acquire TB at age 7 years and older. Physical examination results may be
normal or may reveal post-tussive crackles (Marais et al., 2006).
4.4. Diagnosis of extrapulmonary TB
In this case the clinical picture is used to get an indication of the diagnosis. The diagnosis at
any site should be confirmed by obtaining specimens for bacteriology wherever possible. This
means that fluid aspirated or biopsies taken should be placed in a medium such as saline which
will not kill the bacteria. Too often still biopsy specimens are placed in formalin so that
bacteriological confirmation including sensitivity testing cannot be done. Miliary TB may
manifest sub acutely with low-grade fever, malaise, weight loss, and fatigue. A rapid onset of
fever and associated symptoms may also be observed. History of cough and respiratory
distress may be obtained. Physical examination findings include lymphadenopathy, hepatos‐
plenomegaly, and systemic signs including fever. Respiratory signs may evolve to include
tachypnea, cyanosis, and respiratory distress. Other signs, which are subtle and should be
carefully sought in the physical examination, include papular, necrotic, or purpuric lesions on
the skin or choroidal tubercles in the retina (Marais et al., 2006).
Patients with lymphadenopathy (scrofula or deposits in subcutaneous lymphatic ganglia) may
have a history of enlarged nodes. Fever, weight loss, fatigue, and malaise are usually absent
or minimal. One of the most severe complications of TB is TB meningitis, which develops in
5-10% of children younger than 2 years; thereafter, the frequency drops to less than 1%. A very
high index of suspicion is required to make a timely diagnosis because of the insidious onset
of the disease. A sub-acute presentation usually occurs within 3-6 months after the initial
infection. Nonspecific symptoms such as anorexia, weight loss, and fever may be present. After
1-2 weeks, patients may experience vomiting and seizures or alteration in the sensorium (the
part of the cerebral cortex that receives and coordinates all the impulses sent to individual
nerve centers which includes auditory, gustatory, olfactory, somatosensory and visual
centers). Deterioration of mental status, coma, and death may occur despite prompt diagnosis
and early intervention.
Three stages of TB meningitis have been identified. Stage 1 is defined by the absence of focal
or generalized neurologic signs. Possibly, only nonspecific behavioral abnormalities are found.
Stage 2 is characterized by the presence of nuchal rigidity (inability or discomfort during neck
flexion), altered deep tendon reflexes, lethargy (abnormal lack of energy), and/or cranial nerve
palsies. TB meningitis most often affects the sixth cranial nerve due to the pressure of the thick
basilar inflammatory exudates on the cranial nerves or to hydrocephalus; this results in lateral
rectus palsy. The third, fourth, and seventh cranial nerves may also be affected. Funduscopic
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2001). In a further development applying advanced data extraction and linear discriminant
function analysis, obtained sensitivities were of 68% and 75%, and specificities of 75% and 67%
for Rob and Walter electronic noses, respectively (Imaz. et al., 2001). Further applications of
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and include poor feeding, poor weight gain, cough, lethargy, and irritability. Other symptoms
include fever, ear discharge, and skin lesions. The principles in place are that for one to make
a definitive diagnosis of congenital TB, the infant should have proven TB lesions and that it
should have at least one of the following: 1) skin lesions during the first week of life, including
papular lesions (ulcerated areas of the skin) or petechiae (bleeding into the skin); 2) documen‐
tation of TB infection of the placenta or the maternal genital tract; 3) presence of a primary
complex in the liver and 4) the possibility of postnatal transmission should be ruled out. Signs
of congenital TB include failure to thrive, icterus (jaundice or yellow skin), hepatosplenome‐
galy (enlargement of both the liver and spleen), tachypnea (rapid breathing), and lympha‐
denopathy (involving inflammation of lymphnodes) (Marais et al., 2006). Patients with
asymptomatic infection have a positive tuberculin skin test (TST) result, but they do not have
any clinical or radiographic manifestations. Children with asymptomatic infection may be
identified on a routine healthy-child physical examination, or they may be identified subse‐
quent to TB diagnosis in household or other contacts ( for example, children who recently have
immigrated or adopted children). Primary TB is characterized by the absence of any signs on
clinical evaluation. As discussed above, these patients are identified by a positive TST result.
Tuberculin hypersensitivity may be associated with erythema nodosum and phlyctenular
conjunctivitis (Marais et al., 2006).
Endobronchial TB with lymphadenopathy, which is the disease with enlargement of lymph
nodes, is the most common variety of pulmonary TB. Symptoms are the result of impingement
on various structures by the enlarged lymph nodes. Enlargement of lymph nodes and
persistent cough may result in signs suggestive of bronchial obstruction or hemi-diaphrag‐
matic paralysis, whereas difficulty in swallowing may result from esophageal compression.
Vocal cord paralysis may be suggested by hoarseness or difficulty breathing and may occur
as a result of local nerve compression. Dysphagia (swallowing problems) due to esophageal
compression may also be observed. Pleural effusions due to TB may also occur and usually
occur in older children and are rarely associated with miliary disease. The typical history
reveals an acute onset of fever, chest pain that increases in intensity on deep inspiration, and
shortness of breath. Fever usually persists for 14-21 days. Signs include: tachypnea, respiratory
distress, decreased breath sounds, and, occasionally, features of mediastinal shift (moving of
the tissues and organs that comprise the mediastinum) (Marais et al., 2006).
Progression of the pulmonary parenchymal component of TB leads to enlargement of the
caseous area (caseated = cheese-like necrotised tissue) and may lead to pneumonia, atelectasis
(collapse of lung tissue), and air trapping. This is more likely to occur in young children than
in adolescents. The child usually appears ill with symptoms of fever, cough, malaise, and
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cough, and, rarely, hemoptysis (coughing up of blood or bloody sputum from the lungs or
airway). This condition typically occurs in older children and adolescent and is more common
in patients who acquire TB at age 7 years and older. Physical examination results may be
normal or may reveal post-tussive crackles (Marais et al., 2006).
4.4. Diagnosis of extrapulmonary TB
In this case the clinical picture is used to get an indication of the diagnosis. The diagnosis at
any site should be confirmed by obtaining specimens for bacteriology wherever possible. This
means that fluid aspirated or biopsies taken should be placed in a medium such as saline which
will not kill the bacteria. Too often still biopsy specimens are placed in formalin so that
bacteriological confirmation including sensitivity testing cannot be done. Miliary TB may
manifest sub acutely with low-grade fever, malaise, weight loss, and fatigue. A rapid onset of
fever and associated symptoms may also be observed. History of cough and respiratory
distress may be obtained. Physical examination findings include lymphadenopathy, hepatos‐
plenomegaly, and systemic signs including fever. Respiratory signs may evolve to include
tachypnea, cyanosis, and respiratory distress. Other signs, which are subtle and should be
carefully sought in the physical examination, include papular, necrotic, or purpuric lesions on
the skin or choroidal tubercles in the retina (Marais et al., 2006).
Patients with lymphadenopathy (scrofula or deposits in subcutaneous lymphatic ganglia) may
have a history of enlarged nodes. Fever, weight loss, fatigue, and malaise are usually absent
or minimal. One of the most severe complications of TB is TB meningitis, which develops in
5-10% of children younger than 2 years; thereafter, the frequency drops to less than 1%. A very
high index of suspicion is required to make a timely diagnosis because of the insidious onset
of the disease. A sub-acute presentation usually occurs within 3-6 months after the initial
infection. Nonspecific symptoms such as anorexia, weight loss, and fever may be present. After
1-2 weeks, patients may experience vomiting and seizures or alteration in the sensorium (the
part of the cerebral cortex that receives and coordinates all the impulses sent to individual
nerve centers which includes auditory, gustatory, olfactory, somatosensory and visual
centers). Deterioration of mental status, coma, and death may occur despite prompt diagnosis
and early intervention.
Three stages of TB meningitis have been identified. Stage 1 is defined by the absence of focal
or generalized neurologic signs. Possibly, only nonspecific behavioral abnormalities are found.
Stage 2 is characterized by the presence of nuchal rigidity (inability or discomfort during neck
flexion), altered deep tendon reflexes, lethargy (abnormal lack of energy), and/or cranial nerve
palsies. TB meningitis most often affects the sixth cranial nerve due to the pressure of the thick
basilar inflammatory exudates on the cranial nerves or to hydrocephalus; this results in lateral
rectus palsy. The third, fourth, and seventh cranial nerves may also be affected. Funduscopic
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changes may include papilledema (swelling of the optic disc from increased intracranial
pressure) and the presence of choroid tubercles (chroid plexus = vascular proliferation of the
cerebral ventricles that serves to regulate intraventricular pressure by secretion or absorption
of cerebrospinal fluid).which should be carefully sought. Stage 3, the final stage, comprises
major neurologic defects, including coma, seizures, and abnormal movements such as
choreoathetosis (irregular involuntary movements that may involve the face, neck, trunk,
extremities, or respiratory muscles, giving an appearance of restlessness), paresis (slight or
incomplete paralysis), paralysis of one or more extremities. In the terminal phase, decerebrate
(elimination of cerebral brain function) or decorticate posturing, opisthotonus (a type of spasm
in which the head and heels arch backward in extreme hyperextension and the body forms a
reverse bow), and/or death may occur. Patients with tuberculomas or TB brain abscesses may
present with focal neurologic signs. Spinal cord disease may result in the acute development
of spinal block or a transverse myelitis–like syndrome (an abnormal condition characterized
by inflammation of the spinal cord with associated motor or sensory dysfunction). A slowly
ascending paralysis may develop over several months to years.
4.5. Treatment
4.5.1. General treatment overview
Each of the first-line drugs makes a specific contribution during different periods of drug action
(assuming complete drug susceptibility and the absence of significant immune compromise).
Period 1 lasts 2 to 3 days (van der Weert et al., 2006), during which time fast-growing extrac‐
ellular bacilli, comprising the vast majority of the organism load, are killed, mainly by the
excellent bactericidal activity of isoniazid (INH) (Kampmann et al., 2005). Period 2 lasts 4 to 8
weeks. Slower growing extracellular bacilli are killed (van der Weert et al., 2006) and the rate
of killing is determined more by the physiological state of the bacilli and less by the bactericidal
activity of the drug. During this period, the bactericidal activity of rifampin (RIF) is important
and pyrazinamide (PZA) contributes by killing extracellular bacilli that persist in acidic areas
of inflammation (van der Weert et al., 2006). Period 3 lasts 4 to 6 months. Persistent intracellular
bacilli are eradicated mainly by RIF, although INH will continue to offer protection against
the development of resistance and may assist with organism eradication, especially in
fibrocaseous tissue with poor drug penetration. Host immunity plays an important role
throughout, but is of particular importance to effect organism eradication and prevent disease
relapse, as indicated by the high relapse rate in HIV-infected children.
Practical operational issues are extremely important for effective public health intervention.
Operational issues include access to early and accurate diagnosis, the uninterrupted provision
of quality-assured drugs and appropriate treatment regimens, as well as the establishment of
systems to ensure good treatment adherence. Fixed-dose combinations should be used
whenever possible to reduce the risk of drug resistance and to improve simplicity and
adherence, but quality assurance is essential to ensure optimal bioavailability of all the
constituent drugs (Dekker and Lotter, 2003). With proper implementation, the World Health
Organization's directly observed therapy, short-course (DOTS) strategy addresses most of the
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important operational issues. However, the predominant emphasis of the DOTS strategy on
sputum smear–positive disease excludes the vast majority of children. There is a desperate
need to improve service delivery to children with tuberculosis, particularly in endemic areas
with limited resources (Starke, 2002).
4.5.2. Preventive chemotherapy
Chemoprophylaxis refers to preventive treatment given after exposure (without proof of
infection), whereas treatment of latent infection implies that infection (indicated by a positive
TST) was documented. The term preventive chemotherapy is preferred because it is more
inclusive and incorporates both chemoprophylaxis and treatment of latent infection. The TST
is a fairly accurate measure of infection after exposure in immune-competent children,
although TST conversion, which reflects a sufficiently strong delayed-type hypersensitivity
response, may be delayed for up to 3 months (Marais et al., 2004). Therefore, household
exposure, particularly involving high-risk children, should be treated as infection until the
absence of infection can be convincingly demonstrated. In immune-competent children this
can be done by repeating the TST 3 months after exposure ended (American Thoracic Society,
2000). In immunocompromised children the TST is not a sufficiently reliable test to exclude M.
tuberculosis infection and children with documented exposure should receive preventive
chemotherapy as if they are infected (Marais et al., 2006).
The reality on the ground is that most endemic areas do not have the capacity to follow current
World Health Organization guidelines regarding the use of preventive chemotherapy in
children, which advise active tracing and screening of all children less than 5 years old in
household contact with a sputum smear–positive adult source case. This results mainly from
the huge burden of adult tuberculosis and resource constraints that limit the ability to perform
TST and chest X-ray screening tests. Because the TST and chest X-ray are regarded as prereq‐
uisite screening tests, screening of exposed children and the provision of preventive chemo‐
therapy are not even attempted in most resource-constrained areas. Access to preventive
chemotherapy in these settings may be improved by employing symptom-based screening,
although the benefits and risks of such a simplified approach require further evaluation. A
study from an endemic area indicated that symptom-based screening may identify those
children who require further investigation to exclude active tuberculosis (Marais et al., 2006),
thus allowing asymptomatic household contacts, especially those who are at high risk to
progress to disease, immediate access to preventive therapy despite the inability to perform
TST and chest X-ray–based screening (Marais et al., 2006).
Another consideration is that in some endemic areas the majority of disease transmission,
particularly in children greater than 2 to 3 years of age, occurs outside the household (Verver
et al., 2004). In endemic areas, narrowing the focus of contact tracing to those children who are
at highest risk to progress to disease after exposure or infection (less than 3 years of age
and/or immune compromised) will decrease the burden placed on already overstretched
health care systems, while still ensuring access to preventive chemotherapy for the children
who need it most (Van Zyl et al., 2006). In older (greater than 3 years of age), immune-
competent children the risk of tuberculosis after exposure is low and disease progression is
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changes may include papilledema (swelling of the optic disc from increased intracranial
pressure) and the presence of choroid tubercles (chroid plexus = vascular proliferation of the
cerebral ventricles that serves to regulate intraventricular pressure by secretion or absorption
of cerebrospinal fluid).which should be carefully sought. Stage 3, the final stage, comprises
major neurologic defects, including coma, seizures, and abnormal movements such as
choreoathetosis (irregular involuntary movements that may involve the face, neck, trunk,
extremities, or respiratory muscles, giving an appearance of restlessness), paresis (slight or
incomplete paralysis), paralysis of one or more extremities. In the terminal phase, decerebrate
(elimination of cerebral brain function) or decorticate posturing, opisthotonus (a type of spasm
in which the head and heels arch backward in extreme hyperextension and the body forms a
reverse bow), and/or death may occur. Patients with tuberculomas or TB brain abscesses may
present with focal neurologic signs. Spinal cord disease may result in the acute development
of spinal block or a transverse myelitis–like syndrome (an abnormal condition characterized
by inflammation of the spinal cord with associated motor or sensory dysfunction). A slowly
ascending paralysis may develop over several months to years.
4.5. Treatment
4.5.1. General treatment overview
Each of the first-line drugs makes a specific contribution during different periods of drug action
(assuming complete drug susceptibility and the absence of significant immune compromise).
Period 1 lasts 2 to 3 days (van der Weert et al., 2006), during which time fast-growing extrac‐
ellular bacilli, comprising the vast majority of the organism load, are killed, mainly by the
excellent bactericidal activity of isoniazid (INH) (Kampmann et al., 2005). Period 2 lasts 4 to 8
weeks. Slower growing extracellular bacilli are killed (van der Weert et al., 2006) and the rate
of killing is determined more by the physiological state of the bacilli and less by the bactericidal
activity of the drug. During this period, the bactericidal activity of rifampin (RIF) is important
and pyrazinamide (PZA) contributes by killing extracellular bacilli that persist in acidic areas
of inflammation (van der Weert et al., 2006). Period 3 lasts 4 to 6 months. Persistent intracellular
bacilli are eradicated mainly by RIF, although INH will continue to offer protection against
the development of resistance and may assist with organism eradication, especially in
fibrocaseous tissue with poor drug penetration. Host immunity plays an important role
throughout, but is of particular importance to effect organism eradication and prevent disease
relapse, as indicated by the high relapse rate in HIV-infected children.
Practical operational issues are extremely important for effective public health intervention.
Operational issues include access to early and accurate diagnosis, the uninterrupted provision
of quality-assured drugs and appropriate treatment regimens, as well as the establishment of
systems to ensure good treatment adherence. Fixed-dose combinations should be used
whenever possible to reduce the risk of drug resistance and to improve simplicity and
adherence, but quality assurance is essential to ensure optimal bioavailability of all the
constituent drugs (Dekker and Lotter, 2003). With proper implementation, the World Health
Organization's directly observed therapy, short-course (DOTS) strategy addresses most of the
Tuberculosis - Current Issues in Diagnosis and Management402
important operational issues. However, the predominant emphasis of the DOTS strategy on
sputum smear–positive disease excludes the vast majority of children. There is a desperate
need to improve service delivery to children with tuberculosis, particularly in endemic areas
with limited resources (Starke, 2002).
4.5.2. Preventive chemotherapy
Chemoprophylaxis refers to preventive treatment given after exposure (without proof of
infection), whereas treatment of latent infection implies that infection (indicated by a positive
TST) was documented. The term preventive chemotherapy is preferred because it is more
inclusive and incorporates both chemoprophylaxis and treatment of latent infection. The TST
is a fairly accurate measure of infection after exposure in immune-competent children,
although TST conversion, which reflects a sufficiently strong delayed-type hypersensitivity
response, may be delayed for up to 3 months (Marais et al., 2004). Therefore, household
exposure, particularly involving high-risk children, should be treated as infection until the
absence of infection can be convincingly demonstrated. In immune-competent children this
can be done by repeating the TST 3 months after exposure ended (American Thoracic Society,
2000). In immunocompromised children the TST is not a sufficiently reliable test to exclude M.
tuberculosis infection and children with documented exposure should receive preventive
chemotherapy as if they are infected (Marais et al., 2006).
The reality on the ground is that most endemic areas do not have the capacity to follow current
World Health Organization guidelines regarding the use of preventive chemotherapy in
children, which advise active tracing and screening of all children less than 5 years old in
household contact with a sputum smear–positive adult source case. This results mainly from
the huge burden of adult tuberculosis and resource constraints that limit the ability to perform
TST and chest X-ray screening tests. Because the TST and chest X-ray are regarded as prereq‐
uisite screening tests, screening of exposed children and the provision of preventive chemo‐
therapy are not even attempted in most resource-constrained areas. Access to preventive
chemotherapy in these settings may be improved by employing symptom-based screening,
although the benefits and risks of such a simplified approach require further evaluation. A
study from an endemic area indicated that symptom-based screening may identify those
children who require further investigation to exclude active tuberculosis (Marais et al., 2006),
thus allowing asymptomatic household contacts, especially those who are at high risk to
progress to disease, immediate access to preventive therapy despite the inability to perform
TST and chest X-ray–based screening (Marais et al., 2006).
Another consideration is that in some endemic areas the majority of disease transmission,
particularly in children greater than 2 to 3 years of age, occurs outside the household (Verver
et al., 2004). In endemic areas, narrowing the focus of contact tracing to those children who are
at highest risk to progress to disease after exposure or infection (less than 3 years of age
and/or immune compromised) will decrease the burden placed on already overstretched
health care systems, while still ensuring access to preventive chemotherapy for the children
who need it most (Van Zyl et al., 2006). In older (greater than 3 years of age), immune-
competent children the risk of tuberculosis after exposure is low and disease progression is
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usually indicated by the presence of persistent, slowly progressive symptoms. Therefore,
passive case finding together with adequate diagnostic vigilance seems appropriate in this
low-risk group.
In non endemic areas where resources permit and where the risk of future reinfection is
low, it seems warranted to extend preventive chemotherapy to low-risk children as well,
to eliminate the reservoir of latent infection within the community. INH monotherapy for
6 to 9 months is the best-studied chemoprophylactic regimen and it reduces the tubercu‐
losis  risk  in  exposed  children  by  at  least  two-thirds;  probably  by  more  than  90% with
good  adherence.  However,  poor  adherence  is  a  major  concern,  particularly  in  endemic
areas (Van Zyl et al., 2006).
In real life the effectiveness of a preventive chemotherapy regimen is determined first by its
efficacy and second by adherence to the prescribed regimen. Because of documented poor
adherence to 6–9 months of unsupervised INH monotherapy, consideration should be given
to alternative preventive strategies with comparable efficacy but with improved adherence.
Theoretically the addition of RIF has important advantages; RIF has strong sterilizing activity
to eradicate latent bacilli and its addition will shorten the duration of treatment required
(Mitchison, 2005). It will also improve efficacy in settings where INH mono-resistance is
prevalent. The use of a 3-month INH and RIF regimen for preventive chemotherapy is well
established and trials have shown equivalence to 6 to 9 months of INH alone, although the
evidence is not as comprehensive as that for INH monotherapy (Ena and Valls, 2005).
PZA is another important sterilizing drug and in theory the combination of RIF and PZA
represents the treatment of choice for latent infection. This combination has proven efficacy in
animal but adverse reactions in adults have limited the initial enthusiasm (Priest, 2004).
However, these adverse reactions have not been observed in children, in whom the three-drug
combination of INH, RIF, and PZA is generally well tolerated (Marais et al., 2006). Adherence
may be improved by shortening the duration of treatment, but consideration may also be given
to the provision of supervised preventive therapy. Creative approaches will be required to
achieve this, particularly in places where health care services are already overburdened. With
curative treatment, intermittent (two or three times weekly) therapy during the continuation
phase is as effective as daily therapy to achieve organism eradication, once the organism load
has been sufficiently reduced (Al-Dossary et al., 2002). The same principle would apply to the
treatment of latent infection, where the organism load is low. Targeting high-risk children for
short-course, supervised intermittent preventive therapy seems achievable, but defining
optimal preventive therapy regimens remains a fertile and important area for future research
(Marais et al., 2006).
Vaccination with BCG is the most widely used preventive strategy, although its efficacy
remains controversial and studies have shown that it contributes to this variable protection:
variations in strain-specific immunogenicity, timing and technique of vaccine administration,
genetic factors, the presence or absence of environmental mycobacteria, and the effect of
multiple re-infection events as may occur in highly endemic areas. It is generally accepted that
BCG vaccination offers significant protection against disseminated disease in young children
(below 2 years), but that it offers little or no protection against adult-type tuberculosis.
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However, reports have documented significant protection against the development of adult-
type tuberculosis when BCG was administered to TST-negative adolescents in locations with
a low prevalence of environmental mycobacterial exposure (Bjarveit et al., 2003).
In addition, a report from Turkey indicated that contrary to the prevailing theory, BCG may
also protect against M. tuberculosis infection as based on a positive enzyme-linked immuno‐
spot result. An even more controversial area is the risk versus benefit that BCG provides to
HIV-infected children. There is a definite risk for HIV-infected infants to develop severe forms
of BCG disease after neonatal BCG vaccination (Hesseling et al., 2006), but it remains poorly
quantified. As the risk:benefit ratio has not been determined, the World Health Organization
still advises BCG vaccination of asymptomatic HIV-exposed infants in tuberculosis endemic
areas. Establishing the risk: benefit ratio of BCG vaccination in HIV-infected infants and the
development of novel vaccines with improved efficacy and safety, remain major research
challenges (Marais et al., 2006).
4.5.3. Curative treatment
The main variables that influence the success of chemotherapy, apart from primary drug
resistance, are the bacterial load and the anatomic distribution of bacilli. Cavitary disease
indicates a high bacterial load, as demonstrated by the frequency with which these patients
are sputum smear–positive, which implies an increased risk for random drug resistance
against individual drugs. Disseminated disease may signify penetration of bacilli into the
central nervous system (CNS) (Van den Bosch et al., 2004) implying that adequate drug
penetration across the blood–brain barrier is an important requirement for the treatment of
disseminated disease (Marais et al., 2006).
From a public health perspective the challenge is to develop a pragmatic classification of
childhood tuberculosis that incorporates the diverse spectrum of disease, but focuses pri‐
marily  on treatment  relevance.  The main variables  that  influence the  success  of  chemo‐
therapy  identify  three  groups  of  children  with  tuberculosis:  (1)  those  with  sputum
smear–negative  disease,  (2)  those  with  sputum  smear–positive  (often  cavitary)  disease
and (3) those with disseminated disease. The discussion reflects current treatment guide‐
lines for these three groups as well  as the new regimens to consider on the basis of es‐
tablished treatment principles (Marais et al., 2006).
As a guide for individual patient classification and management five simple questions have
been formulated: (1) Is the child exposed to or infected with M. tuberculosis? (2) Does the child
have active tuberculosis? (3) If the child is exposed or infected, but does not have active
tuberculosis, is preventive chemotherapy indicated? (4) If the child has active tuberculosis,
what is the appropriate treatment regimen? (5) Are there any special circumstances such as
HIV infection, retreatment, or exposure to a drug-resistant source case to consider? The
underlying rationale is universally applicable irrespective of diagnostic or resource con‐
straints; although areas with access to advanced technology may achieve improved levels of
diagnostic certainty.
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However, these adverse reactions have not been observed in children, in whom the three-drug
combination of INH, RIF, and PZA is generally well tolerated (Marais et al., 2006). Adherence
may be improved by shortening the duration of treatment, but consideration may also be given
to the provision of supervised preventive therapy. Creative approaches will be required to
achieve this, particularly in places where health care services are already overburdened. With
curative treatment, intermittent (two or three times weekly) therapy during the continuation
phase is as effective as daily therapy to achieve organism eradication, once the organism load
has been sufficiently reduced (Al-Dossary et al., 2002). The same principle would apply to the
treatment of latent infection, where the organism load is low. Targeting high-risk children for
short-course, supervised intermittent preventive therapy seems achievable, but defining
optimal preventive therapy regimens remains a fertile and important area for future research
(Marais et al., 2006).
Vaccination with BCG is the most widely used preventive strategy, although its efficacy
remains controversial and studies have shown that it contributes to this variable protection:
variations in strain-specific immunogenicity, timing and technique of vaccine administration,
genetic factors, the presence or absence of environmental mycobacteria, and the effect of
multiple re-infection events as may occur in highly endemic areas. It is generally accepted that
BCG vaccination offers significant protection against disseminated disease in young children
(below 2 years), but that it offers little or no protection against adult-type tuberculosis.
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spot result. An even more controversial area is the risk versus benefit that BCG provides to
HIV-infected children. There is a definite risk for HIV-infected infants to develop severe forms
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quantified. As the risk:benefit ratio has not been determined, the World Health Organization
still advises BCG vaccination of asymptomatic HIV-exposed infants in tuberculosis endemic
areas. Establishing the risk: benefit ratio of BCG vaccination in HIV-infected infants and the
development of novel vaccines with improved efficacy and safety, remain major research
challenges (Marais et al., 2006).
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The main variables that influence the success of chemotherapy, apart from primary drug
resistance, are the bacterial load and the anatomic distribution of bacilli. Cavitary disease
indicates a high bacterial load, as demonstrated by the frequency with which these patients
are sputum smear–positive, which implies an increased risk for random drug resistance
against individual drugs. Disseminated disease may signify penetration of bacilli into the
central nervous system (CNS) (Van den Bosch et al., 2004) implying that adequate drug
penetration across the blood–brain barrier is an important requirement for the treatment of
disseminated disease (Marais et al., 2006).
From a public health perspective the challenge is to develop a pragmatic classification of
childhood tuberculosis that incorporates the diverse spectrum of disease, but focuses pri‐
marily  on treatment  relevance.  The main variables  that  influence the  success  of  chemo‐
therapy  identify  three  groups  of  children  with  tuberculosis:  (1)  those  with  sputum
smear–negative  disease,  (2)  those  with  sputum  smear–positive  (often  cavitary)  disease
and (3) those with disseminated disease. The discussion reflects current treatment guide‐
lines for these three groups as well  as the new regimens to consider on the basis of es‐
tablished treatment principles (Marais et al., 2006).
As a guide for individual patient classification and management five simple questions have
been formulated: (1) Is the child exposed to or infected with M. tuberculosis? (2) Does the child
have active tuberculosis? (3) If the child is exposed or infected, but does not have active
tuberculosis, is preventive chemotherapy indicated? (4) If the child has active tuberculosis,
what is the appropriate treatment regimen? (5) Are there any special circumstances such as
HIV infection, retreatment, or exposure to a drug-resistant source case to consider? The
underlying rationale is universally applicable irrespective of diagnostic or resource con‐
straints; although areas with access to advanced technology may achieve improved levels of
diagnostic certainty.
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Sputum smear–negative disease is usually paucibacillary and therefore the risk of acquired
drug resistance is low. Drug penetration into the anatomic sites involved is good and the
success of three drugs (INH, RIF, and PZA) during the 2-month intensive phase, and of two
drugs (INH and RIF) during the 4-month continuation phase, is well established. In the
presence of extensive radiographic disease with or without cavitation, and/or suspicion of INH
resistance, the use of ethambutol (EMB) in addition to the three drugs during the intensive
phase should be contemplated. After completion of the intensive phase, successful organism
eradication may be achieved with intermittent (two or three times weekly) therapy during the
continuation phase (Al-Dossary et al., 2002). The efficacy of shorter treatment durations for
HIV-uninfected immune-competent children with sputum smear–negative disease requires
further evaluation, as a 4-month regimen of INH and RIF may be an acceptable therapy for
some adults with sputum smear– and culture-negative tuberculosis.
Sputum smear–positive disease implies a high organism load and an increased risk for random
drug resistance against individual drugs. Selecting drug-resistant mutants is a particular
concern where INH mono-resistance is prevalent, as this increases the likelihood of selecting
multidrug-resistant (MDR) organisms. The use of four drugs (INH, RIF, PZA, and EMB) during
the 2-month intensive phase should reduce this risk. Once the organism load is sufficiently
reduced, intermittent (two or three times weekly) therapy with INH and RIF during the 4-
month continuation phase is sufficient to ensure organism eradication (Al-Dossary et al.,
2002). However, caution should be exercised when initial treatment response has not been
optimal and in HIV-infected patients. The use of long-acting rifamycins together with INH is
discouraged (Rieder et al., 2001).
Disseminated disease is frequently associated with CNS involvement (Donald et al., 2005). It
is therefore essential to consider the cerebrospinal fluid (CSF) penetration of drugs used in the
treatment of disseminated disease. INH and PZA penetrate the CSF well. RIF and streptomycin
penetrate the CSF poorly, but may achieve therapeutic levels in the presence of meningeal
inflammation. The value of streptomycin is limited by poor CSF penetration and intramuscular
administration. EMB hardly penetrates the CSF, even in the presence of meningeal inflamma‐
tion, and has no demonstrated efficacy in the treatment of TBM. Ethionamide shows good CSF
penetration and has been used successfully as a fourth drug in the treatment of TBM. The fact
that RIF penetrates the CSF poorly in the absence of meningeal inflammation reduces its
sterilization value and may warrant the inclusion of PZA during the continuation phase, to
assist with CNS sterilization.
Several reports have illustrated the efficacy of short-course regimens in the treatment of TB
meningitis, but the risk of CNS relapse is rarely reported. In two of these studies a relapse was
documented despite the completion of 6 months of treatment with INH and RIF with an initial
2 months of PZA. Therefore, it seems prudent to include a fourth drug with good CNS
penetration (such as ethionamide) for the treatment of disseminated disease, at least during
the intensive phase, and to consider PZA for the full 6 months of treatment to reduce the risk
of CNS relapse. CNS relapse is rare in the United States, where PZA is routinely discontinued
after 2 months, but the total treatment duration is 9 to 12 months. Current fixed-dose combi‐
nation tablets provide 4 to 6 mg of INH per kilogram. This dose may be suboptimal, particu‐
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larly in settings where the majority of the bacterial population rapidly acetylates INH (Schaaf
et al., 2005). In addition, the serum level achieved with a similar dose of INH per kilogram is
lower in children than in adults, increasing the risk for suboptimal dosing in children (Schaaf
et al., 2005). The majority of new INH resistance encountered in endemic areas is of an
intermediate or low level, which underscores the importance of optimal INH dosing (Donald
et al., 2004). A standard INH dose of 10 mg/kg seems appropriate in children, as even doses
up to 20 mg/kg are well tolerated (Schaaf et al., 2005); children are less susceptible to the toxic
effects of INH than are adults.
In general, adverse events are less common in children than in adults. The most severe adverse
event is the development of hepatotoxicity, which can be caused by INH, RIF, PZA, or
ethionamide. An elevation of liver enzymes (less than five times normal values) is not an
indication to stop treatment, but the occurrence of liver tenderness, hepatomegaly, or jaundice
should prompt the immediate stopping of all potentially hepatotoxic drugs. Jaundice is often
preceded by a period of days or weeks of malaise and nausea. Hepatic reactions usually occur
in the first weeks of therapy, but may happen at any time during the treatment period. Drug-
related hepatic toxicity is usually caused by a single drug, but rarely a combination of drugs,
which individually cause no problem, may cause hepatic toxicity. Children should be screened
for other causes of hepatitis, as in many cases the anti-tuberculosis drugs are not the cause of
liver function derangement. In South Africa, hepatitis A infection is frequently responsible for
non–drug-related liver function derangement in children receiving anti-tuberculosis treat‐
ment. Potentially hepatotoxic drugs should be reintroduced only after liver functions have
normalized. Non-hepatotoxic drugs should be used in the interim and expert opinion should
be sought.
Ethambutol is usually not advised in children less than 7 years as visual acuity cannot be
evaluated. However, its use may be warranted in children with hepatotoxicity, cavitary
disease, or resistance to first-line drugs; it seems safe at recommended dosages. Ethionamide
frequently causes vomiting, but this can usually be overcome by dividing the daily dose and
by a slow increase up to the full dose during the first week or two of therapy. Recommended
dosages for the various first- and second-line drugs are reflected in the publication by Marais
et al., (2006) as indicated in the Table 1 below:
Despite significant symptomatic improvement radiographic disease resolution may take many
months; persistent radiographic signs are not an indication to change treatment if there is
clinical improvement. Paradoxical exacerbation of symptoms or signs may also occur after
anti-tuberculosis therapy is initiated. This results from immune reconstitution with increased
inflammation, particularly surrounding diseased lymph nodes or tuberculomas, that may
follow nutritional rehabilitation (Marais et al., 2004), and/or antiretroviral therapy. The release
of bacterial toxins after successful anti-tuberculosis treatment may also contribute.
Treatment should be continued unaltered, although the temporary addition of corticosteroids
may be considered. Such adjunctive therapy may be helpful in a number of disease manifes‐
tations where the host inflammatory response contributes to disease pathology such as CNS
involvement, severe lymph node compression of the airways, and pericardial effusion. There
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success of three drugs (INH, RIF, and PZA) during the 2-month intensive phase, and of two
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HIV-uninfected immune-competent children with sputum smear–negative disease requires
further evaluation, as a 4-month regimen of INH and RIF may be an acceptable therapy for
some adults with sputum smear– and culture-negative tuberculosis.
Sputum smear–positive disease implies a high organism load and an increased risk for random
drug resistance against individual drugs. Selecting drug-resistant mutants is a particular
concern where INH mono-resistance is prevalent, as this increases the likelihood of selecting
multidrug-resistant (MDR) organisms. The use of four drugs (INH, RIF, PZA, and EMB) during
the 2-month intensive phase should reduce this risk. Once the organism load is sufficiently
reduced, intermittent (two or three times weekly) therapy with INH and RIF during the 4-
month continuation phase is sufficient to ensure organism eradication (Al-Dossary et al.,
2002). However, caution should be exercised when initial treatment response has not been
optimal and in HIV-infected patients. The use of long-acting rifamycins together with INH is
discouraged (Rieder et al., 2001).
Disseminated disease is frequently associated with CNS involvement (Donald et al., 2005). It
is therefore essential to consider the cerebrospinal fluid (CSF) penetration of drugs used in the
treatment of disseminated disease. INH and PZA penetrate the CSF well. RIF and streptomycin
penetrate the CSF poorly, but may achieve therapeutic levels in the presence of meningeal
inflammation. The value of streptomycin is limited by poor CSF penetration and intramuscular
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tion, and has no demonstrated efficacy in the treatment of TBM. Ethionamide shows good CSF
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meningitis, but the risk of CNS relapse is rarely reported. In two of these studies a relapse was
documented despite the completion of 6 months of treatment with INH and RIF with an initial
2 months of PZA. Therefore, it seems prudent to include a fourth drug with good CNS
penetration (such as ethionamide) for the treatment of disseminated disease, at least during
the intensive phase, and to consider PZA for the full 6 months of treatment to reduce the risk
of CNS relapse. CNS relapse is rare in the United States, where PZA is routinely discontinued
after 2 months, but the total treatment duration is 9 to 12 months. Current fixed-dose combi‐
nation tablets provide 4 to 6 mg of INH per kilogram. This dose may be suboptimal, particu‐
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larly in settings where the majority of the bacterial population rapidly acetylates INH (Schaaf
et al., 2005). In addition, the serum level achieved with a similar dose of INH per kilogram is
lower in children than in adults, increasing the risk for suboptimal dosing in children (Schaaf
et al., 2005). The majority of new INH resistance encountered in endemic areas is of an
intermediate or low level, which underscores the importance of optimal INH dosing (Donald
et al., 2004). A standard INH dose of 10 mg/kg seems appropriate in children, as even doses
up to 20 mg/kg are well tolerated (Schaaf et al., 2005); children are less susceptible to the toxic
effects of INH than are adults.
In general, adverse events are less common in children than in adults. The most severe adverse
event is the development of hepatotoxicity, which can be caused by INH, RIF, PZA, or
ethionamide. An elevation of liver enzymes (less than five times normal values) is not an
indication to stop treatment, but the occurrence of liver tenderness, hepatomegaly, or jaundice
should prompt the immediate stopping of all potentially hepatotoxic drugs. Jaundice is often
preceded by a period of days or weeks of malaise and nausea. Hepatic reactions usually occur
in the first weeks of therapy, but may happen at any time during the treatment period. Drug-
related hepatic toxicity is usually caused by a single drug, but rarely a combination of drugs,
which individually cause no problem, may cause hepatic toxicity. Children should be screened
for other causes of hepatitis, as in many cases the anti-tuberculosis drugs are not the cause of
liver function derangement. In South Africa, hepatitis A infection is frequently responsible for
non–drug-related liver function derangement in children receiving anti-tuberculosis treat‐
ment. Potentially hepatotoxic drugs should be reintroduced only after liver functions have
normalized. Non-hepatotoxic drugs should be used in the interim and expert opinion should
be sought.
Ethambutol is usually not advised in children less than 7 years as visual acuity cannot be
evaluated. However, its use may be warranted in children with hepatotoxicity, cavitary
disease, or resistance to first-line drugs; it seems safe at recommended dosages. Ethionamide
frequently causes vomiting, but this can usually be overcome by dividing the daily dose and
by a slow increase up to the full dose during the first week or two of therapy. Recommended
dosages for the various first- and second-line drugs are reflected in the publication by Marais
et al., (2006) as indicated in the Table 1 below:
Despite significant symptomatic improvement radiographic disease resolution may take many
months; persistent radiographic signs are not an indication to change treatment if there is
clinical improvement. Paradoxical exacerbation of symptoms or signs may also occur after
anti-tuberculosis therapy is initiated. This results from immune reconstitution with increased
inflammation, particularly surrounding diseased lymph nodes or tuberculomas, that may
follow nutritional rehabilitation (Marais et al., 2004), and/or antiretroviral therapy. The release
of bacterial toxins after successful anti-tuberculosis treatment may also contribute.
Treatment should be continued unaltered, although the temporary addition of corticosteroids
may be considered. Such adjunctive therapy may be helpful in a number of disease manifes‐
tations where the host inflammatory response contributes to disease pathology such as CNS
involvement, severe lymph node compression of the airways, and pericardial effusion. There
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is insufficient evidence to demonstrate whether steroids are effective in tuberculous pleural
effusion.
4.5.4. Retreatment
Anti-tuberculosis treatment rarely fails in children and, if it does, every effort should be made
to find the most likely cause. In settings where the prevalence of drug resistance is low the
commonest cause is failure to properly take the medications, which can occur even during
DOT, if supervision is not complete. It is important to remember that non-adherence has a
differential diagnosis; there are psychologic, sociologic, religious, economic, and practical
reasons why people are non-adherent and one must deal with all these issues for chemotherapy
to be successful. With treatment interruption the child may be restarted on the original
treatment regimen while ensuring adequate supervision, as the risk of developing drug
resistance is small in children with paucibacillary disease. If an immune-competent child
presents with a new episode of tuberculosis more than 6 months after completing treatment
Maximum Dosage (mg/kg/dose)
Mode of Action Daily Two or Three
Times/wk
First-line drugs
Isoniazid Bactericidal 10–15 (300 mg) 20–30 (900 mg)
Rifampin Bactericidal and sterilizing 10–20 (600 mg) 10–20 (600 mg)
Pyrazinamide Sterilizing 20–40 (2,000 mg) 50 (2,000 mg)
Ethambutol Bacteriostatic 15–25 (1,200 mg) 30–50 (2,500 mg)
Second-line drugs
Ethionamide or prothionamide Bactericidal 15–20 (1,000 mg) NA
Streptomycin Bacteriostatic 20–40 (1,000 mg) NA
Fluoroquinolones Bactericidal NA
Ciprofloxacin 20–40 (1,500 mg)
Aminoglycosides Bacteriostatic NA
Kanamycin 15–30 (1,000 mg)
Amikacin 15–30 (1,000 mg)
Capreomycin 15–30 (1,000 mg)
Cycloserine or terizidone Bacteriostatic 10–20 (1,000 mg) NA
Para-aminosalicylic acid Bacteriostatic 200–300 (10 g) NA
NA = not applicable. Source: Marais et al., (2006).
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for a previous episode, then it most likely represents re-infection disease and standard first-
line treatment is appropriate. In the case of genuine treatment failure (absence of clinical
response to supervised treatment) drug susceptibility testing is of paramount importance. If
an adult source case is identified with drug-resistant tuberculosis, the child should be treated
according to the drug susceptibility pattern of the source case's strain (Marais et al., 2006).
4.5.5. Treatment of paediatric TB/HIV co-infection
The high risk of HIV-infected children to progress to disease after infection justifies the use of
preventive chemotherapy in children who are latently infected. However, the difficult issue
in endemic areas is how to deal with the ever-present risk of undocumented re-infection within
the community. The prevention or reversal of severe immune compromise by using highly
active antiretroviral therapy (HAART) should preclude the need for repeated or continuous
preventive chemotherapy, although the risk for tuberculosis probably remains higher than in
HIV-uninfected children. The cellular immune response assists with organism eradication and
therefore it is not unexpected that disease relapse has been documented in HIV-infected
children. The value of prolonging the treatment duration from 6 to 9 months, to ensure
organism eradication in HIV-infected children, is under investigation. During a repeat episode
both relapse and reinfection should be considered and every effort should be made to establish
a culture-confirmed diagnosis and to do drug susceptibility testing (Marais et al., 2006).
When initiating treatment (curative treatment or RIF-containing preventive therapy) in HIV-
infected children already receiving HAART or for whom HAART is contemplated, it should
be appreciated that the rifamycins, especially RIF, and some of the nonnucleoside reverse
transcriptase inhibitors and/or protease inhibitors may cause significant drug interactions.
HIV-infected children may also develop particularly pronounced paradoxical reactions after
the institution of HAART, because of immune reconstitution inflammatory syndrome.
Recommendations on optimal drug combinations are frequently revised. The most recent
recommendations can be obtained from the Centers for Disease Control and Prevention
website, at [http://www.cdc.gov/nchstp/tb/].
Latest WHO recommendations advise starting antiretroviral therapy (ART) once anti-TB
therapy (ATT) is established (after a period of 2-8 weeks) for all WHO clinical Stage Four HIV-
infected children and Stage Three children with advanced or severe immunosuppression. For
children in WHO clinical stage with mild or no immunosuppression, ART may be deferred
until 6 months of ATT are completed (WHO, 2006). On-going prospective trials involving
adults and children in TB/HIV endemic countries might provide future guidelines for the ideal
timing of the initiation of anti-retroviral therapy (ART) in patients with HIV receiving TB
therapy. There is already evidence from prospective trials that shows that high mortality is
associated with TB in advanced stages of HIV-disease in children who do not receive ART
promptly. Further research is required to improve our understanding of immune reconstitu‐
tion disease (IRD) in children (Walters et al., 2006). Also, therapeutic drug monitoring (TDM),
where available, should be undertaken when children are receiving concomitant ART and
ATT. TDM data from ethnically similar children in resource-rich countries may in the future
inform dosing recommendations in resource-poor settings where TDM is not available.
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differential diagnosis; there are psychologic, sociologic, religious, economic, and practical
reasons why people are non-adherent and one must deal with all these issues for chemotherapy
to be successful. With treatment interruption the child may be restarted on the original
treatment regimen while ensuring adequate supervision, as the risk of developing drug
resistance is small in children with paucibacillary disease. If an immune-competent child
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Ethambutol Bacteriostatic 15–25 (1,200 mg) 30–50 (2,500 mg)
Second-line drugs
Ethionamide or prothionamide Bactericidal 15–20 (1,000 mg) NA
Streptomycin Bacteriostatic 20–40 (1,000 mg) NA
Fluoroquinolones Bactericidal NA
Ciprofloxacin 20–40 (1,500 mg)
Aminoglycosides Bacteriostatic NA
Kanamycin 15–30 (1,000 mg)
Amikacin 15–30 (1,000 mg)
Capreomycin 15–30 (1,000 mg)
Cycloserine or terizidone Bacteriostatic 10–20 (1,000 mg) NA
Para-aminosalicylic acid Bacteriostatic 200–300 (10 g) NA
NA = not applicable. Source: Marais et al., (2006).
Table 1. First- And Second-Line Antituberculosis Drugs And Recommended Dosages In Children
Tuberculosis - Current Issues in Diagnosis and Management408
for a previous episode, then it most likely represents re-infection disease and standard first-
line treatment is appropriate. In the case of genuine treatment failure (absence of clinical
response to supervised treatment) drug susceptibility testing is of paramount importance. If
an adult source case is identified with drug-resistant tuberculosis, the child should be treated
according to the drug susceptibility pattern of the source case's strain (Marais et al., 2006).
4.5.5. Treatment of paediatric TB/HIV co-infection
The high risk of HIV-infected children to progress to disease after infection justifies the use of
preventive chemotherapy in children who are latently infected. However, the difficult issue
in endemic areas is how to deal with the ever-present risk of undocumented re-infection within
the community. The prevention or reversal of severe immune compromise by using highly
active antiretroviral therapy (HAART) should preclude the need for repeated or continuous
preventive chemotherapy, although the risk for tuberculosis probably remains higher than in
HIV-uninfected children. The cellular immune response assists with organism eradication and
therefore it is not unexpected that disease relapse has been documented in HIV-infected
children. The value of prolonging the treatment duration from 6 to 9 months, to ensure
organism eradication in HIV-infected children, is under investigation. During a repeat episode
both relapse and reinfection should be considered and every effort should be made to establish
a culture-confirmed diagnosis and to do drug susceptibility testing (Marais et al., 2006).
When initiating treatment (curative treatment or RIF-containing preventive therapy) in HIV-
infected children already receiving HAART or for whom HAART is contemplated, it should
be appreciated that the rifamycins, especially RIF, and some of the nonnucleoside reverse
transcriptase inhibitors and/or protease inhibitors may cause significant drug interactions.
HIV-infected children may also develop particularly pronounced paradoxical reactions after
the institution of HAART, because of immune reconstitution inflammatory syndrome.
Recommendations on optimal drug combinations are frequently revised. The most recent
recommendations can be obtained from the Centers for Disease Control and Prevention
website, at [http://www.cdc.gov/nchstp/tb/].
Latest WHO recommendations advise starting antiretroviral therapy (ART) once anti-TB
therapy (ATT) is established (after a period of 2-8 weeks) for all WHO clinical Stage Four HIV-
infected children and Stage Three children with advanced or severe immunosuppression. For
children in WHO clinical stage with mild or no immunosuppression, ART may be deferred
until 6 months of ATT are completed (WHO, 2006). On-going prospective trials involving
adults and children in TB/HIV endemic countries might provide future guidelines for the ideal
timing of the initiation of anti-retroviral therapy (ART) in patients with HIV receiving TB
therapy. There is already evidence from prospective trials that shows that high mortality is
associated with TB in advanced stages of HIV-disease in children who do not receive ART
promptly. Further research is required to improve our understanding of immune reconstitu‐
tion disease (IRD) in children (Walters et al., 2006). Also, therapeutic drug monitoring (TDM),
where available, should be undertaken when children are receiving concomitant ART and
ATT. TDM data from ethnically similar children in resource-rich countries may in the future
inform dosing recommendations in resource-poor settings where TDM is not available.
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4.5.6. Treatment of extrapulmonary paeditric PTB
Treatment is as for pulmonary disease, with isoniazid, rifampicin, pyrazinamide and etham‐
butol for two months followed by isoniazid and rifampicin for four months, except for CNS
disease when treatment should be continued for a full year. Steroids may be used in pericardial
and meningeal disease. Surgery is usually unnecessary, especially where lymph glands and
abscess are present, as long term discharging sinuses may result. Surgery is sometimes
necessary in spinal TB where there is instability and may be needed to overcome strictures in
genito-urinary or gastro-intestinal disease. Occasionally pericardectomy may be required
when pericardial disease causes tamponade.
4.5.7. Treatment of latent paediatric TB infection
Treatment of LTBI, also known as chemoprophylaxis, is important to prevent future disease
activation. The fact that over 50% of hospitalized children with culture-confirmed TB have a
reported close TB contact and do not receive chemoprophylaxis, is an indication of the
important missed opportunities using existing public health interventions. For the last 20 years
the WHO guidelines recommended all children under 5 years in close contact with an
infectious (usually smear positive) case receive 6 months isoniazid. Once active disease has
been excluded, isoniazid monotherapy for 6-9 months has been proven to reduce the TB risk
in exposed children by over 90% with good adherence. More recent studies suggest that 3
months of combined isoniazid and rifampicin are equally effective (Ena and Valls, 2005). In a
recent study with very short follow-up, continuous isoniazid prophylaxis for HIV-infected
children without documented evidence of latent infection, but living in an environment of high
exposure, has also been shown to reduce overall morbidity and mortality from TB and other
infections (Zar et al., 2007). Further trials in HIV-infected children receiving ART are ongoing.
Recommendations for chemoprophylaxis will continue to differ in TB-endemic and non-
endemic settings, because of the perceived risk of exposure. Whilst most paediatricians in
Europe and North America would advocate chemoprophylaxis for HIV infected, TB-exposed
children only, this needs to be interpreted with caution if the exposure is potentially ongoing
or recurrent, and the ability to distinguish LTBI from active disease is limited. In this context,
many practitioners in TB-endemic settings are reluctant to place children on chemoprophylaxis
because of the potential emergence of resistant strains, if indeed the child has active disease
instead of LTBI.
4.5.8. Treatment of drug resistant paediatric TB
Acquisition of resistance rarely occurs in children due to the paucibacillary nature of their
disease but overall, children may also be subject to less selection pressure from anti TB therapy.
Thus most resistance in children is due to primary transmission of a resistant organism, and
MDR /XDR-TB rates in children reflect community transmission rates. Diagnosis requires a
high index of suspicion as the culture yield in children makes definitive microbiological
confirmation difficult. Resistance should be suspected if an index case has known resistant TB;
the child shows initial improvement on anti-TB therapy and then deteriorates; or there is no
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response to initial treatment. Acquired resistance is well described in HIV co-infected adults
previously treated for TB, possibly due to malabsorption of anti-TB drugs (Wells, et al., 2007).
The presence of acquired resistance in the paediatric population is reported and in particular
children with TB/HIV co-infection should be closely monitored (Soeters et al., 2005).
Although the principles of DOTS Plus have been put forward for the management of MDR
TB, at the moment, there is no consensus for any regimen or optimal treatment that should be
used for persons with known exposure to MDR-TB. The recommendation by CDC is a
combination of pyrazinamide and ethambutol, with either pyrazinamide or a fluoroquinolone
and that immunocompetent contacts should be treated for 6 months while immunocompro‐
mised contacts should be treated for 12 months. Current guidelines recommend using at least
four drugs to which the patient is naïve, including an injectable and a fluoroquinolone, in an
initial phase of at least 6 months; followed by at least three of the most active and best tolerated
drugs in a 12-18 month continuation phase.
Standardised regimens have been developed for settings where drug susceptibility testing is
not available (WHO, 2006). Six classes of second-line drugs (SLDs) are available (WHO, 2003)
but experience in children is limited for the majority and multi-centre paediatric trials are
needed. Under optimum circumstances MDR-TB responds well to appropriate therapy.
However delays in diagnosis and treatment, adherence issues, and a lack of child-friendly
formulations and strategies for DOTS all frequently complicate management and contribute
to a high morbidity and mortality (Drobac et al., 2006).
The WHO currently recommends avoidance of chemoprophylaxis in cases of contact with
known MDR-TB and to observe for 2 years if clinically asymptomatic. Children with latent
MDR-TB infection become the reservoir for future transmission following disease reactivation
in adulthood, emphasizing the need to further research and improved management of MDR-
TB infection in children, both at the clinical and operational level.
According to the European Centre for Disease Prevention and Control (ECDC) 2012 Guide‐
lines, there are two valid options to consider for the management of MDR TB and XDR TB
contacts; preventive treatment or follow-up by careful clinical observation. The purpose of
preventive therapy is to prevent the progression of LTBI to TB disease in an individual who
has been exposed to MDR/XDR TB. The concept of preventive therapy has been shown to be
effective for LTBI after contact with drug-susceptible TB but corresponding evidence for
preventive therapy of MDR TB and XDR TB contacts is very scarce. Although for children there
are indications of a positive effect of preventive therapy, for other groups of contacts, the
necessary body of evidence has yet to be generated, and there are ongoing studies to collect
evidence in support of the use of preventive therapy in contacts of MDR TB cases.
There  is  currently  no  evidence  available  on  the  optimal  follow-up  time  in  contacts  of
MDR  TB  or  XDR  TB  with  regard  to  patient  benefits  and  costs  of  the  intervention.  In
young children under five years of age the majority ( over 90%) of TB disease will devel‐
op within 12 months of infection. Infants and children under five years of age, immuno‐
compromised  individuals  due  to  HIV  infection  or  TNF-antagonist  treatment  are  at
increased risk of progression from LTBI to TB disease. These individuals as well as other
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in exposed children by over 90% with good adherence. More recent studies suggest that 3
months of combined isoniazid and rifampicin are equally effective (Ena and Valls, 2005). In a
recent study with very short follow-up, continuous isoniazid prophylaxis for HIV-infected
children without documented evidence of latent infection, but living in an environment of high
exposure, has also been shown to reduce overall morbidity and mortality from TB and other
infections (Zar et al., 2007). Further trials in HIV-infected children receiving ART are ongoing.
Recommendations for chemoprophylaxis will continue to differ in TB-endemic and non-
endemic settings, because of the perceived risk of exposure. Whilst most paediatricians in
Europe and North America would advocate chemoprophylaxis for HIV infected, TB-exposed
children only, this needs to be interpreted with caution if the exposure is potentially ongoing
or recurrent, and the ability to distinguish LTBI from active disease is limited. In this context,
many practitioners in TB-endemic settings are reluctant to place children on chemoprophylaxis
because of the potential emergence of resistant strains, if indeed the child has active disease
instead of LTBI.
4.5.8. Treatment of drug resistant paediatric TB
Acquisition of resistance rarely occurs in children due to the paucibacillary nature of their
disease but overall, children may also be subject to less selection pressure from anti TB therapy.
Thus most resistance in children is due to primary transmission of a resistant organism, and
MDR /XDR-TB rates in children reflect community transmission rates. Diagnosis requires a
high index of suspicion as the culture yield in children makes definitive microbiological
confirmation difficult. Resistance should be suspected if an index case has known resistant TB;
the child shows initial improvement on anti-TB therapy and then deteriorates; or there is no
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response to initial treatment. Acquired resistance is well described in HIV co-infected adults
previously treated for TB, possibly due to malabsorption of anti-TB drugs (Wells, et al., 2007).
The presence of acquired resistance in the paediatric population is reported and in particular
children with TB/HIV co-infection should be closely monitored (Soeters et al., 2005).
Although the principles of DOTS Plus have been put forward for the management of MDR
TB, at the moment, there is no consensus for any regimen or optimal treatment that should be
used for persons with known exposure to MDR-TB. The recommendation by CDC is a
combination of pyrazinamide and ethambutol, with either pyrazinamide or a fluoroquinolone
and that immunocompetent contacts should be treated for 6 months while immunocompro‐
mised contacts should be treated for 12 months. Current guidelines recommend using at least
four drugs to which the patient is naïve, including an injectable and a fluoroquinolone, in an
initial phase of at least 6 months; followed by at least three of the most active and best tolerated
drugs in a 12-18 month continuation phase.
Standardised regimens have been developed for settings where drug susceptibility testing is
not available (WHO, 2006). Six classes of second-line drugs (SLDs) are available (WHO, 2003)
but experience in children is limited for the majority and multi-centre paediatric trials are
needed. Under optimum circumstances MDR-TB responds well to appropriate therapy.
However delays in diagnosis and treatment, adherence issues, and a lack of child-friendly
formulations and strategies for DOTS all frequently complicate management and contribute
to a high morbidity and mortality (Drobac et al., 2006).
The WHO currently recommends avoidance of chemoprophylaxis in cases of contact with
known MDR-TB and to observe for 2 years if clinically asymptomatic. Children with latent
MDR-TB infection become the reservoir for future transmission following disease reactivation
in adulthood, emphasizing the need to further research and improved management of MDR-
TB infection in children, both at the clinical and operational level.
According to the European Centre for Disease Prevention and Control (ECDC) 2012 Guide‐
lines, there are two valid options to consider for the management of MDR TB and XDR TB
contacts; preventive treatment or follow-up by careful clinical observation. The purpose of
preventive therapy is to prevent the progression of LTBI to TB disease in an individual who
has been exposed to MDR/XDR TB. The concept of preventive therapy has been shown to be
effective for LTBI after contact with drug-susceptible TB but corresponding evidence for
preventive therapy of MDR TB and XDR TB contacts is very scarce. Although for children there
are indications of a positive effect of preventive therapy, for other groups of contacts, the
necessary body of evidence has yet to be generated, and there are ongoing studies to collect
evidence in support of the use of preventive therapy in contacts of MDR TB cases.
There  is  currently  no  evidence  available  on  the  optimal  follow-up  time  in  contacts  of
MDR  TB  or  XDR  TB  with  regard  to  patient  benefits  and  costs  of  the  intervention.  In
young children under five years of age the majority ( over 90%) of TB disease will devel‐
op within 12 months of infection. Infants and children under five years of age, immuno‐
compromised  individuals  due  to  HIV  infection  or  TNF-antagonist  treatment  are  at
increased risk of progression from LTBI to TB disease. These individuals as well as other
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identified risk groups require special  attention as part  of  the individual  risk assessment
(WHO, 2007; Salgado and Solovic et al., 2010).
The optimal duration of MDR-TB treatment in children is not known. World Health Or‐
ganization guidelines recommend treatment until  18 months after  the first  negative cul‐
ture (24 months in XDR-TB). As children often have paucibacillary disease, documenting
a culture conversion is usually difficult. Thus, the same duration as in adults would ap‐
ply. The duration of the intensive phase of treatment (when an injectable drug is given)
should  be  at  least  6  months.  Surgical  resection  should  be  considered  when  the  patient
has localized lesions and has persistently positive smear or culture results inspite of ag‐
gressive chemotherapy (Shah, 2012).
4.5.9. BCG vaccination and HIV infection
Approaches for prevention of TB include prevention of infection (through immunization)
or  of  progression  from latent  infection  to  disease  (chemoprophylaxis).  Bacille  Calmette-
Guérin (BCG) vaccine, a live attenuated vaccine derived from Mycobacterium bovis that
was developed in the 1920s, is administered to children at birth in many countries. WHO
guidelines recommend administration of BCG soon after birth to all  infants in countries
with  a  high  TB  prevalence.  Current  WHO  guidelines  advise  that  all  children  below  5
years  of  age,  who  are  in  close  contact  with  a  sputum  smear-positive  index  patient,
should be actively traced, screened for TB, and provided preventive chemotherapy after
active TB has been excluded (Marais et al., 2004).
Although this is good policy, implementation is fraught with challenges, including difficulty
in diagnosing latent TB in a highly BCG-vaccinated population, ruling out incipient active
disease, and the lack of procedures for documentation and follow-up of contact screening and
chemoprophylaxis in national programs. Because the majority of transmission in children
below 3 years of age occurs in the household and they are also the group at highest risk of
progression to disease after primary infection, this activity should be given higher priority in
national infection-control programs. Moreover, active tracing and screening of household
contacts at high risk would allow children with disease to receive a diagnosis earlier, thus
reducing complications.
Furthermore, additional protection by revaccination with BCG has not been demonstrated
(Rodrigues et al., 2005). To date, the efficacy of the BCG vaccination has not been determined
in HIV infected individuals in whom the immune responses to BCG may be reduced, (Hesseli
et al., 2007) although this is the subject of ongoing trials. Due to the risk of disseminated BCG
disease which may rarely complicate use of this live vaccine in immunocompromised indi‐
viduals, BCG vaccination is no longer recommended in children known to be HIV-infected
(Hesseling et al., 2007). In practice, this has had little impact in HIV-endemic countries, where
the HIV-status of the baby is rarely established at birth, the usual time of BCG vaccination.
A large trial in southern India that included over 350,000 participants aged above 1 year
concluded that BCG vaccine did not offer protection against the development of adult
pulmonary TB (WHO, 2006). However, BCG vaccine has been shown to be protective against
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disseminated forms of TB in young children, with a protective estimate ranging from 67%–
79% against TB meningitis and 58%–87% against miliary disease. A theoretical model esti‐
mated that a universal BCG vaccine program would have a beneficial impact in settings with
prevalence rates of greater than 30 sputum smear-positive cases/100,000 population (WHO,
2007). However, there is no evidence of any BCG-induced protective effect in HIV-infected
children. On the contrary, studies have documented BCG-induced disseminated disease and
adverse reactions. Therefore, the WHO recommendations have been revised, making HIV
infection a contraindication for BCG vaccination, even in settings where TB is highly endemic.
Strategies required for effective implementation of this policy change include high uptake of
maternal HIV testing coupled with implementation of proven strategies to prevent mother-to-
child HIV transmission, including maternal treatment with HAART and early virological
diagnosis of HIV infection in infants, followed by treatment.
The revised recommendations present a dilemma for national programs. Although the benefits
of BCG vaccine far outweigh the risk among HIV-uninfected children living in high areas with
a high prevalence of TB, the risk is higher among HIV-infected infants with or without
symptoms at the time of vaccination. National recommendations will need to consider a variety
of factors, including the prevalence of TB in the population, the prevalence of HIV infection,
the availability of HIV testing and facilities for prevention of mother-to-child transmission
during pregnancy, the capacity to conduct follow-up of vaccinated children, and the availa‐
bility of early infant diagnosis of HIV infection. Abandoning the use of BCG vaccine before
newer vaccines become available may put millions of young children at risk of TB. There is an
urgent need for operational research in TB endemic countries to determine the best way to
manage this issue programmatically.
5. On-going research targeting paediatric TB
5.1. New vaccine pipelines
The global commitment of the WHO and the Stop TB (WHO, 2005) campaign has spurred on
the efforts of the international research community to develop a more effective anti-TB vaccine
by the year 2015. In view of the proven efficacy of existing BCG vaccine in preventing disse‐
minated TB in children and reducing child mortality (Roth et al., 2006) two conceptually
different strategies have been pursued: firstly, the development of ‘priming vaccines’, which,
it is hoped, will replace BCG by providing better and longer protection; secondly, the design
of ‘booster vaccines’ to boost pre-existing BCG-derived immunity. Novel vaccines currently
under development all use a “booster-strategy” after priming with BCG in infancy (Doherty
et al, 2007). As the current candidates are progressing through phase I and II trials, including
studies in HIV-infected individuals and age-de-escalation, it is most likely that more than one
vaccine will progress into phase III.
The most advanced vaccine candidate is MVA- 85A, currently in phase II under a prime-boost
strategy with BCG. Four products are in phase I (72f, Hybrid 1, Aeras 402, rBCG-UreC-Hly),
each stemming from PPPs. Many of the candidates are results from the EU FP6 projects, i.e.
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Guérin (BCG) vaccine, a live attenuated vaccine derived from Mycobacterium bovis that
was developed in the 1920s, is administered to children at birth in many countries. WHO
guidelines recommend administration of BCG soon after birth to all  infants in countries
with  a  high  TB  prevalence.  Current  WHO  guidelines  advise  that  all  children  below  5
years  of  age,  who  are  in  close  contact  with  a  sputum  smear-positive  index  patient,
should be actively traced, screened for TB, and provided preventive chemotherapy after
active TB has been excluded (Marais et al., 2004).
Although this is good policy, implementation is fraught with challenges, including difficulty
in diagnosing latent TB in a highly BCG-vaccinated population, ruling out incipient active
disease, and the lack of procedures for documentation and follow-up of contact screening and
chemoprophylaxis in national programs. Because the majority of transmission in children
below 3 years of age occurs in the household and they are also the group at highest risk of
progression to disease after primary infection, this activity should be given higher priority in
national infection-control programs. Moreover, active tracing and screening of household
contacts at high risk would allow children with disease to receive a diagnosis earlier, thus
reducing complications.
Furthermore, additional protection by revaccination with BCG has not been demonstrated
(Rodrigues et al., 2005). To date, the efficacy of the BCG vaccination has not been determined
in HIV infected individuals in whom the immune responses to BCG may be reduced, (Hesseli
et al., 2007) although this is the subject of ongoing trials. Due to the risk of disseminated BCG
disease which may rarely complicate use of this live vaccine in immunocompromised indi‐
viduals, BCG vaccination is no longer recommended in children known to be HIV-infected
(Hesseling et al., 2007). In practice, this has had little impact in HIV-endemic countries, where
the HIV-status of the baby is rarely established at birth, the usual time of BCG vaccination.
A large trial in southern India that included over 350,000 participants aged above 1 year
concluded that BCG vaccine did not offer protection against the development of adult
pulmonary TB (WHO, 2006). However, BCG vaccine has been shown to be protective against
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disseminated forms of TB in young children, with a protective estimate ranging from 67%–
79% against TB meningitis and 58%–87% against miliary disease. A theoretical model esti‐
mated that a universal BCG vaccine program would have a beneficial impact in settings with
prevalence rates of greater than 30 sputum smear-positive cases/100,000 population (WHO,
2007). However, there is no evidence of any BCG-induced protective effect in HIV-infected
children. On the contrary, studies have documented BCG-induced disseminated disease and
adverse reactions. Therefore, the WHO recommendations have been revised, making HIV
infection a contraindication for BCG vaccination, even in settings where TB is highly endemic.
Strategies required for effective implementation of this policy change include high uptake of
maternal HIV testing coupled with implementation of proven strategies to prevent mother-to-
child HIV transmission, including maternal treatment with HAART and early virological
diagnosis of HIV infection in infants, followed by treatment.
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The most advanced vaccine candidate is MVA- 85A, currently in phase II under a prime-boost
strategy with BCG. Four products are in phase I (72f, Hybrid 1, Aeras 402, rBCG-UreC-Hly),
each stemming from PPPs. Many of the candidates are results from the EU FP6 projects, i.e.
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TBVAC and Muvapred, where valuable progress has been achieved. Several other candidates
are still in the pre-clinical phase. For example, mutation of virulence genes produced a TB
strain potentially conferring greater protection with fewer side effects than BCG. In addition,
an improved, recombinant BCG vaccine with a higher efficacy and a better safety profile
moving into phase I clinical trials is a possible prospect.
New research is directed at the development of a multistage TB vaccine containing latency
antigens, an attractive concept, which is actively being pursued (Andersen, 2007). Such a
vaccine could be used as a booster vaccine with the goal of preventing new infections in those
uninfected with MTB and to prevent reactivation in those with LTBI. Unfortunately, the lack
of reliable correlates of protective immunity currently remains a major obstacle to predict
vaccine efficacy in all TB vaccine trials for both adults and children.
6. Existing research gaps
6.1. Research needs
Tracing of MDR TB contacts is important to prevent TB disease and further transmission.
Priority studies needed include those to identify the most effective contact-tracing procedures
for close contacts and the most effective follow-up procedures in healthcare workers constantly
exposed to MDR TB. As part of the management of MDR TB contacts, studies on specific groups
are needed, for example on children below the age of five years, children with HIV infection
and other immunocompromised states. In particular, studies are needed: 1) for treated
contacts: (randomised) clinical trials: 2) to determine which drugs and which drug combina‐
tions and dosages are optimal for preventive therapy; 3) to determine the duration of preven‐
tive therapy; 4) to assess the effectiveness of preventive therapy in conjunction with
antiretroviral treatment; 5) to assess the risk of development of new drug resistance in contacts
receiving (inadequate and adequate) preventive therapy; 6) for untreated contacts, and
healthcare workers constantly exposed to MDR TB: 7) to identify the optimal follow-up period
for different groups of individuals; and 8) to identify the optimal frequency of testing for LTBI
during the follow-up period.
In order to increase adherence to treatment of MDR/XDR TB contacts (and reduce the risk of
development of new drug resistance in contacts), studies are needed: 1) to identify new drugs
with less adverse events and to explore possible (positive and negative) interactions between
combined drugs; 2) to identify biomarkers indicating the risk of progression from LTBI to TB
disease and 3) to assess operational management to shorten preventive therapy. Since the
provision of preventive therapy has economic and logistic implications at the national and
community level, cost-effectiveness and cost-benefit studies are also needed. These studies are
particularly valuable because they can help to inform the decision on intervention policies..
A substantial amount of funding has been injected into research on various aspects of TB but
there are still many issues that require additional research especially in the area of childhood
tuberculosis. The most salient ones include:1) accurately quantifying the global burden of
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childhood tuberculosis especially in the endemic areas; 2) improving the understanding of the
disease interactions with the immune system and re-evaluating the role of BCG and the new
vaccine candidates in protecting children and adults against TB; 3) defining the diagnostic
contribution of novel T-cell–based assays in endemic and non-endemic areas especially with
regard to diagnosis of paediatric tuberculosis; 4) identifying new ways of diagnosing child‐
hood tuberculosis in HIV negative and in TB/HIV co-infection in children, particularly in
resource-limited settings; 5) carrying out operational research aimed at improving the access
of children in endemic areas to preventive therapy and treatment, using the existing DOTS/
DOTS Plus frameworks; 6) evaluating the efficacy of new short-course intermittent preventive
chemotherapy regimens especially those aimed at childhood TB; 7) exploring shorter durations
of treatment in immune-competent children with smear-negative disease; 8) defining the
optimal treatment regimen and treatment duration in children with TB/HIV co-infection; 9)
monitoring the impact of MDR and XDR tuberculosis on children and evaluating regimens for
effective MDR/XDR disease prevention and treatment; 10) developing and evaluating new
drugs that may shorten the treatment duration and/or assist with the treatment of MDR/XDR
disease and emphasizing case finding and reporting as some of the strategies to combat the
escalation of XDR-TB [http://ec.europa.eu/research/research-eu].
6.2. Need for more specific diagnostic tests
In the field of diagnosis, there is an urgent need to replace sputum microscopy the current gold
standard test, with more sensitive tests that are applicable at point of care. Despite the fact that
the technique can only pick up 60% of cases, it has been in use for over a hundred years.
Furthermore, sputum culture is not suitable for extrapulmonary TB and for paediatric TB since
children can not produce sputum. On the other hand, the newer immunological based tests
such as IGRAs are not well suited for use in TB/HIV co-infection and in high burden TB areas,
where they cannot be accurately used to distinguish active from latent TB. Since the majority
of the infected people never actually develop the disease, there is need to have a diagnostic
tool which is able to distinguish latent from active disease and help to identify healthy
individuals from diseased ones. Improved diagnostics are critical to TB care and control.
The need for serious investment in the critical areas especially in new TB diagnostic tools, drug
susceptibility testing, and development of new biomarkers to enable health providers detect
TB disease activity and to determine follow up treatment outcomes cannot be over emphasised.
The fact that a number of new diagnostic tools are in the pipeline, including culture-based tests
to identify M. tuberculosis and those used to determine drug resistance based on molecular
assays and immune response is good news. However, there is still need to ensure that the new
tests can be availed world-wide and be used at the point-of-care even in resource-poor settings,
where there may be limited technical expertise and the necessary equipment. [http://ec.euro‐
pa.eu/research/research-eu]
6.3. Newer biomarkers for TB disease activity, cure and relapse
There are three major reasons that can be used to justify the need for new TB biomarkers : 1)
a diagnostic test which is able to differentiate between healthy individuals with a latent TB
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infection and patients with active dsease is needed; 2) a prognostic test which can be able to
predict the risk of latent TB becoming active needs to be established; 3) there is need for a
diagnostic test that can be used to serve as a surrogate endpoint of disease which can be used
for monitoring drug and vaccine trials in TB. It is envisaged that the basis for these novel
diagnostic measures will be biomics, comprising metabolomic, proteomic and transcriptomic
profiles in custom-made biosignature. Identification of non invasive biomarkers, especially
the molecular assay of M. tuberculosi fragments in urine and the measurement of volatile
biomarkers of volatile organic compounds generated by Mycobacteria TB in the breath or the
oxidative stress resulting from infection is one step in the right direction. [http://ec.europa.eu/
research/research-eu]
6.4. Need for post-exposure vaccines and those effective against all M. tuberculosis strains
The Bacille Calmette-Guerin (BCG) vaccine is currently the only vaccine in use against
tuberculosis. The efficacy of this vaccine is limited to prevention of severe forms of tuberculosis
among children and there are lots of problems in cases of TB/ HIV coinfection.The current
vaccine candidates are being developed for pre-exposure administration but, considering the
fact that one third of the world’s population is already infected, there is a serious need for a
post-exposure vaccine to prevent re-activation. Another shortcoming with the vaccines in the
pipeline is that they can delay clinical TB but cannot achieve sterile eradication. There is need
for combination vaccines that can combine the effects of booster vaccines with another
generation of vaccines that can act to effect sterilisation at the post-exposure stage. Focus
should also be put on the development of a vaccine that can afford protection against the wide
range of M. tuberculosis strains, to ensure universal effectiveness.To avoid complications in
clinical and epidemiological research, the evaluation of all the vaccines should also deal with
confounding factors such as prior BCG vaccination or HIV status and there should be well
worked out guidelines for use of these vaccines in children [http//www.ec.europa.eu/research/
research-eu]
6.5. Development of new drugs
When it comes to the current status of clinical, diagnostic and therapeutic strategies, childhood
TB has been grossly neglected and there is, therefore need for better and standardized
treatment strategy. Although there is a reasonable number of candidates in the discovery and
pre-clinical pipeline, there are still gaps between the different stages of TB drug development,
and drugs specically targeting paediatric TB are still needed. Most of the drugs in the pipeline
use the same mechanisms with the majority aimed at boosting efficacy or shortening the
duration, with very few targeingt dormant stages of the bacillus and, therefore, not suitable
for eradication of latent infections. Thus urgency for serious research into the development of
new drugs and treatment regimens aimed at achieving this therapeutic objective cannot be
over emphasised. Dealing with TB/HIV co-infection is another gap that needs serious attention:
there is need to develop drugs that can prevent dormant mycobacteria from re-activating in
HIV-positive individuals [http://ec.europa.eu/research/research-eu.
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7. Future prospects
7.1. Reducing the burden of childhood tuberculosis
TB in children presents a number of difficult challenges which will only be solved by a shift
in research priorities. Advances in paediatric TB research will provide wider insights and
opportunities for TB control. While development of a new vaccine to prevent TB should be the
ultimate goal, development of better diagnostics represent one of the most important steps
towards improving individual case management and also providing a more robust case
definition for much needed drug and vaccine trials for studies on TB epidemiology and
correlates of protective immunity in childhood. Data on the epidemiology of childhood TB
may in turn help to inform public health policy by providing a window on current transmission
and the effectiveness of control strategies and by identifying children with LTBI for chemo‐
prophylaxis to limit the future propagation of the epidemic. Emphasis should be placed on
reducing the vulnerability of the community because successful control of the tuberculosis
epidemic is the most effective way to reduce the burden of childhood tuberculosis However,
this will require a holistic approach with sustainable poverty alleviation as a key element
[http://www. ec.europa.eu/research/research-eu].
7.2. Involvement of funders and industry
Important resources are required for the exploration of pathways leading to TB diagnostics-
oriented basic science in pathogen biology, biomarker discovery, systems biology and point
of care test development. The current priorities for TB vaccine development are: i) new vaccine
candidates that achieve sterile eradication, and that can progress into phase II and phase III
trials; ii) vaccine testing in a naïve stage on M. tuberculosis uninfected individuals; iii) vaccines
which can achieve post-exposure prophylaxis to those who are already infected (currently 2
billion people); iv) strategies on how to get vaccines from the research bench to the bedside
and into the community. Apart from the protective effect of novel vaccine candidates, priority
should be given also to their delivery route, formulation (storage, shelf-life and distribution)
and utility for HIV-infected individuals, particularly children.
7.3. Back to basic research
As we talk about nano technology and pin point delivery of drugs it is a shame that 130 years
after the Robert Koch’s discovery of M. Tuberculosis we still have huge gaps in our under‐
standing of the biology, immunology and pathophysiology of the bacillus. We are, as yet, not
able to explain fully the molecular, biochemical and immunological mechanisms that enable
TB infection to go on for years and cause severe disease and death. With the availability of
state-of-the-art molecular research tools such as functional genomics and metabolomics a
paradigm shift towards empahsising basic research could help provide answers to some of the
unanswered questions about M.tuberculosis in general, and paediatric TB in particular. The
currently available knowledge has proved insufficient when it comes to the rational design of
vaccines or other control tools and this has resulted in a lot of trial-and-error approaches. With
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the HIV virus still elusive, defeating the dual alliance of TB/HIV co-infection has added another
diamension in the already complicated war against the resistant strains of M. tuberculosis.
Promoting basic research by providing the necessary resources and involving stakehoolders
on the political front can provide solutions to some of the outstanding problems if not solving
all of them. Where there is will, there is a way [http//ec.europa.eu/research/research-eu].
7.4. Concluding remarks
Recent developments for TB diagnostics seem promising fields due to the fact they are fast and
minimally invasive, but they have drawbacks of not being validated in diverse populations
and improved according to the patient’s needs. Refinement of existing tools and development
and testing of new tools are urgently required to improve diagnosis and treatment of TB in
children. Higher global priority and funding will be required to improve on childhood
nutrition and promote improvement in the socioeconomic and environmental condition of
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1. Introduction
Tuberculosis (TB) is an ancient disease, but not a disease of the past. After disappearing
from the world public health agenda in the 1960s and 1970s, TB returned in the early 1990s
for several reasons, including the emergence of the HIV/AIDS pandemic and the increase in
drug resistance. More than 100 years after the discovery of the tubercle bacillus by Robert
Koch, what is the status of TB control worldwide? The evolution of global TB control poli‐
cies, including DOTS (Directly Observed Therapy, Short course) and the Stop TB Strategy,
and assess whether the challenges and obstacles faced by the public health community
worldwide in developing and implementing this strategy can aid future action towards the
elimination of TB.(Lienhardt, Glaziou et al. 2012) The report of the Commission on Macro‐
economics and Health of the World Health Organization has emphasized that tuberculosis
is the most common of the infectious diseases. Tuberculosis is one of the most important
health problems in the world, causing 1.4 million deaths each year, in 2011. (WHO, 2010)
The most of TB cases (82%) was concentrated in 22 countries around the world. In the year
of 2010, in Brazil were detected 81946 cases, with 5000 death (WHO, 2010).
In Rio Grande do Sul, a state in extreme south of Brazil, the incidence of TB in 2011 was 46,1
per 100.000, with 4947 new cases. Porto Alegre, capital of Rio Grande do Sul shows inci‐
dence of 116 in 2009.(Sul 2011; Brazil 2012)
Tuberculosis is the first cause of death in patients with AIDS in Brazil. Patients with co-in‐
fection HIV/TB have had in treatment of Tuberculosis probability of worst outcome.
Rio Grande do Sul, has had the major incidence of TB/HIV co-infection. The co-infection
adversely affects the lives of individuals in both the biological and psychosocial aspects.
(Neves, Canini et al. 2012)
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1. Introduction
Tuberculosis (TB) is an ancient disease, but not a disease of the past. After disappearing
from the world public health agenda in the 1960s and 1970s, TB returned in the early 1990s
for several reasons, including the emergence of the HIV/AIDS pandemic and the increase in
drug resistance. More than 100 years after the discovery of the tubercle bacillus by Robert
Koch, what is the status of TB control worldwide? The evolution of global TB control poli‐
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is the most common of the infectious diseases. Tuberculosis is one of the most important
health problems in the world, causing 1.4 million deaths each year, in 2011. (WHO, 2010)
The most of TB cases (82%) was concentrated in 22 countries around the world. In the year
of 2010, in Brazil were detected 81946 cases, with 5000 death (WHO, 2010).
In Rio Grande do Sul, a state in extreme south of Brazil, the incidence of TB in 2011 was 46,1
per 100.000, with 4947 new cases. Porto Alegre, capital of Rio Grande do Sul shows inci‐
dence of 116 in 2009.(Sul 2011; Brazil 2012)
Tuberculosis is the first cause of death in patients with AIDS in Brazil. Patients with co-in‐
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Some factors can be considered as risk factors for co-infection of TB and HIV, as the im‐
poverishment of the population, use of injecting drugs, the disruption of services on the
epidemiology of  TB control,  the  delay  in  the  diagnosis  of  TB and increased risk  of  ac‐
quiring multi-drug resistant  TB (MDRTB),  essentially  associated to the expansion of  the
disease  in  the  world.(Kritski,  Lapa  e  Silva  et  al.  1998).  Multidrug-resistant  tuberculosis
(MDR-TB) is a major clinical challenge, particularly in patients with human immunodefi‐
ciency  virus  (HIV)  co-infection.(Nathanson,  Nunn et  al.  ;  Farley,  Ram et  al.  2011;  Arjo‐
mandzadegan, Titov et al. 2012; Jain, Dixit et al. 2012; Udwadia 2012)
For the above, in recent years became consensus that the epidemic of TB in developing
countries demands the evaluation of broader approaches, described in the Plan STOP-
TB/OMS control global TB 2006-2015.
Among them have been prioritizing the implementation of:
a) improvements in access to diagnostic system user health; b) culture for mycobacteria in
every patient suspected of TB and HIV positive and all TB patients in retreatment; c) sensi‐
tivity test for suspected cases of resistant TB (retreatment cases, treatment failure, contact
MDR-TB or have been treated at the Health Unit with a high rate TB-MDR/XDR); d) review
and economic evaluation under routine conditions of deployment of new technologies (phe‐
notypic or molecular, automated or not) for the early diagnosis of TB, resistant TB patients
with paucibacillary TB, HIV-infected or suspected drug-resistant TB.
Early detection of tuberculosis (TB) is essential for infection control. Rapid clinical diagnosis
is more challenging in patients who have co-morbidities, such as Human Immunodeficiency
Virus (HIV) infection. Direct microscopy has low sensitivity and culture takes 3 to 6 weeks
(Sharma, Mohan et al. 2005; WHO 2006). Diagnostic testing for tuberculosis has remained
unchanged for nearly a century, but newer technologies hold promise for a revolution in tu‐
berculosis diagnostics. Tests such as the nucleic acid amplification assays commercial and in
house technologies allow more rapid and accurate diagnosis of pulmonary and extrapulmo‐
nary tuberculosis.(Rodrigues Vde, Queiroz Mello et al. 2002; Sanchez, Rossetti et al. 2006;
Scherer, Sperhacke et al. 2007; Scherer, Sperhacke et al. 2011; Hida, Hisada et al. 2012). Xpert
MTB/RIF (Xpert) is actually a promising new rapid diagnostic technology for tuberculosis
(TB) which has characteristics that suggests large-scale roll-out.(Vassall, van Kampen et al.
2011). In developing countries, in house Polymerase Rhain reaction (PCR) based on amplify‐
ing the IS6110 insertion element can be used for the amplification of Mycobacterium tuberculo‐
sis (MTB) DNA and offers the potential of a sensitive, specific and rapid diagnostic for
ruling out or considering pulmonary tuberculosis (PTB) (Mehrotra, Metz et al. 2002; Sar‐
miento, Weigle et al. 2003; Schijman, Losso et al. 2004; Flores, Pai et al. 2005).
The appropriate and affordable use of any of these tests depends on the setting in which
they are employed (Perkins 2000; Brodie and Schluger 2005). New tools for TB diagnosis,
treatment and control are necessary, especially in health settings with a high prevalence of
HIV/TB co-infection.
Although TB is  one the greatest  causes of  mortality worldwide,  its  economic effects  are
not  well  known,  especially  in  Brazil.  Despite  the  fact  that  the  families  did  not  have  to
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pay  for  medications  and  treatment,  given  that  this  service  is  offered  by  the  State,  the
costs to families related to loss of income due to the disease were very high. The propor‐
tion of  public  service  funds utilized for  prevention is  small.  Greater  investment  in  pre‐
vention campaigns not only might diminish the numbers of cases but also might lead to
earlier  diagnosis,  thus reducing the costs associated with hospitalization.  The lack of  an
integrated cost accounting system makes it  impossible to visualize costs across the vari‐
ous sectors.(Costa, Santos et al. 2005)
To make rational decisions about the implementation of new tools in the medical routine,
cost-effectiveness studies are essential(Mitarai, Kurashima et al. 2001; Kivihya-Ndugga, van
Cleeff et al. 2003; Hazbon 2004).
A key step in cost-effectiveness analysis is to identify and value cost. The economic concept
of opportunity cost is central to cost-effectiveness analysis. When a public health agency
spends money to provide health care, this money is not available for housing, education,
highway construction, or as a reduction in income taxes. When a health care organization
spends money for bone transplantation, this money is not available for example for mam‐
mography outreach or something. When an elderly man spends time being vaccinated for
influenza, this time is not available to play golf or to work. An overall conceptual goal in
cost-effectiveness analysis is comprehensive identification of all costs of the intervention and
its alternative, including all of the opportunity costs.
Contributors to cost must be identified before the costs can be valued. The terms used to de‐
scribe the contributors to cost (e.g. direct costs, indirected costs, opportunity costs) are used
in different ways in different textbooks and in published cost-effectiveness analysis.
The definition of cost terms is the opportunity cost is the value of resources in an alter‐
native  use,  the  direct  cost  is  the  value  of  all  goods,  services,  and  other  resources  con‐
sumed  in  the  provision  of  an  intervation  or  in  dealing  with  the  side  effects  or  other
current and future consequence linked to it and the productivity costs are the costs asso‐
ciated with lost  or impaired ability to work or engage in leisure activities  and lost  eco‐
nomic  productivity  due  to  death  attributable  to  the  disease.  These  costs  have  been
substituted for indirect costs. There are several categories of direct costs. The first catego‐
ry of  total  direct  cost  is  direct  health cost,  this  category include costs  with tests,  drugs,
supplies,  personnel,  equipment,  rent,  depreciation,  utilities,  maintenance  and  support
services. The second category of total direct cost is direct non- health care cost, these cost
include  for  example  the  cost  to  patients  to  partake  of  the  intervention  e.g.,  transporta‐
tion,  child  care,  parking).  The  third  category  of  total  direct  cost  is  the  cost  of  informal
caregiver  time,  this  is  the monetary value of  the time of  family members  or  volunteers
who provide home care. The fourth category of total direct cost is the cost is the cost of
the  use  of  patient  time.  Such  studies  provide  insight  into  the  composition  of  different
cost  components,  which  may  be  the  most  important  factor  from  the  patient  and  the
health  service’s  perspectives.  Recent  studies  have  compared  the  cost  effectiveness  of
news tools for diagnosis,  treatment and control  in Tuberculosis.(Amicosante,  Ciccozzi  et
al.  ;  Kowada, Deshpande et al.  ;  Baltussen, Floyd et al.  2005; Barbieri,  Wong et al.  2005;
Bachmann 2006; Dwolatzky, Trengove et al.  2006; Kominski,  Varon et al.  2007; Kowada,
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Takahashi  et  al.  2008;  Rosen,  Taylor  et  al.  2010;  Shi,  Hodges  et  al.  2010;  Vassall,  van
Kampen et al. 2011; Fitzpatrick and Floyd 2012; Lienhardt, Raviglione et al. 2012; Manda‐
lakas, Hesseling et al.  2012).  In a recent study we compared the cost-effectiveness of di‐
rect  microscopy by Ziehl  Neelsen staining (AFB smear)  with  in  house  polymerase  chain
reaction (PCR) and with culture on the first  sputum specimen collection,  including staff
costs, using culture and clinical evaluation as the gold standard (Scherer, Sperhacke et al.
2009). In contrast to the cost-effectiveness analysis described by van Cleef et al.  in a ref‐
erence ambulatory clinic in Kenya, where only culture for mycobacteria was used as the
gold standard (Roos, van Cleeff et al. 1998; van Cleeff, Kivihya-Ndugga et al. 2005). The
cost-effectiveness of the AFB smear plus PCR dot-blot strategy described in recent study
was similar to other strategies, when lower TB prevalence made PCR more expensive for
diagnosis  of  PTB (Roos,  van Cleeff  et  al.  1998;  van Cleeff,  Kivihya-Ndugga et  al.  2005).
(Scherer et. aL., 2009).
The mathematical models may be particularly useful for predicting the long term tenden‐
cy of occurrence of the infection or disease. These models can simulate situations epide‐
miological  and  preventive  or  curative  interventions  beyond  their  theoretical  impact  in
reducing the problem. Such predictive models properly formulated and fed with consis‐
tent  data,  may assist  the  processes  of  planning and management  in  public  health.  Cur‐
rently  several  strategies  have allowed the use  of  Multiple  Logistic  Regression (MLR) in
the construction of predictive models. Models of decisions trees are also used for classifi‐
cation decision making or to provide a decision algorithm for the clinical management of
infectious diseases.(Aguiar, Almeida et al. 2012)
For developing countries, the emergence of continuous technological innovation represents
a double burden. The rapid diffusion of scientific and technical information that are ob‐
served now and monetary action multinational companies create a local demand for innova‐
tion by health professionals, the media and more informed portions of the population,
which further strains the health care system.
Many factors  limit  the  realization of  a  health  technology assessment  (HTA) analysis,  as
the lack of human resources, infrastructure or budget or due to lack of evidence or infor‐
mation costs.
Another obvious problem is that often decisions are based on scientific evidence coming
from developed countries and often in settings where the incidence of disease differs effu‐
sively of Brazilian and Latin American scenario.
Given this  scenario  health  managers  are  often between two objectives:  they have to  in‐
corporate new and more costly technologies to improve the health of the population and
at the same time are responsible for the financial sustainability and access equity of this
in the system health.(Project 2005)
Beyond the suffering caused directly by the disease, TB is requiring significant portions of
the public budget in developing countries. It is estimated that by 2015 they will be required
investments around $12 billion for control of diseases such as AIDS, TB and Malaria. The
increased costs involved in care and control of TB are due also to the increasing number of
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cases of resistant bacteria to different types of chemotherapy. (Polansky, Dymer et al. 1968;
Garcia Rodriguez, Marino Callejo et al. 1994; Weis, Foresman et al. 1999; Gomes, Soares et al.
2003; Elamin, Ibrahim et al. 2008; Kik, Olthof et al. 2009; Steffen, Menzies et al. 2010; Vassall,
Seme et al. 2010; Pereira, Barreto et al. 2012)
Costs of TB diagnosis and treatment may represent a significant burden for the poor and for
the health system in resource-poor countries. Costs incurred by TB patients are high in Rio
de Janeiro, especially for those under DOT. The DOT strategy doubles patients' costs and in‐
creases by fourfold the health system costs per completed treatment. The additional costs for
DOT may be one of the contributing factors to the completion rates below the targeted 85%
recommended by WHO (Steffen, Menzies et al. 2010).
Even in a country with a good health insurance system that covers medication and con‐
sultation costs, patients do have substantial extra expenditures. Furthermore, our patients
lost on average 2.7 months of productive days. TB patients are economically vulnerable.
(Kik, Olthof et al. 2009)
In Brazil, the real costs of TB are estimated or poorly known and the overall costs of TB are
not perceived by governments, given the fragmentation in the involvement of the three gov‐
ernmental levels: local, state and national.
The purpose of this chapter is to describe the direct and indirect costs for diagnosis and
treatment of Pulmonary Tuberculosis in patients infected or not by HIV, admitted to a Hos‐
pital Unit of Public Health.
2. Costs of health system of Brazil
In order to describe the costs of Health system of Brazil, we evaluate the costs directs of di‐
agnosis and treatment of screening of 1000 hypothetical patients suspects of Pulmonary Tu‐
berculosis in according with clinical and laboratory Brazilian recommendations for
treatment (Tuberculose 2004; Conde, Melo et al. 2009).
The cost components for each clinical and laboratory procedures of screening included costs
incurred by the patient, laboratory costs, drugs, consumables and equipment costs. The
strategy for screening was the same recommended for Brazilian Public Health System.
Clinical, radiological and laboratory staff costs were calculated from the salary base of Rio
Grande do Sul (State of Extreme South of Brazi) in 2011.
For each procedure, costs were attributed based on procedure costs of the Brazilian Public
Health System.
Running costs (material costs were used for each 1000 tests evaluated) included all laborato‐
ry materials used in procedures.
All costs were expressed in US$, using an exchange rate of US$ 1= R$ 1,72 (REAIS), the aver‐
age exchange rate from 2010 to 2011. In the treatment costs, those were evaluated related to
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the treatment of inpatients and outpatients. To estimate the values that are spent by the pub‐
lic health system of Brazil with the monitoring and control of TB in a hospital and an outpa‐
tient unit, we simulated two different scenarios:
a. TB cases diagnosed in hospital wards (hospitalized patients)
b. TB cases diagnosed in outpatient environment (outpatients).
The number of days considered to calculate the costs related to the treatment of inpatients
they were considered as the same days that were spent in laboratory procedure.
It was hypothesized that the time to detect Mycobacterium tuberculosis in sputum culture
from patients with pulmonary tuberculosis may be a better indicator for the duration of time
of hospitalization(Ritchie, Harrison et al. 2007).
The time to detect M. tuberculosis in the culture was 30 days in this study. This cohort is the
same as previous published by our group [20]. This value was used as the standard at which
release from isolation could be permitted (Scherer, Sperhacke et al. 2007)
The time spent on laboratory procedure to provide access to the result of the laboratory
technique was assumed to be 30 days for AFB smear plus culture. The number of days con‐
sidered to calculate costs was the same as those spent on laboratory procedure. The number
of days considered to calculate the cost of patient travel costs was assumed to be 2 days for
AFB smear plus culture.
Total treatment included clinical officer and hospital costs, assuming cost per pill, to be US$
0.22, using 3 pills per day, during 180 days; hospital room costs, US$ 7/day; costs with salary
of clinical staff and clinical consultation, US$ 2.52 per patient and clinical nursing consulta‐
tion, US$ 2.52 per patient.
Assuming that, during the treatment (6 months), in ambulatory situation, 6 AFB smear test,
6 chest radiographs, 6 consult of nurse and 2 consult of clinical were performed, we used
this parameters to estimate the costs of ambulatory following the Brazilian recommenda‐
tions for treatment (Tuberculose 2004).
Assuming  that,  during  the  hospitalization  (30  days),  4  AFB  smear  tests,  4  chest  radio‐
graphs, 30 nurse and physician consultations were performed, we used these parameters
to  estimate  the  costs  of  inpatient  assistance  in  hospital,  following  the  Brazilian  recom‐
mendations  for  treatment  (Tuberculose  2004;  Conde,  Melo  et  al.  2009).  Staff  salaries  for
the physician, nurse and radiologist were considered to be US$ 11,163 per year, and for
the chest radiograph technician, the salary was US$ 4,988 per year. The work days were
considered 20 days for all staff.
The days of admission to the hospital were considered to be the same number of days spent
on each laboratory procedure. All estimated costs reflect an estimative of the public health
system of Brazil expenses with the monitoring and control of TB.
The costs were expressed per 1000 suspects, according to the specific bibliographic refer‐
ences for economic analyses, thus, allowing the best decision for investment to be made
(Petitti 2000).
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Table 1A shows the costs at the health service level and Table 1B shows costs due to labora‐
tory investment. The AFB smear plus Culture require (US$ 39,535) for equipment. Table 1C
shows costs incurred by patients.
A. Health service costs
Staff
Number
Salaries of all staff
per year
(US$)
Staff Cost per day
(US$)



















39,535 5 12,507 12.50
C. Estimated costs incurred by patients, including costs for travel, food and income lossd






Total patients Cost 341,000
a Microscopic and Laminar Flow Cabinets,;. Other equipments were not included,
b Income loss of patients was calculated from monthly salary base of Brazil (US$207) and was based on proportional
days spent by patients until access to the result of each laboratory procedure. Patient costs were estimated using the
average of two visits to the laboratory for AFB smear and culture procedures for outpatients; Travel cost was consid‐
ered as US$ 1.4 (one bus ticket ). Food was considered as US$ 10 per meal. Base salary in Brazil was considered (US$ 10
per day /20 days of the work). For inpatients was considered just income loss; Staff costs in the laboratory were based
on proportional days spent on each laboratory procedure; Costs of consumables and equipment were provided by the
program as well as by the manufacturer.
Table 1. Estimative of Costs in US$ in Tuberculosis Diagnosis in Brazil
We annualized the capital cost of the equipment for 5 years, according to the literature [25].
Building costs were not included. Opportunity costs were not applicable.
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the treatment of inpatients and outpatients. To estimate the values that are spent by the pub‐
lic health system of Brazil with the monitoring and control of TB in a hospital and an outpa‐
tient unit, we simulated two different scenarios:
a. TB cases diagnosed in hospital wards (hospitalized patients)
b. TB cases diagnosed in outpatient environment (outpatients).
The number of days considered to calculate the costs related to the treatment of inpatients
they were considered as the same days that were spent in laboratory procedure.
It was hypothesized that the time to detect Mycobacterium tuberculosis in sputum culture
from patients with pulmonary tuberculosis may be a better indicator for the duration of time
of hospitalization(Ritchie, Harrison et al. 2007).
The time to detect M. tuberculosis in the culture was 30 days in this study. This cohort is the
same as previous published by our group [20]. This value was used as the standard at which
release from isolation could be permitted (Scherer, Sperhacke et al. 2007)
The time spent on laboratory procedure to provide access to the result of the laboratory
technique was assumed to be 30 days for AFB smear plus culture. The number of days con‐
sidered to calculate costs was the same as those spent on laboratory procedure. The number
of days considered to calculate the cost of patient travel costs was assumed to be 2 days for
AFB smear plus culture.
Total treatment included clinical officer and hospital costs, assuming cost per pill, to be US$
0.22, using 3 pills per day, during 180 days; hospital room costs, US$ 7/day; costs with salary
of clinical staff and clinical consultation, US$ 2.52 per patient and clinical nursing consulta‐
tion, US$ 2.52 per patient.
Assuming that, during the treatment (6 months), in ambulatory situation, 6 AFB smear test,
6 chest radiographs, 6 consult of nurse and 2 consult of clinical were performed, we used
this parameters to estimate the costs of ambulatory following the Brazilian recommenda‐
tions for treatment (Tuberculose 2004).
Assuming  that,  during  the  hospitalization  (30  days),  4  AFB  smear  tests,  4  chest  radio‐
graphs, 30 nurse and physician consultations were performed, we used these parameters
to  estimate  the  costs  of  inpatient  assistance  in  hospital,  following  the  Brazilian  recom‐
mendations  for  treatment  (Tuberculose  2004;  Conde,  Melo  et  al.  2009).  Staff  salaries  for
the physician, nurse and radiologist were considered to be US$ 11,163 per year, and for
the chest radiograph technician, the salary was US$ 4,988 per year. The work days were
considered 20 days for all staff.
The days of admission to the hospital were considered to be the same number of days spent
on each laboratory procedure. All estimated costs reflect an estimative of the public health
system of Brazil expenses with the monitoring and control of TB.
The costs were expressed per 1000 suspects, according to the specific bibliographic refer‐
ences for economic analyses, thus, allowing the best decision for investment to be made
(Petitti 2000).
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Staff Costs per day
Cost laboratory staff b 1,434
Cost of staff related to the treatment of patientsb 2,791
Costs of chest radiograph staff related to the treatment of
patients
404
Treatment Costs per day
Costs of diagnostic service related to the treatment of no-
hospitalized patients
2,771
Costs of diagnostic service related to the treatment of hospitalized
patients
4,686




Total Patient costs 190,000
Total Health Service costs 9,479,033
Total Screening costs 9,668,815
a For each procedure, costs were attributed based on procedure costs of the Brazilian Public Health System (US$ 1,4 for
AFB smear and US$ 1,9 for Culture) and from CDCT/FEPPS (US$ 11,7 for PCR dot-blot), assuming investment laborato‐
ry equipment for 5 years; bStaff salary was considered; for laboratory technician, US$2,860 per year; for Laboratory
technologist, US$6,400 per year. Staff costs in the laboratory were based on proportional days spent on each laborato‐
ry procedure; Staff salary was considered for clinical physician, nurse and radiologist; US$6,400 per year; for the X-RAY
technician, salary was US$2,860 per year. cThe days of admission to the hospital were considered as the same as the
days spent on each laboratory procedure. The time spent on each laboratory procedure until access to the result of the
laboratory technique was assumed to be 30 days for AFB smear plus Culture. Total treatment included clinical officer
and hospital costs, assuming US$ 0,22 cost per pill, using 3 pills for day, during 180 days; hospital room costs, US$
4,16/day; costs of salary of staff clinical; clinical consultation cost, US$2,52 per patient; clinical nursing consultation, US
$2,52 per patient. Assuming that during the treatment of inpatients (4 months) 4 ZN and 4 chest radiograph were
performed, and during the treatment of no- hospitalized patients (6 months) 6 AFB smear and 6 chest radiograph
were performed, following the Brazilian recommendations for treatment (Tuberculose 2004);
d Travel was considered 2 days for AFB smear plus Culture strategy. Food and income loss for AFB smear plus Culture
strategy was considered 30 days
The health service costs analysis was based on processing 50 AFB smear slides and 14 cultures per day. AFB smear plus
Culture was performed by two trained staff.
Running costs were calculated from investments required to examine 1000 smears.
Table 2. Total cost of screening for 1000 suspects. The total screening costs to AFB smear plus Culture were US$
9,668.815.
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The total cost (in US$) related to the treatment (no hospitalized patients) for AFB smear plus
Culture was US$ 2,771. The cost related to the treatment of hospitalized patients, for AFB smear
plus Culture strategy was US$ 4,686. The cost related to the treatment of (no hospitalized pa‐
tients) and (hospitalized patients), for AFB smear plus Culture strategy was US$ 7,456.
However, in a context of advanced technologies for the diagnosis of tuberculosis, economic
resources has always limited the incorporation and diffusion of new technologies produced
and validated by the academy. It is a challenge for health systems worldwide, and in many
cases, the cause of serious sustainability problems.(Taylor, Drummond et al. 2004; King,
Griffin et al. 2006; Mason, Weatherly et al. 2007; Hughes, Tilson et al. 2009; Weatherly,
Drummond et al. 2009; Shi, Hodges et al. 2010)
The decisions related to incorporation, acquisition, reimbursement or coverage of new tech‐
nologies and those that determine the way in which they should be used are the most im‐
portant in the health system and should be taken in general and the management of health
services in particular.(Greenberg, Peterburg et al. 2005)
The health systems of different countries are diverse with respect to decisions about incor‐
porating technologies and expectations of service users. Tough choices are faced by manag‐
ers at all levels of the health system. This reality makes the TB every year, become more
difficult for the system to provide the user with the most effective intervention theoretically
available, depending on the pressures placed on the health system in relation to increased
costs, the training of human resources, needs updating certification and regulatory instru‐
ments, and investment in physical infrastructure (Newhouse 1992)
Attempts to improve the acceptability of resource allocation decisions around new health
technologies have spanned many years, fields and disciplines. Various theories of decision
making have been tested and methods piloted, but, despite their availability, evidence of
sustained uptake is limited. Since the challenge of determining which of many technologies
to fund is one that healthcare systems have faced since their inception, an analysis of actual
processes, criticisms confronted and approaches used to manage them may serve to guide
the development of an 'evidence-informed' decision-making framework for improving the
acceptability of decisions.(Stafinski, Menon et al. 2011)
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1. Introduction
Tuberculosis (TB) has been present in Latin America since pre-historical times. Paleopatho‐
logical studies have found signs of TB in mummies from many parts of the world. In fact,
whenever human mummies have been found, signs of TB have been observed in bones, lungs
or skin [1].
Although TB may be considered as nearly as old as humankind, the current epidemiological
profile of this disease must not be considered as the natural or expected one, given the large
numbers of prevalent and newly occurring cases. The main questions related with the
persistence and rise of TB in many regions of Latin America, have to do with social processes
and inequalities. In this sense, the different processes usually resulting in TB disease are
directly related with social and economic behavior of human communities [1].
TB constitutes one of the most complex situations in the health field. This complexity both
makes visible, and raises questions about the existing inequities in the political and socio-
cultural structure and in class relations, as it is the result of the health-illness-care process.
Among the main elements permitting operationalization of an analysis of this situation, we
find social vulnerability and accessibility to a whole spectrum of health services (in geograph‐
ical, cultural and economic terms), from opportunistic diagnosis to effective treatment
(meaning cure).
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In this sense, we understand as social vulnerability that set of economic, political, social and
cultural conditions which determine that some individuals become infected by the TB bacillus
while others do not, depending on the structural conditions which favor or hinder exposure
to the disease,1 as well as those differential aspects by which, among those infected, some get
TB disease while others do not, and among those with TB disease some are cured (whether
spontaneously or as a result of anti-TB treatment), others remain chronically ill (possibly with
multi-drug resistance) while others die (generally those presenting the worst socioeconomic
conditions and poorer health in general).
Nevertheless, TB prevention and control programmes are designed as if the disease behaved
in a homogeneous way in all countries and regions, based almost solely on biological and
medical factors, without taking into account socio-cultural, economic and political factors, such
as poverty, malnutrition, health services accessibility and quality, as well as intra and inter-
community political conflicts, among others.
This approach impedes acting on the particularities of marginal populations, which are
precisely the ones presenting the highest rates of morbidity and mortality of this disease,
manifesting various gradients of exposure and susceptibility. This leads governments to act
on the basis of global estimates, even when their interpretation of these is limited and partial,
because the differential exposures and true extent of TB are unknown.
Furthermore, this way of tackling TB does not reflect the reality of the different regions within
a given country, because local or regional variations in rates of morbidity and mortality are
disguised. Such variability could easily be quantified by, at the very least, providing the
standard deviation corresponding to the global values of these rates for each country. Conse‐
quently, areas which should be given priority, paradoxically receive only limited resources for
interventions.
In this sense, it is important to point out that TB, like HIV/AIDS, is one of the diseases for which
estimations of impact in terms of incidence and prevalence are frequently based only on the
registered cases. While it is true that published national and international figures often include
estimates of sub-notification, they do not usually include gradients of the magnitude of the
disease, or of the intra- or inter-regional under-notification rates, nor the differential rates
between different population groups. According to several authors, calculation of the number
of cases of TB disease is possible based on the expected evolution of cases of infection [2] or
through linear regression modeling involving age-specific prevalence values across a range of
differently aged populations [3]. Although this calculation technique for the frequency of TB
and HIV status has been considered [4], there are currently no models in which population
impact has been measured in terms of social factors.
In summary, in general terms, national and international policies to cope with TB ignore this
reality, applying criteria of homogeneity in the calculation of objectives, materials, costs and
logistics, among other aspects. While it is well known that marginal groups are the ones
presenting the highest TB morbidity and mortality rates, their characterisation is not usually
1 According to World Health Organization calculations, one third to the human population is infected with TB bacillus
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considered in the design of programmes for their prevention and control, so that TB continues
to cause high rates of disease, death and ever-rising health costs in these groups, something
which represents a violation of their human rights a consequence of governments having been
incapable of preventing this situation.
Furthermore, the effectiveness of programs of TB Prevention and Control has been questioned
because of their complexity. In this sense, a therapeutic intervention such as the Directly
Observed Therapy – Short Course (DOTS) strategy, and socioeconomic and structural factors
have been topics of discussion with regard the possible impact of one and the other, due to the
decline of TB observed prior the use of antibiotics, as well as the goals met at present by DOTS
strategy. In this regard, a correlation has been documented in Latin America between the early
diagnosis of smear positive TB cases and improved cure rates [5]. So, one of the main emphasis
of strategies to reduce the transmission of Mycobacterium tuberculosis, should be the identifi‐
cation of active TB cases, particularly in deprived and highly exposed populations.
The Africa and Latin America Research Groups Network (Grups de Recerca d’America i Africa
LLatines -GRAAL) has conducted studies in marginal populations which reveal the conditions
of patients, as well as the extent of the disease, of multi-drug resistance (MDR) and of mortality
in these populations, producing figures which differ widely from the official average values.
The main mechanism for tackling these aspects has been through doctoral theses. In this
chapter we give examples of research undertaken in three different contexts of high poverty
and social exclusion in Mexico, Ecuador and Peru.
2. Patch 1: Chiapas, Mexico
Chiapas is one of the poorest states in Mexico, and has one of the highest rates of indigenous
margination as well as an acute lack of health care resources. According to official government
statistics, Chiapas ranks almost last among all Mexican states in terms of health and socioe‐
conomic indicators [6]. It is precisely in Chiapas where, due to the conditions of social
exclusion, poverty, malnutrition and high mortality from infectious contagious diseases, the
Zapatista National Liberation Army (EZLN) initiated an armed rising against the Mexican
government in 1994, which drew attention, both nationally and internationally, to the preca‐
rious living and health conditions of the indigenous and peasant populations, not only in
Chiapas, but throughout the entire country.
Several studies have been carried out by our team in areas of high levels of poverty in Chiapas:
Our first attempt to analyze the pulmonary tuberculosis (PTB) situation arose out of the
discovery that in the only hospital (Comitán General Hospital, Ministry of Health) in the region
of the border with Guatemala for patients not covered by insurance (the majority of whom are
indigenous),2 there was empirical evidence of a high prevalence of PTB cases. In 1994, active
case finding of patients with chronic cough (15 days or more) was carried out among all
patients aged over 14 years seeking care in the hospital for whatever reason [7]. In this study
2 In Chiapas, over 80% of population is not covered by social security [6]
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2 In Chiapas, over 80% of population is not covered by social security [6]
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a rate of 21 positive PTB smears per hundred patients was found (95% CI=15.5-26.6), and the
main factors associated with PTB were age (35-44 years), occupation (engaged in agricultural)
and weight loss. Through a logistic regression model, we found that the subgroup of chronic
cough patients aged 35-44 years, agricultural workers and who had lost weight, had the
greatest likelihood of being PTB positive (68.7% compared to the overall average of 21% in the
studied patients).
In addition, we noted that in the case of men, patients came to the hospital from near, far and
very far distant communities, but in the case of women, the majority of them only came from
communities which were near or very near. So we decided to carry out other studies in the
hospital’s area of influence, with the aim of analyzing factors related with the high PTB
prevalence among users of secondary level care, not only in terms of health system aspects,
but of demographic and socioeconomic characteristics:
a) In 1997 active case-finding was carried out among all patients aged over 14 years seeking
consultation in a random sample of seven primary care centers [8]. We found a PTB positivity
rate of 11.1 (95% CI=6.6-17.2) per hundred patients studied. The factors associated with PTB
were size and poverty level of the locality of residence. Of the coughers identified, 56% sought
care for non-respiratory symptoms.
b) In 1998 active case-finding was carried out among those aged over 14 years who had a cough
of 15 days or more of duration, in a convenience sample of 1,894 households in 32 communities
chosen at random based on the level of poverty and on travel time to reach the nearest health
services (< 1 hour, 1 hour and over). In this study we found a rate of 276.9 per 100,000 persons
studied (95%CI: 161-443) and that the only factor associated with PTB was blood in sputum,
probably due to the homogenous conditions of extreme poverty among the populations
studied [9].
Additionally, we found that the sensitivity of the smear testing was slightly lower than 50%
in the primary care centers and in communities, and that the proportion of patients with active
PTB that was receiving treatment was only 50% in the primary care centers, and 10.5% in the
studied communities [10]. Also, we found high rates of anti-TB treatment defaulting [11], and
very high levels of PTB multidrug-resistance (MDR): 4.6% and 29.2% primary and secondary
MDR-TB, respectively. In fact, 14% of all studied PTB patients had MDR.
According to the logistic regression model fitted, the main variables associated with MDR
were: having received anti-TB treatment previously, cough of three years or more of duration
and not being indigenous. This is the only occasion in all our studies, which the condition of
being indigenous appeared as a protective factor [12].
In 2000-2001 our team, together with Right to Health Defense Group and Physicians for Human
Rights, carried out a population-based study to assess health conditions, and access to health
services in the conflict zone initiated in 1994 between the EZLN and the Mexican government
[6]. We found that the most affected regions by the armed conflict have fared even worse than
the rest of Chiapas State. We performed a household survey in the municipalities most affected
by the armed conflict among three types of communities: opposition communities, pro-
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government communities, and divided communities, i.e. which contained both opposition and
pro-government groups.
This investigation identified serious deficiencies in both detection and treatment of PTB. In the
46 studied communities (n=2,997 households), we detected 29 cases of PTB among the
population aged over 14 years. This means a rate of PTB of 85.3 per 100,000 in the general
population, and of 161.2 among those aged 15 and older, almost three times the rate reported
for the entire state. In this sense, only 13 (45%) cases of the 29 detected, had been identified by
health services and were being treated. Of these 13 cases, one had not received any anti-TB
treatment and six had defaulted from anti-TB treatment.
We also carried out two evaluations of a cohort of patients aged over 14 years diagnosed with
PTB from January 1998 to July 2005, and found poor survival among them. In the first follow-
up (performed during 2004-2006), the principal factors associated with PTB mortality were:
age (45 years and over, OR=1.3; 95% CI=0.98-1.3), 0-3 years of schooling (OR=3.3; 95%
CI=1.1-4.4), not living in the main village of their municipality (OR=1.2; 95% CI=1.0-1.3), living
in a rural community (OR=2.7; 95% CI=1.1-6.8), not having been treated in DOTS (OR=1.2; 95%
CI=1.0-1.3) and having defaulted from treatment (OR=11.5; 95% CI=5.3-24.8) [13].
In the second follow-up (carried out in 2008-2009), the factors associated with PTB mortality
were age (45 years and over) and anti-TB treatment duration of under six months. The median
survival time of those patients aged 45 and over who died was 718 days (range 0 to 3,185),
while the median survival time in the reference group consisting of patients aged 15-34 years,
was 688 days (range 8-1,841). With regard to the duration of anti-TB treatment, the median
survival time among patients with incomplete treatment was 261 days (range 0-1,658), whereas
among those dying in the reference group (with treatment completed), the median survival
time was 1,137 days (range 202-3,185) [14].
The mortality rate in the patients studied was 4.6 per 100 person-years. Of the 78 deaths from
PTB documented in this study, 25% occurred during the first six months following diagnosis
(in other words, during treatment), 38% by the end of the first year from the date of diagnosis,
53% had died by the end of the second year, and 72% after three years.
The most important features of these studies are shown in Table 1.
3. Patch 2: Chine, Ecuador
During the decade from 1997 to 2006, inequalities of wealth and human development were
extremely marked in Ecuador. The indigenous population, such as that residing in the central
Andean province of Cotopaxi, has the highest poverty rates, and has many of its basic needs
unmet. In Ecuador, up until 2006, the TB Prevention and Control Program was based on
passive case finding of patients with respiratory symptoms (health personnel would check
whether a patient visiting a health center had a productive cough of more than 15 days of
duration). In contrast to what happens in cities, in rural areas the organization and functioning
of the program relies on the presence of basic rural health teams; this means that is not
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a rate of 21 positive PTB smears per hundred patients was found (95% CI=15.5-26.6), and the
main factors associated with PTB were age (35-44 years), occupation (engaged in agricultural)
and weight loss. Through a logistic regression model, we found that the subgroup of chronic
cough patients aged 35-44 years, agricultural workers and who had lost weight, had the
greatest likelihood of being PTB positive (68.7% compared to the overall average of 21% in the
studied patients).
In addition, we noted that in the case of men, patients came to the hospital from near, far and
very far distant communities, but in the case of women, the majority of them only came from
communities which were near or very near. So we decided to carry out other studies in the
hospital’s area of influence, with the aim of analyzing factors related with the high PTB
prevalence among users of secondary level care, not only in terms of health system aspects,
but of demographic and socioeconomic characteristics:
a) In 1997 active case-finding was carried out among all patients aged over 14 years seeking
consultation in a random sample of seven primary care centers [8]. We found a PTB positivity
rate of 11.1 (95% CI=6.6-17.2) per hundred patients studied. The factors associated with PTB
were size and poverty level of the locality of residence. Of the coughers identified, 56% sought
care for non-respiratory symptoms.
b) In 1998 active case-finding was carried out among those aged over 14 years who had a cough
of 15 days or more of duration, in a convenience sample of 1,894 households in 32 communities
chosen at random based on the level of poverty and on travel time to reach the nearest health
services (< 1 hour, 1 hour and over). In this study we found a rate of 276.9 per 100,000 persons
studied (95%CI: 161-443) and that the only factor associated with PTB was blood in sputum,
probably due to the homogenous conditions of extreme poverty among the populations
studied [9].
Additionally, we found that the sensitivity of the smear testing was slightly lower than 50%
in the primary care centers and in communities, and that the proportion of patients with active
PTB that was receiving treatment was only 50% in the primary care centers, and 10.5% in the
studied communities [10]. Also, we found high rates of anti-TB treatment defaulting [11], and
very high levels of PTB multidrug-resistance (MDR): 4.6% and 29.2% primary and secondary
MDR-TB, respectively. In fact, 14% of all studied PTB patients had MDR.
According to the logistic regression model fitted, the main variables associated with MDR
were: having received anti-TB treatment previously, cough of three years or more of duration
and not being indigenous. This is the only occasion in all our studies, which the condition of
being indigenous appeared as a protective factor [12].
In 2000-2001 our team, together with Right to Health Defense Group and Physicians for Human
Rights, carried out a population-based study to assess health conditions, and access to health
services in the conflict zone initiated in 1994 between the EZLN and the Mexican government
[6]. We found that the most affected regions by the armed conflict have fared even worse than
the rest of Chiapas State. We performed a household survey in the municipalities most affected
by the armed conflict among three types of communities: opposition communities, pro-
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government communities, and divided communities, i.e. which contained both opposition and
pro-government groups.
This investigation identified serious deficiencies in both detection and treatment of PTB. In the
46 studied communities (n=2,997 households), we detected 29 cases of PTB among the
population aged over 14 years. This means a rate of PTB of 85.3 per 100,000 in the general
population, and of 161.2 among those aged 15 and older, almost three times the rate reported
for the entire state. In this sense, only 13 (45%) cases of the 29 detected, had been identified by
health services and were being treated. Of these 13 cases, one had not received any anti-TB
treatment and six had defaulted from anti-TB treatment.
We also carried out two evaluations of a cohort of patients aged over 14 years diagnosed with
PTB from January 1998 to July 2005, and found poor survival among them. In the first follow-
up (performed during 2004-2006), the principal factors associated with PTB mortality were:
age (45 years and over, OR=1.3; 95% CI=0.98-1.3), 0-3 years of schooling (OR=3.3; 95%
CI=1.1-4.4), not living in the main village of their municipality (OR=1.2; 95% CI=1.0-1.3), living
in a rural community (OR=2.7; 95% CI=1.1-6.8), not having been treated in DOTS (OR=1.2; 95%
CI=1.0-1.3) and having defaulted from treatment (OR=11.5; 95% CI=5.3-24.8) [13].
In the second follow-up (carried out in 2008-2009), the factors associated with PTB mortality
were age (45 years and over) and anti-TB treatment duration of under six months. The median
survival time of those patients aged 45 and over who died was 718 days (range 0 to 3,185),
while the median survival time in the reference group consisting of patients aged 15-34 years,
was 688 days (range 8-1,841). With regard to the duration of anti-TB treatment, the median
survival time among patients with incomplete treatment was 261 days (range 0-1,658), whereas
among those dying in the reference group (with treatment completed), the median survival
time was 1,137 days (range 202-3,185) [14].
The mortality rate in the patients studied was 4.6 per 100 person-years. Of the 78 deaths from
PTB documented in this study, 25% occurred during the first six months following diagnosis
(in other words, during treatment), 38% by the end of the first year from the date of diagnosis,
53% had died by the end of the second year, and 72% after three years.
The most important features of these studies are shown in Table 1.
3. Patch 2: Chine, Ecuador
During the decade from 1997 to 2006, inequalities of wealth and human development were
extremely marked in Ecuador. The indigenous population, such as that residing in the central
Andean province of Cotopaxi, has the highest poverty rates, and has many of its basic needs
unmet. In Ecuador, up until 2006, the TB Prevention and Control Program was based on
passive case finding of patients with respiratory symptoms (health personnel would check
whether a patient visiting a health center had a productive cough of more than 15 days of
duration). In contrast to what happens in cities, in rural areas the organization and functioning
of the program relies on the presence of basic rural health teams; this means that is not
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uncommon for health personnel to be absent. This situation, among others, has resulted in TB
notification being irregular. Although the average incidence reported is 65/100,000,3 given the
important level of under-reporting of TB cases, the true extent of the disease in Ecuador is
unknown.
Setting Frequency Associated Factors
Chiapas, Mexico
(only people 15 years of
age and over)
Prevalence of PTB 21% in a hospital-
based population with symptoms
suggestive of TB
Association with age (35-44 years old),
working in agricultural, and weight loss.
Prevalence of PTB 11.1% among
patients, consulting in primary health
centers (PHC) with symptoms suggestive
of TB
Association with poverty level
Prevalence of PTB 277 per 100,000
persons studied in household surveys
Presence of blood in sputum; 50% of
sensitivity in sputum test performed in
PHC setting. High rate of defaulting
treatment; and very high MDR-TB rates
associated (by Logistic Regression) with
previous PTB treatment, cough for more
than 3 years and not being indigenous.
Cohort of patients with PTB Mortality was associated with poverty and
deprivation characteristics and no access
to DOTS.
Table 1. Pulmonary Tuberculosis (PTB) and associated factors observed within studies performed by GRAAL members
in Mexico.
In Chine, an indigenous community of 653 inhabitants, in the parish of Angamarca, located in
Cotopaxi Region, over 90% of its population have their basic needs unmet [15]. It is situated
at an altitude of 3,500m above sea level and is two hours walk from the nearest health center,
which during the period 2000 to 2004 was practically without staff. One of the co-authors of
the present work (Natalia Romero) collaborated with the health team of this parish, during
her period of rural medical training several years earlier. Following the diagnosis of one PTB
case (the schoolmaster) in 2001, we conducted a study between 2001 and 2003, and found a
prevalence rate of PTB-positive cases of 6.7% for the community as a whole [16].
On the basis of this single case, we saw the convenience of studying the total population of the
community through a household survey (taking into account the experience obtained in
Chiapas, México). The data collected was analyzed using the technique of multiple corre‐
spondence analyses, which allowed us to ascertain the risk and exposure factors in the
community. All persons with chronic productive cough were asked to provide three sputum
3 World Health Organization. Ecuador: Health profile. Available at: http://www.who.int/countries/ecu/es/ (accessed 12
August 2012).
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specimens. Given the degree of social and geographical exclusion of the community, PTB was
diagnosed only by smear test.
Two hundred and two persons were identified with chronic cough (fifteen days or more), 173
of them, productive. Of 92 coughers in which it was possible analyze their sputum, 44 (48%)
were PTB positive (representing 6.7% of the whole population and 11.3% of those aged 15 years
and over). Among men, the highest prevalence was in the 35–44 age group (20.6%) and among
women in the group aged ≥ 45 years (16.7%). Also, 27% of families had between one and four
smear positive members. The factors associated with presence of PTB were: previous history
of active TB (OR=6.0; 95% CI=2.9-12.3), haemoptysis (OR=3.8; 95% CI=1.5-10.0), and history of
participating in seasonal migration (OR=2.44; 95% CI=0.91-6.54) [16].
With the intention of making some contribution to resolving the PTB problem, our team
reached an agreement with the inhabitants of the community of Chine, in order to implement
the DOTS strategy, while at the same time taking account of aspects of the community’s world
view. As consequence of this approach, we obtained a cure rate of 100%, confirmed by three
negative smear-tests during the anti-TB treatment and cultures at the end of it (there were no
defaults and no deaths) [17].
Although TB prevention and control programs encourage patients to visit health services and
follow instructions, if they continue in their tendency to give little attention to socioeconomic,
cultural and anthropological aspects, the results will be the same. How can better outcomes
be expected if health services persist in acting as they always they do, including opening for
restricted hours (from 8 am to 12 pm and from 2 to 6 pm)? In our intervention in Chine, symbolic
referents, the religious dimension and rituals, as well as aspects of daily life (working hours,
school, community and family calendar, seasonal migration, and traditional medical practices,
among others) were taken into account.
The main results obtained in Ecuador, are shown in Table 2.
Chine, Cotopaxi, EcuadorPrevalence of PTB 6.7% in an entire
indigenous community
PTB was associated with prior history of PTB (OR=
6.0; CI 95%: 2.9-12.3), with haemoptysis (OR=
3.8; CI 95%: 1.5-10.0).
Cure rate of 100% based on community consent
for the performing of DOTS strategy
CI: Confidence interval; OR: Odds Ratio
Table 2. Pulmonary Tuberculosis (PTB) and associated factors observed within studies performed by GRAAL members
in Ecuador.
4. Patch 3: Lima, Peru
One of the coauthors of the present work (Olivia Horna), as a nurse responsible for coordi‐
nating the application of DOTS, realized that the TB Program was relaxing various aspects of
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uncommon for health personnel to be absent. This situation, among others, has resulted in TB
notification being irregular. Although the average incidence reported is 65/100,000,3 given the
important level of under-reporting of TB cases, the true extent of the disease in Ecuador is
unknown.
Setting Frequency Associated Factors
Chiapas, Mexico
(only people 15 years of
age and over)
Prevalence of PTB 21% in a hospital-
based population with symptoms
suggestive of TB
Association with age (35-44 years old),
working in agricultural, and weight loss.
Prevalence of PTB 11.1% among
patients, consulting in primary health
centers (PHC) with symptoms suggestive
of TB
Association with poverty level
Prevalence of PTB 277 per 100,000
persons studied in household surveys
Presence of blood in sputum; 50% of
sensitivity in sputum test performed in
PHC setting. High rate of defaulting
treatment; and very high MDR-TB rates
associated (by Logistic Regression) with
previous PTB treatment, cough for more
than 3 years and not being indigenous.
Cohort of patients with PTB Mortality was associated with poverty and
deprivation characteristics and no access
to DOTS.
Table 1. Pulmonary Tuberculosis (PTB) and associated factors observed within studies performed by GRAAL members
in Mexico.
In Chine, an indigenous community of 653 inhabitants, in the parish of Angamarca, located in
Cotopaxi Region, over 90% of its population have their basic needs unmet [15]. It is situated
at an altitude of 3,500m above sea level and is two hours walk from the nearest health center,
which during the period 2000 to 2004 was practically without staff. One of the co-authors of
the present work (Natalia Romero) collaborated with the health team of this parish, during
her period of rural medical training several years earlier. Following the diagnosis of one PTB
case (the schoolmaster) in 2001, we conducted a study between 2001 and 2003, and found a
prevalence rate of PTB-positive cases of 6.7% for the community as a whole [16].
On the basis of this single case, we saw the convenience of studying the total population of the
community through a household survey (taking into account the experience obtained in
Chiapas, México). The data collected was analyzed using the technique of multiple corre‐
spondence analyses, which allowed us to ascertain the risk and exposure factors in the
community. All persons with chronic productive cough were asked to provide three sputum
3 World Health Organization. Ecuador: Health profile. Available at: http://www.who.int/countries/ecu/es/ (accessed 12
August 2012).
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specimens. Given the degree of social and geographical exclusion of the community, PTB was
diagnosed only by smear test.
Two hundred and two persons were identified with chronic cough (fifteen days or more), 173
of them, productive. Of 92 coughers in which it was possible analyze their sputum, 44 (48%)
were PTB positive (representing 6.7% of the whole population and 11.3% of those aged 15 years
and over). Among men, the highest prevalence was in the 35–44 age group (20.6%) and among
women in the group aged ≥ 45 years (16.7%). Also, 27% of families had between one and four
smear positive members. The factors associated with presence of PTB were: previous history
of active TB (OR=6.0; 95% CI=2.9-12.3), haemoptysis (OR=3.8; 95% CI=1.5-10.0), and history of
participating in seasonal migration (OR=2.44; 95% CI=0.91-6.54) [16].
With the intention of making some contribution to resolving the PTB problem, our team
reached an agreement with the inhabitants of the community of Chine, in order to implement
the DOTS strategy, while at the same time taking account of aspects of the community’s world
view. As consequence of this approach, we obtained a cure rate of 100%, confirmed by three
negative smear-tests during the anti-TB treatment and cultures at the end of it (there were no
defaults and no deaths) [17].
Although TB prevention and control programs encourage patients to visit health services and
follow instructions, if they continue in their tendency to give little attention to socioeconomic,
cultural and anthropological aspects, the results will be the same. How can better outcomes
be expected if health services persist in acting as they always they do, including opening for
restricted hours (from 8 am to 12 pm and from 2 to 6 pm)? In our intervention in Chine, symbolic
referents, the religious dimension and rituals, as well as aspects of daily life (working hours,
school, community and family calendar, seasonal migration, and traditional medical practices,
among others) were taken into account.
The main results obtained in Ecuador, are shown in Table 2.
Chine, Cotopaxi, EcuadorPrevalence of PTB 6.7% in an entire
indigenous community
PTB was associated with prior history of PTB (OR=
6.0; CI 95%: 2.9-12.3), with haemoptysis (OR=
3.8; CI 95%: 1.5-10.0).
Cure rate of 100% based on community consent
for the performing of DOTS strategy
CI: Confidence interval; OR: Odds Ratio
Table 2. Pulmonary Tuberculosis (PTB) and associated factors observed within studies performed by GRAAL members
in Ecuador.
4. Patch 3: Lima, Peru
One of the coauthors of the present work (Olivia Horna), as a nurse responsible for coordi‐
nating the application of DOTS, realized that the TB Program was relaxing various aspects of
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the DOTS application, largely motivated by the economic conditions imposed in the area by
the World Bank but also by recommendations from the Pan-American Health Organization
itself: cessation of active case finding of coughers of 15 days or more on the grounds that the
system was of low efficiency, and a switch to an ambulatory form of DOTS rather than in the
patient’s home, changes due to a shortage of funds to pay health technicians performing this
function.
Given this situation combined with a feeling that the number of patients was rising at a higher
rate than that calculated based on national rates, it was decided to perform a study to detect
coughers of 15 days or more making use of the structure of the health system itself. The district
of Ate-Vitarte was chosen to be targeted, since it consists mainly of lands occupied by migrants
from the interior of the country, many forced off their lands due to violence between Peruvian
armed forces and guerrilla movements from the interior, in particular Sendero Luminoso.
For this study, as in the cases of Chiapas, Mexico and of Chine, Ecuador, the health system
approved and participated in order to guarantee anti-TB treatment and medical care for
possible new cases identified by the study. Thus the same scheme was set up as employed
previously in the outpatients department of Comitán hospital, whereby subjects recruited
were people approaching the health system facilities in the area for medical care.
We interviewed 150 persons over 14 years of age who had productive chronic cough (fifteen
days or more) seeking care in health services (primary care and hospitals). Of these, we
obtained sputum samples from 142. The observed PTB prevalence rate was 12% [18], a figure
very similar to that obtained in primary care centers in Chiapas (11%) [8]. None of the
demographic or socioeconomic indicators analyzed were associated with PTB.
Of the variables studied, those found to be significantly associated with PTB, were: working
away from home with respect those working at home (OR=6.99; 95% CI=0.89-54.61), persons
commuting by minibuses compared with persons who used individual forms of transportation
(OR=4.9; 95% CI=1.06-23.09), and commuting time one hour or more in a minibus (OR=3.35;
95% CI=1.12-10.1) [18].
Given the high prevalence of PTB in peripheral areas of Lima, as is the case of Ate-Vitarte
District, and the results mentioned in the previous paragraph, we planned a study to determine
whether the use of minibuses was associated with the spread of PTB. Commuting in these
minibuses means that people travel in overcrowded situations with closed windows regardless
of the weather, making trips of at least 30 minutes duration every day, in the company of TB
patients going to a health center to receive DOTS treatment. Furthermore, if there is a strong
association between using microbuses and the risk of infection, what would be expected
among microbus drivers and fare-collectors that spend more than 8 hours per day in this
environment?
Based on these precedents, we decided to carry out a study to assess infection by Mycobacte‐
rium tuberculosis and working conditions among workers of public transport [19]. In 2008 we
performed a cross-sectional study with 104 workers from two public transport minibus
companies of the Ate-Vitarte District. These minibus workers were interviewed and a tuber‐
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culin skin test (TST) administered. An induration greater than or equal to 10 mm was consid‐
ered positive.
From these 104 workers, TST results were obtained for 73 (70.2%), of whom 56 (77%) were
positive. We found that positivity was associated with the time they had worked on minibuses
(more than two years, OR=11.04; 95% CI=3.17-38.43), and with working more than 60 hours
per week (OR=9.8; 95% CI=2.85-33.72). This exposure gradient, a result of the working hours
and time employed in the transport sector, stresses the importance of workers’ job conditions.
Furthermore, strict revision of clinical histories of active TB patients in the health centers
associated to the health districts of these workers, showed that standardized incidence rates
for transport sector workers were 2.7- 4.5 times higher than those in the total working-age male
and global populations of the health micro-network studied. The associations between TB and
being a transport worker, and between MDR-TB and being a transport worker are both strong
(OR 3.06, 95%CI 2.2-4.2 and OR 3.14, 95%CI 1.1-9.1, respectively). These results indicate that
the use of informal public transport is a risk factor for TB infection and an occupational risk in
countries with characteristics similar to those in Peru [20].
A summary of the main results obtained in Lima, is presented in table 3.
Lima, Peru Incidence of PTB calculated within
general population based on PHC micro-
net data
TB associated with transport occupation (OR=3.06; CI
95%: 2.2-4.2) and with MDR-TB (OR= 3.14; CI 95%:
1.1-1.9)
Prevalence of PTB 12% among
commuters in a suburban area of Lima
Use of informal transport system: working away from
home (OR= 6,99; CI 95%: 0.89-54.61; PPR = 6.06);
commuting in minibuses (OR= 44.9; CI 95%: 1.06-23.09;
PPR=4.09) and commuting more than one hour
(OR=3.35; CI 95%: 1.12-10.1; PPR= 2.07)
Prevalence of Mycobacterium
Tuberculosis infection through PPD test
of 77% among minibus drivers in
informal transport
High work-related exposure: more than two years in job
(OR= 11.04; CI 95%: 3.17-38.43) and working more than
60 hours per week (OR= 9.8; CI 95%: 2.85-33.72).
CI: Confidence interval; OR: Odds Ratio; PPR: Positive Prevalence Ratio
Table 3. Pulmonary Tuberculosis (PTB) and associated factors observed within studies performed by GRAAL members
in Peru
5. The patchwork: What do these findings mean? Are they useful?
TB, far from being under control, as was believed at the end of the decade of the 1990s,
continues to cause many deaths, disability, and health expenditure; indeed, it has been
recognized that the situation may be worsening due to an accumulation of structural condi‐
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the DOTS application, largely motivated by the economic conditions imposed in the area by
the World Bank but also by recommendations from the Pan-American Health Organization
itself: cessation of active case finding of coughers of 15 days or more on the grounds that the
system was of low efficiency, and a switch to an ambulatory form of DOTS rather than in the
patient’s home, changes due to a shortage of funds to pay health technicians performing this
function.
Given this situation combined with a feeling that the number of patients was rising at a higher
rate than that calculated based on national rates, it was decided to perform a study to detect
coughers of 15 days or more making use of the structure of the health system itself. The district
of Ate-Vitarte was chosen to be targeted, since it consists mainly of lands occupied by migrants
from the interior of the country, many forced off their lands due to violence between Peruvian
armed forces and guerrilla movements from the interior, in particular Sendero Luminoso.
For this study, as in the cases of Chiapas, Mexico and of Chine, Ecuador, the health system
approved and participated in order to guarantee anti-TB treatment and medical care for
possible new cases identified by the study. Thus the same scheme was set up as employed
previously in the outpatients department of Comitán hospital, whereby subjects recruited
were people approaching the health system facilities in the area for medical care.
We interviewed 150 persons over 14 years of age who had productive chronic cough (fifteen
days or more) seeking care in health services (primary care and hospitals). Of these, we
obtained sputum samples from 142. The observed PTB prevalence rate was 12% [18], a figure
very similar to that obtained in primary care centers in Chiapas (11%) [8]. None of the
demographic or socioeconomic indicators analyzed were associated with PTB.
Of the variables studied, those found to be significantly associated with PTB, were: working
away from home with respect those working at home (OR=6.99; 95% CI=0.89-54.61), persons
commuting by minibuses compared with persons who used individual forms of transportation
(OR=4.9; 95% CI=1.06-23.09), and commuting time one hour or more in a minibus (OR=3.35;
95% CI=1.12-10.1) [18].
Given the high prevalence of PTB in peripheral areas of Lima, as is the case of Ate-Vitarte
District, and the results mentioned in the previous paragraph, we planned a study to determine
whether the use of minibuses was associated with the spread of PTB. Commuting in these
minibuses means that people travel in overcrowded situations with closed windows regardless
of the weather, making trips of at least 30 minutes duration every day, in the company of TB
patients going to a health center to receive DOTS treatment. Furthermore, if there is a strong
association between using microbuses and the risk of infection, what would be expected
among microbus drivers and fare-collectors that spend more than 8 hours per day in this
environment?
Based on these precedents, we decided to carry out a study to assess infection by Mycobacte‐
rium tuberculosis and working conditions among workers of public transport [19]. In 2008 we
performed a cross-sectional study with 104 workers from two public transport minibus
companies of the Ate-Vitarte District. These minibus workers were interviewed and a tuber‐
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culin skin test (TST) administered. An induration greater than or equal to 10 mm was consid‐
ered positive.
From these 104 workers, TST results were obtained for 73 (70.2%), of whom 56 (77%) were
positive. We found that positivity was associated with the time they had worked on minibuses
(more than two years, OR=11.04; 95% CI=3.17-38.43), and with working more than 60 hours
per week (OR=9.8; 95% CI=2.85-33.72). This exposure gradient, a result of the working hours
and time employed in the transport sector, stresses the importance of workers’ job conditions.
Furthermore, strict revision of clinical histories of active TB patients in the health centers
associated to the health districts of these workers, showed that standardized incidence rates
for transport sector workers were 2.7- 4.5 times higher than those in the total working-age male
and global populations of the health micro-network studied. The associations between TB and
being a transport worker, and between MDR-TB and being a transport worker are both strong
(OR 3.06, 95%CI 2.2-4.2 and OR 3.14, 95%CI 1.1-9.1, respectively). These results indicate that
the use of informal public transport is a risk factor for TB infection and an occupational risk in
countries with characteristics similar to those in Peru [20].
A summary of the main results obtained in Lima, is presented in table 3.
Lima, Peru Incidence of PTB calculated within
general population based on PHC micro-
net data
TB associated with transport occupation (OR=3.06; CI
95%: 2.2-4.2) and with MDR-TB (OR= 3.14; CI 95%:
1.1-1.9)
Prevalence of PTB 12% among
commuters in a suburban area of Lima
Use of informal transport system: working away from
home (OR= 6,99; CI 95%: 0.89-54.61; PPR = 6.06);
commuting in minibuses (OR= 44.9; CI 95%: 1.06-23.09;
PPR=4.09) and commuting more than one hour
(OR=3.35; CI 95%: 1.12-10.1; PPR= 2.07)
Prevalence of Mycobacterium
Tuberculosis infection through PPD test
of 77% among minibus drivers in
informal transport
High work-related exposure: more than two years in job
(OR= 11.04; CI 95%: 3.17-38.43) and working more than
60 hours per week (OR= 9.8; CI 95%: 2.85-33.72).
CI: Confidence interval; OR: Odds Ratio; PPR: Positive Prevalence Ratio
Table 3. Pulmonary Tuberculosis (PTB) and associated factors observed within studies performed by GRAAL members
in Peru
5. The patchwork: What do these findings mean? Are they useful?
TB, far from being under control, as was believed at the end of the decade of the 1990s,
continues to cause many deaths, disability, and health expenditure; indeed, it has been
recognized that the situation may be worsening due to an accumulation of structural condi‐
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tions favoring its appearance and development: increased poverty in important population
nuclei (which are the most susceptible to the disease), migratory movements (whether due to
economic, work, political or even environmental issues), higher incidence of other immuno‐
suppressive diseases (mainly HIV/AIDS and diabetes), or weakening of health of certain
individuals (such as due to malnutrition, and chronic pneumopathies), the increasingly more
common appearance of forms of MDR, and the shortage of health resources to cope with TB,
mainly in areas of greater socioeconomic exclusion. In this sense, the so-called developed
countries have also felt the impacts of the disease, largely due the appearance of HIV/AIDS
and to cases among immigrants who, whether legally or illegally, settle in foreign territories
seeking to improve on the conditions which caused them to leave their places of origin.4 These
populations are generally speaking the most socioeconomically disadvantaged groups.
There is no doubt that TB is an outcome indicator of the socioeconomic, cultural and political
structure of a population. TB is a historical reflection of the forms of social construction,
particularly of the post-industrial revolution era experienced in capitalist countries. TB in this
sense feeds, to a greater or lesser degree, depending on circumstances, on the social context in
order to reproduce, and this fact finds expression, as documented in the present studies, in
various gradients of exposure and susceptibility to the disease, in which the more socioeco‐
nomically disadvantaged groups are the ones most affected by the disease, but the ones which,
paradoxically, usually receive least attention, whether in terms of prevention, diagnosis, or
treatment, and hence cure rates are low.
Two million people die every year from TB, the majority of them in the “under-developed
countries”. The Global Plan to Stop TB 2006-2015 aims to treat 50 million people, save 14 million
lives, and expand equitable access to quality diagnosis and treatment. According to this Global
Plan, by 2010 it was expected “to be using diagnostic test that allow rapid, sensitive and
inexpensive detection of active TB… and introduce the first new TB drug in 40 years. It also
expects to see a new, safe, effective and affordable vaccine available by 2015” [21]. However,
the World Health Organization, Pan-American Health Organization and Governments in
general, establishing targets for TB control programs, take as their basis the reports they receive
from the countries themselves, with the result that programs elaborated are eminently political,
whose objectives and information basis constitute a kind of feedback system which rapidly
departs from reality.
TB control programs thus planned are designed as though the social structure of the countries
was homogeneous, and this impedes acting in such a way as to take account of the particu‐
larities of marginal populations, which are the ones presenting the highest rates of prevalence
of this disease. The usual ways of working lead to government planning and actions being
based on central estimates and tackling of global objectives. For example, the global medium-
term goal for TB control is to halve TB prevalence and death rates by 2015 as compared to 1990
levels, and to achieve a reduction in its incidence, as part of the Millennium Development
Goals (number six) [22,23].
4 The first report of a rise in cases of HIV/AIDS was published in 1991, affecting New York City, and the status of TB was
changed to that of an AIDS-defining disease, although it has been calculated that currently 50% of new TB cases in the
European Union occur among immigrants.
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This type of planning and programming of objectives apparently does not take account of
the particular situations affecting the population, above all those aspects which are notably
different from the global mean values. In fact the few population based studies available,
some  involving  Latin  American  countries,  likewise  fail  to  treat  marginal  populations
specially.  For  example,  if  it  was  not  for  international  support,  few governments  would
have sufficient resources to conduct national health surveys, which are usually carried out
through household interviews, based on self-perceived morbidity, and which hardly ever
include laboratory tests  to  identify diseased individuals  (TB in our case).  Generally,  the
level  of  disaggregation  of  surveys  of  this  type  goes  no  further  than  large  geographical
regions (north, south, east, etc), tending to disguise inter- and intra-regional heterogenei‐
ty, and the data are analyzed based on artificially created convenience categories, not based
on observed patterns of disease or deaths.
In other words, it is usual that global policies emanating from the international agencies and
institutions ignore the true situation, applying criteria of homogeneity in the calculation of
targets, costs of equipment and supplies and staffing levels, among other aspects. Curiously,
despite it being well known that social factors are related with TB, they are not taken into
consideration in order to improve the quality of plans to control it.
In order to identify, analyze and ideally contribute alternative solutions to the problem of
unmet needs of socioeconomically excluded populations, means working with samples which
are not representative of the general population, but rather focused on these sub-populations,
biased precisely due to their conditions. In this sense, our team has been employing the
patchwork approach, involving studies focusing on marginal or susceptible populations, those
with the worst socioeconomic and health conditions. In the case of TB, these circumstances
(poverty, social vulnerability, and shortage of health facilities) are well recognized as one of
the basic determinants of the presence and spread of the disease, but its characterization
usually is not considered by health systems in their solution proposals [24].
For example, in marginalized rural areas, in the best case, active TB case finding is limited in
practice, to identifying chronic coughers among users who seek health care. This results in at
least three possible situations: a) there may be delays in the TB diagnosis (patients arrive in an
advanced stage of the disease);5 if the medical consultation is for reasons other than respiratory
symptoms, TB may not even be detected;6 and, c) that a certain proportion of patients do not
use the health services (due to accessibility barriers which may be geographical, economic or
cultural)7 and hence are not even diagnosed [10].
5 Several studies have shown that groups living in conditions of greater socioeconomic margination present longer delays
in seeking care for health problems [26,27].
6 In several studies we found that PTB status is not associated with the reason for visiting health services [10].
7 Political conflicts (belonging to a particular organization), religious conflicts (not belonging to the religion predominant
in the community), administrative barriers (nearest clinic not the one assigned officially), and conflicts deriving from
access to and utilization of natural resources (water, timber, etcetera) can mean that certain individuals are denied access
to health services, or they are denied medical care or drugs [6].
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tions favoring its appearance and development: increased poverty in important population
nuclei (which are the most susceptible to the disease), migratory movements (whether due to
economic, work, political or even environmental issues), higher incidence of other immuno‐
suppressive diseases (mainly HIV/AIDS and diabetes), or weakening of health of certain
individuals (such as due to malnutrition, and chronic pneumopathies), the increasingly more
common appearance of forms of MDR, and the shortage of health resources to cope with TB,
mainly in areas of greater socioeconomic exclusion. In this sense, the so-called developed
countries have also felt the impacts of the disease, largely due the appearance of HIV/AIDS
and to cases among immigrants who, whether legally or illegally, settle in foreign territories
seeking to improve on the conditions which caused them to leave their places of origin.4 These
populations are generally speaking the most socioeconomically disadvantaged groups.
There is no doubt that TB is an outcome indicator of the socioeconomic, cultural and political
structure of a population. TB is a historical reflection of the forms of social construction,
particularly of the post-industrial revolution era experienced in capitalist countries. TB in this
sense feeds, to a greater or lesser degree, depending on circumstances, on the social context in
order to reproduce, and this fact finds expression, as documented in the present studies, in
various gradients of exposure and susceptibility to the disease, in which the more socioeco‐
nomically disadvantaged groups are the ones most affected by the disease, but the ones which,
paradoxically, usually receive least attention, whether in terms of prevention, diagnosis, or
treatment, and hence cure rates are low.
Two million people die every year from TB, the majority of them in the “under-developed
countries”. The Global Plan to Stop TB 2006-2015 aims to treat 50 million people, save 14 million
lives, and expand equitable access to quality diagnosis and treatment. According to this Global
Plan, by 2010 it was expected “to be using diagnostic test that allow rapid, sensitive and
inexpensive detection of active TB… and introduce the first new TB drug in 40 years. It also
expects to see a new, safe, effective and affordable vaccine available by 2015” [21]. However,
the World Health Organization, Pan-American Health Organization and Governments in
general, establishing targets for TB control programs, take as their basis the reports they receive
from the countries themselves, with the result that programs elaborated are eminently political,
whose objectives and information basis constitute a kind of feedback system which rapidly
departs from reality.
TB control programs thus planned are designed as though the social structure of the countries
was homogeneous, and this impedes acting in such a way as to take account of the particu‐
larities of marginal populations, which are the ones presenting the highest rates of prevalence
of this disease. The usual ways of working lead to government planning and actions being
based on central estimates and tackling of global objectives. For example, the global medium-
term goal for TB control is to halve TB prevalence and death rates by 2015 as compared to 1990
levels, and to achieve a reduction in its incidence, as part of the Millennium Development
Goals (number six) [22,23].
4 The first report of a rise in cases of HIV/AIDS was published in 1991, affecting New York City, and the status of TB was
changed to that of an AIDS-defining disease, although it has been calculated that currently 50% of new TB cases in the
European Union occur among immigrants.
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This type of planning and programming of objectives apparently does not take account of
the particular situations affecting the population, above all those aspects which are notably
different from the global mean values. In fact the few population based studies available,
some  involving  Latin  American  countries,  likewise  fail  to  treat  marginal  populations
specially.  For  example,  if  it  was  not  for  international  support,  few governments  would
have sufficient resources to conduct national health surveys, which are usually carried out
through household interviews, based on self-perceived morbidity, and which hardly ever
include laboratory tests  to  identify diseased individuals  (TB in our case).  Generally,  the
level  of  disaggregation  of  surveys  of  this  type  goes  no  further  than  large  geographical
regions (north, south, east, etc), tending to disguise inter- and intra-regional heterogenei‐
ty, and the data are analyzed based on artificially created convenience categories, not based
on observed patterns of disease or deaths.
In other words, it is usual that global policies emanating from the international agencies and
institutions ignore the true situation, applying criteria of homogeneity in the calculation of
targets, costs of equipment and supplies and staffing levels, among other aspects. Curiously,
despite it being well known that social factors are related with TB, they are not taken into
consideration in order to improve the quality of plans to control it.
In order to identify, analyze and ideally contribute alternative solutions to the problem of
unmet needs of socioeconomically excluded populations, means working with samples which
are not representative of the general population, but rather focused on these sub-populations,
biased precisely due to their conditions. In this sense, our team has been employing the
patchwork approach, involving studies focusing on marginal or susceptible populations, those
with the worst socioeconomic and health conditions. In the case of TB, these circumstances
(poverty, social vulnerability, and shortage of health facilities) are well recognized as one of
the basic determinants of the presence and spread of the disease, but its characterization
usually is not considered by health systems in their solution proposals [24].
For example, in marginalized rural areas, in the best case, active TB case finding is limited in
practice, to identifying chronic coughers among users who seek health care. This results in at
least three possible situations: a) there may be delays in the TB diagnosis (patients arrive in an
advanced stage of the disease);5 if the medical consultation is for reasons other than respiratory
symptoms, TB may not even be detected;6 and, c) that a certain proportion of patients do not
use the health services (due to accessibility barriers which may be geographical, economic or
cultural)7 and hence are not even diagnosed [10].
5 Several studies have shown that groups living in conditions of greater socioeconomic margination present longer delays
in seeking care for health problems [26,27].
6 In several studies we found that PTB status is not associated with the reason for visiting health services [10].
7 Political conflicts (belonging to a particular organization), religious conflicts (not belonging to the religion predominant
in the community), administrative barriers (nearest clinic not the one assigned officially), and conflicts deriving from
access to and utilization of natural resources (water, timber, etcetera) can mean that certain individuals are denied access
to health services, or they are denied medical care or drugs [6].
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In this context, women living in remote and marginalized regions, have a more pronounced
lack of access to health services due to gender reasons: there are differences in the process of
seeking medical care, and in the quality of the care received between women and men [25].
Furthermore, in Chiapas, Ecuador and Peru, as in many other regions of Latin America,
TB cases  notified to  the  information systems of  the  health  sector,  and from which inci‐
dence  rates  are  estimated,  correspond  to  cases  detected  in  health  services  by  acid-fast
bacilli. We have documented that in rural and marginalized areas, its sensitivity is around
50%. This is an important aspect to consider because health system detection of TB cases
is based on smear testing, meaning that in marginalized communities many cases are not
detected.  In consequence,  the target  of  detecting at  least  75% of  cases is  far  from being
reached,  implying  the  presence  of  a  not  unappreciable  risk  of  transmission  of  TB  [9].
Indeed, the detection rate in hospitals studied in Chiapas is below this figure of 75%. The
suboptimal  case  detection  rate  reflects  an  inadequate  of  quality  medical  care,  probably
health personnel are often overwhelmed by daily activities, as well as insufficiently trained,
motivated, aware, and remunerated [10].
In order to increase detection rates, as it was demonstrated, the health system must take into
account the considerable difficulties involved in obtaining and analyzing sputum samples in
marginalized areas: cultural barriers (language spoken, world view) and economic barriers,
as well as technical problems to be overcome in order to obtain adequate quantity and quality
of sputum samples. It is therefore necessary to reduce the cultural and socioeconomic barriers
between health care providers and people [10]. Not surprisingly, some results of our investi‐
gations show that apart from cultural barriers, there are also structural barriers [11].
In the same way, we have found that a very low proportion of patients eligible for anti-TB
treatment effectively receive such treatment, and very high proportions of treatment failures
and incomplete follow-up [10].
Two further aspects deserve special attention in the context of the studies conducted in
Chiapas, Mexico, as well as in Peru: the problem of MDR, and the high mortality among
patients diagnosed of PTB. Both indicators constitute expressions of the complete failure of
the health system which, for whatever reason, did not manage to adequately treat these people,
who consequently either died of TB, or were left as chronic MDR cases (which would lead to
their death also, sooner or later).
In the case of MDR, it is well documented that the vast majority of cases of this type result
from inappropriate treatment and follow up by the health system. According to official
statistics, worldwide, the rates of MDR recorded in 2009 and 2010 were the highest ever, and
trends in MDR rates are unclear in the majority of countries [28]. The observed rates of MDR
in Chiapas suggest that in marginalized and excluded regions, it is a serious public health
problem of alarming proportions. While the MDR rates calculated for the country as a whole
are 1-3% for primary, and 20% for secondary MDR, in our studies these rates were 4.6% and
29%, respectively [12].
Although our results were made known to the health authorities, there are no signs to suggest
that the TB situation has improved: the health system continues failing to diagnose cases
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appropriately and application of the DOTS strategy is very deficient: even if TB patients are
diagnosed, in many cases they begin, but do not complete their anti-TB treatment. In this sense,
we must emphasize the following aspects:
a. It is extremely difficult to perform culture analysis, in order to determine MDR status, in
a patient with less than six months of treatment, due to poor quality sputum samples. The
main obstacles to obtaining good quality sputum samples are: barriers in communication
with indigenous people, distance of the communities from the centers where samples are
processed, unsuitable transport conditions of samples (risk of exposure to sunlight or lack
refrigeration), among others.
b. It is very plausible that in indigenous populations, due to their having less contact with
health services, there are more undiagnosed TB cases and that, among non-indigenous
patients, more TB cases are diagnosed but not necessarily treated adequately [12].
c. A patient confirmed with MDR condition, is practically impossible to treat, given the high
cost of the secondary treatment, and because if the health system is incapable of guaran‐
teeing the follow up of a patient sensitive to the four primary drugs during six months, it
is probably even less able to follow up a MDR patient not only in terms of the time required
(from 6 months to 1.5 or 2 years) but also in terms of level of patient care, due to the possible
secondary effects of the “second line drugs” employed. In this sense, if a program cannot
guarantee appropriate follow up and compliance with treatment among TB patients, it
should not initiate their treatment, thus condemning them to a situation of no hope of
cure, with all that this implies, not only for the patient, but also for his family, who apart
from watching their family member suffer, are also exposed to the possibility of their
catching the disease.
With regard to mortality due to TB, we have found unacceptably high rates. In addition,
a considerable proportion of TB patients die without having received any medical care.8
We found that 55% of patients whose death was related to TB, had died within two years
of being diagnosed, possibly due to delays in diagnosis, and the poor quality of the follow-
up in their anti-TB treatment. Whereas the life expectancy in Chiapas is 72.2 years [29], the
average age of  deceased patients  was 47.4  years,  representing an average of  at  least  24
potential  years  of  life  lost  [13].  We believe  that  the  accumulation  of  unfavorable  living
conditions such as malnutrition, poverty, as well as deficient and/or lack of health services,
makes them an especially vulnerable group. According to official statistics, while in 2009
the PTB mortality for the country was 1.7/100,000 inhabitants in Chiapas it was 3.79 with
the same denominator [14].
Our findings have provided evidence that in the area studied, patients being aged 45 years
and over, not having completed the established six months of treatment, and not having
been treated via  the  DOTS strategy,  are  all  associated with a  higher  risk  of  the  patient
dying from PTB.
8 Eighteen percent of patients traced to their homes, in a study carried out in Chiapas, had died. Of the 40 deaths
presumed to have been associated with PTB, 33 died without having received medical care [13]
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TB cases  notified to  the  information systems of  the  health  sector,  and from which inci‐
dence  rates  are  estimated,  correspond  to  cases  detected  in  health  services  by  acid-fast
bacilli. We have documented that in rural and marginalized areas, its sensitivity is around
50%. This is an important aspect to consider because health system detection of TB cases
is based on smear testing, meaning that in marginalized communities many cases are not
detected.  In consequence,  the target  of  detecting at  least  75% of  cases is  far  from being
reached,  implying  the  presence  of  a  not  unappreciable  risk  of  transmission  of  TB  [9].
Indeed, the detection rate in hospitals studied in Chiapas is below this figure of 75%. The
suboptimal  case  detection  rate  reflects  an  inadequate  of  quality  medical  care,  probably
health personnel are often overwhelmed by daily activities, as well as insufficiently trained,
motivated, aware, and remunerated [10].
In order to increase detection rates, as it was demonstrated, the health system must take into
account the considerable difficulties involved in obtaining and analyzing sputum samples in
marginalized areas: cultural barriers (language spoken, world view) and economic barriers,
as well as technical problems to be overcome in order to obtain adequate quantity and quality
of sputum samples. It is therefore necessary to reduce the cultural and socioeconomic barriers
between health care providers and people [10]. Not surprisingly, some results of our investi‐
gations show that apart from cultural barriers, there are also structural barriers [11].
In the same way, we have found that a very low proportion of patients eligible for anti-TB
treatment effectively receive such treatment, and very high proportions of treatment failures
and incomplete follow-up [10].
Two further aspects deserve special attention in the context of the studies conducted in
Chiapas, Mexico, as well as in Peru: the problem of MDR, and the high mortality among
patients diagnosed of PTB. Both indicators constitute expressions of the complete failure of
the health system which, for whatever reason, did not manage to adequately treat these people,
who consequently either died of TB, or were left as chronic MDR cases (which would lead to
their death also, sooner or later).
In the case of MDR, it is well documented that the vast majority of cases of this type result
from inappropriate treatment and follow up by the health system. According to official
statistics, worldwide, the rates of MDR recorded in 2009 and 2010 were the highest ever, and
trends in MDR rates are unclear in the majority of countries [28]. The observed rates of MDR
in Chiapas suggest that in marginalized and excluded regions, it is a serious public health
problem of alarming proportions. While the MDR rates calculated for the country as a whole
are 1-3% for primary, and 20% for secondary MDR, in our studies these rates were 4.6% and
29%, respectively [12].
Although our results were made known to the health authorities, there are no signs to suggest
that the TB situation has improved: the health system continues failing to diagnose cases
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appropriately and application of the DOTS strategy is very deficient: even if TB patients are
diagnosed, in many cases they begin, but do not complete their anti-TB treatment. In this sense,
we must emphasize the following aspects:
a. It is extremely difficult to perform culture analysis, in order to determine MDR status, in
a patient with less than six months of treatment, due to poor quality sputum samples. The
main obstacles to obtaining good quality sputum samples are: barriers in communication
with indigenous people, distance of the communities from the centers where samples are
processed, unsuitable transport conditions of samples (risk of exposure to sunlight or lack
refrigeration), among others.
b. It is very plausible that in indigenous populations, due to their having less contact with
health services, there are more undiagnosed TB cases and that, among non-indigenous
patients, more TB cases are diagnosed but not necessarily treated adequately [12].
c. A patient confirmed with MDR condition, is practically impossible to treat, given the high
cost of the secondary treatment, and because if the health system is incapable of guaran‐
teeing the follow up of a patient sensitive to the four primary drugs during six months, it
is probably even less able to follow up a MDR patient not only in terms of the time required
(from 6 months to 1.5 or 2 years) but also in terms of level of patient care, due to the possible
secondary effects of the “second line drugs” employed. In this sense, if a program cannot
guarantee appropriate follow up and compliance with treatment among TB patients, it
should not initiate their treatment, thus condemning them to a situation of no hope of
cure, with all that this implies, not only for the patient, but also for his family, who apart
from watching their family member suffer, are also exposed to the possibility of their
catching the disease.
With regard to mortality due to TB, we have found unacceptably high rates. In addition,
a considerable proportion of TB patients die without having received any medical care.8
We found that 55% of patients whose death was related to TB, had died within two years
of being diagnosed, possibly due to delays in diagnosis, and the poor quality of the follow-
up in their anti-TB treatment. Whereas the life expectancy in Chiapas is 72.2 years [29], the
average age of  deceased patients  was 47.4  years,  representing an average of  at  least  24
potential  years  of  life  lost  [13].  We believe  that  the  accumulation  of  unfavorable  living
conditions such as malnutrition, poverty, as well as deficient and/or lack of health services,
makes them an especially vulnerable group. According to official statistics, while in 2009
the PTB mortality for the country was 1.7/100,000 inhabitants in Chiapas it was 3.79 with
the same denominator [14].
Our findings have provided evidence that in the area studied, patients being aged 45 years
and over, not having completed the established six months of treatment, and not having
been treated via  the  DOTS strategy,  are  all  associated with a  higher  risk  of  the  patient
dying from PTB.
8 Eighteen percent of patients traced to their homes, in a study carried out in Chiapas, had died. Of the 40 deaths
presumed to have been associated with PTB, 33 died without having received medical care [13]
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Based on our findings,  we can say that  people from rural  and indigenous communities
suffer  mistreatment by the health services  [30],  meaning,  among other aspects,  deficient
application of  the  DOTS strategy (sometimes due to  shortages  in  the  supply of  anti-TB
drugs [31], or poor follow up), leading to higher mortality and increasing their chances of
becoming MDR cases [12,13].
Another fact that reduces the chances of successfully carrying out patient follow up, is
migratory movements. Migration in the region is mainly due to economic factors, but can also
be for health reasons. Sometimes patients are registered by health services as urban patients
when in fact they are not, or they give a false address in order to obtain the first consultation,
but subsequently return to their rural communities or find another place to live without
notifying the health services.
In addition, health services give little consideration to socio-cultural and anthropological
aspects. For example, in indigenous medicine the process of health and illness involves their
world view, their personal and community histories, in an atmosphere of trust in which
supernatural intervention, transgression of social norms, culpability, or malice on the part of
enemies, are all admissible possible causes of the disease [16,32,33]. In this sense, patients may
seek care from traditional medicine practitioners, who attend them in accordance with their
age-old diagnostic and therapeutic rituals.
On the other hand, the use of public transport is a risk factor of TB not only among users,
but  also  among  minibus  drivers  and  fare-collectors,  and  hence  may  be  considered  an
occupational disease in these workers, who work in conditions such that not only do they
have  precarious  employment,  with  all  its  implications  (temporary  contract,  no  social
security  or  medical  insurance,  among other  aspects)  but  also their  job places  them in a
position of greater vulnerability to TB, since if they don’t work, they don’t get paid, and
hence it is very probable that many of them go to work despite their illness, if  they are
able to do so, only seeking care when the disease really makes it impossible for them to
continue working. In this sense, a worker with active PTB is a source of infection not only
for co-workers but also for passengers. In countries where TB is endemic with increased
circulation of resistant mycobacteria, the situation could be even worse. In a situation of
this kind, the health system should be implementing, at very least, home-based DOTS to
avoid exposure as far as possible, as well as implementing specifically designed occupation‐
al health programs [19,20,34].9
Observation of the particular facts which determine the appearance of TB and its prognosis,
shows that the diagnosis and treatment strategies employed by the health services are just that,
strategies, rather than ends in themselves, something which, unfortunately, is frequently
emphasized. If more clearly focused measures are not taken, TB will not disappear in margi‐
nalized areas, despite the fact that trends in the ecological indices suggest that TB is tending
to decline in Latin American countries; rather, it will persist as a greater public health problem
for years to come.
9  In  fact,  the  authors  believe  that  more  attention  ought  to  be  given  to  the  risk  of  infection,  by  any  aerially
transmitted disease that utilization of public transport represents, for both passengers and the workers.
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In our view, to remain with the idea that TB is decreasing in Latin America, tends to conceal
the failure which the rise in MDR patients represents. In any case, countries are alarmed by
the rise in MDR because of the cost of treatment and its inefficiency, not necessarily for the
health and welfare of TB patients, particularly if they are poor, as our studies suggest.
One discussion point is clear. Objective-oriented programs which attribute to the entire
country the same values of incidence and detection rates present a problem known as “trim‐
med estimation”, meaning that when the established objectives are reached, case finding and
detection are relaxed, or the resources to permit continuing with case finding and/or provision
of treatment, are cut short.
If, together with these data we take into account cases in areas enjoying lower TB incidence,
and if this total was the true number of existing cases, the result would necessarily be a
systematic reduction in incidence rates, leading to false optimism, whose historical cost has
been a relaxation of efforts to prevent and control TB worldwide during the decade of the 1980s
of last century.
Imagine the simple case that we have an incidence rate of X, in a given country. This figure
conditions the work plan for the coming year in terms of supplies, staff, anti-TB treatment
drugs, etcetera. Later on, 70% of the reporting areas indicate a rate of 0.9X, another 15% of
areas a rate of X, and the remaining 15% provide no data on rates, but their population is taken
into account in the denominator. The final rate for this country, based on these hypothetical
figures, would be 0.78X. In other words, not receiving reports from the areas with the worst
conditions provokes an apparent reduction in the global rate.
Unfortunately, even without questioning the figures declared, we know that areas which do
not report (or report, but at best with high levels of under-notification) are the ones with the
poorest conditions, both in terms of the socioeconomic conditions of the population which
theoretically must be cared for, and in terms of the lack of resources and other failures in the
organization and functioning of the program. Thus, by apparently having fewer cases, the
resources dedicated to the TB prevention and control program are also cut back, and this
creates a vicious circle which is difficult to break, so that program outcomes may be false, i.e.
underestimates of the numbers of cases.
There is therefore a clear need to promote studies specifically aiming to analyze the population
groups most vulnerable to TB, and in this way ascertain more precisely their situation, even
when they are not representative of what happens in a given country. Continuing to carry out
representative population based studies can only yield the probably already known rate for
the country as a whole, and the situation of marginal groups will not be reflected in such rate.
In this sense, the patchwork studies contribute very valuable elements which help to make
more visible and understandable the situation of population groups which go unnoticed
in  the  global  rates  utilized  in  public  health.  We  would  encourage  potentiating  studies
which break with the classical schemes, and use methods appropriate for the analysis of
samples  considered  too  small  by  classical  approaches,  but  without  renouncing  the
maximum of scientific rigor, as demonstrated by the doctoral theses developed in projects
conducted in the three settings we have dealt  with,  Chiapas (Mexico),  Chine (Cotopaxi,
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Ecuador),  and Lima (Peru),  and whose results have been published in journals of medi‐
um and high impact factor.
On the other hand, Ecuador and Peru present changes in their control program strategies:
active case finding, incorporation of economic incentives, strategies to reduce stigma among
patients, citizens’ observatories and integration of TB research in academic circles, among other
aspects. It will be fundamental to perform studies which evaluate possible effects of such
changes.
As the studies have shown, a failure to introduce changes in the structure and functioning of
TB prevention and control programs would have as a consequence that this disease will
continue to severely affect the most marginalized sectors of society:
In the field of TB prevention, several authors recognize that effective efforts have not yet been
fully considered, and that it is necessary to improve this issue, for example through better
vaccines and better chemotherapy for preventive treatment [22].
In  the  field  of  TB  diagnosis,  efforts  must  be  made  to  reinforce  active  case  finding  of
coughers,  as  for  example,  incorporating other  diagnostic  tests  which allow better  detec‐
tion of the disease (from the use of cultures, and conducting molecular tests, to the search
for  faster  diagnostic  methods,  such as  biosensors).  Epidemiological  surveillance  systems
rely on smear testing, failing to take into account that in marginalized and rural areas these
tests  with only around 50% sensitivity,  leave large numbers  of  cases  undetected by the
health services, or who will only be captured in advanced stages of the disease [12-14]. It
is  not unusual to find, within a given Latin American country,  that while highly devel‐
oped regions have advanced technologies  available  for  TB diagnosis,  in  others  the only
possibility for diagnosis is the smear test. Nor is it unusual in regions of this type to find
that  smear  testing  is  done  badly,  both  in  numerical  terms  (hardly  ever  obtaining  three
samples from a given patient), and in terms of quality (for reasons attributable to the poor
quality  of  samples,  such as  errors  in  collection,  storage,  transport,  processing and read‐
ing of results) [10,35].
In regard to anti-TB treatment, while the DOTS strategy has achieved a certain level of
effectiveness in curing patients and saving lives, the epidemiological impact has so far been
less than predicted [22], perhaps among other reasons, because treatment programs do not
find patients soon enough to significantly reduce transmission [5]. Thus it is necessary to
ensure: a) training, awareness and supervision of health personnel about the importance of
avoiding patients defaulting from treatment, as well as guaranteeing the appropriate supply
of medication; b) when necessary to adapt the DOTS strategy, both socially and culturally,
taking into account the community health agents, community world view, and implementing
the scheme in the patient’s homes, supporting them and their families economically during
their treatment; and c) that patients and their family are accompanied during the six months
of treatment, in order to cope with possible secondary effects and to overcome possible barriers
(alcoholism, religion, gender issues, seasonal migration, etcetera) which make compliance with
anti-TB treatment difficult.
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6. Conclusions: Tuberculosis as indicator of structural violence and
violations of human rights
One of the main aspects we want to stress in the present work is the fact that analyzing TB
through the measurement of global indicators conceals the situation of vulnerability to the
disease suffered by socioeconomically disadvantaged population groups. The data obtained
in the different studies we have presented show that there is a need for methodological
approaches (such as that known as patchwork studies) which allow the measurement and
analysis of the distribution of TB among different population groups.
It is well known that TB is one of the infectious diseases which has caused the most deaths
among humans [36], above all among the socioeconomically most vulnerable groups [37].
These groups, apart from having higher risks of infection, developing active disease, and dying
due to TB, are also the ones facing the greatest barriers (including information barriers) to
access health services [38]. In this sense, and given that nowadays the medical resources to
cure the disease are available, the fact that even today TB continues to cause deaths may be
considered as an indicator of the violation of human rights in excluded and marginalized
populations, as well as an indicator of “structural violence”, given that it is precisely the social,
economic, cultural and political structures which do not allow certain social groups to achieve
their full potential, while other groups do so, due to the unequal distribution of power and
available resources, placing some in conditions of social privilege and others in situations of
social vulnerability [39].
The social context of TB is strongly related with social justice. The history of TB teaches us that
the improvement of social conditions, work conditions ant the access to better quality food
decreased its mortality in the pre-microbial stage [40].
Taking as a starting point that the appearance, development and distribution of TB is largely
influenced by social determinants, and that public health achievements will depend on actions
outside the health care sector [41], two forms of interventions are necessary: a) those reducing
peoples’ vulnerability, such as poor living and working conditions, and improving nutrition,
among other aspects (such as structural and socioeconomic conditions), and b) by seeking
alternatives that promote higher levels of prevention, diagnosis and cure of TB.
Two clear examples that help to visualize health related inequalities in respect to TB are firstly,
the so-called “10/90 gap”, in reference to the fact that only 10% of worldwide expenditure on
health research and development is devoted to the problems primarily affect the poorest 90%
of the world’s population, and that 90% of worldwide expenditure is devoted to the problems
that affect the richest 10% of the world’s population.
The second example is the comparison between HIV-AIDS and TB. Whereas the first cases of
HIV-AIDS were described during the decade of the 1980s of the last century, today it is one of
the diseases which have received the most resources for its prevention and treatment, and
notable advances have been achieved in these aspects, and in improving survival of patients.
At the end of the last century, it was practically a death sentence, and yet today we have a
series of drugs which increase both survival and quality of life of these patients.
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In contrast, despite the fact that TB has been accompanying humans for thousands of years,
and that the etiological agent was first described in 1882, it is the disease which has alone
caused the greatest numbers of deaths in the adult population worldwide, and for which the
resources currently dedicated are insufficient to lead us to expect, in the foreseeable short or
medium term, the appearance of more effective measures for its control. Perhaps this is because
it is considered a disease of the poor, and thus there is no incentive to “invest” in it? As some
of our colleagues have pointed out: “even if the Global Plan to Stop TB is successfully imple‐
mented and results in the expected rate of reduction in incidence of about 6%, the global
incidence rate in 2050 would still be of the order of 100 per million of inhabitants, i.e. about
100 times greater than the elimination target” [22].
From the viewpoint of international human rights law, by providing woefully substandard
health services to marginalized populations, and failing to assure prevention of disease
through appropriate public health measures, governments violate their obligations in human
rights [6].
In this sense, high rates of TB constitute a reflection of the fact that certain populations face
important obstacles in their exercise of the right to health, and other economic, social and
cultural rights, due to the main social determinants of this disease being associated to social
exclusion and poverty [31]. The presence of TB constitutes a violation of the right to the highest
attainable standard of physical and mental health (“the right to health protection”) which is
inextricably related to the right to life and other human rights that allow an individual to live
with dignity [6,42].
The International Covenant on Economic, Social and Cultural Rights (ICESCR) in its Article
12, Paragraph 2, sets out the steps states should take in order to fulfill the highest attainable
standard of health, and includes “the prevention, treatment and control of epidemic, endemic,
occupational and other diseases, as well as the creation of conditions which would assure to
all medical service and medical attention in the event of sickness”.
The General Comment issued by the Economic, Social and Cultural Rights Committee [43],
establishes that “the underlying determinants of health, such as including adequate sanitation
facilities, hospitals, clinics and other health related buildings, trained medical and professional
personnel” have to be available in sufficient quantity with the States parties, and specifies that
health facilities, goods and services must be available, accessible, acceptable and of adequate
quality.
In this General Comment, accessibility has four overlapping dimensions [43, paragraph 12 (b)]:
First, the principle of non-discrimination,10 on the grounds of sex (poorer quality of care among
women than men), ethnic group (patients from indigenous communities receive poorer care),
color, political filiation (belonging or not to the dominant political party in a region can affect
access to care and to medication), religion (care may be denied to community members not
belonging to the dominant religion), physical or mental disability, health status, sexual
10 Non-discrimination is a core principle for the full realization of the right to health, as for all human rights [6]
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orientation, among others. A violation occurs when there is the intention or effect of nullifying
or impairing the equal enjoyment or exercise of the right to health [43, paragraph 18].
Second, physical accessibility, meaning that health facilities, goods and services must be within
safe physical reach for all groups, specially the vulnerable or marginalized ones, such as ethnic
and indigenous populations.
Third, economic accessibility requires that health facilities, goods and services must be
affordable for all, including socially disadvantaged groups. It points out that poorer persons
should not be disproportionately burdened with health expenses, and those individuals (e.g.
peasants) who through not having access to cash face particular difficulties, need to be
considered in governmental policy and practice.
Fourth, the right to seek, receive and impart information and ideas concerning health issues,
which includes health information in indigenous languages.
With regard to acceptability, it is understood that “health facilities, goods and services must
be respectful of medical ethics and culturally appropriate… [and] requires respect for tradi‐
tional medicines and practices which have not been shown to be harmful to human health”
[43, paragraph 12 (c)].
For adequate quality, it requires that health facilities, goods and services must be scientif‐
ically and medically appropriate and of good quality (skilled medical personnel, scientifi‐
cally approved and unexpired drugs, and hospital equipment, among other aspects) [43,
paragraph 12 (d)].
Unfortunately, the findings of our studies indicate that health care is not sufficiently available
or accessible (in either quantity or quality) to more disadvantaged social groups, creating
mistrust among them of the government health services, something that is reflected in the
relatively high percentage of people that do not use these services, even for vaccinations. This
situation is more marked when health services are not culturally adapted, when people
perceive mistreatment on the basis of their ethnicity or social conditions and health personnel
make disparaging remarks about their habits and demeanor [6].
Other indicators of violation of human rights in TB patients are:
• Failure to improve the level of health in a population. The fact that health indicators, in our
case indicators of TB do not improve in a population, even though they do not worsen,
constitutes a violation of human rights (specifically of the right to “Non-retrogression and
Adequate Progress”).
• The presence of inequalities in access to quality and coverage of health services (in the case
of TB affecting aspects from prevention to cure).
• The lack of meaningful popular participation, in regard to the making of decisions which
involve the design, organization and functioning of health services. It is common to find
that local health services nominate a “health promoter”, charged with various activities such
as vaccination, routine pediatric checkups, etcetera, but this does not necessarily mean the
community has a voice or participates in the definition of its own priorities, decision-making
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cultural rights, due to the main social determinants of this disease being associated to social
exclusion and poverty [31]. The presence of TB constitutes a violation of the right to the highest
attainable standard of physical and mental health (“the right to health protection”) which is
inextricably related to the right to life and other human rights that allow an individual to live
with dignity [6,42].
The International Covenant on Economic, Social and Cultural Rights (ICESCR) in its Article
12, Paragraph 2, sets out the steps states should take in order to fulfill the highest attainable
standard of health, and includes “the prevention, treatment and control of epidemic, endemic,
occupational and other diseases, as well as the creation of conditions which would assure to
all medical service and medical attention in the event of sickness”.
The General Comment issued by the Economic, Social and Cultural Rights Committee [43],
establishes that “the underlying determinants of health, such as including adequate sanitation
facilities, hospitals, clinics and other health related buildings, trained medical and professional
personnel” have to be available in sufficient quantity with the States parties, and specifies that
health facilities, goods and services must be available, accessible, acceptable and of adequate
quality.
In this General Comment, accessibility has four overlapping dimensions [43, paragraph 12 (b)]:
First, the principle of non-discrimination,10 on the grounds of sex (poorer quality of care among
women than men), ethnic group (patients from indigenous communities receive poorer care),
color, political filiation (belonging or not to the dominant political party in a region can affect
access to care and to medication), religion (care may be denied to community members not
belonging to the dominant religion), physical or mental disability, health status, sexual
10 Non-discrimination is a core principle for the full realization of the right to health, as for all human rights [6]
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orientation, among others. A violation occurs when there is the intention or effect of nullifying
or impairing the equal enjoyment or exercise of the right to health [43, paragraph 18].
Second, physical accessibility, meaning that health facilities, goods and services must be within
safe physical reach for all groups, specially the vulnerable or marginalized ones, such as ethnic
and indigenous populations.
Third, economic accessibility requires that health facilities, goods and services must be
affordable for all, including socially disadvantaged groups. It points out that poorer persons
should not be disproportionately burdened with health expenses, and those individuals (e.g.
peasants) who through not having access to cash face particular difficulties, need to be
considered in governmental policy and practice.
Fourth, the right to seek, receive and impart information and ideas concerning health issues,
which includes health information in indigenous languages.
With regard to acceptability, it is understood that “health facilities, goods and services must
be respectful of medical ethics and culturally appropriate… [and] requires respect for tradi‐
tional medicines and practices which have not been shown to be harmful to human health”
[43, paragraph 12 (c)].
For adequate quality, it requires that health facilities, goods and services must be scientif‐
ically and medically appropriate and of good quality (skilled medical personnel, scientifi‐
cally approved and unexpired drugs, and hospital equipment, among other aspects) [43,
paragraph 12 (d)].
Unfortunately, the findings of our studies indicate that health care is not sufficiently available
or accessible (in either quantity or quality) to more disadvantaged social groups, creating
mistrust among them of the government health services, something that is reflected in the
relatively high percentage of people that do not use these services, even for vaccinations. This
situation is more marked when health services are not culturally adapted, when people
perceive mistreatment on the basis of their ethnicity or social conditions and health personnel
make disparaging remarks about their habits and demeanor [6].
Other indicators of violation of human rights in TB patients are:
• Failure to improve the level of health in a population. The fact that health indicators, in our
case indicators of TB do not improve in a population, even though they do not worsen,
constitutes a violation of human rights (specifically of the right to “Non-retrogression and
Adequate Progress”).
• The presence of inequalities in access to quality and coverage of health services (in the case
of TB affecting aspects from prevention to cure).
• The lack of meaningful popular participation, in regard to the making of decisions which
involve the design, organization and functioning of health services. It is common to find
that local health services nominate a “health promoter”, charged with various activities such
as vaccination, routine pediatric checkups, etcetera, but this does not necessarily mean the
community has a voice or participates in the definition of its own priorities, decision-making
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in regard to planning of activities or elaboration and evaluation of health programs for the
community. Veneklasen and colleagues have said [44]: “True rights-based participation
requires programs that enable people to be active, informed and critical agents and citizens,
rather than objects of charity”. In this sense, the International Labor Organization, Conven‐
tion 169 [45] stresses that health services shall, to the extent possible be, “planned and
administered in co-operation with the peoples concerned and take into account their
economic, geographical, social and cultural conditions as well as their traditional preventive
care healing practices and medicines”.
• The lack of accountability in health programs, which in addition are usually not evaluated.
In this sense, the fact that a person is not treated appropriately by the health services, which
in itself constitutes a violation of his right to health, should also imply a right to compen‐
sation by the State, which could take the form of restoration of his health, economic
compensation, satisfaction or guarantees that the situation will not be repeated. On the other
hand, if it is true that more resources are needed, they must be spent in such a way as to
foster self-sufficiency and reduce inequities. Greater health care expenditure does not
necessarily reduce inequalities [5].
• This dimension is also related to the enactment and enforcement of laws to provide sanctions
for gender based violence or sexual abuse of women patients by health personnel, as well
as people affected by mistrust. In addition, a legal framework must be adopted to opera‐
tionalize the protection of patient human rights in the health services, establishing mecha‐
nisms for monitoring their compliance. The figure of a human rights ombudsman is a good
example for monitoring, to investigate and sanction perpetrators in cases of abuse or
malpractice and medical negligence claims [6].
• The lack of multi-sectorial strategies. Governmental programs should not compete among
themselves, but rather be designed inter alia to promote health services, improve adequate
dwelling conditions, education, work, and adequate nutrition. Until this happens, the plight
of marginalized populations will persist. In the last instance, violations of the Economic,
Social and Cultural Rights occur “when a state fails to satisfy a minimum core obligation to
ensure the satisfaction of, at very least, minimum essential levels of the rights” [46].
• The lack of access to health information. Social participation and monitoring are impossible
without access to information. This implies that governments should collect data on a
disaggregated basis (by ethnicity, gender, socio-economic status, language, among other
aspects) and this information, together with the methodologies used, must be readily
available to the public. Of course, it also includes the right of TB patients to see their medical
records, to give informed consent in all procedures, and to confidential management of their
disease.
The performance of patchwork studies has allowed us to identify, evaluate and measure the
situation of marginalized population groups in three different contexts (Chiapas, Mexico;
Chine, Cotopaxi, Ecuador and Lima, Peru). Our findings revealed the poor quality of diagnosis
and treatment of TB patients. Our data can be useful not only in the studied regions, but also
in other countries with similar socioeconomic inequalities, if they are taken into account by
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the health authorities in order to provide all people (especially the more socially vulnerable
groups) with: effective prevention programs, a reliable and timely diagnosis, adequate anti-
TB treatment and follow-up, clear and appropriate information and counseling about TB (what
it is, mechanisms of transmission and possibility of infecting others, etcetera).
In consequence it is necessary change the dysfunctional health system that contributes to the
persistence and intensification of exclusion, voicelessness, and inequity, while simultaneously
defaulting on its potential and obligation to fulfill human rights and contribute to the building
of more equitable, egalitarian and democratic societies. The history of TB teaches us that the
improvement of social justice led to increase the global health conditions and thus, it avoids
the called “social diseases”, including TB. The academic community has much to say and
actively contribute in these aspects. The first step is to do research in order to make visible
excluded people. To analyze, sensitize and lead to better socioeconomic conditions is an
assignment for all of us.
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